Scientific Abstract Listing and Meeting Information

Comments

Transcription

Scientific Abstract Listing and Meeting Information
Scientific Abstract Listing
and Meeting Information
April 18–25, 2015 · Washington, DC
Hotel Reservation Deadline: March 18, 2O15
Early Registration Deadline: March 27, 2O15
The 67th AAN Annual Meeting
Experience innovative research, exceptional education programs, and boundless networking
opportunities at the AAN Annual Meeting in Washington, DC, April 18–25, 2015.
2O15 Deadlines-At-A-Glance
Late January, 2015:
Abstract Notifications Available
March 18, 2015:
Annual Meeting Hotel Reservation Deadline
March 27, 2015:
Annual Meeting Early Registration Deadline
Location
Walter E. Washington Convention Center
Washington, DC
Headquarter Hotel
Marriott Marquis Washington, DC
RED: 14AM Register Online Ad
Place in AANnews and Others?
8.25 x 5.4375 4C + Bleed
Register Online
Customize Your Week with
Easy Online Registration
With online registration, you can:
nn
Register
nn
Book your hotel
nn
Plan your itinerary
nn
Search for programs by topic or day
nn
New! Choose from three registration packages!
See page 8 for details
AAN.com/view/AM15
Table of Contents
Introduction
Wednesday, April 22
Plan to Attend the 67 AAN Annual Meeting . . 2
An Experience No Other Conference Can Match . 3
th
Look What’s New! . . . . . . . . . . . . . . 4
Look What’s Back by Popular Demand . . . . . 5
What’s Included with Your Registration? . . . . 6
Registration . . . . . . . . . . . . . . . . 8
2O15 Award Recipients . . . . . . . . . . . 11
2O15 Research Fellowships . . . . . . . . . 17
Meeting Schedule Overviews
Meeting at a Glance . . . . . . . . . . .
18
I Talks Schedule . . . . . . . . . . . . . . 22
Understanding the Program Listings . . . . . 25
Scientific Session Schedule . . . . . . . . . 26
Annual Meeting Program Schedule . . . . . . 30
Annual Meeting Programs by Topic . . . . . 40
Saturday, April 18
Integrated Neuroscience Session I1�����������������������48
Integrated Neuroscience Session I2 . . . . . . 49
Sunday, April 19
Integrated Neuroscience Session I3�����������������������50
Section Topic Controversies S1 . . . . . . . . 51
Integrated Neuroscience Session I4�����������������������52
Monday, April 20
Integrated Neuroscience Session I5�����������������������53
Section Topic Controversies S2�������������������������������54
Integrated Neuroscience Session I6 . . . . . . 55
Poster Session Schedule and Floor Plan . . . . 56
Poster Session I . . . . . . . . . . . . . . 57
Poster Session IV�������������������������������������������������������88
Scientific Sessions S20–S28�������������������������������������96
Integrated Neuroscience Session I9�����������������������98
Integrated Neuroscience Session I10 . . . . . 99
Poster Session V �����������������������������������������������������100
Platform Blitz Sessions S29–S37 ���������������������������108
Thursday, April 23
Poster Session VI�����������������������������������������������������110
Scientific Sessions S38–S45�����������������������������������118
Invited Science: Epilepsy . . . . . . . . . . 119
Integrated Neuroscience Session I11 ������������������120
Integrated Neuroscience Session I12 . . . . . 121
Poster Session VII ���������������������������������������������������122
Scientific Sessions S46–S53�����������������������������������132
Other Interests
Highlights for Students, Residents, and Fellows 134
Connect at Social Events . . . . . . . . . . 136
Things to do in DC . . . . . . . . . . . . 138
AAN 2015 Annual Meeting On Demand . . . 140
General Information . . . . . . . . . . . . 142
Hotels and Travel
Hotel Reservations . . . . . . . . . . . . 146
Travel Information . . . . . . . . . . . . . 147
Hotel Street Map and Amenities . . . . . . 148
Meeting Listings
67th Annual Meeting Exhibitors . . . . . . . 151
67th Annual Meeting Committee Members . . 153
Meeting Management and Contacts . . . . . 156
Tuesday, April 21
Poster Session II . . . . . . . . . . . . . . 65
Section Topic Controversies S3 . . . . . . . . 73
Scientific Sessions S4–S11 ���������������������������������������74
Invited Science: Stroke . . . . . . . . . . . 75
Integrated Neuroscience Session I7�����������������������76
Integrated Neuroscience Session I8 . . . . . . 77
Poster Session III�������������������������������������������������������78
Scientific Sessions S12–S19�������������������������������������86
Program current as of February 10, 2015. Program subject to change.
Fast, Easy, Online Registration · AAN.com/view/AM15
1
Plan to Attend the 67th AAN Annual Meeting
“Welcome to the 67th AAN Annual
Meeting! The 2014 meeting in Philadelphia
broke attendance records and brought
together the world’s best minds in
neurology—and I have no doubt the 2015
meeting will be just as spectacular. As we all
know, neuroscience research is essential for
our patients and profession, and there is no
better place than an AAN Annual Meeting to
experience the very best science and latest research covering
the breadth of the neurology profession. The always popular
Scientific Program is included free with your registration and
includes a variety of sessions covering hot topics, critical issues,
latest scientific advances and highlights, in addition to more than
2,500 cutting-edge abstracts presented within the poster and
platform sessions.
We’re thrilled to be bringing the world’s largest gathering of
neurology professionals to the U.S. capital this spring, and hope
you’ll join us—either for a few, or all eight days—to be a part of
this truly unique experience that no other conference can match.
I look forward to seeing you in Washington, DC.”
-Stefan M. Pulst, MD, FAAN
Chair, Meeting Management Committee
An Experience No Other Conference Can Match
The AAN Annual Meeting delivers an experience no other conference can match. That’s because at an
AAN Annual Meeting you not only can choose courses based on your area of interest, but you also have access
to a wide array of courses offering updates and review of topics such as multiple sclerosis, epilepsy, movement
disorders, stroke, child neurology, and many more.
Customize the meeting for the schedule that works best for you and/or your practice. With so many exceptional
education programs and scientific sessions available in a variety of subspecialties, plus unparalleled networking
opportunities—all week long—the AAN Annual Meeting can be tailored to be a perfect fit for you no matter
what your interest, career stage, or schedule.
Advancing Neurology. Working for You!
¡¡ For Neurologists
The Annual Meeting is the place for top CME
programming, innovative scientific research,
and opportunities to meet up with neurology’s
thought leaders from around the world. New
Silver and Gold Registration Packages provide
great value for your CME programming,
providing access to all education courses
for one flat rate.
¡¡ For Students and Junior Members
The Annual Meeting is essential, providing
exposure to a variety of interests and unmatched
networking opportunities. Students and
Junior members get significant discounts on
registration and course fees. Learn more about
highlights for students, residents, and fellows
on page 134.
Fast, Easy, Online Registration · AAN.com/view/AM15
¡¡ For Other Physicians and
Advanced Practice Providers
New! Customize the meeting to your needs
with new tracks offering focused education and
scientific programming. Learn more about the
new Clinical Research Track, the new Advanced
Practice Provider Track, and the always popular
Subspecialty in Focus Track on page 25.
Come for 3 days or stay for all 8.
Make the meeting your own!
3
Look What’s New!
Best Science from Subspecialty Meetings
in Stroke and Epilepsy
We are bringing you the best science, even if it wasn’t presented
here first. Top abstracts previously presented at the International
Stroke Conference and the American Epilepsy Society Annual
Meeting will be presented by their authors in 20-minute platform
sessions. Select abstracts from their “best of” lineups emphasize
basic, clinical, and translational sciences as they evolve toward a
more complete understanding of stroke and epilepsy pathophysiology
with the overall goal of developing more effective prevention and
treatment. See pages 75 and 119 for more information.
Neuroscience Is Essential
Keep your eye out for this exciting new promotional effort to launch
at the Annual Meeting reinforcing why neuroscience is essential
to neurology professionals and patients! See page 54 for more
information.
Specialized Learning Tracks
¡¡ Clinical Research Track C
Offers suggested programs geared towards academic
neurologists early in the development of a clinical research
career or who are considering one.
¡¡ Advanced Practice Provider Track A
The APP Track is comprised of current education courses
suggested to provide APPs a “deep dive” into general
neurology, including the Advance Practice Provider
Symposium on Sunday, April 19.
Learn more about the tracks on page 25.
Customized Registration Packages
The Innovation room is your destination for I Talks, a lively,
supplemental learning experience at the Annual Meeting, through
a variety of one- to two-hour presentations throughout the week,
the Walter E. Washington Convention Center. Look for lectures,
presentations, group discussions, and hands-on activities using
advanced multimedia formats that bring learning to life. See a full
schedule on page 22.
The Value of a Neurologist
Monday, April 20, 5:30 p.m.–6:30 p.m.
Can neurologists objectively demonstrate that we provide value
(quality and financial) when added to a care team? At this hot topics
in education session attendees will learn how an AAN work group
used third party payer claims data to identify the value of neurologic
care in the disease areas of stroke, MS, epilepsy, pediatric epilepsy,
headache, and Alzheimer’s disease.
¡¡ Explore how the “value” of care is being defined by payers
and purchasers.
¡¡ Learn how the AAN is approaching an effort to determine the
value of care provided by neurologists in the health care system.
¡¡ Identify the benefits and limitations of using claims data
to determine value of care.
¡¡ Discover areas where data show where neurologists
provide value above other physicians' patient care.
4
Choose the one that’s right for you!
¡¡ Meeting Registration
Education courses available for additional fees.
¡¡ Silver Registration Package
Includes Meeting Registration plus full access to the 2015
Annual Meeting Education Program*.
¡¡ Gold Registration Package—BEST VALUE!
Gain full access to the 2015 Annual Meeting Education
Program*, plus Annual Meeting On Demand, the digital library
of the Annual Meeting. With the Gold Registration Package you
have the flexibility to attend sessions in-person or on demand,
access to the syllabi summaries of more than 160 programs, and
the ultimate CME earning power both during the meeting and
after!
* Skills Workshops, Skills Pavilions, and Leadership Courses excluded from
Silver and Gold Registration Package pricing. Attendee must identify
courses to be included as part of Silver and Gold Registration Package.
Courses are subject to closure due to reaching maximum capacity.
Attendee is only permitted to select courses that he/she plans to be in the
room for. Attendee will not be able to register for courses with conflicting
time schedules.
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Look What’s Back by Popular Demand
ePosters
Highlights in the Field
Look for select scientific posters to be presented on large monitors,
allowing authors to best highlight visually compelling components
such as images, videos, and 3D
models.
Get essential updates covering the past year in your subspecialty
or topic of interest. Sections will provide overviews in their areas,
featuring scientific and
educational abstracts, journal
articles, subspecialty society
updates, tips, resources, and
more.
Section Topic
Controversies
AAN Sections will debate
controversies related to a
specific section topic, including
Stroke and Vascular Neurology,
Sleep Medicine, Neuro-oncology,
and Child Neurology. This
lively format will feature two
speakers arguing a side of the
topic, followed by a rebuttal and
question and answer period.
Platform Blitzes
Following a similar format to
the popular Emerging Science
Session, these dynamic
sessions will feature fiveminute author presentations
followed by five-minutes of
questions and answers. The
session will conclude with all
authors participating in a panel
discussion.
Extend Your Experience with These Annual Meeting Resources
¡¡ Academy Central:
Your one-stop shop for AAN products, services, and more
¡¡ American Brain Foundation:
Support cures for brain disease and see the future of neurology
¡¡ Neurology Career Center in Academy Central and the Exhibit Hall:
Meet employers, search for jobs, and get career tools
¡¡ Resident/Medical Student Rush Line:
Free education program tickets, first-come, first-served
¡¡ Annual Meeting Mobile App:
LITE version available now. Full version available in March
2015.
¡¡ Annual Meeting On Demand:
The digital library of content from the 2015
AAN Annual Meeting presentations
(Now included with the Gold Registration Package)
¡¡ Residents Experience:
A unique place to network, find information, and
participate in informal presentations specifically
geared to those in the early stages of their career
¡¡ International Experience:
Provides an opportunity for international
attendees to network and participate in
discussions on a variety of topics
Fast, Easy, Online Registration · AAN.com/view/AM15
5
F What’s Included with Your Registration?
When planning your week, be sure and take advantage of these FREE education, scientific, practice, advocacy
programs, and social events—going on all week long and at no additional cost to you!
FREE programs to help you:
¡¡ Stay current with the latest research and scientific sessions
¡¡ Network with colleagues
¡¡ Participate in Academy business
Saturday, April 18
F I1 S New Windows into the Brain:
Technological Advances in Frontline
Neurologic Diagnosis via the Visual and
Oculomotor Systems
8:00 a.m.–12:00 p.m.
Management of Asymptomatic
F I2
Cerebrovascular Lesions
1:00 p.m.–5:00 p.m.
F IWebs, Apps, and Social Media:
There’s an AAN Tool for That!
3:00 p.m.–5:00 p.m.
S
Sunday, April 19
F ICreating Innovative,
Interactive Teaching Modules
8:00 a.m.–8:30 a.m.
Clinical Research:
F C170
Introduction and Methods
8:00 a.m.–12:00 p.m.
Dopamine-mediated
F I3
Neural Plasticity in Motor and
Non-motor Circuits
8:00 a.m.–12:00 p.m.
F C171 Opioids and Marijuana
in Your Practice
8:30 a.m.–12:00 p.m.
F IThe Business of Neurology
9:00 a.m.–11:00 a.m.
F INeurology Jeopardy: Things You
May Not Know About Publishing in the
Journal or Its Spin-offs
11:30 a.m.–12:30 p.m.
C
S
F IAnnual Meeting Orientation Session
1:00 p.m.–1:30 p.m.
F S1Section Topic Controversies:
Antiplatelets, Anticoagulants, or
Stenting for Acute Treatment of
Cervical/Cranial Dissection?
1:00 p.m.–2:30 p.m.
F C43 Advanced Practice
Provider Symposium
(registration required)
1:00 p.m.–4:00 p.m.
Clinical Research: Drug
F C172
Development and Clinical Trials
1:00 p.m.–5:00 p.m.
Infectious, Paraneoplastic,
F I4
and Autoimmune Encephalopathies:
Advances in Clinical Diagnosis and
Emerging Insights about Pathogenesis
1:00 p.m.–5:00 p.m.
F IProviding High Value Neurologic Care
2:00 p.m.–4:00 p.m.
F IQuality in Neurology—
Can We Measure and Improve It?
4:30 p.m.–5:30 p.m.
F Capitol City Celebration
6:00 p.m.–10:00 p.m.
A
C
S
Monday, April 20
F ILeadership Meeting
6:30 a.m.–7:30 a.m.
F C59Leadership in Neurology: Be a
Champion for Your Patients and
Protector of Your Subspecialty with
Payers, Policymakers, and the Public
6:30 a.m.–8:00 a.m.
F C60Resident and Fellow Career
Breakfast: The Early Years
(registration required)
6:30 a.m.–8:30 a.m.
F IAAN Business Meeting
8:00 a.m.–8:30 a.m.
Pediatric Neurotrauma:
F I5
From Coma to Concussions
8:00 a.m.–12:00 p.m.
S
6
F C173 Clinical Reasoning:
From a Novice to an Expert
8:30 a.m.–12:00 p.m.
F IIs AAN Member Participation in
Physician-assisted Suicide Ethical?
9:00 a.m.–10:30 a.m.
F INeuroexam SHORTCUTS:
Learn from the Experts
11:00 a.m.–1:00 p.m.
F INeurologist Burnout: What is it? Do I
Have it? What can I do about it?
12:00 p.m.–12:30 p.m.
F S2Section Topic Controversies: Testing
in Prodromal Neurological Disease:
Friend or Foe?
1:00 p.m.–2:30 p.m.
Future Therapies:
F I6
How We Will Be Treating, Preventing,
and Curing Epilepsy in the Year 2025
1:00 p.m.–5:00 p.m.
F C174 All You Need to Know
About Health Information Technology
to Avoid Taking a HIT
1:00 p.m.–5:00 p.m.
F ABPN Maintenance Of Certification
Information Session
1:30 p.m.–3:00 p.m.
F IConquering ICD-10
1:30 p.m.–3:30 p.m.
F C175 Qualitative Research: The
‘How‘ and ‘Why’ of Education
2:00 p.m.–4:30 p.m.
F P1Poster Session I
2:00 p.m.–6:30 p.m.
S
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
I = I Talk Session
F IAAN’s Axon Registry:
Data Powering Neurology’s Future
4:00 p.m.–5:00 p.m.
F Student Interest Groups
in Neurology (SIGN) Meeting
4:00 p.m.–6:45 p.m.
F Exhibit Hall Opening Reception
4:30 p.m.–6:30 p.m.
F Consortium of Neurology Residents
and Fellows Meeting
5:00 p.m.–6:30 p.m.
F IHot Topics in Education:
The Value of a Neurologist
5:30 p.m.–6:30 p.m.
F Residents and Fellows Career
Forum and Reception
6:30 p.m.–9:00 p.m.
F I8 Advances in ALS and Other
Motor Neuron Diseases
1:00 p.m.–5:00 p.m.
F ICase Report 2.0: Implementing the
"CARE" Case Report Guidelines for the
Digital Era
1:30 p.m.–3:30 p.m.
F P3Poster Session III
2:00 p.m.–6:30 p.m.
F Scientific Platform Sessions
3:15 p.m.–5:00 p.m.
F IHow to Hug a Porcupine:
Relationship Building with Congress
and Why It’s Important
4:00 p.m.–5:00 p.m.
F Hot Topics Plenary Session
5:30 p.m.–6:45 p.m.
Tuesday, April 21
Wednesday, April 22
F P2Poster Session II
F P4Poster Session IV
7:30 a.m.–12:00 p.m.
F Presidential Plenary Session
9:00 a.m.–12:00 p.m.
F Exhibit Hall
11:30 a.m.–5:00 p.m.
F IPolicy and Advocacy Hour
with the GRC
12:00 p.m.–1:00 p.m.
F S3Section Topic Controversies: Should
All Brain Tumor Patients Receive
Prophylactic Antiepileptic Drugs?
1:00 p.m.–2:30 p.m.
F Scientific Platform Sessions
1:00 p.m.–2:45 p.m.
F Invited Science: Stroke
1:00 p.m.–2:45 p.m.
F I7 The Global Burden of Neurological
Infections: Epidemiology, Treatment,
and Prevention
1:00 p.m.–5:00 p.m.
7:30 a.m.–12:00 p.m.
F IAnnual Meeting Orientation Session
8:00 a.m.–8:30 a.m.
F Contemporary Clinical Issues
Plenary Session
9:00 a.m.–12:00 p.m.
F Exhibit Hall
11:30 a.m.–5:00 p.m.
F INeurology Compensation
and Productivity Survey and
Dashboard Report
12:30 p.m.–1:30 p.m.
F IHow to Avoid “Death by
PowerPoint” and Workshop
1:30 p.m.–3:30 p.m.
F Scientific Platform Sessions
2:00 p.m.–3:45 p.m.
F I9 Treating Dementia in an Age
of Mixed Disease
2:00 p.m.–6:00 p.m.
The Dynamic Brain in
F I10
Health and Disease: Plasticity
and Reprogramming
2:00 p.m.–6:00 p.m.
F P5Poster Session V
2:00 p.m.–6:30 p.m.
F IYour Abstract Has Been Accepted:
Now What? Working with the Media
4:00 p.m.–5:00 p.m.
F Scientific Platform Blitz Sessions
4:00 p.m.–5:45 p.m.
F Highlights in the Field Sessions
6:00 p.m.–7:00 p.m.
C
Fast, Easy, Online Registration · AAN.com/view/AM15
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
F E merging Science
6:15 p.m.–7:45 p.m.
Thursday, April 23
F P6Poster Session VI
7:30 a.m.–12:00 p.m.
F Frontiers in Neuroscience
Plenary Session
9:00 a.m.–12:00 p.m.
F Exhibit Hall
11:30 a.m.–3:00 p.m.
F IAAN’s Axon Registry: Data
Powering Neurology’s Future
12:00 p.m.–1:00 p.m.
F Scientific Platform Sessions
1:00 p.m.–2:45 p.m.
F Invited Science: Epilepsy
1:00 p.m.–2:45 p.m.
The Promise of Novel
F I11
Biomarker Approaches in Advancing
Treatment
1:00 p.m.–5:00 p.m.
F I12 Obesity and Neurological
Disorders
1:00 p.m.–5:00 p.m.
F IAAN Digital Scavenger Hunt
1:30 p.m.–2:30 p.m.
F P7Poster Session VII
2:00 p.m.–6:30 p.m.
F IYour Abstract Has Been Accepted:
Now What? Tips for a Successful
Presentation
3:00 p.m.–4:00 p.m.
F Scientific Platform Sessions
3:15 p.m.–5:00 p.m.
F ILessons Learned from an Ebola
Patient
5:00 p.m.–5:30 p.m.
F Highlights in the Field Sessions
5:30 p.m.–6:30 p.m.
F Controversies in Neurology
Plenary Session
5:30 p.m.–7:00 p.m.
C
Friday, April 24
F Clinical Trials Plenary Session
12:00 p.m.–1:30 p.m.
F Neurology Year in Review
Plenary Session
4:30 p.m.–6:00 p.m.
F Closing Party
6:00 p.m.–8:00 p.m.
7
Registration
The field of neurology is rapidly changing, and there’s nowhere like the AAN Annual Meeting to make sure
you’re up-to-date. The 67th AAN Annual Meeting in Washington, DC, offers innovative research, exceptional
education programs, and boundless networking opportunities. Log in to the registration site where you can:
¡¡ Register quickly and easily
¡¡ Make your hotel selection and reservation
¡¡ Print your schedule and not miss a thing
at the meeting!
¡¡ Create your itinerary incorporating your
education programs, scientific sessions, and
other Annual Meeting events
Ways to Save
Registration Options
The Annual Meeting offers a great value for the quality and quantity
of programming. Try some of these savings tips:
¡¡ Renew your AAN membership or join the AAN now
for maximum savings on registration and course fees at
AAN.com/view/membership.
¡¡ Register now to avoid increased rates
after the March 27, 2015, early registration deadline.
¡¡ Purchase education programs individually or select the Silver or
Gold Registration Package option and register for any course of
interest for one flat rate.1
Meeting Registration: Meeting Registration with education
courses available for an additional fee.
Silver Registration Package1: The Silver Registration Package
includes all education courses for one flat rate. Choose this
registration option before the meeting or on-site. You can change
to another course at any time, including at the meeting, with no
change fee. However, you will not be able to register for courses with
conflicting time schedules.
Gold Registration Package1: Silver Registration Package
as described above plus Annual Meeting On Demand, the
comprehensive digital library of Annual Meeting presentations.
Registration Fees
Member Type
Students
Senior/Honorary
Junior and
Non-neurologist
Member*
Neurologist
Member**
Nonmember
Meeting
Registration2
Before March 27,
2015
Silver Registration
Package3
Before March 27,
2015
Gold Registration
Package3
Before March 27,
2015
$0
$0
$300
$695
$499
$1,094
$0
$0
$370
$780
$569
$1,179
$100
$400
$599
$130
$500
$699
$305
$1,000
$1,399
$420
$1,200
$1,599
$610
$2,000
$2,499
$840
$2,300
$2,799
1 Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and Gold
Registration Package pricing. Attendee must identify courses to be included as part of Silver and
Gold Registration Package. Courses are subject to closure due to reaching maximum capacity.
Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee
will not be able to register for courses with conflicting time schedules.
2 Includes meeting access only, education courses must be paid for individually.
8
Meeting
Silver Registration Gold Registration
Registration2
Package3
Package3
After March 27, 2015 After March 27, 2015 After March 27, 2015
3 Includes access to meeting and ability to register for education courses at no additional cost.
* Junior Intern, Resident or Junior Fellow, Business Administrator, Non-neurologist Clinician,
Nurse Practitioner, Physician Assistant, Research Scientist, Research Scientist Fellow,
Research Coordinator
** Active, Associate, Fellow
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Three Easy Ways to Register
Online
Fast, easy online registration available at
AAN.com/view/register
Online registration walks you step-by-step through completing
your registration, reserving a hotel, and personalizing your
itinerary with top-tier education courses, scientific sessions,
special Annual Meeting events, and more!
Fax/Mail
A printable registration form is available at
AAN.com/view/register
Download and print a registration form to complete and
mail or fax to:
Mail:Fax:
AAN Registration/CMR
(415) 293-4071
33 New Montgomery, Suite 1100
San Francisco, CA 94105
Deadline: March 27, 2015
Registrations received after March 27, 2015,
will be processed at a higher rate.
Questions
Online: AAN.com/view/register
Email: [email protected]
Telephone
US/Canada: (800) 676-4226 International: (415) 979-2283
Fees
Meeting Registration Fee
The meeting registration fee is mandatory for all registrants and is
determined by AAN member type. For attendees selecting the Silver
and Gold Registration Packages, the meeting registration fee is
included in the price.
Education Programs
Purchase programs individually or select the Silver or Gold
Registration Package to register for any course of interest for one flat
rate (Note: Skills Workshops, Skills Pavilions, and Leadership Courses
excluded from Silver and Gold Registration Package pricing. Attendee
must identify courses to be included as part of Silver and Gold
Registration Package. Courses are subject to closure due to reaching
maximum capacity. Attendee is only permitted to select courses
that he/she plans to be in the room for. Attendee will not be able to
register for courses with conflicting time schedules.).
Fast, Easy, Online Registration · AAN.com/view/AM15
In addition, Junior Members who register for two Education
Programs at full price will receive 50% off the cost of a third
education program of equal or lesser value.
Changes in Education Programs
Select education programs carefully. An administrative fee of $20
($30 after March 27, 2015) will be charged for program cancellations
without a replacement program.
Many programs and events are included with your registration. See
page 6 for details.
Cancelled or Closed Programs
Education programs may be closed due to reaching maximum
capacity or cancelled due to insufficient enrollment. In the event
of cancellation, registration for the cancelled course will be fully
refunded. The AAN is not responsible for airfare, hotel, or other
costs incurred by participants in the event of program or registration
closure or cancellation.
Cancellations/Refunds of Registration
Until March 27, 2015—Refund less $50 administrative fee
March 28–April 10, 2015—Refund less $100 administrative fee
After April 10, 2015—No refund
¡¡ All cancellations must be submitted in writing to
[email protected] or faxed to (415) 293-4071.
¡¡ No-shows will not receive a refund.
¡¡ Name substitutions are not permitted.
¡¡ No refunds will be processed for amounts of $20 or less.
Special Accommodations Deadline: March 27, 2015
The Walter E. Washington Convention Center and the AAN are in
compliance with the Americans with Disabilities Act or Human Rights
Code and strive to accommodate all visitors. Information booths,
designated parking, and assisted listening devices are available. If
you require special accommodation to attend the Annual Meeting,
submit your request while registering online or contact Laurie Dixon
no later than March 27, 2015, at [email protected] or (612) 928-6154.
Kosher meals may be provided at any breakfast or lunch, and
must be arranged on or before March 27, 2015, through the
registration website or by contacting AAN Registration/CMR at
[email protected], (800) 676-4226, or (415) 979-2283. There is a
$50 surcharge per meal. On-site requests cannot be accommodated.
Group Registration Deadline: April 2, 2015
Group registrations are those in which 10 or more individuals’ fees
are paid for with one check or credit card. Special registration
instructions are available online at AAN.com/view/register or by
contacting CMR’s Group Registration at (800) 676-4226 (US/Canada)
or (415) 979-2283 (International) or email [email protected] .
See page 146 for housing information.
9
Proud Sponsor of the
2015 AAN Annual Meeting
Come visit us at
BOOTH 1428
© 2015 Genentech USA, Inc. All rights reserved. NEU/012615/0011
2O15 Award Recipients
The research we celebrate, with the recipients below, has generated paradigm-changing discoveries in epilepsy,
fundamental insights in multiple sclerosis, and pioneering breakthroughs in pain, to name a few of the transformative
advances conceived by these luminaries. We honor those researchers and pay tribute to all those who play a role in
the search for cures for brain disease, from mentors to colleagues to those just starting out on their journey.
AAN Alliance Awards
Founders Award
Sponsored by the American Brain Foundation and endowed by the
Alliance Founders and S. Weir Mitchell Permanent Endowment.
Recipient: Aasef Shaikh, MD, PhD / Lakewood, OH
Impaired Motor Learning in a Disorder of the Inferior
Olive: Is the Cerebellum Confused?
S7: Movement Disorders: Genetics
Tuesday, April 21, 1:00 p.m.
S. Weir Mitchell Award
Sponsored by the American Brain Foundation and endowed by the
Alliance Founders and S. Weir Mitchell Permanent Endowment.
Recipients:Isaac Marin-Valencia, MD / Dallas, TX
Acetate Metabolism Prevails Over Glucose Oxidation
in Brain PDH Deficiency
S25: General Neurology
Wednesday, April 22, 2:00 p.m.
A.B. Baker Award for Lifetime
Achievement in Neurologic Education
Funded by an endowment created by matching funds from the A.B.
Baker Family Trust and Novartis Pharmaceuticals.
Recipient: Eduardo E. Benarroch, MD, FAAN / Rochester, MN
C173: Clinical Reasoning: From a Novice to an Expert
Monday, April 20, 8:30 a.m.
AAN Award for Creative Expression
of Human Values in Neurology
Sponsored by the Neurology Ethics, Law, and Humanities Committee.
Recipient: Lealani Mae Y. Acosta, MD / Nashville, TN
Dreifuss-Penry Epilepsy Award
Sponsored by the American Academy of Neurology and endowed
by members of the AAN Epilepsy Section; Abbott Laboratories, Inc.;
Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.;
GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil
Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma.
John Dystel Prize for
Multiple Sclerosis Research
Presented by the American Academy of Neurology and the National
Multiple Sclerosis Society and made possible through a special
contribution from the John Dystel Multiple Sclerosis Research Fund
at the National Multiple Sclerosis Society.
Recipient: Alastair Compston, MBBS, PhD / Cambridge, UK
S20: Treatment Mechanisms in Multiple Sclerosis
Wednesday, April 22, 2:00 p.m.
Sheila Essey Award:
An Award for ALS Research
Presented by the American Academy of Neurology and the ALS
Association and supported through the philanthropy of the Essey
Family Fund and the ALS Association.
Recipient: Robert Bowser, PhD / Phoenix, AZ
Adriano Chio, MD, FAAN / Turin, Italy
S24: ALS: Mechanisms and Biomarkers
Wednesday, April 22, 2:00 p.m.
American Brain Foundation Chair’s Award
Sponsored by the American Brain Foundation.
Recipient: TBD
Norman Geschwind Prize
in Behavioral Neurology
Sponsored by the American Academy of Neurology and the AAN
Behavioral Neurology Section and endowed through Dr. Geschwind's
family, friends, and colleagues; Pfizer Inc; and the Society for
Behavioral and Cognitive Neurology.
Recipient: Andrew Kayser, MD, PhD / San Francisco, CA
S41: Aging, Dementia, Cognitive, and Behavioral
Neurology: Imaging: Aging and Alzheimer's Disease
Thursday, April 23, 1:00 p.m.
Recipient: Annapurna Poduri, MD, MPH / Boston, MA
S22: Epilepsy/Clinical Neurophysiology (EEG): Basic
Science and Intraoperative Monitoring
Wednesday, April 22, 2:00 p.m.
Fast, Easy, Online Registration · AAN.com/view/AM15
11
2O15 Award Recipients
Mitchell B. Max Award for Neuropathic Pain
Medical Student Essay Awards
Sponsored by the American Academy of Neurology and endowed by
the United States Cancer Pain Relief Committee, the Mayday Fund,
and friends of Dr. Mitchell Max.
Sponsored by the American Academy of Neurology.
Recipient: Robert Dworkin, PhD / Rochester, NY
S10: Pain and Palliative Care
Tuesday, April 21, 1:00 p.m.
Association of Indian Neurologists in
America (AINA) Lifetime Achievement Award
Endowed by the Association of Indian Neurologists of America (AINA).
Recipient: Pradeep K. Sahota, MD, FAAN / Columbia, MO
During the AINA Business Meeting
Tuesday, April 21, 7:15 p.m.
International Scholarship Award
Sponsored by the American Academy of Neurology
International Subcommittee.
Recipients:Mohammadkazem Bakhshandeh Bali / Tehran, Iran
Lucio D'Anna / Portogruaro, Italy
Hui-Fu Wang / Qingdao, China
Lei Chen / Chengdu, China
Antonella Macerollo / London, England
Charlotte Zerna / Dresden, Germany
Rebekah Ahmed / Sydney, Australia
Venugopalan Vishnu / Chandigarh, India
Chamroeun Hun / Phnom Penh, Cambodia
Manjunath Mahadevappa Poojar / Bangalore, India
Lucia Schottlaender / London, England
Ai Huey Tan / Cheras, Malaysia
Fatai Akemokwe / Benin City, Nigeria
International Experience
Sunday, April 19, 1:00 p.m.
Lawrence C. McHenry Award:
An Award for the History of Neurology
Sponsored by the American Academy of Neurology.
Recipient: Michel Shamy, MD, MA, FRCPC /
Ottawa, ON, Canada
Uncertainty, Bias and Assumption in
the Management of BSE, 1984-1996
S44: History of Neurology
Thursday, April 23, 1:00 p.m.
12
Extended Neuroscience Award
Recipient: Sara Shams / Stockholm, Sweden
Cerebrospinal Fluid Profiles with Cerebral
Microbleeds in Dementia
Poster Session II: P2.333
Tuesday, April 21, 7:30 a.m.
G. Milton Shy Award in Clinical Neurology
Recipient: Stuart McCarter / Minneapolis, MN
Diagnostic REM Sleep Muscle Activity Cutoff Values
for Idiopathic REM Sleep Behavior Disorder
Poster Session II: P2.334
Tuesday, April 21, 7:30 a.m.
Roland P. Mackay Award in Historical Aspects
Recipient: Travis Urban / Galveston, TX
Charcot's Pupils: A Legacy of Charcot's Abilities
as Teacher and Mentor
Poster Session II: P2.335
Tuesday, April 21, 7:30 a.m.
Saul R. Korey Award in Experimental Neurology
Recipient: David Fischer / Boston, MA
The Neuroanatomical Basis of Coma in Humans:
Using Functional Connectivity to Assess the Network
Effects of Brainstem Lesions
Poster Session II: P2.336
Tuesday, April 21, 7:30 a.m.
Minority Scholars Program
Sponsored by a grant from the Allergan Foundation.
Recipients: Carlos Eduardo Estrada Alamo /
Harvard Medical School
Jorge Torres /
The David Geffen School of Medicine, UCLA
Mehida Alexandre / Yale School of Medicine
Duriel Hardy / Duke University School of
Medicine
Emmanuel J. Perez /
University of Miami Miller School of Medicine
Paola Mendez-Gomez /
University of Texas Health Science Center,
San Antonio, Texas
Peter Hadar / Perelman School of Medicine,
University of Pennsylvania
Michael Gonzaga / Meharry Medical College
Shamelia Loiseau /
University of Rochester School of Medicine
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
I can
feel good about being a part
of a single-minded team of
ed
em ployees, all equally committ
to the quality of our products,
no matter where in the world
they are made.
I can…
because
Mylan’s priority is to meet or
exceed industry standards.
Our own teams conduct ongoing
reviews to help assure quality
and integrity of products, start
to finish, and strive to continually
improve for optimal quality
and consistency.
Everyone at Mylan has the same
priority: you.
Visit Mylan.com
Veronique
Mylan Senior Plant Director
See what we have to offer at
the 2015 AAN Annual Meeting
this April—Booth #1529
©2015 Mylan Inc. All rights reserved. NON-2015-0005
2O15 Award Recipients
Adys Mendizabal /
Temple University School of Medicine
David Mendez / UT Southwestern
Stefanie Gopaul / Charles R. Drew University,
David Geffen School of Medicine, UCLA
Roger Murayi / Perelman School of Medicine,
University of Pennsylvania
Victoria Adeseye / University of Texas Health
Science Center at Houston
Necrisha Roach/ The Ohio State University
College of Medicine
Movement Disorders Research Award
Sponsored by the American Academy of Neurology, the Parkinson's
Disease Foundation, and the AAN Movement Disorders Section and
endowed by the Parkinson's Disease Foundation.
Recipient: Christopher Goetz, MD, FAAN / Chicago, IL
S40: Movement Disorders: Functional Imaging
in Parkinson's Disease
Thursday, April 23, 1:00 p.m.
Neuro-oncology Investigator Award
Sponsored by the American Academy of Neurology and the
AAN Neuro-oncology Section and supported by friends of Dr. Jerome
Posner.
Recipient: Elizabeth Gerstner, MD, MS / Boston, MA
S18: Neuro-oncology: Imaging and Quality of Life
Tuesday, April 21, 3:15 p.m.
Neuroscience Research Prize
Sponsored by the American Academy of Neurology and the Child
Neurology Society.
Recipients:Yinge Zhao / Rego Park, NY
Lauren Houle / Boca Raton, FL
Monica Lee / Albertson, NY
Poster Session III: P3.320–P3.322
Tuesday, April 21, 2:00 p.m.
Child Neurology Neuroscience
Research Prize
Sponsored by the American Academy of Neurology and the Child
Neurology Society.
Recipient: Amrita Mohanty / Woodbury, MN
Note: The recipient will attend the 44th Child Neurology Society
Annual Meeting in Washington, DC
Palatucci Advocacy Leadership Forum
Advocate of the Year
Sponsored by the AAN Government Relations Committee.
Recipient: Javier Cardenas, MD / Phoenix, AZ
Michael S. Pessin Stroke Leadership Prize
Sponsored by the American Academy of Neurology and endowed by
Dr. Pessin's family, friends, and colleagues.
Recipient: Lauren Sansing, MD, MS / New Haven, CT
S13: Cerebrovascular Disease and Interventional
Neurology: Epidemiology and Risk Factors
Tuesday, April 21, 3:15 p.m.
Potamkin Prize for Research in Pick’s,
Alzheimer’s, and Related Diseases
Sponsored by the American Academy of Neurology, the American
Brain Foundation, and funded through the philanthropy of the
Potamkin Family.
Recipients:Reisa Sperling, MD / Boston, MA
Peter Davies, PhD / New York, NY
S8: Aging, Dementia, Cognitive, and Behavioral
Neurology: Basic Science
Tuesday, April 21, 1:00 p.m.
Donn Dexter, MD, FAAN, Eau Claire, WI
2014 Palatucci Advocacy Leadership Forum Advocate of the Year Recipient
“It’s an honor to be selected. The training I received has allowed me to
become a much better advocate for my patients, practice, profession,
and community. It also dramatically revitalized my career and served to
inspire me in a way I haven’t experienced since my residency. Another
fantastic feature is meeting a group of passionate, intelligent, and
committed neurologists who will continue to inspire and motivate me.”
14
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
COME VISIT OUR BOOTH!
Learn more
about APTIOM
at Booth 1929
Under license from
is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc., is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
©2015 Sunovion Pharmaceuticals Inc. All rights reserved. 2/15 APT053-15
2O15 Award Recipients
American Academy of Neurology
President’s Award
Sleep Science Award
Sponsored by the American Academy of Neurology and the AAN
Sleep Section and endowed by Cephalon, Inc.
Sponsored by the American Academy of Neurology.
Recipient: Thomas Scammell, MD / Boston, MA
S53: Sleep
Thursday, April 23, 3:30 p.m.
Recipient: John C. Mazziotta, MD, PhD, FAAN /
Los Angeles, CA
Neuroendocrine Research Award
Sponsored by the American Academy of Neurology and supported by
friends of Dr. Andrew Herzog.
Recipient: Michael Rogawski, MD, PhD / Sacramento, CA
Presented at the Neuroendocrinology Section meeting
Bruce S. Schoenberg International
Award in Neuroepidemiology
Endowed by GlaxoSmithKline, Inc.
Recipient: Stojan Peric, MD, PhD / Belgrade, Serbia
Clinical and Epidemiological Features of GuillainBarre Syndrome in the Western Balkans
S45: Neuroepidemiology: Multiple Sclerosis,
Cerebrovascular, and Aging
Thursday, April 23, 1:00 p.m.
Jon Stolk Award in Movement Disorders
for Young Investigators
Sponsored by the American Academy of Neurology and endowed by
Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, and Dr.
Dennis Gillings.
Recipient: Allison Willis, MD, MS / Philadelphia, PA
S48: Parkinson's Disease
Thursday, April 23, 3:15 p.m.
Safety and Quality Award
Recipient: TBD
Harold Wolff-John Graham: An Award
for Headache/Facial Pain Research
Sponsored by the American Academy of Neurology and endowed by
Endo Pharmaceuticals.
Recipient: Henrik Schytz, MD, PhD / Glostrup, Denmark
S51: Headache: Epidemiology and Clinical
Thursday, April 23, 3:15 p.m.
Kenneth M. Viste Jr., MD Patient
Advocate of the Year Award
Endowed by gifts from Dr. Viste’s colleagues, friends, and patients.
Recipient: Ira Shoulson, MD, FAAN / Washington, DC
H. Richard Tyler Award
Sponsored by the American Academy of Neurology and the AAN
Archive Committee.
Recipient: Adolfo Ramirez Zamora, MD / Albany, NY
General History Section Meeting
Tuesday, April 21, 12:00 p.m.
Wayne A. Hening
Sleep Medicine Investigator Award
Sponsored by the American Academy of Neurology and endowed by
UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh
Neurology Associates, and friends of Dr. Wayne A. Hening.
Recipient: Mark Wu, MD, PhD / Baltimore, MD
S53: Sleep
Thursday, April 23, 3:15 p.m.
Aleksandar Videnovic, MD, MSc, Boston, MA
2014 Wayne A. Hening Sleep Medicine Investigator Award Recipient
“I am indebted to many colleagues for their support and counsel.
Special gratitude goes to Drs. Christopher Goetz, Phyllis Zee, and Cynthia
Comella whose work motivated me to pursue a career in academic
neurology and influenced my research directions. Their support became
fundamental for my development as a clinician scientist.”
16
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
2O15 Research Fellowships
Clinical Research Training Fellowships
Sponsored by the American Academy of Neurology,
the American Brain Foundation, and TEVA CNS.
Recipients:Felicia Chow, MD
University of California, San Francisco
Albert Davis, MD
Washington University in St. Louis
Gregory Day, MD, MSc
Washington University in St. Louis
Clinical Research Training Fellowship
in the Neurological Application
of Neurotoxins
Funded by the Allergan Foundation.
Recipients:Wei Hu, MD, PhD
University of Florida
David Schmerler, DO
University of Cincinnati
Corey Fehnel, MD
Rhode Island Hospital/Brown University
Clinical Research Training Fellowship
in ALS Research
Carolyn Fredericks, MD
University of California, San Francisco
Sponsored by the American Academy of Neurology, the
American Brain Foundation and the ALS Association.
Emily Gilmore, MD
Yale University
Todd Herrington, MD
Massachusetts General Hospital
Inge Meijer, MD
CHUSJ- Montreal University
Dona Murphey, MD
Baylor College of Medicine
Nigel Pedersen, MBBS
Beth Israel Deaconess Medical Center
William Renthal, MD
Harvard Medical School
Mathula Thangarajh, MD, PhD
Children's National Medical Center, Washington, DC
Susan S. Spencer Clinical Research
Training Fellowship in Epilepsy
Sponsored by the American Academy of Neurology, the
American Brain Foundation, the American Epilepsy Society, and
the Epilepsy Foundation.
Recipient: Leigh Sepeta, PhD
Children's National Medical Center
Practice Research Training Fellowship
Recipient: Hristelina Ilieva, MD
Johns Hopkins School of Medicine
Clinical Research Training Fellowship
in MS
Funded by Genzyme, a Sanofi Company.
Recipient: Vanessa Beynon, MD
Brigham and Women's Hospital
Clinician-Scientist Development Award in
Multiple Sclerosis
Cosponsored by the American Academy of Neurology, the American
Brain Foundation and the National MS Society.
Recipient: Michael Kornberg, MD, PhD
Johns Hopkins School of Medicine
Lawrence M. Brass, MD, Stroke Research
Fellowship
Sponsored by the American Academy of Neurology, the American
Brain Foundation and the American Heart Association/American
Stroke Association.
Recipient: Sunil Sheth, MD
University of California, Los Angeles, CA
Sponsored by the American Academy of Neurology and
the American Brain Foundation.
Recipient: Benjamin Tolchin, MD
Brigham and Women's Hospital, Harvard Medical
School
Fast, Easy, Online Registration · AAN.com/view/AM15
17
Meeting at a Glance
Saturday April 18
Sunday April 19
6:00 a.m.
C22–C25
6:30 a.m.–8:00 a.m.
7:00 a.m.
8:00 a.m.
C1
C2–C7 I1
C8
C9
C26–27 C170
8:00 a.m.–
11:00 a.m.
8:00 a.m.–
12:00 p.m.
8:00 a.m.–
4:00 p.m.
8:00 a.m.–
5:00 p.m.
8:00 a.m.–
11:00 a.m.
Integrated
Neuroscience
C28–34 I3
8:00 a.m.–
Integrated
8:00 a.m.–
12:00 p.m.
12:00 p.m.
8:00 a.m.–12:00 p.m.
9:00 a.m.
C35–38
Neuroscience
8:00 a.m.–
5:00 p.m.
8:00 a.m.–12:00 p.m.
C171
8:30 a.m.–12:00 p.m.
C39
9:00 a.m.–5:00 p.m. (must apply)
10:00 a.m.
C40–C41
10:00 a.m.–12:00 p.m.
11:00 a.m.
12:00 p.m.
OPEN HOUR 12:00 p.m.–1:00 p.m.
1:00 p.m.
C10–16
1:00 p.m.–5:00 p.m.
2:00 p.m.
3:00 p.m.
I2
OPEN HOUR 12:00 p.m.–1:00 p.m.
S1
Integrated
Neuroscience
Section Topic
Controversies
1:00 p.m.–5:00 p.m.
1:00 p.m.–2:30 p.m.
C17–21
C53–54
3:00 p.m.–5:00 p.m.
3:00 p.m.–5:00 p.m.
C42
C43
1:00 p.m.–
4:00 p.m
1:00 p.m.– 1:00 p.m.–
4:00 p.m
5:00 p.m.
C172
C44–
52
1:00 p.m.–
5:00 p.m.
4:00 p.m.
5:00 p.m.
6:00 p.m.
Capitol City Celebration
6:00 p.m.–10:00 p.m.
7:00 p.m.
8:00 p.m.
18
I4
Integrated
Neuroscience
1:00 p.m.–5:00 p.m.
Monday April 20
Tuesday April 21
C55–C58
C59
C60
C88–C93
Run/Walk for Brain Research
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:00 a.m. 6:30 a.m.–8:30 a.m.
(registration
required)
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:30 a.m.
State Society
Leadership
Roundtable
P2
7:00 a.m.–8:30 a.m.
Poster
Session II
AAN Business Mtg
8:00 a.m.–8:30 a.m.
7:30 a.m.–12:00 p.m.
C61–62
C63–71
8:00 a.m.–11:00 a.m.
8:00 a.m.–12:00 p.m.
C76
I5
Integrated
Neuroscience
C72–75
8:00 a.m.–5:00 p.m.
C173
8:30 a.m.–12:00 p.m.
Presidential
Plenary Session
8:00 a.m.–12:00 p.m.
9:00 a.m.–5:00 p.m.
(must apply)
9:00 a.m.–12:00 p.m.
C77
10:00 a.m.–12:00 p.m.
Exhibit Hall
11:30 a.m.–5:00 p.m.
OPEN HOUR
12:00 p.m.–1:00 p.m.
OPEN HOUR 12:00 p.m.–1:00 p.m.
S2
Section Topic
Controversies
1:00 p.m.–2:30 p.m.
C174
C78–86
1:00 p.m.–5:00 p.m.
1:00 p.m.–5:00 p.m.
AAN/ABPN
MOC
Information
Session
Integrated
Neuroscience
I6
S3
Scientific Invited C94
Section Topic Platform Science: 1:00 p.m.–
4:00 p.m.
Controversies Sessions Stroke
1:00 p.m.–5:00 p.m.
1:00 p.m.–2:30 p.m.
C175
2:00 p.m.–4:30 p.m.
1:30 p.m.–3:00 p.m.
P1
P3
2:00 p.m.–6:30 p.m.
2:00 p.m.–6:30 p.m.
Poster
Session I
1:00 p.m.–
2:45 p.m.
1:00 p.m.–
2:45 p.m.
C95
–99
1:00 p.m.–
5:00 p.m.
I7–8
Integrated
Neuroscience
1:00 p.m.–5:00 p.m.
Poster
Session III
Scientific
Platform
Sessions
3:15 p.m.–
5:00 p.m.
Exhibit Hall
Opening
Reception
4:30 p.m.–6:30 p.m.
Hot Topics Plenary Session
Hot Topics
in Education
5:30 p.m.–6:45 p.m.
5:30 p.m.–6:30 p.m.
Paid Programs/Events
Residents and Fellows
Career Forum and Reception
6:30 p.m.–9:00 p.m.
Industry
Therapeutic Updates
7:00 p.m.–10:00 p.m.
Programs/Events Included
with Registration
Additional Events
19
Meeting at a Glance
Wednesday April 22
Thursday April 23
6:00 a.m.
7:00 a.m.
8:00 a.m.
C100–C106
C113–C118
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:00 a.m.
P4
Poster
Session IV
P6
Poster
Session VI
7:30 a.m.–12:00 p.m.
7:30 a.m.–12:00 p.m.
9:00 a.m.
Contemporary Clinical
Issues Plenary Session
Frontiers in Neuroscience
Plenary Session
9:00 a.m.–12:00 p.m.
9:00 a.m.–12:00 p.m.
10:00 a.m.
11:00 a.m.
Exhibit Hall
12:00 p.m.
Exhibit Hall
11:30 a.m.–5:00 p.m.
OPEN
HOUR
11:30 a.m.–3:00 p.m.
Awards Luncheon
OPEN HOUR
12:00 p.m.–1:00 p.m.
12:00 p.m.–1:30 p.m.
1:00 p.m.
2:00 p.m.
3:00 p.m.
Scientific
Platform
Sessions
Scientific
Platform
Sessions
C107–112
2:00 p.m.–6:00 p.m.
2:00 p.m.–3:45 p.m.
I9–10
P5
2:00 p.m.–6:00 p.m.
2:00 p.m.–6:30 p.m.
Integrated
Neuroscience
Poster
Session V
1:00 p.m.–
2:45 p.m.
Invited Science: C119–124
Epilepsy
1:00 p.m.–5:00 p.m.
1:00 p.m.–2:45 p.m.
I11–12
Integrated
Neuroscience
1:00 p.m.–5:00 p.m.
P7
Poster
Session VII
2:00 p.m.–6:30 p.m.
Scientific
Platform
Sessions
4:00 p.m.
3:15 p.m.–5:00 p.m.
Platform Blitz
Sessions
4:00 p.m.–5:45 p.m.
5:00 p.m.
Highlights in
the Field Sessions
6:00 p.m.
Emerging
Science
7:00 p.m.
Highlights in
the Field Sessions
6:00 p.m.–7:00 p.m.
6:15 p.m.–7:45 p.m.
Industry
Therapeutic Updates
7:00 p.m.–10:00 p.m.
8:00 p.m.
20
5:30 p.m.–6:30 p.m.
Controversies in
Neuroscience
Plenary Session
5:30 p.m.–7:00 p.m.
C125–130
6:00 p.m.–9:00 p.m.
Friday April 24
Saturday April 25
C131–C135
C154–C158
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:00 a.m.
C136–140
C141–147
C159
C160–166
8:00 a.m.–12:00 p.m.
8:00 a.m.–4:00 p.m.
8:00 a.m.–11:00 a.m.
8:00 a.m.–12:00 p.m.
C167–169
10:00 a.m.–12:00 p.m.
Clinical Trials
Plenary Session
12:00 p.m.–1:30 p.m.
C148
C149–153
1:00 p.m.–3:00 p.m.
1:00 p.m.–4:00 p.m.
OPEN HOUR
12:00 p.m.–1:00 p.m.
Neurology Year in Review
Plenary Session
4:30 p.m.–6:00 p.m.
Closing Party
6:00 p.m.–8:00 p.m.
Celebrate the end of a great meeting at a
special early-evening happy hour event!
¡ Enjoy music, drinks, and socializing
with colleagues
¡ Make plans to explore beautiful
Washington, DC, afterwards
Paid Programs/Events
Programs/Events Included
with Registration
Additional Events
21
I I Talks Schedule
Saturday, April 18
Sunday, April 19
7:00 a.m.
Monday, April 20
Leadership Meeting
7:00 a.m.–8:00 a.m.
8:00 a.m.
9:00 a.m.
Creating Innovative, Interactive
Teaching Modules
8:00 a.m.–8:30 a.m.
AAN Business Meeting
The Business of Neurology
Is AAN Member Participation
in Physician-assisted Suicide Ethical?
9:00 a.m.–11:00 a.m.
Hosted by the Business and Research Administrators in
Neurology Society, this two-hour interactive session will
facilitate discussions on how to most effectively
incorporate Advance Practice Providers in your practice.
Speakers will also assist attendees in deciphering quality
metrics, explain how it can be used to your benefit when
negotiating with payers.
10:00 a.m.
11:00 a.m.
8:00 a.m.–8:30 a.m.
9:00 a.m.–10:30 a.m.
Will address the definition, ethical framework, and
current legal landscape of Physician-assisted Suicide.
Presented by the Ethics, Law and Humanities Committee.
Neuroexam:
Learn from the Experts
Neurology Jeopardy: Things You May
Not Know About Publishing in the
Journal or Its Spin-Offs
12:00 p.m.
11:30 a.m.–12:30 p.m.
1:00 p.m.
Annual Meeting Orientation Session
11:00 a.m.–1:00 p.m.
1:00 p.m.–1:30 p.m.
Conquering ICD-10
2:00 p.m.
3:00 p.m.
4:00 p.m.
5:00 p.m.
Providing
High Value Neurologic Care
Webs, Apps, and Social Media:
There’s the AAN for That!
3:00 p.m.–5:00 p.m.
Interactive session will help attendees learn:
¡ How use the AAN Annual Meeting app
¡ What a QR code is, how to use a QR
code to download content
¡ How to set up a social media app and
why some physicians find it useful
¡ How to use the Neurology ® app
for tablet devices
2:00 p.m.–4:00 p.m.
This two-hour session will highlight findings from the
AAN’s recent studies in the value of neurology; learn how
neurologists are succeeding in transitioning to high
quality, lower cost care; and strategize for the future of
health care payment and delivery.
1:30 p.m.–3:30 p.m.
As of October 1, 2015, the ICD-10 code set will be
required for all transactions involving reimbursement from
the Center for Medicare and Medicaid Services, as well
as third-party payers. This session will address the
importance of ICD-10, coding basics for the most common
neurologic disorders, electronic resources, and
preparation of office business procedures to
accommodate ICD 10.
AAN’s Axon Registry:
Data Powering Neurology’s Future
Quality in Neurology—
Can We Measure and Improve It?
4:00 p.m.–5:00 p.m.
An overview of the AAN’s new registry, including its value
to members, value to the AAN, timeline, and next steps.
4:30 p.m.–5:30 p.m.
An explaination of quality measures, how data and
measures can drive improvement in practice.
Hot Topics in Education:
The Value of a Neurologist
6:00 p.m.
5:30 p.m.–6:30 p.m.
7:00 p.m.
22
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
The Innovation Room is your destination for a lively, supplemental new Annual Meeting
learning experience through a variety of lectures, presentations, group discussions, and
hands-on activities using advanced media formats that bring learning to life!
Tuesday, April 21
Wednesday, April 22
Thursday, April 23 and Friday, April 24
Additional information will be made available
as more sessions are developed and added.
Keep a watch online for more exciting content.
Annual Meeting Orientation Session
8:00 a.m.–8:30 a.m.
Check back often at AAN.com/view/ITalk
for schedule updates!
Plenary Session
Plenary Session
Plenary Session
Policy and Advocacy Hour
with the GRC
Neurology Compensation and Productivity
Survey and Dashboard Report
AAN’s Axon Registry:
Data Powering Neurology’s Future
12:00 p.m.–1:00 p.m.
Find out what the Government Relations Committee is
doing for AAN members and how to get involved.
12:00 p.m.–1:00 p.m.
Learn about the only survey and report dedicated
solely to neurology compensation and productivity.
12:00 p.m.–1:00 p.m.
An overview of the AAN’s new registry, including its value
to members, value to the AAN, timeline, and next steps.
Case Report 2.0:
Implementing the "CARE" Guidelines
How to Avoid “Death by PowerPoint”
and Workshop
1:30 p.m.–3:30 p.m.
Editors of the journal Neurology will provide didactic
teaching about journal writing, the CARE guidelines, and
the editorial process, as well as a practical hands-on
workshop on the writing of a case report. Attendees will
be expected to bring a case with them, and editorial team
members will assist attendees in the crafting of a case
report worthy of submission to a journal. The course will
be appropriate for residents, fellows, and others who will
be writing case reports for publication.
1:30 p.m.–3:30 p.m.
Explore basic guidelines on how to effectively use
PowerPoint as a tool to enhance learning. Using an
interactive and engaging teaching format called
write/think-pair-share, where participants are asked
to engage with the person sitting next to them every
10 minutes throughout the presentation, the program
will cover general principles, things to avoid, and
best practices.
AAN Digital Scavenger Hunt
1:30 p.m.–2:30 p.m.
Your Abstract Has Been Accepted: Now
What? Tips for a Successful Presentation
3:00 p.m.–3:45 p.m.
How to Hug a Porcupine:
Relationship Building with Congress
and Why It’s Important
Your Abstract Has Been Accepted:
Now What? Working with the Media
4:00 p.m.–4:45 p.m.
4:00 p.m.–5:00 p.m.
Your Abstract Has Been Accepted:
Now What? Part I
5:30 p.m.–6:15 p.m.
23
NEW
Three Registration
Packages Available
Choose the one that works best for you!
• Meeting Registration with education courses available for additional fees.
• Silver Registration Package includes meeting registration plus full access to the
2015 Annual Meeting education program.*
•
Gold Registration Package and BEST VALUE!
Get full access to the 2015 Annual Meeting education program,* plus
Annual Meeting On Demand, the digital library of the Annual Meeting.
Gold Registration Package offers:
•
Flexibility: Attend sessions in-person or on demand
•
Access to the syllabi summaries of more than 160 programs
•
Ultimate CME earning power: Earn CME during the meeting or afterwards via
Annual Meeting On Demand!
Register Today at AAN.com/view/AM15
*Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and
Gold Registration Package pricing. Attendee must identify courses to be included as
part of Silver and Gold Registration Package. Courses are subject to closure due to
reaching maximum capacity. Attendee is only permitted to select courses that
he/she plans to be in the room for. Attendee will not be able to register for courses
with conflicting time schedules.
Understanding the Program Listings
To help simplify the Annual Meeting, all education programs are labeled as courses regardless of day
or time offered or duration of program.
Program Types
C
I
P
S
New Course Feature Icons
Course
Integrated Neuroscience Session
(scientific session combining invited speakers,
data blitz presentations, and poster discussion;
included with meeting registration)
Poster Session (a hall of posters on a
variety of topics)
F The program is included with your registration
$ A registration fee is required
I The program is an I Talk and included with
registration
LThe program is one of the AAN
Leadership Development sessions
AThe course is part of the
Scientific Platform Session
(didactic session featuring abstracts)
Advanced Practice Provider track
CThe program is part of the Clinical Research track
SThe program is part of a Subspecialty in
Focus track
Program Tracks
To assist in your course planning, we’ve designed program tracks consisting of pre-selected courses of interest
geared toward advanced practice providers, academic neurologists, or those with subspecialty interests. Refer
to the Meeting Program Schedule for specific times.
Advance Practice Provider Track
Clinical Research Track
Subspecialty in Focus Tracks
The APP track consists of
suggested courses for neurologic
advanced practice providers to
provide a “deep dive” into
general neurology.
This track offers suggested
programs geared toward
academic neurologists early in the
development of a clinical research
career or who are considering one.
The Subspecialty in Focus Track
is a series of six special, intensive
topic-specific tracks designed
for subspecialists, combining
an education course with an
Integrated Neuroscience Session.
AC5 Resident Basic Science I:
Neuropathology
AC13 Resident Basic Science II:
Neuroanatomy
AC30 Resident Basic Science III:
Neuropharmacology
AC37 Neurology Update I AC38 Genetics in Neurology
AC43 Advanced Practice Provider
Symposium
AC68 Neuroimaging for the
General Neurologist: Brain
AC124 Neuroimaging for the
General Neurologist: Spine and
Peripheral Nerve
AC143 Neurology Update II
CC9 Research Career
Development Symposium: How
to Be Successful in Academic
Neuroscience
CC170 Clinical Research:
Introductions and Methods
SCerebrovascular Disease
Includes: C7 and I2
SNeuro-ophthalmology/
Neuro-otology
Includes: C16 and I1
CC172 Clinical Research: Drug
SMovement Disorders
CFutures in Clinical Research
SNeuro-infectious Disease/
CFutures in Clinical Research
SChild Neurology/
CI10 The Dynamic Brain in
SEpilepsy
Development and Clinical Trials
Luncheon
April 20, 12:00 p.m.–2:00 p.m.
Luncheon Mentoring Sessions
April 21, 12:00 p.m.–2:00 p.m.
Health and Disease: Plasticity
and Reprogramming
Includes: C52 and I3
Neuro-oncology
Includes: C28 and I4
Sports Neurology
Includes: C83 and I5
Includes: C63 and I6
CI11 The Promise of Novel
Biomarker Approaches in
Advancing Treatment
Fast, Easy, Online Registration · AAN.com/view/AM15
25
Scientific Session Schedule
Saturday, April 18, 2015
8:00 a.m.–12:00 p.m.
New Windows into the Brain:
FI1
Technological Advances in Frontline Neurologic
Diagnosis via the Visual and Oculomotor Systems . . . 48
S
1:00 p.m.–5:00 p.m.
Management of Asymptomatic
FI2
Cerebrovascular Lesions . . . . . . . . . . . . . . . . . 49
S
Sunday, April 19, 2015
8:00 a.m.–12:00 p.m.
Dopamine-mediated Neural Plasticity in Motor and
FI3
Non-motor Circuits . . . . . . . . . . . . . . . . . . . . 50
S
1:00 p.m.–2:30 p.m.
FS1 Section Topic Controversies: Antiplatelets,
Anticoagulants, or Stenting for Acute Treatment of
Cervical/Cranial Dissection? . . . . . . . . . . . . . . . 51
1:00 p.m.–5:00 p.m.
Infectious, Paraneoplastic, and Autoimmune
FI4
Encephalopathies: Advances in Clinical Diagnosis
and Emerging Insights about Pathogenesis . . . . . . . 52
S
Monday, April 20, 2015
8:00 a.m.–12:00 p.m.
Pediatric Neurotrauma:
FI5
From Coma to Concussions . . . . . . . . . . . . . . . 53
S
1:00 p.m.–2:30 p.m.
FS2 Section Topic Controversies: Testing in Prodromal
Neurological Disease: Friend or Foe? . . . . . . . . . . 54
1:00 p.m.–5:00 p.m.
Future Therapies: How We Will Be Treating,
FI6
Preventing, and Curing Epilepsy in the Year 2025 . . . 55
S
2:00 p.m.–6:30 p.m.
FP1 Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Tuesday, April 21, 2015
7:30 a.m.–12:00 p.m.
FP2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
9:00 a.m.–12:00 p.m.
FPresidential Plenary Session . . . . . . . . . . . . . . . . 33
1:00 p.m.–2:30 p.m.
FS3 Section Topic Controversies: Should All Brain Tumor
Patients Receive Prophylactic Antiepileptic Drugs? . . 73
26
F = Included with registration
$ = Registration fee required
I = I Talk Session
1:00 p.m.–2:45 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . . 74
S4 Clinical Trial Outcomes in Multiple Sclerosis
S5 Cerebrovascular Disease and Interventional
Neurology: Recovery and Outcome
S6 Epilepsy/Clinical Neurophysiology (EEG):
Health Services and Women’s Issues
S7 Movement Disorders: Genetics
¡
Presentation of the Founders Award
S8 Aging, Dementia, Cognitive, and
Behavioral Neurology: Basic Science
¡
Presentation of the Potamkin Prize for Research in
Pick’s, Alzheimer’s Disease, and Related Diseases
S9 General Neurology: Neurological
Treatments and Therapeutics
S10 Pain and Palliative Care
¡
Presentation of the Mitchell B. Max Award
for Neuropathic Pain
S11 Practice, Policy, and Ethics
1:00 p.m.–2:45 p.m.
Invited Science: Stroke F
. . . . . . . . 75
1:00 p.m.–5:00 p.m.
FI7 The Global Burden of Neurological Infections:
Epidemiology, Treatment, and Prevention . . . . . . . . 76
FI8 Advances in ALS and Other Motor Neuron Diseases . 77
2:00 p.m.–6:30 p.m.
FP3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
3:15 p.m.–5:00 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . . 86
S12 Neuroimmune Mechanisms in Multiple Sclerosis
S13 Cerebrovascular Disease and Interventional
Neurology: Epidemiology and Risk Factors
¡
Presentation of the Michael S. Pessin
Stroke Leadership Prize
S14 Epilepsy/Clinical Neurophysiology (EEG):
Clinical Epilepsy
S15 Movement Disorders: Huntington’s Disease,
Dystonia, and Atypical Parkinsonism
S16 Aging, Dementia, Cognitive, and
Behavioral Neurology: Clinical Science
S17 Muscle and Anterior Horn Cell Diseases:
Mechanisms and Biomarkers
S18 Neuro-oncology: Imaging and Quality of Life
¡
Presentation of the Neuro-oncology
Investigator Award
S19 Neurologic Education
5:30 p.m.–6:45 p.m.
FHot Topics Plenary Session . . . . . . . . . . . . . . . . . 34
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
Wednesday, April 22, 2015
7:30 a.m.–12:00 p.m.
FP4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
9:00 a.m.–12:00 p.m.
FContemporary Clinical Issues Plenary Session . . . . . . 35
2:00 p.m.–3:45 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . . 96
S20 Treatment Mechanisms in Multiple Sclerosis
¡
Presentation of the John Dystel Prize for Multiple
Sclerosis Research
S21 Cerebrovascular Disease and Interventional
Neurology: Prehospital and Acute Ischemic
Stroke Treatment
S22 Epilepsy/Clinical Neurophysiology (EEG):
Basic Science and Intraoperative Monitoring
¡
Presentation of the Dreifuss-Penry Epilepsy Award
S23 Headache: Epidemiology and Clinical
S24 ALS: Mechanisms and Biomarkers
¡
Presentation of the Sheila Essey Award: An Award
for ALS Research
S25 General Neurology
¡
Presentation of the S. Weir Mitchell Award
S26 Neuro-ophthalmology/Neuro-otology
S27 Neuro Trauma, Critical Care, and Sports Neurology
S28 Neuro-rehabilitation
2:00 p.m.–6:00 p.m.
FI9 Treating Dementia in an Age of Mixed Disease . . . . 98
The Dynamic Brain in Health and Disease:
FI10
Plasticity and Reprogramming . . . . . . . . . . . . . . 99
C
2:00 p.m.–6:30 p.m.
FP5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100
4:00 p.m.–5:45 p.m.
FPlatform Blitz Sessions . . . . . . . . . . . . . . . . . . . . 108
S29 Neuroimaging Correlates in Multiple Sclerosis
S30 Cerebrovascular Disease and Interventional Neurology:
Diagnostics, Biomarkers, and Genetics
S31 Epilepsy/Clinical Neurophysiology (EEG):
Epilepsy Therapy
S32 Movement Disorders: Tremor, Ataxia, and More
S33 Aging, Dementia, Cognitive, and Behavioral
Neurology: Biomarkers and Pathology
S34 Neuromuscular Update
S35 Child Neurology and Developmental Neurology
S36 Neuroepidemiology: Movement Disorders,
ALS, and Aging
S37 Global Health and Infectious Disease
Fast, Easy, Online Registration · AAN.com/view/AM15
iPosters!
The virtual poster hall transforms your poster
hall into a mobile experience—both during the
Annual Meeting and after.
¡
Online, interactive, fully searchable
database
¡
5- to 7-minute audio author summaries
of poster
¡
Available for 6 months after the meeting
iPoster participation is subject to author
permissions
Sponsored by:
Scientific Session Schedule
6:00 p.m.–7:00 p.m.
FHighlights in the Field Sessions
H1 Sleep
H2 Movement Disorders
H3 Global Health
H4 Stroke and Vascular Neurology
H5 Multiple Sclerosis
H6 Sports Neurology
H7 Neuromuscular
H8 Clinical Neurophysiology and Autonomic
Nervous System
H9 Neuro-oncology
H10 Women’s Issues in Neurology
H11 Critical Care and Emergency Neurology
1:00 p.m.–5:00 p.m.
The Promise of Novel Biomarker Approaches in
FI11
Advancing Treatment . . . . . . . . . . . . . . . . . . 120
FI12 Obesity and Neurological Disorders . . . . . . . . . . 121
C
2:00 p.m.–6:30 p.m.
FP7 Poster Session VII . . . . . . . . . . . . . . . . . . . .122
6:15 p.m.–7:45 p.m.
Emerging Science . . . . . . . . . . . . . . . . . . . . . 22
F
Thursday, April 23, 2015
7:30 a.m.–12:00 p.m.
FP6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
9:00 a.m.–12:00 p.m.
FFrontiers in Neuroscience Plenary Session . . . . . . . . 36
1:00 p.m.–2:45 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . 118
S38 Diet and Hormonal Factors in Multiple Sclerosis
S39 Cerebrovascular Disease and Interventional
Neurology: Intracerebral Hemorrhage
S40 Movement Disorders: Functional Imaging
in Parkinson’s Disease
¡
Presentation of the Movement Disorders
Research Award
S41 Aging, Dementia, Cognitive, and Behavioral
Neurology: Imaging: Aging and Alzheimer’s Disease
¡
Presentation of the Norman Geschwind Prize
in Behavioral Neurology
S42 New Developments in Peripheral Neuropathies
S43 Neuro-oncology: Basic Science and Clinical Trials
S44 History of Neurology
¡
Presentation of the Lawrence C. McHenry Award:
An Award for the History of Neurology
S45 Neuroepidemiology: Multiple Sclerosis,
Cerebrovascular, and Aging
¡
Presentation of the Bruce S. Schoenberg
International Award in Neuroepidemiology
1:00 p.m.–2:45 p.m.
Invited Science: Epilepsy F
28
����������� 119
3:15 p.m.–5:00 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . 132
S46 Neuromyelitis Optica
S47 Cerebrovascular Disease and
Interventional Neurology
S48 Parkinson’s Disease
¡
Presentation of the John Stolk Award in Movement
Disorders for Young Investigator
S49 Aging, Dementia, Cognitive, and Behavioral
Neurology: Imaging: Behavioral Neurology and
Non-Alzheimer’s Disease Dementias
S50 Treatment Trials in Neuromuscular Diseases
S51 Headache: Imaging and Physiology
Presentation of the Harold Wolff-John Graham: An
¡
Award for Headache/Facial Pain Research
S52 General Neurology: Neural Networks and
Neuromodulation
S53 Sleep
Presentation of the Sleep Science Award
¡
Presentation of the Wayne A. Hening Sleep
¡
Medicine Investigator Award
5:30 p.m.–6:30 p.m.
FHighlights in the Field Sessions
H12 Geriatric Neurology
H13 Neuro-ophthalmology and Neuro-otology
H14 Neural Repair and Rehabilitation
H15 Behavioral Neurology
H16 Neuroendocrinology
H17 Headache and Facial Pain
H18 Epilepsy
5:30 p.m.–7:00 p.m.
FControversies in Neurology Plenary Session . . . . . . 37
Friday, April 24, 2015
12:00 p.m.–1:30 p.m.
FClinical Trials Plenary Session . . . . . . . . . . . . . . . . 38
4:30 p.m.–6:00 p.m.
FNeurology Year in Review Plenary Session . . . . . . . . 39
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Annual Meeting App
Coming Soon
The Mobile App puts all the information you need
conveniently on your phone or tablet:
View your itinerary ¡
Find room locations ¡
Access program slides and syllabi ¡
More ¡
A LITE version is available now,
which allows you to browse
programs, speakers, and
convention details. Full version to
be available prior to the meeting.
Available for
®
iPhone , iPad , or Android
®
®
Supported by:
Annual Meeting Program Schedule
Saturday, April 18, 2015
Sunday, April 19, 2015
8:00 a.m.–11:00 a.m.
$C1 Status Epilepticus
6:30 a.m.–8:00 a.m.
$C22 Neuro Flash: Epilepsy
$C23 Neuro-oncologic Emergencies
$C24 Balance and Gait Disorders
$C25 Cognitive Psychology of Neurologic Errors: Chalk Talk
8:00 a.m.–12:00 p.m.
$C2 Small Fiber Neuropathies: Sensory, Autonomic, and Both
$C3 Deep Brain Stimulation Management
$C4 Neuromyelitis Optica: Scientific and Clinical Update
Resident Basic Science I: Neuropathology
$C5
C6
The
Practice
of Neurology: Issues in
$
Coding and Reimbursement
Current Management of Incidental and
$C7
Asymptomatic Cerebrovascular Lesions
New Windows into the Brain: Technological
FI1
Advances in Frontline Neurologic Diagnosis
via the Visual and Oculomotor Systems . . . . . . . . . 48
A
8:00 a.m.–8:30 a.m.
F
I Creating Innovative, Interactive
Teaching Modules . . . . . . . . . . . . . . . . . . . . 22
S
8:00 a.m.–11:00 a.m.
$C26 Controversies in Neuroethics
$C27 Controversies in Multiple Sclerosis Therapy
S
8:00 a.m.–4:00 p.m.
$C8 Clerkship and Program Directors Conference
8:00 a.m.–5:00 p.m.
Research Career Development Symposium:
$C9
How to Be Successful in Academic Neuroscience
C
C
S
A
1:00 p.m.–5:00 p.m.
$C10 Critical Care EEG Monitoring
$C11 Neuromuscular Junction Disorders
$C12 Neurologic Complications of Medical Disease
Resident Basic Science II: Neuroanatomy
$C13
$C14 Advanced Neurologic Coding
$C15 Severe TBI: From ICU to Rehabilitation
Pitfalls and Pearls: Avoiding Common Diagnostic
$C16
Errors in Neuro-ophthalmology and Neuro-otology
Management of Asymptomatic
FI2
Cerebrovascular Lesions . . . . . . . . . . . . . . . . . 49
A
S
S
3:00 p.m.–5:00 p.m.
F
I Webs, Apps, and Social Media:
There’s an AAN Tool for That! . . . . . . . . . . . . . . 22
$C17 The Neurology of Social Behavior
$C18 Therapy of Movement Disorders:
A Case-based Approach
$C19 Mitochondrial Disorders in Neurology
$C20 Canalith Repositioning for Benign
Paroxysmal Positional Vertigo
C21
Challenging Headache Cases
$
5:30 p.m.–7:30 p.m.
AUPN Clerkship Directors Workshop
F
8:00 a.m.–12:00 p.m.
Clinical Research: Introduction and Methods
FC170
Infectious, Paraneoplastic, Autoimmune?
$C28
Diagnosis and Treatment of Rapidly
Progressive Encephalopathies
$C29 Primer of Behavioral Neurology
Resident Basic Science III:
$C30
Neuropharmacology
$C31 Sports Concussion and Other Mild
Concussive Injuries
C32
Teleneurology and Technologies
$
$C33 Hot Topics in Sleep Neurology
$C34 Child Neurology I
Dopamine-mediated Neural Plasticity
FI3
in Motor and Non-motor Circuits . . . . . . . . . . . . 50
S
8:00 a.m.–5:00 p.m.
$C35 Clinical Epilepsy
$C36 Peripheral Neuropathy
Neurology Update I
$C37
Genetics in Neurology
$C38
A
A
8:30 a.m.–12:00 p.m.
FC171 Opioids and Marijuana in Your Practice
9:00 a.m.–11:00 a.m.
F
I The Business of Neurology . . . . . . . . . . . . . 22
9:00 a.m.–5:00 p.m.
C39
Leadership for Women (must apply)
L
10:00 a.m.–12:00 p.m.
$C40 You Make the Call—an Interactive, Multimedia,
Case-based Approach to Learning EMG
$C41 Therapy of Stroke
11:30 a.m.–12:30 p.m.
F
I Neurology Jeopardy: Things You May Not Know
About Publishing in the Journal or Its Spin-offs . . . . 22
30
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
I = I Talk Session
1:00 p.m.–1:30 p.m.
F
I Annual Meeting Orientation Session . . . . . . . . 22
1:00 p.m.–2:30 p.m.
FS1 Section Topic Controversies: Antiplatelets,
Anticoagulants, or Stenting for Acute
Treatment of Cervical/Cranial Dissection? . . . . . . . 51
1:00 p.m.–4:00 p.m.
$C42 Therapy of Headache
Advanced Practice Provider Symposium
FC43
(registration required)
A
1:00 p.m.–5:00 p.m.
Clinical Research: Drug Development
FC172
and Clinical Trials
$C44 Practical Psychopharmacology for Neurologists
$C45 Neuro-otology
$C46 Hot Topics in Headaches and Related Disorders
$C47 Sports Neurology: Non-concussion Overview
$C48 How to Run a Practice: Business Strategies
for Neurology Private Practices, Academic
Centers, and the Future
$C49 Approach to Sleep Symptoms: Sleepy or Sleepless
$C50 Child Neurology II
$C51 Diagnostic Dilemmas in Multiple Sclerosis
Dopaminergic and Nondopaminergic
$C52
Influences on the Changing Landscape of
Parkinson’s Disease
Infectious, Paraneoplastic, and Autoimmune
FI4
Encephalopathies: Advances in Clinical Diagnosis
and Emerging Insights about Pathogenesis . . . . . . . 52
C
S
S
2:00 p.m.–4:00 p.m.
F
I Providing High Value Neurologic Care . . . . . . . 22
3:00 p.m.–5:00 p.m.
$C53 Palliative Care for the Practicing Neurologist
$C54 Cognitive-motor Disorders: Chalk Talk
Meeting Attendee
Janice Wong, MD
Boston, MA
“For me, it’s learning
the research ideas for
the future. I’m a junior
resident, so I’m enjoying
all the sessions, especially
the genetic talks.”
Fast, Easy, Online Registration · AAN.com/view/AM15
4:30 p.m.–5:30 p.m.
F
I Quality in Neurology—Can We
Measure and Improve It? . . . . . . . . . . . . . . . . . 22
6:00 p.m.–10:00 p.m.
FCapitol City Celebration
Join your friends and colleagues for an exciting evening filled
with entertainment. Each registered attendee will receive one
free ticket to these events. Guest tickets are available through
registration for $50
Monday, April 20, 2015
6:30 a.m.–8:00 a.m.
$C55 Neuro Flash: Approach to Acute CNS Infections
$C56 Vascular Cognitive Impairment and Dementia:
Current Status and Future
$C57 Therapy of Epilepsy
$C58 Neurological Disorders of Famous Composers
FC59 Leadership in Neurology: Be a Champion for
Your Patients and Protector of Your Specialty
with Payers, Policymakers, and the Public
6:30 a.m.–8:30 a.m.
FC60 Resident and Fellow Career Breakfast:
The Early Years (registration required)
7:00 a.m.–8:00 a.m.
F
I Leadership Meeting . . . . . . . . . . . . . . . . . 22
7:00 a.m.–8:30 a.m.
State Society Leadership Roundtable
F
Leadership representatives of state neurological
societies are invited to discuss challenges, strategies,
and practices related to state society creation and
maintenance. Discussion will be facilitated by Academy
staff. Participants will learn from the experiences of
established societies and be introduced to the resources
available from the Academy.
8:00 a.m.–8:30 a.m.
FI AAN Business Meeting . . . . . . . . . . . . . . . . . . 22
A AN members are encouraged to attend and vote on the
proposed bylaws amendment as well as the slate of nominees
for AAN officer and director positions for the 2015-2017 term.
8:00 a.m.–11:00 a.m.
$C61 Clinical E-pearls
$C62 Interpretation of Polysomnography for the
Practicing Neurologist
8:00 a.m.–12:00 p.m.
Treating the New-onset Epilepsy Patient
$C63
$C64 Clinical EMG I
S
31
Annual Meeting Program Schedule
$C65 Botulinum Toxins: Practical Issues and Clinical
$C66
$C67
$C68
$C69
$C70
$C71
FI5
Uses for Neurologists
Multiple Sclerosis Overview I: Basic and
Translational Science
Infections of the Nervous System I:
Common Infections
Neuroimaging for the General
Neurologist: Brain
Introduction to Primary Headache Disorders
Bedside Evidence-based Medicine: How to
Find and Deconstruct Articles in Order to
Take Care of Patients
Neuro-oncology: Primary Brain Tumors
Pediatric Neurotrauma:
From Coma to Concussions . . . . . . . . . . . . . . . 53
A
S
8:00 a.m.–5:00 p.m.
$C72 Dementia Overview
$C73 Therapy in Neurology
$C74 Cerebrovascular Disease
$C75 Neurophysiologic Intraoperative
Monitoring Skills Workshop
9:00 a.m.–5:00 p.m.
C76
Advanced Leadership for Women (must apply)
L
10:00 a.m.–12:00 p.m.
$C77 Update on Ataxias
11:00 a.m.–1:00 p.m.
F
I Neuroexam: Learn from the Experts . . . . . . . . 22
1:00 p.m.–2:30 p.m.
FS2 Section Topic Controversies: Testing in Prodromal
Neurological Disease: Friend or Foe? . . . . . . . . . . 54
32
L
S
1:30 p.m.–3:00 p.m.
AAN/ABPN MOC Information Session
F
1:30 p.m.–3:30 p.m.
F
I Conquering ICD-10 . . . . . . . . . . . . . . . . . . 22
2:00 p.m.–4:30 p.m.
FC175 Qualitative Research: The “How” and “Why”
of Education
2:00 p.m.–6:30 p.m.
FP1 Poster Session I . . . . . . . . . . . . . . . . . . . . . 57
4:00 p.m.–6:45 p.m.
Student Interest Groups in Neurology (SIGN) Meeting
F
9:00 a.m.–10:30 a.m.
F
I Is AAN Member Participation in Physician-assisted
Suicide Ethical? . . . . . . . . . . . . . . . . . . . . . . 22
S
Treatment of Dystonia Skills Pavilion
Improving Your Leadership Skills:
$C86
A Practical Approach
Future Therapies: How We Will Be Treating,
FI6
Preventing, and Curing Epilepsy in the Year 2025 . . . 55
4:00 p.m.–5:00 p.m.
F
I AAN’s Axon Registry:
Data Powering Neurology’s Future . . . . . . . . . . . 22
8:30 a.m.–12:00 p.m.
FC173 Clinical Reasoning: From a Novice to an Expert
1:00 p.m.–5:00 p.m.
FC174 All You Need to Know About Health
Information Technology to Avoid Taking a HIT
$C78 Clinical EMG II
$C79 Overview of Parkinson’s Disease and
Movement Disorders
$C80 Multiple Sclerosis Overview II: Clinical Advances
$C81 Infections of the Nervous System II:
Advanced and Emerging Infections
$C82 Emergency Room Neuro-ophthalmology
Concussion Assessment and
$C83
Management in the Youth Athlete
$C84 Neurologic Complications of Systemic Cancer
$C85 Clinical Usefulness of Botulinum Toxin and
4:30 p.m.–6:30 p.m.
Exhibit Hall Opening Reception
F
5:00 p.m.–6:30 p.m.
Consortium of Neurology Residents and Fellows Meeting
F
5:30 p.m.–6:30 p.m.
F
I Hot Topics in Education: The Value of a Neurologist
6:30 p.m.–9:00 p.m.
Residents and Fellows Career Forum and Reception
F
Tuesday, April 21, 2015
6:30 a.m.–8:00 a.m.
$C88 Morning Report: Multiple Sclerosis
$C89 Now You See It, Now You Know It—Pathognomonic
Neuro-ophthalmology Findings
$C90 Approach to the Shaky Patient
$C91 Career Development for Clinician Educators
$C92 Important Drug Interactions for Neurologists and
Psychiatrists
$C93 Brain Computer Interfaces: Frontiers in Neurology
and Neuroscience
6:30 a.m.–8:30 a.m.
$2015 AAN Run/Walk for Brain Research . . . . . . . . . . . . . . . 136
7:30 a.m.–12:00 p.m.
FP2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
I = I Talk Session
9:00 a.m.–12:00 p.m.
FPresidential Plenary Session
Features the AAN’s premier lecture awards for clinically
relevant research and a presentation by a leading lecturer. Top
researchers speak on some of the most significant findings in
neurology in 2015.
Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, Science Committee
P residential Lecture
Timothy A. Pedley, MD, FAAN
Columbia University
New York, NY
. Houston Merritt Lecture
H
Advances in the World of Epilepsy: Really?!?!
Daniel H. Lowenstein, MD
University of California San Francisco
San Francisco, CA
George C. Cotzias Lecture
Endowed by Roche Pharmaceuticals.
Degenerative Ataxias: From Genes to Therapies
Stefan M. Pulst, MD, FAAN
University of Utah
Salt Lake City, UT
Sidney Carter Award in Child Neurology
Endowed by an Anonymous Donor.
Multiple Sclerosis in Children
Brenda Banwell, MD
Children’s Hospital of Philadelphia
Philadelphia, PA
Robert Wartenberg Lecture
What Has Deep Brain Stimulation Taught
Us About the Neurology of Depression?
Helen S. Mayberg, MD
Emory University School of Medicine
Atlanta, GA
11:30 a.m.–5:00 p.m.
Exhibit Hall
F
12:00 p.m.–1:00 p.m.
F
I Policy and Advocacy Hour with the GRC . . . . . . 22
1:00 p.m.–2:30 p.m.
FS3 Section Topic Controversies: Should All Brain Tumor
Patients Receive Prophylactic Antiepileptic Drugs? . . 73
Fast, Easy, Online Registration · AAN.com/view/AM15
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
1:00 p.m.–2:45 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . . 74
S4 Clinical Trial Outcomes in Multiple Sclerosis
S5 Cerebrovascular Disease and Interventional
Neurology: Recovery and Outcome
S6 Epilepsy/Clinical Neurophysiology (EEG):
Health Services and Women’s Issues
S7 Movement Disorders: Genetics
¡
Presentation of the Founders Award
S8 Aging, Dementia, Cognitive, and
Behavioral Neurology: Basic Science
¡
Presentation of the Potamkin Prize for Research in
Pick’s, Alzheimer’s Disease, and Related Diseases
S9 General Neurology: Neurological
Treatments and Therapeutics
S10 Pain and Palliative Care
¡
Presentation of the Mitchell B. Max Award
for Neuropathic Pain
S11 Practice, Policy, and Ethics
1:00 p.m.–2:45 p.m.
Invited Science: Stroke F
. . . . . . . . 75
1:00 p.m.–4:00 p.m.
$C94 EEG in Children: Developmental Maturation, Variants,
Epilepsy Syndromes, and Identification of Surgical Candidates
1:00 p.m.–5:00 p.m.
$C95 Sports Concussion Skills Pavilion
$C96 Evaluation and Management of Autonomic Disorders
$C97 Neurologic Issues in Pregnancy
$C98 Myelopathies
$C99 Neuro-ophthalmology and Neurovestibular
Exam Lab Skills Pavilion
FI7 The Global Burden of Neurological Infections:
Epidemiology, Treatment, and Prevention . . . . . . . . 76
FI8 Advances in ALS and Other Motor Neuron Diseases . 77
1:30 p.m.–3:30 p.m.
F
I Case Report 2.0:
Implementing the “CARE” Guidelines . . . . . . . . . . 22
2:00 p.m.–6:30 p.m.
FP3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
3:15 p.m.–5:00 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . . 86
S12 Neuroimmune Mechanisms in Multiple Sclerosis
S13 Cerebrovascular Disease and Interventional
Neurology: Epidemiology and Risk Factors
¡
Presentation of the Michael S. Pessin
Stroke Leadership Prize
S14 Epilepsy/Clinical Neurophysiology (EEG):
Clinical Epilepsy
S15 Movement Disorders: Huntington’s Disease,
Dystonia, and Atypical Parkinsonism
33
Annual Meeting Program Schedule
S16
Aging, Dementia, Cognitive, and
Behavioral Neurology: Clinical Science
S17 Muscle and Anterior Horn Cell Diseases:
Mechanisms and Biomarkers
S18 Neuro-oncology: Imaging and Quality of Life
¡
Presentation of the Neuro-oncology
Investigator Award
S19 Neurologic Education
7:00 p.m.–10:00 p.m.
F Industry Therapeutic Updates . . . . . . . . . . . . . . . . . . 131
Industry-sponsored, non-CME programs will be offered and are
open to attendees at no charge. They will provide an opportunity
for pharmaceutical companies, device companies, or other
neurologic-related organizations to share information regarding
their current therapies and projects in the pipeline in accordance
with standards set for industry by the FDA.
4:00 p.m.–5:00 p.m.
F
I How to Hug a Porcupine: Relationship
Building with Congress and Why It’s Important . . . . 22
5:30 p.m.–6:15 p.m.
F
I Your Abstract Has Been Accepted:
Now What? Part I . . . . . . . . . . . . . . . . . . . . 22
5:30 p.m.–6:45 p.m.
FHot Topics Plenary Session
Features translational research related to clinical issues of
importance. Five outstanding physician-scientists provide
summaries of their recent research findings and describe the
clinical implications of the results.
oderator: Randolph S. Marshall, MD, FAAN
M
Member, Science Committee
Wednesday, April 22, 2015
6:30 a.m.–8:00 a.m.
$C100 Mild Cognitive Impairment: Implications for Clinicians
$C101 Hyperkinetic Movement Disorders: Diagnosis and
Treatment
$C102 Syndromes of Autonomic Dysfunction in Children and
Adolescents
$C103 Global Health Challenges: Neurology in Developing
Countries
$C104 Pseudotumor Cerebri
$C105 Neurohospitalist 2.0: Next Steps in the Evolution
$C106 Neuro Flash: Acute Stroke Management
7:30 a.m.–12:00 p.m.
FP4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
8:00 a.m.–8:30 a.m.
F
I Annual Meeting Orientation Session . . . . . . . . 22
Presenters:
Therapeutics in Neuromuscular Disease
Brian K. Kaspar, PhD
Nationwide Children’s Hospital, Columbus, OH
3-D Cultures for Alzheimer’s Disease
Doo Yeon Kim, PhD
Mass General Institute for Neurodegenerative
Disease, Charleston, MA
S ex-specific Programming of
Neurodevelopment by Stress
Tracy L. Bale, PhD
University of Pennsylvania Perelman
School of Medicine, Philadelphia, PA
RNA-targeted Therapies for Neurologic Disease
Timothy M. Miller, MD, PhD
Washington University School of Medicine
St. Louis, MO
igesting the Gut Microbiome:
D
Role in CNS Demyelinating Disease
Meeting Attendee
Mohamed El Hag, MD (Resident)
Cleveland, OH
“[The Annual Meeting
Science Programs give
me] a lot of exposure
to different researchers
and to different work
that people do in the
field of neurology. When you come to this
place, you are exposed to everything: The
cutting-edge science, the new techniques,
the basically new science, the new
indications, the
new guidelines.”
Lloyd H. Kasper, MD
Dartmouth Medical School, Lebanon, NH
34
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
I = I Talk Session
9:00 a.m.–12:00 p.m.
FContemporary Clinical Issues Plenary Session
Highlights issues most critical to practicing neurologists,
including abstracts related to new therapeutic developments,
clinical applications of basic and translational research,
and innovative technical developments. Commentary and
discussion follow each presentation.
oderator: Lisa M. DeAngelis, MD, FAAN
M
Chair, Science Committee
Abstract Presenters/Discussant:
dults with Migraine Have Atypical Correlations
A
between Brain Cortical Thickness and Pain Thresholds
Presenter: Todd J. Schwedt, MD
Mayo Clinic, Phoenix, AZ
Discussant: Peter Goadsby, MD, PhD
University of California, San Francisco
San Francisco, CA
AV9-mediated Gene Therapy in a
A
SMARD1 Mouse Model
Presenter: Stefania Corti, MD, University of Milan
Milan, Italy
Discussant: Massimo Pandolfo, MD, FAAN
Universite Libre De Bruxelles, Brussels, Belgium
B lood Pressure Control and Risk of
Recurrent Lobar Intracerebral Hemorrhage
Presenter: Christopher D. Anderson, MD, MMSc
Massachusetts General Hospital, Boston, MA
Discussant: Kevin N. Sheth, MD, FAHA, FCCM
Yale School of Medicine
New Haven, CT
Invited Speakers:
Decade of Autism Genetics: Building a
A
Foundation for Targeted Treatment Development
Daniel H. Geschwind, MD, PhD, University of
California, Los Angeles, Los Angeles, CA
Gray Zones in the Gray Population: Assessment of
Cognition in Late Life
Steven T. DeKosky, MD, FAAN
University of Virginia in Charlottesville, VA
Pain in a Dish
Brian Wainger, MD, PhD
Massachusetts General Hospital, Boston, MA
Fast, Easy, Online Registration · AAN.com/view/AM15
11:30 a.m.–5:00 p.m.
Exhibit Hall
F
12:00 p.m.–1:00 p.m.
F
I Neurology Compensation and Productivity
Survey and Dashboard Report . . . . . . . . . . . . . . 22
12:00 p.m.–1:30 p.m.
$Awards Luncheon . . . . . . . . . . . . . . . . . . . . 137
1:30 p.m.–3:30 p.m.
F
I How to Avoid “Death by PowerPoint”
and Workshop . . . . . . . . . . . . . . . . . . . . . . 22
2:00 p.m.–3:45 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . . 96
S20 Treatment Mechanisms in Multiple Sclerosis
¡
Presentation of the John Dystel Prize for Multiple
Sclerosis Research
S21 Cerebrovascular Disease and Interventional
Neurology: Prehospital and Acute Ischemic
Stroke Treatment
S22 Epilepsy/Clinical Neurophysiology (EEG):
Basic Science and Intraoperative Monitoring
¡
Presentation of the Dreifuss-Penry Epilepsy Award
S23 Headache: Epidemiology and Clinical
S24 ALS: Mechanisms and Biomarkers
¡
Presentation of the Sheila Essey Award: An Award
for ALS Research
S25 General Neurology
¡
Presentation of the S. Weir Mitchell Award
S26 Neuro-ophthalmology/Neuro-otology
S27 Neuro Trauma, Critical Care, and Sports Neurology
S28 Neuro-rehabilitation
2:00 p.m.–6:00 p.m.
$C107 History of Neurology: The History of Neurologic Disease
from Cortex to Peripheral Nerve
$C108 Autism Spectrum Disorders—What We Know and
Where We Are Going
$C109 Functional Neurologic Disorders
$C110 Differential Diagnosis of Neurologic Infections
$C111 Neuromuscular Ultrasound Skills Pavilion
$C112 Skills for Stroke Emergent Treatment Skills Pavilion
FI9 Treating Dementia in an Age of Mixed Disease . . . . 98
The Dynamic Brain in Health and Disease: Plasticity
FI10
and Reprogramming . . . . . . . . . . . . . . . . . . . 99
C
2:00 p.m.–6:30 p.m.
FP5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100
4:00 p.m.–4:45 p.m.
F
I Your Abstract Has Been Accepted:
Now What? Working with the Media . . . . . . . . . . 22
35
Annual Meeting Program Schedule
4:00 p.m.–5:45 p.m.
FPlatform Blitz Sessions . . . . . . . . . . . . . . . . . . . . 108
S29 Neuroimaging Correlates in Multiple Sclerosis
S30 Cerebrovascular Disease and Interventional Neurology:
Diagnostics, Biomarkers, and Genetics
S31 Epilepsy/Clinical Neurophysiology (EEG):
Epilepsy Therapy
S32 Movement Disorders: Tremor, Ataxia, and More
S33 Aging, Dementia, Cognitive, and Behavioral
Neurology: Biomarkers and Pathology
S34 Neuromuscular Update
S35 Child Neurology and Developmental Neurology
S36 Neuroepidemiology: Movement Disorders,
ALS, and Aging
S37 Global Health and Infectious Disease
6:00 p.m.–7:00 p.m.
FHighlights in the Field Sessions
H1 Sleep
H2 Movement Disorders
H3 Global Health
H4 Stroke and Vascular Neurology
H5 Multiple Sclerosis
H6 Sports Neurology
H7 Neuromuscular
H8 Clinical Neurophysiology and Autonomic Nervous System
H9 Neuro-oncology
H10 Women’s Issues in Neurology
H11 Critical Care and Emergency Neurology
6:15 p.m.–7:45 p.m.
Emerging Science . . . . . . . . . . . . . . . . . . . . . 22
F
7:00 p.m.–10:00 p.m.
F Industry Therapeutic Updates . . . . . . . . . . . . . . . . . . 131
Industry-sponsored, non-CME programs will be offered and are
open to attendees at no charge. They will provide an opportunity
for pharmaceutical companies, device companies, or other
neurologic-related organizations to share information regarding
their current therapies and projects in the pipeline in accordance
with standards set for industry by the FDA.
Thursday, April 23, 2015
6:30 a.m.–8:00 a.m.
$C113 Neuro Flash: Neuro-ophthalmology
$C114 Morning Report: Behavioral Neurology
$C115 Morning Report: Lumbar Radiculopathy, Lumbar Spinal
Stenosis, Low Back Pain, and Post-laminectomy Syndrome
$C116 Prognostication in the Era of Hypothermia
$C117 REM Sleep Behavior Disorder
$C118 What Neurologists Really Need to Know About Normal
Pressure Hydrocephalus
7:30 a.m.–12:00 p.m.
FP6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
36
9:00 a.m.–12:00 p.m.
FFrontiers in Neuroscience Plenary Session
Focuses on translational research related to clinical issues
of importance. Six physician scientists outline their recent
research findings, along with the clinical implications.
Moderator: Paul M. George, MD, PhD, MSE
Member, Science Committee
Presenters:
T ransmission of α-Synuclein in Parkinson’s Disease:
Pathogenesis and Implications for Therapy
V irginia M-Y Lee, PhD
University of Pennsylvania
Philadelphia, PA
Antemortem Signatures of
Neurodegenerative Proteinopathies
Keith A. Josephs Jr., MD
Mayo Clinic
Rochester, MN
Developing Antisense Oligomers as a Genetic
Therapy for Duchenne Muscular Dystrophy
Francesco Muntoni, MD
University College London Institute of Child
Health, London, United Kingdom
Immune Mechanisms in Neurologic Diseases
Howard L. Weiner, MD
Brigham and Women’s Hospital
Boston, MA
T owards a New Connectional Anatomy
of the Human Brain
Marco Catani, MD
King’s College London
London, United Kingdom
Epilepsy: How Genetic Insights Are
Transforming Clinical Practice
Ingrid Scheffer, AO, MBBS, PhD,
FRACP, FAHMS, FAA
Melbourne Brain Centre
Heidelberg, Victoria, Australia
11:30 a.m.–3:00 p.m.
FExhibit Hall
12:00 p.m.–1:00 p.m.
F
I AAN’s Axon Registry:
Data Powering Neurology’s Future . . . . . . . . . . . 22
1:00 p.m.–2:45 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . 118
S38 Diet and Hormonal Factors in Multiple Sclerosis
S39 Cerebrovascular Disease and Interventional
Neurology: Intracerebral Hemorrhage
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
I = I Talk Session
S40 Movement Disorders: Functional Imaging in Parkinson’s Disease
¡
Presentation of the Movement Disorders Research Award
S41 Aging, Dementia, Cognitive, and Behavioral Neurology:
Imaging: Aging and Alzheimer’s Disease
¡
Presentation of the Norman Geschwind Prize
in Behavioral Neurology
S42 New Developments in Peripheral Neuropathies
S43 Neuro-oncology: Basic Science and Clinical Trials
S44 History of Neurology
¡ Presentation of the Lawrence C. McHenry Award:
An Award for the History of Neurology
S45 Neuroepidemiology: Multiple Sclerosis,
Cerebrovascular, and Aging
¡
Presentation of the Bruce S. Schoenberg
International Award in Neuroepidemiology
1:00 p.m.–2:45 p.m.
Invited Science: Epilepsy F
����������� 119
1:00 p.m.–5:00 p.m.
$C119 Borderlands of Neurology and Internal Medicine: Chalk Talk
$C120 Emergency Neurology
$C121 Core Concepts in Pain Management
$C122 Epilepsy Skills Pavilion
$C123 Neuromuscular Bedside Rounds Skills Pavilion
Neuroimaging for the General Neurologist:
$C124
Spine and Peripheral Nerve
The Promise of Novel Biomarker Approaches
FI11
in Advancing Treatment . . . . . . . . . . . . . . . . .120
FI12 Obesity and Neurological Disorders . . . . . . . . . . 121
A
C
2:00 p.m.–6:30 p.m.
FP7 Poster Session VII . . . . . . . . . . . . . . . . . . . .122
3:00 p.m.–3:45 p.m.
F
I Your Abstract Has Been Accepted:
Now What? Tips for a Successful Presentation . . . . 22
3:15 p.m.–5:00 p.m.
FScientific Platform Sessions . . . . . . . . . . . . . . . . . 132
S46 Neuromyelitis Optica
S47 Cerebrovascular Disease and Interventional Neurology
S48 Parkinson’s Disease
¡
Presentation of the John Stolk Award in
Movement Disorders for Young Investigator
S49 Aging, Dementia, Cognitive, and Behavioral
Neurology: Imaging: Behavioral Neurology and
Non-Alzheimer’s Disease Dementias
S50 Treatment Trials in Neuromuscular Diseases
S51 Headache: Imaging and Physiology
¡ Presentation of the Harold Wolff-John Graham:
An Award for Headache/Facial Pain Research
S52 General Neurology: Neural Networks and Neuromodulation
S53 Sleep
Presentation of the Sleep Science Award
¡
Presentation of the Wayne A. Hening Sleep
¡
Medicine Investigator Award
Fast, Easy, Online Registration · AAN.com/view/AM15
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
5:30 p.m.–6:30 p.m.
FHighlights in the Field Sessions
H12 Geriatric Neurology
H13 Neuro-ophthalmology and Neuro-otology
H14 Neural Repair and Rehabilitation
H15 Behavioral Neurology
H16 Neuroendocrinology
H17 Headache and Facial Pain
H18 Epilepsy
5:30 p.m.–7:00 p.m.
FControversies in Neurology Plenary Session
The program features experts discussing the most current and
controversial issues in neuroscience. It is set up as a debate
format in which two speakers argue one side of a single topic,
followed by a rebuttal. Each round concludes with a 10-minute
question and answer period.
oderators:
M
Joseph Jankovic, MD, FAAN
Member, Science Committee,
and Walter A. Rocca, MD, MPH
Chair, Clinical Research
Subcommittee, Member,
Science Committee
Presenters:
S hould Whole Exome Sequencing be
Part of Neurologic Care Today?
Pro: Christine Klein, MD, University of Luebeck
Luebeck, Germany
Con: Claes Wahlestedt, MD, PhD
University of Miami Miller
School of Medicine, Miami, FL
Is the Science of Stem Cells Ready for
Clinical Trials in Neurologic Disease?
Pro: Clive Svendsen, PhD
Cedars-Sinai Medical Center, Los Angeles, CA
Con: C. Warren Olanow, MD, FAAN
Mt. Sinai Medical Center
New York, NY
S hould Neurologists Prescribe Opioids
for Chronic Pain?
Pro: Charles E. Argoff, MD
Albany Medical Center, Albany, NY
Con: Gary M. Franklin, MD, MPH, FAAN
University of Washington, Seattle, WA
37
Annual Meeting Program Schedule
6:00 p.m.–9:00 p.m.
$C125 Case Studies: Dementia
$C126 Case Studies: Unusual Diagnostic and Management of
Cases in Neuromuscular Disease
$C127 Case Studies: Unusual Movement Disorders
$C128 Case Studies: Multiple Sclerosis
$C129 Test Your Knowledge: A Case-based Approach to
Neuroimaging
$C130 Case Studies: Neurologic Consultations in Cancer
Patients
Friday, April 24, 2015
6:30 a.m.–8:00 a.m.
$C131 Neuro Flash: Child Neurology
$C132 Differential Diagnosis of Dementia: Linking Clinical
Syndromes to Biomarkers
C133
The Interface Between Infection and Cerebrovascular
$
Disease
$C134 The Dystonias: Diagnosis, Treatment, and Update on
Causes
C135
Neurotoxicology
$
8:00 a.m.–12:00 p.m.
$C136 Assessment of Rapidly Progressive Dementias and
Related Neurologic Conditions
$C137 Multiple Sclerosis Therapy I: Symptom Management
$C138 Continuum ® Test Your Knowledge: A Multiple-choice
Question Review
$C139 Stroke in Young Adults
$C140 Sleep for the Practicing Neurologist
8:00 a.m.–4:00 p.m.
$C141 Movement Disorders
$C142 Clinical EEG
Neurology Update II
$C143
$C144 Neuro-ophthalmology
$C145 Neurologic Intensive Care
$C146 Spine Neurology: Assessment and Management of
Common Spine Disorders
C147
EMG Skills Workshop: Basic
$
A
2016 Education Course Proposal Process
2016 Annual Meeting: Vancouver, BC, Canada
The AAN invites you to submit an Education Program
suggestion for the 68th Annual Meeting. Proposals are due
by May 15, 2015. To submit your proposal, please visit
AAN.com/view/SubmitProgram.
38
12:00 p.m.–1:30 p.m.
FClinical Trials Plenary Session
This midday seminar covers important clinical topics identified
from other society meetings that affect patient care. The latest
updates within several clinical trials conducted over the course
of the last year will be presented with an open panel discussion
at the conclusion.
oderators:
M
Natalia S. Rost, MD, FAAN
Vice Chair, Science Committee,
and Petra Kaufmann, MD
Member, Clinical Reasearch
Subcommittee
Presenters:
mifampridine Phosphate (FirdapseTM)
A
is safe and Effective in a Pivotal Phase 3 Trial
in LEMS Patients
Shin J. Oh, MD, FAAN
University of Alabama at Birmingham
Birmingham, AL
E ffect of MD1003 (High Doses of Biotin) in
Progressive Multiple Sclerosis: Results of a
Pivotal Phase III Randomized Double Blind
Placebo Controlled Study
Ayman Tourbah, MD, PhD
CHU de Reims, Reims, France
Idebenone Reduces Loss of Respiratory Function
in Duchenne Muscular Dystrophy—Outcome of
a Phase III Double Blind, Randomised, Placebocontrolled Trial (DELOS)
Gunnar Buyse, PhD, MD
University Hospitals K.U. Leuven, Leuven, Belgium
T he Multicenter Randomized Clinical Trial of
Endovascular Treatment for Acute Ischemic
Stroke in the Netherlandsv (MR CLEAN): Update
and Clinical Implications
Diedrik Dippel, MD
Erasmus MC University Medical Center
Rotterdam, The Netherlands
Phenytoin is Neuroprotective in Acute Optic
Neuritis: Results of Phase 2 Randomized
Controlled Trial
Raju Kapoor, MD
National Hospital
London, United Kingdom
1:00 p.m.–3:00 p.m.
$C148 Therapy of Neuromuscular Disease
1:00 p.m.–4:00 p.m.
$C149 Improving Accuracy of Dementia Diagnosis: Case Studies
with Both Imaging and Neuropathology
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
I = I Talk Session
$C150 Principles of Genomic Medicine: Clinical Exome
Sequencing in Neurologic Disease
$C151 Multiple Sclerosis Therapy II: Disease-modifying
Treatment
$C152 The Intractable Headache Patient
$C153 Practical Legal Issues for Neurologists
4:30 p.m.–6:00 p.m.
FNeurology Year in Review Plenary Session
This plenary session will feature six speakers, each focusing on
the latest research that has happened in the last year within a
specific subspecialty topic.
Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, Science Committee
Neuro-oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
ovement Disorders
M
Michael S. Okun, MD, FAAN
University of Florida, Gainesville, FL
euro-rehabilitation
N
Bruce H. Dobkin, MD, FAAN
University of California, Los Angeles
Los Angeles, CA
Vertigo
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
Saturday, April 25, 2015
6:30 a.m.–8:00 a.m.
$C154 Attention Deficit Hyperactivity Disorder Across the
Lifespan
$C155 Physical Exercise and Cognitive Training in Neurological
Disorders
$C156 Neuro Flash: Sleep Medicine
$C157 Paroxysmal Movement Disorders
$C158 Neuro Flash: MRI and Multiple Sclerosis
8:00 a.m.–11:00 a.m.
$C159 Eye Movement Disorders: A Systematic Approach to the
Evaluation of Diplopia
8:00 a.m.–12:00 p.m.
$C160 Non-Alzheimer’s Dementia
$C161 Clinical Approach to Muscle Disease
$C162 Nonmotor Manifestations of Parkinson Disease
$C163 Autoimmune Neurology
$C164 Chronic Migraine Education Program
$C165 Consultations in the Medical Surgical ICU
$C166 How to Analyze Spells by Video-EEG
10:00 a.m.–12:00 p.m.
$C167 Preventing a First Stroke: What Every Neurologist Needs
to Know
$C168 Controversies in Brain Death Determination
$C169 Multiple Sclerosis Essentials
David Newman-Toker, MD, PhD, FAAN
Johns Hopkins University School of Medicine
Baltimore, MD
Pediatric Neurology
Nina F. Schor, MD, PhD
University of Rochester Medical Center
Rochester, NY
ultiple Sclerosis and Neuromyelitis Optica
M
Jeffrey Allan Cohen, MD
Cleveland Clinic
Cleveland, OH
6:00 p.m.–8:00 p.m.
FClosing Party
Celebrate the end of a great meeting at a special earlyevening happy hour event!
¡¡ Enjoy music, drinks, and socializing with colleagues
¡¡ Make plans to explore beautiful
Washington, DC, afterwards
Fast, Easy, Online Registration · AAN.com/view/AM15
Meeting Attendee
Ishida Kyto, MD
New York
“I really appreciate the
speakers who gave a
high-level interpretation
of the clinical trials. We
all know the data. It’s the
interpretation that really
helps us start a discussion and
collaborate nationally.”
39
Annual Meeting Programs by Topic
C Course
H Highlights Session
I Integrated Neuroscience Session
Aging, Dementia, Cognitive, and
Behavioral Neurology
$C15
$C17
$C29
$C44
$C54
$C56
$C72
FP1
FP2
FS8
FI8
FS16
F
$C100
FP4
F
FI9
FI10
FP5
FS33
$C114
$C118
FP6
F
FS41
FI11
FI12
FP7
FS49
FH12
FH15
40
C
S Scientific Session
$C125 Case Studies: Dementia
$C132 Differential Diagnosis of Dementia: Linking Clinical
Severe TBI: From ICU to Rehabilitation
The Neurology of Social Behavior
Primer of Behavioral Neurology
Practical Psychopharmacology for Neurologists
Cognitive-motor Disorders: Chalk Talk
Vascular Cognitive Impairment and Dementia:
Current Status and Future
Dementia Overview
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Aging, Dementia, Cognitive,
and Behavioral Neurology: Basic Science . . . . . . . . 74
Advances in ALS and Other Motor Neuron Diseases . 77
Aging, Dementia, Cognitive,
and Behavioral Neurology: Clinical Science . . . . . . 86
Hot Topics Plenary Session . . . . . . . . . . . . . 34
Mild Cognitive Impairment:
Implications for Clinicians
Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
Contemporary Clinical Issues Plenary Session . 35
Treating Dementia in an Age of Mixed Disease . . . . 98
The Dynamic Brain in Health and Disease:
Plasticity and Reprogramming . . . . . . . . . . . . . . 99
Poster Session V . . . . . . . . . . . . . . . . . . . . .100
Aging, Dementia, Cognitive, and Behavioral Neurology:
Biomarkers and Pathology Platform Blitz . . . . . . . .108
Morning Report: Behavioral Neurology
What Neurologists Really Need to Know About Normal
Pressure Hydrocephalus
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Frontiers in Neuroscience Plenary Session . . . 36
Aging, Dementia, Cognitive, and Behavioral Neurology:
Imaging: Aging and Alzheimer’s Disease . . . . . . . . 118
The Promise of Novel Biomarker Approaches in
Advancing Treatment . . . . . . . . . . . . . . . . . . 120
Obesity and Neurological Disorders . . . . . . . . . . 121
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Aging, Dementia, Cognitive, and Behavioral Neurology:
Imaging: Behavioral Neurology and Non-Alzheimer’s
Disease Dementias . . . . . . . . . . . . . . . . . . . 132
Geriatric Neurology . . . . . . . . . . . . . . . . . . . 37
Behavioral Neurology . . . . . . . . . . . . . . . . . . 37
C
P Poster Session
$C136
$C149
$C154
$C160
Syndromes to Biomarkers
Assessment of Rapidly Progressive Dementias and
Related Neurologic Conditions
Improving Accuracy of Dementia Diagnosis: Case Studies
with Both Imaging and Neuropathology
Attention Deficit Hyperactivity Disorder Across the
Lifespan
Non-Alzheimer’s Dementia
Cerebrovascular Disease and
Interventional Neurology
$C7
S Current Management of Incidental and
Asymptomatic Cerebrovascular Lesions
New Windows into the Brain:
FI1
Technological Advances in Frontline Neurologic
Diagnosis via the Visual and Oculomotor Systems . . . 48
Management of Asymptomatic Cerebrovascular
FI2
Lesions . . . . . . . . . . . . . . . . . . . . . . . . . . 49
$C41 Therapy of Stroke
FS1 Section Topic Controversies: Antiplatelets,
Anticoagulants, or Stenting for
Acute Treatment of Cervical/Cranial Dissection? . . . 51
$C74 Cerebrovascular Disease
S
S
Meeting Attendee
Kathleen M. Fitzgerald, MD
Eugene, OR
“[The Annual Meeting
Science Programs]
are amazing. The
poster sessions are
inspiring. You get these
young researchers
just starting, and they
come out with beautiful things that just
blow you away.”
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
I = I Talk Session
FP1
FP2
FS5
F
FP3
FS13
$C105
$C106
FP4
F
FS21
$C112
FI9
FI10
FP5
FS30
FH4
$C116
FP6
FS39
FI11
FI12
FP7
FS47
$C133
$C139
F
$C167
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Cerebrovascular Disease and Interventional Neurology:
Recovery and Outcome . . . . . . . . . . . . . . . . . . 74
Invited Science: Stroke . . . . . . . . . . 75
Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
Cerebrovascular Disease and Interventional
Neurology: Epidemiology and Risk Factors . . . . . . . 86
Neurohospitalist 2.0: Next Steps in the Evolution
Neuro Flash: Acute Stroke Management
Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
Contemporary Clinical Issues Plenary Session . 35
Cerebrovascular Disease and Interventional
Neurology: Prehospital and Acute Ischemic
Stroke Treatment . . . . . . . . . . . . . . . . . . . . . 96
Skills for Stroke Emergent Treatment Skills Pavilion
Treating Dementia in an Age of Mixed Disease . . . . 98
The Dynamic Brain in Health and Disease:
Plasticity and Reprogramming . . . . . . . . . . . . . . 99
Poster Session V . . . . . . . . . . . . . . . . . . . . .100
Cerebrovascular Disease and Interventional
Neurology: Diagnostics, Biomarkers, and
Genetics Platform Blitz . . . . . . . . . . . . . . . . . 108
Stroke and Vascular Neurology . . . . . . . . . . . . . 36
Prognostication in the Era of Hypothermia
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Cerebrovascular Disease and Interventional
Neurology: Intracerebral Hemorrhage . . . . . . . . . 118
The Promise of Novel Biomarker
Approaches in Advancing Treatment . . . . . . . . . .120
Obesity and Neurological Disorders . . . . . . . . . . 121
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Cerebrovascular Disease and
Interventional Neurology . . . . . . . . . . . . . . . . 132
The Interface Between Infection and
Cerebrovascular Disease
Stroke in Young Adults
Clinical Trials Plenary Session . . . . . . . . . . . 38
Preventing a First Stroke:
What Every Neurologist Needs to Know
C
C
Child Neurology and Developmental Neurology
$C34 Child Neurology I
$C50 Child Neurology II
FI5 S Pediatric Neurotrauma:
$C83
From Coma to Concussions . . . . . . . . . . . . . . . 53
Concussion Assessment and Management
in the Youth Athlete
S
Fast, Easy, Online Registration · AAN.com/view/AM15
FP2
F
FS3
$C94
$C102
F
$C108
FI10
FS35
FP6
F
$C131
$C139
F
$C154
Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Presidential Plenary Session . . . . . . . . . . . . 33
Section Topic Controversies: Should All Brain Tumor
Patients Receive Prophylactic Antiepileptic Drugs? . . 73
EEG in Children: Developmental Maturation,
Variants, Epilepsy Syndromes, and Identification
of Surgical Candidates
Syndromes of Autonomic Dysfunction in
Children and Adolescents
Contemporary Clinical Issues Plenary Session . 35
Autism Spectrum Disorders—What We Know
and Where We Are Going
The Dynamic Brain in Health and Disease:
Plasticity and Reprogramming . . . . . . . . . . . . . . 99
Child Neurology and Developmental
Neurology Platform Blitz . . . . . . . . . . . . . . . . .109
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Frontiers in Neuroscience Plenary Session . . . 36
Neuro Flash: Child Neurology
Stroke in Young Adults
Neurology Year in Review Plenary Session . . . 39
Attention Deficit Hyperactivity Disorder
Across the Lifespan
C
Epilepsy/Clinical Neurophysiology (EEG)
$C1
$C10
$C22
$C35
$C57
$C63
$C75
Status Epilepticus
Critical Care EEG Monitoring
Neuro Flash: Epilepsy
Clinical Epilepsy
Therapy of Epilepsy
Treating the New-onset Epilepsy Patient
Neurophysiologic Intraoperative Monitoring
Skills Workshop
Future Therapies: How We Will Be Treating,
FI6
Preventing, and Curing Epilepsy in the Year 2025 . . . 55
FP1 Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
FP2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Presidential Plenary Session . . . . . . . . . . . . 33
F
S6
Epilepsy/Clinical Neurophysiology (EEG):
F
Health Services and Women’s Issues . . . . . . . . . . 74
$C94 EEG in Children: Developmental Maturation,
Variants, Epilepsy Syndromes, and Identification
of Surgical Candidates
FP3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
FS14 Epilepsy/Clinical Neurophysiology (EEG):
Clinical Epilepsy . . . . . . . . . . . . . . . . . . . . . . 86
FP4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
FS22 Epilepsy/Clinical Neurophysiology (EEG):
Basic Science and Intraoperative Monitoring . . . . . . 96
S
S
41
Annual Meeting Programs by Topic
FP5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100
FS31 Epilepsy/Clinical Neurophysiology (EEG):
FP5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100
FS36 Neuroepidemiology: Movement Disorders,
FH8
FH10
FP6
F
FS45
FP6
F
F
$C122
FP7
FH18
$C142
$C166
Epilepsy Therapy Platform Blitz . . . . . . . . . . . . .108
Clinical Neurophysiology and Autonomic
Nervous System . . . . . . . . . . . . . . . . . . . . . 36
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Frontiers in Neuroscience Plenary Session . . . 36
Invited Science: Epilepsy . . . . . . . 119
Epilepsy Skills Pavilion
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Clinical EEG
How to Analyze Spells by Video-EEG
General Neurology
$C12
$C14
$C19
$C25
FC171
$C37
$C38
$C44
$C61
$C66
$C68
$C73
FP1
$C87
$C92
FP2
F
FS9
$C97
F
$C102
$C103
FP4
F
FS25
$C109
42
Neurologic Complications of Medical Disease
Advanced Neurologic Coding
Mitochondrial Disorders in Neurology
Cognitive Psychology of Neurologic Errors: Chalk Talk
Opioids and Marijuana in Your Practice
Neurology Update I
Genetics in Neurology
Practical Psychopharmacology for Neurologists
Clinical E-pearls
Multiple Sclerosis Overview I:
Basic and Translational Science
Neuroimaging for the General Neurologist: Brain
Therapy in Neurology
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Hot Topics in Education
Important Drug Interactions for Neurologists
and Psychiatrists
Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Presidential Plenary Session . . . . . . . . . . . . 33
General Neurology:
Neurological Treatments and Therapeutics . . . . . . . 75
Neurologic Issues in Pregnancy
Hot Topics Plenary Session . . . . . . . . . . . . . 34
Syndromes of Autonomic Dysfunction in
Children and Adolescents
Global Health Challenges:
Neurology in Developing Countries
Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
Contemporary Clinical Issues Plenary Session . 35
General Neurology . . . . . . . . . . . . . . . . . . . . 97
Functional Neurologic Disorders
A
A
A
$C119
$C120
$C124
FI11
FS52
FH16
F
$C129
$C135
$C138
$C143
$C149
$C150
$C158
$C163
$C168
ALS, and Aging Platform Blitz . . . . . . . . . . . . . .109
Women’s Issues in Neurology . . . . . . . . . . . . . . 36
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Frontiers in Neuroscience Plenary Session . . . 36
Neuroepidemiology: Multiple Sclerosis,
Cerebrovascular, and Aging . . . . . . . . . . . . . . . 119
Borderlands of Neurology and
Internal Medicine: Chalk Talk
Emergency Neurology
Neuroimaging for the General Neurologist:
Spine and Peripheral Nerve
The Promise of Novel Biomarker Approaches
in Advancing Treatment . . . . . . . . . . . . . . . . .120
General Neurology: Neural Networks
and Neuromodulation . . . . . . . . . . . . . . . . . .133
Neuroendocrinology . . . . . . . . . . . . . . . . . . . 37
Controversies in Neurology Plenary Session . . 37
Test Your Knowledge:
A Case-based Approach to Neuroimaging
Neurotoxicology
Continuum ® Test Your Knowledge:
A Multiple-choice Question Review
Neurology Update II
Improving Accuracy of Dementia Diagnosis:
Case Studies with Both Imaging and Neuropathology
Principles of Genomic Medicine:
Clinical Exome Sequencing in Neurologic Disease
Neuro Flash: MRI and Multiple Sclerosis
Autoimmune Neurology
Controversies in Brain Death Determination
A
C
A
Global Health and Infectious Disease
$C28
S Infectious, Paraneoplastic, Autoimmune?
Diagnosis and Treatment of Rapidly Progressive
Encephalopathies
Infectious, Paraneoplastic, and Autoimmune
FI4
Encephalopathies: Advances in Clinical Diagnosis
and Emerging Insights about Pathogenesis . . . . . . . 52
$C55 Neuro Flash: Approach to Acute CNS Infections
$C67 Infections of the Nervous System I:
Common Infections
C81
Infections of the Nervous System II:
$
Advanced and Emerging Infections
FP2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
FI7 The Global Burden of Neurological Infections:
Epidemiology, Treatment, and Prevention . . . . . . . . 76
S
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
I = I Talk Session
Meeting Attendee
David B. Watson, MD
Morgantown, WV
“I attended the Global
Health Challenges:
Neurology in
Developing Countries.
It was eye opening to
learn about the global
burden of disease
and, specifically, the difficulties in treating
epilepsy in developing countries. It won't
affect my current practice, but reminds me
of the need to think outside of the small
world in which I practice. It also reignited
an interest in participating in short-term
medical mission work like I was able to
do in medical school.”
$C103 Global Health Challenges:
$C110
FS37
FH3
FP6
$C133
Neurology in Developing Countries
Differential Diagnosis of Neurologic Infections
Global Health and Infectious Disease Platform Blitz . 109
Global Health . . . . . . . . . . . . . . . . . . . . . . . 36
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
The Interface Between Infection and
Cerebrovascular Disease
Headache
$C21
$C42
$C46
$C69
FP1
FP3
F
FS23
FI12
FS51
FH17
$C152
$C164
Challenging Headache Cases
Therapy of Headache
Hot Topics in Headaches and Related Disorders
Introduction to Primary Headache Disorders
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
Contemporary Clinical Issues Plenary Session . . 35
Headache: Imaging and Physiology . . . . . . . . . . . 96
Obesity and Neurological Disorders . . . . . . . . . . 121
Headache: Epidemiology and Clinical . . . . . . . . . .133
Headache and Facial Pain . . . . . . . . . . . . . . . . 37
The Intractable Headache Patient
Chronic Migraine Education Program
Fast, Easy, Online Registration · AAN.com/view/AM15
Movement Disorders
$C3 Deep Brain Stimulation Management
$C18 Therapy of Movement Disorders:
A Case-based Approach
C24
Balance and Gait Disorders
$
Dopamine-mediated Neural Plasticity
FI3
in Motor and Non-motor Circuits . . . . . . . . . . . . 50
Dopaminergic and Nondopaminergic
$C52
Influences on the Changing Landscape of
Parkinson’s Disease
$C54 Cognitive-motor Disorders: Chalk Talk
$C65 Botulinum Toxins: Practical Issues and
Clinical Uses for Neurologists
$C77 Update on Ataxias
FS2 Section Topic Controversies: Testing in
Prodromal Neurological Disease: Friend or Foe? . . . . 54
$C79 Overview of Parkinson’s Disease and
Movement Disorders
$C85 Clinical Usefulness of Botulinum Toxin and
Treatment of Dystonia Skills Pavilion
FP1 Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
$C90 Approach to the Shaky Patient
FP2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Presidential Plenary Session . . . . . . . . . . . . 33
F
S7
Movement Disorders: Genetics . . . . . . . . . . . . . 74
F
FP3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
FS15 Movement Disorders: Huntington’s Disease,
Dystonia, and Atypical Parkinsonism . . . . . . . . . . 86
$C101 Hyperkinetic Movement Disorders:
Diagnosis and Treatment
FP4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
The Dynamic Brain in Health and Disease: Plasticity
FI10
and Reprogramming . . . . . . . . . . . . . . . . . . . 99
FP5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100
FS32 Movement Disorders: Tremor, Ataxia, and
More Platform Blitz . . . . . . . . . . . . . . . . . . . 108
FH2 Movement Disorders . . . . . . . . . . . . . . . . . . 36
FP6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Frontiers in Neuroscience Plenary Session . . . 36
F
FS40 Movement Disorders: Functional Imaging
in Parkinson’s Disease . . . . . . . . . . . . . . . . . . 118
The Promise of Novel Biomarker Approaches
FI11
in Advancing Treatment . . . . . . . . . . . . . . . . .120
FP7 Poster Session VII . . . . . . . . . . . . . . . . . . . .122
FS48 Parkinson’s Disease . . . . . . . . . . . . . . . . . . .132
$C127 Case Studies: Unusual Movement Disorders
$C131 Neuro Flash: Child Neurology
S
S
C
C
43
Annual Meeting Programs by Topic
$C134 The Dystonias: Diagnosis, Treatment,
and Update on Causes
$C141 Movement Disorders
Neurology Year in Review Plenary Session . . . 39
F
C157
Paroxysmal Movement Disorders
$
$C162 Nonmotor Manifestations of Parkinson Disease
MS and CNS Inflammatory Disease
$C4
$C27
$C51
$C66
$C80
FP1
$C88
FP2
F
FS4
FP3
FS12
F
FP4
FS20
FP5
FS29
FH5
FP6
F
FS38
FI11
FP7
FS46
$C128
$C137
F
$C151
F
$C158
$C169
Neuromyelitis Optica: Scientific and Clinical Update
Controversies in Multiple Sclerosis Therapy
Diagnostic Dilemmas in Multiple Sclerosis
Multiple Sclerosis Overview I:
Basic and Translational Science
Multiple Sclerosis Overview II: Clinical Advances
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Morning Report: Multiple Sclerosis
Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Presidential Plenary Session . . . . . . . . . . . . 33
Clinical Trial Outcomes in Multiple Sclerosis . . . . . . 74
Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
Neuroimmune Mechanisms in Multiple Sclerosis . . . 86
Hot Topics Plenary Session . . . . . . . . . . . . . 34
Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
Treatment Mechanisms in Multiple Sclerosis . . . . . 96
Poster Session V . . . . . . . . . . . . . . . . . . . . .100
Neuroimaging Correlates in
Multiple Sclerosis Platform Blitz . . . . . . . . . . . . 108
Multiple Sclerosis . . . . . . . . . . . . . . . . . . . . 36
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
Frontiers in Neuroscience Plenary Session . . . 36
Diet and Hormonal Factors in Multiple Sclerosis . . . 118
The Promise of Novel Biomarker Approaches
in Advancing Treatment . . . . . . . . . . . . . . . . .120
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Neuromyelitis Optica . . . . . . . . . . . . . . . . . . 132
Case Studies: Multiple Sclerosis
Multiple Sclerosis Therapy I: Symptom Management
Clinical Trials Plenary Session . . . . . . . . . . . 38
Multiple Sclerosis Therapy II:
Disease-modifying Treatment
Neurology Year in Review Plenary Session . . . 39
Neuro Flash: MRI and Multiple Sclerosis
Multiple Sclerosis Essentials
C
Neuro Trauma, Critical Care, and Sports Neurology
$C10
$C15
$C31
$C47
FI5
$C82
$C83
$C95
FS27
FH6
FH11
$C120
FP7
$C145
$C165
S
S
Neuromuscular and Clinical Neurophysiology (EMG)
$C2
$C11
$C36
$C40
$C64
$C78
FP1
FP2
$C96
FI8
FP3
FS17
F
FP4
FS24
$C111
FP5
FS34
FH7
FH8
FP6
44
Critical Care EEG Monitoring
Severe TBI: From ICU to Rehabilitation
Sports Concussion and Other Mild Concussive Injuries
Sports Neurology: Non-concussion Overview
Pediatric Neurotrauma:
From Coma to Concussions . . . . . . . . . . . . . . . 53
Emergency Room Neuro-ophthalmology
Concussion Assessment and Management
in the Youth Athlete
Sports Concussion Skills Pavilion
Neuro Trauma, Critical Care, and Sports Neurology . . 97
Sports Neurology . . . . . . . . . . . . . . . . . . . . 36
Critical Care and Emergency Neurology . . . . . . . . 36
Emergency Neurology
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Neurologic Intensive Care
Consultations in the Medical Surgical ICU
Small Fiber Neuropathies: Sensory, Autonomic and Both
Neuromuscular Junction Disorders
Peripheral Neuropathy
You Make the Call—an Interactive, Multimedia,
Case-based Approach to Learning EMG
Clinical EMG I
Clinical EMG II
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Poster Session II . . . . . . . . . . . . . . . . . . . . . 65
Evaluation and Management of Autonomic Disorders
Advances in ALS and Other Motor Neuron Diseases . . 77
Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
Muscle and Anterior Horn Cell Diseases:
Mechanisms and Biomarkers . . . . . . . . . . . . . . 87
Hot Topics Plenary Session . . . . . . . . . . . . . 34
Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
ALS: Mechanisms and Biomarkers . . . . . . . . . . . 96
Neuromuscular Ultrasound Skills Pavilion
Poster Session V . . . . . . . . . . . . . . . . . . . . .100
Neuromuscular Update Platform Blitz . . . . . . . . . 109
Neuromuscular . . . . . . . . . . . . . . . . . . . . . . 36
Clinical Neurophysiology and Autonomic
Nervous System . . . . . . . . . . . . . . . . . . . . . 36
Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
F = Included with registration
$ = Registration fee required
A = Advanced Practice Provider Track
C = Clinical Research Track
S = Subspecialty in Focus Track
I = I Talk Session
Frontiers in Neuroscience Plenary Session . . . 36
F
FS42 New Developments in Peripheral Neuropathies . . . . 118
$C123 Neuromuscular Bedside Rounds Skills Pavilion
FI11 C The Promise of Novel Biomarker Approaches
$C45
$C82
FP1
$C89
FP7
FS50
$C126
$C99
$C147
F
$C148
$C161
in Advancing Treatment . . . . . . . . . . . . . . . . .120
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Treatment Trials in Neuromuscular Diseases . . . . . 132
Case Studies: Unusual Diagnostic and
Management of Cases in Neuromuscular Disease
EMG Skills Workshop: Basic
Clinical Trials Plenary Session . . . . . . . . . . . 38
Therapy of Neuromuscular Disease
Clinical Approach to Muscle Disease
Neuro-oncology
$C23 Neuro-oncologic Emergencies
$C28 S Infectious, Paraneoplastic, Autoimmune?
FI4
$C71
$C84
FS3
FP3
FS18
FP4
FI10
FH9
FS43
FI11
$C130
F
Diagnosis and Treatment of Rapidly Progressive
Encephalopathies
Infectious, Paraneoplastic, and Autoimmune
Encephalopathies: Advances in Clinical Diagnosis
and Emerging Insights about Pathogenesis . . . . . . . 52
Neuro-oncology: Primary Brain Tumors
Neurologic Complications of Systemic Cancer
Section Topic Controversies: Should All Brain Tumor
Patients Receive Prophylactic Antiepileptic Drugs? . . 73
Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
Neuro-oncology: Imaging and Quality of Life . . . . . . 87
Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
The Dynamic Brain in Health and Disease:
Plasticity and Reprogramming . . . . . . . . . . . . . . 99
Neuro-oncology . . . . . . . . . . . . . . . . . . . . . 36
Neuro-oncology: Basic Science and Clinical Trials . . . 119
The Promise of Novel Biomarker Approaches
in Advancing Treatment . . . . . . . . . . . . . . . . .120
Case Studies: Neurologic Consultations
in Cancer Patients
Neurology Year in Review Plenary Session . . . 39
S
Neuro-rehabilitation
$C15 Severe TBI: From ICU to Rehabilitation
$C93 Brain Computer Interfaces: Frontiers in
$C98
FS28
FI10
FP5
$C115
C
C
Neuro-ophthalmology/Neuro-otology
FI1
$C104
FS26
FP5
$C113
FI12
FH13
$C144
F
$C159
S New Windows into the Brain:
Technological Advances in Frontline Neurologic
Diagnosis via the Visual and Oculomotor Systems . . . 48
Pitfalls and Pearls: Avoiding Common
$C16
Diagnostic Errors in Neuro-ophthalmology
& Neuro-otology
$C20 Canalith Repositioning for Benign
Paroxysmal Positional Vertigo
S
Fast, Easy, Online Registration · AAN.com/view/AM15
Neuro-otology
Emergency Room Neuro-ophthalmology
Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57
Now You See It, Now You Know It—
Pathognomonic Neuro-ophthalmology Findings
Neuro-ophthalmology and Neurovestibular
Exam Lab Skills Pavilion
Pseudotumor Cerebri
Neuro-ophthalmology/Neuro-otology . . . . . . . . . . 97
Poster Session V . . . . . . . . . . . . . . . . . . . . .100
Neuro Flash: Neuro-ophthalmology
Obesity and Neurological Disorders . . . . . . . . . . 121
Neuro-ophthalmology and Neuro-otology . . . . . . . 37
Neuro-ophthalmology
Neurology Year in Review Plenary Session . . . 39
Eye Movement Disorders:
A Systematic Approach to the Evaluation of Diplopia
FP7
FH14
$C146
F
$C155
Neurology and Neuroscience
Myelopathies
Neuro-rehabilitation . . . . . . . . . . . . . . . . . . . 97
The Dynamic Brain in Health and Disease:
Plasticity and Reprogramming . . . . . . . . . . . . . . 99
Poster Session V . . . . . . . . . . . . . . . . . . . . .100
Morning Report: Lumbar Radiculopathy,
Lumbar Spinal Stenosis, Low Back Pain, and
Post-laminectomy Syndrome
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Neural Repair and Rehabilitation . . . . . . . . . . . . 37
Spine Neurology: Assessment and Management
of Common Spine Disorders
Neurology Year in Review Plenary Session . . . 39
Physical Exercise and Cognitive Training in
Neurological Disorders
C
Pain and Palliative Care
$C53
FS10
FP3
F
$C115
Palliative Care for the Practicing Neurologist
Pain and Palliative Care . . . . . . . . . . . . . . . . . 75
Poster Session III . . . . . . . . . . . . . . . . . . . . . 78
Contemporary Clinical Issues Plenary Session . 35
Morning Report: Lumbar Radiculopathy, Lumbar
Spinal Stenosis, Low Back Pain, and
Post-laminectomy Syndrome
45
Annual Meeting Programs by Topic
$C121 Core Concepts in Pain Management
Controversies in Neurology Plenary Session . . 37
F
$C146 Spine Neurology: Assessment and Management
of Common Spine Disorders
$C8
$C14
$C26
$C32
FC171
C39
FC43
$C48
$C53
FC59
FC60
$C70
C76
$C86
F
FC174
FS11
$C105
FP7
$C153
$C168
46
The Practice of Neurology:
Issues in Coding and Reimbursement
Clerkship and Program Directors Conference
Advanced Neurologic Coding
Controversies in Neuroethics
Teleneurology and Technologies
Opioids and Marijuana in Your Practice
Leadership for Women (must apply)
Advanced Practice Provider Symposium
(registration required)
How to Run a Practice: Business Strategies for
Neurology Private Practices, Academic Centers,
and the Future
Palliative Care for the Practicing Neurologist
Leadership in Neurology: Be a Champion for
Your Patients and Protector of Your Specialty
with Payers, Policymakers, and the Public
Resident and Fellow Career Breakfast:
The Early Years (registration required)
Bedside Evidence-based Medicine: How to Find and
Deconstruct Articles in Order to Take Care of Patients
Advanced Leadership for Women (must apply)
Improving Your Leadership Skills:
A Practical Approach
I Hot Topics in Education:
The Value of a Neurologist . . . . . . . . . . . . . . . . 22
All You Need to Know About Health
Information Technology to Avoid Taking a HIT
Practice, Policy, and Ethics . . . . . . . . . . . . . . . . 75
Neurohospitalist 2.0: Next Steps in the Evolution
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Practical Legal Issues for Neurologists
Controversies in Brain Death Determination
L
A
L
L
$C5
$C9
A Resident Basic Science I: Neuropathology
C Research Career Development Symposium:
How to Be Successful in Academic Neuroscience
C13
Resident Basic Science II: Neuroanatomy
$
$C25 Cognitive Psychology of Neurologic Errors: Chalk Talk
Resident Basic Science III: Neuropharmacology
$C30
Clinical Research: Introduction and Methods
FC170
C39
Leadership for Women (must apply)
Clinical Research:
FC172
Drug Development and Clinical Trials
$C58 Neurological Disorders of Famous Composers
FC173 Clinical Reasoning: From a Novice to an Expert
C76
Advanced Leadership for Women (must apply)
Improving Your Leadership Skills:
$C86
A Practical Approach
FC175 Qualitative Research: The “How” and “Why” of Education
$C91 Career Development for Clinician Educators
FS19 Neurologic Education . . . . . . . . . . . . . . . . . . . 87
FP4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88
$C107 History of Neurology: The History of Neurologic
Disease from Cortex to Peripheral Nerve
FP6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110
FS44 History of Neurology . . . . . . . . . . . . . . . . . . . 119
The Promise of Novel Biomarker
FI11
Approaches in Advancing Treatment . . . . . . . . . .120
A
Practice, Policy, and Ethics
$C6
Research Methodology, Education, and History
A
C
L
C
L
L
C
Sleep
$C33 Hot Topics in Sleep Neurology
$C49 Approach to Sleep Symptoms: Sleepy or Sleepless
$C62 Interpretation of Polysomnography for
FS2
FH1
$C117
FI12
FP7
FS53
$C140
$C156
the Practicing Neurologist
Section Topic Controversies: Testing in Prodromal
Neurological Disease: Friend or Foe? . . . . . . . . . . 54
Sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
REM Sleep Behavior Disorder
Obesity and Neurological Disorders . . . . . . . . . . 121
Poster Session VII . . . . . . . . . . . . . . . . . . . .122
Sleep . . . . . . . . . . . . . . . . . . . . . . . . . . .133
Sleep for the Practicing Neurologist
Neuro Flash: Sleep Medicine
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Capitol City
CELEBRATION
Sunday, April 19 6:OO p.m.–1O:OO p.m.
Join your friends and colleagues for an exciting evening
filled with entertainment, including:
Neurobowl®
6:OO p.m.–8:OO p.m.
This popular event is one of the Annual Meeting’s premier
happenings. Neurobowl® showcases the best and brightest
in neurology competing for the coveted Neurobowl® trophy
in an entertaining game-show format.
Main Stage Music: Doctor’s Orders
8:OO p.m.–1O:OO p.m.
This energetic 10-piece variety band based in the
Washington, DC/Baltimore area will have you on your feet
with its diverse repertoire covering everything from
Top 40 to ‘70s to ‘80s to standards. Fronted by dynamic
singer/saxophonist Kyle Johnson and Miriamm Wright—
of Peaches and Herb fame—”the chemistry of the band is
obvious from the first chord,” says guitarist Bill McCarron.
“It’s not like it’s really a conscious effort on our part, we just
have a blast playing together.” No doubt, you’ll have a
blast listening to them.
Neuro Jazz
8:3O p.m.–9:3O p.m.
Swing out to your favorite jazz standards while
enjoying a scrumptious dessert. This four-piece
ensemble, led by AAN member Phillip Pearl,
MD, FAAN, will have your toes tapping and
fingers snapping to some of the most enduring
tunes of our time.
Integrated Neuroscience Session
I1
S New Windows into the Brain:
Saturday, April 18
8:00 a.m.–12:00 p.m.
Technological Advances in Frontline Neurologic
Diagnosis via the Visual and Oculomotor Systems
This program is offered in partnership with the North American Neuro-ophthalmology
Society and the AAN Neuro-ophthalmology/Neuro-otology Section.
Coordinators: Kevin A. Kerber, MD, and Beau Bruce, MD
Part I
8:00 a.m.–9:45 a.m.
8:00 a.m.–8:05 a.m.
Introduction
8:05 a.m.–8:35 a.m.
Invited Speaker
8:35 a.m.–8:40 a.m.
I1-1A Data Blitz
9:55 a.m.–10:25 a.m.
Kevin A. Kerber, MD, and Beau Bruce, MD
Retinal Microvascular Signs and Age-related Macular Degeneration Are
Associated with Incident Cerebral Microbleeds According to Location in
Older People: The AGES-Reykjavik Study Jie Ding, Chengxuan Qiu, Sigurdur
Sigurdsson, Qian Zhang, Gudny Eiriksdottir, Vilmundur Gudnason, Mark Van
Buchem, Mary Frances Cotch, Lenore Launer
Audience Q&A
Invited Speaker
Stop Radiating and Start Re-Positioning: Implementing Optimal Management of
BPPV Kevin A. Kerber, MD
9:25 a.m.–9:30 a.m.
Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit James Grotta
10:30 a.m.–10:35 a.m. I1-3B Data Blitz
Early Diagnosis of Posterior Fossa Stroke with Brainstem Evoked
Potentials Iftekhar Ahmed, Nikki Duggal, Neeta Duggal
10:35 a.m.–10:45 a.m. Audience Q&A
10:45 a.m.–11:15 a.m. Invited Speaker
The Future of Sideline Assessment: Tackling Concussion and TBI
Right Between the Eyes Laura J. Balcer, MD, MSCE, FAAN
11:15 a.m.–11:20 a.m. I1-4A Data Blitz
Sideline Testing in Youth and Collegiate Athletes: What Does Vision Add to the
Concussion Puzzle? Avri Bohm, Lisena Hasanaj, John-Ross Rizzo, Liliana Serrano,
Rachel Nolan, Nicholas Moehringer, Nikki Webb, Courtney Civitano, Dennis
Cardone, Arlene Silverio, Steven Galetta, Laura Balcer
11:20 a.m.–11:25 a.m. I1-4B Data Blitz
A Systematic Video Analysis of Concussion in the National Rugby
League Andrew Gardner, Grant Iverson, Magdalena Wojtowicz, Christopher Levi,
Michael Makdissi, Tanya Quinn, Sandy Shultz, David Wright, Peter Stanwell
I1-2A Data Blitz
Comparative Study Between Benign Paroxysmal Positional Vertigo (BPPV) of the
Horizontal Canal (H-BPPV) and Posterior Canal (P-BPPV) Ana Bisonni, Guillermo
Videla, Juan Ignacio Rojas, Edgardo Cristiano
9:30 a.m.–9:35 a.m.
I1-2B Data Blitz
9:35 a.m.–9:45 a.m.
9:45 a.m.–9:55 a.m.
Audience Q&A
Break
Invited Speaker
10:25 a.m.–10:30 a.m. I1-3A Data Blitz
I1-1B Data Blitz
Molecular Imaging of the Human Retina by Raman Spectroscopy Elena
Martinez-Lapiscina, Oscar Batet, Antoni Gonzalez, Albert Campos, Iker Bilbao,
Dídac Perez, Elena Fraga-Pumar, Rubén Torres-Torres, Yago Rossello, Bernardo
Sanchez-Dalmau, Ivan Amat-Roldan, Pablo Villoslada
8:45 a.m.–8:55 a.m.
8:55 a.m.–9:25 a.m.
9:55 a.m.–11:35 a.m.
In Pursuit of the ‘Eye ECG’: Eye Movement Based Stroke Diagnosis in Acute
Vertigo David E. Newman-Toker, MD, PhD, FAAN
Windows to the Brain: Non-mydriatic Ocular Fundus Photography in Neurological
Emergencies Beau Bruce, MD
8:40 a.m.–8:45 a.m.
Part II
11:25 a.m.–11:35 a.m. Audience Q&A
NIH Stroke Scale Assessment via Tablet-based Mobile Telestroke During
Ambulance Transport Is Feasible—Pilot Data from the Improving Treatment
with Rapid Evaluation of Acute Stroke via Mobile Telemedecine (iTREAT)
Study Matthew Padrick, Sherita Chapman, Timothy McMurri, Prachi Mehndiratta,
Christina Chee, Brian Gunnell, Chance Kimble, Jack Cote, Jason Lippman, Virginia
Burke, David Catell-Gordon, Karen Rheuban, Nina Solenski, Debra Perina, Bradford
Worrall, Andrew Southerland
Guided Poster Rounds
I1-5A
Retinal Segmentation
Distinguishes Neuromyelitis Optica
from Multiple Sclerosis Using Optical
Coherence Tomography Regardless of
Antibody Status Richard Loeb, Ashley
Finch, Adil Javed, Jacqueline Bernard
I1-5B
A Radiographic Target
Sign for Abnormal Vertebral Artery Flow
in Stroke Patients with Acute Vestibular
Syndrome Jorge Kattah, Jeffrey DeSanto,
Ali Saber Tehrani, John Pula, David
Newman-Toker
11:35 a.m.–12:00 p.m.
Nunley, Christopher Ryan, Judith Saxton,
Trevor Orchard, Tina Costacou, Howard
Aizenstein, John Ryan, Rachel Miller,
Caterina Rosano
Campos, Iker Bilbao, Dídac Perez, Elena
Fraga-Pumar, Rubén Torres-Torres, Yago
Rossello, Bernardo Sanchez-Dalmau, Ivan
Amat-Roldan, Pablo Villoslada
I1-5E
I1-5H
Quix Test Predicts Canal
Sidedness in BPPV Kevin Coughlin,
Krysten Sherrod, Jason Miles, Ryan
Fitzgerald, Garrett Barr, Jonathan Salud,
Shawn Adams, Charles Maitland
I1-5F
Determining Inter-rater
Reliability of Eye Tracking Methods for Use
with Persons with Severe Traumatic Brain
Injury Lorene Leung, Rachel Cohn, Therese
O'Neil-Pirozzi, Yelena Guller, Swathi Iyer,
Hong Pan, Emily Stern, Joseph Giacino
Retinal Microvascular Signs
and Age-related Macular Degeneration
Are Associated with Incident Cerebral
Microbleeds According to Location
in Older People: The AGES-Reykjavik
Study Jie Ding, Chengxuan Qiu, Sigurdur
Sigurdsson, Qian Zhang, Gudny Eiriksdottir,
Vilmundur Gudnason, Mark Van Buchem,
Mary Frances Cotch, Lenore Launer
I1-5D
I1-5G
I1-5C
Early Development of
Proliferative Retinopathy Increases Risk
of Cognitive Dysfunction in Middle-aged
Adults with Type 1 Diabetes Karen
48
Molecular Imaging
of the human Retina by Raman
Spectroscopy Elena Martinez-Lapiscina,
Oscar Batet, Antoni Gonzalez, Albert
Comparative Study
Between Benign Paroxysmal Positional
Vertigo (BPPV) of the Horizontal
Canal (H-BPPV) and Posterior Canal
(P-BPPV) Ana Bisonni, Guillermo Videla,
Juan Ignacio Rojas, Edgardo Cristiano
I1-5I
NIH Stroke Scale
Assessment via Tablet-based Mobile
Telestroke During Ambulance Transport Is
Feasible—Pilot Data from the Improving
Treatment with Rapid Evaluation of Acute
Stroke via Mobile Telemedecine (iTREAT)
study Matthew Padrick, Sherita Chapman,
Timothy McMurry, Prachi Mehndiratta,
Christina Chee, Brian Gunnell, Chance
Kimble, Jack Cote, Jason Lippman,
Virginia Burke, David Catell-Gordon, Karen
Rheuban, Nina Solenski, Debra Perina,
Bradford Worrall, Andrew Southerland
I1-5J
Benefits of Stroke
Treatment Delivered Using a Mobile
Stroke Unit James Grotta
I1-5K
Early Diagnosis of Posterior
Fossa Stroke with Brainstem Evoked
Potentials Nikki Duggal, Iftekhar Ahmed,
Neeta Duggal
I1-5L
Sideline Testing in Youth
and Collegiate Athletes: What Does
Vision Add to the Concussion Puzzle? Avri
Bohm, Lisena Hasanaj, John-Ross Rizzo,
Liliana Serrano, Rachel Nolan, Nicholas
Moehringer, Nikki Webb, Courtney
Civitano, Dennis Cardone, Arlene Silverio,
Steven Galetta, Laura Balcer
I1-5M
A Systematic Video
Analysis of Concussion in the National
Rugby League Andrew Gardner,
Grant Iverson, Magdalena Wojtowicz,
Christopher Levi, Michael Makdissi, Tanya
Quinn, Sandy Shultz, David Wright, Peter
Stanwell
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
I2
S Management of Asymptomatic
1:00 p.m.–5:00 p.m.
Cerebrovascular Lesions
This program is offered in partnership with the American Heart Association/American
Stoke Association and the AAN Stroke and Vascular Neurology Section.
Coordinators: Robert D. Brown, MD, FAAN, and J. P. Mohr, MD, FAAN
Part I
1:00 p.m.–2:45 p.m.
1:00 p.m.–1:05 p.m.
Introduction
1:05 p.m.–1:35 p.m.
Invited Speaker
Antonio Culebras, MD, FAAN, FAHA
Asymptomatic Carotid Disease: Uncertainties in Management and Future
Directions in Research. CREST -2 Visited James F. Meschia, MD, FAAN
1:35 p.m.–1:40 p.m.
I2-1A Data Blitz
1:40 p.m.–1:45 p.m.
I2-1B Data Blitz
Are Patients with Carotid Stenosis Receiving Optimal Medical Therapy? Sebastian Koch, Seemant Chaturvedi, Jose Romano
Cognitive Implications of Revascularization in Asymptomatic Carotid
Stenosis Chun-Jen Lin, Feng-Chi Chang, Pei-Chi Tu, Pei-Ning Wang, I-Hui Lee
1:45 p.m.–1:55 p.m.
Audience Q&A
1:55 p.m.–2:25 p.m.
Invited Speaker
2:25 p.m.–2:30 p.m.
I2-2A Data Blitz
2:30 p.m.–2:35 p.m.
I2-2B Data Blitz
2:35 p.m.–2:45 p.m.
Audience Q&A
2:45 p.m.–2:55 p.m.
Break
Intracranial Cavernous Malformations: Natural History, Genetics, Management,
and Future Directions in Research Michael Lawton, MD
Angiographically Occult Micro-arteriovenous Malformation as a Rare Cause of
Recurrent Intracerebral Hemorrhage Anand Patel, Ajay Tunguturi, Ajit Puri,
Majaz Moonis
Exceptional Aggressiveness of Cerebral Cavernous Malformation Disease
Associated with PDCD10 Mutations Tania Rebeiz, Abdul Ghani Mikati, Amy
Akers, Lingiioa Zhang, Issam Awad
Part II
2:55 p.m.–4:35 p.m.
2:55 p.m.–3:25 p.m.
Invited Speaker
3:25 p.m.–3:30 p.m.
I2-3A Data Blitz
3:30 p.m.–3:35 p.m.
I2-3B Data Blitz
3:35 p.m.–3:45 p.m.
Audience Q&A
3:45 p.m.–4:15 p.m.
Invited Speaker
4:15 p.m.–4:20 p.m.
I2-4A Data Blitz
4:20 p.m.–4:25 p.m.
I2-4B Data Blitz
4:25 p.m.–4:35 p.m.
Audience Q&A
Unruptured Brain Arteriovenous Malformations: Management, Controversies,
and Future Directions in Research. The ARUBA Experience J. P. Mohr, MD, FAAN
Predictors of Seizure Presentation Associated with Cerebral Arteriovenous
Malformations in a Prospective Cohort of 1,007 Patients Dale Ding, Robert
Starke, Mark Quigg, Chun-Po Yen, Colin Przybylowski, Blair Dodson, Jason
Sheehan
Withdrawn
Unruptured Intracranial Aneurysms: Uncertainties in Management and Future
Directions in Research Robert D. Brown, MD, FAAN
Prevalence of Asymptomatic Cerebral Aneurysm in General Population and
Ischemic Stroke Patient Ji Hwa Kim, Yeo-Jin Oh, Sang Won Han, Jong Yun Lee,
Kyung-Yul Lee
Impact of Menopausal Age on Size of Unruptured Intracranial Aneurysms and
Their Outcomes with Endovascular Therapy Sushrut Dharmadhikari, Kunakorn
Atchaneeyasakul, Norman Ajiboye, Sudheer Ambekar, Dileep Yavagal
Guided Poster Rounds
I2-5A
Prevalence and Healing
Rates of Duplex Detected Carotid Plaque
Ulcers Sushrut Dharmadhikari, Ari
Bennett, Jose Romano, Nelly Campo,
Sebastian Koch
I2-5BCoated-platelet
Levels Are Associated with Stenosis
Progression in Patients with Carotid
Atherosclerosis Angelia Kirkpatrick,
Andrea Vincent, Nhan Nguyen, George
Dale, Calin Prodan
I2-5C
A Population-based
Study of the Incidence and Case
Fatality of Intracerebral Hemorrhage of
Undetermined Etiology Afzal Mohammad,
Mushtaq Qureshi, Ahmed Malik, Mariam
Suri, Muhammad Suri, Adnan Qureshi
4:35 p.m.–5:00 p.m.
I2-5D
Accurate Outcome
Predictions for Intracerebral Hemorrhage
Patients Are More Likely Than Inaccurate
Predictions to be Influenced by Comorbidities Not Included in Clinical
Scales David Hwang, Cameron Dell, Mary
Sparks, Tiffany Watson, Carl Langefeld,
Mary Comeau, Jonathan Rosand, Thomas
Battey, Sebastian Koch, Mario Perez,
Michael James, Jessica McFarlin, Jennifer
Osborne, Daniel Woo, Steven Kittner, Kevin
Sheth
I2-5E
Patients Consenting to or
Declining Extended Follow-up (Up to Ten
Years) in the Carotid Revascularization
Endarterectomy (CEA) versus Stenting
(CAS) Trial (CREST) Alice Sheffet, Ariane
Mackey, William Brooks, Wayne Clark,
Michael Hill, Jenifer Voeks, Susan Hughes,
MeeLee Tom, Mary Longbottom, Virginia
Howard, Thomas Brott
Fast, Easy, Online Registration · AAN.com/view/AM15
I2-5F
Are patients with Carotid
Stenosis Receiving Optimal Medical
Therapy? Sebastian Koch, Seemant
Chaturvedi, Jose Romano
I2-5G
Cognitive Implications
of Revascularization in Asymptomatic
Carotid Stenosis Chun-Jen Lin, Feng-Chi
Chang, Pei-Chi Tu, Pei-Ning Wang, I-Hui
Lee
I2-5H
Angiographically Occult
Micro-arteriovenous Malformation as a
Rare Cause of Recurrent Intracerebral
Hemorrhage Anand Patel, Ajay Tunguturi,
Ajit Puri, Majaz Moonis
I2-5I
Exceptional Aggressiveness
of Cerebral Cavernous Malformation
Disease Associated with PDCD10
Mutations Tania Rebeiz, Abdul Ghani
Mikati, Amy Akers, Lingiioa Zhang, Issam
Awad
I2-5J
Predictors of Seizure
Presentation Associated with Cerebral
Arteriovenous Malformations in a
Prospective Cohort of 1,007 Patients Dale
Ding, Robert Starke, Mark Quigg, Chun-Po
Yen, Colin Przybylowski, Blair Dodson,
Jason Sheehan
I2-5KWithdrawn
I2-5L
Prevalence of
Asymptomatic Cerebral Aneurysm in
General Population and Ischemic Stroke
Patient Ji Hwa Kim, Yeo-Jin Oh, Sang
Won Han, Jong Yun Lee, Kyung-Yul Lee
I2-5M
Impact of Menopausal
age on Size of Unruptured Intracranial
Aneurysms and Their Outcomes
with Endovascular Therapy Sushrut
Dharmadhikari, Kunakorn Atchaneeyasakul,
Norman Ajiboye, Sudheer Ambekar, Dileep
Yavagal
49
Saturday
April 18
Integrated Neuroscience Session
Integrated Neuroscience Session
I3
S Dopamine-mediated Neural Plasticity in
Sunday, April 19
8:00 a.m.–12:00 p.m.
Motor and Non-motor Circuits
This program is offered in partnership with the International Parkinson and
Movement Disorders Society and the AAN Movement Disorders Section.
Coordinators: Irene Litvan, MD, FAAN, and David G. Standaert, MD, PhD, FAAN
Part I
8:00 a.m.–9:45 a.m.
8:00 a.m.–8:05 a.m.
Introduction
8:05 a.m.–8:35 a.m.
Invited Speaker
9:55 a.m.–10:25 a.m.
Irene Litvan, MD, FAAN, and David G. Standaert, MD, PhD, FAAN
I3-1A Data Blitz
I3-1B Data Blitz
Parkinson’s Disease Progression Is Associated with Increased Putaminal
Serotonin to Dopamine Transporter Ratio: Relevance for Dyskinesias Andreas
Roussakis, Marios Politis, David Towey, Paola Piccini
8:45 a.m.–8:55 a.m.
Audience Q&A
8:55 a.m.–9:25 a.m.
Invited Speaker
I3-2B Data Blitz
Brain Structural and Functional Abnormalities in Parkinson’s Disease Patients
with Freezing of Gait Elisabetta Sarasso, Federica Agosta, Elisa Canu, Maria
Antonietta Volontè, Lidia Sarro, Sebastiano Galantucci, Roberto Gatti, Andrea
Falini, Giancarlo Comi, Massimo Filippi
Audience Q&A
9:45 a.m.–9:55 a.m.
Break
Global Long-term Registry on Efficacy and Safety of Levodopa-carbidopa
Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care
(GLORIA)—Interim Results on Non-motor Symptoms Angelo Antonini, K. Ray
Chaudhuri, Ashley Yegin, Lars Bergmann, Werner Poewe
10:35 a.m.–10:45 a.m. Audience Q&A
10:45 a.m.–11:15 a.m. Invited Speaker
Resting Connectivity Functional MRI in Understanding Cognitive Impairment in
Parkinson's Disease Nina Browner
I3-2A Data Blitz
9:35 a.m.–9:45 a.m.
10:30 a.m.–10:35 a.m. I3-3B Data Blitz
11:15 a.m.–11:20 a.m. I3-4A Data Blitz
Reorganization of Cortico-striatal Circuits in Healthy G2019S LRRK2
Carriers Rick Helmich, Avner Thaler, Bart van Nuenen, Tanya Gurevich, Anat
Mirelman, Karen Marder, Susan Bressman, Avi Orr-Urtreger, Nir Giladi, Bastiaan
Bloem, Ivan Toni
9:30 a.m.–9:35 a.m.
Neuroanatomical Correlates of Cognitive Functioning Across the Parkinson's
Disease Cognitive Spectrum Doug Merkitch, Glenn Stebbins, Bryan Bernard,
Jennifer Goldman
Dopamine-dependent Systems and Their Behavioral Consequences in
Parkinson's Disease: Functional Imaging Studies James Rowe, BA, BM, BCh, PhD
Cellular Mechanisms and Circuitry Involved in Dopamine-dependent
Plasticity Alexandra Nelson, MD, PhD
9:25 a.m.–9:30 a.m.
Invited Speaker
10:25 a.m.–10:30 a.m. I3-3A Data Blitz
Putaminal Dopamine Turnover Predicts Levodopa-induced Motor Complications
in De Novo Parkinson’s Disease Matthias Löhle, Julia Mende, Martin Wolz,
Bettina Beuthien-Baumann, Liane Oehme, Jörg van den Hoff, Jörg Kotzerke, Heinz
Reichmann, Alexander Storch
8:40 a.m.–8:45 a.m.
9:55 a.m.–11:35 a.m.
Non-motor Aspects of Dopamine-dependent Plasticity in Parkinson’s
Disease Daniel Weintraub, MD
Cellular Mechanisms of Striatal Plasticity in Movement Disorders David G. Standaert, MD, PhD, FAAN
8:35 a.m.–8:40 a.m.
Part II
11:20 a.m.–11:25 a.m. I3-4B Data Blitz
Impulse Control Disorders Are Associated with REM Sleep Behavior Disorder in
Patients with Parkinson’s Disease: A Video-polysomnographic Study Maria Livia
Fantini, Maurizio Zibetti, Michela Figorilli, Beudin Patricia, Ana Marques, Debilly
Bérangère, Derost Philippe, Miguel Ulla, Nicolas Vitello, Tiphaine Vidal, Monica
Puligheddu, Alessandro Cicolin, Leonardo Lopiano, Franck Durif
11:25 a.m.–11:35 a.m. Audience Q&A
Guided Poster Rounds
I3-5A
De-novo Amantadine
Treatment Delays Onset of Dyskinesias in
Patients with Parkinson Disease Maja Relja
I3-5B
Self-ratings of Impulsive
and Compulsive Behaviors Decrease
in Parkinson’s Patients Following Deep
Brain Stimulation of the Subthalamic
Nucleus Katherine Kudyba Morone,
Wylie Scott, Daniel Claassen, Nelleke
Van Wouwe, Kristen Kanoff, Olivia Roman,
Lauren Griffin, Joseph Neimat
I3-5C
Learning Processes
in Parkinson’s Disease and Healthy
Aging Madeleine Sharp, Karin Foerde,
Nathaniel Daw, Daphna Shohamy
I3-5D
Effects of Aerobic
Exercise on Striatum and Substantia
Nigra in Parkinson’s Disease Ergun Uc,
Vincent Magnotta, Hans Johnson, Kasra
Zarei, Martin Cassell, Joel Bruss, Kevin
Doerschug, Teri Thomsen, Joel Kline,
Steven Anderson, Matthew Rizzo, Arthur
Kramer, Michelle Voss, Jeffrey Dawson,
Warren Darling
50
11:35 a.m.–12:00 p.m.
I3-5E
Incidence of Impulsive and
Compulsive Behavior Type Adverse Events
with Long-term Rotigotine: A Post-hoc
Analysis Angelo Antonini, Mahnaz
Asgharnejad, Lars Bauer, Frank Grieger,
Babak Boroojerdi
I3-5F Putaminal Dopamine
Turnover Predicts Levodopa-induced
Motor Complications in De Novo
Parkinson’s Disease Matthias Löhle, Julia
Mende, Martin Wolz, Bettina BeuthienBaumann, Liane Oehme, Jörg van den Hoff,
Jörg Kotzerke, Heinz Reichmann, Alexander
Storch
I3-5G Parkinson’s Disease
Progression Is Associated with Increased
Putaminal Serotonin to Dopamine
Transporter Ratio: Relevance for
Dyskinesias Andreas Roussakis, Marios
Politis, David Towey, Paola Piccini
I3-5H Reorganization of Corticostriatal Circuits in Healthy G2019S LRRK2
carriers Rick Helmich, Avner Thaler,
Bart van Nuenen, Tanya Gurevich, Anat
Mirelman, Karen Marder, Susan Bressman,
Avi Orr-Urtreger, Nir Giladi, Bastiaan
Bloem, Ivan Toni
I3-5I Brain Structural and
Functional Abnormalities in Parkinson’s
Disease Patients with Freezing of
Gait Elisabetta Sarasso, Federica Agosta,
Elisa Canu, Maria Antonietta Volontè, Lidia
Sarro, Sebastiano Galantucci, Roberto
Gatti, Andrea Falini, Giancarlo Comi,
Massimo Filippi
I3-5J Neuroanatomical
Correlates of Cognitive Functioning
Across the Parkinson's Disease Cognitive
Spectrum Doug Merkitch, Glenn Stebbins,
Bryan Bernard, Jennifer Goldman
I3-5K Global Long-term Registry
on Efficacy and Safety of Levodopacarbidopa Intestinal Gel in Patients with
Advanced Parkinson’s Disease in Routine
Care (GLORIA)—Interim Results on Nonmotor Symptoms Angelo Antonini, K. Ray
Chaudhuri, Ashley Yegin, Lars Bergmann,
Werner Poewe
I3-5L Resting Connectivity
Functional MRI in Understanding Cognitive
Impairment in Parkinson's Disease Nina
Browner
I3-5M Impulse Control Disorders
Are Associated with REM Sleep Behavior
Disorder in Patients with Parkinson’s
Disease: A Video-polysomnographic
Study Maria Livia Fantini, Maurizio
Zibetti, Michela Figorilli, Beudin Patricia,
Ana Marques, Debilly Bérangère, Derost
Philippe, Miguel Ulla, Nicolas Vitello,
Tiphaine Vidal, Monica Puligheddu,
Alessandro Cicolin, Leonardo Lopiano,
Franck Durif
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Section Topic Controversies
S1 Section Topic Controversies:
Antiplatelets, Anticoagulants, or Stenting for
Acute Treatment of Cervical/Cranial Dissection?
1:00 p.m.–2:30 p.m.
1:00 p.m.–1:05 p.m.Introduction
Antonio Culebras, MD, FAAN, FAHA
1:55 p.m.–2:05 p.m.Rebuttal
Louis R. Caplan, MD, FAAN
1:05 p.m.–1:30 p.m.
Cervical/Cranial Arterial Dissection:
Medical Treatment
Louis R. Caplan, MD, FAAN
2:05 p.m.–2:15 p.m.Rebuttal
Dileep Yavagal, MD
1:30 p.m.–1:55 p.m.
Cervical/Cranial Arterial Dissection: Stenting
Dileep Yavagal, MD
2:15 p.m.–2:30 p.m.
Sunday
April 19
Moderator: Antonio Culebras, MD, FAAN, FAHA
Open Discussion and Questions
Antonio Culebras, MD, FAAN, FAHA
RED: 15AM Gives Back Ad_Lbstract Listing, halfpage horizontal
Usage: High resolution PDF for Abstract Listing
Spec: 8.25” x 5.4375”, +.125” bleeds, BW
Give Back to Our
2015 Annual Meeting
Host City
The AAN is partnering with two charitable organizations to help
give back to the Washington, DC, community during the 2015 AAN
Annual Meeting. Throughout the week of the Annual Meeting, drop
off unused toiletry items in the AAN Gives Back booth to be donated
to Neediest Kids and Children’s Inn at NIH. Your donations will
help children and their families receive vital medical treatments and
students receive necessities to help them achieve academic success.
A Program of The National Center for Children and Families (NCCF)
Monetary donations are also being accepted for
Neediest Kids at the AAN Gives Back booth and online at
AAN.com/view/AANGivesBack. The AAN will match up to
$5,000 for donations received now through April 25.
LEARN MORE AND DONATE AT
AAN.com/view/AANGivesBack
Integrated Neuroscience Session
I4
Sunday, April 19
S Infectious, Paraneoplastic, and Autoimmune
1:00 p.m.–5:00 p.m.
Encephalopathies: Advances in Clinical Diagnosis
and Emerging Insights about Pathogenesis
This program is offered in partnership with the Society for Neuro-oncology and the
AAN Neuro-infectious Disease and Neuro-oncology Sections.
Coordinators: Michael R. Wilson, MD, and Josep O. Dalmau, MD, PhD
Part I
1:00 p.m.–2:45 p.m.
1:00 p.m.–1:05 p.m.
Introduction
1:05 p.m.–1:35 p.m.
Invited Speaker
Michael R. Wilson, MD, and Josep O. Dalmau, MD, PhD
I4-1A Data Blitz
Activation of HERV-K and Response to Antiretroviral Therapy in Patients with
HIV Infection and Motor Neuron Disease Bryan Smith, Richa Tyagi, Wenxue Li,
Mary Wright, Rose McConnell, Elyse Singer, Ty Nguyen, Tanya Lehky, Thomas
Uldrick, Priscila Goncalves, Tariq Alfahad, Joseph Berger, Avindra Nath
1:40 p.m.–1:45 p.m.
I4-1B Data Blitz
Evaluation of Neurofilament Heavy Chain as a Marker of Neuroaxonal Pathology
and Prognosis in Acute Encephalitis Johann Sellner, Nicholas Davies, Robin
Howard, Axel Petzold
1:45 p.m.–1:55 p.m.
Audience Q&A
1:55 p.m.–2:25 p.m.
Invited Speaker
2:25 p.m.–2:30 p.m.
I4-2A Data Blitz
Chronic Complications of Encephalitis: HIV and Beyond Felicia Chow, MD, MAS
Rapidly Progressive Dementia and Myoclonus with Elevated CSF IgG
Index in Young Adult Immigrants: Treatable, but Not Always with
Immunosuppression Cheryl Jay, Lara Zimmermann, Karen DaSilva
2:30 p.m.–2:35 p.m.
I4-2B Data Blitz
Role of C-Jun N-terminal Kinase (JNK) Signaling in Varicella Zoster Virus
Infection of Neurons Arun Venkatesan, Labchan Rajbhandari, Sravya Kurapati,
Tomohiko Sadaoka, Jeffrey Cohen
2:35 p.m.–2:45 p.m.
Audience Q&A
2:45 p.m.–2:55 p.m.
Break
2:55 p.m.–4:35 p.m.
2:55 p.m.–3:25 p.m.
Invited Speaker
3:25 p.m.–3:30 p.m.
I4-3A Data Blitz
3:30 p.m.–3:35 p.m.
I4-3B Data Blitz
Autoimmune Encephalitis at the Confluence of Neuronal and Glial
Autoimmunity Markus Reindl, PhD
Next-generation Sequencing for Encephalitis Diagnostics: Case
Examples Joseph DeRisi, PhD
1:35 p.m.–1:40 p.m.
Part II
Spectrum of MOG Autoantibody-associated Inflammatory Diseases in Pediatric
Patients Silvia Tenembaum, Patrick Waters, Maria Leite, Mark Woodhall, Juan
Princich, Martin Segura, Maria Talarico, Marina Szlago, Angela Vincent
Risk Factors and Final Diagnoses of Patients First Diagnosed as Infectious Acute
Disseminated Encephalomyelitis (ADEM): A Single-center Study Diederik
Koelman, Tanuja Chitnis, Farrah Mateen
3:35 p.m.–3:45 p.m.
Audience Q&A
3:45 p.m.–4:15 p.m.
Invited Speaker
4:15 p.m.–4:20 p.m.
I4-4A Data Blitz
4:20 p.m.–4:25 p.m.
I4-4B Data Blitz
4:25 p.m.–4:35 p.m.
Audience Q&A
Walking on the Gray Side: When Your Patient Does Not Fit the Model Francesc Graus, MD
Methotrexate Experience in Eight Pediatric Patients with Anti-N-methyl-DAspartate-receptor Encephalitis Alfredo Ramirez, Antonio Bravo-Oro, Ildefonso
Rodriguez-Leyva, Carlos Abud-Mendoza
Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118
Patients Amy Jones, Sean Pittock, Vanda Lennon, Scott Eggers, J. Ahlskog,
Andrew McKeon
Guided Poster Rounds
I4-5A
Autoimmune Encephalitis
in the ICU: Serological Spectrum,
Clinical Courses, Complications and
Outcomes Andrew McKeon, Manoj Mittal,
Sara Hocker, Sean Pittock, Eelco Wijdicks,
Alejandro Rabinstein
I4-5B
Clinical Features,
Diagnostic Findings, and Treatment of
Adult-onset Opsoclonus-myoclonus
Syndrome: A Case Series Pooja
Raibagkar, Shamik Bhattacharyya, Olga
Rosenvald Szenberg, Ivana Vodopivec,
Shirley Wray
I4-5C
Gait Disturbance as the
Initial Presenting Symptom in Young
Children with Anti-NMDA Receptor
(Anti-NMDAR) Encephalitis: A Case
Series Anusha Yeshokumar, Jessica Klein,
Kristin Baranano, Carlos Pardo-Villamizar
52
4:35 p.m.–5:00 p.m.
I4-5DNeurological
Manifestations of Acute Dengue
Virus Infection: A Study from Tropical
Country—India Devashish Ruikar, Sita
Jayalakshmi, Mohandas Surath
I4-5E
Quantitative Detection of
Human Herpesvirus-6 with Digital Droplet
PCR in a Patient with Post-transplant HHV6 Encephalitis Bridgette Jeanne Billioux,
Steven Jacobson
I4-5F Activation of HERV-K and
Response to Antiretroviral Therapy in
Patients with HIV Infection and Motor
Neuron Disease Bryan Smith, Richa Tyagi,
Wenxue Li, Mary Wright, Rose McConnell,
Elyse Singer, Ty Nguyen, Tanya Lehky,
Thomas Uldrick, Priscila Goncalves, Tariq
Alfahad, Joseph Berger, Avindra Nath
I4-5H Rapidly Progressive
Dementia and Myoclonus with Elevated
CSF IgG Index in Young Adult Immigrants:
Treatable, but Not Always with
Immunosuppression Cheryl Jay, Lara
Zimmermann, Karen DaSilva
I4-5K I4-5I I4-5L Role of C-Jun N-terminal
Kinase (JNK) Signaling in Varicella
Zoster Virus Infection of Neurons Arun
Venkatesan, Labchan Rajbhandari, Sravya
Kurapati, Tomohiko Sadaoka, Jeffrey Cohen
I4-5J Spectrum of MOG
Autoantibody-associated Inflammatory
Diseases in Pediatric Patients Silvia
Tenembaum, Patrick Waters, Maria Leite,
Mark Woodhall, Juan Princich, Martin
Segura, Maria Talarico, Marina Szlago,
Angela Vincent
Risk Factors and Final
Diagnoses of Patients First Diagnosed
as Infectious Acute Disseminated
Encephalomyelitis (ADEM): A Singlecenter Study Diederik Koelman, Tanuja
Chitnis, Farrah Mateen
Methotrexate Experience
in Eight Pediatric Patients with
Anti-N-methyl-D-Aspartate-receptor
Encephalitis Alfredo Ramirez, Antonio
Bravo-Oro, Ildefonso Rodriguez-Leyva,
Carlos Abud-Mendoza
I4-5M Autoimmune Cerebellar
Ataxia: Treatment Responses and
Outcomes in 118 Patients Amy Jones,
Sean Pittock, Vanda Lennon, Scott Eggers,
J. Ahlskog, Andrew McKeon
I4-5G Evaluation of Neurofilament
Heavy Chain as a Marker of Neuroaxonal
Pathology and Prognosis in Acute
Encephalitis Johann Sellner, Nicholas
Davies, Robin Howard, Axel Petzold
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Integrated Neuroscience Session
I5
S Pediatric Neurotrauma:
Monday, April 20
8:00 a.m.–12:00 p.m.
From Coma to Concussions
This program is offered in partnership with the Child Neurology Society and the
AAN Child Neurology and Sports Neurology Sections.
Coordinators: Mark Wainwright, MD, PhD, and Christopher Giza, MD
8:00 a.m.–9:45 a.m.
Part II
9:55 a.m.–11:35 a.m.
8:00 a.m.–8:05 a.m.
Introduction
9:55 a.m.–10:25 a.m. Invited Speaker
8:05 a.m.–8:35 a.m.
Invited Speaker
10:25 a.m.–10:30 a.m. I5-3A Data Blitz
8:35 a.m.–8:40 a.m.
I5-1A Data Blitz
Mark Wainwright, MD, PhD, and Christopher Giza, MD
Pediatric TBI Physiology and Neurocritical Care Mark Wainwright, MD, PhD
Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains
Following Repetitive Traumatic Brain Injury in Swine John Duda, James Harris,
Emory Kuo, D. Cullen
8:40 a.m.–8:45 a.m.
I5-1B Data Blitz
8:45 a.m.–8:55 a.m.
Audience Q&A
8:55 a.m.–9:25 a.m.
Invited Speaker
9:25 a.m.–9:30 a.m.
I5-2A Data Blitz
Efficacy of Minocycline in Female Rats after Mild Diffuse Traumatic Brain
Injury L. Turtzo, Neekita Janaria, Jacob Lescher, William Tu, Joseph Frank
EEG Monitoring for Moderate/Severe Pediatric TBI Nicholas Abend, MD
Activation of Plasmacytoid Dendritic Cells in Neuromyelitis Optica
Patients Rafael Dias-Carneiro, Marilia Andrade, Felipe Von Glehn Silva, Alliny
Dionete, Adriel Moraes, Carlos Otavio Brandao, Vinicius Boldrini, Alfredo
Damasceno, Fernando Pradella, Guilherme Morais, Paula Russini, Alessandro
Farias, Benito Damasceno, Charles Tilbery, Leonilda Santos
9:30 a.m.–9:35 a.m.
I5-2B Data Blitz
9:35 a.m.–9:45 a.m.
Audience Q&A
9:45 a.m.–9:55 a.m.
Break
Neurologic Exam Findings and Clinical Manifestations of Post-concussion
Syndrome in a Pediatric Population Devon Cohen, Francis Conidi
Neuroimaging of Pediatric TBI TBD
Changes in Resting State Functional Connectivity Across a Season of High
School Football Michael Clark, Samuel Kuzminski, Kevin Guskiewicz, Jeffrey
Petrella
10:30 a.m.–10:35 a.m. I5-3B Data Blitz
DTI Changes in Bilateral Uncinate Fasiculus Following Acute, but Not Chronic
Symptomatic Concussion in Adolescence Rejean Guerriero, Marie Drottar,
William Meehan III, P. Grant, Rebekah Mannix
10:35 a.m.–10:45 a.m. Audience Q&A
10:45 a.m.–11:15 a.m. Invited Speaker
Translational Science of Pediatric TBI and Mechanism-based
Interventions Christopher Giza, MD
11:15 a.m.–11:20 a.m. I5-4A Data Blitz
Sleep and Concussion Review and Evaluation (SCORE): Sleep Disorders in
Pediatric Sports-related Concussions Ping-Ru Ko, Carey Lockhart, John Lockhart,
Maida Chen
11:20 a.m.–11:25 a.m. I5-4B Data Blitz
Physicians' Management Practices and Perceived Health Risks when
Postconcussion Symptoms Persist Sean Rose, Anastasia Fischer, Geoffrey Heyer
11:25 a.m.–11:35 a.m. Audience Q&A
Guided Poster Rounds
I5-5A
Induced Normothermia
in Severe Traumatic Brain Injury
Patients Deborah Green-LaRoche,
Tudor Sturzoiu, Helena Lau, Anna Marisa
Cervantes-Arslanian, Joseph Burns
I5-5B
Psychiatric Symptoms as
a Predictor of Outcome in Patients with
Post-concussive Syndrome Arun Chhabra,
Allison Weathers, Bichun Ouyang
I5-5C
Characteristics of
Post-concussive Headaches in
Children Presenting to the Neurology
Clinic Karameh Kuemmerle
I5-5D
Pathological Correlation
of Diffusion Tensor Imaging and
Magnetization Transfer Biomarkers in a
Preclinical Model of Mild Traumatic Brain
Injury Rashida Williams, William Tu, Jacob
Lescher, Christine Turtzo, Joseph Frank
Monday
April 20
Part I
11:35 a.m.–12:00 p.m.
I5-5E
Younger Children Recover
Faster and Have Less Premorbid
Conditions Than Adolescents with
Concussion Rejean Guerriero, Karameh
Hawash, Michael Pepin, Robert Wolff,
William Meehan III
I5-5F Neuronal Plasmalemmal
Disruptions Are Exacerbated in
Perivascular Domains Following Repetitive
Traumatic Brain Injury in Swine John
Duda, James Harris, Emory Kuo, D. Cullen
I5-5G Efficacy of Minocycline in
Female Rats after Mild Diffuse Traumatic
Brain Injury L. Turtzo, Neekita Janaria,
Jacob Lescher, William Tu, Joseph Frank
Fast, Easy, Online Registration · AAN.com/view/AM15
I5-5H Activation of Plasmacytoid
Dendritic Cells in Neuromyelitis Optica
Patients Rafael Dias-Carneiro, Marilia
Andrade, Felipe Von Glehn Silva, Alliny
Dionete, Adriel Moraes, Carlos Otavio
Brandao, Vinicius Boldrini, Alfredo
Damasceno, Fernando Pradella, Guilherme
Morais, Paula Russini, Alessandro Farias,
Benito Damasceno, Charles Tilbery,
Leonilda Santos
I5-5I Neurologic Exam Findings
and Clinical Manifestations of Postconcussion Syndrome in a Pediatric
Population Devon Cohen, Francis Conidi
I5-5J Changes in Resting State
Functional Connectivity Across a Season
of High School Football Michael Clark,
Samuel Kuzminski, Kevin Guskiewicz,
Jeffrey Petrella
I5-5K DTI Changes in Bilateral
Uncinate Fasiculus Following Acute, but
Not Chronic Symptomatic Concussion in
Adolescence Rejean Guerriero, Marie
Drottar, William Meehan III, P. Grant,
Rebekah Mannix
I5-5L Sleep and Concussion
Review and Evaluation (SCORE): Sleep
Disorders in Pediatric Sports-related
Concussions Ping-Ru Ko, Carey Lockhart,
John Lockhart, Maida Chen
I5-5M Physicians' Management
Practices and Perceived Health Risks
when Postconcussion Symptoms
Persist Sean Rose, Anastasia Fischer,
Geoffrey Heyer
53
Section Topic Controversies
Monday, April 20
S2 Section Topic Controversies: Testing in Prodromal
Neurological Disease: Friend or Foe? 1:00 p.m.–2:30 p.m.
Moderator: Michael J. Howell, MD
1:00 p.m.–1:10 p.m.
Welcome and Introduction of Prodromal
Syndromes Michael Howell, MD
2:00 p.m.–2:25 p.m.
Open Discussion and Questions A. Jon Stoessl, MD, FAAN, and Ken Marek, MD
1:10 p.m.–1:35 p.m.
Prodromal Parkinson’s Disease, Huntington’s
Disease and Alzheimer’s Disease Ken Marek, MD
2:25 p.m.–2:30 p.m.
Summary, Conclusion, and Adjournment Michael Howell, MD
1:35 p.m.–2:00 p.m.
Imaging Studies in Preclinical Parkinson’s Disease
and Genetic Testing A. Jon Stoessl, MD, FAAN
Neuroscience Is…
“Neuroscience Is…” is a nationwide campaign by the American
Academy of Neurology to build public awareness and demonstrate the
importance of neuroscience research in the care of neurology patients
and the development of cures for brain diseases.
Neuroscience is Essential
Why do you think Neuroscience is essential?
Stop by our video booth in the Poster Hall and tell us.
AAN.com/view/NeuroscienceIsEssential
Integrated Neuroscience Session
I6
S Future Therapies: How We Will Be Treating,
1:00 p.m.–5:00 p.m.
Preventing, and Curing Epilepsy in the Year 2025
This program is offered in partnership with the American Epilepsy Society
and the AAN Epilepsy Section.
Coordinators: Amy R. Brooks-Kayal, MD, and Anne Anderson, MD
1:00 p.m.–2:45 p.m.
1:00 p.m.–1:05 p.m.
Introduction
1:05 p.m.–1:35 p.m.
Invited Speaker
Amy R. Brooks-Kayal, MD, and Anne Anderson, MD
Development of Anti-inflammatory and Immune Modulatory
Therapies for Epilepsy Karen Wilcox, PhD
1:35 p.m.–1:40 p.m.
I6-1A Data Blitz
1:40 p.m.–1:45 p.m.
I6-1B Data Blitz
1:45 p.m.–1:55 p.m.
Audience Q&A
1:55 p.m.–2:25 p.m.
Invited Speaker
Indomethacin Increases the Latency to Seizure Onset and Decreased the Number
of Seizures in Zebrafish Seizure Model Patricia Barbalho, Iscia Lopes-Cendes,
Claudia Maurer-Morelli
Role of NOX2 in Seizure Susceptibility of Mice Following Systemic
Inflammation Hung-Ming Wu, Wan-Yu Huang
Cell Signaling Modulators as Novel Disease Modifying
Therapies for Epilepsy Anne Anderson, MD
2:25 p.m.–2:30 p.m.
I6-2A Data Blitz
Everolimus Long-term Safety and Efficacy in Patients with Subependymal Giant
Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC):
Final Analysis of a Phase 2 Study David Franz, Marguerite Care, Katherine
Holland-Bouley, Karen Agricola, Cynthia Tudor, Noah Berkowitz, Sara Miao,
Severine Peyrard, Darcy Krueger
2:30 p.m.–2:35 p.m.
I6-2B Data Blitz
Targeted Treatment of Migrating Partial Seizures of Infancy with Quinidine David
Bearden, Alanna Strong, Dennis Dlugos, Marissa DiGiovine, Ethan Goldberg
2:35 p.m.–2:45 p.m.
Audience Q&A
2:45 p.m.–2:55 p.m.
Break
Part II
2:55 p.m.–4:35 p.m.
2:55 p.m.–3:25 p.m.
Invited Speaker
3:25 p.m.–3:30 p.m.
I6-3A Data Blitz
3:30 p.m.–3:35 p.m.
I6-3B Data Blitz
Lighting the Way: Optogenetic Approaches for Treatment of Epilepsy Ivan Soltesz, PhD
Decreased Amygdala Resting State Functional Connectivity in Patients with Left
Temporal Lobe Epilepsy Jane Allendorfer, Rodolphe Nenert, Basia Szaflarski,
Nancy Cohen, Jeffrey Binder, Zhifeng Kou, Roy Martin, Lawrence Ver Hoef, Jerzy
Szaflarski
Using Neural Networks to Predict the Effects and Guide the Application of
Transcranial Direct Current Stimulation David Fischer, Peter Fried, Alvaro PascualLeone, Michael Fox
3:35 p.m.–3:45 p.m.
Audience Q&A
3:45 p.m.–4:15 p.m.
Invited Speaker
4:15 p.m.–4:20 p.m.
I6-4A Data Blitz
4:20 p.m.–4:25 p.m.
I6-4B Data Blitz
4:25 p.m.–4:35 p.m.
Audience Q&A
Seizure Detection/Prediction Devices and Therapies Gregory A. Worrell, MD
Combining Electroencephalographic Time-frequency and Source Analysis
Methods for Improve Epileptogenic Zones Localization Elena Cuspineda Bravo,
Eduardo Martinez Montes, Ana Olivares Torres, Calixto Machado
Novel Ambulatory EMG-based GTC Seizure Detection Device for Home and
Hospital Use Jose Cavazos, Michael Girouard, Luke Whitmire
Guided Poster Rounds
I6-5A
4:35 p.m.–5:00 p.m.
Assessment of
the Anticonvulsant Effects and
Tolerability Profile of Cannabidiol:
GW Pharmaceuticals’ Preclinical
Program Nicholas Jones, Andrew Hill,
Thomas Hill, Isabelle Peres, Rebecca
Hadid, Stephen Wright, Gary Stephens,
Claire Williams, Benjamin Whalley
I6-5E
I6-5B
I6-5F Intractable Reflex Epilepsy
Treated Successfully with Deep Brain
Stimulation Anteneh Feyissa, Squire
Stead, Jamie Van Gompel, Jeffrey Britton
I6-5COptogenetic
Neuromodulation Genko Oyama,
Nobutaka Hattori
I6-5D
B and Plasma Cells and
Meningeal Follicles Are a Part of NeuroInflammatory Mechanisms Associated
with Rasmussen’s Encephalitis: New Clues
About Pathogenesis Anupama Kumar,
Maria Reyes-Mantilla, Adam Hartman,
Carlos Pardo-Villamizar, Carlos PardoVillamizar
Does a Standardized
Multidisciplinary Approach Improve
Outcomes for Children with NMDA
Receptor Antibody Encephalitis? A
Preliminary Assessment of a Single Center
Experience Mered Parnes, Amber Stocco,
Trung Nguyen, Jun Teruya, Jeanine Graf,
Eyal Muscal
Indomethacin Increases the
Latency to Seizure Onset and Decreased
the Number of Seizures in Zebrafish
Seizure Model Patricia Barbalho, Iscia
Lopes-Cendes, Claudia Maurer-Morelli
I6-5G Role of NOX2 in Seizure
Susceptibility of Mice Following Systemic
Inflammation Hung-Ming Wu, Wan-Yu
Huang
Fast, Easy, Online Registration · AAN.com/view/AM15
I6-5H Everolimus Long-term
Safety and Efficacy in Patients with
Subependymal Giant Cell Astrocytoma
(SEGA) Associated with Tuberous
Sclerosis Complex (TSC): Final Analysis of
a Phase 2 Study David Franz, Marguerite
Care, Katherine Holland-Bouley, Karen
Agricola, Cynthia Tudor, Noah Berkowitz,
Sara Miao, Severine Peyrard, Darcy
Krueger
I6-5I Targeted Treatment of
Migrating Partial Seizures of Infancy with
Quinidine David Bearden, Alanna Strong,
Dennis Dlugos, Marissa DiGiovine, Ethan
Goldberg
I6-5J Decreased Amygdala
Resting State Functional Connectivity
in Patients with Left Temporal Lobe
Epilepsy Jane Allendorfer, Rodolphe
Nenert, Basia Szaflarski, Nancy Cohen,
Jeffrey Binder, Zhifeng Kou, Roy Martin,
Lawrence Ver Hoef, Jerzy Szaflarski
I6-5K Using Neural Networks
to Predict the Effects and Guide the
Application of Transcranial Direct Current
Stimulation David Fischer, Peter Fried,
Alvaro Pascual-Leone, Michael Fox
I6-5L Combining
Electroencephalographic Time-frequency
and Source Analysis Methods for Improve
Epileptogenic Zones Localization Elena
Cuspineda Bravo, Eduardo Martinez
Montes, Ana Olivares Torres, Calixto
Machado
I6-5M Novel Ambulatory EMGbased GTC Seizure Detection Device for
Home and Hospital Use Jose Cavazos,
Michael Girouard, Luke Whitmire
55
Monday
April 20
Part I
Poster Session Schedule and Floor Plan
Monday, April 20
Tuesday, April 21
Wednesday, April 22
2:00 p.m.–6:30 p.m.
FP1 Poster Session I���������������������57
7:30 a.m.–12:00 p.m.
FP2 Poster Session II��������������������65
7:30 a.m.–12:00 p.m.
FP4 Poster Session IV ������������������88
2:00 p.m.–6:30 p.m.
FP3 Poster Session III��������������������78
2:00 p.m.–6:30 p.m.
FP5 Poster Session V������������������100
First Authors stand by Posters
from 5:00 p.m.–6:30 p.m.
First Authors stand by Posters
from 7:30 a.m.–9:00 a.m.
First Authors stand by Posters
from 5:00 p.m.–6:30 p.m.
First Authors stand by Posters
from 7:30 a.m.–9:00 a.m.
First Authors stand by Posters
from 5:00 p.m.–6:30 p.m.
Thursday, April 23
7:30 a.m.–12:00 p.m.
FP6 Poster Session VI ���������������� 110
First Authors stand by Posters
from 7:30 a.m.–9:00 a.m.
2:00 p.m.–6:30 p.m.
FP7 Poster Session VII ���������������122
First Authors stand by Posters
from 5:00 p.m.–6:30 p.m.
HALL A
Escalator
to Concourse Level
U
11 12 13 14 15
1 2 3 4 5 6 7 8 9 10
ePosters
56
66
67
68
69
70
71
72
73
74
84
83
82
81
80
79
78
77
76
75
14
0
13
9
13
8
13
7
13
6
13
5
17
5
17
6
17
7
17
8
17
9
18
0
14
8
14
7
14
6
14
5
14
4
14
3
14
2
14
1
16
7
16
8
16
9
17
0
17
1
17
2
17
3
17
4
12
5
12
6
12
7
12
8
12
9
13
0
13
1
13
2
13
3
13
4
19
0
18
9
18
8
18
7
18
6
18
5
18
4
18
3
18
2
18
1
23
1
23
2
23
3
23
4
23
5
23
6
23
7
23
8
23
9
24
0
25
0
24
9
24
8
24
7
24
6
24
5
24
4
24
3
24
2
24
1
29
1
29
2
29
3
29
4
29
5
29
6
29
7
29
8
29
9
30
0
31
0
30
9
30
8
30
7
30
6
30
5
30
4
30
3
30
2
30
1
35
1
35
2
35
3
35
4
35
5
35
6
35
7
35
8
35
9
36
0
56
57
58
59
60
61
62
63
64
65
94
93
92
91
90
89
88
87
86
85
11
5
11
6
11
7
11
8
11
9
12
0
12
1
12
2
12
3
12
4
20
0
19
9
19
8
19
7
19
6
19
5
19
4
19
3
19
2
19
1
22
1
22
2
22
3
22
4
22
5
22
6
22
7
22
8
22
9
23
0
26
0
25
9
25
8
25
7
25
6
25
5
25
4
25
3
25
2
25
1
28
1
28
2
28
3
28
4
28
5
28
6
28
7
28
8
28
9
29
0
32
0
31
9
31
8
31
7
31
6
31
5
31
4
31
3
31
2
31
1
34
1
34
2
34
3
34
4
34
5
34
6
34
7
34
8
34
9
35
0
48
49
50
51
52
53
54
55
10
4
10
3
10
2
10
1
10
0
99
98
97
96
95
10
5
10
6
10
7
10
8
10
9
11
0
11
1
11
2
11
3
11
4
33
1
33
2
33
3
33
4
33
5
33
6
33
7
33
8
33
9
34
0
33
0
32
9
32
8
32
7
32
6
32
5
32
4
32
3
32
2
32
1
27
1
27
2
27
3
27
4
27
5
27
6
27
7
27
8
27
9
28
0
27
0
26
9
26
8
26
7
26
6
26
5
26
4
26
3
26
2
26
1
21
1
21
2
21
3
21
4
21
5
21
6
21
7
21
8
21
9
22
0
21
0
20
9
20
8
20
7
20
6
20
5
20
4
20
3
20
2
20
1
15
8
15
9
16
0
16
1
16
2
16
3
16
4
16
5
16
6
15
7
15
6
15
5
15
4
15
3
15
2
15
1
15
0
14
9
E
29
28
27
26
25
24
23
22
21
20 19 18 17 16
39
38
37
36
35
34
33
32
31
30
Discussion Posters
47
46
45
44
43
42
41
40
Neuroscience Is...
Video Booth
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session I
Monday, April 20
P1 Poster
Session I
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Discussion Session: Cerebrovascular Disease and Interventional Neurology
2:00 p.m.–6:30 p.m.
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
Predictors of Seizure
Improvement Following Stereotactic
Radiosurgery for Cerebral Arteriovenous
Malformations in a Prospective Cohort
of 229 Patients with AVM-associated
Epilepsy Dale Ding, Mark Quigg, Robert
Starke, Chun-Po Yen, Colin Przybylowski,
Blair Dodson, Jason Sheehan
P1.002 Collateral Score and
Neurologic Worsening in Patients with
Carotid Dissection Judy Jia, Chunyun Cai,
Mohammad Rahbar, Renga Pandurengan,
Amrou Sarraj
P1.003 Susceptibility Weighted
Imaging the of Brain in Infective
Endocarditis Matthew Schrag, Teddy
Youn, Joseph Schindler, David Greer, Ajay
Malhotra
P1.004 Metabolic Syndrome and
Ischemic Stroke Risk by Sex: Metaanalysis Michelle Lin, Gustavo Saposnik,
Qiyun Shi, Amy Towfighi
P1.005 Electrical Stimulation of
Neural Stem Cells Improves Stroke
Recovery Paul George, Tonya Bliss,
Swapnil Mehta, Thuy Hua, GuoHua Sun,
Gary Steinberg
P1.006 Younger Acute Ischemic
Stroke Patients Are at Higher Risk for 30day Readmission Duy Le, Konrad Schlick,
Shlee Song, Mani Nezhad, Jonathan
Eskenazi Markewitz, Kara Melmed, Tamara
Majic, Patrick Lyden
P1.007 Prevalence of Patent Foramen
Ovale in Cryptogenic Strokes of North
Indian Population Gayathri Petluri, Dheeraj
Khurana, Sudesh Prabhakar, Ajay Bahl
P1.009 Prevention of Catheter
Associated Urinary Tract Infections in
Stroke Patients Sushanth Aroor, Pamela
Branson, Ashby Turner, Jessica Lee
P1.010
Predictors for Failure
to Follow-up in Clinic After Ischemic
Stroke Nicholas Osteraas, Laurel Cherian,
Shawna Cutting, James Conners, Sarah
Song, Vivien Lee
P1.008 Analysis of Concurrent
Cerebral Venous Thrombosis and Dural
Arteriovenous Fistula Michelle Johansen,
Andrew Southerland, Bradford Worrall
e-Poster Session: Cerebrovascular Disease and Interventional Neurology I
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P1.011
Improvement in Rates of
Thrombolytic Therapy in Acute Stroke by
a Telestroke Program in Rural Northern
Wisconsin Rebecca Kartje, Susan Klemm,
Lori Heil, Nina Antoniotti, Thomas Martin
P1.012
Endovascular Management
and Outcome of Acute Middle Cerebral
Artery Stroke in the Setting of
Spontaneous Carotid Dissection Deepak
Gulati, Amin Aghaebrahim, Andrew
Ducruet, Brian Jankowitz, Tudor Jovin,
Ashutosh Jadhav
Cerebrovascular Disease and
Interventional Neurology: Case
Reports
P1.021
A Rare Case of Transient
Ischemic Attacks and Acute Ischemic
Stroke from Left Intracranial Arteries
Encased in Meningioma Sahawat
Tantikittichaikul, Pavis Laengvejkal, Ahmed
Eldokla, Jongyeol Kim
P1.022
Creutzfeldt-Jakob Disease
Presenting as Stroke: Case Report and
Literature Review Annemarie Van Heuven,
Mike Boggild, Richard White
P1.023
Bilateral Frontal Cerebral
Infarctions Presenting as Ascending
Weakness: Case Report Christina Mijalski,
Muhib Khan, Brian Silver
P1.013
Greater Risk for
Decompressive Craniectomy in
Large-artery Strokes Due to Cervical
Artery Thamolwan Surakiatchanukul,
Gloria Koskey, Timothy McMurry, Ronald
Grider, Lillian Currie, Heather Turner,
Bradford Worrall, Andrew Southerland
P1.014
Digital Subtraction
Angiography (DSA) Arch Run in Place of
CT Vessel and Perfusion Imaging: Proof of
Concept David Campbell, Ashutosh Jadhav
P1.015
Cerebral Microbleeds
Determine Long-term Mortality in Acute
Ischemic Stroke Patients with Lacunar
Subtype Tae-Jin Song, Chang Younkyung,
Minjung Youn, Ji Hoe Heo, Yong Jae Kim
P1.024
Stroke in a Young Woman
Caused by Carotid Web Joseph Petrsoric,
Lauren DeNiro, Daniel Labovitz
P1.025
The Unusual Suspect Katelyn
Smith, Jafar Kafaie
P1.026
Left Ventricular
Noncompaction with Normal Heart
Function: A Rare Cause of Cardioembolic
Stroke in a Young Adult Clotilde Hainline,
Daniel Antoniello
P1.027
Bilateral Common Carotid
Artery Thrombi Following Cisplatin-based
Chemotherapy Firas Kaddouh, Ajay
Tunguturi, Anand Patel, Elizabeth DeGrush,
Max Mandelbaum, Evdokia Eleftheriou,
Richard Goddeau
Fast, Easy, Online Registration · AAN.com/view/AM15
P1.016
Value of Eye Movement
Exam in Aiding Precise Localization in
Stroke Namir Khandker, David Schmerler,
Supriya Mahajan, Alessandro Serra, Daniel
Strbian
P1.018
P1.017
Bilateral Watershed Territory
Infarct in Non-hemodynamic Significant
Stenoses: Hypereosinophilic Syndrome
(HES) and the Impaired Cerebral Washout
Theory Mohamed-Ali Babi, Mark Gorman,
Margaret Kennedy, Samir Ambrale, Salman
Aljerdi, Christopher Commichau
P1.019
P1.028
P1.032
Transient Neurologic Deficit
Presenting with Cortical Vein Thrombosis
Caused by Intracranial Hypotension: Case
Report Joao Mc-ONeil Plancher, Matthew
Flaherty
P1.029
Manifestations of an
Uncommon Pontine Insult, Eight-and-a-half
Syndrome Robert Mannel, Fahed Saada,
Nader Antonios
P1.030 Fluctuating Mental Status and
Fever of Unknown Origin Annie Daniel,
Justine Brink, Catherine Hosley
P1.031
Atypical Isolated Nuclear
Oculomotor Nerve Syndrome: A Diagnostic
Challenge Carlos Kamiya Matsuoka, Bing
Liao
Systems and Care Process
Parameters as Determinants of Onset-totreatment Times in Acute Ischemic Stroke:
A Simulation Study Drew Levy, David
Norris, Darren Tayama
An Executable Graphical
Model for in Silico Prototyping of Processes
for Acute Stroke Care David Norris, Drew
Levy
P1.020
Stroke in Young Adults: A
4-year Retrospective Hospital-based
Study, First Report from United Arab
Emirates Majid AlAmeri, Abdulla AlNuaimi,
Taoufik Alsaadi
Cystinosis Associated
Vasculopathy Masquerading as Atypical
Migraine Headache Daniel Smith, Hani
Kushlaf
P1.033
Pineal Apoplexy with Cerebral
Infarction Adam Truong, Michael Young,
Nassim Naderi, Arnold Brizuela, Jason
Handwerker, Lama Al-Khoury
P1.034
Symptomatic Cerebral Air
Embolism After Central Venous Catheter
Removal Jannatul Ferdous, Sahawat
Tantikittichaikul, Rashedul Hasan, Ahmed
Eldokla, Jongyeol Kim
P1.035
Diffuse Cerebral Vasospasm
Following Endoscopic Colloid Cyst
Resection Ahmad Shawagfeh, Ahmed
Yassin, Nicholas Levine, Ivo Tremont
57
Monday
April 20
P1.001
Poster Session I
P1.036
Progressive Focal Weakness,
Aphasia, and Somnolence John Werner,
Christa San Luis, Heather Ames, Rebecca
Gottesman, Wendy Ziai
P1.037
DWI Negative Stroke:
Learning Points for Imaging in Acute
Stroke Krishna Nalleballe, Neville Jadeja,
Pradeep Bollu, Sanjeeva Onteddu
P1.038
Diabetic Striatopathy
with Isolated Sensorimotor Symptoms
Masquerading as Intraparenchymal
Hemorrhage Matthew Ehrlich, Andrew
Southerland, Bradford Worrall, Nina
Solenski
P1.039
Primary Cerebral Epithelioid
Hemangiomas Nicholas Osteraas, Laurel
Cherian, James Conners, Vivien Lee
P1.040 Bilateral Ascending Weakness
in a Patient with Azygous Anterior Cerebral
Artery Stroke Emiliya Melkumova, Jared
Noroozi, Charlotte Zisman, Ramandeep
Sahni
P1.041
Ipsilateral Glossoplegia
and Hemiplegia: Acute Medullary and
Cervical Cord Ischemic Stroke Riddhiben
Patel, Salman Rashid, Aimee Luat, Mitchel
Williams, Kumar Rajamani
Cerebrovascular Disease and
Interventional Neurology:
The Spectrum of Small Vessel
Cerebrovascular Disease
P1.042 Recurrent Vascular Events
and Death Following Small Vessel Ischemic
Stroke in the Short, Intermediate and
Long-term Over 8 Years Deidre De Silva,
Natasha Fabiana, John Allen, Fung-Peng
Woon, Hui-Meng Chang, Kamran Ikram,
Tien-Yin Wong, Meng-Cheong Wong
P1.043 Extensive Workup for Embolic
Sources in Lacunar Strokes: Prevalence
in an Academic Setting Yan Wang, Yoon
Choi, Joshuae Gallardo, Ifeoma Nwaneri,
James Brorson
P1.044 Association of Cerebral
Microbleeds with Higher Morbidity and
Mortality in Ischemic Stroke? Roomana
Ahad, Iftekhar Ahmed, Graham Lee, Neeta
Duggal
P1.045 Aggressive Statin Therapy
(AST) and Brain Atrophy/Associated
Leucoaraiosis: MRI 6 Years Observational
Study Gobinathan Devathasan, William
Senna, Lea Dosado
P1.046 Serum Uric Acid Is Positively
Associated with Cerebral White Matter
Hyperintensities in Patients with Acute
Lacunar Infarction: Subgroup Analysis of
the Effect of Cilostazol in Acute Lacunar
Infarction Based on Pulsatility Index of
Transcranial Doppler (ECLIPse) Study Sang
Won Han, Jong Yun Lee, Kyung-Yul Lee,
Joong Hyun Park, Jae Hyeon Park
P1.047
Epidemiology of Cerebral
Amyloid Angiopathy: A Single Center
Experience Prachi Mehndiratta, Christina
Chee, Bradford Worrall
P1.048 Crossed Subcortical
Aphasia Chantale Murray, Carlos Kase,
Thanh Nguyen, Kevin Bickart
58
2:00 p.m.–6:30 p.m.
P1.049
Searching Factors to Predict
for Vascular Aging Dong-Jin Shin, Shin
Dong Hoon
P1.050
Presence of Decreased
Intraepidermal Nerve Fiber Density
Consistent with Small Fiber Neuropathy
in Patients with Central Post-stroke
Pain Yefim Yushvayev-Cavalier, Colum
Amory, Gary Bernardini, Charles Argoff
Cerebrovascular Disease and
Interventional Neurology: Atrial
Fibrillation and Cardioembolic
Stroke
P1.051
N-terminal Pro-B-type
Natriuretic Peptide Predicts Long-term
Mortality but Not Stroke Recurrence in
Acute Ischemic Stroke Patients with a
Cardioembolic Source Seung-Jae Lee,
Dong-Geun Lee, Tae-Ick Chung
P1.060 Embolic Stroke of
Undetermined Source (ESUS): A Single
Center Study from Argentina Lucia
Pertierra, Maximiliano Hawkes, Mauricio
Farez, Maia Gomez-Scheneider, Jose
Pastor-Rueda, Ismael Calandri, Virginia
Pujol-Lereis, Sebastián Ameriso
Cerebrovascular Disease and
Interventional Neurology:
Epidemiology
P1.061
Stroke Patterns and Shortterm Mortality in Marijuana Users and
Non-users: A Cross-sectional Study Manoj
Mittal, Nivedita Adabala
P1.062 The Role of Discharge
Disposition in the Interventional
Management of Stroke (IMSIII) Trial Samir
Belagaje, Rishi Gupta, Lydia Foster, Brett
Kissela, Joseph Broderick
P1.073
Demographic Characteristics
and Prognostic Factors in Acute Ischemic
Stroke in a Tertiary Care Hospital in
Nepal Bikram Gajurel, Krishna Oli
P1.074
Port Harcourt Stroke
Registry: A Prospective Hospital Based
Study Christiana Okunoye, God'spower
Asekomeh, Alagoma Iyagba, Arthur
Onwuchekwa
P1.075
Chronic Kidney Disease
as a Predisposing and Severity Factor
in Ischemic Stroke at the Hospital
Admission Martin Tourreilles, Javier Rolle,
Sebastian Casas, Claudia Gonzalez, Lorena
Cabrera, Andres Perez, Patricio Blaya,
Marcelo Mattiazzi
P1.076
Prevalence and Etiology
of Acute Ischemic Events During
Hemodialysis Laurel Cherian, James
Conners, Shawna Cutting, Vivien Lee, Sarah
Song
Effect of Atrial Fibrillation
on Brain Atrophy and Cognitive Deficits
in Persons Aged ≥65 Years: Analysis of
Cardiovascular Health Study Morad
Chughtai, Cara Bezzina, Ahmed Malik,
Adnan Qureshi
P1.063 Delay of Percutaneous
P1.053
Disparities in Acute Stroke Care Despite
Primary Stroke Center Growth Sergio
Gonzles, Dylan Thibault, Allison Willis
Comparison of Siriraj Stroke
Score with Computerized Tomography in
Establishing the Type of the Stroke Among
Pakistani Population Attiya Rahman,
Qaiser Jamal
P1.065 Effect of Incident Stroke
P1.079
P1.052
Paroxysmal Atrial Fibrillation
Detection Rates in Cryptogenic Stroke
Patients Selected by Stroke Specialists
for Prolonged Cardiac Monitoring Hisham
Salahuddin, Syed Zaidi, Gretchen Tietjen,
Jennifer Cummings, Mouhammad Jumaa
P1.054 High Frequency of
Short Paroxysms of Newly Detected
Atrial Fibrillation After Stroke and
TIA. Systematic Review and Metaanalysis Patricia Riccio, Luciano Alberto
Sposato, Vladimir Hachinski, Gustavo
Saposnik
P1.055 Patients with Known
Atrial Fibrilation and First Ischemic
Stroke. Assessing of Anticoagulation
Status Virginia Parisi, María Lucía
Rattagan, Gabriel Persi, Emilia Gatto
P1.056 A Dedicated Stroke Prevention
in Atrial Fibrillation (SPAF) Clinic for
the Acute Assessment and Initiation of
Anticoagulation in Patients with Atrial
Fibrillation Evan Jolliffe, Ian Rosemergy,
Jeremiah Lanford, David Abernethy
P1.057
The Role of Urinary Tract
Infection in Atrial Fibrillation-related
Ischemic Strokes, A Retrospective
Study Awss Zidan, Ruham A-Nasany,
Ahmed Bedair, Ilya Bragin, Adham Kamel
P1.058 Risk of Ischemic Stroke
During Periods of Warfarin Discontinuation
for Surgical Procedures: A Longitudinal
Study of 4060 Patients with Atrial
Fibrillation Nauman Jahangir, Ahmed
Malik, Muhammad Suri, Adnan Qureshi
P1.059
Ischemic Stroke in Patients
with Elevated Body Mass Index While
on Novel Anticoagulants: A Case Series
Report Haris Kamal, Kelly Smith, Ashkan
Mowla, Peyman Shirani, Robert Sawyer Jr.,
Andrew Fanous, Marilou Ching
Gastrostomy Tube (PEG) Placement in
Patients with Ischemic Stroke in a Large
Urban Hospital Bhrugav Raval, Appaji Rayi,
Molly Jacob, Machteld Hillen
P1.064 Increasing Rural-urban
on Sleep Quality and Hypopnea-apnea
Index: Analysis of Sleep Heart Health
Study Ahmed Malik, Malik Adil,
Muhammad Suri, Shayaan Khan, Adnan
Qureshi
P1.066 Effect of “Snoring Alone”
and “Snoring Plus Phenomenon” on
Cardiovascular Diseases, or Fatal or
Nonfatal Stroke Yousef Mohammad,
Ahmed Malik, Omar Saeed, Muhammad
Suri, Adnan Qureshi
P1.067
Risk of Stroke in
Imaging-proven Subclavian Steal
Syndrome Harrison Bai, Zhili Wang, Yingjie
Zou, Xin Zhao, Luo Zhou, Yanqiao Xiao, Yi
Shu, Dongxu Chou, Xiao Bo, Scott Kasner,
Liming Tan, Yang Li
P1.077
Factors Predictive of Hospice
Care in Patients with Ischemic Stroke Fahd
Sultan, Jessica Lee
P1.078
Ischemic Stroke in Pregnancy
and Postpartum: A Descriptive Case
Series Eliza Miller, Shadi Yaghi, Amelia
Boehme, Joshua Willey, Mitchell Elkind,
Randolph Marshall
P1.080 Sex Differences in TIA
Presentation and Frequency of DWI
Abnormalities on MRI Nicholas Billow, Elie
Harmouche, Michael Ross, Samir Belagaje,
Aaron Anderson, Strikant Rangaraju, James
Greene, Paul MacDonald, Fadi Nahab
Neuroepidemiology:
Cerebrovascular Disease
P1.068Withdrawn
Racial Differences and
Outcomes of Strokes in Patients on
Hemodialysis: A 10-year Retrospective
Study Mohammad Sunbulli, Monica
Dhakar, Kumar Rajamani
P1.069
The Impact of Pre-stroke
Smoking on Post-stroke Mortality Alicia
Zha, Sunil Mutgi, Shaheryar Hafeez, Reza
Behrouz
P1.082 Risk of Stroke Following
P1.070
P1.083
Asymptomatic Compression
of Brainstem by Basilar or Vertebral
Arteries: A Case Series of 20 Patients Ali
Daneshmand, David Thaler
P1.071
Effect of Weight Loss Surgery
on Cardiovascular Death, Nonfatal
Myocardial Infarction, or Nonfatal Stroke
in Overweight and Obese Post-menopausal
Women Omar Saeed, Ahmed Malik, Adnan
Qureshi
P1.072
Childhood Stroke: Comparison
of Strokes Identified in Administrative
Databases with Those Identified in a
Population-based Study John Taylor,
Jane Khoury, Yingying Xu, Heidi Sucharew,
Kathleen Alwell, Charles Moomaw, Paul
Horn, Samrat Yeramaneni, Katrina Peariso,
Pooja Khatri, Joseph Broderick, Brett
Kissela, Dawn Kleindorfer
P1.081
Hypertensive Encephalopathy Michael
Lerario, Alexander Merkler, Gino Gialdini,
Neal Parikh, Babak Navi, Hooman Kamel
Accuracy of Mobile Devices
for Acute Stroke Head CT Interpretation
Among Neurologists in Training Priyank
Khandelwal, Clotilde Balucani, Leah
Steinberg, Jeremy Weedon, Sebina
Bulic, Elie Dancour, Kester Phillips, Carlos
Escasena, Jihan Grant, Steven Levine
P1.084 Delay in Presentation to
Hospital After Acute Stroke: A Multiethnic
Population in New York City Ivan MatosDiaz, John Liang, Amy Walker, David Lucido,
Irene Boniece
P1.085
Temporal Trends of
Outcomes for Acute Kidney Injury in Acute
Intracerebral Hemorrhage from 2002 to
2012: An Analysis of Nationwide Inpatient
Sample Data Abhimanyu Mahajan, Achint
Patel, Girish Nadkarni, Charuhas Thakar
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session I
P1.086 A Four-year Experience of
Symptomatic Intracranial Hemorrhage Rate
Following Intravenous Tissue Plasminogen
Activator at a Comprehensive Stroke
Center Jeffrey Wagner, Alessandro
Orlando, Christopher Fanale, Michelle
Whaley, Kathryn McCarthy, David Bar-Or
P1.087
Secondary Stroke Prevention
Prescribing in a National Cohort Karen
Albright, Amelia Boehme, Virginia Howard,
George Howard, Suzanne Judd, David
Rhodes, Aaron Anderson, Leslie McClure,
Monika Safford, Nita Limdi, Justin Blackburn
P1.088
Elevated Blood Pressure,
Cerebrovascular Reactivity, and the
Default-mode Brain Network: Findings from
the Coronary Artery Risk Development in
Young Adults (CARDIA) Brain MRI Substudy Thaddeus Haight, Nick Bryan, Guray
Erus, Christos Davatzikos, David Jacobs,
Mark D'Esposito, Cora Lewis, Lenore Launer
P1.089 The Changing Epidemiology
of Stroke in Acquired Immune Deficiency
Syndrome (AIDS) Phillip Kucab, Pratik
Bhattacharya
P1.090 Recurrence Risk and
Cognitive Decline in African-American
and Hispanic Survivors of Intracerebral
Hemorrhage Alessandro Biffi, Christopher
Anderson, Thomas Battey, Alison Ayres,
Kristin Schwab, Anand Viswanathan, Steven
Greenberg, Jonathan Rosand
Neuroepidemiology:
Cerebrovascular Disease, Critical
Care, Epilepsy, Child Neurology,
and Sleep
P1.091 New Imaging-based Definition
of Stroke Boosts Annual Incidence of
Recurrent Ischemic Stroke in the United
States by 80% Michelle Lin, Bruce
Ovbiagele, Helena Chui, Amy Towfighi
P1.092 Differences in Ischemic
and Hemorrhagic Strokes in Sri Lanka:
7-year Data from the Ragama Stroke
Registry Udaya Ranawaka, Anushka Peiris,
K Thirumavalavan, Gayani Premawansa,
Anuradhani Kasthuriratne
P1.093 Population-based Study of
Cerebral Microbleeds in Older Adults
Living in Rural Ecuador (the Atahualpa
Project) Victor Del Brulto, Mauricio
Zambrano, Robertino Mera, Oscar Del
Brutto
P1.094
Stroke in a Global World:
Geographical Differences in Stroke
Subtypes and Age at Onset in Two
Different Populations from Europe and
South America Jardiel Casanova-Lanchipa,
Francisco Carod, Luis Miguel Cruz-Ramirez,
Noelia Sanchez-Perez, Fatima SiacaraAguayo, Isabel Gomez-Moreno, Lourdes
Gomez Romero, Luciane Coral, Daniele
Trizotto, CM Moreira
P1.095
Clinical and Demographic
Factors Associated with Poor Outcome
Differ from Those Associated with
Withdrawal of Life Support After Cardiac
Arrest Sachin Agarwal, Teresa May,
Amelia Boehme, Alexandra Reynolds,
Priyank Patel, Barbara McCrum, Soojin Park,
Jan Claassen, Richard Riker, David Seder
P1.096
Premorbid Status
Independently Dictates Good Outcome
After Status Epilepticus Among Comatose
Survivors of Cardiac Arrest Alexandra
Reynolds, Andres Rodriguez-Ruiz, Amelia
Boehme, Priyank Patel, Teresa May,
Christina Falo, Stephan Mayer, Hyunmi Choi,
Soojin Park, Jan Claassen, Sachin Agarwal
P1.097 Critical Care Course of
Patients with Acute Basilar Artery
Occlusion Julio Chalela, Khaled Asi, Joao
Gomes
P1.098
Epidemiology of Epilepsy in
Belarusian Population: A Pilot Study Andrei
Ivashynka, Tatsiana Dokukina
P1.099 Reliability and Validity of the
P1.109
Pediatric Onset Multiple
Sclerosis Patients Tend to Have Slower
Disease Progression Jasem Al-Hashel,
Samar Ahmed, Raed Alroughani
P1.110
Relapse Sequela Is Not
Rare in Aggressive Forms of Relapsing
MS Throughout the First Decade of
Disease Chris Hackett, Edward Gettings,
Carol Schramke, Santosh Ramanathan,
Thomas Scott
P1.111
The CNS Antigen-specific
B Cell Response Correlates with GA
Responsiveness in Remitting-relapsing
Multiple Sclerosis Patients Damiano
Rovituso, Claudia Kaiser, Michael Schroeter,
Christoph Kleinschnitz, Stefanie Kuerten
Brief Problem Monitor: An Abbreviated
Form of the Child Behavior Checklist Brian
Piper, Hilary Gray, Jacob Raber, Melissa
Birkett
P1.112
P1.100
P1.113
Sleep Duration Is Associated
with Worse Neurocognitive Function in
Hispanic/Latinos: Results of the Hispanic
Community Health Study/Study of Latinos
(HCHS/SOL) Alberto Ramos, Wassim
Tarraf, Martha Daviglus, Sonia Davis, Linda
Gallo, Yasmin Mossavar-Rahmani, Frank
Penedo, Susan Redline, Tatjana Rundek,
Ralph Sacco, Daniela Sotres-Alvarez,
Clinton Wright, Phyllis Zee, Hector Gonzalez
Neuroepidemiology: MS and CNS
Inflammatory Disease
P1.101
Testicular Hypofunction and
Multiple Sclerosis Risk: A Record-linkage
Study Julia Pakpoor, Raph Goldacre, Klaus
Schmierer, Gavin Giovannoni, Michael
Goldacre
P1.102
Cancer Risk Associated with
Disease-modifying Drugs in Multiple
Sclerosis: A French Registry-based
Study Mathilde Lefilliatre, Nathalie
Derache, Elodie Guillaume, Karine Droulon,
Guy Launoy, Gilles Defer
P1.103
NMDA Receptor Encephalitis
in Veterans Gurjeet Singh, Evan Lott, John
Greenlee, Stacey Clardy
P1.104
Neuromyelitis Optica in
Veterans Victor Wang, Thomas Clardy,
John Rose, James Burns, Noel Carlson,
John Greenlee, Stacey Clardy
Characterizations of the 2013
Lublin MS Phenotypes in a Single-center
Dataset Edward Gettings, Chris Hackett,
Carol Schramke, Thomas Scott
Quality of Life Perceptions
Correlate with Longitudinal Clinical Relapse
Reduction Metrics in Patients Treated
with Subcutaneous Interferon Beta-1a
Given Three Times a Week Barbara Teter,
Katelyn Kavak, Fernando Dangond, Bianca
Weinstock-Guttman
MS and CNS Inflammatory
Diseases: Symptoms, Specific
Symptomatic Treatment, Comorbidities, and Costs
P1.114
Comorbidity Is Associated
with Increased Pain and Fatigue in Multiple
Sclerosis Kirsten Fiest, John Fisk, Scott
Patten, Helen Tremlett, Christina Wolfson,
Sharon Warren, Kyla McKay, Lindsay
Berrigan, Ruth-Ann Marrie
P1.108
Clinical Predictors of Disease
Progression in Multiple Sclerosis Patients
with Relapsing Onset in a Nationwide
Cohort Raed Alroughani, Saeed Akhtar,
Samar Ahmed, Jasem Al-Hashel
Fast, Easy, Online Registration · AAN.com/view/AM15
P1.123
Prolonged-release Fampridine
as Adjunct Therapy to Active Enabled
Motor Training in Multiple Sclerosis
Patients: A Pilot, Double-blind, Placebocontrolled Study Francois Jacques, Adrian
Schembri, Avi Nativ, Chantal Paquette,
Pawel Kalinowski
P1.124
A Pilot Study of Dalfampridine
for Improving Upper Extremity Function in
Multiple Sclerosis Patients Mark Tullman,
Kara Knetzer, M'Aggie Maranzana, Delea
Payne-Gates, Heather Popham, Amber
Salter, Barry Singer
P1.125
Results from a Randomized
Double-blind Crossover Study Comparing
Oral L-carnitine Versus Placebo and
a Subsequent Physical Rehabilitation
Program for the Treatment of Fatigue
in Multiple Sclerosis Jean-Christophe
Ouallet, Julien Asselineau, David Laplaud,
Sandrine Wiertlewski, Sophie Pittion,
Marc Debouverie, Christine Lebrun Frenay,
Mickael Cohen, Philippe Cabre, Severine
Jeannin, Genevieve Chene, David Brassat,
Aurore Saubusse, Dieynaba Djigo, Jeremy
Chateauraynaud, Bruno Brochet
P1.127
Impaired Cardiac Interoception
in Patients with Multiple Sclerosis Sol
Esteves, Lucas Sedeño, Vladimiro Sinay,
Diana Bruno, Fatima Pagani Cassara, Blas
Couto, Federico Adolfi, Ezequiel Mikulan,
Giselle Kozono, Marcos Pietto, Facundo
Manes, Maria Roca, Agustín Ibañez
P1.118
Demographics and Clinical
Characteristics of Pediatric Onset Multiple
Sclerosis Raed Alroughani, Samar Ahmed,
Jasem Al-Hashel
Changing Course of Multiple
Sclerosis (MS) After Stroke: Excessive
Disease Activity in a MS Patient After
Cerebral Infarction Walter Poellmann,
Michaela Starck, Tania Kuempfel, Juergen
Koehler
P1.116
P1.106
P1.107
P1.122
Adverse Impact of
Comorbidity on Mortality in Multiple
Sclerosis Ruth-Ann Marrie, Stella Leung,
James Marriott, Michael Cossoy, Lawrence
Elliott, James Blanchard, Nancy Yu
P1.115
Cardiovascular Autonomic
Dysfunction in Multiple Sclerosis: A
Metanalysis and Systematic Review Juan
Racosta, Luciano Alberto Sposato, Sarah
Morrow, Lauren Cipriano, Kurt Kimpiski,
Marcelo Kremenchutzky
Risk Factors and Final
Diagnoses of Patients First Diagnosed
as Infectious Acute Disseminated
Encephalomyelitis (ADEM): A Single-center
Study Diederik Koelman, Tanuja Chitnis,
Farrah Mateen
Toxoplasma Gondii
Seropositivity Is Negatively Associated
with Multiple Sclerosis Frauke Stascheit,
Friedemann Paul, Ulrike Grittner, Lutz
Harms, Berit Rosche
Prolonged-release Fampridine
Post-marketing Experience in Alsace,
France Carole Berthe, Jean-Claude
Ongagna, Sylvie Courtois, Claude Gaultier,
Audrey Kopf, Marie-Celine Fleury, Aurelien
Benoilid, Nicolas Collongues, Frederic
Blanc, Christian Zaenker, Jerome De Seze
Multiple Sclerosis
Prevalence in the United States Insured
Population Jonathan Campbell, Piyameth
Dilokthornsakul, Kavita Nair, John Corboy,
Robert Valuck
P1.105
P1.121
P1.117
A Phenome-wide Examination
Uncovers the Comorbidity Burden in Severe
Multiple Sclerosis Zongqi Xia, Matthew
Goodman, Brian Healy, Tanuja Chitnis, Philip
De Jager, Howard Weiner
P1.119
Multiple Sclerosis and
Cancer Deeya Gaindh, Katelyn Kavak,
Barbara Teter, Muhammad Nadeem, Bianca
Weinstock-Guttman
P1.126
Effect of Montelukast on
Gastrointestinal Tolerability in Patients
with Relapsing Forms of Multiple Sclerosis
Receiving Delayed-release Dimethyl
Fumarate: A Multicenter, Randomized,
Double-blind, Placebo-controlled Study
(MITIGATE) Carlo Tornatore, John Walsh,
Monica Mann, Jie Li, Christian Von Hehn
P1.128
Prevalence of Sleep
Disturbances, Fatigue, Anxiety and
Depression in Multiple Sclerosis
(MS) Sven Rupprecht, Steffen Kluckow,
Maryam Yahiaoui-Doktor, Orhan Aktas,
Andrew Chan, Alexander Dressel, Juergen
Faiss, Klaus Gehring, Frank Hoffmann,
Ulf Kallweit, Wolfgang Koehler, Andreas
Kowalik, Michael Lang, Chrstoph Lassek,
Sabine Lobenstein, Wilfried Lüer, Mike
Matzke, Geert Mayer, Joachim Piatkowski,
Udo Polzer, Sebastian Schimrigk, Barbara
Schwandt, Carsten Sievers, Konstanze
Tinschert, Klaus Uwe Zettl, Sylvia Kotterba,
Matthias Schwab
P1.120
Temporomandibular Disorders
(TMD) and Multiple Sclerosis (MS) Lucas
Carvalho, Andre Matta, Osvaldo
Nascimento
59
Monday
April 20
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session I
P1.129
Multiple Sclerosis and Sleep
Disorders: Exploration of Sleep Disordered
Breathing -Apnea Hypopnea Index NonREM Versus REM in a Community Cohort
of Patients with Multiple Sclerosis Who
Report Fatigue Mark Gudesblatt, Steven
Xian, Myassar Zarif, Barbara Bumstead,
Smitha Thotam, Lori Fafard, Konstantina
Bardhi, Marijean Buhse
P1.141
Wernicke’s Encephalopathy
as a Mimicker of a Brainstem Relapse in a
Multiple Sclerosis Patient Ariel Antezana,
Joseph Herbert, Ilya Kister, Steven Galetta
P1.152
MS and CNS Inflammatory
Diseases: Treatment Mechanisms
of Action
P1.153
P1.130
P1.142
P1.131
P1.143
Longitudinal Evaluation of
Falls and Fall Prevention Strategies in
Multiple Sclerosis Michelle Cameron,
Miho Asano, Elizabeth Peterson, Marcia
Finlayson
Homonymous Hemianopsia
in Multiple Sclerosis (MS)—a Rare
Symptom with Need for Etiological
Clarification Walter Poellmann, Wolfgang
Walter Feneberg, Claudia Busch, Renate
Hofreiter, Juergen Koehler
P1.132
Impulsivity Traits in Patients
with Multiple Sclerosis in Bogotá,
Colombia Jaime Toro, Lisseth Burbano,
Camilo Diaz-Cruz, Saúl Reyes, Luisa Blanco,
Luis Orozco-Cabal
P1.133
Helminth Infections
Associated with Multiple Sclerosis Induce
Regulatory B Cells. Investigating the Role
of IL-35 Jorge Correale, Mauricio Farez
P1.134
The Framingham
Cardiovascular Risk Score in Multiple
Sclerosis Marcello Moccia, Roberta
Lanzillo, Raffaele Palladino, Giorgia
Teresa Maniscalco, Anna De Rosa, Cinzia
Valeria Russo, Marco Massarelli, Antonio
Carotenuto, Emanuela Postiglione, Oreste
Caporale, Maria Triassi, Vincenzo Brescia
Morra
P1.135
Pharmacokinetics, Safety
and Tolerability of Siponimod (BAF312) in
Subjects with Different Levels of Hepatic
Impairment Compared to Demographically
Matched Healthy Subjects Kasra ShakeriNejad, Vassilios Aslanis, Uday Kiran
Veldandi, Anne Gardin, Andreas Zaehringer,
Angela Dodman, Zhenzhong Su, Eric
Legangneux
P1.136
Effect of Age and Sex on
Cost of Multiple Sclerosis-related Relapse
Defined by Inpatient Stays Chris Kozma,
Amy Phillips, Julie Locklear
P1.137
Cost-effectiveness (CE) of
Fingolimod Vs. Intramuscular Interferon
Beta-1a in the Treatment of Relapsingremitting Multiple Sclerosis (RRMS) Tara
Nazareth, John Ko, Jipan Xie, William
Reichmann, Chen Zhao, Rahul Sasane
P1.138
Prevalence of Complications
in Multiple Sclerosis in Hospitalized Patient
Among Different Age Groups Chirag
Savani, Parisha Bhatia, Akash Vadhavana,
Achint Patel, Dave Mihir, Vishal Jani
2:00 p.m.–6:30 p.m.
Immune Regulatory Effects
of FTY720 on Dendritic Cells Maria
Antonietta Mazzola, Lily Aly, Russell Griffin,
Parham Nejad, Howard Weiner, Roopali
Gandhi
Immune Regulatory Effects
of FTY720 on Human T Cells Maria
Antonietta Mazzola, Hasan Rajabi, Russell
Griffin, Lily Aly, Bonny Patel, Bonnie Glanz,
Tanuja Chitnis, Howard Weiner, Roopali
Gandhi
P1.144
Comparative Gene Expression
Profiling Between a Generic (M356) and
Brand Copaxone® (Glatiramer Acetate
Injection) Josephine D’Alessandro, Jay
Duffner, Joel Pradines, Christopher Honan,
Thomas Prod’homme, Tanmoy Ganguly,
Ganesh Kaundinya
P1.145
Demonstration of Equivalence
Between a Generic (M356) and Brand
Copaxone® (Glatiramer Acetate
Injection) James Anderson, Tanmoy
Ganguly, Ishan Capila, Christine Bell, Jim
Prescott, Jon Lansing, Joe Glajch, John
Bishop, Ganesh Kaundinya
P1.146Immunomonitoring
Lymphocyte Subpopulations in the
Different Clinical Forms of Multiple
Sclerosis. The Effect of Natalizumab and
Interferon-β Aina Teniente-Serra, Laia
Grau-Lopez, M José Mansilla, Marco
Fernandez-Sanmartin, Anna Ester-Condins,
Cristina Ramo, Eva Martinez-Caceres
P1.147
Evaluation of Immunogenicity
in Patients with Multiple Sclerosis Treated
with Daclizumab HYP Lakshmi Amaravadi,
Alvydas Mikulskis, Nisha Lucas, Katherine
Riester, Marianne Sweetser, Jacob Elkins
P1.148
Daclizumab High-yield Process
(DAC HYP) Has No Effect on Activity of
the Cytochrome P450 (CYP) Enzymes:
Results of a Drug Cocktail Interaction
Study in Subjects with Multiple Sclerosis
(MS) Jonathan Tran, Ahmed Othman,
Yaoshi Wu, Paul Wolstencroft, Jacob Elkins
P1.149
Early, Sustained and
Reversible Pharmacodynamic Effects of
Daclizumab HYP in MS Support Mechanism
of Action Via Modulation of the IL-2
Pathway Lakshmi Amaravadi, Devangi
Mehta, Katherine Riester, James Sheridan,
Jacob Elkins
P1.139
Economic Cost of an MS
Relapse (PEARL Study) Stefan Vormfelde,
Tjalf Ziemssen
The NRF2 Transcriptional
Target, OSGIN1, Contributes to the
Cytoprotective Properties of Monomethyl
Fumarate Melanie Brennan, Maria Matos,
Chao Sun, Suzanne Szak, Robert Scannevin
P1.140
P1.151
Marijuana Usage and
Disability in MS in the NARCOMS
Registry Stacey Cofield, Amber Salter,
Tuula Tyry, Christina Crowe, Sandre
McNeal, Gary Cutter, Robert Fox, Ruth-Ann
Marrie
60
P1.150
Long-term Axonal Repair:
Outcomes in Treatment-refractory MS
Stratified by Treatment and Baseline
Demographics Prior to Alemtuzumab
(ALE) Samuel Hunter, Heli Hunter, Daniel
Kantor
The Effect of Mesenchymal
Stem Cell Transplantation on Diffusion
Tensor Imaging from T2 Lesional
Tissue Erik Offerman, Elizabeth Fisher,
Jian Lin, Ken Sakaie, Sarah Pope Planchon,
Michael Phillips, Mark Lowe, Jeffrey Cohen,
Daniel Ontaneda
Fingolimod Reduces Axonal
Transection During Demyelination Brian
Bai, Simon Lunn, Robin Avila, Jing Wang,
Doug Chmura, Emily Benson, Grahame Kidd,
Satish Medicetty, Bruce Trapp
P1.154
Long-term Fingolimod
Treatment of Multiple Sclerosis Induces
Phenotypical Immunsenescence Nicole
Schwanitz, Andreas Boldt, Muriel Stoppe,
Johannes Orthgiess, Stefan Borte, Ulrich
Sack, Florian Then Bergh
P1.155
Peripheral Immune Cell
Profiles in Fingolimod Treated Multiple
Sclerosis Patients Following Short-term
Drug Interruption Leslie Fitz-Gerald, Ayman
Rezk, Rui Li, Mukanthu Nyirenda, David
Haegert, Paul Giacomini, Amit Bar-Or, Jack
Antel
P1.156
Differential Effects of
Fingolimod on Gene Expression of Helper
and Cytotoxic T-cells in the Blood of MS
Patients Michael Hecker, Brit Fitzner,
Dirk Koczan, Jörg Friess, Luisa Roch, Ina
Schröder, Kristin Flechtner, Hans-Jürgen
Thiesen, Alexander Winkelmann, Uwe Zettl
P1.157
Fingolimod Effects on CD8
Cells in Multiple Sclerosis Anthony Reder,
Suad Causevic, Zhe Wang, Fernando Testai,
Xuan Feng
P1.158
Comparison of Fingolimod and
Interferon-beta Effects on Th1/Th2-related
Chemokine Receptors on Peripheral T Cells
in Patients with Multiple Sclerosis Yuko
Shimizu, Ryotaro Ikeguchi, Kohei Ota, Kazuo
Kitagawa
P1.159
Fingolimod Up-regulates BDNF
Expression Within the CNS and Downregulates Tissue Pathology in a Pre-clinical
Model of Chronic Neuroinflammation Paul
Smith, Valerie Dubost, Volker Brinkmann,
Magali Jivkov, Catherine Huck, Diethilde
Theil
P1.160
Effect of Fingolimod on an
Animal Surgical Wound Healing Model: A
Non-immunosupressive Profile Ricardo
Ginestal, Alberto Cifuentes, Marta
Rodriguez-Mancheno, David Cebrian,
Francisca Garcia-Moreno, Juan Manuel
Bellon
P1.161
Laquinimod Suppresses CNS
Autoimmunity by Activation of Natural
Killer Cells Stefan Nessler, Martina Ott,
Christiane Wegner, Liat Hayardeny, Evelyn
Ullrich, Wolfgang Bruck
P1.162
Pioglitazone Treatment
Enhances Myelin Debris Phagocytosis and
Immunoregulatory Functions of Monocytes
from MS Patients Muktha Natrajan, Kory
Johnson, Abdel Elkahloun, Robin Franklin,
Bibiana Bielekova
P1.163
Dimethyl Fumarate Alters
Microglia Phenotype and Protects
Neurons Against Proinflammatory Toxic
Microenvironments Haiyan Peng, Maria
Matos, Brian Wipke, H Arnold, Robert
Scannevin
P1.164
Effects of Oral Dimethyl
Fumarate on Intestinal Immune Regulation
in Autoimmune Neuroinflammation Ralf
Linker, Stefanie Joerg, Aiden Haghikia, DeHyung Lee, Arndt Manzel, Ralf Gold, Anna
Hammer
Movement Disorders: Parkinson's
Disease DBS
P1.165
Effects of Randomized STNDBS on Gait in Patients with Parkinson’s
Disease Karlo Lizarraga, Jonathan Jagid,
Bruno Gallo, Corneliu Luca
P1.166
Does the Use of Intraoperative
Microelectrode Recording Influence the
Final Location of Lead Implant in Deep
Brain Stimulation in Parkinson’s Disease
Patients? Sujan Reddy, Albert Fenoy, Erin
Furr-Stimming, William Ondo, Mya Schiess,
Raja Mehanna
P1.167
Characteristics of Neuronal
Oscillatory Activity in the Ventrolateral
Thalamus in Patients with Parkinsonian
Tremor and Essential Tremor Ping Zhuang,
Mark Hallett, Tingting Liu, Yuqing Zhang,
Jianyu Li, Yongjie Li
P1.168
Unilateral Vs. Bilateral
Subthalamic Stimulation in Parkinson's
Disease Sara Duffus, Ugonma Chukwueke,
Roy Strowd, Jennifer Green, Ihtsham Haq,
Jessica Tate, Maja Herco, Adrian Laxton,
Stephen Tatter, Mustafa Siddiqui
P1.169
Self-ratings of Impulsive
and Compulsive Behaviors Decrease
in Parkinson's Patients Following Deep
Brain Stimulation of the Subthalamic
Nucleus Katherine Kudyba Morone,
Wylie Scott, Daniel Claassen, Nelleke
Van Wouwe, Kristen Kanoff, Olivia Roman,
Lauren Griffin, Joseph Neimat
P1.170
Distinct Phenotypes of
Speech and Voice Disorders in Parkinson’s
Disease After Subthalamic Nucleus Deep
Brain Stimulation Takashi Tsuboi, Yasuhiro
Tanaka, Hirohisa Watanabe, Gen Sobue
P1.171
Vercise DBS Registry: A
Prospective, Multi-center International
Registry for Parkinson’s Disease Günther
Deuschl, Jan Vesper, Sherry Lin, Nic Van
Dyck, Roshini Jain
P1.172
Accuracy of Deep Brain
Stimulation Electrode Implanted by
Frameless System Using Postoperative
Computer Tomography Jan Bardon, David
Krahulik, Martin Nevrly, Pavel Otruba, Petr
Kanovsky
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session I
P1.173
VANTAGE Trial: A Prospective,
Multi-center Trial Evaluating Deep Brain
Stimulation with a New Multiple-source,
Constant-current Rechargeable System
in Parkinson’s Disease Lars Timmermann,
Roshini Jain, Thomas Brücke, Fernando
Seijo, Esther Suarez San Martin, Claire
Haegelen, Marc Verin, Mohammed
Maarouf, Michael Barbe, Steven Gill, Alan
Whone, Mauro Porta, Domenico Servello,
François Alesch
P1.174
Patient-centered Outcomes
of Deep Brain Stimulation in Parkinson’s
Disease Jessica Karl, Bichum Ouyang,
Leonard Verhagen Metman
Movement Disorders: Parkinson
Plus Syndromes
P1.175
PET Evidence for
Distinct Features of Tau Parkinsonism
and Parkinsonism with Alphasynucleinopathy Chong Lee, Jason Lee,
Joon Mo Koo, Sujeong Kim, Seok Min Kim,
Doris Doudet
P1.176
Are the Mechanisms of Nigral
Cells Neurodegeneration in Typical and
Atypical Parkinsonism Different—MRI and
Mössbauer Spectroscopy Studies Andrzej
Friedman, Radoslaw Kulinski, Jolanta
Galazka-Friedman
P1.177
Alpha-synuclein Pathology
in Colonic Biopsy of a Suspected Multiple
System Atrophy Patient—a Case Report Umer Akbar, Edward Stopa, Douglas
Anthony, John Donahue, Joseph Friedman
P1.178
Basal Ganglia Abnormalities
in Diabetic Uremic Syndrome Koji Fujita,
Yusuke Osaki, Takashi Abe, Masafumi
Harada, Yuishin Izumi, Ryuji Kaji
P1.179
In Vivo Evidence for Transsynaptic Degeneration in the Striatum of
MSA-P Patients: PET Studies with [18F]
FP-CIT and [18F]FDG Joon Mo Koo, Chong
S. Lee, Sujeong Kim, Seok Min Kim, Deniz
Kirik
P1.180
A Geographical Cluster of
Progressive Supranuclear Palsy in Northern
France Lawrence Golbe, Dominique
Caparros-Lefebvre, Luc Buee, Valerie BueeScherrer, Vincent Deramecourt, Claude
Alain Maurage, Andrew Lees
P1.181
The Impact of White Matter
Damage on Cognition in PSP Syndrome: A
DT MRI Study Francesca Caso, Federica
Agosta, Maria Antonietta Volontè,
Alessandra Marcone, Massimiliano Copetti,
Francesca Spagnolo, Monica Falautano,
Andrea Falini, Giancarlo Comi, Massimo
Filippi
P1.182
Coenzyme Q10 Levels
Are Reduced in the Cerebellum of
Multiple System Atrophy Patients Lucia
Schottlaender, Conceicao Bettencourt,
Aoife Kiely, Annapurna Chalasani, Viruna
Neergheen, Janice Holton, Iain Hargreaves,
Henry Houlden
P1.183
Need for Improved
Bone Mineral Density Screening in
Parkinsonism Melissa Nicoletti, Jessica
Rowe, Lisa Shulman, Stephen Reich, F.
Rainer Von Coelln, Melissa Armstrong
Movement Disorders: Parkinson's
Disease Pharmacotherapy
P1.184
Summary of Safety from
Clinical Trial Experience with IPX066,
Extended-release Carbidopa-levodopa, in
Parkinson’s Disease Margery Mark, Rohit
Dhall, David Kreitzman, Sherron Kell, Sarita
Khanna, Ann Hsu, Suneel Gupta
P1.185
Comparison of Safety from
Phase 3 Clinical Trials of IPX066, an
Extended-release Carbidopa-levodopa
Formulation, in Parkinson’s Disease Rohit
Dhall, Margery Mark, David Kreitzman,
Sherron Kell, Sarita Khanna, Ann Hsu,
Suneel Gupta
P1.186
Re-evaluating Rasagiline for
the Symptomatic Treatment of Fatigue in
Parkinson’s Disease: A 3-center, Placebocontrolled, Pilot Study (The REST PD
Trial) Shnehal Patel, Thien Thien Lim, Benzi
Kluger, Ramon Rodriguez, Irene Malaty,
Rafael Palacio, Oluwadamilola Ojo, Yogesh
Gujrati, Camille Swartz, Benjamin Nutter,
Carol Hennessy, Hubert Fernandez
P1.187
Pharmacokinetics and Safety
of ND0612L (Levodopa/Carbidopa for
Subcutaneous Infusion): Results from
a Phase II Study in Moderate to Severe
Parkinson’s Disease Nir Giladi, Yossi
Caraco, Tanya Gureritch, Ruth Djaldetti, Yael
Cohen, Oron Yacobi-Zeevi, Sheila Oren
P1.188
De-novo Amantadine
Treatment Delays Onset of Dyskinesias
in Patients with Parkinson Disease Maja
Relja
P1.189
Efficacy of Apomorphine
Subcutaneous Injections for the
Management of Morning Akinesia in
Parkinson’s Disease Stuart Isaacson,
William Ondo, Fernando Pagan, Mark Lew
P1.190
Rotigotine in Patients with PD
and Unsatisfactory Early-morning Motor
Symptom Control: A Post-hoc Analysis
of Efficacy and Safety by Dose Babak
Boroojerdi, Mahnaz Asgharnejad, Arturo
Benitez, Erwin Surmann, Lars Bauer
P1.191
Comparison of Efficacy
from Phase 3 Clinical Trials of IPX066,
an Extended-release Carbidopalevodopa Formulation, in Parkinson’s
Disease Lawrence Elmer, Ramon Gil, Dee
Silver, Ann Hsu, Sarita Khanna, Sherron Kell,
Suneel Gupta
P1.192
Global Long-term Registry
on Efficacy and Safety of LevodopaCarbidopa Intestinal Gel in Patients with
Advanced Parkinson’s Disease in Routine
Care (GLORIA)—Interim Results in a
Subgroup of Patients with Dyskinesia at
Baseline Werner Poewe, K Ray Chaudhuri,
Lars Bergmann, Ashley Yegin, Stephanie
Dubow, Angelo Antonini
P1.194
The NINDS Parkinson’s
Disease Biomarkers Program Katrina
Gwinn, Karen David, Coryse Hillaire-Clarke,
McAuliffe Matt, Debra Babcock, Beth-Anne
Sieber, Margaret Sutherland
P1.195
Handling Missing Values in
the MDS-UPDRS Christopher Goetz, Sheng
Luo, Lu Wang, Barbara Tilley, Nancy LaPelle,
Glenn Stebbins
P1.196
Continuous Motion Sensor
Assessment of Parkinson’s Disease During
Activities of Daily Living Christopher
Pulliam, Dustin Heldman, Elizabeth Brokaw,
Michelle Burack, Thomas Mera
P1.197
Early Recruitment in Connect.
Parkinson, a National, Randomized,
Controlled Trial of Telemedicine for
Parkinson Disease Ryan Korn, Meredith
Achey, Christopher Beck, Denise Beran,
Cynthia Boyd, Peter Schmidt, Allison Willis,
Sara Riggare, Richard Simone, Kevin Biglan,
E. Ray Dorsey
P1.198
Correlation Between
Unified Parkinson’s Disease Rating
Scale and Global Impression of Change
Scales Khashayar Dashtipour, Jack Chen,
Pejman Dalaie, Karen Frei, Kayvan Kani,
Camellia Kani
P1.199
Database of Evidence-based
Ranked Parkinson Disease Variants Jeffery
Vance, Liyong Wang, Gary Beecham,
Christine Van Broeckhoven, Karen
Nuytemans
P1.207 Tactile Unawareness in
Acute Right Hemispheric Stroke Daniel
Antoniello, Reena Gottesman
P1.208 Lateral Eye Deviation and
Post-stroke Spatial Neglect A. Barrett,
Shreyas Shirodkar, Brian Yao, Peii Chen
P1.209 Anatomical and
Psychophysical Comparison of Subjective
Verticals in Patients with Right Brain
Damage Arnaud Saj, Jacques Honore,
Berenger Braem, Marc Rousseaux
P1.210
Self-report of Correct Inner
Speech Predicts Naming Success, Brain
Activity and Treatment Outcomes in People
with Aphasia William Hayward, Mackenzie
Fama, Kelli Sullivan, Sarah Snider, Elizabeth
Lacey, Rhonda Friedman, Peter Turkeltaub
P1.211
"I Know It but I Can't Say
It": Using Self-report to Understand
the Experience of Inner Speech in
Aphasia Mackenzie Fama, Sarah Snider,
William Hayward, Rhonda Friedman, Peter
Turkeltaub
P1.200 Incidence and Time Trends of
P1.201 Computerized Assessment
Aging, Dementia, Cognitive,
and Behavioral Neurology:
Frontotemporal Degenerations:
Clinical Aspects and Biomarkers
Drug-induced Parkinsonism: A Populationbased Study over 30 Years (1976–2005) Rodolfo Savica, Brandon Grossardt, James
Bower, J. Ahlskog, Walter Rocca
of Apathy in Parkinson's Disease Shows
Specific Motivational and Planning
Deficits Whitney Fitts, Lauren Massimo,
Nicholas Lim, Murray Grossman, Nabila
Dahodwala
P1.202 Prospective, Comparative
Study on Cost-effectiveness of Homebased Motor Monitoring System and
Office-based Medical Assessment in
Advanced Parkinson´s Disease Esther
Cubo Delgado, Natividad Mariscal-Pérez,
Berta Solano, Virginia Becerra, Jana Arribas
Aging, Dementia, Cognitive, and
Behavioral Neurology: Attention
and Aphasia
P1.203 Increased Early Processing of
Task-irrelevant Auditory Stimuli in Older
Adults Kirk Daffner, Erich Tusch, Anne
Fox, Fabio Porto, Brittany Alperin, Phillip
Holcomb
P1.204 The Influence of Executive
Capacity and Age on Attention to Novel
Auditory Events Kirk Daffner, Anne Fox,
Erich Tusch, Fabio Porto, Brittany Alperin,
Phillip Holcomb
P1.193
P1.205 Dementia and the Cocktail
Fast, Easy, Online Registration · AAN.com/view/AM15
Response Inhibition and Bimanual
Coordination: A Cerebral Interhemispheric
Disconnection Ali Shoraka, Dana Otzel,
Eduardo Zilli, Glen Finney, Leilani Doty,
Kenneth Heilman, Adam Falchook
Transcranial Direct Current
Stimulation for the Treatment of Primary
Progressive Aphasia Felix Gervits, Sharon
Ash, Marianna Diloyan, Brianna Morgan, H.
Coslett, Murray Grossman, Roy Hamilton
Movement Disorders: Parkinson's
Disease Research Methods
IPad App for Daily Parkinson
Diary Codrin Lungu, Bona Kim, Mark
Hallett, Kara Lukasiewicz, John Harrington,
Anne Altemus, Jeff Baldwin
P1.206 Effects of Aging on Crossed
Party Salwa Kamourieh, Rodrigo Braga,
Robert Leech, Richard Wise
P1.212
P1.213
Cerebrospinal Fluid
Biomarkers and [11C]Pittsburgh
Compound-B PET Concordance in
Alzheimer Disease Vs. Frontotemporal
Dementia Syndromes Jee Bang, Rik
Ossenkoppele, Leslie Shaw, Zachary
Miller, William Seeley, Lea Grinberg,
Anna Karydas, Adam Boxer, Maria Luisa
Gorno-Tempini, John Trojanowski, Bruce
Miller, William Jagust, Howard Rosen, Gil
Rabinovici
P1.214
The Neuropsychiatric
Inventory Questionnaire (NPI-Q2):
Quantitative and Qualitative Differences
Between Alzheimer Disease and
Frontotemporal Dementia Lydia Hatfield,
Teri Swezey, Matthew Harris, Daniel Kaufer
P1.215
BvFTD Phenocopy Syndrome:
Myth or Reality? Catherine Belin, Didier
Maillet, Gabriel Pop, Antoine Carpentier
P1.216
Pick's Disease Caused by a
Novel MAPT Mutation Zbigniew Wszolek,
Pawel Tacik, Michael DeTure, Kelly Ross,
Wenlang Lin, Monica Sanchez Contreras,
Aleksandra Wojtas, Matthew Baker,
Yari Carlomango, Patricia Brown, Audrey
Strongosky, Catherine Labbe, Shinsuke
Fujioka, Naomi Kouri, Melissa Murray, Rosa
Rademakers, Owen Ross, Dennis Dickson
61
Monday
April 20
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session I
P1.217
Survival in Primary
Progressive Aphasia: Comparison with
BvFTD and FTD-ALS Sara Mitchell,
Christina Caso, Megan Quimby, Kathleen
Kelly, Chenjie Xia, Elena Ratti, Kimiko
Domoto-Reilly, Scott McGinnis, Daisy
Hochberg, Jeanette Gunther, Matthew
Frosch, Bradford Dickerson
P1.218
Seizures and Myoclonus
in the Early Stages of Frontotemporal
Dementia Alexander Beagle, Sonja
Darwish, Elissaios Karageorgiou, Keith
Vossel
P1.219
The Role of Age and Genetic
Markers on Cerebrospinal Fluid Tau Levels
in Pathology-confirmed Frontotemporal
Degeneration Murray Grossman, Corey
McMillan, David Irwin, Vivianna Van
Deerlin, Leslie Shaw, Virginia Lee, John
Trojanowski
P1.220 Utility and Neuroanatomical
Correlates of the FTLD-NACC
Neuropsychology Module in the
Differential Diagnosis of Behavioral Variant
Frontotemporal Dementia and Alzheimer’s
Disease Katya Rascovsky, Eileen Moran,
Laura Baehr, David Irwin, Corey McMillan,
Murray Grossman
P1.221
Confirmation of Grey Matter
Disease Distributions in a Colombian
Cohort of Patients with Frontotemporal
Degeneration Pablo Alexander Reyes,
Diana Matallana, Felipe Uriza, Carlos Cano,
Murray Grossman, Corey McMillan, Katya
Rascovsky
Aging, Dementia, Cognitive,
and Behavioral Neurology:
Frontotemporal Degenerations:
Cognition and Behavior
P1.222Cognitive-behavioral
Changes in Amyotrophic Lateral Sclerosis:
Prevalence, Progression, and Impact on
Patients and Caregivers Meredith Bock,
Y-Nhy Duong, Anthony Kim, Jennifer
Murphy, Catherine Lomen-Hoerth
P1.223 Behavioral Change in ALS
as a Phenotypic Marker of Disease
Subtypes Tom Burke, Marwa Elamin, Peter
Bede, Marta Pinto Grau, Alice Vajda, Russel
McLaughlin, Niall Pender, Orla Hardiman
P1.224 Decision-making in
Amyotrophic Lateral Sclerosis Katya
Rascovsky, Joseph Kable, Eileen Moran,
Christopher Olm, Rebecca Kazinka, Leo
McCluskey, Lauren Elman, Ashley Boller,
Robin Clark, Corey McMillan, Murray
Grossman
P1.225 Eating Behavior and Metabolic
Changes Across the Spectrum of Motor
Neuron Disease and Frontotemporal
Dementia Rebekah Ahmed, Elana Henning,
Lauren Bartley, Glenda Halliday, Olivier
Piguet, Sadaf Farooqi, John Hodges,
Matthew Kiernan
P1.226
Grammar Comprehension
and Executive Function in Patients with
the Behavioral Variant of Frontotemporal
Degeneration (bvFTD) Rebecca Williams,
Sharon Ash, Katya Rascovsky, Murray
Grossman
62
2:00 p.m.–6:30 p.m.
P1.227 Matching Behavioral
Variant Frontotemporal Dementia and
Alzheimer Disease Groups on Dementia
Severity Mariel Deutsch, Michelle Mather,
Elvira Jimenez, Mario Mendez
P1.228
Connected Speech Production
in the Nonfluent Variant of Primary
Progressive Aphasia and Its Relationship
with White Matter Damage Elisa Canu,
Federica Agosta, Sebastiano Galantucci,
Eleonora Catricalà, Pilar Ferraro, Giuseppe
Magnani, Alessandra Marcone, Elisabetta
Coppi, Giancarlo Comi, Andrea Falini,
Massimo Filippi
P1.229 Prosodic Expression in
Frontotemporal Dementia Peter Pressman,
Robert Levenson, Bruce Miller, Maria Gorno
Tempini
P1.230 Baseline Autonomic
Dysfunction Relates to Cognitive
Empathy Impairment in Behavioral Variant
Frontotemporal Dementia Virginia Sturm,
Alice Hua, Sandy Lwi, Katherine Rankin,
Howard Rosen, Bruce Miller, Robert
Levenson, William Seeley
P1.231 A Case of Semantic Dementia
with Picks Pathology Alyssa Caplan, Jon
Elofson, Claire Lis, Howard Rosen, Maria
Gorno Tempini, Lea Grinberg, Bruce Miller
Epilepsy/Clinical
Neurophysiology (EEG):
Pharmaceuticals
P1.232
Perampanel Discontinuation
Is Not Associated with Self-reported
Withdrawal Symptoms in Patients
Completing Phase III Clinical
Studies Michael Rogawski, Haichen Yang,
Reginald Fant, Betsy Williams, Dongyuan
Xing, Cindy Dobrinsky, Antonio Laurenza
P1.233
Abuse Potential of
Antiepileptic Drugs: A Review Using
TM
the VigiBase Pharmacovigilance
Database Barry Gidal, David Blum
P1.234 Changes in Quality of
Life (QoL) and Depressive Symptoms
in a Long-term Open-label Extension
(OLE) of Eslicarbazepine Acetate (ESL)
Monotherapy Studies in Adults with
Refractory Partial-onset Seizures
(POS) Frank Gilliam, Hailong Cheng, David
Blum
P1.235 Lacosamide Does Not Affect
Depression and Anxiety in Patients with
Epilepsy Brian Moseley, Devlin Cole,
Ogonna Iwuora, Jeffrey Strawn, Michael
Privitera
P1.236 Intravenous Fosphenytoin in
Obese Patients: An Evaluation of Dosing
Strategies, Safety and Efficacy Sarah
Clark, Megan Leloux, Sara Hocker, Ross
Dierkhising, Gregory Cascino
P1.237
Comparison of Leviteracetam
Dosing Regimens in End-stage Renal
Disease Patients Undergoing Intermittent
Hemodialysis Harn Shiue, Kara Sands,
Maria Taylor
P1.238 Co-administration of Valproic
Acid and Lamotrigine in the Treatment of
Refractory Epilepsy Mei Jiang
P1.239 Safety and Tolerability of
Lacosamide Monotherapy in Elderly: A
Subgroup Analysis from Lacosamide Trials
in Diabetic Neuropathic Pain Edward
Faught, Marc De Backer, Klaus Eckhardt,
Frank Tennigkeit, Sabine Bongardt, David
Rudd, David Sen, Konrad Werhahn
P1.240 Cross-titration of Lacosamide
with a Sodium Channel Blocker in Patients
with Partial Onset Seizures on a Stable
Dose Regimen of Levetiracetam: Safety
and Efficacy Michel Baulac, William
Byrnes, Paulette Williams, Kimberly
Doggett, Elizabeth Webster, Marc De
Backer, Peter Dedeken
P1.241Carbamazepine
Monotherapy: Relationship Between Drug
Compliance, Serum Levels and Seizure
Control Mustapha Danesi, Adedunni
Olusanya, Francis Ojini, Njide Okubadejo
P1.242 Effect of Adjunctive
Rufinamide in Pediatric Patients with
Inadequately Controlled Lennox-Gastaut
Syndrome (LGS): Interim Pharmacokinetic
and Safety Results from Study 303 Jose
Ferreira, Alexis Arzimanoglou, Shannon
Mendes, Betsy Williams, David Critchley,
Edgar Schuck, Dinesh Kumar, Francesco
Bibbiani
P1.243 Progression to Adjunctive
Therapy Among Commerciallyinsured Patients with Partial Onset
Epilepsy Richard Brook, Fulton Velez, Jacob
Young
P1.244 Adherence and Resource
Utilization with Extended-release Oxtellar
XR® or Immediate-release Oxcarbazepine
(OXC-IR) Treatment in Clinical Practice: A
Standardized Case Record Review Welton
O'Neal, Elizabeth Hur, Katie Andersen,
Trevor Resnick
P1.245 Population Pharmacokinetic
Modeling of Extended-release Topiramate
(SPN-538, Trokendi XR®) in Children with
Epilepsy Scott Brittain, Janet Johnson
P1.246 Topiramate and Zonisamide
Are Not Effective in Secondary Prevention
of Infantile Spasms Rajsekar Rajaraman,
Johnson Lay, Raman Sankar, Shaun Hussain
P1.247
Long-term Efficacy, Safety,
and Impact on Quality of Life of USL255,
Qudexy™ XR (Topiramate) Extendedrelease Capsules: PREVAIL OLE Robert
Hogan, Ian Blatt, Annie Clark, Bob Anders,
Mark Halvorsen, Steve Chung
P1.248 Investigations of USL255,
Qudexy™ XR (Topiramate) Extendedrelease Capsules, Sprinkled onto Soft
Food or Delivered via Enteral Feeding
Tubes Mary Holmay, Annie Clark, Bob
Anders, John Pellock
P1.249
Is Half-life a Clinically
Relevant Measure for Extended-release
Drugs? Data Comparing Immediate- and
Extended-release Topiramate (USL255;
Qudexy™ XR) Barry Gidal, Annie Clark, Bob
Anders
P1.250 Eslicarbazepine Acetate (ESL)
Monotherapy in Adults with Partial-onset
Seizures (POS): An Analysis of Pooled
Data from Two Phase III Studies, with Use
of a Historical Control Ladislav Pazdera,
Jacqueline French, Michael Sperling,
Mercedes Jacobson, Hailong Cheng, David
Blum
P1.251
Assessment of Antiepileptic
Pharmacotherapy for Seizure Control
in Geriatric Patients: New Onset Vs.
Long-standing Epilepsy Golshan Fahimi,
Shahram Izadyar, Rebecca O'Dwyer
P1.252 Effect of Adjunctive
Perampanel on Growth and Development in
Adolescents with Inadequately Controlled
Partial Seizures J. Eric Pina-Garza, Haichen
Yang, Betsy Williams, Dinesh Kumar,
Antonio Laurenza
P1.253 Vigabatrin Efficacy
and Safety in Iranian Epileptic
Children Mohammadkazem Bakhshandeh
Bali, Mohammad Ghofrani
P1.254 Subgroup Analysis by
Race in Perampanel Phase III Clinical
Studies Antonio Laurenza, Haichen Yang,
Betsy Williams, Steven Huang, Michael
Sperling
P1.255Pharmacokinetic,
Pharmacodynamic and Cognitive Effects
of Adjunctive Perampanel in Adolescents
with Inadequately Controlled Partial
Seizures Ziad Hussein, Barry Gidal,
Haichen Yang, Betsy Williams, Dinesh
Kumar, Antonio Laurenza, Jim Ferry, Kimford
Meador
P1.256 Potential Effect of Perampanel
on Photosensitivity in Healthy Subjects
and Patients from Phase III Clinical
Studies Haichen Yang, Betsy Williams,
Dongyuan Xing, Antonio Laurenza
P1.257 Clobazam Vs. Clonazepam for
Adults with Epilepsy: Long-term Results
from a UK Primary Care Database Martin
Brodie, Steve Chung, Alan Wade, Celine
Quelen, Alice Guiraud-Diawara, Clement
Francois, Patrice Verpillat, Vivienne Shen,
Daniel Jones, Jouko Isojarvi
P1.258 Retention Rate and Efficacy
of Clobazem in Comparison to Other
Newer Anticonvulsants in Patients with
Epilepsy Steve Chung, Thandar Aung
P1.259
Effects of Hepatic Impairment
on Clobazam Pharmacokinetics: An
Integrative, Model-based Approach Ene
Ette, Ihor Bekersky, Hui-May Chu, Dwain
Tolbert
P1.260 Clobazam for Dravet
Syndrome: Designing a Clinical Study
Using Pharmacokinetic/Pharmacodynamic
Modeling Deborah Lee, Rachel Omasta,
Colleen Canavan, Mahlaqa Patel, Thomas
Stothoff, Guangbin Peng, Dwain Tolbert
P1.261
Long-term Utilization
Differences Between Children Treated with
Clobazam Vs. Clonazepam for Epilepsy in
the UK Steve Chung, Martin Brodie, Alan
Wade, Celine Quelen, Alice GuiraudDiawara, Clement Francois, Patrice Verpillat,
Vivienne Shen, Daniel Jones, Jouko Isojarvi
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session I
Autonomic Disorders:
Synucleinopathies
P1.262 A Comparative Analysis
of Autonomic Testing and Diagnostic
Consensus Criteria in Autopsy-confirmed
Multiple System Atrophy Wolfgang Singer,
Ann Schmeichel, Joseph Parisi, Eduardo
Benarroch, Robert Fealey, Paola Sandroni, J.
Ahlskog, James Bower, Joseph Matsumoto,
Phillip Low
P1.263 Alpha-Synuclein and
Autonomic Neuropathy Progression
in a Longitudinal Study of Parkinson
Disease Christopher Gibbons, Ningshan
Wang, Jenniffer Garcia, Roy Freeman
P1.264 Clinical Characteristics
and Survival in Multiple System
Atrophy Elizabeth Coon, Mariana Suarez, J.
Ahlskog, Jayawant Mandrekar, Phillip Low,
Wolfgang Singer
P1.273
Autoimmune Autonomic
Ganglionopathy - Symptom Antibody
Correlations Christopher Gibbons, Roy
Freeman
P1.274
Prolonged QTc Interval in
Patients Seropositive for Ganglionic
(α-3) Acetylcholine Receptor
Autoantibody William Cheshire, Kalpathi
Venkatachalam, Mohamad Yamani, Vanda
Lennon
P1.275
Acute Autonomic and Sensory
Neuropathy: A Case Report Joel Gutierrez,
Jose-Alberto Palma, Vijay Vishwanath,
Horacio Kaufmann
P1.276
Prevalence of Ganglionic
AChR Antibodies in Postural Tachycardia
Syndrome (POTS) Steven Vernino, Steve
Hopkins, Luis Okamoto, Bonnie Black, Cindy
Dorminy, Sachin Paranjape, Satish Raj
P1.277 Evidence of Mast Cell
P1.265 Survival in
Activation Disorder in Postural Tachycardia
Syndrome Charlene Hoffman-Snyder, John
Lewis, Lucinda Harris, Priya Dhawan, Brent
Goodman
P1.266 Decreased Cerebrospinal
P1.278
Synucleinopathies David Goldstein,
Courtney Holmes, Yehonatan Sharabi,
Tianxia Wu
Fluid Levels of Chromogranin a in Early
Stages of Parkinson’s Disease May
Predict Earlier Development of Orthostatic
Hypotension Michaela Kaiserova, Hana
Prikrylova Vranova, Jan Galuszka, David
Stejskal, Katerina Mensikova, Jana
Zapletalova, Jan Mares, Petr Kanovsky
P1.267
Pure Autonomic Failure Predictors of Conversion to Clinical CNS
Involvement Sarah Berini, Elizabeth Coon,
Phillip Low, Wolfgang Singer
P1.268 Cardiovascular Dysautonomia
in Prodromal α-Synucleinopathy:
Peripheral Versus Central Autonomic
Degeneration Sven Rupprecht, Christiane
Dahms, Otto Witte, Albrecht Guenther,
Matthias Schwab
P1.269
Identifying an Objective
Benchmark to Initiate Pharmacologic
Treatment of Orthostatic Hypotension in
Parkinson Disease Jose-Alberto Palma,
Jose Martinez, Lucy Norcliffe-Kaufmann,
Juan Gomez-Esteban, Beatriz Tijero Merino,
Koldo Berganzo Corrales, Horacio Kaufmann
P1.270
Progressive Retinal Structure
Abnormalities in Multiple System
Atrophy Jose-Alberto Palma, Carlos
Mendoza-Santiesteban, Jose Martinez,
Lucy Norcliffe-Kaufmann, Thomas Hedges,
Horacio Kaufmann
P1.271
Cranial Nerve Pathology
in Multiple System Atrophy (MSA):
Implications for the in Vivo Evaluation of
Disease Matthew Cykowski, Elizabeth
Coon, Phillip Low, Eduardo Benarroch,
Suzanne Powell, Joseph Parisi
Autonomic Disorders: Autonomic
Neuropathies and Postural
Tachycardia Syndrome
P1.272 Autoantibodies in the Postural
Tachycardia Syndrome Wolfgang Singer,
Christopher Klein, Phillip Low, Vanda Lennon
Autonomic Dysfunction in
Guillain Barre Syndrome: Development of a
Risk Score Scale Miguel Wilken, Mauricio
Farez, Federico Carpani, Fabio Adrian
Barroso
P1.279 Sleep Disorders in
Patients with Postural Tachycardia
Syndrome Mitchell Miglis, Srikanth
Muppidi, Safwan Jaradeh
P1.280Gastrointestinal
Manifestations of Postural Orthostatic
Tachycardia Syndrome Karen
Morgenshtern, Collin Culbertson, Liz Wang,
Anindita Deb, Anna Hohler
P1.281
Vestibular Symptoms Are
Common in Postural Tachycardia Syndrome
(PoTS) Brent Goodman, Priya Dhawan,
Jamie Bogle, David Barrs, Charlene
Hoffman-Snyder
Autonomic Disorders: Other
P1.282
Normative Values for
Sudomotor Axon Reflex Testing Using
QSWEAT™ David Sletten, Andrew
Grandinetti, Stephen Weigand, Tonette
Gehrking, Jade Gehrking, Phillip Low,
Wolfgang Singer
P1.283 Falls During a 10-week
Placebo-controlled Study of Droxidopa
for Neurogenic Orthostatic Hypotension
in Parkinson’s Disease Gerry Rowse,
Stephane Heritier, L. Arthur Hewitt
P1.284 Integrated Efficacy and
Safety Analyses of Droxidopa for
Symptomatic Neurogenic Orthostatic
Hypotension Robert Hauser, Cameron
Szakacs, Horacio Kaufmann
P1.285 Composite Autonomic
Symptom Scale 31 Shows Impaired
Autonomic Bladder and Pupillary Function
in Multiple Sclerosis Patients Julia Koehn,
Tassanai Intravooth, Hösl Katharina, DeHyung Lee, Ralf Linker, Max Hilz, Wolfgang
Singer
Fast, Easy, Online Registration · AAN.com/view/AM15
P1.286 Active Standing Reveals
Subtle Cardiac Autonomic Dysfunction in
Patients with Traumatic Brain Injury Max
Hilz, Markus Jörg, Tassanai Intravooth,
Katharina Hösl, Julia Koehn
P1.287 The Effects of Statin Therapy
on Adrenal and Sexual Functions in Male
Patients with Hyperlipidemia Selda
Korkmaz, Osman Baspinar, Fahri Bayram,
Yasin Simsek, Halit Diri, Tugce Bilecenoglu,
Murat Aksu
P1.288 Autonomic Neurophysiological
Evaluation in Transthyretin-related
Amyloidosis: Heart Rate Variability Is
Impaired Mostly in Patients with Absent
Sympathetic Skin Response Rodolfo
Callejas, Bruno Estanol
P1.289
Cognitive and Motor Function
of Orthostatic Hypotension Patient
Taking Alpha-blocker for Benign Prostate
Hypertrophy—Preliminary Study Hee
Kwon Park, Jong-Hyun Ahn, JiWon Kwon,
Soo-Jeong Kim, Eung-Seok Lee, Cindy Yoon,
Eun-Ki Kim, Joung-Ho Rha
P1.290 Delayed Central Hyperthermia
Responsive to Bromocriptine Rawan
Albadareen, Scott Belliston, Kathrin
Husmann, Yunxia Wang
P1.298 Tolosa-Hunt Syndrome
with Facial Nerve Involvement Mohsen
Pirastehfar, Jin Luo
P1.299 New Etiology for Orthostatic
Headache Ryan Smith, Carrie Robertson,
Ivan Garza
P1.300 Breath-Powered™ Nasal
Delivery of 22 Mg Powdered Sumatriptan
(AVP-825): Migraine Disability and
Functional Outcome in a Phase 3 Study
(TARGET) Peter McAllister, Roger Cady,
Egilius Spierings, John Messina, Per
Djupesland, Joao Siffert, Scott Siegert,
Ramy Mahmoud
P1.301 Characteristics of
Post Concussive Headaches in
Children Presenting to the Neurology
Clinic Karameh Kuemmerle
P1.302 Mutational Analysis of
Whole Blood Transcriptome in Patients
with Migraine with Aura: A Case-control
Study Agustin Oterino, Maria Toriello, Anna
Esteve-Codina, Heath Simon, Silvia Montes,
Rosa Martinez-Nieto, Jesus Castillo,
Jenifer Fernandez, Silvia Gutierrez, Vicente
Quintanilla, Enar Pons, Enrique Palacio
P1.303 Compliance with ICMJE Trial
Headache
Registration Requirements in the Headache
Medicine Literature Melissa Rayhill, Roni
Sharon, Elizabeth Loder
P1.291 Brain Structural and
P1.304 Headache in Patients with
P1.292 Non-invasive Vagus
P1.305 Exercise-induced Intracranial
P1.293 Herpes Simplex Virus Type 1
P1.306 Efficacy and Safety of
P1.294 Evaluation of Retinal Nerve
P1.307 Primary Headaches as a
P1.295
P1.308 Intractable Headache
Neurometabolic Correlates of Visual Snow
Disorder Christoph Schankin, Farooq
Maniyar, Till Sprenger, Denise Chou,
Michael Eller, Peter Goadsby
Nerve Stimulator (gammaCore®) Was
Not Associated with Meaningful
Cardiovascular Adverse Effects Emily
Engel, Justyna Blake, Eric Liebler
Dorsal Root Ganglionitis in a 34-year-old
Male with Occipital Neuralgia Refractory
to Medical and Radiofrequency Ablation
Therapies: A Clinicopathological Report
and Literature Review Jaivir Rathore,
Konstantin Slavin, Ranvir Rathore, Andrei
Rakic, Tibor Valyi-Nagy
Fiber Layer Thickness (RNFLT) with Ocular
Coherence Tomography Spectral Domain
(OCT-SD) in Migraine Patients Ester
Reggio, Clara Chisari, Giulia Ferrigno,
Francesco Patti, Mario Zappia
Metabotropic Glutamate
Receptor Antagonism Reduces
Trigeminovascular Nociceptive
Transmission Maggie Waung, Simon
Akerman, Annabelle Bergenfeld, Peter
Goadsby
P1.296 Case Series: Putting a
Stop to Post-traumatic Headache with
Onabotulinumtoxin A Regina Krel, Neha
Mirchandani, Fernanda Wajnsztajn,
Christopher Stoebe, Warren Spinner
P1.297 Clinical Benefit of
Incobotulinumtoxin-A for the Treatment of
Chronic Migraine Luis Javier Lopez Del Val,
Elena Lopez Garcia, Sonia Santos Lasaosa,
Elena Bellosta Diago
Acute Ischemic Stroke and Frequency of IV
TPA Administration John Wedlake, Vijay
Pandav, Jordan Mayberry, Aminata Traore,
David Thompson, Evgeny Sidorov
Hypertension Due to Insufficient Jugular
Vein Drainage Treated with a Stent Pamela
Correia, A. Angelillo-Waeber, S Binaghi, Ph.
Maeder, Patrik Michel
OnabotulinumtoxinA in a Long-Term,
Open-Label Study for the Prophylaxis
of Headaches in Adult Chronic Migraine
Patients: An Interim Analysis of the
COMPEL Study Andrew Blumenfeld,
Richard Stark, Albert Reppine, Michael
Halstead, Fred Holdbrook, Sheena Aurora
Cause of Non-traumatic Ecchymosis: A
120-year Systematic Review and Pooled
Analysis of Published Case Studies Addie
Peretz, Yohannes Woldeamanuel, Robert
Cowan
Heralding Anti-NMDA Receptor
Encephalitis Clotilde Hainline, Angeliki
Vgontzas, Cinthi Pillai, Matthew Robbins
P1.309 Alexia with Agraphia as a
Rare Presentation of Migraine Omer
Suhaib, Anthony Vaughn
P1.310
Increased Intracranial
Pressure as a Presentation of Lyme Disease
in Children: A Case Series Rawad Obeid,
Sriram Ramgopal, Catalina Cleves, Andrew
Nowak
P1.311
Prevalence of Headaches in
Patients with Seizure Disorders Cristina
Wohlgehagen, Brannon Vines, Jerzy
Szaflarski
63
Monday
April 20
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session I
Secondary Traumatic Stress
Increases Hypervigilance Via Increases
in Proteins Implicated in Peripheral
and Central Sensitization of Trigeminal
Nerves: Potential Role in Migraine
Pathogenesis Paul Durham, Jordan
Hawkins, Moore Nicholas, David Miley
Neuro-ophthalmology/
Neuro-otology I
P1.313
P1.312
2:00 p.m.–6:30 p.m.
P1.327
P1.336
P1.320 Effects of Intervention on
Optical Imaging of Papilledema in the
Idiopathic Intracranial Hypertension
Treatment Trial Mark Kupersmith
The Pulfrich Phenomenon:
An Objective Signature-biomarker of MS
Pathophysiology Millad Sobhanian, Rohit
Agarwal, Amy Conger, Darrel Conger,
Robert Rennaker, Laura Balcer, Owen
White, Randy Kardon, Shin Beh, Teresa
Frohman, Elliot Frohman
Therapeutic Effectiveness of
Sphenopalatine Ganglion (SPG) Stimulation
for Cluster Headache—Pathway Registry
Study Interim Results at 6 Months Jose
Miguel Lainez, Tim Jurgens, Rigmor Jensen,
Holger Kaube, Andreas Boger, Charly Gaul,
Amy Goodman, Anthony Caparso, Arne May
P1.321
P1.328
P1.337 Efficacy of Multimodal
P1.314
Definition of and Comparison
of the "Headache Problem" in Veterans
of the Iraq (OIF) and Afghanistan (OEF)
Wars with and Without Traumatic Brain
Injury (TBI) Using Parameters of Headache
Frequency and Intensity James Couch,
Kenneth Stewart
P1.322
P1.315
P1.323
Pooled Analyses of
Randomized, Double-blind, Placebocontrolled Studies of a Breath Powered™
Nasal Delivery Device Containing 22 Mg
Sumatriptan Powder (AVP-825) in the
Treatment of Episodic Migraine Roger
Cady, Per Djupesland, Ramy Mahmoud,
John Messina, Laszlo Mechtler, Scott
Siegert, Joao Siffert
P1.316
Sexual Function in Female
Patients with Migraine Derya Uluduz,
Sevin Ayan, Harika Ertem, Ugur Uygunoglu,
Baki Goksan, Sabahattin Saip, Aksel Siva
Saccadic Eye Movements in
Parkinson’s Disease: An Eye-tracking and
FMRI Study Joao Lemos, Daniela Pereira,
Luciano Almendra, Diliana Rebelo, Joao
Castelhano, Gil Cunha, Cristina Januario,
Antonio Goncalves, Luis Cunha, Miguel
Castelo-Branco
Prevalence, Demographics,
and Clinical Characteristics of Vertigo
Disorders in a Specialized Multidisciplinary
Outpatient Clinic Jan Burmeister, Eva
Bock, Marcus Gerwig, Markus Frings,
Diana Arweiler-Harbeck, H. Diener, Mark
Obermann
20/40 or Better Visual Acuity
After Optic Neuritis: Not as Good as
We Once Thought Rachel Nolan, Kristin
Galetta, Kannan Narayana, James Wilson,
Peter Calabresi, Elliot Frohman, Steven
Galetta, Laura Balcer
P1.324
Vertical Video Head Impulse
Tests in Patients with Internuclear
Ophthalmoplegia Seung-Han Lee, GwanYeol Cho, Yoon-Chang Oh, Jae-Hwan Choi,
Kwang-Dong Choi
P1.317
Intraventricular Blood and
Pneumocephalus After Epidural Blood
Patch Adam Chen, Machteld Hillen
OCT Shows Different
Relationships Between Macular Layers and
Peripapillary RNFL in Acute Versus Chronic
Papillitis and Papilledema Fawzi Abukhalil,
Mark Morrow
P1.318
P1.326
Botox (onabotulinumtoxinA)
for Treatment of Post Traumatic Chronic
Migraine Headaches (PTCMH) in
Veterans Abhishek Roka, Ashvin Zachariah,
Erika Badiali, Sally Zachariah
P1.319
Depressive and Anxiety
Disorders in Migraine and Chronic
Migraine Letizia Borges, Jose Speciali,
Facundo Ruiz Junior
P1.325
Optical Coherence
Tomography and Visual Evoked Potentials
in Monitoring MS Evolution Letizia
Leocani, Marco Pisa, Giovanni Di Maggio,
Roberto Santangelo, Stefania Medaglini,
Mariaemma Rodegher, Bruno Colombo,
Lucia Moiola, Ubaldo Del Carro, Vittorio
Martinelli, Giancarlo Comi
CSF Characteristics in Patients
with High Frisén Papilledema Grades from
the IIHTT John Pula, Jorge Kattah, Luis
Mejico, Michael McDermott, Michael Wall
P1.329 Retinal Ganglion Cell and
Intravenous Dexamethasone
in Acute Management of Vestibular
Neuritis: A Randomized, Placebocontrolled, Single Blind Trial Ivan Adamec,
Magdalena Krbot Skoric, Tereza Gabelic,
Barbara Barun, Josip Ljevak, Andreja Bujan
Kovač, Ivana Jurjevic, Mario Habek
Therapy for the Treatment of Chronic
Vertigo and Dizziness Mark Obermann, Eva
Bock, Nikolay Sabev, Nils Lehmann, HansChristoph Diener
Inner Plexiform Layer Loss Correlate with
Visual Acuity Loss in LHON: A Highresolution, Longitudinal, Segmentation OCT
Analysis Stephen Moster, Mark Moster,
Robert Sergott
P1.338
P1.330 Visual Performance Testing
P1.339 Conjunctival Biopsy to
in Children with Attention Deficit
Hyperactivity Disorder Bridget Mueller,
Natali Baner, Danielle Leong, Karen Fleiss,
Nicholas Moehringer, Steven Galetta, John
Wells, Laura Balcer
Association of
25-hydroxyvitamin D Levels with RNFL
Thickness and Clinical Tests of Visual
Function in Acute Optic Neuritis Gorm PihlJensen, Jette Lautrup Frederiksen Battisti
Diagnose Neurosarcoidosis in Patients with
Inflammatory Nervous System Disease of
Unknown Etiology Michael Pichler, Eoin
Flanagan, Allen Aksamit, Jacqueline Leavitt,
Diva Salomao, Mark Keegan
P1.331
Otolith Dysfunction in
Benign Paroxysmal Positional Vertigo:
Bilateral Abnormalities of Ocular and
Cervical VEMPs Persist After Successful
Repositioning Maneuvers Tae-Ho Yang,
Sun-Young Oh
P1.332
Inferior Cerebellar Peduncular
Lesion Causes a Distinct Vestibular
Syndrome Kwang-Dong Choi, Jae-Hwan
Choi, Seung-Han Lee
P1.333 Rapidly Progressive Bilateral
Optic Nerve and Retinal Infarctions Due to
Rhinocerebral Mucormycosis Isha Duggal,
Ulrike Kaunzner, Carolina Maciel, Alexandra
Miller, Alexander Merkler, Marc Dinkin
P1.334 OCT Shows Consistent
Relationships Between Macular Layers
and Peripapillary RNFL in Chronic
Demyelinating and Compressive Optic
Neuropathies Mark Morrow, Fawzi
Abukhalil
P1.335 Visual Field Assessment in the
“Split-brain” Patient: Effect of the Method/
laterality of Obtaining Patient Responses
on Apparent Visual Field Defect Size J. Alexander Fraser, Jorge Burneo
NEW Advanced Practice Provider Track Debuts at 2015 Annual Meeting
A
64
Nurse practitioners and physician assistants won’t want to miss this new track
consisting of current education programs suggested to offer a “deep dive” into
general neurology. Only AAN members save with deep discounts on Annual
Meeting registration, so if you’re not a member, join today at the special nurse
practitioner/physician assistant rate of only $100—that’s just a fraction of the
price of the $4,000+ in exclusive discounts and other member benefits! Renew
or join today AAN.com/membership.
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session II
Tuesday, April 21
P2 First
Poster Session II
7:30 a.m.–12:00 p.m.
Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Discussion Session: Neuromuscular and Clinical Neurophysiology (EMG): Genetics
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
P2.004 Electrical Impedance
P2.002 Peripheral Nerve Lymphoma:
P2.005 ATXN2 PolyQ Intermediate
in Tertiary Referral Frequently
Assists in Diagnosis and Therapeutic
Management Cris Ida, P. James B. Dyck,
Duygu Selcen, John Bodensteiner, Michelle
Mauermann, Peter Dyck, Christopher Klein
Clinical, Electrophysiological, Radiographic
and Pathological Findings P. James B.
Dyck, Narupat Suanprasert, Michelle
Mauermann, Kimberly Amrami, Robert
Spinner, Peter Dyck
P2.003 Disease Manifestations in
a Spinal and Bulbar Muscular Atrophy
Patient After Feminization for Gender
Reassignment Tyler Lanman, Dara Bakar,
Ailbhe Burke, Angela Kokkinis, Alice
Schindler, Laura Bott, George Harmison,
Kenneth Fischbeck, Christopher Grunseich
Myography as a Pharmacodynamic
Biomarker in Spinal Muscular
Atrophy William Arnold, Vicki McGovern,
Jia Li, Xiaohui Li, Stephen Kolb, Seward
Rutkove, Arthur Burghes
Repeat Modifies ALS Phenotype and
Survival Adriano Chio, Andrea Calvo,
Cristina Moglia, Antonio Canosa, Gabriella
Restagno, Maura Brunetti, Marco Barberis,
Amelia Conte, Giuseppe Marangi, Serena
Lattante, Marcella Zollino, Mario Sabatelli,
Lucia Corrado, Gabriele Mora, Letizia
Mazzini, Sandra D'Alfonso
P2.006 Utrophin Modulators to Treat
Duchenne Muscular Dystrophy (DMD):
Phase 1b Clinical Trial Results of SMT
C1100 Jon Tinsley, Francesco Muntoni,
Stefan Spinty, Helen Roper, Imelda Hughes,
Valeria Ricotti, Alison Bracchi, Bina Tejura,
David Roblin, Gary Layton, Kay Davies
P2.007 Milder Phenotype in
Facioscapulohumeral Muscular Dystrophy
Patients with the Largest Residual D4Z4
Fragments Jeffrey Statland, Colleen
Donlin-Smith, Stephen Tapscott, Silvere van
der Maarel, Alrabi Tawil
P2.009 Human Skeletal Muscle
Satellite Cells Are a Manageable Tool for
Gene Therapy Simone Spuler, Andreas
Marg, Helena Escobar, Andreas Spuler,
Zsuzsanna Izsvak, Carmen Birchmeier
P2.010
Diabetic Neuropathy and
the Sensory Neuron: New Molecular
Targets Masaki Kobayashi, Chu Cheng,
Cristiane de la Hoz, Douglas Zochodne
P2.008 Protein Misfolding in
Dysferlinopathy: The Novel Animal Model
Dysf-MMex38 Leonie Victoria Heidt,
Michael Bader, Simone Spuler, Verena
Schöwel
Tuesday
April 21
P2.001 Pediatric Nerve Biopsy
e-Poster Session: Neuromuscular and Clinical Neurophysiology (EMG)
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P2.011
Myotoxic Effects of Statins
in Primary Human Muscle Cells Stefanie
Grunwald, Oliver Popp, Nicole Jedraszczak,
Giannino Patone, Gunnar Dittmar, Simone
Spuler
P2.012
An Atypical Presentation
of Neurolymphomatosis: A Case Report
and Literature Review Ann Murray, Frank
Bittner, Kymberly Gyure, Chandler Park,
Amelia Adcock
P2.013
Clinical Characteristics of
Elderly Patients with Amyotrophic Lateral
Sclerosis Tami Nussbaum, Irena Artman,
Vivian Drory
Neuromuscular Disease:
Genetics and Outcomes
P2.021 Congenital Myasthenic
Syndrome (CMS) Caused by Novel
Mutation in LRP4. Phenotypic
Heterogeneity and Defects in
Neuromuscular Transmission (NMT)
Identified in a Second Kinship Duygu
Selcen, Xinming Shen, Bisei Ohkawara,
Kathleen McEvoy, Kinji Ohno, Andrew Engel
P2.014
Congenital Myasthenic
Syndrome Due to DOK7 Mutations in
a Family from Chile Jorge Bevilacqua,
Marian Lara, Jorge Díaz, Ricardo Maselli
P2.017
P2.015
P2.018
Real-time MRI for Evaluation
of Dysphagia in Inclusion Body Myositis
(IBM) Per-Ole Carstens, Shou Zhang, Arno
Olthoff, Eva Bremen, Joachim Lotz, Jens
Frahm, Jens Schmidt
P2.016
Mechanism for Proximal
Median Neuropathy as a Complication
of Reverse Shoulder Arthroplasty: Nerve
Strain Calculated from a Computerized 3-D
Model Cadaver Brachial Plexus Reiner
Henson See, Bashar Katirji, David Preston,
Barbara Shapiro
P2.022 The Enlarging Spectrum
of Nav1.7 Mutations Associated with
Neurological Pain Syndromes Hayet
Salhi, Pascale Fanen, Benoit Funalot,
Valérie Raclin, Yasmine Baba Amer, Samar
Ayache, Francois-Jer Authier, Jean-Pascal
Lefaucheur, Alain Creange, Alain Creange
P2.023 Diagnosis of Congenital
Myasthenic Syndromes by Target Capture/
next Generation Sequencing Jie Lin, Xia
Tian, Victor Zhang, Jing Wang, Lee-jun Wong
Fast, Easy, Online Registration · AAN.com/view/AM15
The Spectrum of Hirayama
Disease: Three Patients’ Magnetic
Resonance Imaging and Electrodiagnostic
Studies Alison Walsh, Goran Rakocevic
Developing a Techniquespecific Nomogram for Temporal
Discrimination Threshold Testing Vesper
Fe Marie Ramos, Alina Esquenazi, Monica
Anne Faye Villegas, Tianxia Wu, Mark
Hallett
P2.020 Clinical Response of
Neuromuscular Patients to IVIG: An Interim
Analysis of the INSIGHTS Registry Todd
Levine, Jonathan Katz, Richard Barohn,
David Saperstein, Mazen Dimachkie, Gil
Wolfe, Lara Katzin, Tahseen Mozaffar, Leslie
Vaughn, Michelle Greer
P2.019
Interposition in the Median
and Ulnar Nerve; a 40-year Followup Stefan Meng, Hanno Millesi, Robert
Schmidhammer, Gregor Kasprian, Anna
Grisold, Wolfgang Grisold
P2.024 Phenotypic Variation Resulting
from GMPPB Mutations with Genotype
Phenotype Observations Braden Jensen,
Steven Moore, Carrie Stephan, Katherine
Mathews
P2.025 Hematopoietic Stem Cell
Transplantation in Adult Onset Adrenoleukodystrophy Florian Eichler, Adam Chen
P2.026 Compound Heterozygosis of
a Splice Site and the Common Ashkenazi
Jewish Mutation in GBE1 Causes Adult
Onset Polyglucosan Body Disease Orhan
H. Akman, Yasemin Kurt, Mary Wallace,
Raphael Schiffmann, Salvatore DiMauro
P2.027 Molecular Combing Compared
to Southern Blot in Measuring D4Z4
Contractions in FSHD Jessica Vasale,
Michael Jocson, Fatih Boyar, Khalida
Liaquat, Carol Hoffman, Vladimira Sulcova,
David Tsao, Kerri Hensley, Yan Liu, Patricia
Chan, Renius Owen, Corey Braastad,
Weimin Sun, Arturo Anguiano, Malgorzata
Jaremko, Zhenyuan Wang, Funda Suer, Sat
Dev Batish, Charles Strom, Joseph Higgins
65
Poster Session II
P2.028 Variability of Expression
in MYH14 Distal SMA Phenotype:
A Single-family, Multi-generational
Evaluation Stanley Iyadurai, John Kissel,
Corey Ruhno, Vicki McGovern, Jennifer
Roggenbuck, Arthur Burghes, Stephen Kolb,
William Arnold
P2.029 Periodic Muscle Paralysis—a
Different Perspective Tudor Munteanu,
Janice Redmond, Yvonne Langan, Francesca
Brett
Neuropathy: Genetics and
Outcomes
P2.030 A Novel TFG Mutation Causes
Charcot-Marie-Tooth Disease Type 2 and
Impairs TFG Function Pei-Chien Tsai, BingWen Soong, Kon-Ping Lin, Yi-Chung Lee
P2.031 Peripheral Neuropathy in
a Family with Sandhoff Disease and
SH3TC2 Deficiency Dara Bakar, Tyler
Lanman, Christopher Grunseich, Ke-lian
Chen, Alice Schindler, Ami Mankodi, Ryan
Traslavina, Tanya Lehky, Eva Baker, Nicholas
Maragakis, Cynthia Tifft, Kenneth Fischbeck
P2.032 Evaluating the Diagnostic
Yield of a Multi-gene Panel for
Charcot-Marie-Tooth and Related
Neuropathies Courtney Downtain
Pickersgill, Sharon Suchy, Tracy Brandt
P2.033Charcot-Marie-Tooth
Disease Type-2P Is Associated with a
Missense Mutation in the RING Domain of
LRSAM1 Meng Zhu, Sezgi Arpag, Audra
Hamilton, Robin Yawn, Stephan Zuchner,
Jun Li
P2.034 Genotypic and Phenotypic
Presentation of TTR- FAP in Turkey Hacer
Durmus, Zeliha Matur, Mehves Poda, Mert
Murat Atmaca, Piraye Serdaroglu, Feza
Deymeer, Yesim Parman
P2.035 Sensory Neuropathy in
Children Presenting with Behr Syndrome
Due to OPA1 Mutations Yann Pereon,
Karine Boyer, Cyril Gitiaux, Guillaume Nicolas,
Armelle Magot, Michele Mayer, Magalie
Barth, Dominique Bonneau, Diana Rodriguez,
Isabelle Desguerre, Sylvie Nguyen The Tich
P2.036 CMT 4H: A Novel Mutation Sharika Rajan, David Chad, Dinesh Nair
P2.037 Two Siblings with
Genetically Proven HNPP and Autonomic
Neuropathy Ilene Ruhoy, John Oakley,
Suman Jayadev, Michael Weiss
P2.038 Sensitivity and Specificity of
the “Ears of the Lynx” MRI Sign in Spastic
Paraparesis with SPG Mutations Joseph
Masdeu, Belen Pascual, Marcondes Franca,
Jr., Michael Gregory, Michlene Daniels,
Nicholas Patronas, Camilo Toro, Maria
Bassi, Perrine Charles
P2.039 Novel SEPT9 Mutation
Underlying Hereditary Neuralgic
Amyotrophy: Variability of Expression and
Invariant Features in Multi-generational
Family Jennifer Roggenbuck, John Kissel,
Stanley Iyadurai
66
7:30 a.m.–12:00 p.m.
Muscle Disease: Genetics,
Pathogenesis, and Pathology
P2.040 Carnitine Responsive Lipid
Storage Myopathy: A Case Report Seref
Demirkaya, Ahmet Cetiz, Hakan Akgun,
Bülent Kurt, Oguzhan Oz, Ümit Ulas
P2.041 Mutations in MEGF10 in
a Patient Presenting with Late Onset
Myopathy and Respiratory Distress Nizar
Chahin, Duygu Selcen, Myra Roche, Karen
Weck, Kirk Wilhelmsen, James Evans,
Jonathan Berg
P2.042 Variants in the COL6A1,
COL6A2, and COL6A3 Genes in Collagen
VI-related Congenital Muscular
Dystrophy Malgorzata Jaremko, Keith
Morneau, Tiffany Smith, Zhenyuan Wang,
Funda Suer, Carol Hoffman, Khalida Liaquat,
Michele McCarthy, Jennifer Lapierre,
Valerie Storozuk, Marc Meservey, Sat Dev
Batish, Joseph Higgins
P2.043 Myoshi Myopathy: A Rare
Mutation in a Brazilian Patient—Case
Report Alzira Carvalho, Miriam Eva Koch
P2.044 Genetic Analysis Reveals
That GNE Myopathy Is an Underdiagnosed
Neuromuscular Disorder Marjan Huizing,
May Christine Malicdan, Frank Celeste,
Thierry Vilboux, Carla Ciccone, William Gahl,
Nuria Carrillo-Carrasco
P2.045 Neuromyotonia: An
P2.050 Frequency of the Expanded
P2.057 Multicenter Epidemiological
P2.051 Screening of CHCHD10
P2.058 Adherence to the AAN ALS
Hexanucleotide G4C2 Repeat in the
C9ORF72 Gene and Clinical Features of
Patients Presenting to ALS Referral Centers
in Buenos Aires, Argentina: Preliminary
Results Gisella Gargiulo Monachelli, Claire
LeBlond, Mariela Bettini, Javier VazquezVarela, Maria Alejandra Figueredo, Andrea
Lautre, Patrick Dion, Maria Laura Garau,
Marcelo Kauffman, Marcelo Francisco
Rugiero, Maria Claudia Gonzalez Deniselle,
Miguel Pagano, Guy Rouleau
in an Italian Cohort of ALS/ALS-FTD
Patients Giulietta Riboldi, Dario Ronchi,
Roberto Del Bo, Nicola Ticozzi, Marina
Scarlato, Daniela Galimberti, Benedetta Del
Menico, Simona Brajkovic, Stefania Corti,
Vincenzo Silani, Nereo Bresolin, Giacomo Comi
P2.052 CHCHD10 Gene Mutations in
ALS Patients of Italian Ancestry Adriano
Chio, Andrea Calvo, Marco Barberis, Maura
Brunetti, Gabriella Restagno, Gabriele
Mora, Mario Sabatelli, Stefania Battistini,
Francesca Conforti, Claudia Caponnetto,
Jessica Mandrioli, Paola Mandich, Marcella
Zollino, Giuseppe Borghero, Maria Murru,
Maria Monsurro, Paolo Volanti, Isabella
Simone, Giancarlo Logroscino, Fabrizio Salvi,
Nilo Riva, Janel Johnson, Bryan Traynor,
Silvana Penco, Christian Lunetta
P2.053 Replication Study of MATR3 in
Unusual Presentation in Inflammatory
Myopathy Rosana Scola, Renata Dal-Prá
Ducci, Paulo Lorenzoni, Lineu Werneck
Familial and Sporadic Amyotrophic Lateral
Sclerosis Nicolas Dupre, Claire Leblond,
Dan Spiegelman, Anna Szuto, Pierre
Provencher, Patrick Dion, Guy Rouleau
P2.046 Disease Progression of GNE
P2.054 Hsa-miR-424 and Has-
Myopathy Melanie Quintana, Joseph
Shrader, Galen Joe, Mark Fitzgerald,
William Gahl, John McKew, Scott Berry,
Nuria Carrillo-Carrasco
P2.047 Premature Senescence in
Primary Muscle Cultures of Myotonic
Dystrophy Type 2 Is Not Associated with
P16 Induction Giovanni Meola, Laura
Valentina Renna, Annalisa Botta, Giulia
Rossi, Barbara Fossati, Elena Costa,
Rosanna Cardani
P2.048 The Metabolic Footprint of
Dysferlinopathy Verena Schoewel, Sarah
Keller, Severine Kunz, Michael Boschmann,
Christian Herrmann, Guido Mastrobuoni, Hadi
Al-Hasani, Stefan Kempa, Simone Spuler
ALS: Genetics and Clinical
Outcomes
P2.049 HFE P.His63Asp
Polymorphism Is Not a Modifier of
ALS Phenotype Gabriele Mora, Marco
Barberis, Gabriella Restagno, Maura
Brunetti, Mario Sabatelli, Marcella Zollino,
Stefania Battistini, Francesca Conforti,
Claudia Caponnetto, Paola Mandich,
Jessica Mandrioli, Silvana Penco, Christian
Lunetta, Giuseppe Borghero, Maria Murru,
Maria Monsurro, Gioacchino Tedeschi,
Paolo Volanti, Isabella Simone, Giancarlo
Logroscino, Francesco Logullo, Fabrizio
Salvi, Nilo Riva, Bryan Traynor, Andrea
Calvo, Adriano Chio
miR-206 Are Overexpressed in the Skeletal
Muscle and Plasma of Patients with
Amyotrophic Lateral Sclerosis (ALS) Helen
Andrade, Milena Albuquerque, Thiago
Peluzzo, Danyella Dogni, Anamarli Nucci,
Iscia Lopes-Cendes, Marcondes Franca, Jr.,
Simoni Avansini
P2.055 Genetic Analysis of MATR3
in a Taiwanese Cohort with Amyotrophic
Lateral Sclerosis Yi-Chung Lee, Bing-Wen
Soong
P2.056 Screening of the Intronic
Expansion in the C9 orf72 Gene and the
ATXN2 Mutation in Argentine Patients
Diagnosed with Amyotrophic Lateral
Sclerosis Belén Tillard, Elisa Cisneros,
Cintia Marchesoni, Ana Pardal, Lucía
Schottlaender, Henry Houlden, Shoai M,
Ernesto Fulgenzi, Eugenia Conti, Di Pace
José, Edgar Carnero, Manuel Perez Akly,
Martín Nogués, Osvaldo Uchitel, Bruno
de Ambrosi, Andrea Lautre, Fabio Adrian
Barroso, Alberto Dubrovsky, Laura Pirra,
Agustin Jauregui, Paula Landriscina,
Alejandro Rodriguez, Paula Goyeneche,
Claudio Mazia, Valeria Lujan Salutto,
Pedro Nofal, Zulma Salazar, Patricio Brand,
Ezequiel Surace, Ricardo Reisin
Study of Amyotrophic Lateral Sclerosis
in the City of Buenos Aires Pérez Akly
Manuel, Gustavo Albanese, Fabio Adrian
Barroso, Mariana Bendersky, Mariela
Bettini, Marianna Di Egidio, Ernesto
Fulgenzi, Luís Fiorotto, Gisella Gargiulo
Monachelli, Agustín Jáuregui, Paula
Landriscina, Claudio Mazia, Mario Melcom,
Ricardo Reisin, Roberto Rey, Gabriel
Rodríguez, Marcelo Francisco Rugiero,
Valeria Lujan Salutto, Belén Tillard
Quality Measures for OEF/OIF Veterans
with Amyotrophic Lateral Sclerosis Shon
Michael, Cynthia Brandt, Perry Miller,
Huned Patwa
P2.059 Autologous Transplantation
of Mesenchymal Stem Cells Secreting
Neurotrophic Factors (Nurown™) in ALS:
Results of a Phase 2 Clinical Trial Panayiota
Petrou, Marc Gotkine, Yael Gothelf, Yossef
Levy, Daniel Offen, Adi Vaknin-Dembinsky,
Zohar Argov, Tamir Ben-Hur, Eldad
Melamed, Dimitrios Karussis
ALS and Motor Neuron Disease
P2.060 Progressive Callosal Damage
in Amyotrophic Lateral Sclerosis Milena
Albuquerque, Thiago Rezende, Helen
Andrade, Anamarli Nucci, Marcondes
Franca, Jr.
P2.061
Phenotypes and Genotypes of
Mitochondrial Disease—Findings from a
National Mitochondrial Disease Cohort Yi
Shiau Ng, Grainne Gorman, Victoria Nesbitt,
Robert Pitceathly, John Grady, Andrew
Schaefer, Alexandra Bright, Catherine
Feeney, Shamima Rahman, Joanna Poulton,
Robert Taylor, Michael Hanna, Douglas
Turnbull, Robert McFarland
P2.062 Vitamin D3 Treatment
Protects Motor Neuron Cells from
Oxidative Stress and ALS-related SOD1
Mutation Dominique Soroka, Chafic Karam,
Nikolay Dokholyan
P2.063 Cardiac Impairment in GNE
Myopathy Luhe Mian, May Christine
Malicdan, Satoru Noguchi, William Gahl,
Marjan Huizing
P2.064 Texture Analysis of MRI
Reveals Basal Ganglia Damage in Patients
with Amyotrophic Lateral Sclerosis
(ALS) Milena Albuquerque, Lara Anjos, Helen
Andrade, Marcia Oliveira, Gabriela Castellano,
Marcondes Franca, Jr., Anamarli Nucci
P2.065 Chronological Process of
Cardiac Sympathetic Function in Patients
with Amyotrophic Lateral Sclerosis Yuji
Tanaka, Megumi Yamada, Akihiro Koumura,
Yuichi Hayashi, Akio Kimura, Takashi Inuzuka
P2.066 C9orf 72 Repeat Expansions
in a Canadian Provincial Cohort Anil
Venkitachalam, Stacey Hume, Setareh Ashtiani,
Susan Christian, Oksana Suchowersky
P2.067 Does a Past History of Cancer
Portend Slower Progression of ALS? Emily
Brady, Erin Manning, Mona Shahbazi,
Lindsay Kaplan, Dale Lange
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session II
P2.068 Spinal Fluid GFAP as Marker
of Astrocyte Activation in Patients with
MND Felix Benninger, Mica Glat, Daniel
Offen, Israel Steiner
P2.069 Vitamin D Levels in Serum
of Amyotrophic Lateral Sclerosis
Patients Rosa Cortese, Eustachio D'Errico,
Alessandro Introna, Gabriella Schirosi,
Antonio Scarafino, Eugenio Distaso, Pietro
Nazzaro, Stefano Zoccolella, Isabella Simone
Neurological Consequences of
Autoimmune Disease
P2.070 Recurrent Guillain Barre
Syndrome—a Report of Three Cases
with Clinical Electrophysiological and
CSF Profile Abubaker Almadani, Ayman
Alboudi, Suhail Alrukn, Pournamy
Sarathchandran, Jihad Inshasi
P2.071 Clinical Features of Anti-
NMDAR Antibody-positive Patients
Predominantly Presenting Chronic Psychosis
with Acute Exacerbations Keiko Tanaka
P2.072 Guillain-Barre Syndrome and
Lambert Eaton Myasthenic Syndrome
Coexisting in a Paraneoplastic Neurologic
Syndrome? Milena Rodriguez Alvarez,
Mark Younan, Irfanali Kugasia, Vipul Shah,
David Sternman, Lisa Thompson
P2.073 Scoliosis in Childhood-
onset Stiff Person Syndrome Tanaporn
Rasameesoraj, Bashar Katirji, Michael
Devereaux
P2.074
Posterior Reversible
Encephalopathy Syndrome in Guillain-Barre
Syndrome: A Case Report and Literature
Review Adam Chen, Jennifer Kim, Galen
Henderson, Aaron Berkowitz
P2.075 Neuro-Behçet's Syndrome:
Case Reports Emphasizing Challenges of
Early Diagnosis Efrata Feldman
P2.076
A Case of Neuro-Behcet’s
Disease Presenting with Central
Neurogenic Hyperventilation Ayham
Alkhachroum, Saba Saeed, Jaspreet Kaur,
Tanzila Shams, Michael De Georgia
P2.077 Spinal Cord Infarction as the
Initial Presentation of Systemic Lupus
Erythematosus Amanda Michael, Ghazala
Hayat
P2.078 Rhabdomyolysis in Stiff
Person Syndrome: Case Report Suhas
Gangadhara, Shreyas Gangadhara, Chetan
Gandhy, Derrick Robertson
Epilepsy/Clinical
Neurophysiology (EEG): EEG
P2.079 Reproducible Direct Cortical
Somatosensory Evoked Potentials
(SSEP) Recorded at Bedside in Epilepsy
Patients Scheherazade Le, Josef Parvizi,
Kimford Meador
P2.080 Evaluation of EEG Patterns in
out of Hospital Cardiac Arrests (OHCA) Due
to Overdose as Predictor of Good Patient
Outcomes Megan Mantica, Maria Baldwin
P2.081 Alpha1/theta Ratio from
Quantitative EEG (qEEG) as a Reliable Marker
for Mild Cognitive Impairment (MCI) in
Patients with Parkinson’s Disease (PD) HAbib
Bousleiman, Menorca Chaturvedi, Ute
Gschwandtner, Florian Hatz, Christian
Schindler, Ronan Zimmermann, Peter Fuhr
P2.082 Treatment of PLEDs-related
Reversible Brain MRI Changes May Predict
a Good Neurological Outcome in the
Absence of Structural Brain Lesions Anza
Memon, Aashit Shah, Maysaa Basha
P2.083 A Retrospective Descriptive
Study of Continuous Electroencephalographic
Monitoring in Patients Requiring Extracorporeal Membrane Oxygenation in the
Pediatric and Neonatal Intensive Care
Unit Arnold Sansevere, Rejean Guerriero,
Ivan Sanchez Fernandez, Jacquelyn Klehm,
Tobias Loddenkemper
P2.084 Registration of the Brain
Activity Under the Influence of Artificial
Electromagnetic Radiation Dmitry Reznikov
P2.085 Correlation of EEG Findings
Epilepsy/Clinical
Neurophysiology (EEG): EEG and
Video EEG
P2.089 To Determine the Incidence
of Seizures Detected on Continuous EEG
(cEEG) Monitoring and Time of Onset to
the First Seizure on Prolonged CEEG in
Adult Patients in Neuro Intensive Care Unit
(NICU) Chirag Shukla, Gerald Banks
P2.090 Interictal Discharges
Associated with Ventricular Bradycardia Nicholas Lanciano, Gena Ghearing,
Alexandra Popescu
P2.091 Continuous EEG Monitoring
Is an Important Tool in Managing Critically
Ill Patients in Intensive Care Units Sudhir
Aggarwal, Jyoti Pillai
P2.092 The Added Value of EEG in
the Prognosis of Newly Diagnosed Patients
with Epilepsy Abdulraheem Al Zahrani,
Fawzi Babtain, Abdulaziz Bajafer, Abdullatif
Al Zahrani, Harsha Bhatia, Muthusamy
Velmurugan
and Prognosis in Patients on Therapeutic
Hypothermia After Cardiac Arrest Yana
Krutoshinskaya, Susan Manganaro, Regina
Krel, Lourdes Bello-Espinosa
P2.093 The Correlation of Epileptiform
P2.086 Acute Effect of Levetiracetam
P2.094Bereitschaftspotential
on Interictal Epileptiform Discharges
in Persons with Idiopathic Generalized
Epilepsy Paul Jarvis, Jodi Spaulding,
Joseph McSherry, Keith Nagle
P2.087 Combining Electroenceph-
alographic Time-frequency and Source
Analysis Methods for Improve Epileptogenic
Zones Localization Elena Cuspineda Bravo,
Eduardo Martinez Montes, Ana Olivares
Torres, Calixto Machado
P2.088 Electrographic Patterns
in Patients with Posterior Reversible
Encephalopathy Syndrome (PRES) and
Seizures Rahul Shah, Carlos Kamiya
Matsuoka, Bing Liao, Sudhakar Tummala
Discharges in Sleep with Ictal Onset in
Schizencephaly Marjan Dolatshahi, Alexei
Yankovsky, Marcus Ng
as a Possible Marker for Non-epileptic
Psychogenic Pseudo-myoclonus? Helen
Barkan
P2.098 Evaluating Peri-ictal Mood
Changes in Patients in an Epilepsy
Monitoring Unit Mary Richert, Mark
Kvarta, Scott Thompson, Jennifer Hopp
Neurogenetics and Ataxia
P2.099 Investigation into the
Molecular Mechanisms Underlying
Idiopathic Intracranial Hypertension Zerin
Alimajstorovic
P2.100
Sudden Adult Death
Syndrome: An Uncommon or Simply
Unrecognised Clinical Entity in Young,
Asymptomatic Adults with M.3243A>G
Disease? Grainne Gorman, Yi Shiau Ng,
Nichola Lax, Charlotte Alston, Andrew
Schaefer, Aleksandar Radunovic, Ali
Alhakim, John Bourke, Robert Taylor, Robert
McFarland, Douglas Turnbull
P2.101
Heterozygous Variant in the
ITPR1 Gene - Responsible of Cerebellar
Ataxia Phenotype Tudor Munteanu, Janice
Redmond
P2.102
Late-onset Spastic Paraplegia
Type 10 (SPG10) Family Presenting with
Bulbar Symptoms—Primary Lateral
Sclerosis (PLS) Mimic Seiji Kaji, Ryosuke
Miyamoto, Yusuke Osaki, Hiroyuki Nodera,
Toshitaka Kawarai, Yuishin Izumi, Ryuji Kaji
P2.095 Novel Ambulatory EMG-based
GTC Seizure Detection Device for Home
and Hospital Use Jose Cavazos, Michael
Girouard, Luke Whitmire
Ehlers-Danlos Syndrome
(Overlap of Classical and Vascular
Type) with Rare Neuromuscular
Phenotype Ravinder Singh, Atchayaram
Nalini, Narayanappa Gayathri, Chnadrajit
Prasad, Preethish Kumar Veeramani, Kiran
Polavarapu, Devaraddi Navali
P2.096 Is There a Role for Cardiac
P2.104
Telemetry in the Epilepsy Monitoring Unit:
Two Case Reports of Convulsive Cardiac
Asystole Previously Mistaken for Seizure
Disorders Aradia Fu, Laura Lehnhoff
P2.097 Yield of Monitoring in an Adult
Epilepsy Monitoring Unit Shubhi Agrawal,
Lauren Turco, Shweta Goswami, Michele
Faulkner, Sanjay Singh
P2.103
Hydrocephalus in
Neurofibromatosis—Three Cases with
Different Etiologies Janet Elgallab, Jerome
Graber
P2.105
Congenital Unilateral Facial
Nerve Hypoplasia and Parotid Gland
Agenesis Kumar Sannagowdara, Matthew
Harmelink, Christopher Inglese, Mohit
Maheshwari
P2.106
Poster Session QR Codes
The QR code is one of the most popular types
of two-dimensional barcodes. The QR tag can
be scanned by smart phones or tablets and
will link the attendee to the selected poster via AAN’s mobile
access. Once the QR tag is scanned, the attendee’s mobile
device will link to the poster title, authors, and links to the
abstract, poster PDF, and audio file. An attendee can scan a
multitude of posters to see the corresponding content.
Please note that each poster presenter needs to provide
permission for his or her poster information to be accessible
in the online poster viewing site.
Fast, Easy, Online Registration · AAN.com/view/AM15
Difference Between the
Blood-brain Barrier and Blood-nerve
Barrier: Analyses Using New Human in
Vitro Blood-brain and Blood-nerve Barrier
Models Abe Masaaki, Yasuteru Sano,
Hideaki Nishihara, Hironori Sano, Yukio
Takeshita, Toshihiko Maeda, Takashi Kanda
P2.107
Ataxia Without Headache:
Atypical Presentation of Spontaneous
Intracranial Hypotension Joseph Nguyen,
Divisha Raheja, Max Lowden
P2.108
Schizencephaly and Agenesis of
the Corpus Callosum Mihaela Vlaicu, Sophie
Gerber, Mathieu Rodallec, Stéphane Palfi
Movement Disorders: Ataxias
P2.109
ANO10 Mutations Cause
Ataxia and Coenzyme Q10 Deficiency Emanuele Barca, Andrea Balreira, Boczonadi
Veronika, Angela Pyle, Boglarka Bansagi, Marie
Appleton, Claire Graham, Iain Hargreaves,
Vedrana Rasic, Hanns Lochmuller, Helen Griffin,
Robert Taylor, Ali Naini, Patrick Chinnery, Michio
Hirano, Catarina Quinzii Hirano, Rita Horvath
67
Tuesday
April 21
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Session II
P2.110
Boucher Neuhäuser Syndrome:
Cerebellar Degeneration, Chorioretinal
Dystrophy and Hypogonadotropic
Hypogonadism—Two Novel Cases and
a Review of 40 Cases from the Literature Alexander Tarnutzer, Christina GerthKahlert, Dagmar Timmann-Braun, Dae-In
Chang, Florian Harmuth, Peter Bauer,
Dominik Straumann, Matthis Synofzik
P2.111
Autoimmune Cerebellar
Ataxia: Treatment Responses and
Outcomes in 118 Patients Amy Jones,
Sean Pittock, Vanda Lennon, Scott Eggers,
J. Ahlskog, Andrew McKeon
P2.112
A Case of Ataxia and Dystonia
in the Setting of a Renal Oncocytoma Ian Bledsoe, Cynthia Comella
P2.113
Whole-exome Sequencing as
a Diagnostic Tool in a Family with Episodic
Ataxia Type 1 Zbigniew Wszolek, Pawel
Tacik, Kimberly Guthrie, Audrey Strongosky,
Daniel Broderick, Douglas Riegert-Johnson,
Alexander Parker, Owen Ross
P2.114
Novel Mutations in
TGM6 with Clinical and Genetic
Characterization Bing-Wen Soong,
Pei-chien Tsai, Yi-Chu Liao, Yi-Chung Lee
P2.115
Unusual Presentation of a
Not So Rare Disease: Implications for
the Differential Diagnosis of Generalized
Dystonia Luiza Piovesana, Fabio Torres,
Paula Azevedo, Marcelo Nunes, Thais
Amaral, Madalena Rosa, Marcondes Franca,
Jr., Iscia Lopes-Cendes, Anelyssa D'Abreu
P2.116
Two Novel Ataxia Phenotypes
in the French-Canadian Population Marie
Beaudin, Laurence Martineau, Nicolas
Chrestian, Charles-Antoine Guay, Anne
Noreau, Gabrielle Houle, Pierre Provencher,
Guy Rouleau, Nicolas Dupre
P2.117
A Case of Rapid-onset
Dystonia-Parkinsonism (RDP) with
Prominent Ataxia Kathleen Sweadner,
Jared Cook, Beverly Snively, Laurie Ozelius,
Camilo Toro, Allison Brashear
P2.118
A Novel KCNMA1 Mutation
Associated with Progressive Cerebellar
Ataxia Julia Staisch, Xiaofei Du, Tomoya
Kubota, João de Souza, Francisco Bezanilla,
Christopher Gomez
Movement Disorders: Fredriech's
Ataxia and Cerebellum
P2.119
Diagnosis of Friedreich’s
Ataxia in Late-onset Progressive Cerebellar
Ataxia Roisin Lonergan, Damien Ferguson
*Joint first author with RL, Susan Byrne, David
Bradley, Yvonne Langan, Janice Redmond
P2.120
Longitudinal Study of Gait
Dysfunction in Friedreich's Ataxia Using
the GAITRite Walkway System Theresa
Zesiewicz, Clifton Gooch, Seok Kim, Jennifer
Farmer, Israt Jahan, Yangxin Huang, Jason
Salemi, Kelly Sullivan, Jeannie Stephenson
P2.121
Magnetic Resonance Is
More Sensitive Than Echocardiography
to Detect Cardiomyopathy in Friedreich’s
Ataxia Alberto Martinez, Ingrid Faber,
Thiago Rezende, Cynthia Bonilha Da Silva,
Thiago Venâncio, Anelyssa D'Abreu,
Iscia Lopes-Cendes, Otávio Coelho-Filho,
Marcondes Franca, Jr.
68
7:30 a.m.–12:00 p.m.
P2.122
Gene Expression Profile in
Peripheral Blood Cells of Friedreich Ataxia
Patients Agessandro Abrahao, Jose
Luiz Pedroso, Patricia de Carvalho Aguiar,
Orlando Barsottini
P2.123
Correlation of GAITRite
Walkway System and Biodex Balance
System Measures to the FARS Score in
Friedreich's Ataxia Patients: A Validation
Study Theresa Zesiewicz, Seok Kim, Clifton
Gooch, Jennifer Farmer, Yangxin Huang,
Jason Salemi, Israt Jahan, Kelly Sullivan,
Lynn Wecker, Jeannie Stephenson
P2.124
Progressive Pyramidal
and Callosal Damage in Friedreich’s
Ataxia Thiago Rezende, Cynthia Silva,
Alberto Martinez, Anelyssa D'Abreu,
Iscia Lopes-Cendes, Fernando Cendes,
Marcondes Franca, Jr.
P2.125
The Splenium of the Corpus
Callosum Sign in Fragile X Associated
Tremor Ataxia Syndrome (FXTAS) Meghan
Hermanson, Miral Jhaveri, Glenn Stebbins,
Emily Dunn, Doug Merkitch, Elizabeth BerryKravis, Deborah Hall
P2.126
Mutation of Senataxin Alters
Disease-specific Transcriptional Networks
in Patients with Ataxia with Oculomotor
Apraxia Type 2 Brent Fogel, Ellen Cho,
Amanda Wahnich, Fuying Gao, Olivier
Becherel, Xizhe Wang, Francesca Fike,
Leslie Chen, Chiara Criscuolo, Giuseppe De
Michele, Alessandro Filla, Abigail Collins,
Angelika Hahn, Richard Gatti, Genevieve
Konopka, Susan Perlman, Martin Lavin,
Daniel Geschwind, Giovanni Coppola
P2.127
Holmes Tremor. Etiology,
Associated Symptoms, Neuroimaging
and Treatment in a Series of Twenty
Cases Gabriela Raina, Maria Graciela
Cersosimo, Silvia Folgar, Juan Giugni,
Cristian Calandra, Juan Pablo Paviolo,
Veronica Tkachuk, Lorena Tschopp, Daniela
Calvo, Alejandro Pellene, Claudia Uribe
Roca, Miriam Velez, Rolando Giannaula,
Manuel Fernandez Pardal, Federico Micheli
P2.132
Spinocerebellar Ataxia 36 in
Three Taiwanese Families Yi-Chu Liao, YiChung Lee, Pei-Chien Tsai, Bing-Wen Soong
P2.144
P2.133
P2.145
Bilateral Caudate Atrophy
Distinguishes Dystonic Vs Non-dystonic
Patients with Machado-Joseph
Disease Thiago Rezende, Alberto Martinez,
Marcelo Nunes, Rachel Guimaraes,
Anelyssa D'Abreu, Iscia Lopes-Cendes,
Marcondes Franca, Jr.
P2.134
Survey of NonmotorsSymptoms in Patients with
Spinocerebellar Ataxia Type 10 Adriana
Moro, Mariana Moscovich, Renato Munhoz,
Walter Arruda, Salmo Raskin, Tetsuo
Ashizawa, Helio Afonso Teive
P2.135
Frequencies of Mutations
in 20 Genes Associated with Hereditary
Ataxia: Experience from a US Clinical
Laboratory Zhenyuan Wang, Marc
Meservey, Michele McCarthy, Sat Dev
Batish, Malgorzata Jaremko, Funda Suer,
Joseph Higgins
Movement Disorders: Genetics
P2.136
Frequency of DTY1 and DYT6
Mutations in a Large Cohort of Brazilian
Patients with Dystonia Luiza Piovesana,
Fabio Torres, Paula Azevedo, Thais Amaral,
Madalena Rosa, Iscia Lopes-Cendes,
Anelyssa D'Abreu
P2.137
Unique Astrocyte Pathology
in a Case of Rapid Onset DystoniaParkinsonism (DYT12) with Novel Mutation
in ATP1A3 Jacinda Sampson, Tamar
Michaeli, Sarah Teed, Brenton Wright, Stanley
Fahn, James Goldman, Jean Paul Vonsattel
P2.138
Dystonia-spasticity in
a Patient with a Novel SLC25A12
Mutation Mered Parnes, Laurie Robak,
Joshua Shulman, Amber Stocco, Joseph
Jankovic
Movement Disorders:
Spinocerebellar Ataxias
Dystonia-causing Mutations
as a Contribution to the Etiology of
Spasmodic Dysphonia Claudio De Gusmao,
Nutan Sharma, Andrew Moses, Trisha
Multhaupt-Buell, Phillip Song, Tania Fuchs,
Ramon Franco, Laurie Ozelius
P2.128
P2.140
Clinical Impact of C9orf72
Repeat Expansion in Spinocerebellar
Ataxias Karla Figueroa, Vikram Shakkottai,
Henry Paulson, Susan Perlman, George
Wilmot, Khalaf Bushara, Christopher Gomez,
Jeremy Schmahmann, Michael Geschwind,
Theresa Zesiewicz, S Subramony, ShengHan Kuo, Tetsuo Ashizawa, Stefan Pulst
P2.129
Spinocerebellar Ataxia Type
3 (Machado-Joseph Disease) in Israel:
Clinical Phenotype and Genotype of a Jew
Yemenite Subpopulation Roy Zaltzman,
Reuven Sharony, Colin Klein, Carlos Gordon
P2.130
Improved Sway Velocities and
Directional Balance Improvement in Two
Individuals with Spinal Cerebellar Ataxia
with Balance-based Torso-weighting: A
Case Series Report Cynthia Gibson-Horn,
Susan Perlman
P2.131
Executive and Motor
Impairment Correlation in SCA-3 Jee
Bang, Joseph Winer, Katherine Possin, Joel
Kramer, Michael Geschwind
P2.139
22q11.2 Deletion Syndrome
Presenting as Parkinson Disease Aliya
Rehman, Radhika Dhamija, Matthew Barrett
ER Stress Marker GRP78
Colocalizes with LRRK2 in Human
Parkinson’s Disease Deepak Gupta,
Zhaoyang Feng
Movement Disorders: Parkinson's
Disease Genetics and Biomarkers
P2.146
Using a Drosophila GBA
Deficiency Model to Understand the Role of
GBA in Parkinson’s Disease Marie Davis,
Kien Trinh, Ruth Thomas, Brittany Whittley,
Thomas Montine, Leo Pallanck
P2.147
Optical Coherence
Tomography in LRRK2-associated
Parkinson Disease Cristina Duque, Cristina
Januário, Joao Lemos, Pedro Luis Martins
da Fonseca, António Correia, Luísa Ribeiro,
Rui Bernardes, António Freire
P2.148
The Frequency of PARKIN,
LRRK2, GBA in Early Onset Parkinson
Disease Patients Who Receive Deep Brain
Stimulation Gian Pal, Deborah Hall, Bichun
Ouyang, Jessica Phelps, Roy Alcalay, Helen
Mejia Santana, Luci Blasucci, Christopher
Goetz, Cynthia Comella, Amy Colcher,
Karen Marder
P2.149Peripheral
ß-glucocerebrosidase Enzyme Activity and
Lipidomics in ß-glucocerebrosidase (GBA1)
Mutation Parkinson Disease Amanda
Glickman, Olaf Bodamer, Britt Johnson,
William Nichols, Mariel Pullman, Robert
Ortega, Brooke Johannes, Deborah
Raymond, Laurie Ozelius, Jacek Bielawski,
Susan Bressman, Lina Obeid, Yusuf Hannun,
Rachel Saunders-Pullman
P2.150
REM Sleep Behavior Disorder
(RBD) May Not Be a Promising Marker for
Development of LRRK2 PD as Measured by
RBD Sleep Questionnaire Robert Ortega,
Roy Alcalay, Anat Mirelman, Cuiling Wang,
Marta San Luciano, Deborah Raymond,
Amanda Glickman, Brooke Johannes, Helen
Mejia-Santana, Karen Marder, Nir Giladi,
Susan Bressman, Rachel Saunders-Pullman
ADCY5-related Movement
Disorder: Broader Spectrum and Genotype/
phenotype Correlations Including New
Cases Dong-Hui Chen, Emily Bonkowski,
Olena Korvatska, Fuki Hisama, Jennifer
Friedman, Marie Davis, Phillip Swanson,
Alona Gad, Laura Amendola, Xindi Guo,
Michael Weiss, Ali Torkamani, Thomas Bird,
Wendy Raskind
P2.151
P2.141
ATP1A3-related Disorders:
A Broadening of the Phenotypic and
Genotypic Presentation Allison Brashear,
Jared Cook, Beverly Snively, Kathleen
Sweadner, Laurie Ozelius
P2.153
P2.142
Genetic Screening Study
in 1005 Subjects with Isolated Cervical
Dystonia Mark LeDoux, Satya Vemula,
Jianfeng Xiao
P2.154
P2.143
P2.155
Prevalence and Severity of
Non-motor Manifestations in Patients with
Gaucher Disease and Heterozygous GBA1
Mutation Carriers Jenny Kim, Dahima
Cintron, Edythe Wiggs, Catherine Groden,
Ellen Sidransky, Grisel Lopez
Using Non-motor Features to
Define Clinical and Biomarker Patterns of
Early Drug-naïve Parkinson Disease Samay
Jain, Seo Young Park, Diane Comer
P2.152
Cardiovascular Risk Factors
Associate with Cholinergic Denervation in
Parkinson Disease Vikas Kotagal, Martijn
Muller, Robert Koeppe, Peter Scott, Roger
Albin, Kirk Frey, Nicolaas Bohnen
Objective Measurement
of Upper Extremity Motor Function in
the Parkinson’s Progression Markers
Initiative Lama Chahine, Liz Uribe,
Penelope Hogarth, Danna Jennings
Predictors of Parkinson
Disease Dementia in a Brazilian
Sample Lidiane Campos, Rachel Guimaraes,
Luiza Piovesana, Paula Azevedo, Anelyssa D'Abreu
Rewriting History—The
Experience of Disease Progression in
Parkinson Disease Lisa Shulman, Brenda
Hanna-Pladdy, F. Rainer Von Coelln, Erik
Barr, Melissa Armstrong, Stephen Reich,
Ann Gruber-Baldini
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session II
Aging, Dementia, Cognitive, and
Behavioral Neurology: Genetics
of Neurodegenerative Disorders
P2.156
Three-way Interaction of
5-HTTLPR, BDNF Vall66Met and COMT
Val158Met Polymorphisms and Its Effect on
Regional Gray Matter Volume in Patients
with Major Depressive Disorder Milutin
Kostic, Elisa Canu, Ana Munjiza, Federica
Agosta, Ivana Novakovic, Dobricic Valerija,
Vera Miler Jerkovic, Tatjana Pekmezovic,
Dusica Lecic Tosevski, Massimo Filippi
P2.157
Common and Rare Genetic
Variations in the Mortalin Gene (HSPA9)
and the Risk of Alzheimer’s Disease and
Parkinson’s Disease Sun J. Chung, Juyeon
Kim, Young Jin Kim, Kiju Kim, Sooyeoun You,
Mi-Jung Kim, Seong Yoon Kim, Jae-Hong Lee
P2.158
Lack of AGG Interspersions in
the Fragile X Mental Retardation 1 (FMR1)
Gene Is Not Associated with Cognitive
Impairment or Motor Dysfunction Erin
Robertson, Aisha Ali, Lili Zhou, David
Bennett, Elizabeth Berry-Kravis, Deborah
Hall
P2.159
Bridging Integrator 1 (BIN1)
Genotypes Induce Alzheimer’s Disease Related Brain Atrophy, Abnormal Glucose
and Aβ Metabolisms in ADNI Cohort HuiFu Wang, Jin-Tai Yu, Lan Tan
P2.160
A Novel Splice Site Mutation
in GRN (p.A237fs [A>T]) in a Large Italian
Family with FTD from the Apulia-FTD
Registry Rosa Capozzo, Celeste Sassi,
Chyntia Crews, Chiara Zecca, Simona Arcuti,
Massimiliano Copetti, Vincenzo Brescia,
Andrew Singleton, Giancarlo Logroscino
P2.161
The Novel P.K317N Mutation
in MAPT Gene with Clinicopathological
Phenotype of Globular Glial
Tauopathy Zbigniew Wszolek, Pawel Tacik,
Michael DeTure, Wenlang Lin, Monica
Sanchez Contreras, Aleksandra Wojtas,
Shinsuke Fujioka, Matthew Baker, Ronald
Walton, Yari Carlomango, Patricia Brown,
Audrey Strongosky, Naomi Kouri, Melissa
Murray, Keith Josephs, Rosa Rademakers,
Owen Ross, Dennis Dickson
P2.162
Colombian Familial Dementia
with Frontotemporal Features Associated
with a Presenilin-1 Mutation Andrea Lopez,
Diana Matallana, Pablo Reyes, Felipe Uriza,
Angela Martinez, Jose Manuel Santacruz,
Angela Iragorri, Ignacio Zarante, Cristian
Triviño, Carlos Cano, Vivianna Van Deerlin,
Eunran Suh, Elizabeth McCarty-Wood,
Corey McMillan, Murray Grossman, Katya
Rascovsky
P2.163
Assessing the Effect of the
Brain-derived Neurotrophic Factor (BDNF)
Val66Met Polymorphism on MRNA
Transcript Levels, Alzheimer’s Disease (AD)
Risk and Cognitive Performance Jeremy
Burgess, Minerva Carrasquillo, Fanggeng
Zou, High Seng Chai, Curtis Younkin,
Mariet Allen, Daniel Serie, Julia Crook,
Vernon Pankratz, Asha Nair, Sumit Middha,
Sooraj Maharjan, Thuy Nguyen, Kimberly
Malphrus, Sarah Lincoln, Gina Bisceglio,
Yan Asmann, Otto Pedraza, Rosebud
Roberts, John Lucas, Glenn Smith, Robert
Ivnik, Mary Machulda, Neill Graff-Radford,
Ronald Petersen, Dennis Dickson, Steven
Younkin, Nilufer Taner
P2.164
Clinicopathologic Phenotypes
of Four Cases with MAPT P301L
Mutation Zbigniew Wszolek, Pawel Tacik,
Monica Sanchez Contreras, Aleksandra
Wojtas, Kelly Ross, Shinsuke Fujioka,
Michael DeTure, Wenlang Lin, Matthew
Baker, Patricia Brown, Audrey Strongosky,
Naomi Kouri, Melissa Murray, Keith
Josephs, Rosa Rademakers, Owen Ross,
Dennis Dickson
P2.165
Molecular Network Analysis
Suggests a Crucial Role of C9orf72 in
the Pathogenesis of Amyotrophic Lateral
Sclerosis/Frontotemporal Dementia Junichi Satoh, Yoshihiro Kino
Aging, Dementia, Cognitive, and
Behavioral Neurology: Memory,
Olfaction, and Alzheimer's
Disease Risk Factors
P2.166
Recovered Recall Memory
After Surgical Removal of Pineal Tumor
and Decompression of the Fornix Toshihiro
Hayashi, Mizuho Yoshida, Kurumi Fujii,
Kensuke Kawai, Shoji Tsuji, Atsushi Iwata
P2.167
In Vivo Evidence for Long-term
Potentiation in Older Adults Fabio Porto,
Anne Fox, Erich Tusch, Farzaneh Sorond,
Abdul Mohammed, Kirk Daffner
P2.168
Semantic Memory, but
Not Episodic Memory, Is Modulated by
Cognitive Reserve in Patients with MCI and
AD Richard Darby, Michael Brickhouse,
David Wolk, Bradford Dickerson
P2.169
Olfactory Impairment in
Alzheimer’s Disease Is Associated with
Widespread Reductions in Deep Gray
Matter Volume Jesper Hagemeier, Usama
Rafique, Chaitanya Amrutkar, Matthew
Woodward, Niels Bergsland, Michael
Dwyer, Ralph Benedict, Robert Zivadinov,
Kinga Szigeti
P2.170
Validation of Olfactory
Deficit as a Biomarker of Alzheimer's
Disease Chaitanya Amrutkar, Matthew
Woodward, Harshit Shah, Ralph Benedict,
Sanjanaa Rajakrishnan, Rachelle Doody, Li
Yan, Kinga Szigeti
P2.171
MRI Correlation of Odor
Identification Deficit as a Biomarker for
Alzheimer’s Disease Usama Ahmad
Rafique, Jesper Hagemeier, Matthew
Woodward, Niels Bergsland, Ralph
Benedict, Robert Zivadinov, Kinga Szigeti
P2.172
Psychological Stress and
Age-related Memory Decline Richard
Caselli, Amylou Dueck, Dona Locke, Bryan
Woodruff, Charlene Hoffman-Snyder, Yonas
Geda
P2.173
Self-reported Sleep Problems
and Incidence of Dementia Angeliki
Tsapanou, Yian Gu, Nikolaos Scarmeas,
Yaakov Stern
P2.174
Increased Risk for Cognitive
Decline in Aging Associated with
Cytomegalovirus Exposure in a Populationbased Cohort Eric McDade, Vishwajit
Nimgaonkar, Robert Yolken, Tianxiu Wang,
Lora McClain, Chung-Chou Chang, Beth
Snitz, Mary Ganguli
Fast, Easy, Online Registration · AAN.com/view/AM15
Aging, Dementia, Cognitive, and
Behavioral Neurology: Other
Dementias and Co-morbidity
MS and CNS Inflammatory
Diseases: In Vitro Studies,
Experimental, and Animal Models
P2.175
P2.186
Clinical, Neuropsychological
and Neuropathology Characteristics
of Mixed Dementia Among Subjects
with Autopsy Confirmed Concomitant
Alzheimer’s Pathology Jagan Pillai, Sam
Butler, Aaron Bonner-Jackson, James
Leverenz
P2.176
The Neuropathology of
Patients with Dementia and Non-dementia
in the Oldest-old Gamze Balci Camsari,
Neill Graff-Radford, Ronald Petersen, David
Knopman, Bradley Boeve, Joseph Parisi,
Dennis Dickson, Melissa Murray
P2.177
Prevalence of Traumatic
Brain Injury in Early Versus Late-onset
Alzheimer's Disease Jeannie Zhang,
Andrew Lin, Elvira Jimenez, Pongsatorn
Paholpak, Edmond Teng, Mario Mendez
P2.178
Preliminary Results of the
NINDS/NIBIB Consensus Meeting to
Evaluate Pathological Criteria for the
Diagnosis of CTE Ann McKee, Victor
Alvarez, Kevin Bieniek, Nigel Cairns, John
Crary, Kristen Dams-O'Connor, Rebecca
Folkerth, C. Dirk Keene, Irene Litvan,
Thomas Montine, Philip Montenigro, Daniel
Perl, Thor Stein, William Stewart, Yorghos
Tripodis, Jean Paul Vonsattel, Wayne
Gordon, Dennis Dickson
P2.179
Epilepsy in Lewy Body Disease
(LBD) Nuria Campora, Maria Fernandez,
Barbara Rosso, Waleska Berrios, Maria del
Carmen Garcia, Edgardo Cristiano, Angel
Golimstok
P2.180Amyloid-β PET Imaging of
Alzheimer Pathology in Parkinson Disease
Dementia Rizwan Akhtar, Laura Brennan,
Sharon Xie, Michael Pontocorvo, Howard
Hurtig, John Trojanowski, Daniel Weintraub,
Andrew Siderowf
P2.181
Striatal Dopamine Transporter
Binding Correlates with Education in
Dementia with Lewy Bodies Guillaume
Lamotte, Rémy Morello, Adrien Lebasnier,
Denis Agostini, Gérard Bouvard, Vincent De
La Sayette, Gilles Defer
P2.182
Brain 18F-FDG PET Hypo-and
Hypermetabolic Patterns in Dementia with
Lewy-bodies Leonardo Iaccarino, Chiara
Cerami, Sandro Iannaccone, Giuseppe
Magnani, Stefano Cappa, Daniela Perani
P2.183
Cognitive Profiles of
Performance in Parkinson's Disease:
Results of a Preliminary Study Rolando
Giannaula, Pablo Sanz, Lorena Rodríguez
Cerasuolo, Alejandra Alfonso, Santiago
Pagano Ajolfi, Juan Maiques, Lina Grasso
P2.184
Clinical Spectrum of
NIID (Neuronal Intranuclear Inclusion
Disease) Hisatomo Kowa, Kenji Sekiguchi,
Hiroaki Sekiya, Fumio Kanda, Tatsushi Toda
P2.185
Hereditary Diffuse
Leukoencephalopathy with Spheroids
(HDLS) Due to CSF1R Mutations: Towards
Early Disease Recognition Darin Okuda,
Bibiana Bielekova, Rena Godfrey, Braeden
Newton, William Gahl, Camilo Toro
Ingested (oral) Anti-IL-12/23
Inhibits EAE Staley Brod, Victoria Bauer
P2.187
Treatment of Experimental
Allergic Encephalomyelitis with
7,8 Dihydroxyflavone: Evidence for
Neuroprotection Vamshi Nimmagadda,
Tapas Makar, Kristal Lam, Susan Judge,
David Trisler, Christopher Bever
P2.188
Inhibition of Lymphocyte
VLA-4 Expression by DMF Exposure
in Experimental Autoimmune
Encephalomyelitis (EAE) Jerold Chun,
Yasuyuki Kihara, Aran Groves
P2.189
ACTH1-39 Protection of
Oligodendrocytes from Damage Relevant to
Multiple Sclerosis Involves Both Direct and
Indirect Mechanisms Robert Lisak, Liljana
Nedelkoska, Joyce Benjamins
P2.190
Helicobacter Pylori
Infection Reduces Disease Severity
in an Experimental Model of Multiple
Sclerosis Bruno Gran, James Crooks,
Katherine Cook, Khiyam Hussain, Kate
O'Brien, Manjit Braitch, Huner Kareem, Cris
Constantinescu, Karen Robinson
P2.191
Cyclophilin D Inhibitor NIM811
Ameliorates Clinical Disease Severity in
Experimental Allergic Encephalomyelitis
(EAE) Unsong Oh, Hanadi Ajam Oughli
P2.192
Selective Depletion of T
Regulatory Cells Reduces but Does Not
Eliminate the Ability of Glatiramer Acetate
to Ameliorate Experimental Autoimmune
Encephalomyelitis Rina Aharoni, Feferman
Tali, Guy Shakhar, Michael Sela, Ruth Arnon
P2.193
Inflammation and Oxidative
Stress Induced by Cigarette Smoke
Exposure in EAE Walter Royal, Joseph
Bryant, Tapas Makar, Horea Rus, Ming Guo,
Nimmagadda Vamshi, Harry Davis
P2.194
FGFR1 Is a Negative
Regulator of LINGO-1 Expression in
EAE Ranjithkumar Rajendran, Mario
Giraldo Velasquez, Christine StadelmannNessler, Martin Berghoff
P2.195
Exacerbated Experimental
Autoimmune Encephalomyelitis in
Ceramide Synthase 6 Knockout Mice Is
Associated with Enhanced Activation/
Migration of Neutrophils Christoph Mayer,
Max Eberle, Philipp Ebel, Julia Barthelmes,
Nadja Tafferner, Nerea Ferreirós Bouzas,
Thomas Ulshoefer, Marina Henke, Annika
Männer de Bazo, Christian Foerch, Andreas
Weigert, Sabine Grösch, Gerd Geisslinger,
Klaus Willecke, Susanne Schiffmann
P2.196
Passive Transfer of NMO-IgG
Does Not Exacerbate EAE in AQP4 Null
Mice Melina Jones, Michael Levy
P2.197
Galectin-4 Dependant Myelin
Sulfatides Regulation of T Cell Function
During Autoimmune Demyelination Marcin
Mycko, Beata Sliwinska, Maria
Cichalewska, Hanna Cwiklinska, Cedric
Raine, Krzysztof Selmaj
69
Tuesday
April 21
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Session II
P2.198
Correlation of Spinal Cord and
CSF Biomarkers to Clinical and Radiological
Measures of CNS Injury in a Mouse Model
of Multiple Sclerosis Andrew Pachner,
Francesca Gilli, Xi Chen, Barjor Gimi
P2.19924-Hydroxy-cholesterol
Synthesis Rate Measured in Blood in a
Preclinical Mouse Model Suggests a Noninvasive Biomarker of Brain Demyelination
and Remyelination Mahalakshmi
Shankaran, Ellen Tsang, Hussein
Mohammed, Po-yin Anne Wong, Joan
Protasio, Frédéric Bernard, Rui Chang,
Tammy Dellovade, Scott Turner
P2.200 Passive Transfer of Glycine
Receptor-antibody IgG Induces Anxiety-like
Behavior in Mice Alexander Carvajal, Leslie
Jacobson, Linda Clover, Bethan Lang, Louise
Upton, Angela Vincent
P2.201 Astrocytic ECGF1/TP and
VEGF-A Drive Blood-brain Barrier Opening
in Inflammatory CNS Lesions Candice
Chapouly, Azeb Argaw, Sam Horng, Kamilah
Castro, Jingya Zhang, Linnea Asp, Benjamin
Laitman, John Mariani, Elena Zaslavsky,
German Nudelman, Gareth John
P2.202 The Protection of A2aR on
BBB Permeability from Th1 Cytokines in
MS Marwan Alahiri, Ying Liu, Bianca Ulloa,
Saud Sadiq
P2.203 Excitatory Synapses: A
Hotspot for Neuronal Injury in Multiple
Sclerosis Gray Matter Matthew Bellizzi,
Harris Gelbard
P2.204 Combinatorial Actions
of Tgfβ and Activin Ligands Promote
Oligodendrocyte Development and CNS
Myelination Dipankar Dutta, Andleeb
Zameer, John Mariani, Jingya Zhang, Linnea
Asp, Jimmy Huynh, Sean Mahase, Benjamin
Laitman, Azeb Tadesse Argaw, Nesanet
Mitiku, Patrizia Casaccia, Fernand Hayot,
Gareth John
MS and CNS Inflammatory
Diseases: Risk Factors for MS
Disease and Course
P2.205 The MS Microbiome
Consortium (MSMC): An Academic Multidisciplinary Collaborative Effort to Elucidate
the Role of the Gut Microbiota in MS Ilana
Katz Sand, Sergio Baranzini, Rob Knight,
Rebecca Straus Farber, Yadira Bencosme,
Rachel Kanner, Refujia Gomez, Sarkis
Mazmanian, Patrizia Casaccia, Bruce Cree
P2.206 Effect of Vitamin D Level in the
Gut Microbiome of MS Patients Stephanie
Tankou, Lynn Bry, George Gerber, Ning Lin,
Bonnie Glanz, Sandra Cook, Fiona Stuart,
Mira Weiner, Kirsy Melo, Roopali Ghandi,
Howard Weiner
P2.207 Hypovitaminosis D and the
Risk of Multiple Sclerosis in Blacks and
Hispanics Annette Langer-Gould, Lie Chen,
Robyn Lucas, Anny Xiang, Lisa Barcellos
7:30 a.m.–12:00 p.m.
P2.208 Lower 25-hydroxyvitamin D
Levels in Patients with a Clinically Isolated
Syndrome Compared to Healthy Controls
Are Not Associated with Lower Levels of
Bioavailable Vitamin D Janina Behrens,
Ludwig Rasche, Rene Giess, Catherina
Pfuhl, Katharina Wakonig, Eric Freitag,
Katrin Deuschle, Judith Bellmann-Strobl,
Friedemann Paul, Klemens Ruprecht, Jan Dörr
P2.209 Multiple Sclerosis Patients
Differ from Healthy Controls on Antioxidant
and Anti-inflammatory Nutrients from
Self-reported Diet History Sandra Cassard,
Pavan Bhargava, Sonya Steele, Nisha
Revirajan, Emmanuelle Waubant, Ellen
Mowry
P2.210 Fatty Acids Directly Impact
CNS Autoimmunity Via the Small
Intestine Aiden Haghikia, Stefanie Jörg,
Duscha Alexander, Johannes Berg, Anna
Hammer, Denis Akkad, Dominik Müller, Ralf
Gold, Ralf Linker
P2.211
Effectiveness of Modified
Dietary Habits on Body Composition
and Fatigue-associated Symptoms in
Relapsing-remitting Multiple Sclerosis
Patients Rocco Totaro, Caterina Di
Massimo, Daniela De Amicis, Carla Di
Scanno, Caterina Di Carmine, Cinzia
Raparelli, Carmine Marini, Maria Giuliana
Tozzi Ciancarelli
Novel Candidate Genes in Familial Multiple
Sclerosis Esther Melamed, Yuying You, Rui
Chen, Sergio Baranzini, Lawrence Steinman,
Michael Snyder, May Han
P2.220 Segmental Sharing Analysis
of Multiple Sclerosis Patients and Controls
from the Faroe Islands Stefanie Binzer,
Kerstin Imrell, Michael Binzer, Kirsten Kyvik,
Jan Hillert, Egon Stenager
P2.221 Ancestry, Haplogroups and
HLA-DRB1 Alleles of Multiple Sclerosis
in Bogotá, Colombia Jaime Toro, Lisseth
Burbano, Camilo Diaz-Cruz, Saúl Reyes,
David Cuéllar-Giraldo, Diana Narváez,
Fabián Cortés, Helena Groot
P2.222 Smoking: Effects on the
Progression of Multiple Sclerosis—a
Cohort Study of Patients Treated with
Immunomodulatory Therapy Jette
Frederiksen, Vera Crone
P2.223 Spinal Cord Involvement in
Incident Multiple Sclerosis Suggests Ethnic
Differences Lilyana Amezcua, Brandon
Beaber, Annette Langer-Gould
P2.231 SCN2A Related Early Onset
Epileptic Encephalopathy Responsive to
Phenobarbital Fiona Baumer, Jurriaan
Peters, Christelle Achkar, Phillip Pearl
P2.232 BCAP31 Mutation Causing
Congenital Dystonia and Central
Hypomyelination Discovered Using Exome
Sequencing Padmaja Vittal, Deborah Hall,
Elizabeth Berry-Kravis
P2.233 Utility of Whole Exome
Sequencing in Evaluation of Juvenile Onset
Motor Neuron Disease Sonika Agarwal,
Timothy Lotze, Lorraine Potocki, Suzanne
Woodbury, Talia Collier, Adekunle Adesina
P2.234 Everolimus Long-term Safety
and Efficacy in Patients with Subependymal
Giant Cell Astrocytoma (SEGA) Associated
with Tuberous Sclerosis Complex (TSC):
Final Analysis of a Phase 2 Study David
Franz, Marguerite Care, Katherine HollandBouley, Karen Agricola, Cynthia Tudor, Noah
Berkowitz, Sara Miao, Severine Peyrard,
Darcy Krueger
P2.235 Long-term Efficacy and
Body Mass Index (BMI) and Multiple
Sclerosis Progression Aliza Ben-Zacharia
Ataxia Due to Novel Mutations in
ACO2 Emanuele Barca, Hanchard Neil, Ali
Naini, Darryl De Vivo, Salvatore DiMauro
Safety of Everolimus for the Treatment of
Subependymal Giant Cell Astrocytoma
(SEGA) Associated with Tuberous Sclerosis
Complex (TSC) in EXIST-1: Approximately
3.5 Years of Exposure David Franz, Elena
Belousova, Steven Sparagana, E Bebin,
Michael Frost, Rachel Kuperman, Olaf
Witt, Michael Kohrman, J Flamini, Joyce
Wu, Paolo Curatolo, Petrus de Vries, Noah
Berkowitz, Julie Niolat, Sergiusz Jozwiak
P2.213 Does Alcohol and Red Wine
P2.225 Congenital Heart Disease in
P2.236 Homozygous Non-sense
P2.212 The Relationship Between
Consumption Play a Role in Multiple
Sclerosis Disease Course? Camilo DiazCruz, Muhammad Taimur Malik, Alicia Chua,
Tamara Kaplan, Bonnie Glanz, Howard
Weiner, Brian Healy, Tanuja Chitnis
P2.214 Latitude and HLA-
DRB1 Alleles Independently Affect
the Emergence of Cerebrospinal
Fluid IgG Abnormalities in Multiple
Sclerosis Masaaki Niino, Shinya Sato,
Toshiyuki Fukazawa, Satoshi Yoshimura,
Shin Hisahara, Takuya Matsushita, Noriko
Isobe, Kazuto Yoshida, Hideki Houzen, Yusei
Miyazaki, Shun Shimohama, Seiji Kikuchi,
Jun-ichi Kira
P2.215 High Inbreeding in the Faroe
Islands Does Not Appear to Constitute a
Risk Factor for Multiple Sclerosis Stefanie
Binzer, Kerstin Imrell, Michael Binzer, Kirsten
Kyvik, Jan Hillert, Egon Stenager
P2.216 Increasing Incidence of
Multiple Sclerosis Among Women
in Buenos Aires: A 21-year Health
Maintenance Organization Based
Study Juan Rojas, Liliana Patrucco, Jimena
Miguez, Diego Giunta, Jose Peroni, Edgardo
Cristiano
P2.217 Delayed Onset and Reduced
Disease Severity of Spontaneous CNS
Autoimmunity by Conjugated Linoleic
Acid-rich Diet Luisa Klotz, Stephanie
Hucke, Marvin Hartwig, Berit Grützke, Ivan
Kuzmanov, Tanja Kuhlmann, Heinz Wiendl
P2.218 Potential Contribution of
Novel Single Nucleotide Variants to
Neurodegeneration in MS Michael Levin,
Sangmin Lee
70
P2.219 Exome Sequencing Unravels
Child Neurology and
Developmental Neurology:
Genetics
P2.224 Early-onset Cerebellar
Neurofibromatosis-1 A. David Rothner,
Manikum Moodley, Lauren Mientkiewicz,
Francine Erenberg
P2.226 Mapk/Erk Activation in an
Mutation in Atlastin-1 Gene Caused Pure
Hereditary Spastic Paraplegia Bohlega
Saeed, Ahmad Abulaban, Samya Hagos,
Aisha Qahtani, Salma Wakil
Animal Model of Social Deficits; a Possible
Link to Autism Alirexa Faridar, Dorothy
Jones-Davis, Eric Rider, Jiang Li, Ilan
Gobius, Laura Marcom, Linda Richards,
Elliott Sherr
P2.237 Novel Mutations in Schwartz-
P2.227 Phenotypic, Molecular,
Physical Impairment, Activity Limitation
and Quality of Life in Duchenne Muscular
Dystrophy (DMD): A Prospective Natural
History Study Nathalie Goemans, Brenda
Wong, Craig McDonald, Ali Jones, Caroline
Mason, Giles Campion
Functional, and Structural Aspects of
Novel DCX and LIS1 Mutations Causing
the Subcortical Band Heterotopia/
lissencephaly (SBH/LIS) Spectrum Dina
Amrom, Gary Brouhard, Susanne Bechstedt,
Katerina Toropova, François Dubeau,
Frederick Andermann, Denis Melançon,
Donatella Tampieri, Samara Reck-Peterson,
Eva Andermann
P2.228 Exome Sequencing Identifies
Carbamazepine Responsive Episodic
Dystonia and Hallucination Due to Pyruvate
Dehydrogenase E2 Mutation Salman
Rashid, Meghan Harper-Shankie, Fatema
Serajee, Ahm Huq
P2.229 Interaction Between Maternal
5-HTT Genotype and Prenatal Stress
Exposure, Confirmation in Two Independent
Samples David Beversdorf, Patrick Hecht,
Michael Tilley, Melissa Hudson, Susan
Connors, Xudong Liu
P2.230 Drisapersen: An Overview
of the Exon-51 Skipping Antisense
Oligonucleotide Clinical Program to
Date in Duchenne Muscular Dystrophy
(DMD) Craig McDonald, Nathalie
Goemans, Thomas Voit, Rosamund Wilson,
Claire Wardell, Giles Campion
Jampel Syndrome with Successes in
Medical Management Manan Shah, Mena
Scavina
P2.238 Evaluating the Progression of
P2.239 Identification of Serum
Biomarkers for Duchenne Muscular
Dystrophy Stavros Giannakopoulos,
Afrodite Lourbakos, Giles Campion, Sjef De
Kimpe
P2.240 Pooled Analyses of Efficacy
Parameters in Patients with Duchenne
Muscular Dystrophy (DMD): Results
from the Drisapersen (DRIS) Clinical Trial
Program Nathalie Goemans, Thomas Voit,
Craig McDonald, Rosamund Wilson, Claire
Wardell, Giles Campion
P2.241 Two Novel Compound
Heterozygous Mutations in ACAD9 in a
Patient with Infantile-onset Hypertrophic
Cardiomyopathy, Hypotonia, and Lactic
Acidosis Valentina Emmanuele, Melissa
Wasserstein, Jiuhong Pang, Sindu Krishna,
Kurenai Tanji, Peter Nagy, Michio Hirano
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session II
P2.242 Compound Heterozygous
Autosomal Recessive Hereditary Spastic
Paraplegia with Thin Corpus Callosum
in Two Sisters of Non-consanguineous
Extraction in the North-West of
Ireland John Quealy, Kevin Murphy
Child Neurology and
Developmental Neurology:
Cognition, Behavior and Genetics
P2.243 A Functional MRI Study
of Exploratory Behaviors in Early
Adolescence Andrew Kayser, Zdena Op de
Macks, Ronald Dahl, Michael Frank
P2.244 Withdrawn
P2.245 Social Cognition as a
Predictor of Social Competence in
Children and Adolescents After Epilepsy
Surgery Karishma Khullar, Paul Horn,
Katherine Holland, Hansel Greiner,
Francesco Mangano, Anna Byars
P2.246 Case of Congenital Hypotonia
Due to a Rare Genetic Deletion: 46,XX
(del)14q32.2q32.3 Matthew Harmelink,
Kumar Sannagowdara, Nadir Khan
P2.247 Bilateral Striatal Necrosis in a
Chinese Family, a New Type? Bi Hongyan
P2.248 The Effect of Perinatal Stroke
on Spatial Orientation Kara Murias, Irene
Liu, Sana Tariq, Jason Barton, Adam Kirton,
Giuseppe Iaria
P2.249 Hospital Care for Mental
Health Conditions and Substance Abuse
in Children with Underlying Neurological
Disorders Taylor Gianangelo, Allison Willis,
Dylan Thibault
P2.250 FMRI Correlates of
Sustained Attention in Pediatric Multiple
Sclerosis Ermelinda De Meo, Maria Rocca,
Lucia Moiola, Angelo Ghezzi, Pierangelo
Veggiotti, Ruggero Capra, Maria Amato,
Agnese Fiorino, Lorena Pippolo, Maria
Carmela Pera, Giancarlo Comi, Andrea
Falini, Massimo Filippi
P2.251 Retrospective Chart Review
of Neurodevelopmental Outcomes in
Children with Congenital Cerebellar
Malformations Elana Pinchefsky, Christine
Saint-Martin, Michael Shevell, Myriam Srour
P2.252 Spinal Muscular Atrophy
and Progressive Myoclonic Epilepsy: A
Lysosomal Disorder Due to Mutation of
Acid Ceramidase Joanna Gan, Brooke
Hjelm, Jane Tian, Richard Lewis, Michele
Tagliati, Tyler Pierson
Cerebrovascular Disease and
Interventional Neurology:
Genetics and Stroke
P2.253 Ischemic Stroke as the
Presenting Symptom in a Young Patient
with Essential Thrombocythemia Caused
by CALR Gene Mutation Nicolaas
Anderson, Katherine Bonsell
P2.254 Acute Ischemic Stroke Due to
P2.255 Development of a Lacune:
What Do We Find in CADASIL? Swati
Sathe, Edward Beninati, Eytan Raz, Matilde
Inglese
P2.256 Amyloid Beta Related Angiitis
in the Setting of Anticoagulation Cynthia
Costa, Rawan Albadareen, Jayashree
Sundararajan, Jeffrey Burns
P2.257 Late Adult Onset MELAS,
Presenting as Non-convulsive Status
and Atypical Strokes Bhrugav Raval,
Mohammad El-Ghanem, Machteld Hillen
P2.258 Recurrent Right Middle
Cerebral Artery Territory Infarctions in a
Patient with JAK2 (V617F) Point Mutation
Positive Polycythemia Rubra Vera Sharmila
Suri Mohanram, Premkumar Nattanmai
Chandrasekaran
P2.259 Evaluation of Clinico-
radiological, Molecular and Histological
Diagnosis of M.3243A>G-related MELAS
Syndrome Yi Shiau Ng, Grainne Gorman,
Andrew Schaefer, Robert Taylor, Robert
McFarland, Douglas Turnbull
P2.260 Central Retinal Artery
Occlusion in Patients with Sickle Cell
Disease Hashim Zeb, Morad Chughtai,
Ahmed Malik, Adnan Qureshi, Fareed Suri
P2.261
Comparison of
Hypercoagulable Evaluation in Perinatal
and Pediatric Ischemic Stroke David Doan,
Andrew Barreto, Kasey Gildersleeve, Amrou
Sarraj, Ian Butler
P2.262 Aspirin Resistance Is
Associated with Increased Stroke Severity
and Infarction Volume Mi Sun Oh, KyungHo Yu, Byung-Chul Lee
Cerebrovascular Disease and
Interventional Neurology: Carotid
Disease and IMT
P2.263 Low Fixed Dose of IV Heparin as
Adjunct to Internal Carotid Artery Angioplasty
and Stent Placement in Patients with
Recent Ischemic Symptoms: A Prospective
Protocol Muhammad Suri, Nauman
Jahangir, Mushtaq Qureshi, Adnan Qureshi
P2.264 Carotid Plaque Thickness Is
Positively Associated with Decreased Bone
Mineral Density Sang Won Han, Joong
Hyun Park, Jae Hyeon Park, Jong Yun Lee,
Kyung-Yul Lee
P2.265 Are Patients with Carotid
Stenosis Receiving Optimal Medical
Therapy? Sebastian Koch, Seemant
Chaturvedi, Jose Romano
P2.266 Acute Glaucoma Exacerbation
Following Carotid Artery Stenting Amer
Malik, Keith DeSousa, Sushrut
Dharmadhikari, Gillian Gordon-Perue, Rahul
Dave, Jose Romano, Dileep Yavagal
P2.267 Outcomes of Elective Carotid
Stenting in the Octogenarians Aws Alawi,
Sonal Mehta, Randall Edgell, Eliahu Feen,
Amer Alshekhlee
Left Ventricular Noncompaction Syndrome
from a Novel Mutation of the Lamin A/C
Gene Nuttawan Vongveeranonchai,
Shivam Mittal, Ciro Ramos Estebanez,
Michael De Georgia
Fast, Easy, Online Registration · AAN.com/view/AM15
P2.268 Patients Consenting to or
Declining Extended Follow-up (Up to Ten
Years) in the Carotid Revascularization
Endarterectomy (CEA) Versus Stenting
(CAS) Trial (CREST) Alice Sheffet, Ariane
Mackey, William Brooks, Wayne Clark,
Michael Hill, Jenifer Voeks, Susan Hughes,
MeeLee Tom, Mary Longbottom, Virginia
Howard, Thomas Brott
P2.269 Carotid Intima-media
Thickness, but Neither Framingham
Risk Score nor Omnibus Risk Score, Is
Associated with Stroke Among Nigerian
African Hypertensive Patients Mayowa
Owolabi, Onoja Akpa, Atinuke Agunloye
P2.270 Prevalence and Healing
Rates of Duplex Detected Carotid Plaque
Ulcers Sushrut Dharmadhikari, Ari Bennett,
Jose Romano, Nelly Campo, Sebastian Koch
P2.271 Evaluation of the Patients with
Internal Carotid Artery Occlusion by ESSEN
Score Yongbo Zhang, Ying Lv, Yan Fei Han,
Jimei Li
P2.272 Cognitive Implications of
Revascularization in Asymptomatic Carotid
Stenosis Chun-Jen Lin, Feng-Chi Chang,
Pei-Chi Tu, Pei-Ning Wang, I-Hui Lee
P2.280 Should TCDs Be Routinely
Used for Evaluating Intracranial Circulation
for Screening High Risk Patients Prior to
Cardiac Surgery? Quang Vu, Laura Bishop,
Matthew Edwards, Charles Tegeler, Aarti
Sarwal
P2.281 Ischemic and Hemorrhagic
Cerebrovascular Events After Left
Ventricular Assist Devices Pouya TahsiliFahadan, David Curfman, Albert Davis,
Noushin Yahyavi-Firouz-Abadi, Michael
Nassif, Shane LaRue, Gregory Ewald,
Allyson Zazulia
Cerebrovascular Disease and
Interventional Neurology: RCVS
and Malignant Cerebral Edema
P2.282 Reversible Cerebral
Vasoconstriction Syndrome Following a
Carotid Endarterectomy Ajay Tunguturi,
Anand Patel, David Paydarfar
P2.283 Magnesium for the
Symptomatic Treatment of Reversible
Cerebral Vasoconstriction Syndrome
(RCVS): Case Report Christina Mijalski,
Brian Silver, Muhib Khan
P2.284 Recreational Drug Use and
Cerebrovascular Disease and
Interventional Neurology: PFO
and Other Cardiac Disease
RCVS: Should Toxicity Screens Become
Standard in RCVS Diagnostics? Neha
Mirchandani, Imad Khan, Fernanda
Wajnsztajn
P2.273 Recurrent Ischemic Strokes
P2.285 A Rare Complication in a
and Headaches Originating from Lambl’s
Excrescence Oana Dumitrascu, Evgeny
Tsimerinov
P2.274 Clinical Characteristics of PFO
Stroke in Pregnancy Lei Chen, Wenjun
Deng, T Wickham, David McMullin D, Lo
Eng H, Ferdinando Buonanno, MingMing
Ning
P2.275 Cerebral Ischemic Events
Associated with Transcatheter Aortic
Valve Replacement (TAVR): A Systematic
Review Nabeel Herial, Najwa Mohammad,
Chughtai Morad, Mushtaq Qureshi, Adnan
Qureshi
P2.276 Outcomes of In-hospital
Cardiopulmonary Resuscitation in Stroke
Patients Admitted in the United States,
Years 2005-2011 Mohammad Qureshi,
Malik Adil, Gabriel Vidal, Ahmed Malik,
Fahad Saeed, Mushtaq Qureshi, Adnan
Qureshi
P2.277 Metabolomic Analysis of
PFO-related Stroke Shows Immediate
and Persistent Decrease of Homocysteine
Post PFO Closure Wenjun Deng, Chris
Beecher, Charles Burant, Mary Lopez, Frank
De Jong, Igor Palacios, Ignacio Inglessis,
Scott Silverman, Kathleen Feeney, Mikaela
Elia, Thomas Wickham, David McMullin, G
William Dec, Ferdinand Buonanno, Eng Lo,
MingMing Ning
P2.278 The Need for Performance
Protocols for TEE and TCD in Detection
of Right to Left Shunts James Frey, Carol
Darbonne, Jason Chang, Mohamed Teleb
Tuesday
April 21
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Common Setting: Ondansetron-related
Hemorrhagic Reversible Posterior
Leukoencephalopathy Syndrome (PRES)
Following Gastric Bypass MohamedAli Babi, Salman Aljerdi, Mark Gorman,
Ryan Clouser, Gilman Allen, Christopher
Commichau
P2.286 Management of Refractory
ICP with Hypothermia in a Case
of Malignant Posterior Reversible
Encephalopathy Syndrome Shaista Alam,
Nicole Mahdi, Fred Rincon
P2.287 Improvement in Midline
Shift Is Associated with Survival After
Decompressive HemiCraniectomy in Large
Hemispheric Infarctions Joanna Ramiro,
Rajat Dhar, Eliahu Feen, Abhay Kumar
P2.288 Hemispheric Differences
in Malignant Middle Cerebral Artery
Stroke Thor Stead, Vaibhav Rastogi, Rachel
Penumudi, Damon Lamb, John Williamson,
Vishunmurthy Hedna
P2.289 Angiographic and Clinical
Correlates of Cerebral Hemodynamic
Changes with Diamox Challenge Assessed
by Quantitative Magnetic Resonance
Angiography Mersedeh Bahr Hosseini,
Sophia Shakur, Sepideh Amin-Hanjani,,
Fady Charbel, Ali Alaraj
P2.290 Mixed Vasopressin
Antagonism as a Directed Therapy
for Cerebral Edema in Acute Stroke
Patients Vishnumurthy Hedna, Mushtaq
Qureshi, Najwa Mohammad, Adnan Qureshi
P2.279 Enterobacter Cloacae
Endocarditis Presenting as an Ischemic
Stroke Robert Mannel, Scott Silliman
71
Poster Session II
7:30 a.m.–12:00 p.m.
Cerebrovascular Disease and
Interventional Neurology:
Inflammation and Immunology
P2.303 Assessment of Stroke
P2.291 Susac’s Syndrome: Review of
P2.304 Exploring Self-reported
Clinical and Imaging Findings Sarita Said
Said, Jennifer Lee, Shyamsunder Sabat, T.
Thomas Zacharia
P2.292 FDG-PET as a Radiological
Biomarker in Patients with Takayasu
Arteritis Balakrishnan Shankar, Elango
Kalaimani, Ranganathan Lakshmi
Narasimhan, Govindaraj Srinivasan Raman,
Bhanu Kesavamurthy
P2.293 Primary Angiitis of the Central
Nervous System (PACNS) Presenting
with Intracerebral Hemorrhage Moayd
Alkhalifah, Pierre Fayad, Matthew Omojola,
Michelene Hearth-Holmes, Rodney
McComb
P2.294 Delays in Diagnosis and
Treatment of Central Nervous System
Vasculitis Lead to Poor Outcomes Amanda
Jagolino, Adeola Olowu, Chunyan Cai,
Mohammad Rahbar, Chad Tremont, Sean
Savitz, Amrou Sarraj
P2.295 Temporal Trends of Mortality
in Acute Ischemic Stroke in Systemic
Lupus Erythematosus: A Propensitymatched Analysis of Nationwide
Inpatient Data Achint Patel, Girish
Nadkarni, Abhimanyu Mahajan, Ioannis
Konstantinidis, Priya Simoes, Alexandre
Benjo, Shiv Kumar Agarwal, Krishna
Pakanati, Madhav Menon, Narender
Annapureddy
P2.296 Methotrexate Neurotoxicity
Knowledge and Attitudes Among Riyadh
Medical Students: A Cross-sectional
Study Mohamed Alzawahmah
Lifestyle and Career Choices Among
Vascular Neurology Fellows Sebina Bulic,
Steven Levine, Priyank Khandelwal, Elaine
Auerbach, Nerses Sanossian
P2.305 Cerebral Blood Flow in TIA
Patients Presenting Acutely: Implications
for Stroke Prevention in Qatar Leopold
Streletz, Naveed Akhtar, Ahmed El Sotouhy,
Saadat Kamran, Darine Dimassi, Damian
Jenkinson, Ibtisam Ali, Ahmed Khattab
P2.306 Transient Ischemic Attacks in
Post-menopausal Women with History of
Migraines Have Lower Risk for Subsequent
Ischemic Strokes Haseeb Rahman, Ahmed
Malik, Abraham Thomas, Adnan Qureshi
P2.307 Is CT Scan in Patients
with Suspected TIA Necessary: A
Quality Improvement Initiative Sanam
Baghshomali, Laura Bishop, Brian Hiestand,
Patrick Reynolds, Cheryl Bushnell
P2.308 Epidemiology of Ischemic
Strokes and Transient Ischemic Attacks in
the Oldest Old Rocio Garcia Santibanez,
Maryna Skliut
P2.309 Nationwide Patterns of
Magnetic Resonance Imaging Utilization
Among Stroke and Transient Ischemic
Attack Patients in the Emergency
Department Alvin Ng, Katherine Fu,
Shuhan He, Steven Cen, William Mack,
David Liebeskind, Nerses Sanossian
Mimicking Stroke Quynh Pham, David
Ermak
HIV, PML, and CMV
P2.297Meningovascular
P2.310 S.O.S. Progressive Multifocal
Neurosyphilis Presenting as Ischemic
Stroke in an HIV Positive Patient Anita
Tipirneni, Gillian Gordon-Perue, Keith
DeSousa, Sebastian Koch, Jose Romano,
Amer Malik
P2.298Withdrawn
P2.299 HMGB1 Contributes to
Inflammatory Response Through RAGE
After Acute Intracerebral Hemorrhage in
Rats Dan Li
Cerebrovascular Disease and
Interventional Neurology:
Education and TIA
P2.300 Impact of Community Stroke
Education and Comprehensive Stroke
Care in South Texas Ameer Hassan,
Wondwossen Tekle, Christina Sanchez,
Vishal Jani, Lisa Jones-Fullingim
P2.301 Stroke Knowledge in the
Population of São Bernardo Basic Health
Unit (Belo Horizonte, Brazil) Fidel Meira,
Daiane Magalhães, Luiz Silva, Felipe
Machado, Lucas Oliveira, Cecilia Monteiro,
Ariana Chagas, Luiza Andres, Ana Silva
P2.302 Stroke Awareness in
Outpatients Diego Nadile, Maria Gonzalez
Toledo, Yamila Gomez, Francisco Muñoz
Giacomelli, Matias Delfitto, Javier Moschini,
Fatima Pagani Cassara, Agustina Tamargo,
Alejandro Thomson, Francisco Klein
72
Leukoencephalopathy: Teleneurology for a
Rare Disease Shruti Agnihotri, Igor Koralnik
P2.311
A Case of Recurrent PML
Associated with Cortical Intra-neuronal
JC Virus Inclusions in a Woman with
HIV Josef Gutman, Karen Weidenheim,
Patrick LaSala, Jerome Graber
P2.312
Quantitative Susceptibility
Mapping Suggests a Paramagnetic
Effect in Progressive Multifocal
Leukoencephalopathy Clarisse CarraDalliere, Nicolas Menjot de Champfleur,
Xavier Ayrignac, Deverdun Jeremy, Pierre
Labauge
P2.313
Cystatin C Is Associated with
Neurocognitive Impairment in Older HIV+
Adults Marissa Sakoda, Pariya Fazeli, Scott
Letendre, Dilip Jeste, Igor Grant, David
Moore
P2.314
Endothelial Function and CNS
Measures in Primary HIV Infection Pre-and
Post Early ART Sebastian Urday, Zaina
Zayyad, Julia Peterson, Felicia Chow, Kevin
Robertson, Richard Price, Priscilla Hsue,
Serena Spudich
P2.315
Frequency of HIV-associated
Neurological Disorders over Four Years of
Follow-up: Results from the Multicenter
AIDS Cohort Study Ned Sacktor, Sandra
Reynolds, Richard Skolasky, Cynthia Munro,
James Becker, Eileen Martin, Ann Ragin,
Andrew Levine, Eric Miller
P2.316
Cerebrospinal Fluid (CSF)
Findings of Patients with HIV Associated
Neurocognitive Disorders (HAND) Patricia
McNamara, Padraic Dunne, Brian Lawlor,
Janice Redmond, Colin Doherty, Derek
Doherty, Colm Bergin
P2.317
Peripheral Neuropathy Is
Common and Associated with Functional
Impairment in HIV+ and HIV- Individuals
in Rural Uganda Deanna Saylor, Gertrude
Nakigozi, Noeline Nakasujja, Xiangrong
Kong, Kevin Robertson, Ronald Gray, Maria
Wawer, Ned Sacktor
P2.318
Opsoclonus Myoclonus
Ataxia Syndrome Due to Mycobacterium
Tuberculosis Rhombencephalitis in a
Patient with HIV Juan Parada, Immer
Armendariz Betancour
P2.328 Quality Indicators for
the Assessment and Management
of Neurological Patients. The Quality
and Safety ABC Program. Experience
Neurological Center, the American British
Cowdray Medical Center. México Aurelio
Mendez-Dominguez, Roberto Alfonso
De Leo-Vargas, Alejandro Alfonso-Diaz,
Guillermo Reyes-Caballero, Patricia ConchaHein, Claudia Cabrera
P2.329 VCJD in the United States—
Analysis of 4 Cases Devry Saenz, Danah
Marafie, Atul Maheshwari, Haitham
Hussein
P2.330Polysomnographic
P2.319
Assessment of Sleep Disorders in Rural
Areas of Low- and Middle-income
Countries. A Feasibility Study in Atahualpa
(Rural Coastal Ecuador) Pablo Castillo,
Melanie Lawson, Bethlehem ShimeliseChamblin, Kelsie Phelan, Elizabeth Cusick,
Jadry Gruen, Mauricio Zambrano, Oscar Del
Brutto
Global Neurology
P2.331 Clinical Spectrum of Ciguatera
CMV Transverse Myelitis
Presenting as Partial Brown-Sequard
Syndrome Yinan Zhang, Divyanshu Dubey,
Pradeep Modur
P2.320 Unintentional Injuries Among
People with Epilepsy in Bhutan Tali Sorets,
Erica McKenzie, Joe Cohen, Sydney Cash,
Edward Leung, Damber Nirola, Sonam
Deki, Lhab Tshering, Emma Wolper, Farrah
Mateen
P2.321 Nodding Syndrome in Uganda:
Poisoning in the Family After Consuming
Amberjack Fish Nancy Rosales, Rachana
Gandhi, Efrain Salgado
P2.332 Nocardial Intramedullary
Abscess; A Case Report and Review of
Literature Sarah Lapointe, Catherine
Legault, Robert Altman
Risk Factors at Disease Onset Rajarshi
Mazumder, Valerie Palmer, Peter Spencer,
Peter King, Ryan Stadnik, Michael Lasarev,
Margaret Kabahenda, David Kitara, Diane
Stadler
Medical Student Essay
Award Recipients
P2.322 Rapidly Progressive Dementia
Profiles with Cerebral Microbleeds in
Dementia Sara Shams
and Myoclonus with Elevated CSF
IgG Index in Young Adult Immigrants:
Treatable, but Not Always with
Immunosuppression Cheryl Jay, Lara
Zimmermann, Karen DaSilva
P2.323 Health Beliefs Regarding
Cerebral Palsy in Botswana: A Qualitative
Study Payal Patel, James Baier, Esther
Barinov, Esha Kurana, Baphaleng
Monokwane, David Bearden
P2.324 Neuropsychiatric Disorders
Among Syrian and Iraqi Refugees in
Jordan, 2012-2013: A Retrospective,
Cohort Study Erica McKenzie, Paul Spiegel,
Adam Khalifa, Farrah Mateen
P2.333 Cerebrospinal Fluid
P2.334 Diagnostic REM Sleep
Muscle Activity Cutoff Values for
Idiopathic REM Sleep Behavior
Disorder Stuart McCarter
P2.335 Charcot's Pupils: A
Legacy of Charcot's Abilities as
Teacher and Mentor Travis Urban
P2.336 The Neuroanatomical
Basis of Coma in Humans: Using
Functional Connectivity to Assess
the Network Effects of Brainstem
Lesions David Fischer
P2.325 Cerebral Palsy in
Children in Botswana: Outcomes and
Comorbidities Esther Baranov, James
Baier, Baphaleng Monokwane, Esha
Khurana, David Bearden
P2.326 Defining the Epilepsy
Management Gap in a Prospective Cohort
in Bhutan Erica McKenzie, Damber Nirola,
Lhab Tshering, Sonam Deki, Joe Cohen,
Sydney Cash, Emma Wolper, Edward Leung,
Tali Sorets, Andrew Lim, Hannah McLane,
Chencho Dorji, Farrah Mateen
P2.327 Closing the Treatment Gap for
Neurological Diseases in Less Resourced
Countries Vijay Chandra, Anwar Nazneen
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Section Topic Controversies
S3 Section Topic Controversies: Should All Brain Tumor
Patients Receive Prophylactic Antiepileptic Drugs?
1:00 p.m.–2:30 p.m.
1:00 p.m.–1:05 p.m. Introduction Howard Colman, MD, PhD, and Nicole
Ullrich, MD, PhD
1:05 p.m.–1:25 p.m.
Seizures in Adult and Pediatric Brain Tumor
Patients—Unique Features and Scope of the
Problem Howard Colman, MD, PhD, and Nicole
Ullrich, MD, PhD
1:25 p.m.–2:10 p.m.
Should all Brain Tumor Patients Receive
Prophylactic Anti-epileptic Drugs Debate Jeffrey J.
Raizer, MD, and Elizabeth Wells, MD
2:10 p.m.–2:30 p.m.
Open Discussion, Questions, Conclusions, Summary
and Adjournment Howard Colman, MD, PhD, and
Nicole Ullrich, MD, PhD
CESC: 15AM Women in Leadership Ad, Horizontal Halfpage> AMRAP
Placed in AMRAP
8.25”x5.4375” + .125” Bleed, 2C
Take Your Commitment
to Your Profession
to the Next Level
2015 AAN Leadership Programs
Whether you want to be a mentor or an advocate, to guide or
inspire others, you need to cultivate the skills to be an effective leader.
Monday, April 20, 2015, 1:00 p.m.–5:00 p.m.
Improving Your Leadership Skills: A Practical Approach
Leadership has been defined as “having a sound vision and convincing others to follow you.” This course
will assist you in implementing the vision and offer practical tips and case examples on how to persuade
others to follow.
Directors: Terrence L. Cascino, MD, FAAN, Rochester, MN
Ralph L. Sacco, MD, MS, FAHA, FAAN, Miami, FL
Tuesday
April 21
Moderators: Nicole Ullrich, MD, and Howard Colman, MD
Scientific Sessions
S4 Clinical Trial Outcomes
in Multiple Sclerosis
1:00 p.m.
S4.001
Peginterferon Beta-1a Is Effective
as Early as Twelve Weeks Following
Treatment Initiation in Patients with
Relapsing Multiple Sclerosis Scott
Newsome, Bernd Kieseier, Shulian
Shang, Shifang Liu, Serena Hung,
Bjoern Sperling
1:15 p.m.
S4.002
Long-term Safety and Tolerability
of Peginterferon Beta-1a: Interim
Analysis from ATTAIN, a Phase
3 Extension Study Marcelo
Kremenchutzky, Shifang Liu, Yue
Cui, Serena Hung, Ali Seddighzadeh,
Vladimir Evilevitch
S5 Cerebrovascular
Disease and Interventional
Neurology: Recovery and
Outcome
1:00 p.m.
S5.001
Comparison of Prognosis in Terms
of Recurrent Vascular Events, Death
and Functional Outcome Following
Ischemic Stroke Due to Lacunar
Versus Non-lacunar Etiology at Serial
Time-points over 8 Years Deidre De
Silva, Natasha Fabiana, John Allen,
Fung Peng Woon, Hui-Meng Chang,
Kamran Ikram, Tien-Yin Wong,
Meng-Cheong Wong
1:30 p.m.
S4.003
Daclizumab HYP Versus Interferon
Beta-1a in Relapsing-remitting
Multiple Sclerosis: Primary Results of
the DECIDE Study Ludwig Kappos,
Krzysztof Selmaj, Douglas Arnold,
Eva Havrdova, Alexey Boyko,
Michael Kaufman, Heinz Wiendl,
John Rose, Steven Greenberg,
Marianne Sweetser, Katherine
Riester, Jacob Elkins
1:15 p.m.
S5.002
Deep Repetitive Transcranial
Magnetic Stimulation and Cycling
Improve Lower Limb Function in
Chronic Stroke: A Randomized,
Placebo-controlled, Crossover
Study Raffaella Chieffo, Fabio
Giatsidis, Elise Houdayer, Mario
Fichera, Arturo Nuara, Elisabetta
Coppi, Laura Ferrari, Giovanni Di
Maggio, Roberto Santangelo,
Antonella Poggi, Maria Sessa,
Mauro Comola, Abraham Zangen,
Giancarlo Comi, Letizia Leocani
1:45 p.m.
S4.004
MS Patients Under Daclizumab
Therapy Mount Normal
Immune Responses to Influenza
Vaccination Yen-Chih Lin, Paige
Winokur, Andrew Blake, Tianxia
Wu, Jody Manischewitz, Lisa King,
Elena Romm, Hana Golding, Bibiana
Bielekova
1:30 p.m.
S5.003
Stroke Survivors and Caregivers
Preferences for Mobile APPs: A
Nationwide Population-based
Survey Gilles Nadege, Sarah
Zelonis, Laura Beving, Dee Burton,
Christina Ventura-DiPersia, Saroj
Kunnakkat, Clotilde Balucani, Amy
Jensen, Steven Levine
2:00 p.m.
S4.005
First Dose Effects of Fingolimod: An
In-depth Analysis of the First 2500
START Patients Volker Limmroth,
Wilhelm Haverkamp, Ralf Dechend,
Susanne Hoyer, Michael Lang,
Judith Haas, Richter Stephan, Bert
Wagner, Stephan Schmidt, Tjalf
Ziemssen
1:45 p.m.
S5.004
Evaluating the Impact of Insurance
Precertification on Discharge of
Stroke Patients to Skilled Nursing
Facility or Inpatient Rehabilitation
Center. Andrew Smith, Ashish
Kulhari, Julie Wolfram, Anthony
Furlan
2:15 p.m.
S4.006
Long-term Safety of Fingolimod: An
Interim Analysis of the LONGTERMS
Cohort Jeffrey Cohen, Philipp Von
Rosenstiel, Rebecca Gottschalk,
Ashish Pradhan, Ying Zhang, Ludwig
Kappos
2:30 p.m.
S4.007
Durable Effect of Alemtuzumab on
Clinical Outcomes in Treatmentnaive Relapsing-remitting Multiple
Sclerosis Patients: Four-year Followup of CARE-MS I Alastair Compston,
Gavin Giovannoni, Douglas Arnold,
Edward Fox, Hans-Peter Hartung,
Eva Havrdova, Krzysztof Selmaj,
David Margolin, Jeffrey Palmer,
Michael Panzara, Alasdair Coles
74
2:00 p.m.
S5.005
Body Weight and Survival After
Stroke: Exploring the “Obesity
Paradox” in the Framingham
Study Hugo Javier Aparicio,
Jayandra Himali, Alexa Beiser,
Carlos Kase, Philip Wolf, Sudha
Seshadri
2:15 p.m.
S5.006
Smoker's Paradox in Hospitalizations
with Acute Ischemic Stroke: An
Analysis of Nationwide Inpatient
Sample Data Achint Patel, Vishal
Jani, Girish Nadkarni, Mihir Dave,
Abhimanyu Mahajan, Mounzer
Yassin-Kassab, Syed Hussain
2:30 p.m.
S5.007
HDAC4 Shuttling Promotes Neuronal
Remodeling After Stroke Amjad
Shehadah, Haifa Kassis, Michael
Chopp, Cynthia Roberts, Zheng
Gang Zhang
Tuesday, April 21
S6 Epilepsy/Clinical
Neurophysiology (EEG):
Health Services and
Women's Issues
1:00 p.m.
S6.001
Mullerian Inhibitory Substance
(MIS) Levels Are Associated with
Seizure Occurrence in Women
with Epilepsy Cynthia Harden,
Page Pennell, Jacqueline French,
Anne Davis, Connie Lau, Rutendo
Kashambwa, Benjamin Kaufman,
Emilia Bagliella, Ariel Kirshenbaum
1:15 p.m.
S6.002
Re-analyses of Outcomes from
Fetal Valproate Exposure in the
NEAD Study Kimford Meador, Gus
Baker, Ryan May, Nancy Browning,
Morris Cohen, Rebecca Bromley,
Jill Clayton-Smith, Laura Kalayjian,
Andres Kanner, Joyce Liporace,
Page Pennell, Michael Privitera,
David Loring
1:30 p.m.
S6.003
Contraceptive Practices of
Women with Epilepsy: Findings
of the Epilepsy Birth Control
Registry Andrew Herzog, Hannah
Mandle, Anne Davis, W. Hauser
1:45 p.m.
S6.004
Improving the Prescription of Folic
Acid to Women Taking Antiepileptic
Drugs Anumeha Sharma, Jennifer
Cavitt, Michael Privitera, Brian
Moseley
2:00 p.m.
S6.005
The Single Seizure Clinic Model:
Does It Work? Effects on Wait-times
and Patient Outcomes Rizvi Syed,
Lizbeth Hernandez-Ronquillo, Gary
Hunter, Farzad Moien Afshari, Karen
Waterhouse, Jose Tellez-Zenteno
2:15 p.m.
S6.006
The Association Between
Antiepileptic Drug Dosing Frequency
at Monotherapy Initiation and Direct
Health Care Costs in the United
States Fulton Velez, Jennifer
Korsnes
2:30 p.m.
S6.007
Development and Validation of
an Epilepsy Epidemiologic Case
Definition for Use with Australian
Administrative Health Data Michael
Tan, Ian Wilson, Vanessa Braganza,
Sophie Ignatiadis, Raymond Boston,
Vijaya Sundararajan, Mark Cook,
Wendyl D'Souza
S7 Movement Disorders:
Genetics
1:00 p.m. Presentation of
Founders Award
Recipient:
Aasef Shaikh, MD, PhD
Lakewood, OH
1:15 p.m.
S7.002
Phosphorylated PS1292 LRRK2 to
Total LRRK2 Concentration Ratio
in Urine Exosomes Distinguishes
LRRK2-PD and Idiopathic PD Roy
Alcalay, Kyle Fraser, Andrew West
1:30 p.m.
S7.003
Glucocerebrosidase Activity in
Parkinson Disease with and Without
GBA Mutations Roy Alcalay, Oren
Levy, Cheryl Waters, Stanley Fahn,
Blair Ford, Sheng-Han Kuo, Pietro
Mazzoni, Karen Marder, Michael
Pauciulo, William Nichols, Ziv
Gan-Or, Guy Rouleau, Wendy Chung,
Pavlina Wolf, Petra Oliva, Joan
Keutzer, Xiaokui Zhang
1:45 p.m.
S7.004
Zebrafish (Danio Rerio) as a Model
for Glucocerebrosidase 1 (GBA1)
Deficiency Oliver Bandmann,
Marcus Keatinge, Marc Da Costa,
Aswin Menke, Yu-Chia Chen, Pertti
Panula
2:00 p.m.
S7.005
Association Studies of
Neuropathologically Confirmed
Cases and Controls Reveals That
the PARK10 Locus Is a Major
Contributor to Sporadic Parkinson
Disease. Jeffery Vance, Gary
Beecham, Dennis Dickson, William
Scott, Gerard Schellenberg, Karen
Nuytemans, Eric Larson, Joseph
Buxbaum, John Trojanowski,
Vivianna Van Deerlin, Howard
Hurtig, Deborah Mash, Thomas
Beach, Juan Troncoso, Olga
Pletnikova, Matthew Frosch,
Bernardino Ghetti, Tatiana Foroud,
Lawrence Honig, Karen Marder,
Jean Paul Vonsattel, Samuel
Goldman, Harry Vinters, Owen Ross,
Zbigniew Wszolek, Liyong Wang,
Derek Dykxhoorn, Margaret PericakVance, Thomas Montine, James
Leverenz, Ted Dawson, Eden Martin
S8 Aging, Dementia,
Cognitive, and Behavioral
Neurology: Basic Science
1:00 p.m. Presentation of
Potamkin Prize for Research in
Pick’s, Alzheimer’s, and Related
Diseases
Recipients:
Reisa Sperling, MD
Boston, MA
Peter Davies, PhD
New York, NY
1:30 p.m.
S8.003
Adiponectin Deficiency Induced
Cognitive Impairment in Aging
Mice Through Reductions in
Insulin Sensitivity and AMPK
Activation Roy Chun-Laam Ng
1:45 p.m.
S8.004
Lack of Exacerbation of
Neurodegeneration in a Double
Transgenic Mouse Model of Mutant
LRRK2 and Tau Fadi Mikhail, Noel
Calingasan, Lichuan Yang, Luca
Parolari, Aarthi Subramanian, M.
Beal
2:00 p.m.
S8.005
Autophagy Activators Rescue
and Alleviate the Pathogenesis of
a FTLD-TDP Model with TDP-43
Proteinopathies IFang Wang, KuenJer Tsai, Che-Kun Shen
2:15 p.m.
S8.006
Mutant PS1 and Altered Glycolipids
Synthesis Tatsuro Mutoh, Sayuri
Shima, Akihiro Ueda, Kunihiko
Asakura, Araki Wataru, Eri Muto,
Massimo Masserini, Shinji Ito
2:30 p.m.
S8.007
Reactivation of Lysosomal
Calcium Efflux Rescues Abnormal
Lysosomal Storage in FIG4 Deficient
Cells Jianlong Zou, Bo Hu, Sezgi
Arpag, Audra Hamilton, Carlos
Vanoye, Jun Li
2:15 p.m.
S7.006
Variants Associated with Gaucher
Disease in Multiple System
Atrophy Jun Mitsui, Takashi
Matsukawa, Hidenao Sasaki,
Ichiro Yabe, Masaaki Matsushima,
Alexandra Durr, Alexis Brice, Hiroshi
Takashima, Shoji Tsuji
2:30 p.m.
S7.007
Short Hairpin RNA Targeting
Endogenous Alpha-synuclein
Prevents Degeneration of
Dopaminergic Neurons in the Rat
Rotenone Model of Parkinson's
Disease Edward Burton, Alevtina
Zharikov, Victor Tapias, Jason
Cannon, Qing Bai, J. Greenamyre
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Invited Science: Stroke
S9 General Neurology:
Neurological Treatments
and Therapeutics
1:00 p.m.
S9.001
Translational Genetics to Identify
the Druggable Space of Neurological
Diseases Nikolaos Patsopoulos,
Garrett Wong
1:15 p.m.
S9.002
Anti-CD52 Treatment Induces CD39+
Regulatory Cells and Suppresses EAE
Disease Progression Anudeep Pand,
Yan Wang, Eli Kasper, Kiel Telesford,
Javier Ochoa-Repáraz, Azizul Haque,
Lloyd Kasper, Sakhina Begum-Haque
1:30 p.m.
S9.003
Phase 2 Open-label Extension Study
of Patisiran, an Investigational
RNAi Therapeutic for the
Treatment of Familial Amyloid
Polyneuropathy Teresa Coelho,
Ole Suhr, Isabel Conceicao, Marcia
Waddington Cruz, Hartmut Schmidt,
Buades Juan, Josep Campistol,
Jean Pouget, John Berk, Rick
Falzone, Lindsey White, Brian
Bettencourt, Jeff Cehelsky, Sara
Nochur, Akshay Vaishnaw, Jared
Gollob, David Adams
1:45 p.m.
S9.004
Acetyl-DL-leucine for Treatment
Niemann-Pick Type C: A Case
Series Michael Strupp, Tatiana
Bremova
2:00 p.m.
S9.005
Infliximab for the Treatment of CNS
Sarcoidosis: Clinical and Radiological
Outcomes Gelfand Jeffrey, Laura
Koth, Stephen Hauser, Ari Green
2:15 p.m.
S9.006
Identification and Evaluation of
Potential Remyelination Therapeutics
for Multiple Sclerosis Brian Bai,
Simon Lunn, Robin Avila, Satish
Medicetty, Bruce Trapp
2:30 p.m.
S9.007
Development of Therapeutic
Area-specific Data Standards for
Brain Diseases Jon Neville, Steve
Kopko, Bess LeRoy, Mark Gordon,
Susan De Santi, Andreas Jeromin,
Ellen Mowry, Mark Austin, Patricia
Cole, Kenneth Marek, Gerald Novak,
Klaus Romero, Bob Stafford, Emily
Hartley, Amy Palmer, Rhonda
Facile, Kewei Chen, Adam Fleisher,
Joanne Odenkirchen, Enrique Avilés,
Fred Lublin, Eric Reiman, Geoffrey
Manley, Lynn Hudson, Diane
Stephenson
S10 Pain and Palliative
Care
1:00 p.m. Presentation of
Mitchell B. Max Award for
Neuropathic Pain
Recipient:
Robert Dworkin, PhD
Rochester, NY
1:15 p.m.
S10.002
Clinical and Molecular Profiling of
Muscle Pain in Myotonic Dystrophy
Type 2 Vinko Palada, Rabih
Moshourab, Stefan Kempa, Michael
Boschmann, Gary Lewin, Simone
Spuler
1:30 p.m.
S10.003
Alterations in Brain Gray Matter
Volume Are Associated with
Reduced Evoked-pain Connectivity
Following Acute Pregabalin
Administration Tudor Puiu, Anson
Kairys, Lynne Pauer, Tobias SchmidtWilcke, Eric Ichesco, Johnson
Hampson, Vitaly Napadow, Daniel
Clauw, Richard Harris
1:45 p.m.
S10.004
Gene Therapy for Neuropathic Pain
by Silencing of TNF-α Expression
with Lentiviral Vectors Targeting
the Dorsal Root Ganglion in
Mice. Nobuhiro Ogawa, Tomoya
Terashima, Hiromichi Kawai, Hideto
Kojima, Kazuhiro Oka, Lawrence
Chan, Hiroshi Maegawa
2:00 p.m.
S10.005
Chronic Regional Pain Syndrome:
A Preliminary Report on Molecular
Mechanisms and Structural
Correlates Beth Murinson, Zelda
Ghersin, Eli Peled
2:15 p.m.
S10.006
Do Social Media Improve
Dissemination of Clinical Practice
Guidelines (CPG)? Thomas Getchius,
Rebecca Penfold-Murray, Julie
Cox, Richard Dubinsky, Christopher
Bever, Gary Gronseth, Pushpa
Narayanaswami
S11 Practice, Policy, and
Ethics
1:00 p.m.
S11.001
Perfect Care Improves Value for
Ischemic Stroke Patients, Hospitals,
and Payors Michael Dobbs, Sarah
Heck, Kelley Elkins, Julia Blackburn,
Bernard Boulanger
1:15 p.m.
S11.002
Successful Reduction of
Unnecessary Indwelling Catheter
Utilization in Acute Ischemic Stroke
Patients at a Certified Primary Stroke
Center Fahed Saada, Scott Silliman
Notes from the International Stroke
Conference: Late-Breaking News
on Endovascular Trials for Acute
Ischemic Stroke*
Tuesday, April 21, 1:00 p.m.–2:45 p.m.
1:00 p.m–1:15 p.m.
MR CLEAN The Multicenter Randomized Clinical Trial
of Endovascular Treatment for Acute Ischemic Stroke in
the Netherlands: Updated Results
1:15 p.m–1:30 p.m.
EXTEND-IA (Extending the Time for Thrombolysis in
Emergency Neurological Deficits—Intra-Arterial) Trial
1:30 p.m.
S11.003
Time Delays in Patient Placement:
A Common Occurrence with a
Simplified Solution Ilan Danan,
Emiliya Melkumova, Robert Fekete
1:30 p.m–1:45 p.m.
1:45 p.m.
S11.004
Implementation of a Novel “Brain
Code” Medication Distribution
System for Neurological Emergencies
at a Tertiary Care Hospital Jamie
LaBuzetta, Frank Chu, Anushirvan
Minokadeh, Brian Lemkuil, Kevin
Box, Navaz Karanjia
1:45 p.m–2:00 p.m.
2:00 p.m.
S11.005
Analysis of Patient Portal
Message Content in an Academic
Multi-specialty Neurology
Practice Michael Boffa, Allison
Weathers, Bichum Ouyang
2:15 p.m.
S11.006
Who Is My Physician? How
to Improve Communication
Between Patients and Health Care
Providers. Michelle Molina, Jared
Noroozi, Charlotte Zisman, Jin Li
2:30 p.m.
S11.007
Engaging Residents in Stroke Quality
Measures with Financial Incentives
and Electronic Checklist Marissa
Dean, Salman Rashid, Wilhelmine
Wiese-Rometsch, Camelia Arsene,
Corinne Hamstra, Suzanne White,
Syed Hussain
2:30 p.m.
S10.007
Advance Directives and Palliative
Care in ALS Patients. The Piedmont
and Valle D’Aosta Register
Experience Andrea Calvo, Umberto
Manera, Antonio Canosa, Davide
Bertuzzo, Stefania Cammarosano,
Cristina Moglia, Antonio Ilardi,
Adriano Chio
Fast, Easy, Online Registration · AAN.com/view/AM15
SWIFT-PRIME (Solitaire™ FR With the Intention For
Thrombectomy as Primary Endovascular Treatment for
Acute Ischemic Stroke) Trial
ESCAPE (Endovascular treatment for Small Core and
Anterior circulation Proximal occlusion with Emphasis on
minimizing CT to recanalization times) Trial
2:00 p.m–2:15 p.m.
REVASCAT (RandomizEd trial of reVasculArization
with Solitaire™ FR device vs. best mediCal therapy
in the treatment of Acute stroke due to anTerior
circulation large vessel occlusion presenting
within eight-hours of symptom onset) Trial
2:15 p.m–2:30 p.m.
From MERCI to MR CLEAN: Lessons Learned
About the Role of Mechanical Thrombectomy
in Acute Ischemic Stroke
2:30 p.m–2:45 p.m.
Facilitated Discussion with the Expert Panel
*Program subject to change
75
Tuesday
April 21
1:00 p.m.–2:45 p.m. Integrated Neuroscience Session
I7
Tuesday, April 21
The Global Burden of Neurological Infections:
Epidemiology, Treatment, and Prevention
1:00 p.m.–5:00 p.m.
Coordinators: Avindra Nath, MBBS, FAAN, and Igor J. Koralnik, MD
Part I
1:00 p.m.–2:45 p.m.
Part II
2:55 p.m.–4:35 p.m.
1:00 p.m.–1:05 p.m.
Introduction
2:55 p.m.–3:25 p.m.
Invited Speaker
1:05 p.m.–1: 35 p.m.
Invited Speaker
3:25 p.m.–3:30 p.m.
I7-3A Data Blitz
1:35 p.m.–1:40 p.m.
I7-1A Data Blitz
3:30 p.m.–3:35 p.m.
I7-3B Data Blitz
1:40 p.m.–1:45 p.m.
I7-1B Data Blitz
1:45 p.m.–1:55 p.m.
Audience Q&A
3:35 p.m.–3:45 p.m.
Audience Q&A
1:55 p.m.–2:25 p.m.
Invited Speaker
3:45 p.m.–4:15 p.m.
Invited Speaker
2:25 p.m.–2:30 p.m.
I7-2A Data Blitz
4:15 p.m.–4:20 p.m.
I7-4A Data Blitz
2:30 p.m.–2:35 p.m.
I7-2B Data Blitz
4:20 p.m.–4:25 p.m.
I7-4B Data Blitz
4:25 p.m.–4:35 p.m.
Audience Q&A
Avindra Nath, MBBS, FAAN, and Igor J. Koralnik, MD
Human African Trypanosomiasis (Sleeping Sickness) Peter G E Kennedy, MD
HIV Infection Serena Spudich, MD
The Changing Epidemiology of Stroke in Acquired Immune Deficiency Syndrome
(AIDS) Phillip Kucab, Pratik Bhattacharya
Cerebral Palsy in Children in Botswana: Outcomes and Comorbidities Esther
Baranov, James Baier, Baphaleng Monokwane, Esha Khurana, David Bearden
Etiologies of New Onset Seizure in HIV-infected Zambian Adults Omar Siddiqi,
Melissa Elafros, Izukanje Sikazwe, Chris Bositis, Igor Koralnik, Michael Potchen,
William Theodore, Lisa Kalungwana, Gretchen Birbeck
Higher Framingham Risk Score Is Associated with HIV-associated Dementia in
Rural Uganda Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja,
Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer
Chronic Meningitis Joseph R. Zunt, MD
West Nile Virus CNS Disease Kenneth L. Tyler, MD, FAAN
Neurocysticercosis and Epilepsy in Bhutan: A Cross-sectional Study Kate Brizzi,
Damber Nirola, Erica McKenzie, Sonam Deki, Lhab Tshering, Sonam Pelden,
Tshokey Tshokey, Chencho Dorji, Farrah Mateen
VCJD in the United States—Analysis of 4 Cases Devry Saenz, Danah Marafie,
Atul Maheshwari, Haitham Hussein
HIV Associated Neurocognitive Disorders (HAND) in Nigeria: Clinical Rating
Versus Global Deficit Score Methods Jibreel Jumare, Akolo Christopher, Mariana
Cherner, Anya Umlauf, Kanayo Okwuasaba, Lindsay Eyzaguirre, Ruxton Adebiyi,
Dakum Paul, Joyce Johnson, Terence Hendrix, Alash'le Abimiku, William Blattner,
Walter Royal
2:35 p.m.–2:45 p.m.
Audience Q&A
2:45 p.m.–2:55 p.m.
Break
HTLV-1-associated Myelopathy/tropical Spastic Paraparesis: Clinical and
Neuroimaging Findings Francisco Carod, Hudson Mesquita
Guided Poster Rounds
I7-5A
Myriad Manifestations of a
Global Infectious Disease Aparna Prabhu,
Ramya Raghupathi, Jonathan Dissin
I7-5B
Closing the Treatment
Gap for Neurological Diseases in Less
Resourced Countries Vijay Chandra,
Anwar Nazneen
I7-5C
Peripheral Neuropathy Is
Common and Associated with Functional
Impairment in HIV+ and HIV- Individuals
in Rural Uganda Deanna Saylor, Gertrude
Nakigozi, Noeline Nakasujja, Xiangrong
Kong, Kevin Robertson, Ronald Gray, Maria
Wawer, Ned Sacktor
I7-5D
Clinical, Laboratory
Findings and Complications of Scrub
Typhus- Meningoencephalitis: Case
Series Prasanna Venkatesan Eswaradass,
C Eswaradass
76
4:35 p.m.–5:00 p.m.
I7-5E
Detection of Human T-cell
Lymphotropic Virus Type I Proteins in
Exosomes from HAM/TSP Patient CSF
by Novel Nanotrap Technology Monique
Anderson, Benjamin Lepene, Fatah
Kashanchi, Steven Jacobson
I7-5F
The Changing Epidemiology
of Stroke in Acquired Immune Deficiency
Syndrome (AIDS) Phillip Kucab, Pratik
Bhattacharya
I7-5G
Cerebral Palsy in
Children in Botswana: Outcomes and
Comorbidities Esther Baranov, James
Baier, Baphaleng Monokwane, Esha
Khurana, David Bearden
I7-5H
VCJD in the United
States—Analysis of 4 Cases Devry
Saenz, Danah Marafie, Atul Maheshwari,
Haitham Hussein
I7-5I
HIV Associated
Neurocognitive Disorders (HAND) in
Nigeria: Clinical Rating Versus Global
Deficit Score Methods Jibreel Jumare,
Akolo Christopher, Mariana Cherner, Anya
Umlauf, Kanayo Okwuasaba, Lindsay
Eyzaguirre, Ruxton Adebiyi, Dakum Paul,
Joyce Johnson, Terence Hendrix, Alash'le
Abimiku, William Blattner, Walter Royal
I7-5J
Etiologies of New
Onset Seizure in HIV-infected Zambian
Adults Omar Siddiqi, Melissa Elafros,
Izukanje Sikazwe, Chris Bositis, Igor
Koralnik, Michael Potchen, William
Theodore, Lisa Kalungwana, Gretchen
Birbeck
I7-5K
Higher Framingham Risk
Score Is Associated with HIV-associated
Dementia in Rural Uganda Ned Sacktor,
Deanna Saylor, Gertrude Nakigozi,
Noeline Nakasujja, Xiangrong Kong, Kevin
Robertson, Ronald Gray, Maria Wawer
I7-5L
Neurocysticercosis and
Epilepsy in Bhutan: A Cross-sectional
Study Kate Brizzi, Damber Nirola, Erica
McKenzie, Sonam Deki, Lhab Tshering,
Sonam Pelden, Tshokey Tshokey, Chencho
Dorji, Farrah Mateen
I7-5MHTLV-1-associated
Myelopathy/tropical Spastic
Paraparesis: Clinical and Neuroimaging
Findings Francisco Carod, Hudson
Mesquita
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Integrated Neuroscience Session
I8
Advances in ALS and Other Motor Neuron Diseases
1:00 p.m.–5:00 p.m.
Coordinators: Catherine Lomen-Hoerth, MD, PhD, and Tahseen Mozaffar, MD, FAAN
1:00 p.m.–2:45 p.m.
Part II
2:55 p.m.–4:35 p.m.
1:00 p.m.–1:05 p.m.
Introduction
2:55 p.m.–3:25 p.m.
Invited Speaker
1:05 p.m.–1:35 p.m.
Invited Speaker
3:25 p.m.–3:30 p.m.
I8-3A Data Blitz
1:35 p.m.–1:40 p.m.
I8-1A Data Blitz
3:30 p.m.–3:35 p.m.
I8-3B Data Blitz
Catherine Lomen-Hoerth, MD, PhD, and Tahseen Mozaffar, MD, FAAN
ALS Clinical Trials: What Have We Learned Merit E. Cudkowicz, MD, MSC
Transplantation of an IPSC-derived CD15+CXCR4+VLA4+ Neural Stem Cell
Subpopulation as a New Therapy for ALS Chiara Simone, Monica Nizzardo,
Federica Rizzo, Monica Bucchia, Agnese Ramirez, Nereo Bresolin, Giacomo Comi,
Stefania Corti
1:40 p.m.–1:45 p.m.
I8-1B Data Blitz
A Single-center, Randomized, Double-blind, Placebo-controlled, Six-month
Clinical Trial Followed by an Open-label Extension to Evaluate the Safety,
Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase
Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral
Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 Benjamin Brooks, Elena
Bravver, Mohammed Sanjak, Velma Langford, Cynthia Lary, Mohamed Alwan,
Joanne Nemeth, Priscilla Russo, Nicole Smith, Nicole Lucas, Mindy Nichols,
Sharon Belcher, Kathryn Wright, Amber Ward, Scott Holsten, Michael Fischer,
William Bockenek, Urvi Desai, Scott C Lindblom, Thomas Pacicco, Kazuko
Matsuda, Joanna Dojillo
1:45 p.m.–1:55 p.m.
Audience Q&A
1:55 p.m.–2:25 p.m.
Invited Speaker
Advances in Our Understanding of the Basic Science of ALS Robert H. Brown Jr., MD, DPhil
2:25 p.m.–2:30 p.m.
I8-2A Data Blitz
Transthyretin as Potential Biomarker for C9ORF72-related Diseases Marka Van
Blitterswijk, NiCole Finch, Matthew Baker, Xue Wang, Kevin Bieniek, Mariely
Dejesus-Hernandez, Tania Gendron, Yan Asmann, Michael Heckman, Patricia
Brown, Keith Josephs, Joseph Parisi, David Knopman, Ronald Petersen, Leonard
Petrucelli, Bradley Boeve, Neill Graff-Radford, Kevin Boylan, Dennis Dickson, Rosa
Rademakers
2:30 p.m.–2:35 p.m.
Taking the Genetics of ALS to the Next Step Orla Hardiman, MD, FRCP, FAAN
Large-scale Exome Sequencing in ALS Identifies New Risk Genes and
Pathways Matthew Harms, Elizabeth Cirulli, Brittany Lasseigne, Tim Harris,
Richard Myers, David Goldstein
ATXN2 PolyQ Intermediate Repeat Modifies ALS Phenotype and
Survival Adriano Chio, Andrea Calvo, Cristina Moglia, Antonio Canosa, Gabriella
Restagno, Maura Brunetti, Marco Barberis, Amelia Conte, Giuseppe Marangi,
Serena Lattante, Marcella Zollino, Mario Sabatelli, Lucia Corrado, Gabriele Mora,
Letizia Mazzini, Sandra D'Alfonso
3:35 p.m.–3:45 p.m.
Audience Q&A
3:45 p.m.–4:15 p.m.
Invited Speaker
4:15 p.m.–4:20 p.m.
I8-4A Data Blitz
4:20 p.m.–4:25 p.m.
I8-4B Data Blitz
4:25 p.m.–4:35 p.m.
Audience Q&A
The Overlap of ALS and Frontotemporal dementia Michael J. Strong, MD, FAAN
Grey and White Matter MRI Signatures of the Frontotemporal Lobar
Degeneration Continuum Massimo Filippi, Federica Agosta, Sebastiano
Galantucci, Giuseppe Magnani, Alessandra Marcone, Daniele Martinelli, M.
Antonietta Volonte, Nilo Riva, Sandro Iannaccone, Pilar Ferraro, Francesca Caso,
Adriano Chio, Andrea Falini, Giancarlo Comi
Longitudinal Assessment of Frontal Cognitive Impairment in Patients with Motor
Neuron Disease Pilar Maria Ferraro, Federica Agosta, Edoardo Spinelli, Elisa
Canu, Nilo Riva, Massimiliano Copetti, Andrea Falini, Giancarlo Comi, Massimo
Filippi
I8-2B Data Blitz
The ALS/FTD C9ORF72 Hexanucleotide Expansion Disrupts Nucleocytoplasmic
Transport Thomas Lloyd, Ke Zhang, Chris Donnelly, Jeffrey Rothstein
2:35 p.m.–2:45 p.m.
Audience Q&A
2:45 p.m.–2:55 p.m.
Break
Guided Poster Rounds
I8-5A
ALS and Military
Occupation: A Population-based
Case-control Study in the Danish
Registries Ryan Seals, Marianthi-Anna
Kioumourtzoglou, Johnni Hansen, Ole
Gredal, Marc Weisskopf
I8-5B
Head Injury Does Not Alter
Disease Progression or Neuropathological
Outcomes in ALS Christina Fournier, Marla
Gearing, Saila Upadhyayula, Mitch Klein,
Jonathan Glass
I8-5C
Threshold Tracking
TMS: A Novel Diagnostic Technique for
Amyotrophic Lateral Sclerosis Nimeshan
Geevasinga, Parvathi Menon, Con
Yiannikas, James Howells, Matthew
Kiernan, Steve Vucic
I8-5D
Advance Directives and
Palliative Care in ALS Patients. The
Piedmont and Valle D’Aosta Register
Experience Andrea Calvo, Umberto
Manera, Antonio Canosa, Davide Bertuzzo,
Stefania Cammarosano, Cristina Moglia,
Antonio Ilardi, Adriano Chio
4:35 p.m.–5:00 p.m.
I8-5E
The ALSUntangled Table of
Evidence Richard Bedlack
I8-5F
Transplantation of an
IPSC-derived CD15+CXCR4+VLA4+
Neural Stem Cell Subpopulation as a New
Therapy for ALS Chiara Simone, Monica
Nizzardo, Federica Rizzo, Monica Bucchia,
Agnese Ramirez, Nereo Bresolin, Giacomo
Comi, Stefania Corti
I8-5G
A Single-center,
Randomized, Double-blind, Placebocontrolled, Six-month Clinical Trial
Followed by an Open-label Extension
to Evaluate the Safety, Tolerability and
Clinical Endpoint Responsiveness of
the Phosphodiesterase Type 4 (PDE4)
Inhibitor Ibudilast (MN-166) in Subjects
with Amyotrophic Lateral Sclerosis
(ALS) - STEP-IBUDILAST-ALS-DBOLE-1 Benjamin Brooks, Elena Bravver,
Mohammed Sanjak, Velma Langford,
Cynthia Lary, Mohamed Alwan, Joanne
Nemeth, Priscilla Russo, Nicole Smith,
Nicole Lucas, Mindy Nichols, Sharon
Belcher, Kathryn Wright, Amber Ward,
Fast, Easy, Online Registration · AAN.com/view/AM15
Scott Holsten, Michael Fischer, William
Bockenek, Urvi Desai, Scott C Lindblom,
Thomas Pacicco, Kazuko Matsuda, Joanna
Dojillo
I8-5H
Transthyretin as
Potential Biomarker for C9ORF72-related
Diseases Marka Van Blitterswijk, NiCole
Finch, Matthew Baker, Xue Wang, Kevin
Bieniek, Mariely Dejesus-Hernandez, Tania
Gendron, Yan Asmann, Michael Heckman,
Patricia Brown, Keith Josephs, Joseph
Parisi, David Knopman, Ronald Petersen,
Leonard Petrucelli, Bradley Boeve, Neill
Graff-Radford, Kevin Boylan, Dennis
Dickson, Rosa Rademakers
I8-5I
The ALS/FTD C9ORF72
Hexanucleotide Expansion Disrupts
Nucleocytoplasmic Transport Thomas
Lloyd, Ke Zhang, Chris Donnelly, Jeffrey
Rothstein
I8-5J
Large-scale Exome
Sequencing in ALS Identifies New Risk
Genes and Pathways Matthew Harms,
Elizabeth Cirulli, Brittany Lasseigne, Tim
Harris, Richard Myers, David Goldstein
I8-5K
ATXN2 PolyQ Intermediate
Repeat Modifies ALS Phenotype and
Survival Adriano Chio, Andrea Calvo,
Cristina Moglia, Antonio Canosa, Gabriella
Restagno, Maura Brunetti, Marco Barberis,
Amelia Conte, Giuseppe Marangi, Serena
Lattante, Marcella Zollino, Mario Sabatelli,
Lucia Corrado, Gabriele Mora, Letizia
Mazzini, Sandra D'Alfonso
I8-5L
Grey and White Matter MRI
Signatures of the Frontotemporal Lobar
Degeneration Continuum Massimo Filippi,
Federica Agosta, Sebastiano Galantucci,
Giuseppe Magnani, Alessandra Marcone,
Daniele Martinelli, M. Antonietta Volonte,
Nilo Riva, Sandro Iannaccone, Pilar Ferraro,
Francesca Caso, Adriano Chio, Andrea
Falini, Giancarlo Comi
I8-5M
Longitudinal Assessment of
Frontal Cognitive Impairment in Patients
with Motor Neuron Disease Pilar Maria
Ferraro, Federica Agosta, Edoardo Spinelli,
Elisa Canu, Nilo Riva, Massimiliano Copetti,
Andrea Falini, Giancarlo Comi, Massimo
Filippi
77
Tuesday
April 21
Part I
Poster Session III
Tuesday, April 21
P3 Poster
Session III
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Discussion Session: Movement Disorders
2:00 p.m.–6:30 p.m.
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
P3.001 Identifying Parkinson Disease
with Non-motor Features and CSF
Biomarkers: A Case-control Study Samay
Jain, Seo Young Park, Diane Comer,
Deborah Rudoy, Larry Ivanco
P3.002 A New Screening Tool
for Behavioral Disturbances in HD:
The Huntington’s Disease-behavioral
Questionnaire (HD-BQ) Jody Corey-Bloom,
Andrew Herndon, Anastasia Lam, Daniel
Goble, Paul Gilbert
P3.003 New Observations in the
Fragile-X Associated Tremor/Ataxia
Syndrome (FXTAS) Phenotype Avram
Fraint, Padmaja Vittal, Aimee Szewka, Bryan
Bernard, Elizabeth Berry-Kravis, Deborah
Hall
P3.004 Global Long-term Registry on
Efficacy and Safety of Levodopa-Carbidopa
Intestinal Gel in Patients with Advanced
Parkinson’s Disease in Routine Care
(GLORIA)—Interim Results on Non-motor
Symptoms Angelo Antonini, K. Ray
Chaudhuri, Ashley Yegin, Lars Bergmann,
Werner Poewe
P3.005 Embouchure Dystonia:
Phenomenology, Natural History and
Mimicks Pichet Termsarasab, Steven Frucht
P3.007 Non-motor Symptoms in Early
Drug-naive Parkinson Disease Rui Liu,
David Umbach, Shyamal Peddada, Zongli
Xu, Alexander Tröster, Xuemei Huang,
Honglei Chen
P3.008 Analysis of Heart Rate
Variability in Functional Movement
Disorder Patients Victoria Liu, Carine
Maurer, Kathrin LaFaver, Ryan Toledo, Mark
Hallett
P3.006 Neuroanatomical Correlates
of Cognitive Functioning Across
the Parkinson's Disease Cognitive
Spectrum Doug Merkitch, Glenn Stebbins,
Bryan Bernard, Jennifer Goldman
P3.009 XCiDaBLE: An Observational,
Prospective Trial Evaluating Xeomin
(incobotulinumtoxinA) for Cervical Dystonia
or Blepharospasm in the United States—
Final Results from the Cervical Dystonia
Cohort Hubert Fernandez, Fernando Pagan,
Fabio Danisi, David Greeley, Kapil Sethi,
Amit Verma
P3.010
Reorganization of Corticostriatal Circuits in Healthy G2019S LRRK2
Carriers Rick Helmich, Avner Thaler,
Bart van Nuenen, Tanya Gurevich, Anat
Mirelman, Karen Marder, Susan Bressman,
Avi Orr-Urtreger, Nir Giladi, Bastiaan Bloem,
Ivan Toni
e-Poster Session: Movement Disorders
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P3.011
Abnormal Climbing Fiberpurkinje Cell Synaptic Connections in the
Essential Tremor Cerebellum Sheng-Han
Kuo, Chi-Ying Lin, Elan Louis, Phyllis Faust,
Arnulf Koeppen, Jean Paul Vonsattel
P3.012
Intracranial Germinoma
Associated Rubral Tremor Mimicking
Neuro-Behcet Disease: Importance of a
Tissue Diagnosis Roy Strowd, Peter Burger,
Matthias Holdhoff, Lawrence Kleinberg,
Alessandro Olivi, Carlos Pardo-Villamizar,
Michael Okun, Nicoline Shiess
P3.013
5-Meo-DALT-induced Cyclic
Myoclonus Thananan Thammongkolchai,
Pichet Termsarasab, Ayham Alkhachroum,
Yogesh Gujrati, Steven Frucht, Bashar Katirji
Movement Disorders: Myoclonus,
Paroxysmal Dyskinesias, and
Parkinson's Disease
P3.014
Zonisamide Responsive
Familial Myoclonus Dystonia Pavan
Tummala, Pratap Chand
P3.015
Ultrasound as Diagnostic
Tool for Diaphragmatic Myoclonus: A Case
Report Vesper Fe Marie Ramos, Barbara
Karp, Codrin Lungu, Katharine Alter, Mark
Hallett
P3.016
Impaired DNA Damage
Response in the Pathogenesis of Multiple
System Atrophy: A Histopathological
Study Rhea Yan Ying Tan, Kiyobumi Ota,
Hidehiro Mizusawa, Takanori Yokota, Kinya
Ishikawa
P3.023 Motor Abilities and Driving
as an Unusual Presentation of Multiple
Sclerosis Samar Ahmed, Jasem Al-Hashel,
R Khan, Raed Alroughani
Performance in Parkinson’s Disease
(PD) Ion Beratis, Nikos Andronas, Dionysia
Kontaxopoulou, Stella Fragkiadaki,
Athanasia Liozidou, Alexandra Economou,
John Papatriantafyllou, Panagiotis
Papantoniou, Leonidas Stefanis, George
Yannis, Sokratis Papageorgiou
P3.022 Demographics, Comorbidities
P3.024Levodopa/Carbidopa
P3.021 Spinal Segmental Myoclonus
and Clinical Features in Hospitalized
Patients with Myoclonus Debra Ehrlich,
Matthew Swan, Matthew Robbins, Steven
Herskovitz, Mark Milstein
78
Intestinal Gel Infusion Therapy in Advanced
Parkinson Disease—the Saudi Arabian
Experience Bohlega Saeed, Thamer
Alkhairallah, Fahad Alajlan, Hussam Abou
Al-Shaar, Nael Hasan, Khalid Alkahtani
P3.017
White Matter Abnormalities
as a Marker of Parkinson’s Disease
Cognitive Impairment: A Diffusion Tensor
Imaging Study Jennifer Goldman, Doug
Merkitch, Bryan Bernard, Glenn Stebbins
P3.019Withdrawn
P3.020 Increased Pain Sensitivity
P3.018
and Increased Impulsivity Appear
Related: Pain-related FMRI in Parkinson’s
Disease Bradley Avery, Robert Coghill,
Ihtsham Haq
P3.025 The Effects of Comorbid
P3.027 MODERATO, a Randomized,
Helicobacter Pylori Infection
Is Associated with Worse Severity of
Parkinson’s Disease Ai Huey Tan, Sanjiv
Mahadeva, Abdul Malik Thalha, Chiun
Khang Kiew, Chia Ming Yeat, Sheang
Wen Ng, Sheau Phing Ang, Siew Kian
Chow, Mun Fai Loke, Jamunarani Vadivelu,
Norlinah Ibrahim, Hoi Sen Yong, Chong-Tin
Tan, Susan Fox, Connie Marras, Anthony
Lang, Shen Yang Lim
Traumatic Brain Injury on Motor and
Non-motor Symptoms of Parkinson’s
Disease Catherine Stachnik, Brandon
Barton
P3.026 Rotigotine in Combination
with the MAO-B Inhibitor Selegiline in
Early Parkinson’s Disease: A Post-hoc
Analysis Mahnaz Asgharnejad, Lars Bauer,
Frank Grieger, Babak Boroojerdi
Double-blind, Placebo-controlled Study
to Assess the Effect of Rasagiline on
Mild Cognitive Impairment in Patients
with Parkinson’s Disease: An Ongoing
Study Daniel Weintraub, Robert Hauser,
Azhar Choudhry
Movement Disorders: Tics,
Dyskinesias, and Chorea
P3.028 Isolated Lingual Dyskinesias
in Multiple Sclerosis Jung Park, Katharine
Alter, Mark Hallett
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session III
P3.029 Co-occurrence of Klinefelter
Syndrome and Tourettism: A Case
Report Leonardo Brito De Almeida,
Michael Okun, Irene Malaty
P3.030 Mutations in the AMPA
Receptor Complex Protein FRRS1L Cause
an Inherited Huntington-like Choreadementia Syndrome Mustafa Salih,
Marianna Madeo, Lauren Fields, Tyler
Jepperson, Mohammed Seidahmed, Heba El
Khashab, Muddathir Hamad, Michael Kruer
P3.031 A Movement Disorders
Paradox: Case Report of a Patient with
Gene-positive Huntington’s Disease
Who Presented with DaTScan Positive
and Levodopa Responsive Parkinson’s
Disease Ryan Hadden, Victor Sung
P3.032 Refractory Dyskinetic
Movements Associated with NMDA
Encephalitis Abdulrahman Alwaki,
Christopher Goshgarian, Khadija Irshad,
Arun Chandok
P3.033 Hemichorea in a Patient with
Diabetic Ketoacidosis Ahmed Yassin,
Sheetal Shroff, Shrestha Patel, Asif Parker,
Megan Berman, George Jackson
P3.042 Assessing Migraine: An
Enquiry into Prophylactic Treatment
Patterns by Diagnosis: The AMEND
Study Anoop Reddy, Amanda Policastro,
Albert Reppine, John Sekab, Chris Purdy,
Laura Dalfonso, Raf Magar
P3.043 Headache in Patients with
Celiac Disease and Its Response to Glutenfree Diet Ameghino Lucía, Mauricio Farez,
Ismael Calandri, Maria Goicochea
P3.044 Overdiagnosis of Idiopathic
Intracranial Hypertension (IIH) Adeniyi
Fisayo, Valerie Biousse, Nancy Newman,
Beau Bruce
P3.045 Not Everything That
Worsens on Standing Is Intracranial
Hypotension! Kaustubh Limaye, Zabeend
Mahuwala, Ricky Lee
P3.046 Development of an Interactive
Educational Bedside Assessment Tool with
Validation in Headache Clinic Daniel Fok,
Aravind Ganesh, Rahul Mehta, Nathalie
Jette, Lara Cooke
P3.047 Breath Powered™ Nasal
in Chorea Complicating Common
Variable Immune Deficiency (CVID) with
Subcutaneous Immunoglobulin (SCIG)
Infusions Ravdeep Kaur, Leslie Cristiano,
Guha Krishnaswamy
Delivery of 22 Mg Sumatriptan Powder
(AVP-825): An Exploratory Analysis of
Response in Migraine Patients Grouped
by Baseline Headache Intensity from the
Phase 3 TARGET Study Roger Cady, Peter
McAllister, Egilius Spierings, John Messina,
Per Djupesland, Scott Siegert, Ken Shulman,
Ramy Mahmoud
P3.035 Paroxysmal Kinesigenic
P3.048Subarachnoid
P3.034 Prolonged Remission
Dyskinesia in Taiwan: A Genetic and
Clinical Study of 57 Patients Yo-Tsen Liu,
Yi-Chung Lee, Chien Chen, Shang-Yeong
Kwan, Bing-Wen Soong
P3.036 ADCY5 Genetic Screening
in Benign Early Onset Chorea Niccolò
Mencacci, Roberto Erro, Joshua Hersheson,
Sarah Wiethoff, Nicholas Wood, Henry
Houlden, Kailash Bhatia
Headache
P3.037 Idiopathic Stabbing Headache
in Children and Adolescents Gabriel Mandel
Pneumocephalus: A Cause of Severe
Headache as a Result of Obstetric Epidural
Anesthesia Fahed Saada, Robert Mannel,
Suparna Krishnaiengar
P3.049 SUNCT Responding to
Botulinum Toxin Subhashie Wijemanne,
Joseph Jankovic
P3.050 The Association Between
Functional Abdominal Symptoms and
Migraine in Adult Patients Providing More
Evidence That Abdominal Migraine Occurs
in Adults Christi Pendergraft, David Gordon,
David Thompson
P3.038 Characterization of
P3.051
P3.039 Refractory Chronic Cluster
P3.052 Status Migrainosus:
Headache Features in FMR1 Premutation
Carriers Stuart Bergman-Bock, Maura
Walsh, Elizabeth Berry-Kravis, Deborah Hall
Headache: A Consensus Statetment on
Clinical Definition from the European
Headache Federation Dimos Dimitrios
Mitsikostas
P3.040 Comparison of Serum
S100B and Neuron Specific Enolase
Levels in Episodic Migrane and Chronic
Migrane Patients and Their Value for
Etiopathogenesis Muhammed Berilgen,
Murat Gonen, Bülent Müngen, Caner Demir,
Sevim Ozdogan
P3.041 Long-term Safety of the ATI
Neurostimulation System for the Treatment
of Cluster Headache Anthony Caparso,
Soren Hillerup, Jorgen Rostgaard, Alexandre
Assaf, Tim Jurgens, Mads Barloese,
Miguel Lainez, Michelle-Olivia Bigazzi, Amy
Goodman, Rigmor Jensen, Arne May
Cost-effective Approach to
the Chemodenervation Using Onabotulinum
ToxinA: An Observational Study Prityi Rani,
Jessy Walia, Niranjan Singh, Irving Asher
Predictors of Longer Hospital Stay Sumul
Modi, Devanshi Dharaiya
P3.053 Autonomic Dysfunction in
Adolescents with Headaches Augusto
Morales, Stoichita Andreea, Jessica Demarest
P3.054 High-volume Suboccipital
Nerve Injections for Chronic Cluster
Headache with Long-term Efficacy
Data Todd Rozen
P3.055 Amitriptyline in
the Management of Cluster
Headache Natarajan Visvanathan,
Mutharasu Chinnu, Radha Mahadevan
P3.056 Outcome of 370 Patients with
Trigeminal Neuralgia Who Underwent
Microvascular Decompression with Silastic
Graft Between 1997 and 2014 Corlos Bangel
Fast, Easy, Online Registration · AAN.com/view/AM15
P3.057 Evolution of the Impact of
Headache in an Exceptional Context of
External Operations, Studied Through
a Military Population in Afghanistan,
Assigned to the Staff of the Kaia's Military
Field Hospital Laurent Guilloton, Ondine
Bruneau, Marion Trousselard, Pierre Antoine
Blanc, Thierry de Greslan, Alain Drouet,
Fabien Zagnoli
P3.058 Neurologic Complications of
Osler-Weber-Rendu Syndrome: A Case
Report and Literature Review Salman
Farooq, Ashkan Mowla, Mahmoud
AbdelRazek, Azher Iqbal, Robert Sawyer
P3.059 Secondary Efficacy Outcomes
from COMPASS: A Comparison of Breath
Powered™ Device Containing 22 Mg
Sumatriptan Powder (AVP-825) Versus
Oral 100 Mg Sumatriptan in Episodic
Migraine Stephen Silberstein, Stewart
Tepper, Roger Cady, John Messina, Ramy
Mahmoud, Per Djupesland, Paul Shin, Joao
Siffert
P3.060 Sjögren’s Syndrome, an Underdiagnosed Etiology of Facial Pain? Hossein
Ansari
P3.061
Novel SLC20A2 Gene
Mutations Causing Idiopathic Basal
Ganglia Calcification in Two Italian Patients
Presenting with Migraine Elisa Rubino,
Elisa Giorgio, Innocenzo Rainero, Patrizia
Ferrero, Salvatore Gallone, Lorenzo Pinessi,
Laura Orsi, Salvatore Gentile, Sergio Duca,
Alfredo Brusco
P3.062 Cluster Headache—a
Nationwide Study of 387 Cases Maria
Eduarda Nobre De M Costa
P3.063 Intracranial Hypotension
Manifesting as Recurrent Thunderclap
Headache with Aphasia Michael Ruff
P3.064 Central Vestibular
System Modulation in Vestibular
Migraine—a Voxel-based Morphometry
Study Sebastian Wurthmann, Steffen
Naegel, Nina Theysohn, H. Diener, Mark
Obermann
P3.065 An Unusual Case of Post-
traumatic Headache Complicated by
Intracranial Hypotension Sara Siavoshi,
Carrie Dougherty, Jessica Ailani
P3.066 A FORMal Analysis: An
Analysis of UCNS Certified Headache
Center Patient Intake Forms Roni Sharon,
Paul Mathew, Joseph Viknevich, Melissa
Rayhill, Larry Charleston
Cerebrovascular Disease and
Interventional Neurology:
Ischemic Stroke Outcome
P3.067 The Effects of Clinical
Variables on Functional Outcomes in
Patients Undergoing Decompressive
Hemicraniectomy for Malignant MCA
Infarctions Kader Abdelerahman, Varoon
Thavapalan, Carissa Pineda, Fred Rincon,
Rodney Bell, Matthew Vibbert
P3.068 Recanalization and Initial Poor
Collateral Circulation Determine the Effect
of Collateral Recruitment on Functional
Outcomes Benjamin Yong Qiang Tan,
Kong Yee, Hock Luen Teoh, Raymond Seet,
Bernard Chan, Rahul Rathakrishnan, Derek
Soon, Vijay Sharma, Leonard Yeo
P3.069 A Mobile Application for
Predicting 90-day Outcomes After IV
Thrombolysis in Ischemic Stroke Karin
Nystrom, David Asuzu, Hardik Amin, Joseph
Schindler, Charles Wira, David Greer, Nai
Fang Chi, Janet Halliday, Kevin Sheth
P3.070 Mechanisms and Outcomes
of Ischemic Stroke in Pregnancy and
Postpartum: A Retrospective Crosssectional Study Eliza Miller, Shadi Yaghi,
Amelia Boehme, Joshua Willey, Mitchell
Elkind, Randolph Marshall
P3.071 Effect of Cigarette Smoking
on Outcomes of Acute Ischemic Stroke
Treated with Intravenous Thrombolysis: Is
There Any Paradox in the Brain? Haitham
Hussein, Nicki Niemann, Logan Stuck,
Adnan Qureshi
P3.072 Predictors of Early Mortality
and Bad Outcome in Ischemic Stroke Ariel
Luzzi, Maria Zurru, Claudia Alonzo, Laura
Brescacin, Santiago Pigretti, Luis Camera,
Pedro Colla Machado, Gabriel Waisman,
Edgardo Cristiano
P3.073 Does Emergency Department
Length of Stay Affect the 90-day
Functional Outcome After Acute Ischemic
Stroke? Anand Patel, Artin Minaeian, Ajay
Tunguturi, Richard Goddeau, Nils Henninger
P3.074
Elevated VLDL Is Associated
with Cardioembolic Stroke and Improved
Functional Outcome in Patients with
Acute Ischemic Stroke Alexander George,
Dominique Monlezun, Jr, Alyana Samai,
Elizabeth Waring, Lauren Dowell, Melisa
Valmoria, Sheryl Martin-Schild
P3.075 Does the Grade of Diastolic
Dysfunction Predict Short-term Outcomes
of Acute Ischemic Stroke Patients? Melisa
Valmoria, Dominique Monlezun, Jr, Marco
Elegante, Lauren Dowell, Elizabeth Warren,
Alexander George, Ramy El-Khoury, Sheryl
Martin-Schild
P3.076
Persistent Elevation of Factor
VIII and Long-term Patient Outcomes in
Ischemic Stroke Alyana Samai, Amelia
Boehme, Alexander George, Lauren Dowell,
Laurie Schluter, Ramy El Khoury, Sheryl
Martin-Schild
Cerebrovascular Disease and
Interventional Neurology:
Hemorrhagic and Ischemic
Stroke
P3.077 Clinical Outcomes of
Metastatic Intra-cerebral Hemorrhage and
Role of Acute Radiotherapy Umair Afzal,
Michael Mendoza, Julius Latorre
P3.078 Seasonal and Barometric
Variations in the Incidence of Lobar and
Deep Intracerebral Hemorrhage Asaf
Honig, Ruth Eliahu, Ronen Leker
79
Tuesday
April 21
2:00 p.m.–6:30 p.m.
Poster Session III2:00 p.m.–6:30 p.m.
P3.079 On What Type of ICH Patient
Do Neurologists Order EEG? Alissa
Gadpaille, Amelia Boehme, Karen Albright,
Kara Sands, Harn Shiue, Mark Harrigan
P3.080 Seizures in Subcortical
Ischemic and Hemorrhagic Strokes Robin
Dharia, Carissa Pineda
P3.081 Effect of Weekend Admission
on Inhospital Outcomes Among Children
with Ischemic and Hemorrhagic
Strokes Malik Adil, Gabriel Vidal, Ahmed
Malik, Mushtaq Qureshi, Adnan Qureshi
P3.082 A Population-based Study
of the Incidence and Case Fatality of
Intracerebral Hemorrhage of Undetermined
Etiology Afzal Mohammad, Mushtaq
Qureshi, Ahmed Malik, Mariam Suri,
Muhammad Suri, Adnan Qureshi
P3.083 Implication of Deep Versus
Cortical Ischemia on DWI-aspects in
Anterior Circulation Large Vessel Occlusion
Ischemic Stroke Christopher Streib, Srikant
Rangaraju, Ashutosh Jadhav, Tudor Jovin
P3.084 CT Angiogram Helps to Predict
Ischemic Stroke in Dizzy Patients, but NOT
Better Than the Clinical Examination Karen
Chen, Andrea Schneider, Elisabeth Marsh
P3.085 Embolic Stroke with
Spontaneous Recanalization Sourabh
Lahoti, Sankalp Gokhale, Louis Caplan,
Patrik Michel, Yves Samson, Charlotte
Rosso, Kaustubh Limaye, Archana Hinduja,
Aneesh Singhal, Syed Ali, Richard Kryscio,
Nikita Dedhia, Shirish Hastak, David
Liebeskind, L Pettigrew
P3.091 Validation of the ICH Score
and Predicting ICH Outcomes in the
Modern Neurological Intensive Care
Unit Omran Kaskar, Larry Goldstein,
Michael James
P3.092 Time-to-INR Reversal,
Predictors of Hematoma Expansion and
In-hospital Mortality in Warfarin-related
Intracerebral Hemorrhage Richa Patel,
Hesham Masoud, Helena Lau, Jose Romero,
Viken Babikian, Joseph Burns, Carlos Kase,
Ashkan Shoamanesh
P3.093 Admission Hypomagnesemia
Predicts Primary Intracerebral Hemorrhage
Volume Harn Shiue, Amelia Boehme, Kara
Sands, Sheryl Martin-Schild, Angela Hays
Shapshak, Michael Lyerly, Alissa Gadpaille,
Ayaz Khawaja, April Sisson, Muhammad
Alvi, Alexander George, Mark Harrigan
P3.094 Significance of Hemodynamic
P3.086 Intraventricular Hemorrhage
P3.095 Accessing Care for
Intracerebral Hemorrhage: An Unexpected
Paradox? Michael Lyerly, Karen Albright,
Reza Bavarsad Shahripour, Kara Sands,
Harn Shiue, April Sisson, Mark Harrigan
P3.096 Warfarin and Antiplatelet
Symptom of ICH Patient Characteristics
and EEG Utilization Alissa Gadpaille, Karen
Albright, Amelia Boehme, Muhammad Alvi,
Kara Sands, Ayaz Khawaja, Harn Shiue,
Mark Harrigan
Medication Use Are Independently
Associated with Poor Functional Outcomes
Following Spontaneous Intracerebral
Hemorrhage Santosh Murthy, Yogesh
Moradiya, Jesse Dawson, Kennedy Lees,
Daniel Hanley, Wendy Ziai
P3.088 Troponin Elevation
P3.097 CT Angiography
in Spontaneous Intracranial
Hemorrhage Pavan Tummala, Nabil
Makhlouf, Abhay Kumar
P3.089 Review of Primary
Intraventricular Hemorrhage Reveals
Dichotomous Outcomes Bilaal Sirdar,
Sarah Song, Kathryn Ess, Renee Jhu,
Shawna Cutting
P3.090 Predictors and Outcome of
Mechanical Ventilation for Patients with
Primary Intracerebral Hemorrhage Ayaz
Khawaja, Amelia Boehme, Angela Hays
Shapshak, David Miller, Reza Bavarsad
Shahripour, Muhammad Alvi, Gyanendra
Kumar, Mark Harrigan
80
P3.101
Interdisciplinary Project Aimed
at Reducing the Duration of Intravenous
Nicardipine in Intracerebral Hemorrhage
Patients Lynn Do, Justin Petrovic, Carmil
Azran, Kathryn Crozier, S. Josephson
P3.102
Apolipoprotein E4 Allele
Increases Total Cholesterol and Lowdensity Lipoprotein Levels in Primary
Intracerebral Hemorrhage Chia-Ling Phuah,
Miriam Raffeld, Alison Ayres, Alessandro
Biffi, Anand Viswanathan, Steven Greenberg,
Jonathan Rosand, Christopher Anderson
Attend the AAN Business Meeting at 8:00 a.m. on
Monday, April 20, during the 2015 AAN Annual Meeting
in Washington, DC, to make your voice heard on matters
of importance to you, and cast your vote for the 2015
AAN Board of Directors. Learn more about the nominees
at AAN.com/view/BoardSlate .
and Heart Rate Variability in the Acute
Phase of Spontaneous Intra-Cerebral
Hemorrhage Michael Mendoza, Sameer
Sharma, Julius Gene Latorre
P3.087 Seizure as the Presenting
Incidence of Ischemic Strokes
in the Minimally Invasive Surgery Plus
Rt-PA for Intracerebral Hemorrhage
Evacuation (MISTIE II) Phase II Clinical
Trial Lucia Rivera Lara, Saman NekoovaghtTak, Rachel Dlugash, Nichol McBee, Mario
Zuccarello, Daniel Hanley, Wendy Ziai
Have a Voice in Your Academy
Cerebrovascular Disease and
Interventional Neurology:
Intracerebral Hemorrhage
Growth Is Associated with Worse
Functional Outcomes After Intracerebral
Hemorrhage Matthew Maas, Anna
Romanova, Michael Berman, Brandon
Francis, Eric Liotta, Andrew Naidech
P3.100
in Spontaneous Intracerebral
Hemorrhage Swarna Rajagopalan, Laura
Cifrese, S Azizi
P3.098 Prophylactic Anticonvulsants
in Intracerebral Hemorrhage Jason
Mackey, Ashley Blatsioris, Elizabeth Moser,
Ravan Carter, Angie Reagan Secrest,
Abigail Hulin, Darren O'Neill, Aaron CohenGadol, Thomas Leipzig, Linda Williams
P3.099Decompressive
Hemicraniectomy for Spontaneous
Supratentorial Intracerebral Hemorrhage:
A Descriptive Analysis Kasey Gildersleeve,
Mohammad Hirzallah, Renga Pandurengan,
Nicole Gonzales
P3.103
The Prevalence of
Admission Leukocytosis and Systemic
Inflammatory Response Syndrome
(SIRS) in Intracerebral Hemorrhage (ICH)
Patients and Its Association with Primary
Infection Shaheryar Hafeez, Alicia Zha,
Noah Grose, Sunil Mutgi, Reza Behrouz
Cerebrovascular Disease and
Interventional Neurology:
Subarachnoid Hemorrhage
P3.104
Neurocritical Care Outcomes
in Angiogram-negative Subarachnoid
Hemorrhage Michael Errico, Alejandro
Spiotta, Aquilla Turk, III, Raymond Turner,
Imran Chaudry, Julio Chalela
P3.105
Global Cerebral Edema After
Subarachnoid Hemorrhage Is Associated
with a Peripheral Immune Response Kaushik
Parsha, Suhas Bajgur, Nasim Rezanejad,
Nancy Edwards, Tiffany Chang, Kiwon Lee,
Sean Savitz, Huimahn Choi
P3.106
Outcomes in Subarachnoid
Hemorrhage After the Introduction of
a Neurocritical Care Service Jamie
LaBuzetta, Cynthia Gonzalez, Josh
Duckworth, Brian Lemkuil, Anushirvan
Minokadeh, Navaz Karanjia
P3.107
Clinical Spectrum of
Nontraumatic Convexity Subarachnoid
Hemorrhage Vivien Lee, James Conners,
Sayona John, Rajeev Garg
P3.108
Treatment of Ruptured
Intracranial Aneurysms with the Pipeline
Embolization Device Norman Ajiboye
P3.109
Alpha-1 Antitrypsin Deficiency
in Cerebral Aneurysms Ali Mahta, Michael
Weaver, Francis Kueppers
P3.110
Effect of Age on Transcranial
Doppler Velocities in Patients with
SAH Michelle Nunes, Ivan Silva, Ari
Wachsman, Joao Gomes, Javier Provencio
P3.111
Hormone Replacement
Therapy and the Risk of Subarachnoid
Hemorrhage in Post-menopausal
Women Omar Saeed, Ahmed Malik, Adnan
Qureshi
P3.112
Ultra Early Vasospasm
Following Subarachnoid Hemorrhage
Associated with Increased Morbidity and
Mortality Poor Outcome Fawaz Al-Mufti,
Michael Schmidt, Emma Mayer, Shouri
Lahiri, Neha Dangayach, Soojin Park, Sachin
Agarwal, Stephan Mayer, Jan Claassen
Cerebrovascular Disease and
Interventional Neurology:
Subarachnoid Hemorrhage and
Miscellany
P3.113
A Population-based Study
of the Incidence and Case Fatality
of Non-aneurysmal Subarachnoid
Hemorrhage Adnan Qureshi, Nauman
Jahangir, Mushtaq Qureshi, Archie Defillo,
Ahmed Malik, Muhammad Suri
P3.114
Impact of Menopausal Age on
Size of Unruptured Intracranial Aneurysms
and Their Outcomes with Endovascular
Therapy Sushrut Dharmadhikari, Kunakorn
Atchaneeyasakul, Norman Ajiboye, Sudheer
Ambekar, Dileep Yavagal
P3.115
Ruptured Giant Middle
Cerebral Artery Aneurysm in Infancy Reem
Al Youbi, Mohammed Jan
P3.116
A Decade After International
Subarachnoid Aneurysm Trial: Coiling as a
First Choice Treatment in the Management
of Intracranial Aneurysms—Technical
Feasibility and Early Management
Outcomes Gurmeen Kaur, Gaurav Goel,
Vipul Gupta, Swati Chinchure, Aditya Gupta,
Ajaya Jha
P3.117
Loading Doses of Aspirin
and Clopidogrel Prior to Enterprise
Stent-assisted Repair of Intracranial
Aneurysm—a Pilot Study Yahia Lodi,
Varun Reddy, Ashok Devasenapathy, Karmel
Shehadeh, Anas Hourini, Chun-An Chou
P3.118
Outcome of Aneurysmal
Subarachnoid Hemorrhage at a
Comprehensive Stroke Center Wengui Yu,
Kimberly Alva, Tamara Majic, Tapan Kavi,
Asma Moheet, Wouter Schievink, Michael
Alexander
P3.119
Alpha Variability for
Prediction of Delayed Cerebral Ischemia
Can Be Improved with Quantitative
Measurement Shawniqua Williams
P3.120
Venus Sinus Stenting for
Pseudotumor Cerebri: A Multicenter
Experience with Various Stents and
Deployment Techniques Sudeepta
Dandapat, Fazeel Siddiqui, Mushtaq
Qureshi, Augusto Elias, Sushant Kale,
Adnan Qureshi
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session III
P3.121
MRI Features in Ischemic
Stroke Patients with Early Epileptic
Seizures Alla Borisovna Guekht, Alexander
Yakovlev, Tatiana Danilova, Roman Luzin,
Vladislav Gaskin, Ildar Kamalov, Dina
Khasanova
P3.122
Stroke Patients and Diagnostic
Testing, Take Two—the Weekend Waiting
Game! Sally Mathias, Jessica Lee
Neuro-oncology: Glioma
Therapeutics
P3.123
Transplanted MGMTP140K
Gene-modified CD34+ Cells in Patients
with Newly Diagnosed Glioblastoma
Chemo Protect Bone Marrow and Lead
to Prolonged Survival Maciej Mrugala,
Jennifer Adair, Brian Beard, Daniel
Silbergeld, Lia Halasz, Jason Rockhill, HansPeter Kiem
P3.124
Changes in the Apparent
Diffusion Coefficient (ADC) on MRI in
Bevacizumab-treated Glioblastoma Alissa
Thomas, Myron Zhang, Bryanna Gulotta,
Kaitlin Woo, Zhigang Zhang, Thomas Kaley,
Sasan Karimi, Julio Arevalo Perez, Igor
Gavrilovic, Robert Young
P3.125
Phase II Study of Verubulin
(Azixa, MPC-6827) with Radiation Therapy
and Temozolomide in Newly Diagnosed
Glioblastoma Multiforme Patients:
Incomplete Report on Safety, Tolerability,
and Responses Jay-Jiguang Zhu, Santosh
Kesari, Lawrence Recht
P3.126
Salvage Therapy with
Lomustine for Temozolomide Refractory
Recurrent Anaplastic Astrocytoma: A
Retrospective Study Marc Chamberlain
P3.127
Treatment Responses in
Adult Brainstem Gliomas with IDH1/2
Mutations Sarah Hodges, Patrick
Malafronte, William Skinner, Corey Carter,
Jonathan Gilhooly, Brett Theeler
P3.128
Temporal Trend in
Postoperative Seizure Prophylaxis Use in
Glioma Patients Sarah Lapointe, Marie
Florescu, Chanez Djeffal, Karl Bélanger,
Dang Nguyen
P3.129
Antimitotic NovoTTF Therapy
for a Progressive Glioblastoma Patient with
Fournier Gangrene: Non-interference with
Wound Healing and Why It Works Eric
Wong, Loretta Barron, James Hwong,
Andrew Wagner
Neuro-oncology: CNS
Metastases and Other Neurologic
Complications of Cancer
P3.133
Newly Diagnosed Single Brain
Mass—Implementation and Performance
of a Hospital-wide Management
Pathway Isabel Arrillaga-Romany, Aneesh
Singhal, Susann Jarhult, Corey Gill, Aurelie
Cordier, Benjamin White, SooAe Jones,
Michelle Pisapia, Daniel Cahill, William
Curry, Joshua Goldstein, Tracy Batchelor
P3.134
High-dose Methotrexate for
Metastatic Breast Cancer to the Central
Nervous System: A Single-institution
Review of Forty-six Patients Margaret
Schwartz, Sean Grimm, Priya Kumthekar,
Simran Singh, Sherese Fralin, Irene
Helenowski, Alfred Rademaker, Lynnette
Onuselogu, Jeffrey Raizer
P3.135
Clinical Experience of
519 Cases with Leptomeningeal
Metastasis Jae-Won Hyun, In Hye Jeong,
Su-Hyun Kim, Ho Kim
P3.136
Neurological Complications
of Ipilimumab Therapy in Patients with
Metastatic Melanoma Aline Herlopian,
Fade Mahmoud, Ryan David, Rohan Samant,
Murat Gokden, Laura Hutchins, Shirley Ong
P3.137
Intramedullary Metastasis
from Ovarian Cancer: A Systematic Review
of the Literature Damoun Safarpour,
Fattaneh Tavassoli, Bahman Jabbari
P3.138
Encephaloclastic Cyst Induced
by Intraventricular Topotecan Divya
Mella, Carlos Kamiya Matsuoka, Bing Liao,
Sudhakar Tummala, John De Groot
P3.139
Multiple Embolic Brain
Metastases, Strokes and Intracranial
Hemorrhage from a Cardiac Malignant
Mesenchymal Tumor: A Case Report Amy
Chan, Matthew Schrag, Anita Huttner,
Joachim Baehring
P3.140
Peripheral Facial Nerve Palsy
Caused by Perineural Spread from a Parotid
Tumor Anna Grisold, Leyla Alpaslan, Stefan
Meng, Wolfgang Grisold
P3.141Calcineurin-inhibitor-induced
Pain Syndrome Clinically Mimicking
Guillain-Barre’ Syndrome in a Pediatric
Transplant Patient Aldo Doerner Rinaldi,
Jennifer Bain, Staci Arnold, Monica Bhatia,
Rama Ayyala, Jahannaz Dastgir
P3.131
Acute Reversible Toxic
Leukoencephalopathy Due to the
Chemotherapeutic Agent Folfox in a Patient
with Negative IVS14+1G>A Mutation in the
DPD (dihydropyrimidine Dehydrogenase)
Gene Bradley Molyneaux, Premkumar
Nattanmai Chandrasekaran
P3.132
Neuro-oncology: CNS Lymphoma
and Other Hematologic
Malignancies
P3.130
Identification of CSNK1E and
MELK as Essential Kinases to GBM and
as Future Therapeutic Targets Lily Pham,
Yanping Liang, Zhi Sheng
Ipilimumab for Recurrent
Glioblastoma (GBM) Lauren Schaff,
Andrew Lassman, Samuel Goldlust, Timothy
Cloughesy, Samuel Singer, Fabio Iwamoto
The Utility of Comprehensive
Genetic Analysis of Gliomas in Clinical
Practice Aya Haggiagi, Christina Corpuz,
Andrew Lassman, Fabio Iwamoto
P3.142
P3.143Methotrexate
Encephalopathy as a Cause of Alternating
Hemiplegia Charles Sullivan, John Quealy,
Jurate Olsevskaite, Peter MacEneaney,
Clodagh Ryan, Orna O'Toole
Fast, Easy, Online Registration · AAN.com/view/AM15
P3.144
Co-morbid Lymphomatosis
Cerebri and Testicular Lymphoma in a Case
of Rapidly Progressive Dementia Matthew
Tremblay, Matthew Ashley, Harry Vinters,
Ming Guo
P3.145
Neurological Manifestations
of Erdheim Chester Disease: A Case Series
of 3 Patients Bhavesh Trikamji, Shrikant
Mishra
P3.146
Rare Case of Central
Nervous System Invasion of Mantle Cell
Lymphoma with Serial Negative Magnetic
Resonances: Case Report and Literature
Review Ryna Then, Margi Patel
P3.147
Relapse Patterns in Primary
CNS Diffuse Large B-cell Lymphoma Nancy
Wang, Corey Gill, Rebecca Betensky, Tracy
Batchelor
P3.148
Neurologic Manifestations of
Intravascular Large B-cell Lymphoma Pouya Tahsili-Fahadan, Armin Rashidi,
Patrick Cimino, Bob Bucelli, Salah Keyrouz
P3.149
A Rare Complication of
Paraneoplastic Autoimmune Disorder in
Langerhans Cell Histiocytosis Thandar
Aung, Christopher Dardis
P3.150
Diffuse Leptomeningeal RosaiDorfman Disease: A Case Report Mitra
Afshari, Jeffrey Raizer
P3.151
Case Report:
Neurolymphomatosis Mimicking GuillainBarre Syndrome in a Patient with Splenic
Marginal Zone Lymphoma Kathryn
Stevens, Christopher Groth
P3.152
Marginal Zone Lymphoma
Associated with Paraneoplastic Cerebellar
Degeneration Alexandra Issa, Ramakrishna
Battini, Jerome Graber
Neuromuscular Disease:
Therapeutics
P3.153
The Safety Profile of Home
Infusion of Intravenous Immunoglobulin
in Neuroimmunological Disorders Ankit
Pahwa, Melissa Allan, Howard Sander,
Nizar Souayah
P3.154
Trans-splicing as a
Therapeutic Approach for Dysferlindeficient Muscular Dystrophies Susanne
Philippi, Stephanie Lorain, Guillaume
Precigout, Simone Spuler, Luis Garcia
P3.155
Botulinum Toxin A for
Treatment of Sialorrhea in Neurologic
Diseases: 2-year Prospective
Study Pierangelo Barbero, Carlo Alberto
Artusi, Stefania De Mercanti, Marco
Tinivella, Marco Busso, Marinella Clerico,
Luca Durelli
P3.156
Retrospective Efficacy
Evaluation of Immunoglobulin Infusions
(IVIG) in Patients with Chronic Inflammatory
Demyelinating Polyradiculoneuropathy
(CIDP) Alison Walsh, Marinos Dalakas,
Goran Rakocevic
P3.158
Local and Remote Spread
of Botulinum Toxin Effect; the Role of
Concurrent Medications and Treatment
with Pyridostigmine John Kelemen
P3.159
Starting Steroids Dose,
Need for Additional Immunosuppression
and Long-term Outcome in Myasthenia
Gravis Marcelo Rugiero, Mariela Bettini,
Marcelo Chaves, Maria Araoz, Edgardo
Cristiano
P3.160
Rescue Treatment in Guillain
Barre Syndrome: Is It Useful? Ayman
Alboudi, Abubaker Almadani, Jihad Inshasi,
Suhail Alrukn, Shareefa Abdool, Pournamy
Sarathchandran
Neuromuscular Disease:
Diagnostic Testing
P3.161
Reliability and Validity
of of the FSHD Composite Outcome
Measure Katy Eichinger, Shree Pandya,
Colleen Donlin-Smith, Chad Heatwole,
Alrabi Tawil, Jeffrey Statland
P3.162
Electrical Impedance
Myography and Quantitative
Ultrasonography: Tools to Quantify Tongue
Health Courtney McIlduff, Sung Yim, Tom
Geisbush, Aleksandar Mijailovic, Adam
Pacheck, Seward Rutkove
P3.163
Electrical Impedance
Myography (EIM) in Congenital Muscular
Dystrophy (CMD): Two-year Follow-up
Data Tanya Lehky, Daniel Schwartz,
Janannaz Dastgir, Carsten Bonnemann
P3.164
Confirmation Bias and
Specificity of Electromyography for
Radiculopathy Pushpa Narayanaswami,
Tom Geisbush, Lyell Jones, Michael Weiss,
Tahseen Mozaffar, Seward Rutkove
P3.165
Stimulated Jitter Analysis
(Stim-JA) for Neuromuscular Junction
(NMJ) Disorders in Children Jenny Lin,
Sumit Verma
P3.166
What Does the Six Minute
Walk Test Reflect in Myotonic Dystrophy
Type 1 (DM1)? Katy Eichinger, Jeanne
Dekdebrun, Charles Thornton, Richard
Moxley, Shree Pandya
P3.167
Ultrasound to Improve the
Diagnostic Yield of Sural Nerve Conduction
Studies David White
P3.168
A Carpal Tunnel Syndrome
Grading System Including CSI-diagnosed
Mild Cases: Relation to Presenting
Features and Outcomes Simran Singh,
Dilip Pandey, Lawrence Zeidman
P3.169
MuSK Autoantibodies in
Myasthenia Gravis: Experience with
>28,000 Specimens Tested in a Clinical
Laboratory Amy Goldberger, Brian
Sansoucy, Keith Morneau, Kaylan Burnham,
Sat Dev Batish, Funda Suer, Zhenyuan
Wang, Malgorzata Jaremko, Joseph
Higgins
P3.157Pharyngoesophageal
Dilation and Botulinum Toxin Therapy for
Dysphagia in Patients with Inclusion Body
Myositis Christopher Parres
81
Tuesday
April 21
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session III2:00 p.m.–6:30 p.m.
Neuromuscular Disease: Clinical
Neurophysiology
P3.170
Defective Fast Inactivation
Recovery of Nav1.4 in Congenital
Myasthenic Syndrome Christoph Lossin,
William Arnold, Daniel Feldman, Sandra
Ramirez, Liuyuan He, Darine Kassar, Adam
Quick, Tara Klassen, Marian Lara, Joanna
Nguyen, John Kissel, Ricardo Maselli
P3.171
Abnormal Gating of Axonal
Slow Potassium Current in Crampfasciculation Syndrome Yoshimitsu
Shimatani, Hiroyuki Nodera, Shibuta
Yoshiko, Miyazaki Yoshimichi, Sonoko
Misawa, Satoshi Kuwabara, Ryuji Kaji
P3.172
Cranial EMG Helps
Differentiate SBMA from ALS Regardless
of Bulbar Symptoms Rajat Lahoria,
Christopher Klein, Nathan Young, Nathan
Staff, Margherita Milone, Eric Sorenson,
William Litchy
P3.173
Multipoint Incremental Motor
Unit Number Estimation of the Extensor
Digitorum Brevis and Abductor Hallucis
Muscles Jeff Shije, Shafeeq Ladha
P3.174
Electrophysiological Predictors
of Seropositive and Seronegative Myasthenia Gravis Rachana Gandhi, Evelio Velis,
Efrain Salgado, Nestor Galvez-Jimenez
P3.175
Sequential Transcranial
Magnetic Stimulation Demonstrates
Dynamic Changes on Neck Flexion in
Monomelic Amyotrophy / Hirayama
Disease Preethish Kumar Veeramani,
Atchayaram Nalini, Chandrajit Prasad, Kiran
Polavarapu
P3.176
Normative Nerve
Conduction Study (NCS) Data in the Saudi
Population Jameel Rasheedi, Qurban Ali,
Zaitoon Shivji, Manzoor Shah, Yousef AlSaid, Aymaan Al-Falah, Alaa Subhi, Ahmed
Basndwah, Edward Cupler
P3.177
Post-denervation Muscle
Hypertrophy: A Rare Complication of
Brachial Plexopathy Pedro Vivar Cruz,
Kourosh Rezania, Peter Pytel, Rex Haydon,
Raymond Roos
P3.178
Success Rate of Obtaining
Baseline Somatosensory and Motor Evoked
Potentials in Consecutive Cranial and
Spinal Surgeries Brian Droker, Parastou
Shilian, Andres Gonzalez
Neuropathy: Clinical
Neurophysiology and Outcome
P3.179
Clinical and
Electrophysiological Features of Multifocal
Motor Neuropathy Cullen O'Gorman,
Eric Sorenson
P3.180
Recurrent Isolated Sixth
Nerve Palsy in Relapsing-remitting
Chronic Inflammatory Demyelinating
Polyneuropathy Najwa Al-Bustani, Michael
Weiss
P3.181
Charcot-Marie-Tooth Disease:
Clinical and Genetic Spectrum in a Tunisian
Series Amira Nasri, Imen Kacem, Youssef
Sidhom, Yosr Hizem, Mouna Ben Djebara,
Amina Gargouri, Eric Leguern, Riadh Gouider
82
P3.182
Hereditary Neuropathy with
Liability to Pressure Palsies (HNPP) and
Leprosy Neuropathy: A Comparative Nerve
Conduction Study Aline Oliveira, Gilberto
Andrade, Patricia Onofre, Vanessa Marques,
Wilson Marques
P3.183
The Usefulness of Proximal
Radial Motor Conduction in Acute
Compressive Radial Neuropathy Bum Chun
Suh, Kun Hyun Kim, Hyung Jun Park, KeeDuk Park, Pil-Wook Chung, Heui-Soo Moon,
Yong Bum Kim, Won Tae Yoon
P3.184
A Case of Immune-mediated
Polyneuropathy in a Patient with
Paraprotein-associated Systemic Capillary
Leak Syndrome Kara Stavros, Charlotte
Cunningham-Rundles, David Simpson
P3.185
Eosinophilic Granulomatosis
with Polyangiitis Presenting with
Polyneuropathy—a Case Series Fernando
Santos-Pinheiro, Yuebing Li
P3.186
Asymptomatic Neuropathy at
the Elbow—a Marker for Diabetes Akshay
Shah, Said Beydoun
P3.187
Therapeutic Effects of Cinacalcet
on Diabetic Peripheral Neuropathy Hye Won
Kim, Cheol Whee Park
P3.188
Bortezomib—New Option
for Aggressive Chronic Inflammatory
Demyelinating Polyradiculoneuritis Kalliopi
Pitarokoili, Anke Reinacher-Schick, Min-Suk
Yoon, Ralf Gold
P3.194
Prevalence of Depression
and Anxiety Among Patients with Epilepsy
Attending the Epilepsy Clinic at Sheikh
Khalifa Medical City, UAE: A Cross
Sectional Study Khadija El-Hammasi,
Mufeed Raoof, Tarek Shahrour, Mustafa
Shakra, Lamya Turkawi, Buthaina Almaskari,
Taoufik Alsaadi
P3.205 The Yale Seizure Cluster
P3.195
Qatar Ayman Al Jurdi, Abdullah El
Zafarany, Faten Aqeel, Abuhadra Nour,
Mujahed Laswi, Yasser Alsamman, Basim
Uthman, Dirk Deleu, Hassan Jassim Al Hail,
Boulenouar Mesraoua, Naveed Akhtar,
Ziyad Mahfoud, Gayane Melikyan, Naim
Haddad
Reduction of Treatmentlimiting Non-psychotic Behavioral Adverse
Events Associated with Levetiracetam
(LEV): An Open-label, Prospective Study of
Patients with Epilepsy Switching from LEV
to Brivaracetam (BRV) Treatment Stephen
Yates, Toufic Fakhoury, Wei Liang, Klaus
Eckhardt, Joseph D'Souza
P3.196
Gender Differences in the
Incidence of Psychiatric Co-morbidity in
Patients with Epilepsy Justine Chan, Jing
Chen, Kanishk Makhija, Michele Faulkner,
Sanjay Singh
Assessment of Anxiety,
Depression, and Quality of Life in Patients
with Epilepsy Using Three Spanish
Validated Scores: GAD-7, PHQ-9 and
QOLIE-10-P Rodolfo Callejas, Ildefonso
Rodriguez-Leyva
MS and CNS Inflammatory
Diseases: Tools for Clinical
Assessment and Therapeutic
Response
Suicide Risk and Epilepsy.
Four-year Follow Up Tamargo Agustina,
Analia Calle, Elena Fontela, Maria Gonzalez
Toledo, Diego Nadile, Fatima Pagani
Cassara, Alejandro Thomson, Patricia
Acosta, Alfredo Thomson
P3.199
P3.191
Comparative Cognitive
Effects of Lacosamide Versus
Carbamazepine David Loring, Kimford
Meador, Alan Boyd, William Byrnes, Deanne
Dilley, Simon Borghs, Marc De Backer, Tyler
Story, Peter Dedeken, Elizabeth Webster
P3.192
A Comparison of Instruments
to Measure Depressive Symptoms Among
Patients with Refractory Partial-onset
Seizures T. Christopher Bond, Fulton Velez,
Kathryn Anastassopoulos, Xuezhe Wang,
Joyce Cramer, Hailong Cheng, Rui Sousa,
David Blum
P3.193
Baseline Depressive
Symptoms as Predictive of Seizure
Frequency Reduction Among Epilepsy
Patients with Partial-onset Seizures: A
Pooled Analysis of Phase III Clinical Trials of
Adjunctive Treatment with Eslicarbazepine
Acetate T. Christopher Bond, Fulton Velez,
Kathryn Anastassopoulos, Xuezhe Wang,
Joyce Cramer, Hailong Cheng, Rui Sousa,
David Blum
Model for Investigation of Epilepsy in
Developing Countries Chamroeun Hun,
Tola Hok, Ros Sina, LyKheng Heng, PrakPiseth Riengsay, Samleng Chan, Devender
Bhalla
P3.198
P3.189
Topiramate (TPM) Input Rate
and Impaired Verbal Fluency: Observations
with Different Formulations Susan Marino,
Scott Brittain, Serguei Pakhomov
P3.207 Epilepsy in Cambodia—a
P3.208 Insurance Disparity in Utilizing
Epilepsy/Clinical
Neurophysiology (EEG): Health
Services
P3.190
P3.206 Mapping Epilepsy in
P3.197
Epilepsy/Clinical
Neurophysiology (EEG): Cognition
and Behavioral Health
“Speechless” After a Seizure:
A Rare Case of Postictal Aphemia Gulshan
Uppal, Niravkumar Barot, Paul Van Ness
Study: Prevalence, Characteristics, and
Impact on Healthcare Utilization Tenzin
Choezom, Shiliang Zhang, Hitten Zaveri,
Sreya Radhakrishna, Angela Gauthier,
Rasesh Joshi, Jennifer Bonito, Lawrence
Hirsch, Kamil Detyniecki
Making Epilepsy Treatment
More Affordable: Can Rationalizing
Prescriptions Reduce Cost? Mamta Singh,
Saloni Kapoor, Victor Patterson, Asuri
Prasad, V Sreenivas
P3.200 Effectiveness of Problem-
based Online CME in Improving the
Diagnosis and Management of LennoxGastaut Syndrome Ron Schaumburg,
Nimish Mehta
P3.201 Lacosamide Monotherapy
Treatment Pathways in Epilepsy Patients
in a US Managed Care Population Tracy
Durgin, Rolin Wade, Chi-Chang Chen,
Dionne Hines, Charles Makin
P3.202 Beyond Access: Disparities
in Epilepsy Quality of Care According to
Insurance Status Diego Mendez, Jonathan
Jesus, Rogger Andrade, Joel Weissman,
Daniel Hoch, Lidia Maria Moura
P3.203 Use of Best Practice Alerts in
Electronic Medical Records to Improve Care
for Women of Childbearing Age Taking
Anti-seizure Medications Lu Lin, Castleman
David, Catherine Glover, Jill Vieley, Paul Van
Ness
P3.204 Acceptance of a
Telemanagement System to Support
Epilepsy Self-care Arif Kabir, McKenzie
Bedra, Lania Cooper, Alan Krumholz, Joseph
Finkelstein
Continuous EEG Monitoring Among
Hospitalizations with Epilepsy: Analysis
from Nationwide Inpatient Sample Mihir
Dave, Achint Patel, Chirag Savani, Parisha
Bhatia, Matthew Eccher
P3.209 Remote Tracking of Walking
Activity in MS Patients in a Real-world
Setting James McIninch, Shoibal Datta,
Pronabesh DasMahapatra, Emil Chiauzzi,
Rishi Bhalerao, Alicia Spector, Sherrie
Goldstein, Liz Morgan, Jane Relton
P3.210 Propensity Score Adjustment
for Comparative Efficacy Studies of
Disease Modifying Agents in Multiple
Sclerosis Carrie Hersh, Claire Hara-Cleaver,
Jeffrey Cohen, Robert Bermel, Daniel
Ontaneda
P3.211
Creating an Integrated
Multiple Sclerosis Clinical Trial Analysis
Database Kartik Raghupathi, Emily James,
Amy Pace, Carmen Castrillo, Fabio Pellegrini
P3.212 Effects of Nintendo Wii Fit
Plus® Balance Program Training on Postural
Stability in Multiple Sclerosis Patients:
A Pilot Study Francesco Patti, Vincenzo
Cimino, Silvia Messina, Gianfranco Raciti,
Clara Chisari, Valeria Dibilio, Carmela
Leone, Donata Veca, Anna Russo, Francesco
Zagari, Mario Zappia
P3.213
Automated Quantification
of Motor Dysfunction in Multiple
Sclerosis Using Depth-sensing Computer
Vision Marcus D'Souza, Jessica Burggraaff,
Peter Kontschieder, Jonas Dorn, Christian
Kamm, Prejaas Tewarie, Cecily Morrison,
Thomas Vogel, Abigail Sellen, Antonio
Criminisi, Frank Dahlke, Bernard Uitdehaag,
Ludwig Kappos
P3.214 Novel, Easy-to-use Prediction
Tool Accurately Estimates Probability of
"aggressive MS" at 2-year Follow Up Ilya
Kister, Gary Cutter, Amber Salter, Joseph
Herbert, Eric Chamot
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
P3.215
Patient-reported Outcome
(PRO) Measures Used in Secondaryprogressive Multiple Sclerosis (SPMS)
Studies: A Systematic Review Chunhyun
Park, Crystal Watson
P3.227 Rabin Color Cone Contrast
P3.216 Waveform Entropy of Motor
P3.228 Quantitative Measurement
Evoked Potentials—a Sensitive Indicator of
Corticospinal Tract Damage Luke Canham,
Nick Kane, Agyepong Oware, Peter Walsh,
Kelly Blake, Jenny Homewood, Jonathan
Witherick, Kirsty Inglis, David Cottrell
Testing and Retinal Structure in Multiple
Sclerosis Arnow Samuel, Hao Yiu,
Christopher Songster, Denise Bolivar, Jeffrey
Gelfand, Ari Green
of Vibration as a Clinical Biomarker of
Neurodegeneration in MS Sonya Bakshi,
Brandon Loughridge, Sonya Steele, Joan
Ohayon, Tianxia Wu, Blake Dewey, Govind
Nair, Daniel Reich, Irene Cortese
P3.217
An Exploratory Analysis of
Predictors of Disease-modifying Drug
Adherence Using Data from a Panel Survey
of Patients with Multiple Sclerosis Julie
Locklear, Amy Phillips, Chris Kozma
P3.229 Association of Wellness
P3.218 Screening for Cognitive
P3.230 Differences in Treatment
Impairment in the Neurologist's
Office Sarah Morrow, Lynn McEwan,
Jamie Steckley, Daniel Mendonca, Heather
Rosehart, Marcelo Kremenchutzky
P3.219 The Multiple Sclerosis at
Home Access (MAHA) Project Kathleen
Healey, Toby Warden, Neil Jouvenat, Mac
McLaughlin, Rana Zabad
P3.220 Usability and Acceptability
of the ASSESS MS Movement Recording
Tool in Multiple Sclerosis Using Depthsensing Computer Vision Cecily Morrison,
Marcus D`Souza, Kit Huckvale, Jonas Dorn,
Jessica Burggraaff, Christian Kamm, Saskia
Steinheimer, Peter Kontschieder, Thomas
Vogel, Antonio Criminisi, Bernard Uitdehaag,
Frank Dahlke, Ludwig Kappos, Abigail Sellen
P3.221 Experiences with A Self
Developed Accelerometer in Multiple
Sclerosis Tunde Csepany, Lilla Racz, Csilla
Ver, Laszlo Kardos, Judit Soltesz, Andrea
Matyas, Gergely Hofgart, Laszlo Csiba
P3.222 National Swedish MS
Register Based Study: The Symbol Digit
Modalities Test as a Predictor of Work
Disability Virginija Karrenbauer, Philip
Brenner, Jan Hillert, Petter Tinghög
P3.223 Development of a
Comprehensive Motor Function
Assessment Battery for Multiple Sclerosis
Using Perceptive Computing Alexander
Brandt, Janina Behrens, Karen Otte,
Sebastian Mansow-Model, Elona Gusho,
Sebastian Mertens, Anuschka Grobelny,
Theresa Krüger, Friedemann Paul
P3.224 Education Effect of Online
Video/slide Program on Recognition
of Disease Progression in Multiple
Sclerosis Stacey Ullman, Aliza BenZacharia, Stephen Krieger
P3.225 Relationship Between
Cognitive Status and Perception of Ease
of Use of an Electronic Autoinjector for
Subcutaneous Interferon Beta-1a Ajay
Gupta, Fernando Dangond, Brooke
Hayward, Gabriel Pardo
P3.226 Composite Cerebellar
Functional Severity Score (CCFS) Is
Specific to Cerebellar Dysfunction in
Multiple Sclerosis Maya Tchikviladzé,
Jean Christophe Corvol, Catherine Lubetzki,
Caroline Papeix, Alexandra Durr, Sophie
Tezenas Du Montcel
Practices in MS Patients Using Self
Reported Disability Scores and MS
Characteristics Mary Rensel, Youran Fan,
Suji Baskar
Strategies in Multiple Sclerosis
According to Experience: A Survey of
Multiple Sclerosis Experts and General
Neurologists Murat Kurtuncu, Tuncer Asli,
Zeynep Caliskan, Serhan Sevgi, Husnu
Efendi, Sagduyu Kocaman Ayse, A. Cemal
Ozcan, Murat Terzi, Turan Omer, Sabahattin
Saip, Rana Karabudak, Aksel Siva
P3.231 Differences in the Diagnosis
and Follow Up of Multiple Sclerosis
Patients According to the Experience
of Neurologists: Results of a National
Survey Asli Tuncer, Murat Kurtuncu,
Zeynep Caliskan, Serhan Sevgi, Husnu
Efendi, Ayse Sagduyu, Cemal Ozcan, Murat
Terzi, Omer Turan, Sabahattin Saip, Aksel
Siva, Rana Karabudak
P3.232 A Pragmatic Literature
Review of Network Meta-analyses of
Disease-modifying Drugs in the Treatment
of Multiple Sclerosis Amy Phillips, Rachel
Beckerman, Nathaniel Smith, Julie Locklear,
Yushan Jiang, Caroline Solon
P3.233 Assessing Cognition in MS
Clinical Trials: The Cognitive Assessment
Interview (CAI) Allison Marzillano, Brittany
Speed, Bianca Cersosimo, Kathleen
Sherman, Michael Shaw, Wendy Fang,
Lamia Haider, Patricia Melville, Lauren
Krupp, Leigh Charvet
P3.234 Consensus Opinion of
US Neurologists on Practice Patterns
in Radiologically or Clinically Isolated
Syndromes and Relapsing-remitting
Multiple Sclerosis Carlo Tornatore, J.
Theodore Phillips, Omar Khan, Aaron Miller
P3.235 The State of Multiple
Sclerosis Survey: Relationship of
Expectations, Decision-making,
Communication, and Satisfaction with
Treatment Sibyl Wray, Maggie Alexander,
Martin Duddy, David Jones, Nancy Law,
Gilmore O'Neill, Antonio Uccelli, Robert
Weissert, Mar Tintoré
P3.236 How Satisfied with Their
Treatment Are Patients with MS?
Psychometric Evaluation of the Treatment
Satisfaction Questionnaire for Medication
(TSQM) Patrick Vermersch, Jeremy Hobart,
Catherine Dive-Pouletty, Sylvie Bozzi,
Patricia Coyle
Poster Session III
P3.238 Treatment Satisfaction over
Time for United States (US) Patients with
Multiple Sclerosis (MS) Treated with
Natalizumab Crystal Watson, John Foley,
Kavita Nair, Judith Stephenson, Timothy
Niecko, Sonalee Agarwal
MS and CNS Inflammatory
Diseases: Treatment Efficacy,
Safety, and Tolerability
P3.239 Efficacy of Delayed-release
Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis (RRMS) in
“Non-responders” to Prior Treatment
with Interferon Beta Oscar Fernandez,
Gavin Giovannoni, Robert Fox, Ralf Gold,
J. Theodore Phillips, Minhua Yang, Annie
Zhang, Nuwan Kurukulasuriya
P3.240 Dimethyl Fumarate Associated
Lymphopenia in Clinical Practice Erin
Longbrake, Anne Cross
P3.241 Safety and Efficacy of
Dimethyl Fumarate in Patients with
Multiple Sclerosis—Real World
Experience Claudia Chaves, Caitlin Dionne,
Rik Ganguly, Ann Camac
P3.242 Results of a Delphi Panel to
Address Management of Gastrointestinal
Side Effects Observed with Use of Delayedrelease Dimethyl Fumarate J. Theodore
Phillips, April Erwin, Stephanie Agrella,
Marcelo Kremenchutzky, John Kramer,
Jonathan Kendter, Heather Abourjaily,
Jitesh Rana, Robert Fox
P3.243 Systematic Review and Mixed
Treatment Comparison of Delayed-release
Dimethyl Fumarate and Other Diseasemodifying Therapies in Treatment-naïve
Patients with Relapsing-remitting Multiple
Sclerosis Robert Fox, Michael Hutchinson,
Eva Havrdova, Nuwan Kurukulasuriya,
Kashif Siddiqui, Sujata Sarda
P3.244 Comparison of Fingolimod
and Dimethyl Fumarate in the Treatment
of Multiple Sclerosis: One Year
Experience Brandi Vollmer, Julie Seibert,
Stefan Sillou, Patrick Dowdle, John Corboy,
Timothy Vollmer, Kavita Nair, Enrique
Alvarez
P3.245 Assessing Comparative
Outcomes from Teriflunomide and
Dimethyl Fumarate Studies in Relapsing
MS: Use of “Number Needed to Treat”
Analysis Thomas Leist, Mark Freedman,
Aaron Miller, Catherine Dive-Pouletty,
Xavier Montalban
P3.246 Impact of Fingolimod on
Achieving No Evidence of Disease Activity
and Worsening (NEDA)-4 in Previously
Treated Patients with High Disease
Activity Nicola De Stefano, Till Sprenger,
Maria Pia Sormani, Eva Havrdova, ErnstWilhelm Radue, Niklas Bergvall, Daniela
Piani Meier, Davorka Tomic, Ludwig Kappos
P3.247 Comparison of First-line
Fingolimod Efficacy Compared with Firstline Interferon-beta or Glatiramer Therapy
in MS Patients with Active Disease Using
Propensity-matched Registry Data Tim
Spelman, Niklas Bergvall, Guillermo
Izquierdo, Raed Alroughani, Pamela
McCombe, Ricardo Fernández Bolaños,
Dana Horakova, Eva Havrdova, Celia OrejaGuevara, Jeannette Lechner-Scott, Mark
Slee, Maria Trojano, Helmut Butzkueven
P3.248 Relapse Outcomes in Patients
with Multiple Sclerosis Treated with
Fingolimod After Previous Treatment
with Injectable Disease-modifying
Therapies Jacqueline Nicholas, Tobias
Derfuss, Daniel Ontaneda, Xiangyi Meng,
Kathleen Hawker
P3.249 Efficacy and Safety of
Fingolimod: The French Grand-Est
Cohort Ayman Tourbah, Eric Berger, Marc
Debouverie, Jerome De Seze, Etienne
Godet, Thibault Moreau
P3.250 Cardiac Safety Profile
During First-dose Monitoring Period of
Fingolimod (Gilenya) Treatment in Patients
with Relapsing Remiting MS: Data from
the Argentinean Registry (REAL). Interim
Results Gaston Kuperman
P3.251 36 Month PANGAEA: A
5-year Non-interventional Study of Safety,
Efficacy and Pharmacoeconomic Data
for Fingolimod Patients in Daily Clinical
Practice Tjalf Ziemssen, Hans-Joerg
Schwarz, Alexander Fuchs, Christian
Cornelissen
P3.252 Multifocal Sequential Relapse
Following Cessation of Fingolimod Therapy:
A Case Report Jason Appleton, Gordon
Mazibrada
P3.253 Effectiveness of Fingolimod
Compared with Interferons and Glatiramer
Acetate for the Treatment of Multiple
Sclerosis: A Matched Comparison of
Treatments from the PANGAEA and PEARL
Studies Hans-Peter Duerr, Jonathan Alsop,
Niklas Bergvall, Christian Cornelissen,
Stefan Viktor Vormfelde, Tjalf Ziemssen
P3.254 Comparison of Relapse Rates
in Multiple Sclerosis Patients Switching
from Glatiramer Acetate to Fingolimod
Versus Those Remaining on Glatiramer
Acetate Li Yunfeng, Tara Nazareth,
Huanxue Zhou, Ko John, Kathleen Hawker,
Stephen Arcona, Rahul Sasane
P3.255 Interim Analysis II from REAL
Study: Quality of Life and Persistence
with Fingolimod Treatment in Relapsing
Remitting Multiple Sclerosis Patients in
Argentina Gastn Kuperman
P3.256 Similar Local Tolerability
Profiles Following Double-blind Treatment
with Generic or Branded Glatiramer
Acetate in Multiple Sclerosis Krzysztof
Selmaj, Frederik Barkhof, Christian Wolf,
Anna Belova, Janine Oberye, Evelyn van den
Tweel, Roel Mulder, Norbert Koper, Gerrit
Voortman, Jeffrey Cohen
P3.237 Impact of Global Education
on Decision-making Related to Disease
Modifying Therapy in Multiple Sclerosis Ron Schaumburg, Stephen Krieger
Fast, Easy, Online Registration · AAN.com/view/AM15
83
Tuesday
April 21
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session III2:00 p.m.–6:30 p.m.
P3.257 Pharmacokinetics of
Daclizumab High-yield Process (DAC
HYP) with Repeated Administration of
the Clinical Subcutaneous Regimen in
Subjects with Relapsing-remitting Multiple
Sclerosis Jonathan Tran, Ahmed Othman,
Yaoshi Wu, Alvydas Mikulskis, Paul
Wolstencroft, Jacob Elkins
P3.258 The Effect of Dosing Interval
Extension and Patient Weight on Long-term
Natalizumab Pharmacokinetics John Foley,
Ryan Metzger, Tamara Hoyt, Angelene
Christensen
P3.262 Safety, Tolerability, and
Efficacy of Rituximab in the Treatment of
Multiple Sclerosis: 285 Patients Treated
in a Single Center Julie Seibert, Jace
Blackburn, Brandi Vollmer, Jeffrey Bennett,
John Corboy, Augusto Miravalle, Teri
Schreiner, Timothy Vollmer, Enrique Alvarez
P3.263 Experience with Long-term
Rituximab Use in a Multiple Sclerosis
Clinic Megan Barra, Khac Huy Vo, James
Stankiewicz
P3.264 An Open Labeled
Estimation of Treatment Effectiveness with
Versus Without an MS Relapse (PEARL
Study) Stefan Vormfelde, Tjalf Ziemssen
Observational Study of Rituximab and
Plasma Exchange (PLEX) in Progressive
Multiple Sclerosis (MS) Sara Qureshi,
Jaspreet Abraham, Diana Logan, Teresa
Frohman, Elliot Frohman
P3.260 Improvement in Disability with
P3.265 Listeria Meningitis
P3.259 Disability, Health Status, and
Alemtuzumab Is Associated with Quality of
Life Improvement Over 3 Years in Patients
Who Relapsed on Prior Therapy Mariko
Kita, Jeffrey Cohen, Thibault Moreau, Eva
Havrdova, Rafael Arroyo-Gonzalez, Joseph
Herbert, Linda Kasten, David Margolin,
Gavin Giovannoni
P3.261
Complicating Alemtuzumab Treatment
for Multiple Sclerosis Antonios Bayas,
Andreas Rank, Markus Naumann
P3.266 Rebound of Cognitive
Impairment After Natalizumab
Discontinuation in Multiple Sclerosis
Patients Pietro Iaffaldano, Rosa Viterbo,
Damiano Paolicelli, Vita Direnzo, Mariangela
D'Onghia, Maria Trojano
Durable Effect of
Alemtuzumab on Disability Improvement
in Patients with Relapsing-remitting
Multiple Sclerosis Who Relapsed on a
Prior Therapy Christopher LaGanke, Bruce
Hughes,
Regina Berkovich,
JeffreyListing,
Cohen, halfpage horizontal
RED: 15AM Award
Luncheon
Ad_Abstract
Gavin Giovannoni,
Linda Kasten,
Usage: High resolution
PDF for Abstract
ListingDavid
Margolin, Eva Havrdova
Spec: 8.25” x 5.4375”, +.125” bleeds, 4C
P3.267 Safety and Efficacy of
Extended Dose Natalizumab in Multiple
Sclerosis: An Ongoing Multicenter
Study Lana Zhovtis Ryerson, Joseph
Herbert, Ilya Kister, John Foley, Bianca
Weinstock-Guttman, Carmelo Tornatore,
Krupa Pandey, Gina Remington, Darin
Okuda, Channa Kolb, Elliot Frohman
P3.268 Post-marketing Safety Profile
of Interferon Beta-1a Subcutaneously in
Patients with Multiple Sclerosis Treated
in the US: A Retrospective Cohort
Study Meredith Smith, Meritxell Sabidó
Espin, Anton Trochanov, Mark Samuelson,
Sandra Guedes, Florent-Frederic Richy
P3.269 Risk of Disease Progression
After Starting Dimethyl Fumurate (DMF):
Data from the Providence Multiple Sclerosis
Center’s DMF Registry Kyle Smoot, Kiren
Kresa-Reahl, Chiayi Chen, Tamela Stuchiner,
Bobbie Lee Roth, Stanley Cohan
P3.270 Cumulative Review of
Thrombotic Microangiopathy, Thrombotic
Thrombocytopenic Purpura and Hemolytic
Uremic Syndrome Reports with
Subcutaneous Interferon β-1a Ali-Frederic
Ben-Amor, Anton Trochanov
P3.272 Decreased Relapse Activity
for Those Who Switch to Natalizumab from
Alternative Disease Modifying Therapies:
An Observational Study Robert McQueen,
Terrie Livingstone, Timothy Vollmer, John
Corboy, Kavita Nair, Jonathan Campbell
P3.273 Spontaneous Intracerebral
Hemorrhage During Natalizumab
Treatment for Relapsing Remitting Multiple
Sclerosis Carrie Hersh, Jeffrey Cohen
P3.274
Natalizumab Treatment
Preserves Cognitive Function and Stabilizes
MS Cortical Pathology Lior Or Bach,
Shmuel Miron, Anat Achiron
P3.275 Improved Cognition
and Depression in Patients with MS
After Two Years of Treatment with
Natalizumab Annett Kunkel, Juergen Faiss,
Wolfgang Koehler, Martin Fischer
P3.276 Physical Aspects of Quality
of Life (QoL) over 3 Years in Patients
with Multiple Sclerosis (MS) Initiating
Natalizumab Treatment Earlier Versus Later
in the Course of Disease Kavita Nair, John
Foley, Judith Stephenson, Timothy Niecko,
Sonalee Agarwal, Crystal Watson
P3.271 Observational Prospective
Study in Multiple Sclerosis Patients Treated
with Dimethylfumarate Jennifer Aboab,
Romain Deschamps, Antoine Gueguen,
Michael Obadia, Antoine Moulignier, Olivier
Gout
2015 Awards Luncheon
Wednesday, April 22 • 12:00 p.m.–1:30 p.m.
Join AAN leaders as they honor the recipients of the 2015 AAN and American Brain
Foundation awards. From enterprising high school students to world-renowned researchers,
this program recognizes some of the top accomplishments in neuroscience research.
Walter F. Mondale has been named the 2015 Public Leadership in Neurology Award recipient
and will accept the award during the awards luncheon. This award honors an individual or group
outside of the medical profession who is dedicated to advancing public understanding and
awareness of neurologic disease, being effective advocates for neuroscience research, and making
significant contributions to improve patient care.
Poster Session III
P3.277 Effect of Fingolimod on No
Evidence of Disease Activity (NEDA-4)
and Safety in Young Adult Patients
with Relapsing-remitting Multiple
Sclerosis Angelo Ghezzi, Goeril Karlsson,
Dieter Haering, Jutta Gärtner, Tanuja
Chitnis, Daniela Pohl, Norman Putzki
P3.278 Glatiramer Acetate and
Pregnancy in Women with Multiple
Sclerosis—Results from the German
Multiple Sclerosis and Pregnancy
Registry Kerstin Hellwig, Sandra Herbstritt,
Ralf Gold
P3.279 Open-label Study of Autologous
Bone-marrow-derived Mesenchymal Stem
Cells in Multiple Sclerosis Cristina Ramo,
Jose Vicente Hervas, Enrique Andreu, Felipe
Prosper, Susana Inoges, Jaime Kulisevsky,
Roberto Belvís
P3.280 Is Baseline MRI Predictive
of Response to Fingolimod Treatment in
Multiple Sclerosis? Camilo Diaz-Cruz, Brian
Healy, Muhammad Taimur Malik, Svetlana
Egorova, Mariann Polgar-Turcsanyi, Mark
Anderson, Shahamat Tauhid, Gloria Kim,
Rohit Bakshi, Tanuja Chitnis
P3.288 Effectiveness of Switching
to Rituximab over Fingolimod or Dimethyl
Fumarate After Natalizumab in Preventing
Disease Activity in Multiple Sclerosis Enrique
Alvarez, Brandi Vollmer, Blacburn Jace,
John Corboy, Timothy Vollmer, Stefan Sillou,
Kavita Nair, Julie Seibert
P3.289 The Safety and Efficacy of
Switching from Natalizumab to Dimethy
Fumarate: Real World Experience Faria
Amjad, Nasima Afsari, Carmelo Tornatore
P3.290 Efficacy of Oral Multiple
Sclerosis Therapies in Patients Switching from
Natalizumab NgocHanh Vu, Harold Moses,
Subramaniam Sriram, Siddharama Pawate
P3.291 Risk of Rebound in Multiple
Sclerosis After a Switch from Natalizumab
to Fingolimod. Early Onset Versus Delayed
Onset Rocio Hernandez Clares, Ruben
Carrasco Torres, Ester Carreon, Encarnación
Andreu, Jose Meca La Llana, Jjavier Martin
Fernandez
P3.292 Early Cyclophosphamide
Among Multiple Sclerosis Patients Newly
Initiating Treatment with a Self-injectable
Versus Oral Disease-modifying Drug Julie
Locklear, Amy Phillips, Michael Munsell,
Molly Frean, Joseph Menzin
Pulses Therapy Is Able to Reduce
Disease Reactivation After Natalizumab
Discontinuation: Preliminary Results from a
Multicentric Database Marco Capobianco,
Marianna Lo Re, Francesca Sangalli, Lucia
Moiola, Paola Perini, Paolo Gallo, Leandro
Provinciali, Maura Danni, Anna Repice, Luca
Massacesi, Francesco Patti, Silvia Messina,
Antonio Bertolotto
P3.282 Characteristics of Switchers
P3.293 Real-world Clinical Outcomes
P3.281 An Assessment of Adherence
to Newer Therapies in the NARCOMS
Registry Amber Salter, Stacey Cofield,
Stephen Glenski, Tuula Tyry, Gary Cutter,
Robert Fox, Ruth-Ann Marrie
P3.283 Demographic and Clinical
Assessment of Multiple Sclerosis Patients
Undergoing Immunomodulatory Treatment
in Poland Slawomir Wawrzyniak, Dorota
Koziarska, Alina Kulakowska, Monika
Adamczyk-Sowa
P3.284 Disease Course in Multiple
Sclerosis (MS) Patients Switching from
Fingolimod to Natalizumab Helmut
Butzkueven, Ludwig Kappos, Maria Trojano,
Yi Chen, Qunming Dong, Harold Koendgen,
Shibeshih Belachew
P3.285 Functional System Changes
Associated with Relapse: The CombiRx
Experience Stacey Cofield, Fred Lublin,
Gary Cutter, Tarah Gustafson, Jerry
Wolinsky
P3.286 Evaluation of the Tolerability
Profile of Peginterferon Beta-1a Using
the Delphi Technique Leslie Leahy, Diego
Centonze, June Halper, DeRen Huang, Scott
Newsome, Chris Robertson, Xiaojun You,
Bjorn Sperling
P3.287 Natalizumab Discontinuation
Study: Taper Protocol May Prevent Disease
Reactivation Bianca Weinstock-Guttman,
Jesper Hagemeier, Vasu Saini, Katelyn
Kavak, Kara Patrick, Deepa Ramasamy,
Nadeem Muhammad, Ellen Carl, David
Hojnacki, Robert Zivadinov
in Relapsing-remitting Multiple Sclerosis
Patients Who Switch from Natalizumab
to Delayed-release Dimethyl Fumarate: A
Multicenter, Retrospective, Observational
Study (STRATEGY) Stanley Cohan, Jonathan
Calkwood, Christopher LaGanke, Carlo
Tornatore, Harold Moses, Kyle Smoot, Monica
Mann, Ven Meka, Macaulay Okwuokenye,
Christophe Hotermans, Leslie Meltzer
P3.294 Relapse and Rebound Risks
After Natalizumab Discontinuation in
Patients with Multiple Sclerosis Claudia
Chaves, Rik Ganguly, Caitlin Dionne, Ann
Camac
P3.295 An Analysis of Monthly
Surveillance 3T MRI in MS Patients
Switched from Long-term Natalizamab to
Teriflunomide in a Controlled, Prospective
Study Keith Edwards, Stanley Cohan,
Francisco Gomez, James Thomas
P3.296 Switching from Natalizumab
to Fingolimod. Clinical and Radiological
Response. A Centre’s Experience Rocio
Hernandez Clares, Ester Carreon Guarnizo,
Encarnación Andreu Reinón, Ruben
Carrasco Torres, Adelaida Leon Hernandez,
Gema Salgado, Pepe Meca Lallana
P3.298 Antiretroviral Central
P3.312
P3.299 Efficacy of Pregabalin in the
P3.313
P3.300 Pain Prevalence in the
P3.314
Nervous System Penetration Does Not
Reduce Chronic Pain in People Living
with HIV Nathaniel Robbins, Kanokporn
Chaiklang, Khuanchai Supparatpinyo
Treatment of Prediabetic Neuropathic
Pain Alejandra Gonzalez-Duarte, Karla
Cárdenas-Soto, Mónica Lem, Roy Freeman
Elderly Jelena Pavlovic, Cuiling Wang,
Mindy Katz, Carol Derby, Molly Zimmerman,
Richard Lipton
P3.301 Neurology and Palliative Care:
A Barriers Analysis Ludo Vanopdenbosch,
David Oliver
P3.302 Total Intracranial Volume and
Current Total Brain Volume Are Linked to
Level of Pain in Older Adults Ali Ezzati,
Mindy Katz, Michael Lipton, Richard Lipton
P3.303 Tanezumab Does Not Cause
Sympathetic Nervous System Dysfunction
in Clinical Osteoarthritis Studies Mark
Brown, Martin Koltzenburg, Ha Nguyen,
Christine West, Kenneth Verburg
P3.304 The Efficacy of Pregabalin for
Treating Pain Associated with Diabetic
Peripheral Neuropathy in Patients with
Type I or Type II Diabetes Mellitus Bruce
Parsons, Chunming Li, Birol Emir
P3.305 Provocative Infrared
Telethermography in Knee Osteoarthritis:
The Role of the Sympathetic Nervous
System in Pain Trevor Gerson, Meryem
Saracoglu, Sara Connolly, Amy Kirsling, R
Harden
P3.306 Effects of Acupuncture on
Neuropathic Pain: A Systematic Review
and Meta-analysis Alexandra Dimitrova,
Charles Murchison, Barry Oken
P3.307 Prevalence of B12 Deficiency
in Patients Presenting with Non-specific
Pain and Other Sensory Symptoms: A
Clinical Observational Study Karadan
Ummer, Mohan Noone
P3.308 Gamma Knife Radiosurgery
for Trigeminal Neuralgia. A Long-term
Study on Outcome and Predictors of Pain
Relief Vijayakumar Javalkar, Shihao Zhang,
Osama Ahmed, Anil Nanda
Differential Effects of Pain
and Weakness on Function in Chiari
Malformation and Syrinx; A Longitudinal
Study Fredric Cantor, Aerial Spencer,
Jessica Mack, John Heiss
P3.315
Skin Hyperpigmentation
in Complex Regional Pain Syndrome
(CRPS) Robert Knobler
P3.316
Severe Ascending Muscle
Spasms Associated with Diffuse Perineural
Tarlov Cysts Damoun Safarpour, Sarah
Mulukutla, Baber Khokhar, Bahman Jabbari
P3.317Withdrawn
P3.318
Palliative Sedation in a
Case of Severe Progressive Dystonia and
Intractable Pain Neha Kramer, Jacob
Strand, Sara Hocker, Keith Swetz
P3.319
Exploring Misconceptions in
Palliative Care in a Multi-disciplinary ALS
Clinic Lindsay Kaplan
Neuroscience Research Prize
Recipients
P3.320 Modulating the Innate
Immune System Through the
Stimulation of TLR9 with CpG ODN as
a Therapy for Alzheimer’s Disease in a
TgSwDI Mouse Model in Both Acute
and Long-term Studies Monica Lee
P3.321 Investigation of
Autophagy in Huntington’s disease
using a Mutant Huntington Knock-in
Striatal Cell Line Lauren Houle
P3.322 A Novel Peptide Alters
the Alzheimer’s β-amyloid Equilibrium
to Protect Against Aβ Oligomer
Neurotoxicity Yinge Zhao
Referrals to Pain Management Ilya Bragin,
Dmitry Dvoskin, Awss Zidan, Rosamma
Joseph, Parakulam Sebastian Thomas
P3.310 Pain Intensity and Pain
Pain and Palliative Care
P3.297 Pain Control Is an Independent
P3.311
Fast, Easy, Online Registration · AAN.com/view/AM15
Comparison of Patients with
Chronic Non-cancer Pain Taking and Not
Taking Chronic Opioid Therapy Peter
Przekop, Allison Przekop, Mark Haviland
P3.309 Characteristics of Neurology
Interference in Older Adults: Role of
Gender, Obesity and Inflammation Vahid
Eslami, Mindy Katz, Robert White, Erin
Sundermann, Julie Jiang, Ali Ezzati,
Richard Lipton
Predictor of Self-reported Mental Health
Among Patients with Chronic Neurological
Conditions Lidia Maria Moura, Eli
Schwamm, Lee Schwamm
A Retrospective Analysis of
and Proposed Framework for Palliative
Care Discussions in Patients with Multiple
System Atrophy Anita Dayal, Teneille
Gofton
Using a Patient Registry
to Improve Understanding of the
Variability, Progression, and Treatment
of Pain Christina Cook, Risa Tyo, Steven
Gershon, Michael Burdi
85
Tuesday
April 21
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Scientific Sessions
S12 Neuroimmune
Mechanisms in Multiple
Sclerosis
3:15 p.m.
S12.001
Increased Intrathecal Inflammation in
Progressive Multiple Sclerosis Mika
Komori, Andrew Blake, Yen-Chih Lin,
Peter Kosa, Danish Ghazali, Paige
Winokur, Muktha Natrajan, Simone
Wuest, Elena Romm, Tianxia Wu,
Bibiana Bielekova
S13 Cerebrovascular
Disease and Interventional
Neurology: Epidemiology
and Risk Factors
3:15 p.m. Presentation
of Michael S. Pessin Stroke
Leadership Prize
Recipient:
Lauren Sansing, MD, MS
New Haven, CT
3:30 p.m.
S12.002
Immune Infiltrates Expressing
Podoplanin (PDPN) Are Present
in Multiple Sclerosis but Not
Glioblastoma Alyssa Nylander,
Sriram Ramanan, Danielle
Debartolo, Calvin Park, David Hafler,
David Pitt
3:30 p.m.
S13.002
Subclinical Cerebral Vessel Lesions
and Risk of Stroke: The Northern
Manhattan Study Emmanuel Perez,
Chuanhui Dong, Charles DeCarli,
Mitsuhiro Yoshita, Clinton Wright,
Maria Santiago, Mitchell Elkind,
Ralph Sacco
3:45 p.m.
S12.003
The Role of Fractalkine (CX3CL1) in
Regulation of CD4+ Cell Migration
to the Central Nervous System in
Patients with Relapsing-remitting
Multiple Sclerosis Silva Markovic
Plese, Kevin Blauth, Xin Zhang,
Manisha Chopra
3:45 p.m.
S13.003
The Risk of a Diagnosis of Cancer
After Ischemic Stroke: Two Year
Follow-up Study of 3247 Cancer Free
Ischemic Stroke Patients Adnan
Qureshi, Ahmed Malik, Omar Saeed,
Adil Malik, Muhammad Suri
4:00 p.m.
S12.004
Vascular and Angiogenic Factors
in a Non-human Primate Model of
Multiple Sclerosis (MS): Human
Biomarker Cross-reactivity with EAE
in the Common Marmoset Emily
Leibovitch, Giovanna Manzano,
Steven Jacobson
4:15 p.m.
S12.005
Relative Expression of Anti-oxidant
Genes in Adult Human Progenitor and
Mature Oligodendrocytes Qiao Ling
Cui, Pavel Gris, Timothy Kennedy,
Jack Antel
4:30 p.m.
S12.006
The Effect of IL-10 on M2-activated
Human Microglia Luke Healy, Craig
Moore, Hanane Touil, Samuel
Ludwin, Amit Bar-Or, Jack Antel
4:45 p.m.
S12.007
Detection of Human T-cell
Lymphotropic Virus Type I Proteins
in Exosomes from HAM/TSP
Patient CSF by Novel Nanotrap
Technology Monique Anderson,
Benjamin Lepene, Fatah Kashanchi,
Steven Jacobson
4:00 p.m.
S13.004
Rapid Weather Changes Are
Associated with Increased Ischemic
Stroke Risk: A Case Crossover
Study Florian Rakers, Rene
Schiffner, Sven Rupprecht, Antje
Brandstädt, Otto Witte, Peter
Schlattmann, Matthias Schwab
4:15 p.m.
S13.005
The Preventable Stroke: Definition
and Implications Mark Fisher, Lisa
Moores, Mohamad N. Alsharif,
Krunal Shah, Annlia Paganini-Hill
4:30 p.m.
S13.006
CARES (Changing and Advancing
Risk Factor Control Through
Educations After Stroke): A Pilot
Trial of a Transitions in Care Postdischarge Telephone Intervention
for Stroke Patients Lillie Hudson,
Marilyn Corrales, Lilian Moreno,
Natalie Valle, Ali Razmara, Tara
Dutta, Liliana Ramirez-Gomez, Amy
Towfighi
4:45 p.m.
S13.007
A Culturally Tailored Education
Intervention for Korean Seniors
Increases Stroke Knowledge Sarah
Song, John Son, Frances Barry,
Heejung Park, Heeeun Park, Connie
Chung, Joseph Chung, Chi-Hong
Tsieng, Gery Ryan, Barbara Vickrey
Tuesday, April 21
S14 Epilepsy/Clinical
Neurophysiology (EEG):
Clinical Epilepsy
3:15 p.m.
S14.001
The Implantation Effect: Seizure
Frequency in Patients That Have
Underwent Intracranial Surgical
Implantation Versus Superficial Scalp
Monitoring Michael Lane, Barbara
Jobst, Cynthia Kahlenberg, Vijay
Thadani, Krzysztof Bujarski, David
Roberts
3:30 p.m.
S14.002
Increased Cerebral Oxygenation
Precedes Generalized Tonic Clonic
Seizures Brian Moseley, Jeffrey
Britton, Elson So
3:45 p.m.
S14.003
Transcutaneous PCO2 and Seizures
in the Epilepsy Monitoring Unit:
Associations with Markers of Seizure
Severity Derek J. Chong, Palak
Patel, Alla Ahmed, Nilofer Khan,
Bryan Still, Evan Marzouk, Daniel
Friedman, Orrin Devinsky
4:00 p.m.
S14.004
The EpiNet Collaboration: Do
Neurologists Around the World
Agree when Diagnosing Epilepsy?—
Results of a Multinational
Study. Peter Bergin, Ettore Beghi,
Wendyl D'Souza, Lynette Sadleir,
Manjari Tripathi, Mark Richardson,
Elisa Bianchi
4:15 p.m.
S14.005
“Review of Systems" Questionnaire
as a Predictive Tool for Psychogenic
Non-epileptic Seizures. Liliana
Robles, Sharon Chiang, Holly
Rutherford, Zulfi Haneef
4:30 p.m.
S14.006
Episodic Memory Deficits Are
Related to Gray Matter Volume
and Functional Connectivity
Abnormalities in Temporal Lobe
Epilepsy Gaelle Doucet, Xiao-Song
He, Paul Barnett, Christopher
Skidmore, Ashwini Sharan, Michael
Sperling, Joseph Tracy
4:45 p.m.
S14.007
Decreased Amygdala Resting
State Functional Connectivity in
Patients with Left Temporal Lobe
Epilepsy Jane Allendorfer, Rodolphe
Nenert, Basia Szaflarski, Nancy
Cohen, Jeffrey Binder, Zhifeng Kou,
Roy Martin, Lawrence Ver Hoef,
Jerzy Szaflarski
S15 Movement Disorders:
Huntington's Disease,
Dystonia, and Atypical
Parkinsonism
S16 Aging, Dementia,
Cognitive, and Behavioral
Neurology: Clinical
Science
3:15 p.m.
S15.001
Reliability of the Severity
Subscale of the Revised Toronto
Spasmodic Torticollis Rating Scale
(TWSTRS-2) Cynthia Comella,
Joel Perlmutter, H. Jinnah, Stewart
Factor, Christopher Goetz, Charles
Adler, Richard Barbano, Susan Fox,
Joseph Jankovic, Ramon Rodriguez,
William Severt, Stephen Reich,
Natividad Stover, Wendy Galpern,
Ami Rosen, Glenn Stebbins
3:15 p.m.
S16.001
Glutamic Acid Decarboxylase Antibody Encephalitis Mimicking
Creutzfeldt-Jakob Disease: A Case
Report and Literature Review Frank
Bittner, Ann Murray, Javier Gonzalez
3:30 p.m.
S15.002
Can the Mutant Huntingtin
Gene Product Spread from Cell
to Cell: Evidence from Neuronal
Allografts in Huntington's Disease
Patients Francesca Cicchetti, Steve
Lacroix, Giulia Cisbani, Nicolas
Vallières, Martine Saint-Pierre,
Isabelle St-Amour, Ranna Tolouei,
Jeremy Skepper, Robert Hauser,
Diego Mantovani, Roger Barker,
Thomas Freeman
3:45 p.m.
S15.003
Thalamic Volume Is Reduced in
Multiple Types of Dystonia Jeffrey
Waugh, Jake Kuster, Jacob
Levenstein, N Makris, Trisha
Multhaupt-Buell, Lewis Sudarsky,
Hans Breiter, Nutan Sharma, Anne
Blood
4:00 p.m.
S15.004
Monitoring Loss of Striatal
Phosphodiesterase 10A (PDE10A)
with [18F]MNI-659 and PET: A
Biomarker of Early Huntington
Disease (HD) Progression. David
Russell, Danna Jennings, Olivier
Barret, Gilles Tamagnan, Vincent
Carroll, David Alagille, Thomas
Morley, Caroline Papin, John Seibyl,
Kenneth Marek
4:15 p.m.
S15.005
No Excess of Loss-of-function of
COQ2 Variants in Pathologically
Confirmed Multiple System
Atrophy Lucia Schottlaender, Henry
Houlden
4:30 p.m.
S15.006
Prevalence of Depression and
Anxiety in Atypical Parkinsonian
Patients. Leonardo Brito De
Almeida, Michael Okun, Nikolaus
McFarland
4:45 p.m.
S15.007
Longitudinal Voxel-based Analysis
of Brain Atrophy over 6 and 12
Months in CBD and PSP from Two
Multicenter Studies Shubir Dutt,
Richard Binney, Hilary Heuer,
Priyanka Bhatt, Dana Waltzman,
Suneth Attygalle, Phi Luong, Lisa
Voltarelli, Jonathan Elofson, Namita
Multani, Carmela Tartaglia, Irene
Litvan, Scott McGinnis, Bradford
Dickerson, Joel Kramer, Bruce
Miller, Clifford Jack, Howard Rosen,
Adam Boxer
86
3:30 p.m.
S16.002
Atrial Fibrillation in Patients with
Neuropathological Diagnosis of
Primary Alzheimer’s Disease Patricia
Riccio, Luciano Alberto Sposato,
Estefania Ruiz Vargas, Jon Toledo,
John Trojanowski, Vladimir
Hachinski
3:45 p.m.
S16.003
Multimorbidity and Increased Risk
of Mild Cognitive Impairment Maria
Vassilaki, Ruth Cha, Jennifer St.
Sauver, Michelle Mielke, Yonas
Geda, Mary Machulda, David
Knopman, Ronald Petersen, Rosebud
Roberts
4:00 p.m.
S16.004
Predicting the Risk of Mild Cognitive
Impairment in the Mayo Clinic Study
of Aging Michelle Mielke, Vernon
Pankratz, Rosebud Roberts, David
Knopman, Clifford Jack, Yonas Geda,
Walter Rocca, Ronald Petersen
4:15 p.m.
S16.005
APOEε2 Is Associated with Milder
Clinical and Pathological Alzheimer’s
Disease Alberto Serrano-Pozo,
Jing Qian, Sarah Monsell, Rebecca
Betensky, Bradley Hyman
4:30 p.m.
S16.006
EHT™ Coffee Extract: A
Neuroprotective Agent and
Modulator of PP2A Methylation with
Anti-inflammatory and Antioxidant
Properties Kristen Huber, Michael
Voronkov, Jose Fernandez, Karl
Rouzard, Akira Iishi, Eduardo Perez,
Maxwell Stock, Jeff Stock
4:45 p.m.
S16.007
Dextromethorphan/Quinidine
(AVP-923) Efficacy and Safety
for Treatment of Agitation in
Persons with Alzheimer’s Disease:
Results From a Phase 2 Study
(NCT01584440) Jeffrey Cummings,
Constantine Lyketsos, Pierre Tariot,
Elaine Peskind, Uyen Nguyen,
Nadine Knowles, Paul Shin, Joao
Siffert
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
3:15 p.m–5:00 p.m.
3:15 p.m.
S17.001
A Quantitative Analysis of Muscle
Microvasculature in Areas of
Perifascicular Fiber Atrophy (PFA)
and Adjacent Unaffected Fascicular
Areas (UFA) in Dermatomyositis
(DM). Rajat Lahoria, Andrew Engel
3:30 p.m.
S17.002
Necrotizing Autoimmune Myopathy:
Comparison of Clinical Features
and Treatment Outcomes Among
Different Etiologies Charles
Kassardjian, Vanda Lennon,
Margherita Milone
3:45 p.m.
S17.003
Orally-administered TRPV1
and TRPA1 Activators Inhibit
Electrically-induced Muscle Cramps
in Normal Healthy Volunteers Glenn
Short, Brooke Hegarty, Roderick
MacKinnon, Bruce Bean, Christoph
Westphal, Jennifer Cermak
4:00 p.m.
S17.004
Regulatory Factors of Autophagy
and Triglyceride Accumulation in
Lipid Storage Myopathies Corrado
Angelini, Anna Nascimbeni,
Elisabetta Tasca
4:15 p.m.
S17.005
Biomarkers of Disease Severity in
Myotonic Dystrophy During Skeletal
Muscle Rehabilitation Corrado
Angelini, Chiara Fritegotto, Paola
Cudia
4:30 p.m.
S17.006
Astrocyte Mediated Toxicity
Leads to Motor Neuron Death in
Spinal Muscular Atrophy Dimitra
Papadimitriou, Sudarshan Phani,
Arnaud Jacquier, Virginia LeVerche,
Radhika Pradhan, Shingo Kariya,
Umrao Monani, Diane Re, Serge
Przedborski
4:45 p.m.
S17.007
A Unique Presentation of a Novel
Mutation in the SETX Gene Anna
Bjornsdottir, Yunis Mayasi, Martin
Sigurdsson, Johnny Salameh
5:00 p.m.
S17.008
The Diagnostic Utility of Nerve
Conduction Studies and Skin Biopsy
for Diabetic Neuropathy (DPN):
A Bayesian Analysis A. Smith,
Margaret Lessard, J. Singleton
S18 Neuro-oncology:
Imaging and Quality of Life
3:15 p.m. Presentation of
Neuro-oncology Investigator
Award
Recipient:
Elizabeth Gerstner, MD, MS
Boston, MA
3:30 p.m.
S18.002
Non-invasive Monitoring of
Treatment Response in IDHmutant Glioma Patients by 3D
Functional Spectroscopic Mapping
of 2-Hydroxyglutarate Ovidiu
Andronesi, Franziska Loebel,
Wolfgang Bogner, Malgorzata
Marjanska, Jorg Dietrich, Tracy
Batchelor, Elizabeth Gerstner,
Andrew Chi, Bruce Rosen, Daniel
Cahill
3:45 p.m.
S18.003
Structural Brain Changes in
Patients Undergoing Autologous
Stem Cell Transplantation for
Lymphoma Isabel Arrillaga-Romany,
Kourosh Jafari-Khouzani, Yi-Bin
Chen, Bruce Rosen, Tracy Batchelor,
Jorg Dietrich
4:00 p.m.
S18.004
A Retrospective Study of Home
Hospice Care in Primary Malignant
Brain Tumors Eli Diamond, David
Russell, Kathyrn Bowles, Maria
Kryza-Lacombe, Jeanne Dennis,
Paulina Kim, Holly Prigerson
4:15 p.m.
S18.005
Quality of Life and Symptoms in
Terminal High-grade Glioma Joel
Phillips, Tobias Walbert
4:30 p.m.
S18.006
Pregnancy in Glioma
Patients Jacqueline Stone, Jerome
Graber, Thomas Kaley
4:45 p.m.
S18.007
Complementary and Alternative
Medicine in the Primary Brain Tumor
Population and Its Association with
Health-reported Quality of Life Dina
Randazzo, Mary Affronti, Eric Lipp,
Frances McSherry, James Herndon,
II, Charlene Flahiff, Elizabeth Miller,
Sarah Woodring, Maria Freeman,
Patrick Healy, Janet Minchew,
Susan Boulton, Annick DesJardins,
Tulika Ranjan, Gordana Vlahovic,
Henry Friedman, Katherine Peters
S19 Neurologic Education
3:15 p.m.
S19.001
Neurology Resident Documentation
Using an Electronic Medical
Record (EMR) in the Outpatient
Continuity Clinic and Its Financial
Implications John Liang, David
Lucido, Weiyi Gao, Jean Peng, Vicki
Shanker
3:30 p.m.
S19.002
A Curriculum for the
Milestones Shamik Bhattacharyya,
Tracey Milligan
3:45 p.m.
S19.003
Validation of the Alzheimer’s
Prevention and Risk Knowledge
Score (APRKS) Richard Isaacson,
Jessica Gordon, Alon Seifan
4:00 p.m.
S19.004
Milestone-compatible Neurology
Resident Assessments: A Role for
Observable Practice Activities Lyell
Jones, Elliot Dimberg, Christopher
Boes, Scott Eggers, David Dodick,
Jeremy Cutsforth-Gregory, Andrea
Leep Hunderfund, David Capobianco
The Resident
Experience
Saturday, April 18 through Friday, April 24
The Resident Experience offers a unique
opportunity for Medical students,
Residents, and Fellows to explore an
array of career resources and network
with peers. Participants can learn more
about AAN resources and attend
special presentations.
4:15 p.m.
S19.005
Procedural Headache Medicine
in Neurology Training: A Survey
of US Residency Program
Directors Matthew Robbins, Carrie
Robertson, Jessica Ailani, Morris
Levin, Deborah Friedman, David
Dodick
Tuesday
April 21
S17 Muscle and Anterior
Horn Cell Diseases:
Mechanisms and
Biomarkers
4:30 p.m.
S19.006
Internet Teaching of the Neurologic
Examination and OSCE Performance
in the Neurology Clerkship Cara
Harth, Yaqi Xue, Jie Yang
4:45 p.m.
S19.007
Formal Faculty Assessment of
Bedside Skills for 3rd Year Medical
Students on the Neurology Clerkship:
The Year Two Experience Robert
Thompson Stone, Christopher
Mooney, Erika Wexler, Jonathan
Mink, Ralph Jozefowicz
Fast, Easy, Online Registration · AAN.com/view/AM15
87
Poster Session IV
Wednesday, April 22
P4 First
Poster Session IV
Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Discussion Session: MS and CNS Inflammatory Diseases
7:30 a.m.–12:00 p.m.
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
P4.001 Effect of Fingolimod Versus
Interferon-beta1a on No Evidence of
Disease Activity or Worsening (NEDA4) in the TRANSFORMS Study Xavier
Montalban, Jeffrey Cohen, Frederik Barkhof,
Bhupendra Khatri, Hans Hartung, Shannon
Ritter, Daniela Piani Meier, Davorka Tomic,
Ludwig Kappos
P4.002 Treatment with ATX-
MS-1467 Persistently Triggers IL-10, But
Not Pro-inflammatory Cytokine Release
and Induces a Population of Lag3+CD4+
Cells in a Humanized HLA/TCR Mouse
Model Adriano Soares de Souza, Stefan
Rudin, Dongzi Yu, Shinji Okitsu, Blake
Tomkinson, Tammy Dellovade
P4.003 An Open Label Add-on Trial of
P4.005 Fampridine Modulates
P4.008 Comparative Effects of
P4.004 Combined Analysis of
P4.006 Failure of Early Lesion
P4.009 Decreased Amino Acid
Cetirizine for Neuromyelitis Optica Ilana
Katz Sand, Michelle Fabian, Lawrence Cook,
Mirna Chehade, Madhan Masilamani,
Thomas Kraus, Colleen Farrell, Shelly
Phelps, Mary Ellen Riffle, John Rose,
Thomas Moran, Fred Lublin
DIR and PSIR Images Discloses a High
Cortical Lesion Load in Multiple Sclerosis
Cortex Alice Favaretto, Davide Poggiali,
Andrea Lazzarotto, Giuseppe Rolma,
Francesco Causin, Francesca Rinaldi, Paola
Perini, Paolo Gallo
Thalamic Resting State Functional
Connectivity and Ameliorates Fatigue in
Multiple Sclerosis Patients Maria Rocca,
Paola Valsasina, Bruno Colombo, Paolo
Preziosa, Vittorio Martinelli, Andrea Falini,
Giancarlo Comi, Massimo Filippi
Repair in Multiple Sclerosis Lesions with
Persistent Phase RIM Martina Absinta,
Pascal Sati, Massimo Filippi, Joan Ohayon,
Irene Cortese, Daniel Reich
P4.007 Daclizumab HYP Versus
Interferon β-1a Across Patient
Demographic and Disease Activity
Subgroups in the DECIDE Phase 3
Study Heinz Wiendl, Eva Havrdova, John
Rose, Katherine Riester, Claire Tsao, Steven
Greenberg
Dimethyl and Monomethyl Fumarate (DMF/
MMF) on Human Myeloid Cells Laurence
Poliquin-Lasnier, Mackenzie A. MichellRobinson, Lindsay Osso, Nika Zorko, Craig
Moore, Luke M. Healy, Anne-Marie Trudelle,
Paul Giacomini, Amit Bar-Or, Jack Antel
Catabolism in Multiple Sclerosis Affects
Immune Homeostasis Jorge Correale,
Mauricio Farez
P4.010
Humoral Responses to
Systemic and Organ Specific Autoantigens in Multiple Sclerosis Kishore
Malyavantham, Bianca Weinstock-Guttman,
Lakshmanan Suresh, Robert Zivadinov,
Thomas Shanahan, Darlene Badgett, Murali
Ramanathan
e-Poster Session: MS and CNS Inflammatory Diseases I
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P4.011
B Cells Responding to Viral
Antigens Can Provoke a T Cell Response
Against Myelin Antigens nicholas
sanderson, Maria Zimmermann, Raija
Lindberg, Ludwig Kappos, Tobias Derfuss
P4.012
Slowly Eroding Lesions in
Multiple Sclerosis Varun Sethi, Govind
Nair, Blake Dewey, Colin Shea, Arun
Venkataraman, Tianxia Wu, Kelly Yang,
Daniel Reich
P4.013
The Topographical Model of
Multiple Sclerosis: A New Visualization of
Disease Course Stephen Krieger
MS and CNS Inflammatory
Diseases: Pediatric MS and MS
Variants
P4.021 The Epidemiology of Pediatric
Multiple Sclerosis in the United States
Using Data from the Pediatric Health
Information System (PHIS) Amy Lavery,
Brenda Banwell, Amy Waldman
88
P4.014
Vitamin D as a Predictor
of Functional Deficits in Multiple
Sclerosis Kathryn Fitzgerald, Kassandra
Munger, Mark Freedman, Hans Hartung,
David Miller, Xavier Montalban, Gilles Edan,
Frederik Barkhof, Rupert Sandbrink, Ludwig
Kappos, Gustavo Suarez, Christoph Pohl,
Alberto Ascherio
P4.015
Quantifying Visual Pathway
Axonal and Myelin Loss in Neuromyelitis
Optic Praveena Manogaran, Shannon
Kolind, Irene Vavasour, Alex Lange, David Li,
Anthony Traboulsee
P4.022 Binocular Low-contrast
Acuity and the Symbol Digit Modalities
Test Improve the Ability of the Multiple
Sclerosis Functional Composite to
Predict Disease in Pediatric Multiple
Sclerosis Amy Waldman, Salim Chahin,
Brenda Banwell, Grant Liu, Laura Balcer
P4.023 Self-efficacy and Functional
Disability as Barriers to Physical Activity
Participation in Pediatric Multiple
Sclerosis Carolyn Sawicki, Stephanie
Grover, Dominique Kinnett-Hopkins,
Robert Motl, Marcia Finlayson, Jane
Schneiderman, E. Ann Yeh
P4.016
Long-term Evolution of
Magnetization Transfer Ratio in Multiple
Sclerosis Lesions Yufan Zheng, Richard
Rudick, Jar-Chi Lee, Elizabeth Fisher
P4.017
Relationship Between Timed
25-foot Walk Impairment and Diffusion
Tensor Imaging Markers in Multiple
Sclerosis Sylvia Klineova, Rebecca
Farber, Colleen Farrell, Matilde Inglese,
Catarina Saiote, Bradley Delman, Lawrence
Tanenbaum, Fred Lublin, Stephen Krieger
P4.018
Clinical Course, Radiologic
Features, and Treatment Response in
Patients with Tumefactive Demyelinating
Lesions in Toronto Kristen Krysko, Liesly
Lee, Paul O'Connor
P4.024 Risk of a Second Clinical
Attack in Pediatric Patients with a First
Demyelinating Clinical Attack Suggestive
of Multiple Sclerosis Pietro Iaffaldano,
Giuseppe Lucisano, Angelo Ghezzi,
Giancarlo Comi, Vincenzo Brescia Morra,
Francesco Patti, Alessandra Lugaresi, Carlo
Pozzilli, Maria Amato, Helmut Butzkueven,
Raed Alroughani, Vahid Shaygannejad,
Seyed Aidin Sajedi, Guillermo Izquierdo,
Giuseppe Salemi, Enrico Millefiorini,
Giacomo Lus, Marta Simone, Vito Lepore,
Maria Trojano, on behalf of Italian iMedWeb
Registry, and MSBase Investigators
P4.019Progressive
Autoimmune Neuromyotonia with
Low Voltage-gated Potassium
Channel-complex IgG and CASPR2IgG Following Remote Inflammatory
Polyradiculoneuropathy Jenny Linnoila,
Charles Kassardjian, Cullen O'Gorman,
Nathan Staff, William Litchy, Margherita
Milone, Vanda Lennon, Christopher Klein
P4.020 Retinal Segmentation
Distinguishes Neuromyelitis Optica from
Multiple Sclerosis Using Optical Coherence
Tomography Regardless of Antibody
Status Richard Loeb, Ashley Finch, Adil
Javed, Jacqueline Bernard
P4.025 Cognitive Impairment Is
Associated with Behavioral Problems in
Pediatric Multiple Sclerosis (MS) Bianca
Cersosimo, Colleen Schwarz, Nikita Gupta,
Nneka Amadiume, Anita Belman, Lauren
Krupp, Leigh Charvet
P4.026 Vision, Fatigue, and Quality
of Life in Pediatric Multiple Sclerosis
and Monophasic Demyelinating
Diseases Salim Chahin, Brenda Banwell,
Laura Balcer, Amy Waldman
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session IV
P4.027 Gut Microbiome in Early
Pediatric Multiple Sclerosis: A Case-control
Study Helen Tremlett, Douglas Fadrosh,
Susan Lynch, Janace Hart, Jennifer Graves,
Sabeen Lulu, Gregory Aaen, Anita Belman,
Leslie Benson, Charlie Casper, Tanuja
Chitnis, Mark Gorman, Lauren Krupp,
Timothy Lotze, Jayne Ness, Shelly Roalstad,
Moses Rodriguez, John Rose, Jan-Mendelt
Tillema, Bianca Weinstock-Guttman,
Emmanuelle Waubant
P4.028 Inhibition of Adult
Neurogenesis in a Marburg´s Variant of
Multiple Sclerosis Celia Oreja-Guevara,
Julia García-López, Rafael SánchezSánchez, Aida Orviz-García, Ines GonzálezSuárez, Alberto Rábano, Ulises GómezPinedo, Jorge Matías-Guiu
P4.029 Perivascular Inflammation
in Baló-like Concentric Sclerosis—
Preliminary Results from a 7T MRI Case
Series Janina Behrens, Tim Sinnecker,
Joseph Kuchling, Lutz Harms, Klemens
Ruprecht, Thoralf Niendorf, Friedemann
Paul, Jan Dörr, Jens Wuerfel
MS and CNS Inflammatory
Diseases: Progressive Multifocal
Leukoencephalopathy Risk
P4.030 Natalizumab-related PML Is
Possible Even with Recent Negative JCV
Antibody Testing Marie-Sarah Brosseau,
Gary Stobbe, Deb Cramer, Hillary Lipe,
Annette Wundes
P4.031 Anti-JC Virus (JCV) Antibody
P4.035 Use of IL- 2 for Management
of Natalizumab-associated Progressive
Multifocal Leukoencephalopathy Yinan
Zhang, Divyanshu Dubey, Allen DeSena,
Donna Graves, Elliot Frohman, Benjamin
Greenberg
P4.036 A Longitudinal Assessment
of John Cunningham Virus (JCV) Index in a
Real-world MS Population Tamara Hoyt,
Angelene Christensen, Angela Foley, Ryan
Metzger
P4.037
Correlation Between Anti-JCV
and Anti-CMV Antibodies Michael Auer,
Wegene Borena, Holm-von Laer Dorothee,
Florian Deisenhammer
P4.038 Co-incidence of Anti-
JCV and Anti-CMV Antibodies in MS
Patients Florian Deisenhammer, Michael
Auer, Wegene Borena, Dorothee Holm-von
Laer
P4.039 CD62L (L-selectin) Is Not
a Reliable Biomarker for Predicting
Risk of Progressive Multifocal
Leukoencephalopathy in Natalizumabtreated Multiple Sclerosis Patients Linda
Lieberman, Wanyong Zeng, Tatiana Plavina,
Carol Singh, Kevin Otipoby, Christine Loh,
Leonid Gorelik, Ellen Cahir McFarland
in Multiple Sclerosis Patients in Italy.
Report of the Italian Group for MS-PML
Study Cinzia Cordioli, Nicola De Rossi,
Simonetta Gerevini, Maria Pia Amato, Fabio
Bandini, Paola Cavalla, Marco Capobianco,
Luciano Deotto, Milena Alessandra De Riz,
Ernesta Ferrari, Maria Letizia Fusco, Angelo
Ghezzi, Luigi Maria Grimaldi, Alessandra
Lugaresi, Lucia Moiola, Patrizia Susanna
Mar Perrone, Luca Prosperini, Monica
Rezzonico, Marco Rovaris, Giuseppe Salemi,
Marco Salvetti, Claudio Solaro, Carla
Tortorella, Ruggero Capra
P4.041
Recurrent Opticospinal
Inflammatory Disease in Association to
Ipilimumab Rana Zabad, Neil Jouvenat,
Alissa Marr
P4.042 Swelling of the Outer Retinal
P4.043 The TIGIT/CD226/CD155
Axis Is Differentially Expressed in
MS and Glioblastoma: Implications
for Autoimmunity and Tumor Immune
Escape Daniel Lowther, Sriram Ramanan,
Danielle DeBartolo, Calvin Park, Xiangguo
Duan, David Hafler, David Pitt
P4.044 Distinct MRI Patterns
Differentiate Multiple Sclerosis with
Cavitary Lesions and Vanishing White
Matter Disease Xavier Ayrignac, Nicolas
Menjot de Champfleur, Sophie Menjot de
Champfleur, Astrid Corlobe, Clarisse CarraDalliere, Pierre Labauge
Fast, Easy, Online Registration · AAN.com/view/AM15
P4.057 Neuropsychological Profile
of Patients with Immune Mediated
Encephalopathy Marcos Fernandez Suarez,
Ramiro Fernandez Castaño, Romina Tirigay,
Daniel Politis, Raul Melano, Ricardo Allegri
P4.058 Characteristics of
Autoimmune Encephalitis at Two Teaching
Hospitals Divyanshu Dubey, Anshudha
Sawhney, Benjamin Greenberg, Worthy
Warnack, Pravin Khemani, Steven Vernino
P4.047 Cartilage and the
Brain: Encephalitis in Relapsing
Polychondritis Johanna Hamel, Andrew
Goodman
Late Cerebellar Atrophy
and Long-term Outcome in Anti-NMDA
Receptor Encephalitis Takahiro Iizuka,
Hidehiro Someko, Hiroki Oonuma, Atsuko
Kubo, Masaaki Nakamura, Daisuke Ishima,
Juntaro Kaneko, Eiji Kitamura, Ray Masuda,
Josep Dalmau, Kazutoshi Nishiyama
P4.048 Plasmapheresis in
P4.060 Serum Antibodies Isolated
Corticosteroid-resistant Acute
Disseminated Demyelination: Report of
Two Adult Cases Shailee Shah, Sharon
Stoll, Thomas Leist
P4.049 Ma2 Autoantibody-negative
Multifocal Paraneoplastic Neurological
Disorder Associated with Metastatic
Testicular Cancer Jenny Linnoila, Vanda
Lennon, Sean Pittock
P4.050 Hereditary Diffuse
P4.051
Layers in Acute Optic Neuritis Rhian
Raftopoulos, Chieh-Li Chen, Simon
Hickman, Ahmed Toosy, Claudia WheelerKingshott, Daniel Altmann, Shahrukh Mallik,
David Paling, Marios Yiannakas, Klaus
Schmierer, Rose Sheridan, Basil Sharrack,
Gavin Giovannoni, Laura Balcer, David
Miller, Hiroshi Ishikawa, Raju Kapoor
P4.034 Natalizumab-related PML
in the ICU: Serological Spectrum,
Clinical Courses, Complications, and
Outcomes Andrew McKeon, Manoj Mittal,
Sara Hocker, Sean Pittock, Eelco Wijdicks,
Alejandro Rabinstein
P4.040 Differential Diagnosis of
P4.032 Optimizing the Natalizumab
of Progressive Multifocal
Leukoencephalopathy in a Natalizumabtreated Patient Stefania De Mercanti, Carlo
Alberto Artusi, Marinella Clerico, Marco
Iudicello, Alessandro Vacca, Eleonora
Virgilio, Luca Durelli
P4.046 Autoimmune Encephalitis
Leukoencephalopathy with Spheroids:
A Volumetric Comparison with Multiple
Sclerosis and Healthy Controls Tobias
Granberg, Oluf Andersen, Cristina Sundal,
Virginija Danylaité Karrenbauer
Transverse Myelitis: Retrospective Cohort
Study in Argentina Alejandro Köhler,
Francisco Varela, Lucas Alessandro, Ismael
Calandri, Mauricio Farez, Jorge Correale
P4.033 Atypical Presentation
Features of Limbic Form of Hashimoto’s
Encephalopathy Toru Kishitani, Akiko
Matsunaga, Masamichi Ikawa, Tomomi
Kame, Osamu Yamamura, Tadanori
Hamano, Osamu Watanabe, Keiko Tanaka,
Yasunari Nakamoto, Makoto Yoneda
MS and CNS Inflammatory
Diseases: CNS Inflammatory
Diseases and Differential
Diagnosis
Index Differentiates Risk of Progressive
Multifocal Leukoencephalopathy
(PML) in Natalizumab-treated Multiple
Sclerosis (MS) Patients with No Prior
Immunosuppressant (IS) Use: An Updated
Analysis Geoffrey Kuesters, Tatiana
Plavina, Sophia Lee, Denise Campagnolo,
Sandra Richman, Shibeshih Belachew,
Meena Subramanyam
Dose Interval to Reduce PML Risk—
Lessons from the Pharmacokinetics of
Therapy Discontinuation John Foley,
Ryan Metzger, Tamara Hoyt, Angelene
Christensen
P4.045 Clinical and Immunological
Combined Therapy with
Infliximab and Methotrexate in a Case
of Neurosarcoidosis with Chiasmatic
Involvement at Onset Begoa Palazon, Rocio
Hernandez Clares, Ester Carreon Guarnizo,
Maria Cerdan, Judith Jimenez Veiga, Gema
Salgado, Javier Martin, Jose Meca La Llana
P4.052 Auricular Polychondritis
Presenting as Non-infectious,
Non-paraneoplastic Limbic
Encephalitis Scheherazade Le, James Ho,
Rowza Rumma
P4.053 Acute Evidence of
CNS Inflammation in Patients with
Mitochondrial Diseases Yael Hacohen,
Sona Narula, Amy Waldman, Sarah
Hopkins, James Brenton, Amit Bar-Or,
Angela Vincent, Brenda Banwell
P4.054 ALD Connect: A
Patient Powered Research Network
Harmonizes Efforts to Cure
Adrenoleukodystrophy Keith Van Haren,
Florian Eichler, Ben Lenail, Ali Fatemi,
Kathleen Zackowski, Gerald Raymond,
Amber Salzman, Inna Tsvang, Joshua
Bonkowsky, Robert Brown, John Fink,
Kathleen O'Sullivan-Fortin, Rachel Salzman,
Alexander Sherman
P4.055 Unusual Association of Acute
Motor and Sensory Axonal Polyneuropathy
(AMSAN) with EBV in the Absence of a
Preceding Illness: A Case Report Abdalla
Hassan, Prajwal Boddu, Azmatullah
Hussaini, Raina Gupta
P4.056 A Case Report of Rheumatoid
Meningitis, an Unusual Complication of
Rheumatoid Arthritis Bhaskar Roy, Justine
Brink, Ekaterina Bakradze, Fatmah Al Zahmi,
Dean Uphoff, Isaac Silverman
P4.059
from Neuro-Behcet’s Disease Patients
Mediate Neuronal Death and Cognitive
Impairment Erdem Tuzun, Ece Erdag, Ceren
Sahin, Cem Kucukali, Mehmet Kaya, Murat
Kurtuncu, Recai Turkoglu, Feyza Aricioglu
P4.061
Screen for Novel Antiastrocytic Antibodies in Patients
with Autoimmune and Paraneoplastic
Encephalitis Kyong Shin, Melina Jones,
Michael Levy
P4.062 A Rare Presentation of Neuro-
Behcet's Disease (NBD) David Harris, Syed
Omar Shah, Jacqueline Urtecho, Rodney Bell
P4.063 Single Cell PCR Analysis of
the Intrathecal Plasma Cell Repertoire in
Autoimmune Encephalitis Manish Malviya,
Nico Melzer, Christian Elger, Heinz Wiendl,
Hans Hartung, Norbert Goebels
P4.064 Acute Bulbar Palsy as
Presentation of Anti-NMDA Receptor
Encephalitis: A Case Report Takahiro Iizuka,
Masaaki Nakamura, Daisuke Ishima, Juntaro
Kaneko, Josep Dalmau, Kazutoshi Nishiyama
P4.065 Patient with Established,
Seropositive Neuromyelitis Optica Presenting
in Status Epilepticus Due to NMDA Receptor
Antibodies Ashutosh Kumar, Victor Sung,
John Rinker, William Meador
P4.066 Successful Treatment of NMDA
Receptor Antibody Associated Encephalitis
Using Intrathecal Methotrexate Chengwei
Peng, Siddharama Pawate
P4.067
CNS Demyelination During
Anti TNF-alpha Therapy Kristine Dahl,
Jette Lautrup Frederiksen Battisti
P4.068 TNF-alpha Inhibitor
Associated Myelopathies: A Neurological
Complication in Patients with
Rheumatologic Disorders Paula Barreras,
Maureen Mealy, Carlos Pardo-Villamizar
P4.069 Distinguishing Slow
Flow Spinal Arteriovenous Fistulas
from Idiopathic Transverse Myelitis:
A Retrospective Study of 94
Patients Jasmine Dudankar, James Chen,
Maureen Mealy, Phillipe Gailloud, Carlos
Pardo-Villamizar, Michael Levy
P4.070
Acute HIV Infection in a
Child Presenting with Transverse Myelitis
and Subsequent Neuromyelitis Optica
Diagnosis Amanda Moen, Daniel Olson,
Mark Abzug, Jeffrey Bennett, Teri Schreiner
89
Wednesday
April 22
7:30 a.m.–12:00 p.m.
Poster Session IV
P4.071
7:30 a.m.–12:00 p.m.
Prevalence of Optical
Coherence Tomography (OCT) Abnormalities
in a Cohort of HLTV-1 Associated
Myelopathy/ Tropical Spastic Paraparesis
(HAM/TSP) Patients Nathan Tagg, Sonya
Bakshi, Winston Liu, Emily Leibovitch,
Govind Nair, Joan Ohayon, Daniel Reich,
Steven Jacobson, Irene Cortese
P4.082 Pre-symptomatic Detection of
P4.072
P4.083 Role of ATP-binding Cassette
Diagnostic and Therapeutic
Management of Non-traumatic Acute
Myelopathy Based on Clinical Experience
with 66 Cases Begoa Palazon, Ester
Carreon Guarnizo, Rocio Hernandez Clares,
Gema Salgado, Judith Jimenez Veiga,
Javier Martin, Jose Meca La Llana
P4.073 Myelitis. Clinical and
Radiological Differences Between Multiple
Sclerosis and Other Etiologies Silvia
Presas, Laia Grau-Lopez, Jose Vicente
Hervas, Anna Massuet-Vilamajo, Cristina
Ramo
P4.074
Extra-pontine Lesions
of CLIPPERS (Chronic Lymphocytic
Inflammation with Pontine Perivascular
Enhancement Responsive to
Steroids) Hiroaki Sekiya, Kenji Sekiguchi,
Hisatomo Kowa, Yukiko Morinaga, Tomoo
Itoh, Fumio Kanda, Tatsushi Toda
P4.075
A Case of Duane
Syndrome, Developmental Venous
Anomalies, Hydrocephalus, and Multiple
Sclerosis: Possible Link or Just a Coincidence? Ahmed Obeidat, Aram Zabeti
P4.076
How Often Is CADASIL
Diagnosed as Multiple Sclerosis? Swati
Sathe, Edward Nunziato
Aging, Dementia, Cognitive, and
Behavioral Neurology: Basic and
Pre-clinical Studies
P4.077 Evaluations of the Effect of
Subchronic Administration of Crude Khat
Extract (Catha Edulis F.) on Learning and
Memory in Mice Mohammed Faiz, Ephrem
Engidawork, Teshome Nedi
P4.078
Selective Reduction of
Oxidative Stress Markers in the SAMP8
Mouse Brain by a Distinct Spearmint
Extract with Antioxidant Properties Susan
Farr, Brenda Fonseca, Kelli Herrlinger, Kristin
Nieman, Michael Ceddia, Linda Fullmer,
Michael Niehoff, Brandon Lewis, Andrew
Welleford, D Butterfield, John Morley
P4.079
Adolescent Exposure of
Genetic Mutant Mice to Cannabis Produces
Cognitive Deficits Bagrat Abazyan, Sofya
Abazyan, Olga Mychko, Alexey Shevelkin,
Chunxia Yang, Atsushi Kamiya, Mikhail
Pletnikov
P4.080 The Interactive Effects of
Ketamine and Magnesium on Brainderived Neurotrophic Factor (BDNF) and
Depressive-like Behavior Sara Razmjou,
Darcy Litteljohn, Shawn Hayley
P4.081 In Vivo Drug Discovery
for Tauopathy Using Novel Zebrafish
Models Edward Burton, Qing Bai
90
Cytoplasmic TDP-43 Accumulation Using
Tissue-engineered Skin Model Derived
from C9ORF72-FALS Patients Nicolas
Dupre, Bastien Paré, Lydia TouzelDeschênes, Peter Gould, Stephan Saikali,
Jean-Pierre Bouchard, Patrick Dion, François
Berthod, Guy Rouleau, Francois Gros-Louis
Transporters in Efflux of Amyloid-ß at the
Human Blood-brain Barrier Yasuteru Sano,
Masaaki Abe, Hideaki Nishihara, Yukio
Takeshita, Takashi Kanda
P4.084 PACAP Deficit and Cognitive
Function in Mild Cognitive Impairment and
Alzheimer Dementia Pengcheng Han,
Richard Caselli, Leslie Baxter, Geidy Serrano,
Thomas Beach, Eric Reiman, Jiong Shi
Aging, Dementia, Cognitive, and
Behavioral Neurology: Prognosis
and Longitudinal Course of
Dementia
P4.085 Neuroimaging-based Staging
of Pathological Spread in Patients with
Known Tau Pathology Corey McMillan,
David Irwin, Laura Baehr, Kylie Ternes,
Christopher Olm, Vivianna Van Deerlin,
Virginia Lee, John Trojanowski, Murray
Grossman
P4.086 A Multi-center Cross-
validation of FDG- and Amyloid-PET as
in Vivo Biomarkers for the Prediction of
MCI Progression Leonardo Iaccarino,
Konstantinos Chiotis, Pierpaolo Alongi, Chiara
Cerami, Alessandra Marcone, Valentino
Bettinardi, Sandro Iannaccone, Stefano
Cappa, Agneta Nordberg, Daniela Perani
P4.087 Prognostic Significant
of Subtypes of MCI for Dementia and
Mortality: Data from the NEDICES
Cohort Alvaro Sanchez-Ferro, Felix
Bermejo-Pareja, Israel Contador, Rocio
Trincado, David Lora, Alex Mitchell, Jesús
Hernández-Gallego, Sara Llamas, Alberto
Villarejo Galende, Julian Benito-Leon
P4.088Self-administered
Gerocognitive Examination (SAGE)
Score Changes over Time in Subjective
Cognitive Impairment (SCI), Mild
Cognitive Impairment (MCI), Dementia
Converters, and Alzheimer’s Disease (AD)
Patients Douglas Scharre, Shu-Ing Chang,
Haikady Nagaraja, Maria Kataki, Natalie
Wheeler, Anahita Adeli
P4.089 Hippocampal Volume as a
Biomarker for Enrichment in Clinical Trials
in Amnestic Mild Cognitive Impairment: A
Comparison of Performance Characteristics
in ADNI-1 and AddNeuroMed Gerald
Novak, Andy Simmons, Eric Westman,
Patricia Cole, Mark Gordon, Enchi Liu, Simon
Lovestone, Diane Stephenson
P4.090 Grey Matter and White
Matter MRI Markers of Cognitive
Progression in Early and Late Onset
Variants of Alzheimer’s Disease Federica
Agosta, Francesca Caso, Daniele Mattavelli,
Massimiliano Copetti, Giuseppe Magnani,
Elisa Canu, Alessandra Marcone, Monica
Falautano, Giancarlo Comi, Andrea Falini,
Massimo Filippi
P4.091 Brain Structural Correlates of
Trajectories to Cognitive Impairment in the
Cardiovascular Health Study—Cognition
Study James Becker, Mikhail Popov,
Fabrizio Lecci, H. Gach, Brian Junker, Lewis
Kuller, Oscar Lopez
P4.092 Empirically Defining
Trajectories of Late-life Cognitive and
Functional Decline and Classifying Potential
Trajectory Class Membership Helen
Hochstetler, Paula Trzepacz, Shufang
Wang, Peng Yu, Michael Case, JeannieMarie Leoutsakos, David Henley, Elisabeth
Degenhardt, Constantine Lyketsos
P4.093 Combining Novel Verbal
Fluency Scores and Structural MRI for
Prognosis of MCI David Clark, Ellen Woo,
Kristy Hwang, Sona Babakchanian, Jennifer
Eastman, Leslie Ramirez, Liana Apostolova
P4.094 Predictors of Convertion
from CDR 0,5 to CDR 1 Using a Mutimodal
Assesment in a Latin American Population.
A Study of ADNI-ARG Ricardo Allegri,
Marcos Fernandez Suarez, Federico Nahas,
Fernando Ventrice, Maria Russo, Ezequiel
Surace, Maria Clarens, Maria Martin,
Fernanda Tapajoz, Paula Harris, Patricio
Chrem Mendez, Ramon Leiguarda, Carlos
Romero, Silvia Vazquez, Gustavo Sevlever
P4.095 Longitudinal Assessment of
Frontal Cognitive Impairment in Patients
with Motor Neuron Disease Pilar Maria
Ferraro, Federica Agosta, Edoardo Spinelli, Elisa
Canu, Nilo Riva, Massimiliano Copetti, Andrea
Falini, Giancarlo Comi, Massimo Filippi
Aging, Dementia, Cognitive, and
Behavioral Neurology: Rapidly
Progressive and Inflammatory
Dementias
P4.096 Rapidly Progressive Dementia
P4.102
Reversible Amyloid
CSF Biomarker in Immune Mediated
Encephalopathy Marcos Fernandez Suarez,
Ezequiel Surace, Miguel Riudavets, Silvia
Vazquez, Gustavo Sevlever, Ricardo Allegri
P4.103
Characterization of the First
American Case of Familial Prion Disease
Due to the PRNP-G114V Mutation Fadi
Mikhail, Crystal Busch, Eric Norstrom, Peter
Pytel, Pierluigi Gambetti, James Mastrianni
P4.104
Limbic Encephalitis
Exacerbations and Remissions Charted by
Microglial PET Scan: A Case Study Rhonna
Shatz, Harry Chugani
Neuromuscular Disease: Basic
Science
P4.105
Aging-associated Motor Axon
Nav1.8 Channelopathy in Mice Christian
Krarup, Mette Rosberg, Susana Herrero,
Dennis Klein, Rudolf Martini, Mihai
Moldovan
P4.106
Epidermal Innervation of the
Rat Footpad and Correlation with Pain
Behavior Following Partial Sciatic Nerve
Injury Joost Jongen, Malik Bechakra,
Barthold Schuttenhelm, Tiziana Pederzani
P4.107
Neuroprotective Effects of
Laquinimod in Lewis Rat Experimental
Autoimmune Neuritis Kalliopi Pitarokoili,
Björn Ambrosius, Lisa Schrewe, Liat
Hayardeny Nisimov, Michael Hayden, Ralf
Gold
P4.108Immunohistochemical
Analysis of ErbB4, a Causative Gene
Product for ALS19, in the Spinal Cord of
Sporadic ALS Patients Yuji Takahashi,
Ayako Shioya, Chihiro Matsumoto, Terunori
Sano, Shigeo Murayama, Miho Murata,
Yuko Saito
and Brain Atrophy Caused by Primary
Central Nervous System Extranodal NK/Tcell Lymphoma, Nasal Type Yoshimitsu
Shimatani, Ryosuke Miyamoto, Shigeo
Murayama, Yuishin Izumi, Oki Ryosuke,
Ryuji Kaji
P4.109
P4.097 Use of the RBANS and NPI-Q
P4.110
in Autoimmune Encephalopathy Brendan
Kelley, Robin Bratt
P4.098 A Genetic Form of Creutzfeldt
Jakob Disease: A Case Report Tereza
Svrcinova, Jan Mares, Zuzana Mouchova,
Petr Kanovsky
P4.099 Thiamine Depletion in
Sugar Catabolism: Yet Another Cause of
Wernicke-Korsakoff Syndrome Michael
Lane, Sanjay Anandaram, Elijah Stommel
P4.100
Genetic Prion Disease Caused
by a Q160X PRNP Mutation Presenting with
an Orbitofrontal Syndrome Julio Rojas,
Jamie Fong, Giovanni Coppola, Andrea
Legati, Anna Karydas, Katherine Rankin, Jee
Bang, Zachary Miller, Michael Geschwind
P4.101
Protean Manifestations
of IgG Encephalopathy. A Potentially
Reversible Cause of Rapidly Declining
Mental Status? Roomana Ahad, Govind
Pandompatam, Iftekhar Ahmed
Identification of Widespread
Alterations in RNA Metabolism in Sporadic
Inclusion-body Myositis Using SILACbased Quantitative Proteomics Maximilian
Berger, Tobias Opialla, Andreas Marg,
Stefan Kempa, Simone Spuler
Identification of Splicing
Changes in the Blood and Muscle in
Congenital Myotonic Dystrophy Nicholas
Johnson, Russell Butterfield, Katie Mayne,
Diane Dunn, Stefan Pulst, Robert Weiss
P4.111
Identification of High Glucose
Induced Cell Signaling Human in Schwann
Cells Zhao Zhong Chong, Hongxin Chen,
Tong Liu, Hong Li, Nizar Souayah
P4.112
Neuregulin 1 Type III
Overexpression Alters Neuromuscular
Junctions (NMJ) and Myelin Thickness in
the Heterozygous R98C Knock-in Mouse
Model of CMT1B Yunhong Bai, Chiara
Pisciotta, Suola Wang, Xingyao Wu, Markus
H Schwab, Klaus Armin Nave, Michael Shy
P4.113 The Effect of Hyperglycemia
on Human Schwann Cells Hongxin Chen,
Howard Sander, Nizar Souayah
P4.114
Multiparametric Recordings of
the Nerve Action Potential Mark Stecker,
Melanie Wegener
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session IV
Neuromuscular Disease: Health
Services and Outcome Measures
Development and
Validation of the Chronic Acquired
Polyneuropathy- Patient Reported Index
(CAP-PRI) to Measure Quality of Life in
Patients with Chronic Immune-mediated
Polyneuropathies Kelly Gwathmey, Vera
Bril, Carolina Barnett, Eduardo Ng, Thomas
Brannagan, Michael Hehir, William David,
Karissa Gable, Jennifer Dineen, Jeff Guptill,
Lisa Hobson-Webb, Reza Sadjadi, Mark
Conaway, Amruta Joshi, Ted Burns
P4.133
Effects of Automed Sputum
ALS: Health Services and
Aspirating Device for the Patients with
Congenital Muscular Dystrophy Using TPPV Outcomes Measures
Takayasu Fukudome, Hidenori Matsuo
P4.125 Caregiver Burden Does Not
P4.117 Incentivizing Clinical Registry
Affect Patient Survival in Amyotrophic
Participation—Findings from the Muscular Lateral Sclerosis; Investigating Factors
Dystrophy Association U.S. Neuromuscular Contributing to Burden Tom Burke, Marwa
Disease Registry Jodi Wolff, Valerie Cwik
Elamin, Miriam Galvin, Orla Hardiman, Niall
Pender
P4.118 Patient Reported Quality of
Life Measures in Limb-girdle Muscular
P4.126 Quality Measure-driven
Dystrophy: Correlation with Clinical
Interdisciplinary Template for Care of
Outcomes Tina Duong, Carolina Tesi
Veterans with ALS Ileana Howard, Eilis
Rocha, Heather Gordish-Dressman, Lauren
Bodreau, Richard Bedlack
Morgenroth, Robert Leshner, Susan Sparks
P4.127 Feasibility Study of the
P4.119 Development and Preliminary Use of Telemedicine in the Care of ALS
Validation of a New Impairment Measure
Patients Michael Pulley, Alan Berger,
for Myasthenia Gravis Carolina Barnett
Wayne Hodges, Rebecca Brittain
Tapia, Vera Bril, Moira Kapral, Abhaya
Kulkarni, Aileen Davis
P4.135
P4.115
Trends in Outcome and
Hospitalization Charges of Infantile
Botulism in the United States: A
Comparative Analysis Between Kids'
Inpatient Database (KID) and National
Inpatient Sample (NIS) Ankit Pahwa,
Tamara Opila, Mohammad El-Ghanem,
Nizar Souayah
P4.124
P4.116
Have a Voice in Your Academy
Attend the AAN Business Meeting at 8:00 a.m. on
Monday, April 20, during the 2015 AAN Annual Meeting
in Washington, DC, to make your voice heard on matters
of importance to you, and cast your vote for the 2015
AAN Board of Directors. Learn more about the nominees
at AAN.com/view/BoardSlate .
P4.121
A Description of Pain in
Amyotrophic Lateral Sclerosis Helen
Stephens, Susan Walsh, Divisha Raheja,
Zachary Simmons
P4.120
The Effect of Gender
and Bimodal Age Distribution on
Hospitalization Charges and Outcomes for
Myasthenia Gravis Patients Treated with
Intravenous Immunoglobulin Compared
to Plasmapheresis Tamara Opila, Howard
Sander, Nizar Souayah
P4.122
Diaphragm Ultrasound:
A Potential Outcome Measure in
Amyotrophic Lateral Sclerosis Karen
Karwa, Angela Malek, David Stickler
P4.123
The Reliability of Patient
Reported Outcome Measures (PROMs)
for Inflammatory Myopathies Obtained in
the Home Infusion Care Model Gretchen
Ayer, Lisa Christopher-Stine, Shafeeq
Ladha, Tahseen Mozaffar, Yuen So, Nicholas
Silvestri
P4.128
Utility of Screening for
Monoclonal Gammopathy in ALS Tara
Quesnell, Mazen Dimachkie, Mamatha
Pasnoor, Richard Barohn, Laura Herbelin,
Arthur Dick, Yunxia Wang, Melanie Glenn,
Omar Jawdat, April McVey, Jeffrey Statland
P4.129
A Corticospinal Tract Model
to Explain Clinical Deficits in ALS Rahul
Remanan, Janki Panchal, Vahid Tohidi,
Lindsay Kaplan, Shara Holzberg, Mona
Shahbazi, Dale Lange
P4.130
The NIH C9ORF72 ALSFTD Study: Correlation of Clinical and
Physiological Measures Mary Kay Floeter,
Laura Braun, Devin Bageac, Bryan Traynor,
Tanya Lehky, Olivia Schanz
P4.131
How Common Are "ALS
Reversals?" Richard Bedlack, Timothy
Vaughan, Paul Wicks, James Heywood,
Ervin Sinani, Roger Selsov, Eric Macklin,
Alexander Sherman
P4.132
Evaluating Clinical Staging
for ALS Saugat Dey, Guillermo Alexander,
Terry Heiman-Patterson
Fast, Easy, Online Registration · AAN.com/view/AM15
Models of ALS Disease Onset
and Progression: Insights from the Pre-fALS
Study Michael Benatar, Robert Carlile,
Eliana Reyes, Sumaira Hussain, Natasha
Garcia, Peter Andersen, Christine Stanislaw,
Joanne Wuu
P4.134
The ALSUntangled Table of
Evidence Richard Bedlack
Neuroepidemiology: ALS
Prospective Incidence of ALS
in a Canadian Population Natalie Parks,
Timothy Benstead, Ian Grant
P4.136
Potential Risk Factors Among
Adults with Amyotrophic Lateral Sclerosis
(ALS) Leah Bryan, Paul Mehta, Vinicius
Antao, Wendy Kaye, Marchelle Sanchez,
Oleg Muravov, D. Kevin Horton
P4.137
Case-control Assessment of
Potential Familial and Environmental Risk
Factors for Amyotrophic Lateral Sclerosis in
Minnesota Caitlin Harper, Eric Sorenson
P4.138
Association of Amyotrophic
Lateral Sclerosis (ALS) with Solvent
and Chemical Exposure During Military
Deployment John Beard, David Umbach,
Kelli Allen, Jean Keller, Dale Sandler, Silke
Schmidt, Lawrence Engel, Freya Kamel
P4.139
Social Deprivation and
Population Density Are Not Associated
with Areal Risk of Amyotrophic Lateral
Sclerosis James Rooney, Mark Heverin,
Alice Vajda, Katy Tobin, Arlene Crampsie,
Anthony Staines, Orla Hardiman
P4.140
Cardiovascular Disease and
Diagnosis of Amyotrophic Lateral Sclerosis:
A Population-based Study Marianthi-Anna
Kioumourtzoglou, Ryan Seals, Ole Gredal,
Johnni Hansen, Marc Weisskopf
P4.141
Diabetes, Obesity and
Diagnosis of Amyotrophic Lateral Sclerosis:
A Population-based Study Marianthi-Anna
Kioumourtzoglou, Ran Rotem, Ryan Seals,
Ole Gredal, Johnni Hansen, Marc Weisskopf
P4.142
Possible Environmental
Causes of Amyotrophic Lateral Sclerosis
in Northern New England: A Preliminary
Analysis Tracie Caller, Patricia Henegan,
Angeline Andrew, Elijah Stommel
P4.143
Ethnic Differences in the
Phenotype and Outcome of Amyotrophic
Lateral Sclerosis: A Meta-analysis of
Population-based Studies Benoit Marin,
Giancarlo Logroscino, Farid Boumediene,
Anais Labrunie, Marie Claude Babron,
Anne-Louise Leutenegger, Pierre-Marie
Preux, Ettore Beghi
P4.144
Amyotrophic Lateral Sclerosis
(ALS) with Laboratory Abnormalities of
Unknown Significance (LAUS)—Where
Does It Begin and Where Does It
End? Benjamin Brooks, Elena Bravver, Velma
Langford, Mohamed Alwan, Nicole Smith,
Nicole Lucas, Mindy Nichols, Sharon Belcher,
Cynthia Lary, Joanne Nemeth, Priscilla Russo,
Kathryn Wright, Amber Ward, Scott Holsten,
Michael Fischer, William Bockenek, Urvi
Desai, Scott C Lindblom, Thomas Pacicco,
Mohammed Sanjak
Neuroepidemiology:
Movement Disorders, ALS, and
Neuromuscular
P4.145
Familial, Autosomal-dominant
Neurodegenerative Parkinsonism with
Cognitive Deterioration Spanning Five
Generations in a Genetically Isolated
Population of South-eastern Moravia,
Czech Republic Katerina Mensikova, Marek
Godava, Petr Kanovsky, Pavel Otruba, Michaela
Kaiserova, Miroslav Vastik, Lenka Mikulicova,
Tereza Bartonikova, Radek Vrtel, Radek Vodicka,
Sandra Kurcova, Petr Jugas, Josef Ovecka,
Ludmila Sachova, Frantisek Dvorsky
P4.146
Estimating the Proportion
of Essential Tremor and Parkinson’s
Disease Patients Referred for Deep
Brain Stimulation: Five-year Data from
Columbia University Medical Center (20092014) Meir Kestenbaum, Elan Louis
P4.147
What Factors Are
Associated with Racial Differences in Mild
Parkinsonian Signs? Chinwe Nwadiogbu,
Nabila Dahodwala, Whitney Fitts, Helen
Partridge, Jason Karlawish
P4.148
Diabetes Severity
Is Associated with Worse
Parkinsonism Nabila Dahodwala, Doria
Gold, Chinwe Nwadiogbu, Whitney Fitts,
Jason Karlawish
P4.149
Antiparkinson Drug Use
in Response to Practice Parameter
Publication, Drug Availability, and
‘Unofficial’ Prescribing Forces James
Crispo, Yannick Fortin, Lise Bjerre, Dafna
Kohen, Donald Mattison, Santiago PerezLloret, Matthew Emons, Allison Willis,
Daniel Krewski
P4.150
Recruiting Patients
for Research, Clinical Trials, and
Epidemiological Studies Using the National
Amyotrophic Lateral Sclerosis (ALS)
Registry Paul Mehta, Vinicius Antao, D.
Kevin Horton
P4.151
Ethnic Differences in the
Incidence of Amyotrophic Lateral Sclerosis:
A Meta-analysis of Population-based
Studies Benoit Marin, Boumediene Farid,
Giancarlo Logroscino, Babron Marie Claude,
Leutenegger Anne Louise, Pierre-Marie
Preux, Ettore Beghi
P4.152
Evaluation of the Application
of the European Guidelines for Diagnosis
and Clinical Care of Amyotrophic Lateral
Sclerosis Philippe Couratier, Ettore Beghi,
Christophe Vial, Emilien Bernard, Geraldine
Lautrette, Pierre Clavelou, Nathalie Guy
Renouil, Gwendal Lemasson, Emmanuel
Rousso, Sabrina Debruxelles, Pascal Cintas,
Marie Christine Arne Bes, Jean-Christophe
Antoine, Jean-Phillippe Camdessanche,
Rudelle Candice, Marie Nicol, Giancarlo
Logroscino, Pierre-Marie Preux, Benoit
Marin
P4.153
Transglutaminase 6
Antibodies in the Serum of Patients with
Amyotrophic Lateral Sclerosis Vivian
Drory, Avi Gadoth, Margolit Bleiberg, Tirza
Klein, Beatrice Nefussy
91
Wednesday
April 22
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Session IV
P4.154
Epidemiology of CharcotMarie-Tooth in Lebanon: Clinical, Genetic
and Electrophysiological Correlation_ Pilot
Study Rosette Jabbour, Salam Koussa,
Valerie Delague, Andre Megarbane, Samir
Atweh
Neurological Consequences of
Medical Disease
P4.155
Functional Network
Connectivity in Comatose Survivors of
Cardiac Arrest Yousef Hannawi, Haris Sair,
Shanshan Li, Joshua Kornbluth, Audrey
Vanhaudenhuyse, Steven Laureys, Russell
Chabanne, Betty Jean, Habib Benali,
Vincent Perlbarg, Charles-Edouard Luyt,
Louis Puybasset, James Pekar, Brian Caffo,
Robert Stevens
P4.156
Neuropathy After Gastric
Bypass Surgery: A Review of 8
Cases Kewei Yu, Jindong Xu, Guangbin Xia
P4.157
Neurologic Complications
After Abdominal Aortic Aneurysm Repair:
A Comparison Between Endovascular and
Open Procedure Mary Elizabeth Kovacik
Eicher, Faisal Aziz, Milind Kothari
P4.158
Neurological Complications
and Organ Rejection in Transplant. Is There
a Connection? Maria Gonzalez Toledo,
Analia Calle, Diego Nadile, Fatima Pagani
Cassara, Agustina Tamargo, Alejandro
Thomson, Alfredo Thomson
P4.159
The Man Who Stopped
Speaking: An Unusual Presentation of an
Osmotic Demyelination Syndrome in a
Patient with Panhypopituitarism Shivika
Chandra, Katherine Peicher, Shwetha
Sudhakar, Jeena Varghese
P4.160
Inflammatory Polyneuropathy
After Bariatric Surgery—Two Case
Reports Joana Dias, Cecilia Vidal, Raquel
Silveira, Marcos De Freitas
P4.161
Repeated Exposure to
Hypobaria in U2 Pilots Is Associated
with Reduced Aggregate Cortical
Thickness Daniel Simmons, Andrew
Bursaw, Paul Sherman, Peter Kochunov,
Stephen McGuire
P4.162
Dysphagia Secondary to Diffuse
Idiopathic Skeletal Hyperostosis Aradhana
Mehta, Nidhi Mehta
P4.163
Horizontal Gaze Palsy and
Progressive Scoliosis (HGPPS); Case
Report Fatmah Alzahmi
P4.164
Intravascular Lymphoma
Masquerading as Neuromyelitis
Optica Spectrum Disorder: An Atypical
Presentation Christina Hupman,
Carlos Singer
7:30 a.m.–12:00 p.m.
P4.166
Neural Correlates of Residual
Brain Activity in PVS Patients by Means
of P300 Paradigm Using the Subject’s
Own Name Ana Olivares Torres, Jorge
Iglesias Fuster, Elena Cuspineda Bravo,
Javier Sanchez Lopez, Cecilia Perez Gesen,
Daymara del Río Bazan, Carlos Beltran Leon,
Calixto Machado Curbelo
P4.167
Comparisons of
Ultrasonographic Measurements Between
Patients with and Without Carpal Tunnel
Syndrome Jung Bin Shin, Seong Woo Kim,
Hyoung Seop Kim, Ha Ra Jeon
P4.168
Pattern of Tongue Weakness
and Subjective Speech and Swallowing
Deficits in Unilateral Hypoglossal Nerve
Palsy: Case Series of 8 Patients Yeyao Joe
Yu, Pierre Bourque
P4.169
Isolated Hypoglossal Nerve
Palsy as Initial Presentation of Pancreatic
Cancer Nabil Khandker, Nimalya
Ganeshalingam, Scott Vota, Claudia Testa
P4.170
Modified Clinical Examination
of Hypoglossal Nerve Sankar
Bandyopadhyay
P4.171
EEG Patterns as Predictors of
Outcome in Patients with Vegetative State
and Minimally Conscious State Tinatin
Kherkheulidze, Maia Beridze, Maka
Khaburdzania
P4.172
Faciobrachial Dystonic
Seizures in a Patient Without Limbic
Encephalitis Yuri Bronstein, Mitchell
Danesh, Marko Petrovic, Nazely Ashikian,
Robert Arbuckle
P4.173
Clinical Manifestations of
Neurobrucellosis: The Importance of
Diagnosis at Early Stages Greta Sahakyan
Discrepant Clinical Signs
Among Patients with Organic Neurological
Disease—Prospective Study Orwa Aboud,
Ayman Al-salaimeh, Kinshuk Sahaya,
Archana Hinduja
P4.181
Redefining True Leukocytosis
in the Traumatic Lumbar Puncture Rizvi
Syed, Mohsen Ghafarian, Farzad Moien
Afshari
P4.182
Diagnostic Yield and Clinical
Impact of Brain Biopsy for Cryptogenic
Neurological Disease: A Systematic
Review and Meta-analysis of 831
Cases Harrison Bai, Yingjie Zou, Zhili
Wang, Xin Zhao, Yanqiao Xiao, yiqun Jiang,
Dongxu Chou, Yi Shu, Xiang Jun, Xiao Bo,
Liming Tan, Yang Li
P4.183
Utilizing Additive
Manufacturing in Medical Education of
Neuropathology: A Feasibility Study Korak
Sarkar, Gustavo Alvarez-Suchini, Puneet
Ralhan, David Ripley, John Welin
P4.184
Inter-rater Reliability
of Automated Pupillometer
Assessments Weidan Zhao, DaiWai Olson,
Sonja Stutzman, Ciji Saju, Margaret Wilson,
Venkatesh Aiyagari
P4.185
New Windows into the Brain:
Technological Advances in Detecting and
Treating Neurological Disorders Julian
Bailes
Research Methodology and
Education
P4.186
Comprehensive Opportunities
for Research and Teaching Experience
(CORTEX): A Mentorship Program JoseRafael Zuzuarregui, Anna Hohler
P4.174
P4.187
Neurodiagnosis and Health
Outcomes
P4.188
Gender-specific Differences
in Adult Type I Chiari Malformation
Morphometrics Paige Marty, Aintzane
Urbizu, Alfons Macaya, Juan Sahuquillo,
Maria Antonia Poca, Bryn Martin
P4.175
Application of Teleneurology
to Outpatient Care in a Major Metropolitan
Area Steven Schreiber, Christopher Lo
P4.176
A Neurohospitalist-staffed
Discharge Clinic: Bridging and Shortening
the Gap from Inpatient to Outpatient
Neurology Care Maulik Shah, Vanja
Douglas, Brian Scott, John Betjemann, S.
Josephson
Neurodiagnostics
Prevalence of Unrecognized
Depression in Patients Admitted in Medical
and Surgical Departments of a Tertiary
Care Hospital: A Comparative Analysis,
Karachi, Pakistan Attiya Rahman, Adnan
Aziz, Qaiser Jamal, Muhammad Siddiqui
P4.165
P4.178
Music and Motor-related
Neuronal Activity During Deep Brain
Stimulation Rebecca Achey, Darlene Lobel,
Damir Janigro
P4.180
P4.177
An Inquiry of Brain Computer
Interfaces for Home Usage Stylianos
Avramidis, Mirjam Palosaari Eladhari,
Theodoros Avramidis
Overcoming Framing Bias
in Stroke Neurologists’ Assessments
of the Minimally Clinically Important
Difference for Novel Acute Ischemic Stroke
Therapies Jessica Cranston, Brett Kaplan,
Jeffrey Saver
A Comprehensive Simulation
Curriculum for Neurology Residents—
Preparing for Future Challenges in
Neurology Priyanka Sabharwal, Sami Saba,
Demian Szyld, Barry Czeisler, Koto Ishida,
Aaron Lord, Janet Rucker, Laura Balcer,
Howard Sander, Steven Galetta
P4.189
The Impact of Care
Integration in Patients with High
Complexity, Low Frequency Neurologic
Diagnoses on Outcomes, Costs, and
Family Engagement David Urion, Jennifer
McCrave, Richard Antonelli
P4.190
The TOS2 Study: An
International Multi-centre Audit
Assessing the Standard of Neurological
Examination Jason Appleton, Andreea
Ilinca, Arne Lindgren, Andreas Puschmann,
Majed Habahbeh, Khurram Siddiqui, Rajith De
Silva, Matthew Jones, Richard Butterworth,
Mark Willmot, Tom Hayton, Michael Lunn,
Peter Nightingale, David Nicholl
P4.191
Expert Clinical Reasoning Is
Not Just Local But Hyperlocal—Insights
into Context Specificity from a Multicentre
Neurology Script Concordance Test Nigel
Tan, Kevin Tan, Gominda Ponnamperuma,
Sanchalika Acharyya, Derek Heng,
Charmaine Manauis, Dong Haur Phua,
Derek Soon
P4.192
Student Perceptions of a Selfregulated Learning Program in a Neurology
Clerkship Douglas Larsen
P4.193
Impact of a Novel Videobased Curriculum for Teaching Clinical
Reasoning in Neurology Roy Strowd,
Rachel Marie Salas, Anthony Kwan,
Charlene Gamaldo
P4.194
The Columbia Evidence
Based Neurology Manual: A Step Towards
Evidence Based Practice Christina Blum,
Eliza Miller, Joshua Willey
P4.195 A Randomized-controlled Trial
Comparing Efficacy and User Satisfaction
of Audio Podcasts Versus a Traditional
Lecture on Multiple Sclerosis in Family
Medicine Resident Education Tyson Brust,
Lara Cooke, Michael Yeung
P4.196
Use of Drugs by Medical
Students Before the Exams Paola
Fontanetti, Fernanda Sá, Marcella Souza,
Arnaldo Godoy
P4.197
Effective Learning Resources
for a Neuroscience and Behavior Course
for First Year Medical Students—Get
Neurology out of the Textboxes Rainald
Schmidt-Kastner
P4.198
Improving Patient Attendance
in Neurology Outpatient Resident
Clinic Mariam Wasim, Ravi Vakani, George
Barrio
P4.199
Is Clinical Neurology Exposure
Increasing in Medical Schools Throughout
the United States? Jeffrey Kornitzer,
Machteld Hillen, Caroline Hayes-Rosen,
Andrea Hidalgo, Wenzhuan He
P4.200 Improving Neurology
Resident Satisfaction and ACGME Survey
Parameters by Initiating Weekly Program
Director Meetings Kelly Baldwin
P4.201 Medical Student Consumerism
During Neurology Clerkship: Sentiment
Comparison of Student Emails with Sample
Admissions Essay Robert Fekete
P4.202 Clinical Research Continuum:
Big Data FOR and FROM Clinical
Trials Alexander Sherman
P4.203 Assessing Individual
Learning Styles in Neurology Residency
Education Jeanie McGee
P4.204 How Well Do Neurology
Residents Recognize Neurological
Illness? An Analysis of the Close the Loop
Resident Clinical Acumen Assessment
Project Rachel Brandstadter, Christine
Hannigan, Sarah Zubkov, Stephen Krieger
P4.179
Characterizing Self-reported
Mental and Physical Health Scores in an
Ambulatory General Neurology Practice:
Feasibility and Preliminary Results Lee
Schwamm, Eli Schwamm, Lidia Maria
Moura
92
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session IV
P4.205 Automation of Clinical
Assessments via Machine Learning and
Paired Comparisons Jonas Dorn, Marcus
D'Souza, Peter Kontschieder, Cecily
Morrison, Jessica Burggraaff, Christian
Kamm, Prejaas Tewarie, Thomas Vogel,
Abigail Sellen, Antonio Criminisi, Frank
Dahlke, Bernard Uitdehaag, Ludwig Kappos,
Peter Chin
P4.206 Are Informal “Sign-out
Rounds” Beneficial for 3rd Year Medical
Students on the Neurology Clerkship? Erika
Wexler, Ruth Schneider, Marina Rubin,
Andrew Huffer, Wolfgang Muhlhofer, Agust
Hilmarsson, Tobias Kulik, Clifford Meyers,
Robert Thompson-Stone, Ralph Jozefowicz
P4.207 A Voluntary Stress-
management Workshop for Neurology
Residents: Design, Implementation, and
Impact Sarah Dolgonos, Kamil Detyniecki
P4.208 What Is Your EEG Number?
Resident Training and Competency Lynn
Liu, Adam Juersivich, Thomas Wychowski
P4.209 Structure of Neuroscience
Clerkships in Medical Schools and
Matching in the Neurosciences Dara
Albert, Rimas Lukas, James Brorson,
Christina Amidei, Karan Dixit, Han Yin
Neuro-oncology: Quality of Life
and Symptom Management
P4.210
Placebo-controlled, Doubleblind, Randomized Pilot Study to Evaluate
the Effects of Low-dose Naltrexone on
Quality of Life and Fatigue in Newly
Diagnosed High-grade Glioma Katherine
Peters, Mary Affronti, Sarah Woodring,
Eric Lipp, Patrick Healy, Frances McSherry,
James Herndon, Charlene Flahiff, Elizabeth
Miller, Maria Freeman, Janet Minchew,
Ben Zalutsky, Bonnie Taylor, Susan Boulton,
Dina Randazzo, Annick DesJardins, Gordana
Vlahovic, Darell Bigner, Henry Friedman
P4.211
Acetazolamide for Treatment
of Drop Attacks Due to Symptomatic
Plateau Waves: A Case Report Surabhi
Ranjan, David Schiff
P4.217
Awake Craniotomy—
Utility, Seizures, After-discharges and
Tolerance Gowri Lakshminarayan, Jaime
Lopez
P4.218
Treatment of Brain Radiation
Necrosis with Hyperbaric Oxygen: Report
of 6 Cases Shivam Mittal, David Rowe,
Mitchell Machtay, Syed Ali, Warren Selman,
Andrew Sloan, Lisa Rogers
P4.219Electroencephalography
Correlates of Intracranial Hypertension
in 4 Patients with Leptomeningeal
Metastases Carl Gold, Nicole Odom, Aya
Haggiagi, Lauren Schaff, Yazmin Odia
Neuro-oncology: Rare Tumors
P4.220 Predicting Death from
Ganglioglioma in Children: A Retrospective
Series of 40 Patients at the Barrow
Neurological Institute Glynnis Zieman,
Christopher Dardis, Andrea Gomes,
Adrienne Scheck, Jennifer Eschbacher,
Stephen Coons, Lynn Ashby
P4.221 Chordoma Whole Genome
Sequencing Thomas Cusack,
Christopher Dardis
P4.222 Retrospective Analysis of
Chordoma Patients 1998-Present at the
Barrow Neurologic Institute: Features
and Findings Thomas Cusack, Christopher
Dardis
P4.223 A Rare Case of Metastatic
Esthesioneuroblastoma Cynthia Armand,
Mary Welch
P4.224 SRC Proto-oncogene Mutation
Found in an Adult Atypical Teratoid/
Rhabdoid Tumor: A Case Report Kaye
Sedarsky, Meryl Severson, Patrick Cooper,
William Skinner, Patrick Malafronte, Brett
Theeler
P4.225 Gliomatosis Cerebri
Masquerades as a Granulomatous
Process Jamie Labuzetta, Asheen Rama,
Brian Lemkuil, Navaz Karanjia
P4.226 Glioblastoma Multiforme
Neuro-oncology: Paraneoplastic
Disorders
P4.230 Unusual Case of Motor
Neuron Disease as a Paraneoplastic
Process Clement Pillainayagam, Divya
Mella, Jennifer Johnson, Karin Woodman
P4.231 An Unusual Cause of
Recurrent Ischemic Stroke: Trousseau’s
Syndrome from Gastric Cancer Neville
Jadeja, Jenny Johnson, Ainie Soetanto,
Krishna Nalleballe, Lauren DeNiro, Irfan
Qureshi, Jerome Graber
P4.232 Guillain-Barre Syndrome After
Treatment with Dabrafenib for Metastatic
Recurrent Melaloma Catherine Maurice,
Butler Marcus, Warren Mason
P4.233 Treatment Responsive
GABA(B)-receptor Limbic Encephalitis
Presenting as New Onset Super-refractory
Status Epilepticus (NORSE) in a Deployed
U.S. Soldier Jeffrey Hainsworth, Akira
Shishido, Craig Carroll, Rebecca Fasano,
Brett Theeler
P4.234 Progressive Peripheral
Neuropathy and Gait Ataxia as the Initial
Manifestation of Breast Cancer Shira
McMahan, Ramon Lugo, Nestor GalvezJimenez, Efrain Salgado, Dennys Reyes
P4.235 Paraneoplastic Syndrome
Masking as Peripheral Vertigo Joseph
Nguyen, Robert Knipe, Divisha Raheja,
Max Lowden
P4.236 CRMP-5 Antibody in Para-
neoplastic Optic Neuritis and Sensory Motor
Neuropathy Associated with Small Cell Lung
Cancer Ai Sumida, Hilary Glazer, Micheline
McCarthy, Yolanda Reyes-Iglesias
P4.237 Anti-Ri Antibody Associated
Paraneoplastic Brainstem and Cerebellar
Dysfunction as the Presenting Sign of
Small Cell Lung Carcinoma Yuanquan
Yang, Helen Shum, Missak Haigentz, Eric
Mariuma, Mark Suhrland, Sara Maleki,
Nattasha Acevedo, Edwin Gulko, Jack
Farinhas, Mary Welch
P4.212
Quality of Life in Adults with
Gliomas: Literature Review Kateryna
Kurako, Efrain Salgado
Masquerading as a Tumefactive
Demyelinating Lesion: A Case
Report Kunal Agrawal, Ted Rothstein,
Mohamad Koubeissi
P4.238 A Rare Case of Primary
P4.213
P4.227 Peripheral Primitive
P4.239 Concomitant Opsoclonus
The Longitudinal Evaluation
of Quality of Life in Patients with Newly
Diagnosed Malignant Glioma Nancy Ann
Oberheim Bush, Emelia Barani, Margaretta
Page, Annette Molinaro, Nicholas Butowski,
Susan Chang, Jennifer Clarke
P4.214
Safety of Posterior Fossa
Parenchymal Biopsy Oliver Tobin
P4.215
Systemic Chemotherapy
Decreases Resting Brain Glucose
Metabolism Jorg Dietrich, Victor Gerbaudo,
Alexander Zaitsev, Jon Hainer, Wendy
Plesniak, Ron Kikinis, Laura Horky
P4.216
Successful Treatment of
Intracranial Inflammatory Pseudotumor
with Cyclophosphamide Tiffani Stroup, Adil
Javed, Nancy Arndt, Rimas Lukas, Kourosh
Rezania, Sean Polster
Neuroectodermal Tumor of the Central
Nervous System / Extraosseous Ewing’s
Sarcoma (pPNET): Analysis of a Series of
Cases Lucas Alessandro, Lucia Pertierra,
Ismael Calandri, Sebastian Cerrato, Bernadette
Calabrese, Naomi Arakaki, Alejandro Muggeri,
Blanca Diez, Gustavo Sevlever
P4.228 Primary Pineal Malignant
Melanoma Treated with Radiotherapy
and Associated with Loss of BAP1: A
Case Report Nattasha Acevedo-Ramirez,
Jerome Graber, Patrick LaSala, Karen
Weidenheim, Madhur Garg
P4.229 Biomarkers for Brain
Tumors—a Feasibility Study Using Mass
Spectrometric Proteomic Analysis Yin Liu,
Lawrence Sandberg, Clifford Herrmann,
Ravi Raghavan
Fast, Easy, Online Registration · AAN.com/view/AM15
Mediastinal Seminoma (PMS) Associated
with Anti-Hu Paraneoplastic Syndrome
(PS) Faria Amjad, Carmelo Tornatore
and Ataxia and Limbic Encephalitis Due
to Dual Anti-Ri and Anti-Yo Positive
Antibodies Jennifer Kim, Jennifer Lyons
Neuro-oncology: Basic Science
P4.240 Loss of Foxp3+ Regulatory
T Cell Function in Glioblastoma Daniel
Lowther, Amanda Hernandez, Xiangguo
Duan, Murat Gunel, David Hafler
P4.241
Identification of Novel
Therapeutic Targets for Glioblastoma Stem
Cells Sarah Young, Yanping Liang, Susan
Murphy, Sujuan Guo, Zhi Sheng
P4.242 Neurotrophin Receptors TrkB
and TrkC Promote Brain Tumor Initiating
Cells Growth and Are Novel Targets for
Glioma Therapy Rajappa Kenchappa
P4.243 The Association Between
Expression of Neurotrophic Factors in
Peripheral Blood Mononuclear Cells
and Cognitive Functions in Lung Cancer
Patients Slawomir Michalak, Joanna
Rybacka–Mossakowska, Joanna Gazdulska,
Iwona Golda-Gocka, Wojciech Kozubski,
Rodryg Ramlau
P4.244 In Vitro and in Vivo Effects of
Ionizing Radiation on Cell Cycle Progression
and Self-renewal of Subventricular Zone
Neural Precursors Hongxin Chen, Sonia De
Toledo, Matthew Goodus, Edouard Azzam,
Steve Levison, Nizar Souayah
P4.245 Soluble AXL: A Possible
Circulating Biomarker for Tumor Burden in
Neurofibromatosis Type 1 Ming-Jen Lee,
Gunnar Johansson, Po-Chun Peng, Po-Yuan
Huang, Hsiung-Fei Chien, Kuo-Tai Hua, MinLiang Kuo, Chin-Tin Chen
P4.246 Control of VEGF Release
Via TGF-β Superfamily Members in
Glioblastoma Katharina Seystahl, Isabel
Tritschler, Emese Szabo, Dorothee Gramatzki,
Ghazaleh Tabatabai, Michael Weller
P4.247
An Oncolytic Myxoma
Virus Construct (M011L Knock-out)
Induces Apoptosis and Is a Potent Proapoptotic Therapy in Both Human and
Immunocompetent Murine Glioblastoma
Cancer Stem Cells Models Alexandra
Pisklakova
P4.248 Targeting Iron Homeostasis
for the Treatment of Glioblastoma
Multiforme John Leschke, Christopher
Chitambar
P4.249 Late Activation of Human
Microglial Cells by High Dose Ionizing
Radiation Nizar Souayah, Hongxin Chen,
Sonia De Toledo, Edouard Azzam
Epilepsy/Clinical
Neurophysiology (EEG): Basic
Science and Pharmaceuticals
P4.250 Decreased Epileptic Discharge
of Pubertal CA1 Hippocampus Is Due to
Increased Expression of α4βδ GABA-A
Receptors Lisa Merlin, Lie Yang, Sheryl
Smith
P4.251
Role of NOX2 in Seizure
Susceptibility of Mice Following Systemic
Inflammation Hung-Ming Wu, Wan-Yu
Huang
P4.252 Characterization of the
Epilepsy Gene DEPDC5 in a Mouse
Embryonic Stem Cell Model Massimo
Pandolfo, Chantal Depondt, Angélique Arts,
Simona Donatello
P4.253 Compound Heterozygosity
of Two MECP2 Deletions with Paternal
Inheritance of a Late-truncating
Mutation in a Female with Atypical Rett
Syndrome Amanda Lindy, Melissa Rumple,
Melanie Morrow, Anita Shanmugham,
Tamara Zach, Dianalee McKnight
P4.254 Computer Simulation to Test
the Concept of Dose Forgiveness in the
Era of Extended-release (XR) Drugs Scott Brittain
93
Wednesday
April 22
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Session IV
P4.255 Assessment of
the Anticonvulsant Effects and
Tolerability Profile of Cannabidiol:
GW Pharmaceuticals’ Preclinical
Program Nicholas Jones, Andrew Hill,
Thomas Hill, Isabelle Peres, Rebecca Hadid,
Stephen Wright, Gary Stephens, Claire
Williams, Benjamin Whalley
P4.256 Impact of Inhaled Marijuana
on CEEG Spike Count in a 33-year-old
Man with Idiopathic Epilepsy: A Case
Report Hannah Park, Julie Roth
P4.257 Pharmacokinetic Evaluations
of Oral and Intravenous Carbamazepine
Using a Model-based Approach Dwain
Tolbert, William Ravis, Aziz Karim
P4.258 Population Pharmacokinetic
(PK) Evaluation and Missed Dose
Simulations for Eslicarbazepine Acetate
(ESL) Monotherapy Soujanya Sunkaraneni,
Luann Phillips, Vaishali Chudasama,
Elizabeth Ludwig, David Blum, Jill FiedlerKelly
P4.259 Clobazam Drug-drug
Interactions: A Mechanism-based
Characterization Using a Model-based
Approach Dwain Tolbert, Ihor Bekersky,
Hui-May Chu, Ene Ette
Epilepsy/Clinical
Neurophysiology (EEG):
Pharmaceuticals
P4.260 Conversion to Lacosamide
Monotherapy: Post-hoc Analysis on
Responder and Seizure Freedom Rates by
Patients’ Baseline Characteristics Philippe
Ryvlin, Michael Sperling, Steve Chung, John
Stern, Robert Wechsler, Svetlana Dimova,
Marc De Backer, Tyler Story, Melissa Brock,
Cindy McShea, Paulette Williams, Konrad
Werhahn
P4.261
High Predictability of
Plasma Lacosamide and No Relevant
Differences by Age and Gender Following
Normalization Carina Schaefer, Willi
Cawello, Jens-Otto Andreas
P4.262 Safety and Effectiveness of
Lacosamide as a First Add-on (FAO) or Later
Add-on (LAO) Treatment of Partial-onset
Seizures (POS) in Adults: An Open-label
Trial Plamen Tzvetanov, Wendy Waldman
Zadeh, Antonio Escartin, William Byrnes,
Frank Tennigkeit, Peter Dedeken, Marc De
Backer, Simon Borghs, Ting Li
P4.263 Immediate Steady-state
Concentrations in Plasma After Oral
or Intravenous Lacosamide Loading
Dose Carina Schaefer, Willi Cawello, JensOtto Andreas
P4.264 Tolerability of Lacosamide 200
Mg/day Starting Dose: Post-hoc Analysis
of Conversion to Lacosamide Monotherapy
Study Konrad Werhahn, Svetlana Dimova,
Cindy McShea, Paulette Williams, Melissa
Brock, William Byrnes, Marc De Backer,
Edward Faught
94
7:30 a.m.–12:00 p.m.
P4.265 Safety and Effectiveness of
Lacosamide as Adjunctive Treatment for
Partial-onset Seizures (POS) in Hispanic/
Latino Patients from Mexico: Post-hoc
Analysis of an Open-label Trial Hugo
Ceja Moreno, Plamen Tzvetanov, Wendy
Waldman Zadeh, Antonio Escartin, William
Byrnes, Frank Tennigkeit, Simon Borghs,
Cindy McShea, Peter Dedeken, Marc De
Backer, Imane Wild
P4.266 Lacosamide Added to a
Baseline Monotherapy in Patients with
Partial-onset Seizures (POS): Efficacy and
Safety Across Center Types in the VITOBA
Study Matthias Noack-Rink, Christian
Brandt, Thomas Mayer, Stephan Arnold,
Uwe Runge, Francisco Ramirez, Thomas
Lauterbach, Peter Dedeken
P4.267
Lacosamide Added to an
Existing Monotherapy in Epilepsy Patients
with Partial-onset Seizures: A Subgroup
Analysis of Elderly Patients in the VITOBA
Study Uwe Runge, Stephan Arnold,
Thomas Mayer, Matthias Noack-Rink,
Francisco Ramirez, Marc De Backer, Frank
Tennigkeit, Konrad Werhahn
P4.268 Generic Antiepileptic Drugs: A
Review of Issues Surrounding Formulation
Switching Huy Nguyen, Annie Clark, Mark
Halvorsen, Mary Holmay, Gregory Gilmet
P4.269 Galenic Formulation
of Midazolam (MDZ) Intranasal(IN):
Evaluation of Plasma Levels and Tolerance
in Healthy Volunteers in Argentina Maria
Pacha, Martin Kriebaum, Oscar Martinez,
Guillermo Bramuglia, Maria Kravetz, Fabian
Buontempo, Esteban Otamendi, Diego
Chiappetta
P4.270 Profound Hypothermia
Secondary to Clobazam Use in Epilepsy:
A Novel Association Bennett Lavenstein,
Marc Difazio, Scott Demarest
P4.271 Evaluation of Safety in
Exceeding Maximum Doses of Commonly
Used Antiepileptic Drugs in Pediatric
Patients Sunita Misra, Shannon DiCarlo,
Mindl Messinger, Gary Clark
P4.272 Effect of an Antiepileptic
Drug (AED) Holiday in the Epilepsy
Monitoring Unit (EMU) on Subsequent
Seizure Frequency After Reinstituting in
Medically Refractory Epilepsy Patients—a
Prospective Observational Controlled
Study Geetika Bajpai
P4.273 Antiepileptic Drugs
Withdrawal: Risk Factors for Seizure
Relapses in a Brazilian Sample Victor
Calil da Silveira, Pedro Sudbrack Oliveira,
Cristiane Afonso, Luiza Tavares Ramos
P4.274
Fracture Risk Associated
with Enzyme-inducing Antiepileptic Drugs
in Patients with Epilepsy: A Systematic
Review J. Alexander Fraser, Jorge Burneo,
Lisa-Ann Fraser
P4.275 A Cost-comparison Model
to Estimate the Potential Health Care
Cost Impact of Increased Sodium Channel
Blocker Use Among Adjunctively-treated
Patients with Partial-onset Seizures Fulton
Velez, Viktor Dansk, Malin Berling, Maria
Malmenäs
P4.276
In Vitro Pharmacokinetic
Profile of Brivaracetam (BRV) Reveals Low
Risk of Drug-drug Interaction (DDI) and
Unrestricted Brain Permeability Hugues
Chanteux, Sophie Kervyn, Brigitte Gerin,
Maria Rosa, Nathalie Latour, Armel Stockis,
Jean-Marie Nicolas
P4.277 Incidence of Falls,
Fractures, and Injuries with Adjunctive
Eslicarbazepine Acetate (ESL) in Patients
with Refractory Partial-onset Seizures
(POS): A Pooled Analysis of Three Placebocontrolled Trials William Rosenfeld, Selim
Benbadis, Pavel Klein, Luigi Specchio, Pedro
Kowacs, Helena Gama, Francisco Rocha,
Raymond Claus, David Blum
P4.278 Idiosyncratic Interactions
Between the Ketogenic Diet and Valproic
Acid: A Case Series Inna Hughes, Kelly
Russo, David Wang
P4.279 Antiepileptic Medications
and Depression in Patients with Epilepsy
(PWE) Ihab Ahmed, Sunil Nair, Kimberly
Cole, Anum Riaz, Imran Ali
Cerebrovascular Disease and
Interventional Neurology: Acute
Ischemic Stroke Care
P4.280 Strategies for Optimizing
Acute Ischemic Stroke Care by Reducing
Door to Needle Time in a Major Academic
Center Justin Abraham, Caitlin Oksienik,
Rodney Bell, Christopher Skidmore, Diana
Tzeng, Carissa Pineda
P4.281 Outcomes of Intravenous
Tissue Plasminogen Activator in
Nonagenarians with Acute Ischemic
Stroke Varun Chaubal, Elizabeth Wise,
Kari Moore, Ann Jerde, Bystrek Laura, Kerri
Remmel, Wei Liu
P4.282 Bridging in Acute Ischemic
Stroke in India—Experience of Indo-US
Stroke Project Dheeraj Khurana, PN Sylaja,
Jeyaraj Pandian, MV Padma, Subhash Kaul,
Deepti Arora, Tijy Thankachan, Parmdeep
Kaur, Aneesh Singhal
P4.283 Prospective Study of Acute
Ischemic Stroke Sub-types in a Tertiary
Care Hospital in South India Butchi
Garuda, Aruna Kumari Uppaturi, T. Sateesh
Kumar, S. Gopi
P4.284 Safety and Effectiveness
of Intravenous Recombinant Tissue
Plasminogen Activator in Acute
Ischemic Stroke Patients on Aspirin and
Clopidogrel Mushtaq Qureshi, Shayaan
Khan, Nauman Jahangir, Ahmed Malik,
Michelle Thampson, Asif Khan, Muhammad
Suri, Adnan Qureshi
P4.285 Routine Troponin
Measurements Are Unnecessary in Acute
Ischemic Stroke Evaluations Farwa Ali,
Jimmy Young, Alejandro Rabinstein, Kelly
Flemming, Jennifer Fugate
P4.286 Elevated Cardiac Troponin-T in
Acute Ischemic Stroke Han-kyeol Kim, Ji
Hwa Kim, Kyung-Yul Lee
P4.287 Utility of
Electroencephalography in the Care of
Acute Ischemic Stroke Patients Tara
Kimbrough, Dominique Monlezun, Jr, Nicole
Ulrich, Nelson Mandrell, Joel Lanceta,
Alyana Samai, Maria Chavez-Keatts, Adam
Friedant, Lauren Dowell, Ramy El Khoury,
Sheryl Martin-Schild
P4.288 The Impact of Door to Stroke
Unit Time on Post-stroke Complications
Rate: A Single Center Experience Ali
Al-Khathaami, Mohammed Al-Jumah,
Suleiman Kojan, Ashraf Elmetwally,
Mohammed Alskaini, Naser Alotaibi
Cerebrovascular Disease and
Interventional Neurology: Acute
Ischemic Stroke Treatment
P4.289 Use of Recombinant Tissue
Plasminogen Activator in Young Patients
with Ischemic Stroke Luciana Leon,
Pablo Bonardo, Julieta Mazziotti, Lorena
Jure, Andrea Sotelo, Eduardo Bendersky,
Alberto Zinnerman, Pedro Nofal, Luciano
Alberto Sposato, Patricia Riccio, Ricardo
Reisin, Manuel Fernandez Pardal, Alejandra
Martinez
P4.290 Early Dramatic Recovery
After Endovascular Reperfusion in Acute
Ischemic Stroke Andrey Lima, Diogo
Haussen, Samir Belagaje, Aaron Anderson,
Fadi Nahab, Srikant Rangaraju, Michael
Frankel, Raul Nogueira
P4.291 Primary Acute Stroke
Thrombectomy in 3 Hours from Middle
Cerebral Artery Occlusion—a Pilot
Study Yahia Lodi, Varun Reddy, Ashok
Devasenapathy, Karmel Shehadeh, Anas
Hourini, Chun-An Chou
P4.292 Does Resident Level
of Training Affect Time to TPA
Treatment? Laura Bishop, Amy Guzik
P4.293 Application of the 2013
AHA/ASA Guidelines for Use of TPA in
Acute Ischemic Stroke at Assaf Harofeh
Medical Center, a Tertiary Medical Center
in Israel Carmel Armon, Itzhak Kimiagar,
Shani Kalmanovich Avnery, Ofer Gonen,
Zvika Sacagiu, Evelina Shevtzov, Youval
Leonov, Alex Blatt, Shmuel Bar-Hayim
P4.294 Outcomes in Wake-up Strokes
Receiving Intra-arterial Therapy Varuh
Naragum, Shabbir Hussain Merchant,
Qaisar Shah
P4.295 Unchanged Utilization of
Endovascular Treatment in Acute Ischemic
Stroke Patients in the Post IMS-III
Era Ameer Hassan, Cara Bezzina, Ahmed
Malik, Lisa Jones-Fullingim, Christina
Sanchez, Wondwossen Tekle, Adnan
Qureshi
P4.296 Thrombolysis in Strokes
of Uncertain Onset—Can CT Perfusion
Scanning Help Us Make Safe and Effective
Decisions David Collas, Sumanjit Gill
P4.297 Predictors of Hematoma
Volume in the Patients Treated with
Intravenous Alteplase Sung Hyuk Heo, Ji
Hoon Lee, Dokyung Lee, Kyoung Jin Hwang,
Dae-Il Chang, Seon Hee Bu, Jong Min Song,
Ho-Geol Woo
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session IV
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
of Acute Middle Cerebral Artery
Occlusion: Comparison of Percutaneous
Transluminal Angioplasty and Mechanical
Embolectomy Roman Herzig, Katerina
Blejcharova, Martin Roubec, Martin
Kuliha, Daniel Sanak, Eva Vitkova, Dagmar
Krajickova, Ales Tomek, Daniel Vaclavik,
Vaclav Prochazka, Martin Kocher, Antonin
Krajina, Frantisek Charvat, Jana Zapletalova,
David Skoloudik
Cerebrovascular Disease and
Interventional Neurology: Acute
Interventional Treatment for
Ischemic Stroke
P4.299 Arterial Reocclusion and
Distal Embolization During Endovascular
Treatment Using New Generation Stent
Retrievers in Acute Ischemic Stroke
Patients Nabeel Herial, Mushtaq Qureshi,
Asif Khan, Nauman Jahangir, Hashim Zeb,
Nazli Janjua, Muhammad Suri, Adnan
Qureshi
P4.300 Correlation Between
Flat Panel Computed Tomography and
Conventional Computed Tomography for
Detection of Post Endovascular Treatment
Hemorrhages Asif Khan, Seyedmehdi
Payabvash, Mushtaq Qureshi, Omar Saeed,
Muhammad Suri, Adnan Qureshi
P4.301 Temporary Discontinuation
of Warfarin for Endovascular Procedures
and Risk of Ischemic Stroke Ahmed Malik,
Mushtaq Qureshi, Hashim Zeb, Archie
Defillo, Michelle Thompson, Muhammad
Suri, Adnan Qureshi
P4.302 “Reverse Locked-in
Syndrome”: A Rare Presentation After
Endovascular Recanalization of Top-of-thebasilar Artery Occlusion Pooja Raibagkar,
Jennifer Kim, Tamara Kaplan, Ram Chavali,
Meaghan Nitka, Sherry Chou, Brian Edlow
P4.303 Significance of Periclot MMP-
9 in Ischemic Stroke Patients Undergoing
Intra-arterial Interventions Anne Song,
Briana Prager, Chanda Brennan, Ken Uchino,
Muhammad Hussain, Peter Rasmussen,
Damir Janigro
P4.304 Intra-arterial Therapy Is Safe
and Effective in Patients Aged ≥ 80 Donald
Frei, Jan Leonard, Kristin Salottolo,
Christopher Fanale, Jeffrey Wagner,
Michelle Whaley, Kathryn McCarthy, David
Loy, David Bar-Or
P4.305 Predictors of Outcome of
Acute Ischemic Stroke Patients Less
Than Eighty Years Old Compared to
Those Eighty Years Old and Older Who
Underwent Stent Retriever Thrombectomy
for Middle Cerebral Artery Occlusion—a
Pilot Study Varun Reddy, Yahia Lodi, Ashok
Devasenapathy, Karmel Shehadeh, Anas
Hourini, Chun-An Chou
P4.306 Why Are Most Stroke Patients
Deemed Poor Candidates for Intraaterial
Therapy? A Prospective Study Dushyant
Damania, Anthony Noto, Nancy Kung,
Jason Liew, Heather Finley, Rajiv Mangla,
Amrendra Miranpuri, Bogachan Sahin,
Babak Jahromi
P4.307 Occurrence of Femoral
P4.318
Dorsal Lead Migrations in
a Dystonia Patient Following Deep Brain
Stimulation Wei Hu, Alberto Bona, Daniel
Martinez-Ramirez, Aparna Wagle Shukla,
Kelly Foote, Michael Okun
P4.330 Does Oral Zinc
Cerebrovascular Disease and
Interventional Neurology:
Acute Stroke, Prehospital, and
Telemedicine
P4.319
Prospective Trial Evaluating Xeomin
(incobotulinumtoxinA) for Cervical Dystonia
or Blepharospasm in the United States—
Final Results from the Blepharospasm
Cohort Hubert Fernandez, Joseph Jankovic,
John Holds, Daniel Lin, John Burns, Kapil
Sethi, Amit Verma
Nerve Injury Among Patients Undergoing
Transfemoral Percutaneous Catheterization
Procedures in United States Mohammad
El-Ghanem, Adnan Qureshi
P4.308 Time Is Brain: A Quality
Improvement Project to Improve Stroke
Outcomes by Educating EMS Karanbir
Singh, Pooja Sofat, Noureldin Abdelhamid,
Deeya Gaindh, Ghasan Ahmad, Mohammad
Masud, Robert Sawyer, Nicholas Silvestri
P4.309 Reducing Door-to-needle
Times for Treatment of Acute Ischemic
Stroke: Quality Improvement Initiative
at a High-volume Comprehensive Stroke
Center Biggya Sapkota, Abdelazim
Sirelkhatim, Thomas Devlin, Nataria
Pitiyanuvath, Caryl Dellinger, Francis
Fesmire
P4.310
Early Triage of Acute Ischemic
Stroke Patients Using Mobile Stroke
Unit Shortens Time to Intra-arterial
Therapy Andrew Buletko, Russell Cerejo,
Ather Taqui, Ahmed Itrat, Seby John, Gabor
Toth, Ken Uchino, Muhammad Hussain,
Peter Rasmussen
P4.311
Protocol Driven Stroke Ward
and Stroke Registry Results in Increased
Rate of Thrombolysis in Acute Stroke
Care Naveed Akhtar, Saadat Kamran, S
Joseph, M Santos, P Bourke, A D'Souza,
Yahia Imam, Ashfaq Shuaib
P4.312
Posterior Versus Anterior
Circulation Strokes: Differences at a
Community Level Nancy Kung, Dushyant
Damania, Jason Liew, Curtis Benesch,
Babak Jahromi
P4.313
Longer Ambulance Transport
Time Is Associated with Worse Outcomes
in “Drip and Ship” Stroke Patients Thomas
Kodankandath, Rohan Arora, Jane Shaji,
Reuben Burshtein, Richard Libman, Nina
Kohn, Michele Gribko, Jeffrey Katz
P4.314
The Speed and Reliability
of Pre-hospital Point-of-care Laboratory
Testing on the Mobile Stroke Treatment
Unit Natalie Organek, Ather Taqui, Russell
Cerejo, Ahmed Itrat, Andrew Buletko, Sung
Cho, Lila Sheikhi, Stacey Winners, Peter
Rasmussen, Muhammad Hussain, Ken
Uchino
P4.315Withdrawn
P4.316
Thrombolysis in the Very
Elderly: Application to Telestroke
Networks Charlotte Zerna, Kristian Barlinn,
Jessica Kepplinger, Lars-Peder Pallesen,
Timo Siepmann, Heinz Reichmann, Volker
Puetz, Ulf Bodechtel
Movement Disorders: Dystonia
P4.317
Hyoid Muscle Dystonia:
A Previously Undescribed Segmental
Dystonia of the Neck Erin Norby, Edythe
Strand, Joseph Duffy, Dale Ekbom, Diana
Orbelo, Joseph Matsumoto
Fast, Easy, Online Registration · AAN.com/view/AM15
Advanced Neuroimaging
Techniques to Assess Brain Structural
Abnormalities in Writer’s Cramp Primary
Dystonia Lidia Sarro, Federica Agosta,
Alexandra Tomic, Paola Valsasina, Marina
Svetel, Sebastiano Galantucci, Alessandro
Sodero, Nikola Kresojevic, Vladimir Kostic,
Massimo Filippi
P4.320 Athlete’s Dystonia Jeremy
Cutsforth-Gregory, James Bower
P4.321 Long-term Motor Learning
in Focal Hand Dystonia (FHD) Prachaya
Srivanitchapoom, Ejaz Shamim, Suk Yun
Kang, Seung-Hyun Jin, Elise Houdayer, Pierre
Diomi, Nivethida Thirugnanasambandam,
Tianxia Wu, Sherry Vorbach, Biset-Meunier
Sabine, Mark Hallett
P4.322 Cortical Assesment in
Craniocervical Dystonia Larissa Vilany,
Thiago Rezende, Luiza Piovesana, Lidiane
Campos, Paula Azevedo, Fabio Torres,
Marcondes Franca, Jr., Augusto AmatoFilho, Iscia Lopes-Cendes, Fernando Cendes,
Anelyssa D'Abreu
P4.323 Activation of a Small Cluster
of Excitatory Neurons in the Medial
Medulla Induces a Phenotype That
Resembles Cervical Dystonia Brian Ellison,
Audrey Worley, Tamara Samardzic, Veronica
VanderHorst
Supplementation Augment the Effect of
Botulinum Neurotoxin in Dystonia? Yuan
Xing, Padraig O'Suilleabhain
P4.331 XCiDaBLE: An Observational,
P4.332 Regional Differences in
Botulinum Neurotoxin-A (BoNT-A) Injection
Practices and Techniques in the Treatment
of Cervical Dystonia: A Comparison
Between the US and Europe Peter Misra,
Richard Trosch, Pascal Maisonobe, Savary Om
P4.333 Randomised Double-blind
Clinical Trial of Botulinum Toxin Subtype
A2 (A2NTX) in Comparison with Subtype
A1 (onabotulinumtoxinA) (ClinicalTrials.gov
NCT01910363) Ryuji Kaji, Ai Miyashiro,
Nori Sato, Toshiaki Takeuchi, Seiji Kaji, Taiki
Furumoto
P4.334 Safety Profile of Repeat
OnabotulinumtoxinA Doses of 400U for the
Treatment of Upper Limb Spasticity Lynn
James, Rozalina Dimitrova, Grace Pan,
Charles Asare, Catherine Thompson
P4.335 Limbic Encephalitis
Associated with Anti-voltagegated Potassium Channel Complex
Antibodies Mimicking Creutzfeldt-Jakob
Disease Ming-Jai Liu, Gregory Chang
P4.324 The Impact of Cervical
Wednesday
April 22
P4.298 Endovascular Treatment
Dystonia on Work Productivity: An
Analysis from the CD Patient Registry for
the Observation of OnabotulinumtoxinA
Efficacy (CD PROBE) Eric Molho, Mark
Stacy, Patrick Gillard, P. Charles, Charles
Adler, Joseph Jankovic, Marc Schwartz,
Mitchell Brin
P4.325 Spasmodic Dysphonia Primary
Dystonia Is Associated with Cortical and
Subcortical Alterations: A Multimodal
Imaging Study Lidia Sarro, Federica
Agosta, Alexandra Tomic, Paola Valsasina,
Marina Svetel, Sebastiano Galantucci,
Alessandro Sodero, Nikola Kresojevic,
Vladimir Kostic, Massimo Filippi
P4.326 Abnormal Activation of
Motion Perception-related Brain Networks
in Primary Dystonia Koji Fujita, Wataru
Sako, An Vo, Aziz Ulug, David Eidelberg
P4.327 Effect of OnabotulinumtoxinA
on Pain in Patients with Cervical Dystonia:
Results from CD PROBE Atul Patel, Marc
Schwartz, Aubrey Manack, Mitchell Brin, P.
Charles
P4.328 A Structured Interview
Evaluating Botulinum Toxin Type A
Treatments for Blepharospasm Kapil Sethi,
John Fezza, John Burns, Julie Woodward,
Daniel Truong, Thomas Hedges, Philippe
Taupin, Amit Verma
P4.329 Differences in Clinical
Features and Management of Patients with
CD: An Analysis of Data from the US and
Europe Richard Trosch, Peter Misra, Pascal
Maisonobe, Savary Om
95
Scientific Sessions
S20 Treatment
Mechanisms in Multiple
Sclerosis
2:00 p.m. Presentation of
John Dystel Prize for Multiple
Sclerosis Research
Recipient:
Alastair Compston, MBBS, PhD
Cambridge, UK
2:30 p.m.
S20.003
Pregnancy Does Not Prevent Disease
Re-activation After Natalizumab
Suspension in Patients with
Multiple Sclerosis Maria Amato,
Bahia Hakiki, Luisa Pastò, Marta
Giannini, Lorenzo Razzolini, Carla
Tortorella, Mariangela D'Onghia,
Maria Trojano, Eleonora Cocco,
Marta Melis, Maria Marrosu,
Valeria Di Tommaso, Deborah
Farina, Alessandra Lugaresi, Pietro
Annovazzi, Angelo Ghezzi, Claudio
Gasperini, Alfonso Iudice, Roberta
Fantozzi, Paolo Bellantonio, Silvia
Messina, Francesco Patti, Silvia
Masera, Paola Cavalla, Alessandra
Protti, Maria Rossi, Rocco Totaro,
Laura De Giglio, Carlo Pozzilli, Emilio
Portaccio
2:45 p.m.
S20.004
Therapeutic Role of Poly-I: C on
Myelin Repair Chandramohan
Natarajan, Song-Yi Yao,
Subramaniam Sriram
3:00 p.m.
S20.005
Laquinimod Regulates Inflammatory
Gene Induction in a Human Model
of Reactive Astrogliosis John
Mariani, Trinh Pham, Jingya Zhang,
Jeremy Seto, Boris Hartmann, Liat
Hayardeny Nisimov, Gareth John
3:15 p.m.
S20.006
Characterization of a Next
Generation Anti-CD52
Antibody William Siders, Ben
Greene, Alison McVie-Wylie,
Meredith Bailey, Vijay Dhawan,
Paula Boutin, Annie Best, Carla
Lawendowski, Michael Turner, Bruce
Roberts, Johanne Kaplan, Rebecca
Sendak
3:30 p.m.
S20.007
Identification of Gene Networks
and Pathways Associated with
Nabiximols Treatment in Multiple
Sclerosis Patients. Filippo Martinelli
Boneschi, Laura Ferrè, Melissa
Sorosina, Elisabetta Mascia,
Arturo Nuara, Vittorio Martinelli,
Letizia Leocani, Ferdinando Clarelli,
Federica Esposito, Giancarlo Comi
S21 Cerebrovascular
Disease and Interventional
Neurology: Prehospital
and Acute Ischemic Stroke
Treatment
2:00 p.m.
S21.001
Benefits of Stroke Treatment
Delivered Using a Mobile Stroke
Unit James Grotta
2:15 p.m.
S21.002
Pre-hospital Imaging and
Thrombolysis in Acute Stroke in
an Urban US Setting: Results of
the Cleveland Pre-hospital Acute
Stroke Treatment (PHAST) Study
Group. Farren Briggs, Ather Taqui,
Russell Cerejo, Ahmed Itrat, Megan
Donohue, Natalie Organek, Andrew
Buletko, Lila Sheikhi, Maureen
Buttrick, Zeshaun Khawaja,
Dolora Wisco, Stacey Winners,
Andrew Reimer, Jennifer Frontera,
Edward Manno, Fredric Hustey,
Damon Kralovic, Rasmussen Peter,
Muhammad Hussain, Ken Uchino
2:30 p.m.
S21.003
NIH Stroke Scale Assessment Via
Tablet-based Mobile Telestroke
During Ambulance Transport Is
Feasible—Pilot Data from the
Improving Treatment with Rapid
Evaluation of Acute Stroke Via
Mobile Telemedecine (iTREAT)
Study Matthew Padrick, Sherita
Chapman, Timothy McMurry, Prachi
Mehndiratta, Christina Chee, Brian
Gunnell, Chance Kimble, Jack
Cote, Jason Lippman, Virginia
Burke, David Catell-Gordon, Karen
Rheuban, Nina Solenski, Debra
Perina, Bradford Worrall, Andrew
Southerland
2:45 p.m.
S21.004
A Door-to-needle Time Under
30 Minutes Can Be Achieved
and Can Improve Functional
Outcomes Michelle Whaley, Lisa
Caputo, Mark Kozlowski, Christopher
Fanale, Jeffrey Wagner, David
Bar-Or
3:00 p.m.
S21.005
Comparison of On-hour Vs Off-hour
Patient Cohorts at a Primary Stroke
Center: Onset-to-treatment Duration
and Clinical Outcomes After IV
Thrombolysis Karin Nystrom,
David Asuzu, Hardik Amin, Joseph
Schindler, Charles Wira, David
Greer, Nai Fang Chi, Janet Halliday,
Kevin Sheth
3:15 p.m.
S21.006
Temporal Trends of Emergency
Department Arrival Times After
Acute Ischemic Stroke: A Populationbased Study Brian Katz, Jane
Khoury, Kathleen Alwell, Charles
Moomaw, Brett Kissela, Matthew
Flaherty, Daniel Woo, Opeolu
Adeoye, Pooja Khatri, Simona Ferioli,
Jason Mackey, Sharyl Martini,
Felipe De Los Rios La Rosa, Dawn
Kleindorfer
Wednesday, April 22
S22 Epilepsy/Clinical
Neurophysiology (EEG):
Basic Science and
Intraoperative Monitoring
2:00 p.m. Presentation of
Dreifuss-Penry Epilepsy Award
Recipient:
Annapurna Poduri, MD, MPH
Boston, MA
2:15 p.m.
S22.002
Consequences of ATP1a3
Dysfunction: Characterization of
a Novel Model and Underlying
Pathophysiology Arsen Hunanyan,
Nina Fainberg, Molly Linabarger,
Eric Arehart, A Leonard, Syed
Adil, Ashley Helseth, Amanda
Swearingen, Stacy Forbes, Ramona
Rodriguiz, Theodore Rhodes,
Xiaodi Yao, Nadine Kabbi, Daryl
Hochman, William Wetsel, Ute
Hochgeschwender, Mohamad
Mikati
2:30 p.m.
S22.003
Brivaracetam (BRV) Achieves Brain
SV2A Occupancy Faster Than
Levetiracetam (LEV) Joel Mercier,
Daniel Holden, Anand Deo, Krista
Fowles, Sophie Kervyn, Nabeel
Nabulsi, Jean-Marie Nicolas, Henrik
Klitgaard, Yiyun Huang, Joseph
D'Souza, Richard Carson, Jonas
Hannestad
2:45 p.m.
S22.004
Connectivity of the Area Tempestas
with the Limbic System Mark
Skopin, Mithilesh Siddu, Mohamad
Koubeissi
3:00 p.m.
S22.005
B and Plasma Cells and Meningeal
Follicles Are a Part of Neuroinflammatory Mechanisms
Associated with Rasmussen’s
Encephalitis: New Clues About
Pathogenesis Anupama Kumar,
Maria Reyes-Mantilla, Adam
Hartman, Carlos Pardo-Villamizar,
Carlos Pardo-Villamizar
3:15 p.m.
S22.006
Intraoperative Motor Evoked
Potentials (MEPs) Monitoring Beyond
the Aortic Clamp Period of Open
Thoracoabdominal Aneurysm Repair
(TAA) Further Decreases the Risk of
Post-operative Paraplegia Reiner
Henson See, Oluwole Awosika,
Richard Cambria, Mark Conrad,
Virendra Patel, Glenn LaMuraglia,
Rae Allain, Mirela Simon
S23 Headache:
Epidemiology and Clinical
2:00 p.m.
S23.001
Primary Efficacy Outcomes from
COMPASS: A Comparison of Breath
Powered™ Device Containing
22 Mg Sumatriptan Powder
(AVP-825) Versus 100 Mg Oral
Sumatriptan in Acute Treatment of
Migraine Stewart Tepper, Roger
Cady, Stephen Silberstein, John
Messina, Ramy Mahmoud, Per
Djupesland, Paul Shin, Joao Siffert
2:15 p.m.
S23.002
Are Triptans Safe in Basilar
and Hemiplegic Migraine? A
Retrospective Chart Review Gurjeet
Singh, Jeanette Sherman, George
Zinkhan
2:30 p.m.
S23.003
Consistency of Response in the
COMPASS Study [Breath Powered™
Nasal Delivery of 22 Mg Sumatriptan
Powder (AVP-825) Versus 100 Mg
Oral Sumatriptan in Acute Migraine:
A Comparative Clinical Trial] Richard
Lipton, Dawn Buse, Ken Shulman,
Joao Siffert
2:45 p.m.
S23.004
The Real-world Impact of
OnabotulinumtoxinA on Headacherelated ER Visits and Hospitalizations
in the Management of Chronic
Migraine Zsolt Hepp, Noah Rosen,
Sepideh Varon, Patrick Gillard, Jenny
Chia, Nitya Mathew, David Dodick
3:00 p.m.
S23.005
Efficacy of SPG Stimulation in
Relieving Acute Cluster Pain: Results
from >5000 Attacks Treated During
Long-term Follow-up of the Pathway
CH-1 Study Jose Miguel Lainez,
Rigmor Jensen, Arne May, Charly
Gaul, Amy Goodman, Anthony
Caparso, Jean Schoenen
S24 ALS: Mechanisms
and Biomarkers
2:00 p.m. Presentation of
Sheila Essey Award: An Award for
ALS Research
Recipients:
Robert Bowser, PhD
Phoenix, AZ
Adriano Chio, MD
Turin, Italy
2:30 p.m.
S24.003
Head Injury Does Not Alter Disease
Progression or Neuropathological
Outcomes in ALS Christina Fournier,
Marla Gearing, Saila Upadhyayula,
Mitch Klein, Jonathan Glass
2:45 p.m.
S24.004
The ALS/FTD C9ORF72
Hexanucleotide Expansion
Disrupts Nucleocytoplasmic
Transport Thomas Lloyd, Ke Zhang,
Chris Donnelly, Jeffrey Rothstein
3:00 p.m.
S24.005
Threshold Tracking TMS: A
Novel Diagnostic Technique
for Amyotrophic Lateral
Sclerosis Nimeshan Geevasinga,
Parvathi Menon, Con Yiannikas,
James Howells, Matthew Kiernan,
Steve Vucic
3:15 p.m.
S24.006
ALS Monocytes Exhibit
a Pro-inflammatory Gene
Expression Weihua Zhao, David
Beers, Hooten Christopher, Stanley
Appel
3:30 p.m.
S24.007
Variability of Expression in SETXrelated Motor Neuron Disease:
A Single Family, Multigeneration
Evaluation Jennifer Roggenbuck,
Dawn Allain, Stanley Iyadurai,
Stephen Kolb, John Kissel
3:15 p.m.
S23.006
Migraine Diagnosis and Treatment: A
Knowledge and Needs Assessment
Among Primary Care Providers Mia
Minen, Lori Tishler, Elizabeth Loder,
David Silbersweig
3:30 p.m.
S23.007
The Place of Corticosteroids in
Migraine Attack Management:
A 65-year Systematic Review
with Pooled Analysis and Critical
Appraisal Yohannes Woldeamanuel,
Alan Rapoport, Robert Cowan
3:30 p.m.
S22.007
Early Onset Epileptic Encephalopathy
and Deficient Myelination as a Result
of Autosomal Recessive Mutations
in the AARS Gene Guy Helman, Cas
Simons, Laurie Griffin, Amy Pizzino,
Miriam Bloom, Ryan Taft, Anthony
Antonellis, Ya Ming Hou, Adeline
Vanderver
3:30 p.m.
S21.007
Are Physicians More Vigilant
in Recognizing Acute Posterior
Circulation Stroke Symptoms?—
Experience of a Tele-stroke
Network. Ramesh Madhavan,
Pratik Bhattacharya, Deepmala
Nandanwar, Omar Basha, Fnu
Abhishek, Kumar Rajamani
96
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Scientific Sessions
S25 General Neurology
2:00 p.m. Presentation of
S. Weir Mitchell Award
Recipient:
Isaac Marin-Valencia, MD
Dallas, TX
2:15 p.m.
S25.002
Defining Central Nervous System
Involvement in Patients with
Acquired Demyelinating Peripheral
Neuropathies Laura Vacchi, Maria
Rocca, Nilo Riva, Raffaella Fazio,
Elisabetta Pagani, Mauro Comola,
Andrea Falini, Giancarlo Comi,
Massimo Filippi
2:30 p.m.
S25.003
Regional Differences in the Brain
Levels of GABA and Glutamate/
Glutamine Between Patients
with Cyclic Vomiting Syndrome
and Matched Healthy Controls
Revealed by 3D MR Spectroscopic
Imaging Ovidiu Andronesi, Ronald
Garcia, Wolfgang Bogner, Shahar
Castel, Braden Kuo, Vitaly Napadow
2:45 p.m.
S25.004
Public Review: The National
Institute of Neurological
Disorders and Stroke (NINDS)
Congenital Muscular Dystrophy
(CMD), Facioscapulohumeral
Muscular Dystrophy (FSHD)
and Myotonic Dystrophy (DM)
Common Data Elements (CDE)
Recommendations Joy Esterlitz,
Joanne Odenkirchen, Marybeth
Montoro, Sherita Ala'i, Elizabeth
McNeil, Robin Conwit
3:00 p.m.
S25.005
Network for Excellence in
Neuroscience Clinical Trials,
NeuroNEXT: Increasing Efficiency in
Clinical Trial Management Marianne
Kearney, Dixie Ecklund, Michael
Bosch, Brenda Thornell, Elizabeth
McNeil, Janice Cordell, Christopher
Coffey, Merit Cudkowicz
3:15 p.m.
S25.006
Quality Improvement Project:
Improving the Follow up of Patients at
the Neurology Resident’s Clinic After
Hospital Discharge Rocio Garcia
Santibanez, John Liang, Yamin
Shwe, Sarah Wesley, Santiago
Mazuera, Ivan Matos-Diaz, Clinton
Lauritsen, Diego Tovar, Roni Sharon,
Rabih Kashouty, George Lai, Allison
Navis, Jungyeon Park, Kourosh
Kahkeshani, Weiyi Gao
S26 Neuroophthalmology/Neurootology
2:00 p.m.
S26.001
Molecular Imaging of the
Human Retina by Raman
Spectroscopy Elena MartinezLapiscina, Oscar Batet, Antoni
Gonzalez, Albert Campos, Iker
Bilbao, Dídac Perez, Elena FragaPumar, Rubén Torres-Torres, Yago
Rossello, Bernardo Sanchez-Dalmau,
Ivan Amat-Roldan, Pablo Villoslada
2:15 p.m.
S26.002
Sideline Testing in Youth and
Collegiate Athletes: What Does
Vision Add to the Concussion
Puzzle? Avri Bohm, Lisena Hasanaj,
John-Ross Rizzo, Liliana Serrano,
Rachel Nolan, Nicholas Moehringer,
Nikki Webb, Courtney Civitano,
Dennis Cardone, Arlene Silverio,
Steven Galetta, Laura Balcer
2:30 p.m.
S26.003
Differentiating Vertical Misalignment
Using Different Head Positions: A
Reappraisal Joao Lemos, Adnan
Subei, Mario Sousa, José Coelho,
Luis Cunha, Christopher Glisson, Eric
Eggenberger
2:45 p.m.
S26.004
Risk Factors for Poor Visual
Outcome in Idiopathic Intracranial
Hypertension Patients with Mild
Visual Loss Byron Lam, Julie
Falardeau, William Fletcher, Robert
Granadier, Reid Longmuir, Anil
Patel, Hau He, Michael McDermott,
Michael Wall
3:00 p.m.
S26.005
How Does Disease of Optic Nerves
Affect Acute Non-visual Light
Effects Predominantly Mediated
by Melanopsin Ganglion Cells? Aki
Kawasaki, Lorette Leon, Sylvie
Collomb, Mirjam Münch
3:15 p.m.
S26.006
Randomized Controlled Trial
Evaluating Threshold Sound
Conditioning in the Treatment of
Sensorineural Hearing Loss Sungho
Cho, Eunyee Kwak, Sangyeop Kwak,
Jaime Lopez
S27 Neuro Trauma,
Critical Care, and Sports
Neurology
2:00 p.m.
S27.001
Lingering Impairments in Postural
Control Despite Clinical Concussion
Recovery Thomas Buckley, Kelsey
Evans, Barry Munkasy
2:15 p.m.
S27.002
ApoE Status Related to Memory
Scores but Not Hippocampal
or Thalamic Volume in Combat
Sports Sarah Banks, Charles
Bernick
2:30 p.m.
S27.003
Early Prediction Model for Prognosis
After Cardiac Arrest in the Era of
Hypothermia Preet Varade, Kushak
Suchdev, Navid Seraji-Bozorgzad,
Gregory Norris, Mohammad Ibrahim,
Wazim Mohamed
2:45 p.m.
S27.004
Incidence of Headache in Retired
NFL Players. Correlation with
Diffusion Tensor MRI Imaging and
Neuropsychological Testing. Francis
Conidi
3:00 p.m.
S27.005
Acute Traumatic Coagulopathy
Accompanying Traumatic Brain Injury
Is Associated with Worse Long Term
Cognitive and Functional Outcomes:
A Retrospective Analysis of the
COBRIT Data. Peter Abdelmalik,
Jack Jallo, Fred Rincon
3:15 p.m.
S27.006
Neuronal Plasmalemmal Disruptions
Are Exacerbated in Perivascular
Domains Following Repetitive
Traumatic Brain Injury in Swine John
Duda, James Harris, Emory Kuo,
D. Cullen
3:30 p.m.
S27.007
Volumetric Analysis in Individuals
with Single Vs. Multiple Head
Injuries Christian Shenouda, Tanvi
Devi, Mitra Yousefi, Leighton Chan
3:30 p.m.
S26.007
A Radiographic Target Sign for
Abnormal Vertebral Artery Flow in
Stroke Patients with Acute Vestibular
Syndrome Jorge Kattah, Jeffrey
DeSanto, Ali Saber Tehrani, John
Pula, David Newman-Toker
S28 Neuro-rehabilitation
2:00 p.m.
S28.001
A Phase III Randomized, Doubleblind, Placebo-controlled Study
to Assess the Efficacy and
Safety of AbobotulinumtoxinA
(Dysport®) in Adults with Upper
Limb Spasticity Allison Brashear,
Christina Marciniak, Steven Edgley,
Fatma Gul, Peter Hedera, Peter
McAllister, Michael O'Dell, Bruce
Rubin, Walker Heather, Claire Vilain,
Philippe Picaut, Jean-Michel Gracies
2:15 p.m.
S28.002
Topline Results from a Randomized,
Placebo-controlled, Phase III Study
Investigating the Safety and Efficacy
of IncobotulinumtoxinA in Treating
Post-stroke Spasticity of the Upper
Limb Kapil Sethi, Elie Elovic,
Michael Munin, Christina Marciniak,
Reinhard Hiersemenzel, Angelika
Hanschmann
2:30 p.m.
S28.003
Balance-based Torso-weighting
Results in Fall Reduction During
Sensory Organization Test for People
with Multiple Sclerosis Cynthia
Gibson-Horn, Gail Widener, Diane
Allen, Kristin Horn
2:45 p.m.
S28.004
Brain Functional Changes After
a Somatosensory Discrimination
Training in Healthy Young
Subjects Elisabetta Sarasso,
Federica Agosta, Paola Adamo,
Federico Temporiti, Andrea Falini,
Roberto Gatti, Massimo Filippi
3:00 p.m.
S28.005
Promoting Locomotor Learning with
Spinal Direct Current Stimulation—
Pilot Data Oluwole Awosika, Marco
Sandrini, Rita Volochayev, Benjamin
Xu, Mary Kay Floeter, Mark Hallett,
Leonardo Cohen
Wednesday
April 22
2:00 p.m–3:45 p.m.
3:15 p.m.
S28.006
Assessment of Cerebrovascular
Dysfunction After Traumatic
Brain Injury: MRI-BOLD Versus
NIRS Franck Amyot, Kimbra Kenney,
Carol Moore, Erika Silverman, Emily
Spessert, Leah Harburg, Ramon
Diaz-Arrastia
3:30 p.m.
S28.007
Network Control Theory as a
Mediator of Transcranial Magnetic
Stimulation Effects John Medaglia,
Roy Hamilton, Sharon ThompsonSchill, Shi Gu, Danielle Bassett
3:30 p.m.
S25.007
Quix Test Predicts Canal Sidedness
in BPPV Kevin Coughlin, Krysten
Sherrod, Jason Miles, Ryan
Fitzgerald, Garrett Barr, Jonathan
Salud, Shawn Adams, Charles
Maitland
Fast, Easy, Online Registration · AAN.com/view/AM15
97
Integrated Neuroscience Session
I9
Wednesday, April 22
Treating Dementia in an Age of Mixed Disease
2:00 p.m.–6:00 p.m.
Coordinators: Randolph S. Marshall, MD, FAAN, and Ronald M. Lazar, PhD, FAAN
Part I
2:00 p.m.–3:45 p.m.
2:00 p.m.–2:05 p.m.
Introduction
2:05 p.m.–2:35 p.m.
Invited Speaker
Randolph S. Marshall, MD, FAAN, and Ronald M. Lazar, PhD, FAAN
I9-1A Data Blitz
2:40 p.m.–2:45 p.m.
I9-1B Data Blitz
2:45 p.m.–2:55 p.m.
Audience Q&A
2:55 p.m.–3:25 p.m.
Invited Speaker
Anti-S100B Autoantibodies in Cerebral Small Vessel Disease Chanda Brennan,
Humberto Choi, Vikram Puvenna, Michael Phillips, Peter Mazzone, Damir Janigro
The Neuropathology of Patients with Dementia and Non-dementia in the Oldestold Gamze Balci Camsari, Neill Graff-Radford, Ronald Petersen, David Knopman,
Bradley Boeve, Joseph Parisi, Dennis Dickson, Melissa Murray
Reconsidering Harbingers of Alzheimer’s Disease: Risk factors, Biomarkers, and
White Matter Hyperintensities Adam Brickman, PhD
3:25 p.m.–3:30 p.m.
I9-2A Data Blitz
3:30 p.m.–3:35 p.m.
I9-2B Data Blitz
White Matter Hyperintensity Associated with Cerebral Amyloidosis Independent
of Hypertension History Julia Scott, Duygu Tosun-Turgut, Meredith Braskie, Paul
Thompson, Michael Weiner, Charles DeCarli, Owen Carmichael
Differential Progression of White Matter Hyperintensities in Earlyonset Compared to Late-onset Alzheimer’s Disease: A Longitudinal MRI
Study Nicodemus Oey, Hani Zainal, Alvin Cenina, Nagaendran Kandiah
3:35 p.m.–3:45 p.m.
Audience Q&A
3:45 p.m.–3:55 p.m.
Break
3:55 p.m.–5:35 p.m.
3:55 p.m.–4:25 p.m.
Invited Speaker
4:25 p.m.–4:30 p.m.
I9-3A Data Blitz
4:30 p.m.–4:35 p.m.
I9-3B Data Blitz
4:35 p.m.–4:45 p.m.
Audience Q&A
4:45 p.m.–5:15 p.m.
Invited Speaker
5:15 p.m.–5:20 p.m.
I9-4A Data Blitz
5:20 p.m.–5:25 p.m.
I9-4B Data Blitz
5:25 p.m.–5:35 p.m.
Audience Q&A
Blood Pressure Management in Vascular Cognitive Impairment Randolph S.
Marshall, MD, FAAN
Cellular Mechanisms that Link Alzheimer’s Disease and Vascular
Dementia Berislav V. Zlokovic, MD, PhD
2:35 p.m.–2:40 p.m.
Part II
Heart-health Intervention Reduces Cognitive Decline in Mild Cognitive
Impairment of the Cerebrovascular Type: A Randomized, Placebo-controlled
Clinical Trial Gregory Jicha, Richard Murphy, Martha Biddle, Debra Moser
The Association Between Pulse Pressure and Memory Functioning over Time
Depends on Baseline Systolic Blood Pressure Eric McDade, Zhaowen Sun, ChingWen Lee, Beth Snitz, Chung-Chou Chang, Mary Ganguli
Sleep and Alzheimer's Disease: A Bi-directional Relationship David M. Holtzman, MD, FAAN
Sleep Duration Is Associated with Worse Neurocognitive Function in Hispanic/
Latinos: Results of the Hispanic Community Health Study/Study of Latinos
(HCHS/SOL) Alberto Ramos, Wassim Tarraf, Martha Daviglus, Sonia Davis, Linda
Gallo, Yasmin Mossavar-Rahmani, Frank Penedo, Susan Redline, Tatjana Rundek,
Ralph Sacco, Daniela Sotres-Alvarez, Clinton Wright, Phyllis Zee, Hector Gonzalez
The Association of Sleep Apnea and Stroke with Cognitive Performance:
The REasons for Geographic and Racial Differences in Stroke (REGARDS)
Study Jennifer Molano, Dawn Kleindorfer, Leslie McClure, Frederick Unverzagt,
Virginia Wadley, Virginia Howard
Guided Poster Rounds
5:35 p.m.–6:00 p.m.
I9-5A
Atrial Fibrillation in Patients
with Neuropathological Diagnosis of
Primary Alzheimer’s Disease Patricia
Riccio, Luciano Alberto Sposato, Estefania
Ruiz Vargas, Jon Toledo, John Trojanowski,
Vladimir Hachinski
I9-5E
Early Diagnosis of
Vascular Cognitive Impairment Is
Associated with Improved Adherence
with Medical Treatment of Vascular Risk
Factors Angelia Kirkpatrick, Elliott Ross,
Leslie Guthery, Calin Prodan
I9-5I I9-5B
I9-5F I9-5J Mixed Membership
Trajectory Model of Cognitive Impairment
in the Cardiovascular Health Study—
Cognition Study Fabrizio Lecci, Brian
Junker, Lewis Kuller, Oscar Lopez, James
Becker
I9-5C
Neuroticism Increases with
Age in Cognitively Normal Older Adults
Who Are PiB-positive Carolyn Fredericks,
Virginia Sturm, Alice Hua, Murat Bilgel,
Dean Wong, Susan Resnick, William
Seeley
I9-5D
Relation of Cognitive
Impairment and Insulin Resistance
in Hispanic Patients with Parkinson’s
Disease Angel Vinuela, Carmen Serrano,
Maria Margarida, Yamil Gerena, Karen
Valdesuso, Ana Mosquera, Valerie Wojna
98
Anti-S100B Autoantibodies
in Cerebral Small Vessel Disease Chanda
Brennan, Humberto Choi, Vikram Puvenna,
Michael Phillips, Peter Mazzone, Damir
Janigro
I9-5G The Neuropathology of
Patients with Dementia and Non-dementia
in the Oldest-old Gamze Balci Camsari,
Neill Graff-Radford, Ronald Petersen, David
Knopman, Bradley Boeve, Joseph Parisi,
Dennis Dickson, Melissa Murray
I9-5H White Matter
Hyperintensity Associated with Cerebral
Amyloidosis Independent of Hypertension
History Julia Scott, Duygu Tosun-Turgut,
Meredith Braskie, Paul Thompson, Michael
Weiner, Charles DeCarli, Owen Carmichael
Differential Progression
of White Matter Hyperintensities in
Early-onset Compared to Late-onset
Alzheimer’s Disease: A Longitudinal MRI
Study Nicodemus Oey, Hani Zainal, Alvin
Cenina, Nagaendran Kandiah
Heart-heath Intervention
Reduces Cognitive Decline in
Mild Cognitive Impairment of the
Cerebrovascular Type: A Randomized,
Placebo-controlled Clinical Trial Gregory
Jicha, Richard Murphy, Martha Biddle,
Debra Moser
I9-5K The Association Between
Pulse Pressure and Memory Functioning
over Time Depends on Baseline Systolic
Blood Pressure Eric McDade, Zhaowen
Sun, Ching-Wen Lee, Beth Snitz, ChungChou Chang, Mary Ganguli
I9-5L Sleep Duration Is
Associated with Worse Neurocognitive
Function in Hispanic/Latinos: Results of
the Hispanic Community Health Study/
Study of Latinos (HCHS/SOL) Alberto
Ramos, Wassim Tarraf, Martha Daviglus,
Sonia Davis, Linda Gallo, Yasmin
Mossavar-Rahmani, Frank Penedo, Susan
Redline, Tatjana Rundek, Ralph Sacco,
Daniela Sotres-Alvarez, Clinton Wright,
Phyllis Zee, Hector Gonzalez
I9-5M The Association of
Sleep Apnea and Stroke with Cognitive
Performance: The REasons for Geographic
and Racial Differences in Stroke
(REGARDS) Study Jennifer Molano, Dawn
Kleindorfer, Leslie McClure, Frederick
Unverzagt, Virginia Wadley, Virginia
Howard
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Integrated Neuroscience Session
I10C The Dynamic Brain in Health and Disease:
Plasticity and Reprogramming
2:00 p.m.–6:00 p.m.
Coordinators: Mark F. Mehler, MD, FAAN, and Mark Albers, MD, PhD
Invited Speaker Session
2:00 p.m.–4:05 p.m.
2:00 p.m.–2:05 p.m.
3:05 p.m.–3:35 p.m.
2:05 p.m.–2:35 p.m.
3:35 p.m.–4:05 p.m.
Introduction Mark F. Mehler, MD, FAAN, and Mark Albers, MD, PhD
New Treatments for Neurodevelopmental and Neurodegenerative
Disorders Joseph O. Gleeson, MD
Novel Forms of Plasticity in the Adult Mammalian Brain Hongjun Song, PhD
New Approaches to Promote Motor Recovery After Stroke John Krakauer, MD
2:35 p.m.–3:05 p.m.
Fate Plasticity in the Cerebral Cortex: Generating New Corticospinal
Neurons Brad Molyneaux, MD
Data Blitz Session
4:05 p.m.–4:45 p.m.
I10-1A
4:10 p.m.–4:15 p.m.
I10-1B
Genetic Association Study of Cognitive Performance Jonathan Katz, Chuanhui
Dong, Yaakov Stern, Clinton Wright, Susan Blanton, Ralph Sacco
Tractography Activation Patterns in Dorsolateral Prefrontal Cortex Suggest
Better Clinical Responses in Deep Brain Stimulation (DBS) of the Anterior Limb
of the Internal Capsule and Nucleus Accumbens (ALIC-NA) for Obsessivecompulsive Disorder (OCD) Christian Hartmann, J. Lujan, Ashutosh Chaturvedi,
Wayne Goodman, Michael Okun, Cameron McIntyre, Ihtsham Haq
4:15 p.m.–4:20 p.m.
I10-2A
4:20 p.m.–4:25 p.m.
I10-2B
HDAC4 Shuttling Promotes Neuronal Remodeling After Stroke Amjad Shehadah,
Haifa Kassis, Michael Chopp, Cynthia Roberts, Zheng Gang Zhang
Personal Experience with Dance and Cortical Gray Matter Thickness in the
Cognitively Normal and Mild Cognitive Impaired Elderly Shai Porat, Kristy
Hwang, Ellen Woo, Theodore Zanto, Naira Goukasian, Liana Apostolova
4:25 p.m.–4:30 p.m.
I10-3A
4:30 p.m.–4:35 p.m.
I10-3B
4:35 p.m.–4:40 p.m.
I10-4A
4:40 p.m.–4:45 p.m.
I10-4B
Network Control Theory as a Mediator of Transcranial Magnetic Stimulation
Effects John Medaglia, Roy Hamilton, Sharon Thompson-Schill, Shi Gu, Danielle
Bassett
In Vivo Evidence for Long-term Potentiation in Older Adults Fabio Porto, Anne
Fox, Erich Tusch, Farzaneh Sorond, Abdul Mohammed, Kirk Daffner
Deep Repetitive Transcranial Magnetic Stimulation and Cycling Improve Lower
Limb Function in Chronic Stroke: A Randomized, Placebo-controlled, Crossover
Study Raffaella Chieffo, Fabio Giatsidis, Elise Houdayer, Mario Fichera, Arturo
Nuara, Elisabetta Coppi, Laura Ferrari, Giovanni Di Maggio, Roberto Santangelo,
Antonella Poggi, Maria Sessa, Mauro Comola, Abraham Zangen, Giancarlo Comi,
Letizia Leocani
A Stimulating Idea: Treating Mixed ET/PD Tremor with Novel DBS
Approach Ramsey Falconer, Sean Rogers, Christopher Kalhorn
Guided Poster Rounds
I10-5A
The Longitudinal
Relationship Between Inflammatory
Burden and Gait Speed Is Influenced
by White Matter Microstructural
Characteristics: Secondary Analysis of
the Health ABC Study Neelesh Nadkarni,
Robert Boudreau, Oscar Lopez, Howard
Aizenstein, Stephen Kritchevsky, Kristine
Yaffe, Stephanie Studenski, Anne Newman,
Caterina Rosano
I10-5B
Cortical Reorganization and
Magnetoencephalographic Correlates for
Paretic Hand Recovery After Stroke ChihWei Tang, Fu-Jung Hsiao, Po-Lei Lee,
Yun-An Tsai, Ya-Fang Hsu, I-Hui Lee
I10-5C
Brain Structural
Abnormalities in Patients with Major
Depression with or Without Generalized
Anxiety Disorder Comorbidity Elisa
Canu, Milutin Kostic, Federica Agosta,
Ana Munjiza, Pilar Ferraro, Danilo Pesic,
Massimiliano Copetti, Amir Peljto, Dusica
Lecic Tosevski, Massimo Filippi
4:45 p.m.–5:15 p.m.
I10-5D
In Vitro and in Vivo
Effects of Ionizing Radiation on Cell
Cycle Progression and Self-renewal
of Subventricular Zone Neural
Precursors Hongxin Chen, Sonia De
Toledo, Matthew Goodus, Edouard Azzam,
Steve Levison, Nizar Souayah
I10-5E
Induction of Functional
and Structural Plasticity by Intermittent
Theta Burst Stimulation in Post-stroke
Aphasia Joseph Griffis, Rodolphe Nenert,
Jane Allendorfer, Jerzy Szaflarski
I10-5F
Genetic Association Study
of Cognitive Performance Jonathan Katz,
Chuanhui Dong, Yaakov Stern, Clinton
Wright, Susan Blanton, Ralph Sacco
Roundtable Discussion
Fast, Easy, Online Registration · AAN.com/view/AM15
I10-5G
Tractography Activation
Patterns in Dorsolateral Prefrontal Cortex
Suggest Better Clinical Responses in Deep
Brain Stimulation (DBS) of the Anterior
Limb of the Internal Capsule and Nucleus
Accumbens (ALIC-NA) for Obsessivecompulsive Disorder (OCD) Christian
Hartmann, J. Lujan, Ashutosh Chaturvedi,
Wayne Goodman, Michael Okun, Cameron
McIntyre, Ihtsham Haq
I10-5H
HDAC4 Shuttling Promotes
Neuronal Remodeling After Stroke Amjad
Shehadah, Haifa Kassis, Michael Chopp,
Cynthia Roberts, Zheng Gang Zhang
I10-5I
Personal Experience with
Dance and Cortical Gray Matter Thickness
in the Cognitively Normal and Mild
Cognitive Impaired Elderly Shai Porat,
Kristy Hwang, Ellen Woo, Theodore Zanto,
Naira Goukasian, Liana Apostolova
I10-5J
Network Control Theory
as a Mediator of Transcranial Magnetic
Stimulation Effects John Medaglia, Roy
Hamilton, Sharon Thompson-Schill, Shi Gu,
Danielle Bassett
I10-5K
In Vivo Evidence for Longterm Potentiation in Older Adults Fabio
Porto, Anne Fox, Erich Tusch, Farzaneh
Sorond, Abdul Mohammed, Kirk Daffner
I10-5L
Deep Repetitive
Transcranial Magnetic Stimulation and
Cycling Improve Lower Limb Function in
Chronic Stroke: A Randomized, Placebocontrolled, Crossover Study Raffaella
Chieffo, Fabio Giatsidis, Elise Houdayer,
Mario Fichera, Arturo Nuara, Elisabetta
Coppi, Laura Ferrari, Giovanni Di Maggio,
Roberto Santangelo, Antonella Poggi,
Maria Sessa, Mauro Comola, Abraham
Zangen, Giancarlo Comi, Letizia Leocani
I10-5M
A Stimulating Idea: Treating
Mixed ET/PD Tremor with Novel DBS
Approach Ramsey Falconer, Sean Rogers,
Christopher Kalhorn
5:15 p.m.–6:00 p.m.
99
Wednesday
April 22
4:05 p.m.–4:10 p.m.
Poster Session V
Wednesday, April 22
P5 First
Poster Session V
Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Discussion Session: Aging, Dementia, Cognitive, and Behavioral Neurology
2:00 p.m.–6:30 p.m.
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
P5.001 Differentiating the Logopenic
and Nonfluent/Agrammatic Variants of
Primary Progressive Aphasia by Selective
Word Comprehension Impairment Collin
York, Sharon Ash, Katya Rascovsky, Murray
Grossman
P5.002 Cumulative, Additive Benefits
of Memantine-Donepezil Combination Over
Component Monotherapies in Moderate
to Severe Alzheimer’s Dementia: A Pooled
Area Under the Curve Analysis Alireza
Atri, Suzanne Hendrix, Vojislav Pejovic,
Robert Hofbauer, John Edwards, Jose Luis
Molinuevo, Stephen Graham
P5.003 The Longitudinal Evaluation of
Familial Frontotemporal Dementia Subjects
(LEFFTDS) Protocol: Known Kindreds and
Preliminary Data Bradley Boeve, Howard
Rosen, Adam Boxer, Bradford Dickerson,
Howard Feldman, Nupur Ghoshal, Jill
Goldman, Neill Graff-Radford, Murray
Grossman, Ging-Yuek Hsiung, Edward Huey,
David Irwin, Clifford Jack, Kejal Kantarci,
David Knopman, John Kornak, Ian R.A.
Mackenzie, Bruce Miller, Leonard Petrucelli,
Rosa Rademakers, Leslie Shaw, Arthur
Toga, John Trojanowski, Zbigniew Wszolek
P5.004 Pseudo-continuous Arterial
Spin Labeling Is Sensitive to Changes in
Cerebral Blood Flow in Semantic Variant
Primary Progressive Aphasia and Nonfluent/Agrammatic Primary Progressive
Aphasia Christopher Olm, Benjamin
Kandel, Brian Avants, John Detre, James
Gee, Corey McMillan, Murray Grossman
P5.005 Initial Experience with
[18F]AV1451 PET in AD and Non-AD
Tauopathies Gil Rabinovici, Daniel
Schonhaut, Rik Ossenkoppele, Suzanne
Baker, Andreas Lazaris, Sam Lockhart,
Henry Schwimmer, James O'Neil, Miguel
Santos, Zachary Miller, Brianne Bettcher,
Adam Boxer, Howard Rosen, Maria Gorno
Tempini, Bruce Miller, William Jagust
P5.006 Clinical Correlates and
Baseline Predictors of Progressive Brain
Atrophy in Progressive Supranuclear Palsy:
Results from the AL-108-231 Davunetide
Trial Richard Tsai, Iryna Lobach, Jennifer
Whitwell, Matthew Senjem, Clifford Jack,
Adam Boxer
P5.007 White Matter Hyperintensity
Associated with Cerebral Amyloidosis
Independent of Hypertension History Julia
Scott, Duygu Tosun-Turgut, Meredith
Braskie, Paul Thompson, Michael Weiner,
Charles DeCarli, Owen Carmichael
P5.008 Occupational Attainment
Delays Cognitive Decline in Frontotemporal
Degeneration Lior Rennert, Sharon Xie,
Lauren Massimo, Katya Rascovsky, Corey
McMillan, Murray Grossman
P5.009 Defining the White Matter
Hyperintensity Penumbra: A Pulsed
Arterial Spin Labeling Study Nutta-on
Promjunyakul, David Lahna, Jeffrey Kaye,
Hiroko Dodge, Deniz Erten-Lyons, William
Rooney, Lisa Silbert
P5.010
Sensitivity and Specificity
of New Criteria for the Diagnosis of
Corticobasal Degeneration Clara Boyd,
Michael Tierney, Eric Wassermann,
Salvatore Spina, Adrian Oblak, Bernardino
Ghetti, Jordan Grafman, Corey McMillan,
Edward Huey
e-Poster Session: Aging, Dementia, Cognitive, and Behavioral Neurology
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P5.011
Sirtuin 3 Is Down-regulated in
Apolipoprotein E4 Carriers with Alzheimer’s
Disease Junxiang Yin, Peng Cheng Han,
Richard Caselli, Thomas Beach, Geidy
Serrano, Eric Reiman, Jiong Shi
P5.012
Quantitative Digital
Image Analysis of Pick’s Disease
Neuropatholgy David Irwin, Mathew
Byrne, Corey McMillan, Virginia Lee, Murray
Grossman, John Trojanowski
P5.013
GRN-related Frontotemporal
Lobar Degeneration TDP43 Type A
Presenting as a Case of Posterior Cortical
Atrophy Sara Mitchell, Diane Lucente,
Mykol Larvie, Matthew Frosch, Bradford
Dickerson
Aging, Dementia, Cognitive, and
Behavioral Neurology: Amyloid
and Biomarkers
P5.021 Fibrillar Amyloid: Thinking
Globally, Not Acting Locally Andre
Altmann, Bernard Ng, Susan Landau,
William Jagust, Michael Greicius
100
P5.014
Using Conversation Analysis
to Help Diagnose Dementia Daniel
Blackburn, Markus Reuber
P5.015
Mitochondrial Encephalopathy
with Lactic Acidosis and Stroke (MELAS)
Presenting as an Apparent Neoplastic
Process Aaron Rothstein, Ihtsham Haq
P5.016
Concordance Between
11C-PIB-PET and AB42 in a Memory
Clinic Patricio Chrem Mendez, Leandro
Urrutia, German Falasco, Silvia Vazquez,
Ricardo Allegri
P5.022 Cross Validation of Imaging
and CSF Biomarkers in a Clinical
Setting Daniela Perani, Chiara Cerami,
Silvia Caminiti, Leonardo Iaccarino, Roberto
Santangelo, Andrea Falini, Giuseppe
Magnani
P5.023
Presence of Cerebral Amyloid
Modulates Phenotype and Pattern of
Neurodegeneration in Early Parkinson’s
Disease Corey McMillan, David Wolk
P5.017
Differential Progression
of White Matter Hyperintensities in
Early-onset Compared to Late-onset
Alzheimer’s Disease: A Longitudinal MRI
Study Nicodemus Oey, Hani Zainal, Alvin
Cenina, Nagaendran Kandiah
P5.019
P5.018
Decline in Naming in Patients
with Primary Progressive Aphasia Is
Associated with the Strength of Functional
Correlation Between Homologous Prefrontal Cortices in the Initial MRI Andreia
Faria, Aaron Meyer, Donna Tippett, Rajani
Sebastian, Susumu Mori, Rhonda Friedman
P5.020 Description of a Method:
P5.024 The Effects of Asymptomatic
P5.026Quantitative α-synuclein Level
B-amyloid Positivity on Cerebral
Metabolism and CSF-pTau Levels Monica
Gentchev, David Zhu, Andrea Bozoki
P5.025 Neuroticism Increases with
Age in Cognitively Normal Older Adults
Who Are PiB-positive Carolyn Fredericks,
Virginia Sturm, Alice Hua, Murat Bilgel,
Dean Wong, Susan Resnick, William Seeley
Verbal Episodic Memory and
Spatial Memory Correlate Differentially
with Hippocampal Volume in Older
Adults Ali Ezzati, Vahid Eslami, Michael
Lipton, Mindy Katz, Martin Sliwinski,
Richard Lipton
Assessment of Phosphorylated Tau
Protein by Immunohistochemistry in the
Skin of Patients with Neurodegenerative
Diseases Juan Carrizales-Rodriguez, Maria
Jimenez-Capdeville, Ildefonso RodriguezLeyva, Erika Chi
Is Associated with Higher Diffuse Amyloid
Plaque and Amyloid Oligomer Burdens HoYann Jong, Randall Woltjer, Hiroko Dodge,
Jeffrey Kaye, Lisa Silbert, Deniz Erten-Lyons
P5.027 Role of Plasma Clusterin
in Mild Cognitive Impairment,
Alzheimer’s Disease, and Vascular
Dementia Venugopalan Vishnu,
Manish Modi, Manju Mohanty, Niranjan
Khandelwal, Bhagwant Mittal, Sudesh
Prabhakar
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session V
P5.028 Investigating Blood Gene
Expression Levels as a Biomarker for
LOAD Mariet Allen, Xue Wang, Daniel
Serie, Jeremy Burgess, Michaela
Kachadoorian, Samantha Strickland, Thuy
Nguyen, Kimberly Malphrus, Sarah Lincoln,
Minerva Carrasquillo, Steven Younkin,
Julia Crook, Yan Asmann, Ronald Petersen,
Nilufer Taner
P5.029 Tau Protein Concentrations
Are Significantly Increased in CSF
Extracellular Vesicles of Patients with Mild
Cognitive Impairment Due to Alzheimer’s
Disease Innocenzo Rainero, Maria Chiara
Deregibus, Silvia Boschi, Elisa Rubino,
Pierpaola Fenoglio, Lorenzo Pinessi,
Giovanni Camussi
P5.030 Increased Cerebrospinal Fluid
Total-tau Levels in Hereditary Behavioralvariant Frontotemporal Dementia David
Irwin, Corey McMillan, Katya Rascovsky,
EunRan Suh, Leslie Shaw, Steven Arnold,
Virginia Lee, Vivianna Van Deerlin, John
Trojanowski, Murray Grossman
Neuroepidemiology: Aging,
Dementia, Cognitive, and
Behavioral Neurology, General
Neurology, and Research
Methodology and Education
P5.037 Insights into the Classification
of Myasthenia Gravis Tetsuya Akaishi,
Yasushi Suzuki, Yuriko Nagane, Shigeaki
Suzuki, Hiroyuki Murai, Tomihiro Imai,
Masakatsu Motomura, Takuhiro Yamaguchi,
Kazuo Fujihara, Masashi Aoki, Kimiaki
Utsugisawa
P5.038 Breadth Vs. Volume: The
Outpatient Neurology Clinic Experience in
Medical Education Dara Albert, Angela
Blood, Yoon Soo Park, James Brorson,
Rimas Lukas
Neuroepidemiology: Headache,
Global Health, and Infectious
Disease
P5.039 Perception of the Family
Burden of Chronic Migraine: Results of the
CaMEO (Chronic Migraine Epidemiology
and Outcomes) Study Dawn Buse, David
Dodick, Aubrey Manack
P5.040 Effects of Demographic
and Socioeconomic Characteristics on
Barriers to Chronic Migraine Consultation,
Diagnosis, and Treatment: Results from the
CaMEO (Chronic Migraine Epidemiology
and Outcomes) Study David Dodick,
Richard Lipton, Michael Reed, Kristina
Fanning, Aubrey Manack, Adrian Holden
Factor for Cognitive Dysfunction in Adults
with Sickle Cell Disease Dana Jorgensen,
Enrico Novelli, Elizabeth Sarles, Anne Ritter,
John Cole, Meryl Butters, Caterina Rosano
Prevalence of Migraine
Headache and Its Weight on Neurological
Burden in Africa: A 43-year Systematic
Review and Meta-analysis of Communitybased Studies Yohannes Woldeamanuel,
Anna Andreou, Robert Cowan
P5.032
P5.042 Pain Comorbidities of Episodic
P5.031 Hemoglobin Is a Potential Risk
Early Development of
Proliferative Retinopathy Increases Risk
of Cognitive Dysfunction in Middle-aged
Adults with Type 1 Diabetes Karen Nunley,
Christopher Ryan, Judith Saxton, Trevor
Orchard, Tina Costacou, Howard Aizenstein,
John Ryan, Rachel Miller, Caterina Rosano
P5.033 Early Clinical Features of
Familial and Sporadic Frontotemporal
Dementia in an Italian FTD Cohort—
the Apulia FTD Population-based
Registry Rosa Capozzo, Simona Arcuti,
Rosanna Tortelli, Maria Rosaria Barulli,
Alessandra Grasso, Marianna Tursi, Bruno
Brancasi, Franco Valluzzi, Vincenzo Solfrizzi,
Francesco Carnicella, Claudia Dell'Aquila,
Angelo Zenzola, Gerardo Ciardo, Bruno
Tartaglione, Patrizia Milzi, Francesco Panza,
Giancarlo Logroscino
P5.034 Incidence and Predictors of
Poststroke Depression: Results from the
Framingham Heart Study Joel Salinas,
Alexa Beiser, Jayandra Himali, Jonathan
Rosand, Sudha Seshadri, Erin Dunn
P5.035 Demographics and Impact on
Diagnosis of Neurological Consultations in
the ICU Natalie Weathered, Laura Lennihan
P5.036 Healthcare Utilization
After a Diagnosis of Conversion
Disorder Alexander Merkler, Neal Parikh,
Simriti Chaudhry, Alanna Chait, Nicole
Allen, Babak Navi, Hooman Kamel
P5.041
and Chronic Migraine: Results from the
CaMEO (Chronic Migraine Epidemiology
and Outcomes) Study Scher Ann, Richard
Lipton, Kristina Fanning, Joan Largent
P5.043 HIV Associated
Neurocognitive Disorders (HAND) in
Nigeria: Clinical Rating Versus Global
Deficit Score Methods Jibreel Jumare,
Akolo Christopher, Mariana Cherner, Anya
Umlauf, Kanayo Okwuasaba, Lindsay
Eyzaguirre, Ruxton Adebiyi, Dakum Paul,
Joyce Johnson, Terence Hendrix, Alash'le
Abimiku, William Blattner, Walter Royal
P5.044 Adult Tuberculous Meningitis
in Qatar: A Descriptive Retrospective
Study from Its Referral Center Yahia Imam,
Hassan Ahmedullah, Naveed Akhtar, KC
Chacko, Saadat Kamran, Faraj Al-Alousi,
Zubaida Al-Suwaidi, Muna Almaslmani,
Abdullatif Al-Khal, Dirk Deleu
P5.045 Etiologies of New Onset
Seizure in HIV-infected Zambian
Adults Omar Siddiqi, Melissa Elafros,
Izukanje Sikazwe, Chris Bositis, Igor
Koralnik, Michael Potchen, William
Theodore, Lisa Kalungwana, Gretchen
Birbeck
P5.046 Predictors of Poor Outcome
in Bacterial Meningitis: Retrospective
Analysis of Nationwide Inpatient
Sample Devanshi Dharaiya, Sumul Modi,
Stefania Maraka
Fast, Easy, Online Registration · AAN.com/view/AM15
P5.047 Pilot Study of a
P5.057 GDF15 (Growth Differentiation
P5.048 Cluster of Acute Flaccid
P5.058 Initial Results from the
Neuroepidemiologic Screening Tool in Rural
Uganda Deanna Saylor, Gertrude Nakigozi,
Noeline Nakasujja, Xiangrong Kong, Kevin
Robertson, Ronald Gray, Maria Wawer, Ned
Sacktor
Paralysis and Cranial Nerve Dysfunction
in Children Temporally Associated with an
Enterovirus D68 Outbreak in Colorado Teri
Schreiner, Kevin Messacar, John Maloney,
Adam Wallace, Jan Ludke, Samuel
Dominguez
P5.049 Prevalence and Comorbid
Factors Associated with Distal Symmetric
Polyneuropathies in HIV+ and HIV- Adults
in Urban and Rural Zambia Michelle
Kvalsund, Takondwa Chidumayo, Johanna
Hamel, Douglas Heimburger, Gretchen
Birbeck
P5.050 Mortality Predictors in
Bacterial Meningitis Patients Who
Developed Hydrocephalus Khadija Irshad,
Sumul Modi, Imama Naqvi, Devanshi
Dharaiya
Biomarkers of Neuromuscular
Disease
P5.051
Progression to Clinically
Meaningful Changes in ALSFRS-R
Bulbar and Fine Motor Domains Is
Faster in Bulbar Onset and in Limb
Onset Amyotrophic Lateral Sclerosis
Patients Respectively Elena Ratti, James
Berry, Mark Vangel, Eric Macklin, David
Schoenfeld, Merit Cudkowicz
P5.052 Skeletal Muscle, Cardiac, and
Pulmonary Imaging Biomarkers of Disease
Activity in a Trial of Exon-skipping for Boys
with Duchenne Muscular Dystrophy Ami
Mankodi, Robert Janiczek, Noura Azzabou,
Lasya Gaur, Courtney Bishop, Harmen
Reyngoudt, Martijn Froeling, Rexford
Newbould, Andrew Arai, Pierre Carlier,
Kenneth Fischbeck
P5.053 Myofiber HLA-DR
Expression Is a Distinctive Biomarker
for Overlap Myositis and Inclusion Body
Myositis Jessie Aouizerate, Marie De
Antonio, Guillaume Bassez, Cyril Gitiaux,
Romain Gherardi, Franois-J Authier
P5.054 Search for Potential
Biomarkers at Baseline in a Large
ALS Cohort Study (ALS COSMOS):
Plasma Creatinine and Urinary 8-oxodeoxyguanosine Hiroshi Mitsumoto,
Regina Santella, Jonathan Hupf, Clement
Furlong, Serge Cremers, Teress Votto,
Jessica Singleton, Raymond Goetz, Irina
Gurvich, Bjorn Oskarsson, Jose Americo
Fernandes-Filho, Chris Gennings, Pam
Factor-Litvak
P5.055 A Promising Marker to Detect
Chronic Pain Syndrome Elizabeth Strong,
Jafar Kafaie
Factor 15) Is the New Biomarker
for Muscle-related Mitochondrial
Diseases Yasutoshi Koga, Shuichi Yatsuga,
Hajime Arahata, Akiko Ishii, Tatsuyuki
Kakuma
NeuroNEXT SMA Infant Biomarker
Study Stephen Kolb, Christopher Coffey,
Jon Yankey, William Arnold, Seward
Rutkove, Amy Bartlett, John Kissel
P5.059
Myotonic Discharges
in Autophagic Vacuolar Myopathies:
A Potentially Useful Marker Ludwig
Gutmann, Laurie Gutmann, Steven Moore
P5.060 A Promissing Method of CTS
Investigation: Median-radial Nerve Action
Potential Splitting (MRS) Pablo Winckler,
Thais Rodrigues, Isabel Bandeira, Josep
Vall-Solé, Pedro Schestatsky
Neuromuscular Disease:
Pathogenesis and Pathology
P5.061
In Vitro Pharmacokinetic
Evaluation of Eteplirsen, SRP-4045, and
SRP-4053; Three Phosphorodiamidate
Morpholino Oligomers (PMO) for the
Treatment of Patients with Duchenne
Muscular Dystrophy (DMD) P Sazani, T
Magee, JS Charleston, C Shanks, J Zhang,
M Carver, J Saoud, E Kaye
P5.062 Atypical Presentation of
Sporadic Inclusion Body Myositis Sheetal
Shroff, Milvia Pleitez
P5.063 Sarcopenic Obesity in
Myasthenia Gravis Charlene Hafer-Macko
P5.064 Mononeuropathy Multiplex
Associated with Hemophagocytic
Lymphohistiocytosis Mimicking
Vasculitis Chad Hoyle, Darine Kassar,
William Arnold, Miriam Freimer
P5.065Clinicopathological
Features of Patients with Neuromuscular
Disease Showing CD8-MHC-1 Complex
Pathology Chiseko Ikenaga, Meiko Maeda,
Shoji Tsuji, Jun Shimizu
P5.066 Clinical Significance of Cation
Channel Antibodies in Motor Neuron
Disease Rachel Donaldson, Yuebing Li
P5.067
Clinical and Molecular
Genetics Spectrum of Thymidine Kinase
2 Deficiency Caterina Garone, Emanuele
Barca, Karin Kleinsteuber, Alice Donati,
Salvatore DiMauro, Michio Hirano
P5.068 Guillain Barre Syndrome:
Predictors of Requirement of Mechanical
Ventilation Devanshi Dharaiya, Sumul
Modi, Imama Naqvi
P5.069 Pain Characteristics Do Not
Distinguish Fibromyalgia Patients with
Abnormal Skin Biopsy Victoria Lawson,
Jesse Grewal, Kevin Hackshaw, Phillip
Mongiovi
P5.056 The Neuromuscular Features
of Light Chain Deposition Disease Ling
Zhang, Mark Ferrante, Helen Ly, Tulio
Bertorini
101
Wednesday
April 22
2:00 p.m.–6:30 p.m.
Poster Session V
Neuropathy: Pathogenesis and
Pathology
P5.070 Diffusion Tensor Imaging
(DTI) of the Cervical Cord in Sensory
Neuronopathies Jean Levi Ribeiro de Paiva,
Raphael Fernandes Casseb, Alberto Rolim
Muro Martinez, Anamarli Nucci, Marcondes
Cavalcante França Jr
P5.071
Hearing Loss in CharcotMarie-Tooth (CMT) Disease Tiffany Grider,
Lenore Holte, Tracy Weisbrod, Brian Bundy,
Michael Shy
P5.072 Characterization of Pain
in Patients with Charcot-Marie-Tooth
Diseases Derek Huang, Christopher Lee,
Jun Li
P5.073
Phenotypic Spectrum
and Management of 25 Patients ATTR
Val122Ile Hayet Salhi, Jean Pascal
Lefaucheur, Farida Gorram, Stéphane
Rappeneau, Benoit Funalot, Pascale Fanen,
Bruno Coste, Thibaud Damy, Violaine PlantéBordeneuve
P5.074
Genotypic Evaluation of
Patients with Chronic Inflammatory
Demyelinating Polyneuropathy: Study
of the PMP22 Gene Duplication/
Delection Alex Silva, Amilton Barreira,
Mario Emilio Dourado Junior, Acary Oliveira,
Wilson Marques
P5.075
Dysregulation of
Cytokines Mediates Painful Diabetic
Neuropathy Hsinlin Cheng, Jacqueline
Dauch, Brandon Yanik
P5.076
Hypertensive Neuropathy
in Phrenic Nerve: An Experimental
Study Valria Paula Fazan, Anaceres
Rodrigues, Renata Ferreira, Jaci Castania,
Helio Salgado
P5.077 Increased Plasma
Level of Pigment Epithelium-derived
Factor Is Associated with Diabetic
Neuropathy Delaram Safarpour, Varun
Shandal, Siok Dun, Jaw-Kang Chang,
Jessica Wagoner, Babak Rezaei, Serge
Belinga, Krishna Nalleballe, Rong-Ming Lyu,
Nae Dun, Jin Luo
P5.078
Magnetic Resonance
Neurography in the Diagnosis of
Noncompressive Lumbosacral
Radiculoplexus Neuropathies Nathaniel
Robbins, Nancy Benedetti, Brian Scott,
Cynthia Chin, Vanja Douglas
Epilepsy/Clinical
Neurophysiology (EEG): Status
Epilepticus
P5.079 Prognostic Factors of
Status Epilepticus in Adults: A 6-year
Retrospective Study Hoi Ki, Kate Lui, Hiu
Tung, Colin Lui
P5.080 Cefepime- Induced
Nonconvulsive Status Epilepticus (NCSE),
Associated with Posterior Reversible
Encephalopathy Syndrome (PRES): A Case
Report Emiliya Melkumova, Venkat Ramani
102
2:00 p.m.–6:30 p.m.
P5.081 Takotsubo Cardiomyopathy
Due to Status Epilepticus—an
Underreported and Lethal Sequela Imad
Khan, Neha Mirchandani, Galyna
Pushchinska
P5.082 Status Epilepticus Secondary
to Hyperammonemia Manan Shah, Yogita
Fotaria, Charles Szabo
P5.083 Good Outcome Despite Early
Refractory Myoclonic Status Epilepticus
After Cardiopulmonary Arrest: A Case
Report Alexandra Reynolds, Lauren Schaff,
Michelle Bell, John Brust, Sachin Agarwal
P5.084 Refractory Status Epilepticus
Secondary to Atypical Rasmussen
Encephalitis Successfully Managed with
Aggressive Immunotherapy Sung Cho,
Andrew Zeft, Elia Pestana Knight, Prakash
Kotagal, Elaine Wyllie, Ahsan Naduvil
Valappil
P5.085 Clobazam as Add-on Therapy
in Refractory Status Epilepticus Sanjeev
Sivakumar, Mohammad Ibrahim, Gregory
Norris, Dennis Parker, Jr., Aashit Shah,
Wazim Mohamed
P5.086 Primary Hyperammonemic
Encephalopathy as a Mimicker of
Non-convulsive Status Epilepticus:
Therapeutic Implications of Underlying
Etiology Nandhagopal Ramachandiran,
Fathiya Al-Murshedi, Povothoor Jacob,
Arunodaya Gujjar, Abdullah Al-Asmi
P5.087
Mortality, Causes,
and Predictors of Death in Status
Epilepticus Yoojin Lee, Eun Ju Choi, Jin Pyo
Hong, Joong Koo Kang
P5.088 Does Status Epilepticus Per
Se Cause Cerebrospinal Fluid Pleocytosis
in the Absence of Infection? Farzad Moien
Afshari, Noman Hassan, Gary Hunter
Epilepsy/Clinical
Neurophysiology (EEG): Nonepileptic Seizures
P5.089 Comparison of Clinical and
Neuropsychiatric Profiles of Patients
with Intermittent PNES (iPNES) and
Non-epileptic Psychogenic Status
(NEPS) Kanika Arora, Pawan Rawal,
Barbara Dworetzky, Jerzy Szaflarski
P5.090 Assessment of Subjective
Seizure Symptoms in Psychogenic
Non-epileptic Seizures: The Revised
Psychosensory-psychomotor Phenomena
Interview (PPPI-PNES) Sana Sharrack,
Jack Garlovsky
P5.091 Psychogenic Nonepileptic
Seizures in Men: Comparison of
Clinical and Psychosocial Features
Between Afro-American and Caucasian
Patients Abuhuzeifa Abubakr, Ilse
Wambacq
P5.092 Clinical and Neuropsychiatric
Profiles of Patients with Psychogenic
Non-epileptic Seizures (PNES) and
Epilepsy Kanika Arora, Pawan Rawal,
Barbara Dworetzky, Jerzy Szaflarski
P5.093 Comparison of Characteristics
of Patients with Non-epileptic Versus
Epileptic Seizures in Epilepsy Monitoring
Unit Aradia Fu, Samara Cerven, David
Denny, Naudia Moorley, Steve Chung
P5.094
Public Awareness, Knowledge
and Attitude Toward Epilepsy in Aseer
Region, Saudi Arabia Community Based
Cross Sectional Study Adel Alhazzani,
Abdulaziz Alqahtani, Khalid Asiri, Hassan
Alamri, Ahmed Aboelyazeed
P5.095 The Relationship Between
Level of Education and Public Awareness,
and Attitude Toward Epilepsy—
Community Based Cross Sectional Study
from Aseer Region, Saudi Arabia Ali
Alqahtani, Adel Alhazzani, Nawaf Alqahtani,
Abdullatef Muhaya, Ahmed Aboelyazeed
Edema, Encephalopathy, and
Encephalitis
P5.096 Changes in Serum Osmolality
Are Associated with Brain Volume Change
in Severe Hepatic Encephalopathy Eric
Liotta, Anna Romanova, Bryan Lizza,
Brandon Francis, Michael Berman, Andrew
Naidech, Matthew Maas
P5.097 Autoimmune Encephalitis: Are
Immunomodulatory Therapies Effective? A
Retrospective Review of Functional Ratings
Prior to and Post Treatment Naveen
George, Alexander Rae-Grant, Jar-Chi Lee,
Sneha Ramesh, Pravin George
P5.098 Severe Global Cerebral Edema
Secondary to Hypercapnic Respiratory
Acidosis Responsive to Hyperosmolar
Therapy: A Case Report David Roh, Fawaz
Al-Mufti, Alexander Merkler, Nicholas
Morris, Sachin Agarwal, Jan Claassen,
Soojin Park
P5.099 Recurrent Encephalopathy and
Seizures as a Manifestation of Ibuprofen
Meningoencephalitis Anik Amin, Steven
Lewis
Inflammation and Neurotoxicities
P5.106
Lateropulsion—the Case of a
Flip Flopper Amy Chan, Joachim Baehring
P5.107
Occurrence of Post-lumbar
Puncture Headache in an Academic LP
Clinic Brian Mac Grory, Babar Khokhar
P5.108Nonparaneoplastic
Autoimmune Dementia: Cognitive Profiles
and Predictors of Immunotherapy Response
in a Latin American Cohort Galeno Rojas,
Julieta Quiroga, Ricardo Reisin, Luciana
Leon Cejas, Pablo Bonardo, Ignacio Demey,
Carlos Rugilo, Oscar Martinez, Alfredo
Thomson, Luz Lopez Llano, Juan Ollari,
Manuel Fernandez Pardal
P5.109Cannabinomimetic
Neurotoxicity Divya Mella, Sheetal Shroff,
Robert Smith, Elena Shanina
P5.110
Disulfiram Toxicity Presenting
with Peripheral Neuropathy and Unique
Lesions on MRI Brain Nazely Ashikian,
Yuri Bronstein, Mitchell Danesh, Francisco
Torres
P5.111Inflammatory
Radiculomyelopathy Associated with
SAPHO Syndrome Ricardo Dornas, Osvaldo
Nascimento, Camila Pupe, Caroline Bittar,
Carlos Bruno Nogueira, Felipe Vianna, Bruno
Coutinho, Frederico Prado
P5.112
Diagnostic Criteria of Chronic
Inflammatory Demyelinatig Polyneuropathy
in Diabetes Mellitus Itay Lotan, Mark A.
Hellman, Israel Steiner
P5.113
Unusual Cause of Severe
Back Pain in a Patient with Isolated IgG
Deficiency Awss Zidan, Vishal Shah,
Deborah Bradshaw
P5.114
Interferon-alpha in a Patient
with West Nile Virus Myelitis: A Case
Report Rouzbeh Fateh, Flavia Nelson, Sonia
Krish, Rodrigo Hasbun, John Lindsey
P5.100
Intraventricular Tobramycin
for Bacterial Meningitis Na Tosha Gatson,
Divya Mella, Jennifer Johnson, Lucido
Ponce Mejia, Monica Loghin
P5.101
Ischemia, Myelitis, and Vascular
Malformations
Recurrent Encephalitis After
Seasonal Influenza Vaccine Priya Narwal,
Annie Daniel, Christine Mintz, Amre Nouh
Mild Encephalopathy with
Reversible Splenial Lesion Related
to Antiepileptic Drugs: Report of 3
Cases Suraj Rajan, Kristin King, Gulshan
Uppal, Anantha Vellipuram, Niranjan Singh
P5.102
Hypercytokinemia Induced
Encephalopathy Following Melphalan
Administration Matthew Freeman,
Divyanshu Dubey, Om Neeley, Gregory
Carter
P5.103
Fatal Cerebral Edema After
Trazodone Overdose David Avila
P5.104
Steroid Responsive
Encephalopathy Associated with
Autoimmune Thyroiditis (SREAT)
with Stroke Like Symptoms. A Case
Report Vijayakumar Javalkar, Syed Abbas,
Meghan Harris
P5.105
Catatonia in Limbic
Encephalitis Treated with Electroconvulsive
Therapy Karin Mente, Jeffrey Kim,
Alexander Rae-Grant
P5.115
P5.116
Transient Global Amnesia
Syndrome: Report of Patients Evaluated
in the First 24 Hours Marcela Uribe Roca,
Julieta Quiroga Narvaez, Fatima Pantiu,
Gisele Pacio, Luciana Leon Cejas, Galeno
Rojas, Sol Pacha, Oscar Martinez, Pablo
Bonardo, Ricardo Reisin, Manuel Fernandez
Pardal
P5.117
Clinical and Radiological
Evolution in a Patient with Extrapontine
Myelinolysis David Roeltgen
P5.118
SLIPPERS: Supratentorial
Lymphocytic Inflammation with
Parenchymal Perivascular Enhancement
Responsive to Steroids: A Case
Report Cynthia Armand, Jerome
Graber, Fred Lado, Patrick LaSala, Karen
Weidenheim
P5.119
Severe Necrotizing
Myelopathy from Toxacariasis Rick
Magun, Jamie Silva
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session V
P5.120
FibroCartilaginous Embolism,
an Underdiagnosed Cause of Spinal
Cord Infarction; Critical Review of
Literature, New Diagnostic Criteria,
Mechanisms Mahmoud AbdelRazek,
Ashkan Mowla, Nicholas Silvestri, Salman
Farooq, Haris Kamal, Noureldin Abdelhamid,
Robert Sawyer, Gil Wolfe
P5.121
Unusual Extensive Collateral
Venous Network in a Patient with Multiple
Cerebral Venous Thromboses Sara Duffus,
Laura Bishop, Ryan Hughes, Ihtsham Haq
P5.122
Mycoplasma Pneumoniae
Infection Presenting as Stroke and
Meningoencephalitis with Aortic and
Subclavian Aneurysms Without Pulmonary
Involvement—a Rare Case Report Jihad
Inshasi, Pournamy Sarathchandran,
Abubaker Almadani, Suhail Alrukn, Ayman
Alboudi
P5.123
Gray Matter Predominant
Longitudinally Extensive Transverse
Myelitis: A Rare Association
with Metastatic Papillary Thyroid
Carcinoma Poorvi Dalal, Shaheryar Hafeez,
Asma Zakaria
P5.124
Alice in Wonderland
Syndrome Associated with a Temporoparietal Cavernoma Jeffrey Kornitzer,
Michelle Philips, David Marks, Huey-Jen
Lee, Nizar Souayah
P5.125
Cerebral Fat Embolism
Syndrome an Uncommon Form of
Coma Ayman Al-salaimeh, Manoj Kumar,
Archana Hinduja
Cerebrovascular Disease and
Interventional Neurology:
Biomarkers and Emerging
Science
P5.126
Acute Cerebral Infarction as
the Presenting Feature of Anti-PL-7 Antisynthetase Syndrome Nonnie McNicholas,
Michael Henry, Aisling Ryan
P5.127
Major Hemorrhagic
Complications Are Associated with Lower
Coated-platelet Levels in Patients with
Non-lacunar Brain Infarction Calin Prodan,
Julie Stoner, George Dale
P5.128
Relationship Between
ADAMTS13 Activity, Von Willebrand Factor
Antigen Levels and Platelet Function in the
Early and Late Phases After TIA or Ischemic
Stroke Stephen Murphy, Richard Starke,
Paul Harrison, Martin Brown, Paul Sidhu,
Ian Mackie, Marie Scully, Samuel Machin,
Dominick Mccabe
P5.129
Activated Protein C Exert
Its Anti-apoptotic Activity Mediates
Via PARP Inhibition Against Oxygenglucose Deprivation in Cultured Neuronal
Cells Mukesh Sriwastva, Remesh K,
Kameshwar Prasad, Renu Saxena, S
Vivekanandhan
P5.130
Factor VIII Level Is Not
Modifiable by Improved Glycemic Control
in Patients with Ischemic Stroke Alyana
Samai, Amelia Boehme, Alexander George,
Laurie Schluter, Ramy El Khoury, Sheryl
Martin-Schild
P5.131
Stroke Impairs Bactericidal
Function in Phagocytes Alexander Dressel,
Johanna Ruhnau, Karsten Schulze, Lara
Blümke, Bernadette Gaida, Sönke Langner,
Christof Kessler, Barbara Bröker, Antje
Vogelgesang
P5.132
Serum Activity of Angiotensin
Converting Enzyme 2, a Potential Stroke
Biomarker, Is Decreased in the Acute Phase
of Rat and Human Ischemic Stroke Doug
Bennion, Christian Rosado, Emily Haltigan,
Alexander Irwin, Robert Regenhardt,
Michael Waters, Colin Sumners
P5.133
Troponin T Serum Level Is
Not Associated with the Location and
Volume of Acute Brain Infarction Michal
Kral, Daniel Sanak, Tomas Veverka, Martin
Hutyra, Eva Cechakova, David Skoloudik,
Petr Kanovsky
P5.134
To Determine the Impact of
Serum Albumin Levels on Admission with
the Outcomes in Patients Receiving IV-t-PA
(Alteplase) for Treatment of Acute Ischemic
Stroke Kaustubh Limaye, Sourabh Lahoti,
Archana Hinduja
P5.135
High-sensitivity C-reactive
Protein, Erythrocyte Sedimentation Rate
and Lactic Acid Are Associated with
Internal Carotid Artery Occlusion in Chinese
Stroke Patients Yongbo Zhang, Ying Lv,
Dan Xie, Qin Zhang, Yufang Sun, Jimei Li
Cerebrovascular Disease and
Interventional Neurology: Clinical
Research Tools, Methods, and
Innovations
P5.136
A Systematic Review
of Informed Consent in Acute Stroke
Trials William Feldman, Anthony Kim, S.
Josephson, Daniel Lowenstein, Winston
Chiong
P5.137
Probabilistic Model to Predict
the Effect Size of Acute Stroke Trials Kasra
Khatibi, Maarten Lansberg
P5.138
Itemized NIHSS Subsets
Predict Positive MRI Strokes in Patients
with Mild Deficits Shadi Yaghi, Charlotte
Herber, Joshua Willey, Amelia Boehme,
Howard Andrews, Randolph Marshall,
Ronald Lazar, Bernadette Boden-Albala
P5.139
REDCap UVA Vascular
Neurology Database Shareena Rahman,
Claire McKinley, Thomas Tandy, Andrew
Southerland, Bradford Worrall, Prachi
Mehndiratta, Colleen Harmon
P5.140
Interrater Reliability of the
National Institutes of Health Stroke Scale:
Rating by Emergency Room Physicians
and Neurologists in a Population-based
Study Brian Katz, Jane Khoury, Kathleen
Alwell, Charles Moomaw, Dawn Kleindorfer
P5.143
Establishment of Stroke Ward
Results in Immediate Reduction of Major
Complications Naveed Akhtar, Saadat
Kamran, A D'Souza, Yahia Imam, P Bourke,
S Joseph, M Santos, Ashfaq Shuaib
P5.144
Evaluating the Clopidogrelproton Pump Inhibitor Interaction by
Comparing Platelet Aggregation to ADP
with Clopidogrel in the Presence of Proton
Pump Inhibitors Francis Gengo, Eugene
Przespolewski, Erica Westphal, Michelle
Rainka, John Hourihane, Vernice Bates
Cerebrovascular Disease and
Interventional Neurology: Quality
Research and Initiatives
P5.145
Five Year Results of a Stroke
Care Network in Appalachia Michael
Dobbs, Danny Rose, Lisa Bellamy, Robert
Edwards
P5.146
Quality of In-hospital Stroke
Care in Veterans Affairs Hospitals Michael
Lyerly, Danielle Sager, Jessica Coffing,
Theresa Damush, Gary Cutter, Peter King,
Linda Williams
P5.147
Effectiveness of a Structured
Teaching Program in Improving the
Knowledge and Skills of the Care Givers
and Preventing Secondary Complications in
Hospitalized Stroke Patients Rohit Bhatia,
Arunima Thomas, Meena Agarwal
P5.148
Health Coaching for
Secondary Prevention in TIA Clinic Waimei
Tai, Melinda Carter, Jared Conley, Lucy
Kalanithi, Nancy Isenberg, James Bartscher
P5.156
Pontine Infarct Due to
Isolated Basilar Artery Dissection Causing
Supranuclear Facial Palsy Shivam Mittal,
Michael De Georgia
P5.157
Intracranial Arterial
Dissections Resulting from Increased
Sympathetic Drive Prachi Mehndiratta,
Sonal Mehta, Christopher Durst, Matthew
Ehrlich, Bradford Worrall
P5.158
Systemic Inflammatory
Markers in Cerebral Artery Dissection Daiana Dossi, Mauricio Farez, Federico
Carpani, Ismael Calandri, Virginia Pujol
Lereis, Guillermo Povedano, Sebastian
Ameriso
P5.159
Intra-arterial Thrombolysis
and Endovascular Treatment Is Safe and
Effective in Patients with Ischemic Stroke
Due to Dissection Judd Jensen, Jeffrey
Wagner, Kristin Salottolo, David Loy, David
Bar-Or
P5.150
Assessment of Hospital
Readmissions in Stroke Patient Population
from the Stroke Center at the University of
Kentucky: As a Quality Measure Abdullah
Al Sawaf, Jessica Lee
P5.161
P5.151
P5.162
P5.152
Cerebrovascular Disease and
Interventional Neurology:
Recovery and Rehabilitation
Analysis of 30 Day
Unexpected Readmission Rates in Stroke
Patients at an Academic Acute-care
Hospital David Kushner, Estin Kelly, Rachel
Morrison, Katherine Camfield
Improving Resident
Performance in Acute Stroke Management
Through Simulation Based Training Jami
Johnsen, Luciana Catanese, Judith Clark,
Julie Grimes, Benjamin Saunders, Pamela
Corey, Hesham Masoud
P5.142
P5.154
Fast, Easy, Online Registration · AAN.com/view/AM15
Acute and Long-term
Management of Symptomatic Internal
Carotid Artery Dissection in the Setting
of Newly Diagnosed Cerebral Amyloid
Angiopathy: To Anticoagulate, or Not to
Anticoagulate? Ilan Danan, Jared Noroozi,
Stephen Marks
The Presence of an Advanced
Practice Nurse Stroke Program Coordinator
Decreases Door-to-needle Times Michelle
Whaley, Lisa Caputo, Jeffrey Wagner
P5.149
Is YouTube and Stroke a Bad
Liaison? Harsh Gupta, Rajan Patel, Sajish
Jacob, Archana Hinduja
Two-year Adherence to a
Stroke Prevention Program in a Latin
American Cohort Ariel Luzzi, Claudia
Alonzo, Laura Brescacin, Maria Zurru,
Santiago Pigretti, Pedro Colla Machado,
Luis Camera, Gabriel Waisman, Edgardo
Cristiano
P5.155
Outcome of Acute Ischemic
Stroke Caused by Cervicocephalic
Arterial Dissection Following Intravenous
Thrombolysis and/or Endovascular
Treatment Ghasan Ahmad, Peyman Shirani,
Ashkan Mowla, Mohammad Masud, Adnan
Khan, Robert Sawyer, Marilou Ching,
Annemarie Crumlish
Does Hospitalist Directed
Care Reduce the Length of Stay for Acute
Ischemic Stroke Patients and Improve
Adherence to the “Get with the Guidelines”
Inpatient Quality Measures? Wondwossen
Tekle, Ameer Hassan, Christina Sanchez,
Ahmed Malik, Erlinda Abantao, Olive
Sanchez, Lisa Jones-Fillingum, Adnan
Qureshi
P5.141
Cerebrovascular Disease and
Interventional Neurology:
Dissection
P5.153
Timing of Follow-up
After Acute Ischemic Stroke and
Readmissions Andrew Buletko, Zeshaun
Khawaja
P5.160
Cervical Artery Dissections
in the Vancouver General Hospital (VGH)
Stroke Database: A Common Stroke
Mechanism? Laura Wilson, Athari
Salmeen, Thalia Field, Samuel Yip
Carotid Spot Sign: An Early
Marker of Carotid Artery Injury Tirisham
Gyang, Julius Latorre
P5.163
The Cerebellar Participation
in Spontaneous Post-stroke Aphasia
Recovery: A Longitudinal FMRI
Study Rodolphe Nenert, Jane Allendorfer,
Jennifer Vannest, Scott Holland, Jerzy
Szaflarski
P5.164
Transcranial Magnetic
Stimulation (TMS) as a Tool for Stroke
Motor Recovery: What Are We
Targeting? Muhammed Gunduz, Katherine
Nearing, Douglas Labar, Tsagaris Zoe, Gary
Thickbroom, Mar Cortes, Matthew Fink,
Dylan Edwards
P5.165
Cortical Reorganization and
Magnetoencephalographic Correlates for
Paretic Hand Recovery After Stroke ChihWei Tang, Fu-Jung Hsiao, Po-Lei Lee,
Yun-An Tsai, Ya-Fang Hsu, I-Hui Lee
103
Wednesday
April 22
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session V
2:00 p.m.–6:30 p.m.
P5.166
White Matter Integrity
Predicts Language Deficits in Chronic
Post-stroke Aphasia Shihui Xing, Elizabeth
Lacey, Xiong Jiang, Laura Skipper,
Mackenzie Fama, Peter Turkeltaub
P5.179
Co-occurrence of
Spatial Neglect and Perseveration
Contributes to Cognitive and Functional
Impairment Meghan Caulfield, Peii Chen,
A. Barrett
MS and CNS Inflammatory
Diseases: MS Disease Course,
Activity, Progression, Cognition,
and Quality of Life
P5.200 A Genders and Culture
P5.167
P5.180
P5.190
P5.201 Validation of the Brief
Using a Delphi Panel to
Identify a Treatment Paradigm for Injecting
Botulinum Toxin to Treat Common Postures
in Post-stroke Upper Limb Spasticity David
Simpson, Atul Patel, Abraham Alfaro,
Ziyad Ayyoub, David Charles, Khashayar
Dashtipour, Alberto Esquenazi, Glenn
Graham, John McGuire, Ib Odderson
P5.168
Monitoring Treatment Effects
of Transcranial Magnetic and Direct Current
Stimulation in Patients with Post-stroke
Aphasia: A Meta-analysis Study Priyanka
Shah, Felix Gervits, Jose Torres, Juliann
Purcell, Roy Hamilton
P5.169
Functional and Cognitive
Prognosis in Young Stroke Manuel
Martinez, Alejandra Calderon, Luis Amaya,
Jose Guerrero, Raul Carrera
P5.170
Uncontrolled Discharge
Diastolic Blood Pressure Is Associated
with Favorable Outcome After Ischemic
Stroke Konrad Schlick, Duy Le, Mani
Nezhad, Kara Melmed, Jonathan Eskenazi,
Shlee Song, Patrick Lyden
P5.171
Short-term Functional
Outcome and Its Predictors in a Hospitalbased Cohort of Nigerians with Acute
Stroke Kolawole Wahab, Emmanuel Sanya,
Babatunde Ademiluyi, Abiodun Bello,
Wemimo Alaofin
P5.172
Cortical Deficits and Prior
Stroke Predict Stroke Recurrence in
Patients with Mild Deficits Shadi Yaghi,
Joshua Willey, Howard Andrews, Amelia
Boehme, Randolph Marshall, Bernadette
Boden-Albala
Neuro-rehabilitation: Stroke
P5.173
Memantine Treatment for
Post-stroke Aphasia: A Case Control
Study Jennie Valles, Juliana Kennedy,
Mery Elashvili, Carolin Dohle
P5.174
Preliminary Assessment of
the Motor Activity Log-28 in Patients with
Chronic Stroke Alexandra Simpson, Susan
Conroy, Christopher Bever
P5.175
Prism Adaptation Improves
Neglect-related Motor Perseveration Amit
Chaudhari, A. Barrett
P5.176
Walking Quality During
Inpatient Stroke Rehabilitation Assessed
by Wireless Sensing Andrew Dorsch, Seth
Thomas, Bruce Dobkin
P5.177
Induction of Functional
and Structural Plasticity by Intermittent
Theta Burst Stimulation in Post-stroke
Aphasia Joseph Griffis, Rodolphe Nenert,
Jane Allendorfer, Jerzy Szaflarski
P5.178
Evaluation of a Clinician Worn
Device for the Quantitative Assessment
of Abnormal Muscle Tone Type and
Severity Elizabeth Brokaw, Ilia Itin,
Dustin Heldman, Joseph Giuffrida, Erwin
Montgomery
104
Robot-assisted Therapy
Improves Motor Function in Individuals
After Cerebral Hemispherectomy Susan
Shaw, Remy Chu Jr, Eirik Blydt-Hansen,
Mindy Aisen
P5.181
Medication Selfadministration After Stroke Mosunmola
Oyawusi, Benjamin Levy, Antoinette Gentile,
Gretchen March, Kimberly Hreha, Geraldine
Pagaoa-Cruz, Jenny Masmela, Elizabeth
Galletta, Sharon Holman, Cristin McKenna,
Jeffrey Zhang, A. Barrett
P5.182
What’s the Difference
Between Rest and Rest? Defining Baseline
Brain States Important for Cognition Erica
Pool, Anthony Chen, Courtney Gallen, Sahar
Yousef, Michael Silver, Mark D'Esposito
Neuro-rehabilitation: MS/SCI
P5.183
Arachnoiditis Mimicking an
Intrathecal Catheter Tip Granuloma Pruthu
Patel, Charles Brock, Emil Gaitour
P5.184
Feasibility of Telerehabilitation
in Patients with Significant Mobility
Disability Due to Multiple Sclerosis Joseph
Finkelstein, McKenzie Bedra, Susan Conroy,
Christopher Bever
P5.185
The Effect of Cooling on
Community-based Walking in Heatsensitive Patients with Multiple Sclerosis:
Findings from the Use of Wireless Activity
Monitoring Andrew Dorsch, Seth Thomas,
Barbara Giesser
P5.186
Comparison of the Kurtkze
Expanded Disability Status Scale and
the Functional Independence Measure:
Measures of Multiple Sclerosis Related
Disability Meheroz Rabadi, Andrea Vincent
P5.187
Identification and
Management of Dynamic Cord
Compression Using Dynamic Magnetic
Resonance Imaging Deepti Anbarasan, G.
Alexander Jones, Jonathan Howard
P5.188
A Network-based
Cognitive Rehabilitation in Patients with
Multiple Sclerosis and Mild Cognitive
Impairment Micaela Mitolo, Annalena
Venneri, Basil Sharrack
P5.189
Detection of Postural Sway
Abnormalities by Wireless Inertial Sensors
in Minimally Disabled Patients with
Multiple Sclerosis Andrew Solomon, Jesse
Jacobs, Karen Lomond, Susan Kasser,
Sharon Henry
Evaluation of the Revised 2013
MS Clinical Course Definitions in the CLIMB
Real World Cohort Tanuja Chitnis, Brian
Healy, Bonnie Glanz, Rohit Bakshi, Riley
Bove, Philip De Jager, Maria Houtchens,
Dorlan Kimbrough, Christopher Severson,
James Stankiewicz, Lynn Stazzone, Howard
Weiner
Comparison of Psychological and Social
Aspects of Quality of Life in Multiple
Sclerosis Patients Heidemarie Lex, Sana
Syed, Jacob Sloane, Wolfgang Freidl
International Cognitive Assessment
for Multiple Sclerosis (BICAMS) in
Argentina Sandra Vanotti, Ralph Benedict,
Fernando Caceres
P5.202 Adding Brain Volume Loss to
No Evidence of Disease
Activity—Past, Present, and
Future Richard Rudick, Amy Pace, Kartik
Raghupathi, Carmen Castrillo, Robert Hyde
the Modified Rio Scoring System Improves
Prediction of Future Disability Progression:
Analyses from Fingolimod Phase III
Trials Maria Pia Sormani, Ludwig Kappos,
Till Sprenger, Daniela Piani Meier, Dieter
Haering, Davorka Tomic, Nicola De Stefano
P5.192
P5.203 Monitoring Disease
P5.191
‘Doctor, Can I Stop My
Medicine?’ Analysis of Disease Course
After Stopping Disease-modifying
Therapy in Stable MS Patients Ilya
Kister, Timothy Spelman, Pierre Duquette,
Marc Girard, Jeannette Lechner-Scott,
Francois Grand'Maison, Mark Slee,
Suzanne Hodgkinson, Alessandra Lugaresi,
Maria Edite Rio, Maria Trojano, Helmut
Butzkueven, Joseph Herbert
P5.193
Do Individuals with
Radiologically Isolated Syndrome Have
a Different Clinical Outcome Once
They Convert to Clinically Isolated
Syndrome? Aksel Siva, Melih Tutuncu,
Orhun Kantarci, Ugur Uygunoglu, Pinar Acar,
Asli Kurne, Mark Keegan, Ayse Altintas,
Sabahattin Saipoglu, Rana Karabudak,
Daniel Pelletier, Darin Okuda, Christine
Lebrun Frenay
P5.194
Cognition in MS Across
the Lifespan Ariana Frontario, Colleen
Schwarz, Margaret Kasschau, Jillian Chan,
Brian Harel, Adrian Schembri, Nneka
Amadiume, Lauren Krupp, Leigh Charvet
P5.195
Isolated Cognitive Relapses
and Long-term Cognitive Decline in
Multiple Sclerosis Matteo Pardini, Antonio
Uccelli, Jordan Grafman, Özgür Yaldizli,
Giovanni Mancardi, Luca Roccatagliata
P5.196
German Validation of the Brief
International Cognitive Assessment for
Multiple Sclerosis (BICAMS) Iris-Katharina
Penner, Patrick Kandziora, Jana Poettgen,
Christoph Heesen, Michael Lang, Herbert
Schreiber
P5.197
Social Cognition Impairment
According to the Clinical Phenotype of
Multiple Sclerosis Cecile Dulau, Antoinette
Prouteau, Mathilde Deloire, Helene Diaz,
Aurore Saubusse, Julie Charre-Morin, Bruno
Brochet
P5.198
Depression and MRI Metrics
in the CombiRx Trial Lael Stone, Stacey
Cofield, Tarah Gustafson, Amber Salter,
Gary Cutter, Flavia Nelson, Ponnada
Narayana, Fred Lublin, Jerry Wolinsky
P5.199
Marital Status and Functional
Systems Scores in a Population-based
Multiple Sclerosis Cohort Jill Settle,
William Culpepper, Mitchell Wallin
Progression in Aging Population with
Multiple Sclerosis Vasu Saini, Katelyn
Kavak, Muhammad Nadeem, Zilfah
Younus, Channa Kolb, Barbara Teter, Bianca
Weinstock-Guttman
P5.204 Loss of Lower Limb Motor
Evoked Potentials (MEP) as a Sign of
Primary Progressive Multiple Sclerosis
(PPMS) Progression Rainer Paine, Bibiana
Bielekova, Tanya Lehky
P5.205 Prognostic Value of Visual
Evoked Potentials in Patients with Multiple
Sclerosis Eva Costa Arpn, Clara Dominguez
Vivero, Tania Garcia, José Luis Relova
Quinteiro, Jose Maria Prieto Gonzalez,
Manuela Lema Bouzas
P5.206 Pregnancy Does Not Prevent
Degeneration of Retinal Axons in Multiple
Sclerosis Sven Schippling, Ilya Ayzenberg,
Marius Ringelstein, Orhan Aktas, Sebastian
Lukas, Ralf Gold, Kerstin Hellwig
P5.207 Multiple Sclerosis, Cognitive
Profile and Cognitive Testing: Predictability
of SDMT and Computerized Cognitive
Testing in Differentiating Employment
Versus Unemployment in Patients with
Multiple Sclerosis Mark Gudesblatt,
Myassar Zarif, Barbara Bumstead, Marijean
Buhse, Lori Fafard, Daniel Golan, Cynthia
Sullivan, Jeffrey Wilken, Glen Doniger
P5.208 Stress Burden and
Satisfaction with Treatment in Caregivers
and Patients with Multiple Sclerosis. MSfeeling Study Meca-Lallana Jose, Maria
Del Mar Mendibe Bilbao, Rocio HernandezClares, Ana Belen Caminero Rodriguez,
Javier Jose Mallada, Pablo Davila Gonzalez,
Moises Garces, Montserrat Gomez, Jorge
Millan Nadal, Gerardo Soriano Hernandez,
Maria Campo Amigo
MS and CNS Inflammatory
Diseases: Biomarkers and
Disease Mechanisms
P5.209 Cytokine Profile in the
Cerebrospinal Fluid of MS and CIDP
Patients Arianna Sartori, Serena Bonin,
Manola Comar, Jacopo Fantini, Alessio
Bratina, Rita Moretti
P5.210 Prostaglandin F2α Receptor
Mediates Oligodendrocyte Precursor
Injury/Death: Potential Role in Multiple
Sclerosis M. Paz Soldan, Linda Schmidt,
Blair Wood, John Rose, Noel Carlson
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session V
P5.211
Evaluation of CSF and
Serum Fetuin-A, CSF S100B and GFAP
as Predictive Markers in Multiple
Sclerosis Ayse Altintas, Sinem AkkasYazici, Hayrettin Tumani, Vera Lehmensiek
P5.212
Transglutaminase 6 Is a
Potential Biomarker of Disease Activity
and Astrocytic Proliferation in MS Daniel
Gratch, Benjamin Pagano, Kelsey
McDermott, Massimiliano Cristofanilli, Saud
Sadiq
P5.213
Cerebrospinal Fluid
Haptoglobin (Hp) Levels Are Elevated in MS
Patients with Progressive Disease Bianca
Ulloa, Marwan Alahiri, Ying Liu, Saud Sadiq
P5.214
Fetuin-A Correlates
with Cortical Demyelination and Is a
CSF Biomarker of Disease Activity in
Progressive MS Mark Landy, Violaine
Harris, Ying Liu, Saud Sadiq
P5.215
Fetuin-A, a CSF Biomarker of
MS Disease Activity, Is Upregulated at the
Blood Brain Barrier Langan Ruth-Anne,
Violaine Harris, Mark Landy, Saud Sadiq
P5.216
Proteomic Analysis in CSF
Identified Subtype Specific and Shared
Molecular Pathways for Multiple Sclerosis
Clinical Phenotypes Timucin Avsar, İlknur
Durasi, Ugur Uygunoglu, Melih Tutuncu,
Nuri Demirci, Sabahattin Saipoglu, Osman
Sezerman, Aksel Siva, Eda Turanli
P5.217
CSF and Serum Levels of
Interleukin-6, Interleukin-8, Interleukin-10,
Beta-2-microglobulin and Orosomucoid at
the Time of First Clinical Symptoms in MS
Patients Zuzana Matejcikova, Jan Mares,
Jana Klosova, Vladimira Sladkova, Silvia
Skalska, Tereza Svrcinova, Jana Zapletalova,
Petr Kanovsky
P5.218
Cerebrospinal Fluid
Osteopontin and Neurofilament Levels
Mark Different Patterns of Brain Atrophy
in Clinically Isolated Syndrome Vita
Direnzo, Carla Tortorella, Stefano Zoccolella,
Maddalena Ruggieri, Mariangela
Mastrapasqua, Damiano Paolicelli, Franca
Dicuonzo, Maria Trojano
P5.219
Existence and Significance
of Antibody Against the Inward Rectifying
Potassium Channel KIR4.1 in Patients
with Multiple Sclerosis in Western Part of
Turkey Derya Kaya, Egemen Idiman, Nuri
Karabay, Zekiye Altun, Sumeyye Çevik, Zaur
Mehdiyev
P5.220 Clinical and Etiopathological
Evaluation of the Patients with OCB
IgG Pattern-IV and V Positivity Ugur
Uygunoglu, Ayse Altintas, Sinem AkkasYazici, Guher Saruhan-Direskeneli, Sibel P.
Yentur, Sabahattin Saipoglu, Aksel Siva
P5.221 Biomarkers and Relapse in
CombiRx Hemant Tiwari, Amit Patki, Stacey
Cofield, Tarah Gustafson, Fred Lublin, Jerry
Wolinsky, Gary Cutter
P5.222 Ocular Motor Biomarkers
of Progressive Cerebral Dysfunction in
Multiple Sclerosis Meaghan Clough,
Lynette Millist, Teresa Frohman, Elliot
Frohman, Owen White, Joanne Fielding
P5.223 Retinal Neuronal and Axonal
Loss over Time as Markers of Disease
Progression and Activity in Multiple
Sclerosis: A Pilot Study Salim Chahin,
James Wilson, Clyde Markowitz, Dina
Jacobs, Ari Green, Peter Calabresi, Elliot
Frohman, Steven Galetta, Laura Balcer
P5.234 Myelin Oligodendrocyte
Glycoprotein Is the Primary Myelin Protein
Target of CSF B-cell Antibodies in MS Pak
Ho Au, Christopher Sears, Jerry Lin, Saud
Sadiq
P5.235Immunophenotyping
Nerve Fiber Integrity and Blood Flow
Velocity in Multiple Sclerosis Hong Jiang,
Silvia Delgado, Jin Yuan, Wentao Yan, Delia
Cabrera DeBuc, Byron Lam, Jianhua Wang
of Cerebrospinal Fluid Cells in Virusassociated Neurologic Diseases Yoshimi
Akahata, Raya Massoud, Breanna Caruso,
Joan Ohayon, Bridgette Billioux, Gloria Von
Geldern, Bryan Smith, Avindra Nath, Steven
Jacobson
P5.225 Decreased Optic Nerve Head
P5.236 Humoral Response to
P5.224 Impairment of the Retinal
Blood Flow Index Highlights Abnormal
Retinal Microcirculation in Multiple
Sclerosis Rebecca Spain, Zunqiu Chen, Yali
Jia, Ou Tan, David Huang, Dennis Bourdette
P5.226 Clinical Relevance of
Anti-aquaporin Antibody (anti-AQP4)
in Demyelinating Disease of Central
Nervous System (CNS)—a Case-control
Study Sankar Gorthi, Arindam Mukherjee,
C Narayanan, Yedvendra Sirohi
P5.227 Interleukine 17 Is Not
Detected in Active MS Patients' Sera but in
CSF in Radiologically and Clinically Isolated
Syndromes Christine Lebrun Frenay, Mikael
Cohen, Florence Bucciarelli, Barbara SeitzPolski, Aurelie Cornille, Beatrice Pignolet,
Sylvia Benzaken, David Brassat
P5.228 The Relation Between
Meningeal Inflammation, Cortical
Demyelination and White Matter Lesional
Activity in Chronic Multiple Sclerosis:
A Pilot Study Valeria Ramaglia, Iliana
Michailidou, Hanane Touil, Corbert van
Eden, Inge Huitinga, Jennifer Gommerman,
Amit Bar-Or
P5.229 Immune Regulatory
Mechanisms Involved in IL-27 Induced
Tolerogenic Myeloid DCs Felipe Von Glehn
Silva, Gopal Murugaiyan, Bonny Patel,
Maria Antonietta Mazzola, Sushrut Jangi,
Chantal Kuhn, Leonilda Santos, Howard
Weiner, Roopali Gandhi
P5.230 B1 Cells Are Unaffected
by Immune Modulatory Treatment in
Remitting-Relapsing Multiple Sclerosis
Patients Damiano Rovituso, Stefanie
Heller, Michael Schroeter, Christoph
Kleinschnitz, Stefanie Kuerten
P5.231 Th1 and Th17 Cytokines Profile
and Its Relation to Demographic, Clinical
and Radiological Features in Early Disease
Stage Multiple Sclerosis Ana Cristina
Wing, Claudia Cristina Vasconcelos, Thais
Ferreira, Fernanda Rueda, Solange Maria
Das Gr Camargo, Taissa Kasahara, Regina
Alvarenga, Cleonice Bento
P5.232 Deep Sequencing of T-cell
Receptor Repertoire Reveals Enrichment
of Highly Expanded Clonotypes in
Cerebrospinal Fluid from Patients with
Multiple Sclerosis Alessandra De Paula
Alves Sousa, Kory Johnson, Richard
Nicholas, Sam Darko, David Price, Daniel
Douek, Steven Jacobson, Paolo Muraro
P5.233 Thermal Stable
Immunoglobulin G Antibodies in Multiple
Sclerosis Ian Stewart, Xiaomeng Li, Yiting
Liu, Michael Graner, Xiaoli Yu
Fast, Easy, Online Registration · AAN.com/view/AM15
Epstein-Barr Virus Is Associated with
Cortical Pathology in Patients with Multiple
Sclerosis Murali Ramanathan, Nicole
Cerza, Bianca Weinstock-Guttman, Jesper
Hagemeier, Ellen Carl, Darlene Badgett,
Deepa Ramasamy, Robert Zivadinov
P5.237 Excess Lipid Accumulation
in Cortical Neurons in Multiple Sclerosis
May Lead to Autophagic Dysfunction and
Neurodegeneration Insil Kim, Danielle
DeBartolo, Sriram Ramanan, Gerald Ponath,
David Pitt
P5.245 Blood-brain Barrier
Permeability and Brain Injury in CIS
Patients Tomas Uher, Dana Horakova,
Michaela Tyblova, David Zeman, Eva
Krasulova, Katerina Mrazova, Zdenek Seidl,
Manuela Vaneckova, Jan Krasensky, Bianca
Weinstock-Guttman, Murali Ramanathan,
Eva Havrdova, Robert Zivadinov
P5.246 Does CSF Infrared
Spectroscopy Useful in Diagnosing
RRMS Patients During the First Clinical
Attack? Levent Ocek, Bedile Irem
Tiftikcioglu, Dilek Yonar, Yasar Zorlu, Zeki
Tekgul, Feride Severcan
P5.247
What Does an Isolated
Cerebrospinal Fluid Monoclonal Band
Mean: A Tertiary Centre Experience Turan
Poyraz, Derya Kaya, Egemen Idiman,
Sümeyye Cevik, Nuri Karabay, Duygu Arslan,
Yasemin Karakaptan
P5.248 Brain Temperature Is
Elevated in Relapsing-remitting Relative
to Progressive Multiple Sclerosis Victoria
Leavitt, Alayar Kangarlu, Feng Liu, Claire
Riley, James Sumowski
P5.238 Metabolite Profiling of
Cerebrospinal Fluid Derived from MS
Patients Danielle Blemur, Fozia Mir, Saud
Sadiq
MS and CNS Inflammatory
Diseases: NMO and NMO
Spectrum Disorders I
P5.239 Functional Characterization
P5.249 New Acute Severity Scale for
of Myeloid Dendritic Cells in Peripheral
Blood of Patients with Multiple
Sclerosis Juergen Haas, Alexander
Schwarz, Mirjam Korporal-Kuhnke, Brigitte
Wildemann
P5.240 Retinal Structure Injury
and CSF Humoral Response in Multiple
Sclerosis Jessica Chorostecki, Navid
Seraji-Bozorgzad, Fen Bao, sherridan Reed,
Christina Caon, Carla Santiago Martinez,
Evanthia Bernitsas, Elliot Frohman, Omar
Khan
P5.241 The Role of Chronic
Inflammation on Amyloid Burden in
Multiple Sclerosis Gabriele De Luca,
Richard Hickman, Alissa Gutnikova,
Michelle Vogelaar, Elliott Ridgeon, Georgina
Colquhoun, Margaret Esiri
P5.242 Global Metabolomics
Identifies Perturbation of Multiple
Metabolic Pathways in Multiple
Sclerosis Pavan Bhargava, Ellen Mowry,
Peter Calabresi
P5.243 Estrogen Receptor Alpha in
Peripheral Blood Lymphocytes of Multiple
Sclerosis Patients: A Pivotal Study of
Its Role in Pregnant Patients Marinella
Clerico, Santina Cutrupi, Simona Rolla,
Stefania De Mercanti, Andrea Iannello,
Eleonora Virgilio, Michele De Bortoli, Luca
Durelli
P5.244 Multiple Sclerosis and
Epstein-Barr Virus: Antibodies to
Nuclear Antigen 1 Also Bind a Human
Ribonucleoprotein John Lindsey
Neuromyelitis Optica Relapses Michael
Levy, Maureen Mealy, Sven Jarius,
Friedemann Paul, Orhan Aktas, Simon
Broadley, Philippe Cabre, May Han, Anu
Jacob, Gareth John, Maria Leite, Romain
Marignier, Ichiro Nakashima, Jacqueline
Palace, Sven Schippling, Anthony
Traboulsee, Brian Weinshenker, Dean
Wingerchuk
P5.250 Pregnancy Outcome in
Aquaporin-4 Positive Neuromyelitis
Optica Spectrum Disorder Matthew Nour,
Ichiro Nakashima, Ester Coutinho, Mark
Woodhall, Filipa Sousa, Jon Revis, Yoshiki
Takai, Jithin George, Joanna Kitley, Maria
Santos, Joseph Nour, Fan Cheng, Hiroshi
Kuroda, Tatsuro Misu, Ana Martins-daSilva, Gabriele De Luca, Angela Vincent,
Jacqueline Palace, Patrick Waters, Kazuo
Fujihara, Maria Leite
P5.251 Influence of Female Sex
and Fertile Age on Neuromyelitis Optica
(NMO) Nadja Borisow, Ingo Kleiter, Corinna
Trebst, Anna Gahlen, Katrin Fischer, Sven
Jarius, Friedemann Paul, Kerstin Hellwig
P5.252 Immunological Analysis of
MOG Autoantibody Positive NMOSD
and Aquaporin-4 Autoantibody Positive
NMOSD Satoru Tanaka, Akihiro Kubota,
Hikoaki Fukaura, Kyoichi Nomura, Douglas
Sato, Kazuo Fujihara
P5.253 NMO IgG: The Impact of
the NMO Biomarker on Diagnosis and
Treatment of NMO and NMOSD Luis
Tornes, Leticia Tornes, Melissa Ortega,
Sylvia Delgado, Janice Maldonado, William
Sheremata, Kottil Rammohan
P5.254 Processing Speed and
Informant Reports of Executive Functioning
in Neuromyelitis Optica Ana Arenivas,
Maureen Mealy, Adam Kaplin, Michael Levy
105
Wednesday
April 22
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session V
P5.255 Depressive State and Chronic
Fatigue in Neuromyelitis Optica Tetsuya
Akaishi, Ichiro Nakashima, Tatsuro Misu,
Kazuo Fujihara, Masashi Aoki
P5.256 Cognitive Function and Fatigue
in Patients with Neuromyelitis Optica:
Comparison with MS Subtypes Cris
Constantinescu, I-Jun Chou, Radu
Tanasescu, Christopher Tench, Su-Yin Lim,
Giulio Podda
MS and CNS Inflammatory
Diseases: NMO and NMO
Spectrum Disorders Treatment
P5.257 Bevacizumab Is Safe in Acute
Relapses of Neuromyelitis Optica Michael
Levy, Maureen Mealy
P5.258 Rituximab as First-line
Therapy in Neuromyelitis Optica: Efficiency
and Tolerability Raphael Bernard-Valnet,
Christine Lebrun Frenay, Bertrand Audoin,
Bertrand Bourre, Sophie Pittion, Sandrine
Wiertlewski, Romain Marignier, Jonathan
Ciron, Bruno Brochet, David Brassat, Helene
Zephir
P5.259 Autologous Hematopoietic
Stem Cell Transplantation in Neuromyelitis
Optica—an Update Jodie Burton, Jan
Storek, Peter Duggan, Fiona Costello,
Luanne Metz
P5.260 Efficacy of Rituximab in
Refractory Neuromyelitis Optica Jerome
De Seze, Collongues Nicolas, David Brassat,
Elisabeth Maillart, Pierre Labauge, Jean
Ouallet, Bruno Brochet, Thibault Moreau,
Bertrand Bourre, Bertrand Audoin, Sandra
Vukusic, Romain Marignier
P5.261
Laquinimod Prevents NMOIginduced Disease Exacerbation in a Model
of Neuromyelitis Optica Azeb Tadesse
Argaw, Linnea Asp, Jingya Zhang, Patrick
Waters, Liat Hayardeny Nisimov, Michael
Levy, Gareth John
P5.262 Efficacy and Safety of
Tocilizumab as Second Line Therapy in
Neuromyelitis Optica Unresponsive to
Rituximab Jose Meca Lallana, Rocio
Hernandez Clares, Ester Carreon Guarnizo,
Judith Jimenez Veiga, Begoña Palazon
Cabanes, Gema Salgado Cecilia, Adelaida
Leon Hernandez, Ruben Carrasco Torres,
Maria Cerdan Sanchez, Jose Javier Martin
Fernandez
P5.263 Dalfampridine for
Symptomatic Treatment of Neuromyelitis
Optica Clerc Christine, Bertrand Bourre,
Bereau Mathieu, Helene Zephir, Chanson
Jean-Baptiste, Nicolas Collongues,
Frederic Blanc, Christophe Zaencker, Patrick
Vermersch, Jerome De Seze
P5.264 Safety of Rituximab as First-
line Therapy in Neuromyelitis Optica (NMO)
and NMO-spectrum Disorders: Five Years
of Experience Ester Carreón-Guarnizo,
Rocio Hernández-Clares, Begoña PalazónCabanes, Rubén Carrasco-Torres, Gema
Salgado, Judith Jimenez-Veiga, Adelaida
León-Hernández, Jose Javier MartínFernández, Jose Meca-Lallana
106
2:00 p.m.–6:30 p.m.
P5.265 Prospective Evaluation of
Maintenance Plasma Exchange (mPLEX)
for Attack Prevention in Neuromyelitis
Optica Spectrum Disorder: Preliminary
Feasibility, Safety, and Efficacy Data Dean
Wingerchuk, Brian Weinshenker, Jonathan
Carter, Sean Pittock, Vanda Lennon, Andrew
McKeon, Claudia Lucchinetti, Mark Keegan
P5.266 Use of Tocilizumab in
a Pediatric Patient with Aggressive
Neuromyelitis Optica Spectrum
Disorder Sona Narula, Amy Waldman,
Grant Liu, Brenda Banwell, Melissa Lerman
MS and CNS Inflammatory
Diseases: NMO and NMO
Spectrum Disorders II
P5.267 Diverse Spinal Cord Pathology
in Neuromyelitis Optica Robert Charlson,
Jonathan Howard
P5.268 Activation of Plasmacytoid
Dendritic Cells in Neuromyelitis Optica
Patients Rafael Dias-Carneiro, Marilia
Andrade, Felipe Von Glehn Silva, Alliny
Dionete, Adriel Moraes, Carlos Otavio
Brandao, Vinicius Boldrini, Alfredo
Damasceno, Fernando Pradella, Guilherme
Morais, Paula Russini, Alessandro Farias,
Benito Damasceno, Charles Tilbery, Leonilda
Santos
P5.269 Aquaporin-4 Antibody
Negative Neuromyelitis Optica with
Extensive Hemispheric Brain Lesion: A
Pathological Study Recai Turkoglu, Fugen
Aker, Handan Misirli, Erdem Tuzun
P5.270 Neuromyelitis Optica's Related
Optic Neuritis Can Be Distinguished by
Optic Nerve Enhancement Characteristics
and Resistance to Steroids Dan Buch,
Julien Savatovsky, Romain Deschamps,
Olivier Gout
P5.271 Serum Chitinase 3-like 1
Levels in Patients with Multiple Sclerosis
and Neuromyelitis Optica Derya Kaya,
Zekiye Altun, Egemen Idiman, Nuri Karabay,
Sumeyye Cevik, Duygu Arslan
P5.272 The Plasma Antiaquaporin
Antibodies and the Outcome of Myelitis in
Neuromyelitis Optica and Neuromyelitis
Optica Spectrum Disorders: Any
Relationship? Egemen Idiman, Fethi
Idiman, Derya Kaya, Sümeyye Cevik, Zekiye
Altun, Zaur Mehdiyev
P5.273 Natural Course of
Neuromyelitis Optica (NMO) in Patients
with No Long-term Treatment Ayse
Altintas, Mecbure Nalbantoglu, Ugur
Uygunoglu, Gokcen Gozubatik-Celik,
Sabahattin Saipoglu, Aksel Siva
P5.274
Recurrent Optic Neuritis
(rON) Is Characterised by Anti-MOG
Antibodies: A Follow-up Study Konstantina
Chalmoukou, Panos Stathopoulos, Harry
Alexopoulos, Sofia Akrivou, Marinos
Dalakas
P5.275 Spectrum of MOG
Autoantibody-associated Inflammatory
Diseases in Pediatric Patients Silvia
Tenembaum, Patrick Waters, Maria Leite,
Mark Woodhall, Juan Princich, Martin
Segura, Maria Talarico, Marina Szlago,
Angela Vincent
P5.276
Characterization of the
Spectrum of Argentinean Neuromyelitis
Optica According to the Diagnostic Criteria
and AQP4 IgG Serostatus Andres Villa,
Eliana Garino, Silvia Tenembaum, Luciana
Melamud
Movement Disorders: Tremor
P5.277 Tremor on Smiling Deepak
Kalra, Srivadee Oravivattanakul
P5.278 Reduced Purkinje Cell Counts
in Essential Tremor Cases Vs. Controls:
Further Support for the Neurodegenerative
Hypothesis of Essential Tremor Elan Louis,
Matthew Choe, Phyllis Faust
P5.279 Unilateral Focused Ultrasound
Thalamotomy in Essential Tremor: 3-year
Safety and Efficacy Data Binit Shah,
Tiffini Voss, Diane Huss, W. Jeffrey Elias,
Madaline Harrison, Johanna Loomba,
Mohamed Khaled, Robert Frysinger
P5.280 Optimal Speech Outcome
Requires Precise Stimulation Location
in Deep Brain Stimulation for Essential
Tremor Joseph Matsumoto, Tepanta
Fossett, Minsoo Kim, Joseph Duffy, Edythe
Strand, Andrew McKeon, Kendall Lee,
Squire Stead, Andrea Adams, Bryan Klassen
P5.281 Dexmedetomidine Affects
an Essential Tremor During DBS
Surgery Evgeny Tsimerinov, Zarine
Harutyunyan, Michele Tagliati
P5.282 A Stimulating Idea: Treating
Mixed ET/PD Tremor with Novel DBS
Approach Ramsey Falconer, Sean Rogers,
Christopher Kalhorn
P5.283 Self-perception of Tremor and
Dyskinesia Umer Akbar, Danielle Dousa,
Ana Abrantes, Joseph Friedman
P5.284 Progressive Cerebellar
Atrophy in Patients with Tremorpredominant Parkinson’s Disease Camila
Piccinin, Luiza Piovesana, Rachel Guimaraes,
Maria Santos, Brunno Campos, Lidiane
Campos, Paula Azevedo, Fabio Torres,
Marcondes França Jr, Augusto Amato-Filho,
Iscia Lopes-Cendes, Fernando Cendes,
Anelyssa D'Abreu
P5.285 Deep Brain Stimulation (DBS)
Improves Refractory Tremor Caused by
Central Pontine Myelinolysis (CPM) Jason
Gerrard, Damoun Safarpour, Duarte
Machado, Bahman Jabbari
P5.286 Analysis of Parkinson's
Disease Prodromal Symptoms Among
Essential Tremor Subjects: Is Essential
Tremor a Risk Factor for the Development
of Parkinson's Disease? Richard Salazar,
Emily Peters, Linda Daniel, Amber Heck
Movement Disorders:
Huntington's Disease
P5.287 Predictive Testing for
Huntington’s Disease (HD): Clinical
Characteristics and Motivations
of Individuals at One Academic
Center Andrew Herndon, Seon Nam,
Lauren Korty, Jody Corey-Bloom
P5.288 Using a Wii Balance Board to
Measure Disease Onset in Huntington’s
Disease Andrew Herndon, Jody CoreyBloom, Anastasia Lam, Paul Gilbert, Daniel
Goble
P5.289 Phenotypic Variability in
Huntington Disease: An Observational
Prospective Study Filipe Sobral Blanco,
Luísa Simões da Cunha, Fradique Moreira,
Ana Sofia Morgadinho, Joao Lemos,
Cristina Januário
P5.290 Assessing Psychiatric
Symptoms in Individuals with, and at Risk
for, Huntington’s Disease Jody CoreyBloom, Andrew Herndon, Stephen Howell
P5.291 Objective Measurement
of Gait Abnormalities in Huntington
Disease Using a Shoe-worn Inertial
Sensor Penelope Hogarth, Arthur Lenahan,
Alicia Portillo, Ravi Ramachandran, Katie
Stenson, Anna Legedza, Martyn Botfield,
Fay Horak, James McNames, Mahmoud
El-Gohary
P5.292 Time Processing in
Huntington’s Disease Agostino Patricia,
Emilia Gatto, Cesarini Martin, Ana
Sanguinetti, Jose Luis Etcheverry, Diego
Golombek
P5.293 Intermediate CAG Repeats
in Huntington´s Disease. Analysis of
the European Huntington´s Disease
Cohort Network´s Registry Esther Cubo
Delgado, Maria Antonia Ramos-Arroyo,
Saul Martinez-Horta, Asuncion MartinezDescalls
P5.294 Huntington’s Disease and the
Heart: Electrocardiogram Abnormalities
Suggest Cardiac Involvement Christopher
Stephen, Steven Hersch, Herminia Rosas
P5.295 Optical Coherence
Tomography in Huntington Disease
Patients Emilia Gatto, Virginia Laura
Parisi, Susana Ochoa, Dario Scocco, Estela
Fernandez Rey
P5.296 A Case of "Prodromal"
Huntington's Disease with
Neuropathology Daphne Robakis, Jean
Paul Vonsattel, Karen Marder
P5.297 Therapeutic Benefit of a
HTT-lowering Antisense Oligonucleotide
Targeting the CAG-repeat in the R6/2
Huntington’s Disease Mouse Model Nicole
Datson, Susan Mulders, Jeroen van der
Giessen, Anchel Gonzalez, Giles Campion,
Judith Van Deutekom
Neuro-ophthalmology/
Neuro-otology II
P5.298 Visualization of Nerve
Fiber Orientation in the Human Optic
Chiasm Using Photomicrographic Image
Analysis Christian Lueck, Neeranjali Jain,
Swaranjali Jain, Xiaofei Wang, Andrew
Neely, Murat Tahtali, Sanjiv Jain
P5.299 Contrast Sensitivity Visual
Acuity Is Degraded in REM Sleep Behavior
Disorder Jacqueline Sanchez, Matthew
Khayata, Whitney Hough, Peggy Vogt, Eric
Keasler, Garrett Barr, David Huang, Charles
Maitland
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
P5.300 Attenuated Hunter Syndrome:
A Rare Cause of Simultaneous Retinal and
Optic Nerve Disease Kannan Narayana,
Heather Lau, Rachel Nolan, Janet Rucker,
Laura Balcer, Steven Galetta
P5.301 Acute Retinal Necrosis in the
Setting of Varicella Zoster Vasculopathy—
Case Report and Review of Literature Ali
Saeed, David Kaufman, Eric Eggenberger
P5.302 Retinal Pathology in Idiopathic
Moyamoya Angiopathy Detected by Optical
Coherence Tomography Philipp Albrecht
P5.303 Vertigo and Nystagmus in
Orthostatic Hypotension Kwang-Dong
Choi, Jae-Hwan Choi, Seung-Han Lee, Ji
Soo Kim
P5.304 Obesity and Overweight Are
Highly Prevalent in Pediatric Secondary
Pseudotumor Cerebri Syndrome Grace
Paley, Claire Sheldon, Evanette Burrows,
Marianne Chilutti, Grant Liu, Shana
McCormack
P5.305 Association Between
Sociodemographic Factors and Outpatient
Appointment Adherence in Patients with
Idiopathic Intracranial Hypertension Asha
Shah, Heather Moss
P5.306 Localization of Synaptic
Proteins in Nerve Fibers of the Rat
Cornea Samuel Geurkink, Branden Carr,
Kenneth Miller
P5.307 Retinal Oximetry-derived
Biomarkers of Metabolic Dysfunction in
MS Marlen Lucero, Amy Conger, Darrel
Conger, Millad Sobhanian, Victoria Stokes,
Teresa Frohman, Owen White, Laura Balcer,
Peter Calabresi, Robert Rennaker, Elliot
Frohman, Shin Beh
P5.308 Characterization of Idiopathic
Intracranial Hypertension (IIH) in
Qatar Mais Alkawaz, Nour Barakat, Fatema
AlMannaie, Marc Dinkin
P5.309 Asymmetry of the Vertical
Translational Vestibulo-ocular Reflex in
Idiopathic Downbeat Nystagmus Mark
Walker, Alessandro Serra
P5.313
Clinical Features, Diagnostic
Findings, and Treatment of Adult-onset
Opsoclonus-myoclonus Syndrome: A
Case Series Pooja Raibagkar, Shamik
Bhattacharyya, Olga Rosenvald Szenberg,
Ivana Vodopivec, Shirley Wray
P5.314
Retinal Ganglion Cell Injury in
Early Pediatric Onset MS Jennifer Graves,
Hardeep Chohan, Benjamin Cedars, Samuel
Arnow, Hao Yiu, Emmanuelle Waubant, Ari
Green
P5.315
Miller Fisher Syndrome from
Asialo-GM1 Antibodies: “How Can a
Rare Disease Become Rarer?” Amanda
Tomlinson, Laxmi Dhakal, William Freeman
P5.316
Extraocular Muscle
Fatigue Evaluation in Mitochondrial
Neurogastrointestinal Encephalomyopathy
(MNGIE) Claudia Vinciguerra, Pamela
Federighi, Francesca Rosini, Elena
Pretegiani, Elena Cardaioli, M.T. Dotti,
Francesco Sicurelli, Antonio Federico,
Alessandra Rufa
P5.317
Validation of Strategies to
Streamline High and Low Contrast Visual
Acuity Testing in ALS Subjects Lindsay
Boven, Qin Li Jiang, Heather Moss
P5.318
Coning Following Lumbar
Puncture in a Patient with Idiopathic
Intracranial Hypertension Christian Lueck,
Andrew Hughes, Adeniyi Borire
P5.319
Retinal Lesion Evolution
in Susac Syndrome Alexander Brandt,
Timm Oberwahrenbrock, Fiona Costello,
Karen Gertz, Ilka Kleffner, Friedemann Paul,
Richard Bergholz, Jan Dörr
P5.320 Comparative Study Between
Benign Paroxysmal Positional Vertigo
(BPPV) of the Horizontal Canal (H-BPPV)
and Posterior Canal (P-BPPV) Ana Bisonni,
Guillermo Videla, Juan Ignacio Rojas,
Edgardo Cristiano
P5.321 Burkitt’s Lymphoma
Presenting with Bilateral Abducens
Palsy Ela Akay, Paul Maddison
P5.310
Afferent and Efferent Visual
System Involvement in Cerebrotendinous
Xanthomatosis Francesca Rosini, Elena
Pretegiani, Andrea Mignarri, Antonio
Federico, Pierre Daye, Lance Optican, M.T.
Dotti, Alessandra Rufa
P5.311
Saccadic Oscillations After
Doping Suggest a Possible Mechanism
for Cerebellar and Omnipause Neurons
Dysfunction Elena Pretegiani, Francesca
Rosini, Raffaele Rocchi, Federica
Ginanneschi, Lance Optican, Alessandra
Rufa
P5.312
Comparison of Cirrus and
Spectralis Optical Coherence Tomography:
Factors Associated with Differences
in Retinal Nerve Fiber Thickness
Measurement James Wilson, Salim
Chahin, Dina Jacobs, Clyde Markowitz,
Peter Calabresi, Elliot Frohman, Steven
Galetta, Laura Balcer
Fast, Easy, Online Registration · AAN.com/view/AM15
Annual Meeting Edition
Planning for the 2015 AAN Annual
Meeting—and earning 10 FREE
Self-Assessment CME credits—
has never been easier:
1. Take the convenient online pre-test by April 17,
2015, to assess your knowledge and receive
recommendations for Annual Meeting courses
and areas to improve
2. After attending the meeting, successfully
complete the online post-test to receive
your CME
An AAN Member Exclusive—
FREE to Members Only!
AAN.com/view/NeuroSAEAM
Platform Blitz Sessions
Wednesday, April 22
Utilizing a similar format to the popular Emerging Science Sessions, these dynamic sessions will feature five-minute author presentations
followed by five-minutes of questions and answers. The session will conclude with all authors participating in a panel discussion.
S29 Neuroimaging
Correlates in Multiple
Sclerosis Platform Blitz
4:00 p.m.
S29.001
Factors Associated with Spinal
Cord Atrophy in the First Five
Years After a Clinically Isolated
Syndrome Wallace Brownlee,
Patricia Alves Da Mota, Ferran
Padros, Josephine Swanton,
Katherine Miszkiel, Daniel Altmann,
Sebastien Ourselin, Claudia
Wheeler-Kingshott, Olga Ciccarelli,
David Miller
4:10 p.m.
S29.002
FLAIR* MRI Improves Diagnostic
Accuracy in Multiple Sclerosis Ilena
George, Pascal Sati, Martina
Absinta, Irene Cortese, Elizabeth
Sweeney, Colin Shea, Daniel Reich
4:20 p.m.
S29.003
FLAIR* for the Non-invasive
Histological Diagnosis of Multiple
Sclerosis Tom Campion, Paul Smith,
Benjamin Turner, Daniel Altmann,
Pascal Sati, Jane Evanson, Ilena
George, Marc Miquel, Daniel Reich,
Klaus Schmierer
4:30 p.m.
S29.004
Novel Semi-quantitative Ageadjusted MRI Scale Correlates Highly
with Clinical Disability in Multiple
Sclerosis Patients Peter Kosa, Mika
Komori, Ryan Waters, Tianxia Wu,
Irene Cortese, Joan Ohayon, Kaylan
Fenton, Jamie Cherup, Tomas
Gedeon, Bibiana Bielekova
4:40 p.m.
S29.005
Cortical Lesion Burden on 7-tesla
MRI Is Associated with Cognitive
and Physical Disability in Multiple
Sclerosis Daniel Harrison,
Snehashis Roy, Dzung Pham, Susan
Courtney, Brian Caffo, Peter Van Zijl,
Peter Calabresi
4:50 p.m.
S29.006
Thalamic Atrophy over Time
in Relapsing Forms of MS: A
Large, 5-year, Observational MRI
Study Christina Azevedo, Sankalpa
Khadka, Shuang Liu, Daniel Pelletier
5:00 p.m.
S29.007
Default-mode Network
Changes in MS Patients with
Depression: A Link to Cognitive
Impairment? Gioacchino Tedeschi,
Sabrina Esposito, Rosaria Sacco,
Marida Della Corte, Alessandro
d'Ambrosio, Renato Docimo, Luigi
Lavorgna, Antonio Gallo, Mario
Cirillo, Fabrizio Esposito, Simona
Bonavita
5:10 p.m.
S29.008
Spontanous Remyelination Has a
Major Impact on Clinical Disability
in Multiple Sclerosis: A Longitudinal
PET Study with 11C-PIB Benedetta
Bodini, Mattia Veronese, Daniel
Garcia-Lorenzo, Marco Battaglini,
Emilie Poirion, Leorah Freeman,
Caroline Papeix, Bernard Zalc, Maya
Tchikviladze, Catherine Lubetzki,
Michel Bottlaender, Federico
Turkheimer, Bruno Stankoff
5:20 p.m.
S29.009
Advanced Imaging in Lesion and
Normal-appearing White Matter over
2 Years in MS Patients Treated with
Alemtuzumab Irene Vavasour, Alex
MacKay, David Li, Cornelia Laule,
Anthony Traboulsee
5:30 p.m.
Panel Discussion
S30 Cerebrovascular
Disease and Interventional
Neurology: Diagnostics,
Biomarkers, and Genetics
Platform Blitz
4:00 p.m.
S30.001
Metabolomic Analysis Reveals Novel
Small Molecule Plasma Markers of
Hyperacute Ischemic Stroke Wenjun
Deng, Chris Beecher, Charles Burant,
Frank De Jong, Mary Lopez, Thomas
Wickham, Mikaela Elia, Kathleen
Feeney, David McMullin, Ferdinand
Buonanno, Eng Lo, MingMing Ning
4:10 p.m.
S30.002
TIA Biomarkers Determined Through
Proteomics Paul George, Michael
Mlynash, Christopher Adams, Calvin
Kuo, Stephanie Kemp, Madelleine
Garcia, Gregory Albers, Jean-Marc
Olivot
4:20 p.m.
S30.003
Yield and Safety of Brain Biopsy
in Patients with Suspected CNS
Vasculitis Jose Torres, Caitlin
Loomis, Steven Messe
4:30 p.m.
S30.004
Pathophysiological Decrease in
the Regional Cerebral Blood Flow
in Hashimoto's Encephalopathy:
A Multiple-case SPECT
Study Masamichi Ikawa, Tomoko
Muramatsu, Katsuya Sugimoto,
Akiko Matsunaga, Osamu
Yamamura, Tadanori Hamano,
Yasunari Nakamoto, Hidehiko
Okazawa, Makoto Yoneda
4:40 p.m.
S30.005
Serial Transcranial Doppler
for Diagnosis and Monitoring
of Cerebral Vasoconstriction
Syndrome Sebastian Koch, Frank
Cabera, Yosdely Cabera, Alan Flores
4:50 p.m.
S30.006
General Anesthetic Use and
Clopidogrel Resistance During
Neurovascular Stenting
Procedures Yamin Shwe, Santiago
Ortega-Gutierrez, Jinu Kim, Karen
Chen, Srinivasan Paramasivam, Alex
Berenstein, Johanna Fifi
5:00 p.m.
S30.007
Coated-platelet Levels Are
Associated with Stenosis
Progression in Patients with Carotid
Atherosclerosis Angelia Kirkpatrick,
Andrea Vincent, Nhan Nguyen,
George Dale, Calin Prodan
5:10 p.m.
S30.008
Trends in 24-hours Sodium and
Potassium Intake, and Association
with All-cause Mortality Among US
Stroke Survivors Amy Towfighi,
Michelle Lin, Daniela Markovic,
Bruce Ovbiagele
5:20 p.m.
S30.009
Exceptional Aggressiveness of
Cerebral Cavernous Malformation
Disease Associated with PDCD10
Mutations. Tania Rebeiz, Abdul
Ghani Mikati, Amy Akers, Lingiioa
zhang, Issam Awad
5:30 p.m.
Panel Discussion
S31 Epilepsy/Clinical
Neurophysiology (EEG):
Epilepsy Therapy Platform
Blitz
4:00 p.m.
S31.001
Review of Suicidality Events in
Perampanel Clinical Studies Alan
Ettinger, Cindy Dobrinsky, Haichen
Yang, Betsy Williams, Dongyuan
Xing, Randi Fain, Antonio Laurenza
4:10 p.m.
S31.002
Reducing Severity of Comorbid
Psychiatric Symptoms in an Epilepsy
Clinic Using a Colocation Model:
Results of a Pilot Intervention Jasper
Chen, Tracie Caller, Erik Kobylarz,
Krzysztof Bujarski, Vijay Thadani,
Barbara Jobst
4:20 p.m.
S31.003
Generic Versus Brand-name
Lamotrigine Bioequivalence
in Generic-sensitive Epilepsy
Patients: A Field Test of the Public
Bioequivalence Standard Tricia Ting,
Wenlei Jiang, Jessica Wong, Jace
Jones, Allan Krumholz, Maureen
Kane, James Polli
4:30 p.m.
S31.004
Safety and Adverse Events Related
to Laboratory Test Results in
Perampanel Phase III Epilepsy
Clinical Studies Timothy Welty,
David Vossler, Haichen Yang, Betsy
Williams, Dinesh Kumar, Antonio
Laurenza, Barry Gidal
4:40 p.m.
S31.005
Seizure Outcome After Switching
Antiepileptic Drugs: A Matched,
Prospective Study Jon Finamore,
Michael Sperling, Tingting Zhan,
Christopher Skidmore, Maromi Nei,
Scott Mintzer
4:50 p.m.
S31.006
Assessment of Enrollment Criteria
in Clinical Trials for Drug Resistant
Epilepsy Christopher Cheng,
Daniel Friedman, Danielle Becker,
Jacqueline French
5:00 p.m.
S31.007
Adjunctive Perampanel for the
Treatment of Drug-resistant Primary
Generalized Tonic-clonic (PGTC)
Seizures in Patients with Idiopathic
Generalized Epilepsy (IGE): A Doubleblind, Randomized, Placebo-controlled
Phase III Trial Jacqueline French,
Gregory Krauss, Robert Wechsler,
Xuefeng Wang, Bree DiVentura,
Christian Brandt, Eugen Trinka,
Terence J O'Brien, Antonio Laurenza,
Anna Patten, Francesco Bibbiani
5:10 p.m.
S31.008
MRI-guided Stereotactic Laser
Ablation of Mesial Temporal Structures
for the Treatment of Refractory
Temporal Lobe Epilepsy Ramses
Ribot, Jonathan Jagid, Enrique
Serrano, Merredith Lowe, Gustavo
Rey, Leticia Tornes, Andres Kanner
5:20 p.m.
S31.009
A Randomized, Double-blind,
Placebo-controlled, Multicenter,
Parallel-group Study to Evaluate the
Efficacy and Safety of Adjunctive
Brivaracetam in Adult Patients
with Partial-onset Seizures Pavel
Klein, Jimmy Schiemann, Michael
Sperling, John Whitesides, Wei
Liang, Tracy Stalvey
5:30 p.m.
Panel Discussion
S32 Movement Disorders:
Tremor, Ataxia, and More
Platform Blitz
4:00 p.m.
S32.001
Reduced Purkinje Cell Dendritic
Arborization and Loss of Dendritic
Spines in Essential Tremor Elan
Louis, Jean-Paul Vonsattel, Phyllis
Faust
4:10 p.m.
S32.002
Antisense Oligonucleotides for
the Treatment of Spinocerebellar
Ataxia Type 2 (SCA2) Daniel Scoles,
Matthew Schneider, Meera Pratap,
Gene Hung, Frank Rigo, Frank
Bennett, Thomas Otis, Stefan Pulst
4:20 p.m.
S32.003
Exome Sequencing Improves Clinical
Diagnosis of Sporadic or Familial
Cerebellar Ataxia Brent Fogel, Hane
Lee, Joshua Deignan, Samuel Strom,
Sibel Kantarci, Xizhe Wang, Fabiola
Quintero-Rivera, Eric Vilain, Wayne
Grody, Susan Perlman, Daniel
Geschwind, Stanley Nelson
4:30 p.m.
S32.004
Episodic Ataxia Type 1: Natural
History, Quality of Life and Patientreported Symptoms. Tracey Graves,
Robert Griggs, Brian Bundy, Joanna
Jen, Robert Baloh, Michael Hanna
4:40 p.m.
S32.005
Study of Beta Cells and Neurons
Indicate Incretin Analogs as Potential
Therapeutics for Friedreich’s
Ataxia. Massimo Pandolfo, Mariana
Igoillo-Esteve, Amélie Hu, Ewa
Gurgul-Convey, Laila Romagueira
Bichara Dos Santos, Jonas JeanChristophe, Decio Eizirik, Miriam
Cnop
4:50 p.m.
S32.006
Predictors of Poor Outcome in
Neuroleptic Malignant Syndrome:
Retrospective Analysis of
Nationwide Inpatient Sample Sumul
Modi, Devanshi Dharaiya
5:00 p.m.
S32.007
Fewer Than Two Hours of Daily
Centromedian Thalamic Stimulation
Produces Significant Tic Reduction in
Tourette Syndrome: Two-year Followup of a Personalized, Scheduled DBS
Duty Cycle Strategy Justin Rossi,
Jonathan Shute, Aysegul Gunduz,
Kelly Foote, Michael Okun
5:10 p.m.
S32.008
An Analysis of Psychoactive
Drugs Used in PD: A UF NPF-QII
Study Daniel Martinez-Ramirez,
Juan Giugni, Amanda Eilers, Alberto
Bona, Leili Shagholi, Bilal Ahmed,
Sol De Jesus, Leonardo Almeida,
Valerie Rundle-Gonzalez, Erin
Hastings, Michael Okun
5:20 p.m.
S32.009
CSF Aβ1-42 Predicts Cognitive
Impairment in De Novo PD
Patients Mark Terrelonge, Karen
Marder, Daniel Weintraub, Roy
Alcalay
5:30 p.m.
Panel Discussion
S33 Aging, Dementia,
Cognitive, and Behavioral
Neurology: Biomarkers and
Pathology Platform Blitz
4:00 p.m.
S33.001
Transthyretin as Potential Biomarker
for C9ORF72-related Diseases Marka
Van Blitterswijk, NiCole Finch,
Matthew Baker, Xue Wang,
Kevin Bieniek, Mariely DejesusHernandez, Tania Gendron, Yan
Asmann, Michael Heckman, Patricia
Brown, Keith Josephs, Joseph Parisi,
David Knopman, Ronald Petersen,
Leonard Petrucelli, Bradley Boeve,
Neill Graff-Radford, Kevin Boylan,
Dennis Dickson, Rosa Rademakers
4:10 p.m.
S33.002
Long and Short Telomere Lengths Are
Associated with Risk of Amnestic
Mild Cognitive Impairment Rosebud
Roberts, Lisa Boardman, Ruth Cha,
Vernon Pankratz, Ruth Johnson,
Teresa Christianson, Lewis Roberts,
Ronald Petersen
4:20 p.m.
S33.003
Neural Origin Plasma Exosomes
Provide Novel Biomarkers for Brain
Insulin Resistance in Alzheimer's
Disease Dimitrios Kapogiannis,
Adam Boxer, Erin Abner, Arya
Biragyn, Umesh Masharani, Lynda
Frassetto, Ronald Petersen, Bruce
Miller, Edward Goetzl
4:30 p.m.
S33.004
Progranulin Protein Plasma and CSF
Levels in a Large Well-characterized
Dementia and Healthy Aging
Cohort. Zachary Miller, Laura Mitic,
Jennifer Tran, Iryna Lobach, Anna
Karydas, Ginette Serrero, Rodney
Pearlman, Howard Rosen, Bruce
Miller, Adam Boxer
4:40 p.m.
S33.005
Anti-S100B Autoantibodies in Cerebral
Small Vessel Disease Chanda
Brennan, Humberto Choi, Vikram
Puvenna, Michael Phillips, Peter
Mazzone, Damir Janigro
4:50 p.m.
S33.006
Skin Cells Express Altered Proteins
That Characterize the Most Common
Neurodegenerative Diseases Ildefonso
Rodriguez-Leyva, Erika Chi-Ahumada,
Ana Calderon-Garcidueñas, Veronica
Medina-Mier, Guadalupe MartelGallegos, Sergio Zarazua, Maria
Jimenez-Capdeville
5:00 p.m.
S33.007
Clinicopathological Correlation
of Psychotic Symptoms in
Neurodegenerative Diseases Georges
Naasan, Estrella Morenas-Rodriguez,
Lucia Lopez, Suzie Shdo, Lea Grinberg,
William Seeley, Ellen Gelpi, Alberto
Lleo, Bruce Miller, Katherine Rankin
5:10 p.m.
S33.008
Prevalence of Cerebral Amyloid
Angiopathy on Autopsy in Autosomal
Dominant Alzheimer’s Disease John
Ringman, Sarah Monsell, Andy
Nguyen, Spencer Tung, Yan Zhou,
Denise Ng, Harry Vinters
5:20 p.m.
S33.009
Resveratrol Is Safe and Well-tolerated
in Individuals with Mild-moderate
Dementia Due to Alzheimer’s
Disease. R Turner, Ronald Thomas,
Suzanne Craft, Christopher van Dyck,
Jacobo Mintzer, Brigid Reynolds,
James Brewer, Robert Rissman,
Rema Raman, Paul Aisen
5:30 p.m.
108
Panel Discussion
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Platform Blitz Sessions
S34 Neuromuscular
Update Platform Blitz
4:00 p.m.
S34.001
Gne Myopathy Zebrafish Models with
Impaired Sialylation Dino Maglic,
Leoyklang Petcharat, Pongsathorn
Chaiyasap, Kevin Bishop, Raman
Sood, Patricia Zerfas, William Gahl,
Marjan Huizing, May Malicdan
4:10 p.m.
S34.002
A New Muscle Glycogen Storage
Disease Associated with Glycogenin-1
Deficiency Edoardo Malfatti, Johanna
Nilsson, Carola Hedberg-Oldfors,
Aurelio Hernandez-Lain, Gabriel
Viennet, Cristina Dominguez-Gonzalez,
Fabrice Michel, Hasan Ackman,
Cornelia Kornblum, Peter Van den
Bergh, Norma Romero, Andrew Engel,
Salvatore DiMauro, Anders Oldfors
4:20 p.m.
S34.003
Mutant SNAP25B Causes Novel
Congenital Myasthenic Syndrome
(CMS), Cortical Hyperexcitability,
Ataxia, and Intellectual Disability Xin
Ming Shen, Duygu Selcen, Joan
Brengman, Andrew Engel
4:30 p.m.
S34.004
LRP4 Antibodies Are Frequent in
Serum and CSF from Amyotrophic
Lateral Sclerosis Patients John
Tzartos, Paraskevi Zisimopoulou,
Anastasios Tsonis, Panagiota
Evangelakou, Michail Rentzos, Nikos
Karandreas, Vasiliki Zouvelou, Thomas
Thomaidis, Giuseppe Lauria, Francesca
Andreetta, Renato Mantegazza, Talma
Brenner, Panayiota Petrou, Dimitrios
Karusis, Socrates Tzartos
4:40 p.m.
S34.005
Large-scale Exome Sequencing in
ALS Identifies New Risk Genes and
Pathways Matthew Harms, Elizabeth
Cirulli, Brittany Lasseigne, Tim Harris,
Richard Myers, David Goldstein
4:50 p.m.
S34.006
A Small-molecule Activator of Hsf1,
Nrf1, and Nrf2 Mitigates Polyglutamine
Toxicity in Spinal and Bulbar Muscular
Atrophy Models Carlo Rinaldi, Laura
Bott, Nisha Badders, Elaine Bautista,
George Harmison, Ke-lian Chen, J Paul
Taylor, Nico Dantuma, Kenneth Fischbeck
5:00 p.m.
S34.007
Aggregates of Mutant DNMT1 Are
Linked to a Spectrum of Neurological
Disorders Jonathan Baets, Xiaohui
Duan, Yanhong Wu, Gordon Smith,
William Seeley, Ines Mademan, Nicole
McGrath, Noah Beadell, Julie Khoury,
Maria-Victoria Botuyan, Georges Mer,
Gregory Worrell, Kaori Hojo, Jessica
Delone, Matilde Laura, Yo-Tsen Liu, Jan
Senderek, Joachim Weis, Peter Van
den Bergh, Shana Merrill, Mary Reilly,
Henry Houlden, Murray Grossman,
Steven Scherer, Peter De Jonghe, Peter
Dyck, Christopher Klein
5:10 p.m.
S34.008
CMT Caused by a Mutation in
Dystrophin-related Protein 2: Exome
Sequencing Reveals a New Clinical
Paradigm Kathryn Brennan, Yunhong
Bai, Suola Wang, Shawna Feely,
Chiara Pisciotta, Laurie Gutmann,
Steven Moore, Diane Sherman,
Peter Brophy, Stephan Zuchner,
Michael Shy, Michael Gonzalez
5:20 p.m.
S34.009
Development of ISIS-TTRRx for
Transthyretin Familial Amyloid
Polyneuropathy (TTR-FAP) Frederick
Derosier, Jesse Kwon, Elizabeth
Ackerman, Erin Lettow, Mason
Yamashita, Steven Hughes
5:30
p.m.
Panel Discussion
S35 Child Neurology and
Developmental Neurology
Platform Blitz
S36 Neuroepidemiology:
Movement Disorders, ALS,
and Aging Platform Blitz
4:00 p.m.
S35.001
A Diffusion Tensor MRI Study of
Pediatric Patients with Severe
Non-traumatic Brain Injury Sandra
Strazzer, Maria Rocca, Erika Molteni,
Elisabetta Pagani, Katia Colombo,
Susanna Galbiati, Giacomo Boffa,
Valentina Pastore, Giancarlo Comi,
Massimo Filippi
4:00 p.m.
S36.001
Accuracy of Clinical Diagnosis
of Parkinson’s Disease: A
Systematic Review and Bayesian
Meta-analysis Giovanni Rizzo,
Simona Arcuti, Davide Martino,
Massimiliano Copetti, Andrea
Fontana, Giancarlo Logroscino
4:10 p.m.
S35.002
Transdermal Nicotine Patch as a Novel
Treatment for Epilepsy Associated
with a Mutation in the Nicotinic
Acetylcholine Receptor Diana
Sieciechowicz, Michael Kohrman
4:20 p.m.
S35.003
Towards a Histological Diagnosis
of Childhood Small Vessel CNS
Vasculitis. Maryam Nabavi Nouri,
Pascal Tyrrell, Marinka Twilt,
Anastasia Dropol, Shehla Sheikh,
Susanne Benseler, Cynthia Hawkins
4:30 p.m.
S35.004
Differential Contribution of Cerebellar
Resting State Functional Connectivity
Abnormalities to Cognitive Impairment
in Pediatric and Adult Patients with
Multiple Sclerosis Sara Cirillo,
Maria Rocca, Lucia Moiola, Angelo
Ghezzi, Pierangelo Veggiotti, Ruggero
Capra, Maria Amato, Agnese Fiorino,
Lorena Pippolo, Maria Carmela
Pera, Giancarlo Comi, Andrea Falini,
Massimo Filippi
4:40 p.m.
S35.005
Microvascular Abnormalities in
Adrenoleukodystrophy: Effects
of ABCD1 Deficiency Upon Brain
Endothelium. Patricia Musolino, Yi
Gong, Snyder Juliet, Sandra Jimenez,
Eric Grabowski, Josephine Lok, Eng Lo,
Matthew Frosch, Florian Eichler
4:10 p.m.
S36.002
Risk of Parkinson's Disease
After Traumatic Brain Injury
Versus Nonbrain Trauma Raquel
Gardner, James Burke, Jasmine
Nettiksimmons, Allison Kaup,
Deborah Barnes, Samuel Goldman,
Caroline Tanner, Kristine Yaffe
4:20 p.m.
S36.003
Nursing Home and End-of-life Care
in Parkinson Disease. Delaram
Safarpour, Dylan Thibault, Cynthia
Boyd, Cori DeSanto, Ray Dorsey,
Brad Racette, Allison Willis
4:30 p.m.
S36.004
Cervical Dystonia (CD) Incidence
and Diagnostic Delay in a
Multiethnic Health Maintenance
Organization. Sara LaHue, Kathleen
Albers, Samuel Goldman, Jeffrey
Klingman, Raymond Lo, Connie
Marras, Amethyst Leimpeter, Robin
Fross, Kathleen Comyns, Zhuqin Gu,
Maya Katz, Laurie Ozelius, Susan
Bressman, Rachel SaundersPullman, Cynthia Comella, Lorene
Nelson, Stephen Van Den Eeden,
Caroline Tanner
4:40 p.m.
S36.005
Military Service and Amyotrophic
Lateral Sclerosis in a US Populationbased Cohort Marc Weisskopf,
Merit Cudkowicz, Norman Johnson
4:50 p.m.
S35.006
Defining the Expanding Clinical
Spectrum of Pediatric Onset Stiffperson Syndrome (p-SPS): A Case
Series Anusha Yeshokumar, Deanna
Saylor, Scott Newsome
4:50 p.m.
S36.006
ALS and Military Occupation: A
Population-based Case-control Study
in the Danish Registries Ryan Seals,
Marianthi-Anna Kioumourtzoglou,
Johnni Hansen, Ole Gredal, Marc
Weisskopf
5:00 p.m.
S35.007
Predictive Value of Size of Portwine Stains in Sturge-Weber
Syndrome Malgorzata Dymerska,
Anna Kirkorian, Emma Kaplan,
Catherine Bachur, Doris Lin, Bernard
Cohen, Anne Comi
5:00 p.m.
S36.007
Mixed Membership Trajectory
Model of Cognitive Impairment in
the Cardiovascular Health Study—
Cognition Study Fabrizio Lecci, Brian
Junker, Lewis Kuller, Oscar Lopez,
James Becker
5:10 p.m.
S35.008
Does a Standardized Multidisciplinary
Approach Improve Outcomes for
Children with NMDA Receptor
Antibody Encephalitis? A Preliminary
Assessment of a Single Center
Experience Mered Parnes, Amber
Stocco, Trung Nguyen, Jun Teruya,
Jeanine Graf, Eyal Muscal
5:10 p.m.
S36.008
Mediterranean-type Diet and
Brain Volumes in an Elderly
Population Yian Gu, Adam
Brickman, Christian Habeck,
Qolamreza Razlighi, Jose Luchsinger,
Jennifer Manly, Nicole Schupf,
Richard Mayeux, Yaakov Stern,
Nikolaos Scarmeas
5:20 p.m.
S35.009
Complementary and Alternative
Medicine in an Outpatient Pediatric
Neurology Clinic: Prevalence of Use
and Attitudes Toward CAM and
Prescription Medications Daniel
Kenney, Paul Youssef, Sarah
Jenkins, Ann Harris, Suresh Kotagal
5:20 p.m.
S36.009
Additive Role of a Cognitive
Frailty Model and Inflammatory
State on the Risk of Disability.
The Italian Longitudinal Study on
Aging Michele Giannini, Vincenzo
Solfrizzi, Francesco Panza, Rosa
Capozzo, Rosanna Tortelli, Maria
Rosaria Barulli, Davide Seripa,
Nicola Quaranta, Alberto Pilotto,
Emanuele Scafato, Carlo Sabbà,
Giancarlo Logroscino
5:30 p.m.
Panel Discussion
5:30 p.m.
Panel Discussion
S37 Global Health and
Infectious Disease
Platform Blitz
4:00 p.m.
S37.001
Activation of HERV-K and Response
to Antiretroviral Therapy in Patients
with HIV Infection and Motor Neuron
Disease Bryan Smith, Richa Tyagi,
Wenxue Li, Mary Wright, Rose
McConnell, Elyse Singer, Ty Nguyen,
Tanya Lehky, Thomas Uldrick, Priscila
Goncalves, Tariq Alfahad, Joseph
Berger, Avindra Nath
4:10 p.m.
S37.002
Performance Characteristics
of the WHO Ten Question
Screen in Children with HIV in
Botswana James Baier, Esther
Baranov, Baphaleng Monokwane,
Esha Khurana, David Bearden
4:20 p.m.
S37.003
Higher Framingham Risk Score Is
Associated with HIV-associated
Dementia in Rural Uganda Ned
Sacktor, Deanna Saylor, Gertrude
Nakigozi, Noeline Nakasujja,
Xiangrong Kong, Kevin Robertson,
Ronald Gray, Maria Wawer
4:30 p.m.
S37.004
Global Cost and Availability of
Neurodiagnostic Tests: A Surveybased Analysis Hannah McLane,
Aaron Berkowitz, Emma Wolper,
Erica McKenzie, Sarah Wahlster,
Farrah Mateen
4:40 p.m.
S37.005
Evaluation and Immunomodulatory
Treatment at the NIH of Children
with Nodding Syndrome from
Northern Uganda Ariane Soldatos,
Thomas Nutman, Catherine Groden,
Colleen Wahl, Sara Inati, Gretchen
Buckler, Elise O'Connell, Bernard
Opar, Josephine Aryek-Kwe, Robert
Downing, Scott Dowell, William
Gahl, Avindra Nath
Wednesday
April 22
4:00 p.m–5:45 p.m.
4:50 p.m.
S37.006
Evaluation of Neurofilament Heavy
Chain as a Marker of Neuroaxonal
Pathology and Prognosis in Acute
Encephalitis Johann Sellner,
Nicholas Davies, Robin Howard,
Axel Petzold
5:00 p.m.
S37.007
Serum and CSF Cytokines in
Patients with Active CNS Lyme
Disease, Other Inflammatory
CNS Diseases, Encephalopathy
Following Treated Lyme Disease,
Other Encephalopathies, and Normal
Controls John Halperin, Javier
Pacheco-Quinto, Aimee Herdt,
Elizabeth A. Eckman
5:10 p.m.
S37.008
Balamuthia Mandrillaris
Meningoencephalitis and Central
Nervous System Vasculitis
Diagnosed by Next-generation
Sequencing of Cerebrospinal
Fluid Niraj Shanbhag, Michael
Wilson, Michael Reid, Neel Singhal,
Barlas Benkli, Jeffrey Gelfand,
Hannah Sample, Matthew Wood,
Andrew Bollen, Joseph DeRisi
5:20 p.m.
S37.009
Refractory Status Epilepticus
(RSE) in Powassan Virus (POWV)
Encephalitis Mubashir Pervez,
Umair Afzal, Burk Jubelt
5:30 p.m.
Panel Discussion
109
Poster Session VI
Thursday, April 23
P6 Poster
Session VI
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Discussion Session: Treatments, Therapeutics, and Biomarkers
7:30 a.m.–12:00 p.m.
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
P6.001 Relationship Between Health
Insurance Status and Patient-reported
Health Outcomes Among Caucasian Native
English Speakers Lidia Maria Moura, Eli
Schwamm, Lee Schwamm
P6.002 Dysferlin Exon 32 Excision
by Oligonucleotides of the DNAanalogue Tricyclo-DNA as a Therapeutic
Approach to Dysferlin-deficient Muscular
Dystrophies Susanne Philippi, Simone
Spuler, Christian Leumann, Luis Garcia
P6.003 Are CSF Tau and Phospho Tau
Levels Really Biomarkers of Amyotrophic
Lateral Sclerosis? Antonio Scarafino,
Rosaria Leante, Alessandro Introna, Rosa
Cortese, Eugenio Distaso, Eustachio
D'Errico, Isabella Simone
P6.004 Treatment with Ultra-high
Dose of Methylcobalamin Attenuates
Motor Dysfunction and Neuropathological
Changes in Wobbler Mouse Motor Neuron
Disease Ken Ikeda, Yasuo Iwasaki, Ryuji
Kaji
P6.005 Biomarker - Discovery
in G-CSF Mediated Clinical ALS
Stabilization Siw Johannesen, Andrei
Khomenko, Dobri Baldaranov, Ines Kobor,
Josefine Blume, Tim-Henrik Bruun, Jochen
Grassinger, T Kammermaier, Albert Ludolph,
Michael Deppe, Gerhard Schuierer, Wilhelm
Schulte-Mattler, Armin Schneider, Rico
Laage, Ulrich Bogdahn
P6.006 An Unusual Case of Cadasil
with Occipital Lobe Involvement Shrikant
Mishra, Neal Rao, Charles Flippen, Brent
Fogel, Gasser Hathout, Mariam Thomas,
Jaffer Kattan, Bhavesh Trikamji
P6.007 Functional MRI Mapping of
Hepatic Encephalopathy as an Insight into
Alertness Niral Patel, Nisha Bhatia, WenChing Liu, Michael Zagardo, Michael Xu,
Sonu Dhillon, Hrachya Nersesyan
P6.008 Abstract Reasoning Is
Associated with Corpus Callosum Area
in Neuropsychiatric Systemic Lupus
Erythematosus Patients Alicja KalinowskaLyszczarz, Mikolaj Pawlak, Slawomir
Michalak, Wlodzimierz Paprzycki, Katarzyna
Pawlak-Buś, Piotr Leszczynski, Mariusz
Puszczewicz, Wojciech Kozubski
P6.009 Safety and Feasibility
of G-CSF Compassionate Use in ALS
Patients Andrei Khomenko, Dobri
Baldaranov, Siw Johannesen, Ines Kobor,
Josefine Blume, Tim-Henrik Bruun, Jochen
Grassinger, Tina Kammermaier, Albert
Ludolph, Michael Deppe, Gerhard Schuierer,
Wilhelm Schulte-Mattler, Tim Friede, Rico
Laage, Armin Schneider, Ulrich Bogdahn
P6.010
Hereditary Spastic
Paraplegia: Characterization of an
Albertan Cohort Anil Venkitachalam, Erica
McKenzie, Setareh Ashtiani, Cathleen
Huculak, Linda MacLaren, Oksana
Suchowersky
e-Poster Session: Cerebrovascular Disease and Interventional Neurology II
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P6.011
Stroke Physician Vs
Stroke Neurologist—Can Anyone
Thrombolyse? Aaron Gaekwad, Andrew
Lee, Michelle Bronca, Lata Cheruvu, Owen
Davies, Marc Agzarian, Celia Chen
P6.012
Outcomes in ICH Patients
Should Be Stratified by Age with Attention
to Race and ICH Score Amelia Boehme,
Karen Albright, April Sisson, Angela Hays
Shapshak, Gyanendra Kumar, Mitchell
Elkind, Mark Harrigan
Imaging and Biomarkers in
Neurological Disease
P6.021 Alpha Rhythm and the
Default Mode Network: An EEG-fMRI
Study Anthony Bowman, Joseph Griffis,
Kristina Visscher, Allan Dobbins, Tim
Gawne, Mark DiFrancesco, Jerzy Szaflarski
P6.022 A Registration Method
for Improving Test-retest Reliability in
Probabilistic Diffusion Tractography Jeffrey
Waugh, Jake Kuster, Jacob Levenstein,
Hans Breiter, Nutan Sharma, Anne Blood
P6.023 Regional Brain Atrophy in
MND as a Diagnostic Marker Derived by
Routine High Resolution MRI Gerhard
Winkler, Alaleh Raji, Roland Opfer, Lothar
Spies
110
P6.013
Varicella-Zoster Hemorrhagic
Encephalitis in an AIDS Patient Daniel
Vela-Duarte, David Pasquale, Murray Flaster
P6.014
Subarachnoid Hemorrhage
as the Initial Neurologic Manifestation
in Thrombotic Thrombocytopenic
Purpura Jerry Wei, Atul Ramesh,
Constantine Farmakidis, Krishna Nalleballe,
Neville Jadeja
P6.015
Correlation Between CTA
and Subsequent DSA Collateral Scores in
Acute Ischemic Stroke Alejandro Santillan,
Stephen Chen, Lee Birnbaum
P6.024 The Etiology of Cortical
Lesions in Marchiafava-Bignami Disease
Is Nicotinic Acid Deficiency: A Case Report
and Review of the Literature Takayuki
Kosaka, Yoko Yoshida, Toshihiro Sakurai,
Yanosuke Kouzaki, Tomohiro Takita, Chiaki
Asao
P6.025 Longitudinal Imaging in
Marchiafava-Bignami Disease Annapoorna
Bhat, Bhrugav Raval, David Marks
P6.026 Incidence of Meningeal
Enhancement on Brain MRI Secondary
to Prior Lumbar Puncture Sarah Wesley,
Rocio Garcia Santibanez, John Liang,
DeWitt Pyburn
P6.016
Case Report: Cerebral
Venous Sinus Thrombosis Involving
Native Persistent Falcine Sinus Ikjae Lee,
Matthew Flaherty, Thomas Tomsick, James
Leach
P6.017
Pre-arrest Patient
Characteristics Explain Most Interhospital
Variation in Outcomes After Cardiac
Arrest Teresa May, Alexandra Reynolds,
Amelia Boehme, Barbara McCrum, Priyank
Patel, Soojin Park, Jan Claassen, Richard
Riker, David Seder, Sachin Agarwal
P6.027 Quantitative Susceptibility
Mapping (QSM) as a Biomarker for
C9orf72 Familial ALS Emily Brady, Andrew
Schweitzer, Tian Liu, Yi Wang, Mona
Shahbazi, Alexander Shtilbans, Apostolos
Tsiouris, Dale Lange
P6.028 Intraventricular Silicone
Mimicking Intracerebral Hemorrhage:
A Case Report and Review of the
Literature Peggy Nguyen, Benjamin
Emanuel
P6.029 Dorsal Thoracic Arachnoid
Web and the Scalpel Sign Jayaganth
Jayabal
P6.030 Proximal MR Neurography
in Hansen’s Neuritis Manjunath Poojar,
Ravinder Singh, Atchayaram Nalini, Jitender
Saini, Anita Mahadevan, Veeranna Gadad
P6.018
Spinal Cord and Cranial
Bing-Neel Syndrome Complicated by
Stroke Alejandro Vargas, Karan Dixit, John
Quigley, Fernando Testai
P6.019
Depression, Not Fatigue,
Predicts Quality of Life After Stroke Gina
Milone, Clotilde Balucani, Stephanie Hong,
Dimitre Stefanov, Steven Levine
P6.020 Complication Rates of 3%
Hypertonic Saline Infusion Through
Peripheral Intravenous Access Claudia
Perez, Pamela Coffie, Cory Kacir, Jojo Koshy,
Stephen Figueroa
Neurotherapeutics
P6.031 Patient Factors Do Not Predict
Thrombolysis in Stroke Mimics Kasey
Gildersleeve, Renga Pandurengan, Nicole
Gonzales
P6.032 Comprehensive Postmarketing
Review of Visual Defects Reported with
Topiramate Lisa Ford, Goldberg Jeffrey,
Fred Selan, Howard Greenberg, Yingqi Shi
P6.033 Use of Intrathecal Antibiotic
Administration for Treatment of CNS
Infections in a Neuro-ICU: A Case
Series Chandan Mehta, Mathew Jones,
Mauricio Ruiz Cuero, Tamer Abdelhak,
Mohammed Rehman, Jody Wellwood,
Tracey Lasak-Myall, Panayiotis Varelas
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VI
P6.034 Ropinirole in Bipolar
Depression: A Retrospective
Review Horacio Capote, Michelle Rainka,
Erica Westphal, Carolyn Ross, Andrea
Laudisio, Brett Pinger, Francis Gengo
P6.035 Quantitative Imaging
P6.046 Incidence of Impulsive and
Compulsive Behavior Type Adverse Events
with Long-term Rotigotine: A Post-hoc
Analysis Angelo Antonini, Mahnaz
Asgharnejad, Lars Bauer, Frank Grieger,
Babak Boroojerdi
P6.059 The Impact of Clinical
P6.071
P6.060 Data-mining of Genomic Data
P6.072 Brain Structural and
Symptoms on Quality of Life in Patients
with Advanced Stage Parkinson's Disease
and Their Caregivers Nina Browner
in Parkinson’s Disease for Links to Hypoxiaresponse and Vascular Factors Rainald
Schmidt-Kastner, Jacqui Wilneff, Chris
Nguyen, Kim McKain, Julie Dela Cruz, Harry
Steinbusch, Bart Rutten
Biomarkers of Brain Edema After 23%
Saline in Liver Failure Eric Liotta, Bryan
Lizza, Anna Romanova, James Guth,
Michael Berman, Timothy Carroll, Daniel
Ganger, Daniela Ladner, Brandon Francis,
Matthew Maas, Andrew Naidech
P6.047 The Effect of a Cholinesterase
P6.036 Dosing, Side Effects, and
Uncovering Comorbid Dermatologic
Conditions in Parkinson’s Disease Kimberly
O'Neill, Ramsey Falconer, Sean Rogers,
Reversa Mills, Ellen Valadez, Fernando
Pagan
Characterisation of Cognitive
Decline Over 5 Years in an Incident
Parkinson’s Disease Cohort: Results from
the CamPaIGN Study Catherine McAllister,
Caroline Williams-Gray, Sarah Mason,
Thomas Foltynie, Rosemary Abbott, Pradeep
Nathan, Roger Barker
P6.049 Dalfampridine Extended
P6.062 Echogenicity of the Substantia
Long-term Outcomes for IVIg Use in
Treatment of Neurological Conditions:
Data from the Immunoglobulin Diagnosis,
Evaluation, and Key Learnings (IDEaL)
Patient Registry Sean Kearns, Loretta
Kristofek, Bill Bolgar, Luqman Seidu
Inhibitor on Balance in Parkinson’s
Disease Amie Peterson, Martina Mancini,
Fay Horak, Seth Kareus, Bernadette
Schoneburg, MIchael Fleming, John Nutt
P6.048 Overlooking the Skin:
D Deficiency in Neuromuscular
Clinics Sankar Bandyopadhyay, Sol De
Jesus
Release in Patients with Parkinson’s
Disease Related Gait Dysfunction: A
Randomized Double Blind Trial Corneliu
Luca, Gloria Nadayil, Chuanhui Dong, Edelle
Field-Fote, Carlos Singer
P6.038 Wernicke’s Encephalopathy
P6.050 Risk of Premotor Symptoms
P6.037 A Pilot Study of Vitamin
Masquerading as Creutzfeldt-Jakob
Disease Travis Taylor, Kelly Baldwin
P6.039 Cannabis Use in Epilepsy and
Anorexia—Two "N-of-one" Trials Denis
Petro
P6.040 Peduncular Hallucinosis
in a Patient with Metastasic Lung
Cancer—Case Report and Review of the
Literature Lisseth Burbano, Jaime Toro
Movement Disorders:
Parkinson's Disease
P6.041 Interim Results of a Phase 3b
Study Assessing the Safety and Efficacy
of Levodopa-carbidopa Intestinal Gel on
Non-motor Symptoms in Subjects with
Advanced Parkinson’s Disease Jordan
Dubow, Krai Chatamra, Susan Eaton, Coleen
Hall, Janet Benesh
P6.042 Spontaneous Pupillary Hippus
Is Markedly Suppressed in Patients with
Idiopathic Parkinson's Disease Kartik
Mangipudi, Jacqueline Cristini, Philip
Hanna, Michael Rosenberg
P6.043 Orthostatic Hypotension and
Its Relationship to the Brain Circulation
of Patients with Parkinson’s Disease: A
Transcranial Doppler Assessment Carlos
Camargo, Eduardo Martins, Henrique
Hoffmann, Jissa Jeanette, Marcelo YoungBlood, Marcelo Schafranski, Marcelo Ferro,
Edmar Myochi, Marcos Lange
P6.044 Decreased Burden Among
Caregivers of Patients with Parkinson’s
Disease Psychosis (PDP) Treated with
Pimavanserin, a Selective 5-HT2A Inverse
Agonist Dag Aarsland, Roger Mills, Hilde
Williams, Kathy Chi-Burris, Michaela
Karistedt, Clive Ballard
P6.045 Sensory Attenuation in
Parkinson’s Disease Antonella Macerollo,
Jui-Cheng Chen, Prasad Korlipara, James
Kilner, Mark Edwards
in Patients with Newly Diagnosed PD: A
Nationwide Population-based Study MingHong Chang
P6.051
Head Injury at Early Ages
Is Associated with Risk of Parkinson’s
Disease Kathryn Taylor, Marie-Helene
Saint-Hilaire, Lewis Sudarsky, David Simon,
Bonnie Hersh, David Sparrow, Howard Hu,
Marc Weisskopf
P6.052 Illusions and Hallucinations
Are Present in Different Phenotypes of
Parkinson’s Disease: A Case-series Kelsey
Juster-Switlyk, Rodolfo Savica, David
Shprecher, Edward Zamrini
P6.053 Height and Weight Changes
P6.061
Nigra in Patients with De Novo Parkinson's
Disease. Relationship with Parkinsonian
Phenotypes Jose Santiago S. Bestoso
P6.063 Learning Processes in
Parkinson’s Disease and Healthy
Aging Madeleine Sharp, Karin Foerde,
Nathaniel Daw, Daphna Shohamy
P6.064 Demonstration of Abnormality
of Intrinsically Photosensitive Retinal
Ganglion Cells (ipRGCs) in Patients with
Parkinson’s Disease Adnaan Zaffer,
Jasvinder Chawla, Youngsook Park, Mary
Jost, Jaswinder Singh, Martin Gorbien,
Bruce Gaynes
P6.065 Motor Associations of Iron
Deposition in Patients with Parkinson’s
Disease Martin-Bastida Antonio, Marios
Politis, Clare Loane, Lao-Kaim Nicholas,
Natalie Valle-Guzman, Zinovia Kefalopoulou,
Gesine Paul, H Widner, Thomas Foltynie,
Roger Barker, Paola Piccini
After Deep Brain Stimulation in Patients
with Parkinson Disease: Role of Clinical
Subtypes Dennys Reyes, Hesham
Abboud, Gencer Genc, Andre Machado,
Scott Cooper, Michal Gostkowski, Hubert
Fernandez
P6.066 Association of the Side of
P6.054 Can Drug-induced
P6.067
Parkinsonism Reveal Pre-motor Parkinson
Disease? James Morley, Gang Cheng,
Jacob Dubroff, Jayne Wilkinson, John Duda
P6.055 The Incidence of Falls and
Fractures in Patients with Parkinson’s
Disease in a US Population Linda Kalilani,
Mahnaz Asgharnejad, Tuire Palokangas,
Tracy Durgin
P6.056 Effects of Medical
Onset of Motor Symptoms to Prevalence of
Various Domains of Non-motor Symptoms
(NMS) in Parkinson's Disease Raja
Boddepalli, Tarannum Khan, Emilio De
Narvaez
Freezing of Gait Early
in Parkinson: Atypical Versus Typical
Parkinson Disorders Aman Deep, Abraham
Lieberman, Rohit Dhall, An Tran, Ming-Jai
Liu
P6.068 Plasma ApoA1 Associates
with Age at Onset and Motor Severity in
Early Parkinson Disease Patients Christine
Swanson, Yosef Berlyand, Sharon Xie, Roy
Alcalay, Lama Chahine, Alice Chen-Plotkin
Comorbidities on Parkinson Disease
Patients’ Quality of Life Tracy Fulton,
Fernando Pagan
Movement Disorders:
Parkinson's Disease Imaging
P6.057 24-hour Efficacy Profile of
P6.069 11C-FECIT-PET Presynaptic
Rotigotine in Patients with Advanced
Parkinson’s Disease: A Post-hoc
Analysis Lawrence Elmer, Mahnaz
Asgharnejad, Babak Boroojerdi, Frank
Grieger, Lars Bauer
P6.058 Apathy and Clinical
Patterns of Presentation of Parkinson’s
Disease Arianna Sartori, Jacopo Fantini,
Alessio Bratina, Rita Moretti
Fast, Easy, Online Registration · AAN.com/view/AM15
Dopaminergic Degeneration in Ventral
Striatum in Early Parkinson’s Disease Silvia
Caminiti, Damiano Baroncini, Leonardo
Iaccarino, Valentino Bettinardi, Maria
Volonté, Daniela Perani
P6.070 Disrupted Functional
Connectivity of Amygdala-based Networks
in Parkinson's Disease Patients with Severe
Olfactory Dysfunction Hirohisa Watanabe,
Bagarinao Epifanio, Noritaka Yoneyama,
Kazuhiro Hara, Kazuya Kawabata, Kazunori
Imai, Masaaki Hirayama, Takashi Tsuboi,
Gen Sobue
Resting Connectivity
Functional MRI in Understanding Cognitive
Impairment in Parkinson's Disease Nina
Browner
Functional Abnormalities in Parkinson’s
Disease Patients with Freezing of
Gait Elisabetta Sarasso, Federica Agosta,
Elisa Canu, Maria Antonietta Volontè, Lidia
Sarro, Sebastiano Galantucci, Roberto Gatti,
Andrea Falini, Giancarlo Comi, Massimo
Filippi
P6.073 Unilateral Microelectrode
Mapping to Guide Bilateral Deep Brain
Stimulation Electrode Implantation: A
Retrospective Study of DBS Programming
Outcomes Todd Herrington, Joshua Simon,
Emad Eskandar
P6.074
Increased Activation of the
Frontal Lobe Is Associated with Freezing of
Gait in Patients with Parkinson's Disease:
An FNIRS Study Inbal Maidan, Hagar
Bernad-Elazari, Eran Gazit, Anat Mirelman,
Jeffrey Hausdorff, Nir Giladi
P6.075
Posterior Lentiform Nucleus
Hyperperfusion as a Diagnostic Marker
for Parkinson’s Disease—a Pseudocontinuous Arterial Spin Labeling Perfusion
Weighted MRI Study Chaorui Huang,
Jonathan Dyke, Melissa Nirenberg, Panida
Piboolnurak, Henning Voss, Apostolos
Tsiouris, Claire Henchcliffe, William Severt,
M. Beal
P6.076
Elevated Thalamic GABA
Levels in Parkinson Disease, Measured by
3 Tesla MR Spectroscopy, Correlate with
Disease Severity Sarah Zauber, Shalmali
Dharmadhikari, Sandy Snyder, Ulrike Dydak
P6.077 Ventral Striatum Involvement
in Non Manifesting Carriers of the G2019S
Mutation in the LRRK2 Gene Avner Thaler,
Anat Mirelman, Rick Helmich, Bart van
Neunen, Tanya Gurevich, Karen Marder,
Susan Bressman, Avi Orr-Urtreger, Bastiaan
Bloem, Talma Hendler, Nir Giladi
Movement Disorders:
Imaging Techniques
P6.078 Striatal Dopaminergic
Functioning in Hereditary Spastic
Paraplegia Type 11 Ingrid De Vasconcellos,
Alberto Martinez, Katiane Raisa Servelhere,
Celso Ramos, Iscia Lopes-Cendes, Bárbara
Amorim, Marcondes Franca, Jr.
P6.079
Investigation of the
Transcallosal Ventral Premotor
Connection Jung Park, Mark Hallett
P6.080 Impaired Sensorimotor
Feedback in Functional Movement
Disorder: A Resting State FMRI
Study Carine Maurer, Silvina Horovitz,
Kathrin LaFaver, Mark Hallett
P6.081 Loss of Phosphodiesterase
10A (PDE-10A) Signalling Is Associated
with Progression and Severity in Patients
with Parkinson’s Disease Flavia Niccolini,
Thomas Foltynie, Tiago Reis Marques,
Sridhar Natesan, Shitij Kapur, Nils Muhlert,
Andri Tzortzi, Eugenii Rabiner, Roger Gunn,
Paola Piccini, Marios Politis
111
Thursday
April 23
7:30 a.m.–12:00 p.m.
Poster Session VI
P6.082 Thalamic GABAa Receptor
Expression Is Inversely Correlated with
Axial Motor Impairments in Parkinson
Disease Nicolaas Bohnen, Kirk Frey, Vikas
Kotagal, Robert Koeppe, Peter Scott, Roger
Albin, Martijn Muller
P6.083 Abnormal High Iron Deposition
in the Central Olfactory System in Earlystage Parkinson's Disease Jianli Wang,
Qing Yang, Thyagarajan Subramanian
P6.084 Cortical Distinctions
in Parkinson Disease Patients with
Predominant Gait Dysfunction Daniel
Claassen, Herb Joshua, David Isaacs, Olivia
Roman, Peter Hedera, Benoit Dawant,
Landman Bennett, David Zald, Joseph
Neimat, Manus Donahue, Scott Wylie,
Swati Rane
P6.085 Parkinson’s Disease (PD)
Patient Experience with the ClearPoint(TM)
Interventional MRI (iMRI)-guided Method
for Placement of Deep Brain Stimulation
(DBS) Leads Sara LaHue, Maya Katz,
Nicholas Galifianakis, Marta San Luciano,
Nathan Ziman, Sarah Wang, Caroline
Racine, Philip Starr, Paul Larson, Jill Ostrem
Neuromuscular Disease:
Imaging and Biomarkers
P6.086 Can Ulnar Nerve Cross-
7:30 a.m.–12:00 p.m.
P6.091 Structural MRI Reveals
Distributed Cortical Thinning in Patients
with Pure Lower Motor Neuron Disease
Variants Edoardo Gioele Spinelli, Federica
Agosta, Pilar Ferraro, Nilo Riva, Paola
Valsasina, Massimiliano Copetti, Evelina
Prudente, Adriano Chio, Sandro Iannaccone,
Vincenzo Silani, Andrea Falini, Giancarlo
Comi, Massimo Filippi
P6.092 Muscle Magnetic Resonance
Imaging in Spinal Muscular Atrophy 3:
Specific Pattern and Progression Hacer
Durmus, Piraye Serdaroglu, Yesim Parman,
Memduh Dursun, Feza Deymeer
P6.093 Distinctive Magnetic
Resonance Imaging Findings of Muscle
in Duchenne Muscular Dystrophy Kiran
Polavarapu, Manjunath Poojar, Preethish
Veeramani, Rose Dawn Bharath,
Atchayaram Nalini, Ravinder Jeet Singh,
Priya Treesa Thomas
P6.094 Prognostic Value of 18F-FDG
PET/CT in MG Patients Without Any
Thymic Mass Detected in CT Scan: Caseseries of 14 Patients Guillaume Baille,
Claude Hossein-Foucher, Helene Zephir,
Patrick Vermersch, Arnaud Lacour
ALS: Imaging, Biomarkers, and
Clinical Testing
sectional Area Replace Electrodiagnostic
Studies in the Diagnosis of Ulnar Nerve
Entrapment? Shumaila Sultan, Jonas
Vanags, Michael Rosario, Lisa HobsonWebb
P6.095 The NIH C9ORF72 ALS-
P6.087 Cortical Thinning and
P6.096 Quantitative MRI of the
White Matter Tract Damage in
Relation to Cognition in Motor Neuron
Diseases Federica Agosta, Pilar Ferraro,
Edoardo Spinelli, Elisa Canu, Nilo Riva,
Massimiliano Copetti, Evelina Prudente,
Adriano Chio, Sandro Iannaccone, Andrea
Falini, Giancarlo Comi, Massimo Filippi
P6.088 The Diagnostic Value of
Cortical Thickness Measures and Diffusion
Tensor MRI Metrics in the Clinical
Phenotypes of MND Pilar Maria Ferraro,
Federica Agosta, Edoardo Spinelli, Nilo
Riva, Massimiliano Copetti, Paola Valsasina,
Evelina Prudente, Adriano Chio, Sandro
Iannaccone, Vincenzo Silani, Andrea Falini,
Giancarlo Comi, Massimo Filippi
P6.089 Bimelic Amyotrophy:
A Phenotypic Variant of Monomelic
Amyotrophy /Hirayama Disease
Having Identical Features on MR
Imaging Preethish Kumar Veeramani,
Atchayaram Nalini, Kiran Polavarapu,
Jitender Saini, Ravinder Singh
P6.090 Chronic Sensory
Deafferentation Results in Cerebellar
and Basal Ganglia Structural
Abnormalities Alberto Martinez, Raphael
Casseb, Jean Paiva, Brunno Campos,
Guilherme Beltramini, Gabriela Castellano,
Anamarli Nucci, Marcondes Franca, Jr.
112
FTD Study: Correlation of Clinical and
Quantitative Imaging Measures Mary
Kay Floeter, Olivia Schanz, Laura Danielian,
Laura Braun, Bryan Traynor, Devin Bageac
Spinal Cord Is a Reliable Marker to Monitor
Disease Progression in ALS Lucas Branco,
Milena de Albuquerque, Helen Andrade,
Anamarli Nucci, Felipe Bergo, Marcondes
Franca, Jr.
P6.097 Utility of Diffusion Tensor
Imaging in Amyotrophic Lateral Sclerosis:
Potential Biomarker and Cognitive Profile
Association Marcelo Rugiero, Marcelo
Chaves, Mariela Bettini, Maria Fernandez,
Juan Ignacio Rojas, Maria Garcia Basalo,
Edgardo Cristiano, Angel Golimstok
P6.098 Frequent Hepatic Steatosis
in ALS: Implication for Systemic
Involvement Yuishin Izumi, Naoko
Takamatsu, Naoki Muguruma, Kazuhiro
Ukimoto, Susumu Nishio, Masaya Oda,
Hiroyuki Nodera, Ryuji Kaji
P6.099 Elevated Creatine Kinase
Is Associated with a Better Prognosis
in Patients with Amyotrophic Lateral
Sclerosis Muhammad Rafiq, Ellen Lee,
Christopher McDermott, Pamela Shaw
P6.100
Urate Levels Predict Disease
Progression and Survival in Amyotrophic
Lateral Sclerosis (ALS) Katharine
Nicholson, Sabrina Paganoni, Amy Shui,
David Schoenfeld, Alexander Sherman,
James Berry, Merit Cudkowicz, Nazem
Atassi
P6.101
Are Arterial Hypertension
and Diabetes Modifiers of ALS Phenotype
and Outcome? A Population-based
Study Andrea Calvo, Cristina Moglia,
Antonio Canosa, Davide Bertuzzo, Francesco
Galmozzi, Paolo Cugnasco, Marinella
Clerico, Stefania De Mercanti, Enrica
Bersano, Stefania Cammarosano, Antonio
Ilardi, Umberto Manera, Riccardo Sideri,
Kalliopi Marinou, Edo Bottacchi, Fabrizio
Pisano, Roberto Cantello, Letizia Mazzini,
Gabriele Mora, Adriano Chio
P6.102
Canine Degenerative
Myelopathy—an Emerging Disease Model
for ALS Raghav Govindarajan, Joan Coates
P6.103
Is Worse Prognosis in Older
ALS Patients More Than Just a Matter of
Years? Stacy Rudnicki, Tawfiq Al-Lahham,
Betul Gundogdu, Kaustubh Limaye, Zabeend
Mahuwala, Hillary Williams
P6.104
Neuroprotective Effect
of Bexarotene in the SOD1G93A
Mouse Model of Amyotrophic Lateral
Sclerosis Javier Riancho, Maria Ruiz-Soto,
Maria T Berciano, Jose' Berciano, Miguel
Lafarga
P6.105
Reduction in Cerebral
Antioxidant, Glutathione (GSH), in Patients
with ALS: A Preliminary Study In Young
Choi, Phil Lee, Jeffrey Statland, April McVey,
Mazen Dimachkie, William Brooks, Richard
Barohn
MS and CNS Inflammatory
Diseases: Neuroimaging
P6.106
Cortical Lesions of Multiple
Sclerosis: Signal, Morphological and
Vascular Abnormalities at Ultra High Field
(7T) MRI Yulin Ge, Ilya Kister, Sanjeev
Chawla, Tim Sinnecker, Joseph Herbert,
Friedemann Paul, Jens Wuerfel
P6.107
MRI Reveals Connectivity
of Cortical Lesions to White Matter
Lesions in Multiple Sclerosis Jan-Mendelt
Tillema, Stephen Weigand, John Port,
Jayawant Mandrekar, Yunhong Shu, Claudia
Lucchinetti, Istvan Pirko
P6.108
Diffusion Tensor Imaging
Abnormalities in Multiple Sclerosis
Cortical Lesions and Normal-appearing
Grey Matter and Their Associations with
Disability Özgür Yaldizli, Matteo Pardini,
Varun Sethi, Nils Muhlert, Zheng Liu, Tarek
Yousry, Daniel Tozer, Rebecca Samson,
Claudia Wheeler-Kingshott, David Miller,
Declan Chard
P6.109
Relationship Between RNFL
Thickness and Brain Cortical Lesions
in Primary-progressive MS Christian
Cordano, Maria Petracca, Phillip Rubin,
Colleen Farrell, Aaron Miller, Fred Lublin,
Matilde Inglese
P6.110
Different Stages of Acute
Multiple Sclerosis Lesions Demonstrated
on R2* and Quantitative Susceptibility
Mapping Derived from Gradient Echo (GRE)
MRI Lijie Tu, Yan Zhang, Ajay Gupta, Thanh
Nguyen, Susan Gauthier, Yi Wang
P6.111
Optimal Detection of
Infratentorial Lesions with a Combined
Dual-echo Sequence: “P2T” Maria Gaitan,
Paulina Yañes, Pascal Sati, Carlos Romero,
Daniel Reich, Jorge Correale
P6.112
White Matter Lesion Central
Veins Can Distinguish MS from Ischemic
Lesions, Irrespective of 3T MRI T2*
Sequence Amal Samaraweera, Paul
Morgan, Ian Driver, Rob Dineen, Nikolaos
Evangelou
P6.113
Exploring Phase Contrast
Mechanisms of Multiple Sclerosis Lesions
at 7T Roland Henry, Wei Bian, Yan Li,
Regina Schlaeger, Alyssa Zhu, Angela
Jakary, David Leppert, Nicolas Seneca,
Sarah Nelson, Bruce Cree
P6.114
MR Frequency Differentiates
MS Lesion Severity Shannon Kolind,
Vanessa Wiggermann, Samantha Tan,
Enedino Hernández Torres, David Li, Nicolas
Seneca, David Leppert, Irene Vavasour,
Anthony Traboulsee, Alexander Rauscher
P6.115
Different Patterns of Lesion
Formation in Early and Late Stages of
Multiple Sclerosis Revealed by Phase
Imaging at 7T Ivan Bozin, Yulin Ge, Joseph
Kuchling, Petr Dusek, Sanjeev Chawla, Lutz
Harms, Klemens Ruprecht, Thoralf Niendorf,
Friedemann Paul, Ilya Kister, Tim Sinnecker,
Jens Wuerfel
P6.116
Improved Specificity
of Multiple Sclerosis Lesion
Segmentation from Dual-sensitivity MRI
Morphometry Dominik Meier, Nicola
Moscufo, Michele Cavallari, Subhash
Tummala, Charles Guttmann, Howard
Weiner, Rohit Bakshi
P6.117
Increased Prevalence of
Contrast Enhancing Lesions in Multiple
Sclerosis Migraine Patients Elliot Graziano,
Jesper Hagemeier, Bianca WeinstockGuttman, Sirin Ghandi, Deepa Ramasamy,
Robert Zivadinov
P6.118
MRI Detection of Hypointense
Brain Lesions in Patients with Multiple
Sclerosis: T1 Spin Echo Vs. Gradient
Echo Sheena Dupuy, Shahamat Tauhid,
Gloria Kim, Renxin Chu, Subhash Tummala,
Shelley Hurwitz, Rohit Bakshi
P6.119
Differentiating Iron and
Non-iron Related Pathological Features of
Multiple Sclerosis Lesions Using Ultra High
Field MRI Sanjeev Chawla, Ilya Kister, Tim
Sinnecker, Jean Brisset, Petr Dusek, Joseph
Herbert, Friedemann Paul, Jens Wuerfel,
Yulin Ge
P6.120
The Role of Asymptomatic
Spinal Lesions in Predicting Future Attacks
in Multiple Sclerosis Patients in a Real
Word Clinical Setting Chiara Zecca,
Gianna Carla Riccitelli, Emanuele Pravatà,
Alessandro Cianfoni, Claudio Staedler, Carlo
Cereda, Giulio Disanto, Letizia Panicari,
Claudio Gobbi
P6.121
1-H MRSI in Patients
with Relapsing Multiple Sclerosis at 7
Tesla Roland Henry, Yan Li, Alyssa Zhu,
David Leppert, Nicolas Seneca, Sarah
Nelson, Bruce Cree
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VI
P6.122
Blood-based Transcriptomic
and Clinical/MRI Measures Correlate in
Primary-progressive MS Maria Petracca,
Charalambos Athanassiou, Maria Chikina,
Colleen Farrell, Michelle Fabian, Fred Lublin,
Matilde Inglese, Christophe Gerald
P6.123
The Putative Functional
SCN10A Gene Variant Predicts Functional
Status and Cerebello-thalamic Circuit
Integrity in Multiple Sclerosis Arash
Nazeri, Tina Roostaei, Shokufeh Sadaghiani,
Mohammad Ali Sahraian
P6.124
Clusters of Focal Cortical
Thinning in Relapsing-remitting Multiple
Sclerosis Lior Or Bach, Yael Nissan,
Shmuel Miron, Anat Achiron
P6.125
Improved Detection of
Microstructural Damage in Normal
Appearing Gray and White Matter in
Relapsing Remitting Multiple Sclerosis
by Applying GRASE Sequence Doriana
Landi, Angela Daniela Coniglio, Domenico
Lupoi, Anna Ghazaryan, Emma Falato,
Mariamaddalena Filippi, Stefano Vollaro
P6.126
Association of Multiple
Sclerosis Normal Appearing White Matter
Abnormality with Periventricular Location
and Secondary Progression Declan Chard,
Zheng Liu, Matteo Pardini, Oezguer Yaldizli,
Varun Sethi, Nils Muhlert, Claudia WheelerKingshott, Rebecca Samson, David Miller
P6.127
Disruption of Hippocampal
Resting State Functional Connectivity in
MS: Relation with WM Lesions and Clinical
Measures Gianna Carla Riccitelli, Maria
Rocca, Paola Valsasina, Emanuele Pravatà,
Marta Radaelli, Filippo Martinelli Boneschi,
Paolo Preziosa, Claudio Gobbi, Andrea Falini,
Giancarlo Comi, Massimo Filippi
P6.128
Susceptibility Contrast in High
Field MRI of Multiple Sclerosis Brains as
a Function of Tissue Iron, Myelin, Calcium
and Axon Content Simon Hametner,
Emma Boyd, Siddharama Pawate, Vasiliki
Ikonomidou, Seth Smith, Hans Lassmann,
Welch Brian, Francesca Bagnato
P6.129
The Relationship of a Multiparameter MRI Measure of Motor Network
Efficiency with Disability in Multiple
Sclerosis Matteo Pardini, Özgür Yaldizli,
Varun Sethi, Nils Muhlert, Zheng Liu,
Rebecca Samson, Daniel Altmann, Maria
Ron, Claudia Wheeler-Kingshott, David
Miller, Declan Chard
P6.130
Larger Intracranial Volume
Affords Reserve Against Disability
in Relapsing-remitting Multiple
Sclerosis: Implications for Clinical Trial
Research James Sumowski, Maria Rocca,
Victoria Leavitt, Alessandro Meani, Sarlota
Mesaros, Jelena Drulovic, Paolo Preziosa,
Giancarlo Comi, Massimo Filippi
P6.131
The Use of Diffusion Tensor
Imaging (DTI) as an Outcome Measure
in Progressive Multiple Sclerosis Clinical
Trials Danish Ghazali, Blake Snyder, Ava
Ganik, William Kelley, Govind Nair, Bibiana
Bielekova
P6.132
Relapsing Multiple Sclerosis
Exhibits Reduced Normal Appearing White
Matter Glutamate Levels Julia Schubert,
Erin MacMillan, Roger Tam, David Leppert,
Nicolas Seneca, Eduardo Vianna, Anna
Dzyakanchuk, Shannon Kolind, Anthony
Traboulsee
P6.141
MS and CNS Inflammatory
Diseases: MRI Measurements of
Cognition and Fatigue in MS
P6.142
P6.133
Consistent Decreased
Functional Connectivity Among
the Main Cortical and Subcortical
Functional Networks in MS: Relationship
with Disability and Cognitive
Impairment Massimo Filippi, Paola
Valsasina, Laura Vacchi, Victoria Leavitt,
Giancarlo Comi, Andrea Falini, Maria Rocca
P6.134
Processing Face
Encoding in Multiple Sclerosis: A FMRI
Investigation Laura Vacchi, Maria Rocca,
Gianna Carla Riccitelli, Mariaemma
Rodegher, Vittorio Martinelli, Francesca
Possa, Andrea Falini, Giancarlo Comi,
Massimo Filippi
P6.135
Regional White Matter
Abnormalities and Cognitive Impairment
in MS: A Multicenter TBSS Study Alvino
Bisecco, Maria Rocca, Elisabetta Pagani,
Olga Ciccarelli, Christian Enzinger, Antonio
Gallo, Hugo Vrenken, Maria Laura Stromillo,
Tarek Yousry, Franz Fazekas, Gioacchino
Tedeschi, Frederik Barkhof, Nicola De
Stefano, Massimo Filippi
P6.136Connectivity-based
Parcellation of the Thalamus in Multiple
Sclerosis and Its Implications for Cognitive
Impairment: A Multicenter Study Alvino
Bisecco, Maria Rocca, Elisabetta Pagani,
Laura Mancini, Christian Enzinger, Antonio
Gallo, Hugo Vrenken, Maria Laura Stromillo,
Massimiliano Copetti, David Thomas, Franz
Fazekas, Gioacchino Tedeschi, Frederik
Barkhof, Nicola De Stefano, Massimo Filippi
P6.137
White and Gray Matter
Correlates of Executive Functions and
Social Cognition Impairment in MS Blas
Couto, Diana Bruno, Lucas Sedeño,
Vladimiro Sinay, Fatima Pagani Cassara,
Sol Esteves, Facundo Manes, Maria Roca,
Agustin Ibañez
P6.138
Hippocampal-related Memory
Network in Multiple Sclerosis: A Structural
Connectivity Analysis Sara Llufriu, Maria
Rocca, Elisabetta Pagani, Gianna Carla
Riccitelli, Bruno Colombo, Mariaemma
Rodegher, Andrea Falini, Giancarlo Comi,
Massimo Filippi
P6.139
Association Between
Magnetic Resonance Imaging and
Cognitive Outcomes in Early Multiple
Sclerosis Bardia Nourbakhsh, Julia
Nunan-Saah, Amir-Hadi Maghzi, Laura
Julian, Rebecca Spain, Daniel Pelletier,
Emmanuelle Waubant
P6.140
Effective Connectivity
Differences During an Executive Control
Task Between MS Subtypes and Healthy
Individuals Ekaterina Dobryakova, Maria
Rocca, Paola Valsasina, John DeLuca,
Giancarlo Comi, Massimo Filippi
Fast, Easy, Online Registration · AAN.com/view/AM15
New Insights on the
Pathophysiology of Fatigue in MS: A FMRI
Study of the Motor Network Gianna Carla
Riccitelli, Maria Rocca, Alessandro Meani,
Mariaemma Rodegher, Bruno Colombo,
Andrea Falini, Giancarlo Comi, Massimo
Filippi
Different MRI Measures
Predict Clinical Deterioration AND
Cognitive Impairment in MS: A 5-year
Longitudinal Study Paolo Preziosa, Maria
Rocca, Sarlota Mesaros, Massimiliano
Copetti, Melissa Petrolini, Jelena Drulovic,
Elisabetta Pagani, Massimo Filippi
P6.143
Gray Matter Volume
Correlates with Information Processing
as Measured by the Symbol Digit
Modalities Test (SDMT) but Not with
Physical Disability as Measured by the
Expanded Disability Status Scale (EDSS)
in Patients with Secondary Progressive
Multiple Sclerosis (SPMS): Analysis of
Baseline Correlations from the ASCEND
Natalizumab Study Raj Kapoor, Douglas
Arnold, Aaron Miller, Mark Freedman,
Myla Goldman, Hans-Peter Hartung, Eva
Havrdova, Douglas Jeffery, Finn Sellebjerg,
Carmen Castrillo-Viguera, Yun Chen, Diego
Cadavid, Daniel Mikol
P6.144
Contribution of Cortical
Lesions to Cognitive Dysfunction in the
PPMS Population: Comparison of Double
Inversion Recovery (DIR) and Phase
Sensitive Inversion Recovery (PSIR)
Sequences Using a 3 Tesla MRI Asaff
Harel, Maria Petracca, Yadira Bencosme,
Ilana Katz Sand, Fred Lublin, Matilde
Inglese, Antonia Ceccarelli
P6.145
A Longitudinal Evaluation
of Cerebellar Grey-matter Damage and
Its Functional Significance in Multiple
Sclerosis Alfredo Damasceno, Benito
Damasceno, Fernando Cendes
P6.146
Remapping of FMRI
Functional Connectivity During Resting
State in Multiple Sclerosis Represents
Compensatory Mechanisms Sue-Jin Lin,
Aiping Liu, Jane Wang, David Leppert,
Nicolas Seneca, Eduardo Vianna, Anna
Dzyakanchuk, Shannon Kolind, Anthony
Traboulsee, Martin McKeown
P6.147
Localising the Lesion
in Fatigue—Insights from Primary
Progressive Multiple Sclerosis Luke
Canham, Nick Kane, Agyepong Oware,
Peter Walsh, Kelly Blake, Jenny Homewood,
Daniel Kent, Robert Dineen, Paul Morgan,
Evangelou Nikos, Amal Samaraweera,
Jonathan Witherick, Kirsty Inglis, David
Cottrell
P6.148
Posterior Corpus Callosum
Atrophy Is Correlated with Worse
Performance on Inter-hemispheric Speed
of Processing Task in Unimpaired MS
Patients Joshua Bacon, Andrew Kim,
Tamar Bacon, Ilya Kister, Yvonne Lui, Joseph
Herbert
P6.149
T1 Lesion Load at Early MS
Stages Does Not Influence Cognitive
Performances Five Years Later Natalia
Moll, Françoise Reuter, Karine Baumstarck,
Wafaa Zaaraoui, Maxime Guye, Jean
Philippe Ranjeva, Bertrand Audoin, Jean
Pelletier
P6.150
Microstructural White Matter
Damage in Fatigued Multiple Sclerosis
Patients: A DTI-TBSS Study Alessandro
D'Ambrosio, Alvino Bisecco, Giuseppina
Caiazzo, Renato Docimo, Luigi Lavorgna,
Mario Cirillo, Fabrizio Esposito, Simona
Bonavita, Gioacchino Tedeschi, Antonio
Gallo
P6.151
Precipitation of Cognitive
Fatigue Modulates Brain Resting-state
Functional Connectivity After Effort in
Multiple Sclerosis Patients Claudio Gobbi,
Emanuele Pravatà, Gianna Carla Riccitelli,
Carlo Sestieri, Massimo Caulo, Alessandro
Cianfoni, Chiara Zecca
P6.152
The Effects of
Natalizumab and Fingolimod on Clinical,
Neuropsychological, and MRI Measures
in Relapsing Remitting Multiple Sclerosis:
A One-year Comparative Study Paolo
Preziosa, Maria Rocca, Gianna Carla
Riccitelli, Mariaemma Rodegher,
Massimiliano Copetti, Lucia Moiola,
Francesco Mele, Andrea Falini, Giancarlo
Comi, Massimo Filippi
MS and CNS Inflammatory
Diseases: MRI Atrophy
Measurements and Correlations
P6.153
Gender Differences in Brain
Volume of Patients with Multiple Sclerosis
Across Disease Phenotypes Navid
Seraji-Bozorgzad, Fen Bao, Reena Pullukat,
Michael Aronov, Jasmin Bhangu, Carla
Santiago Martinez, Jessica ChorosteckiVigrass, Christina Caon, Imad Zak, Omar
Khan
P6.154
Whole Brain Volume
Measurements in Multiple Sclerosis: Crosssectional Data Comparison Between Three
Methods Chenyu Wang, Heidi Beadnall,
Sean Hatton, Giovanni Bader, Davorka
Tomic, Diego Silva, Michael Barnett
P6.155
Comparison of 1.5 Versus
3 Tesla MRI Scanner in Quantification
of Brain Atrophy in MS Andreas
Lysandropoulos, Annemie Ribbens, Saurabh
Jain, Anke Maertens, Wim Van Hecke,
Nicolas Mavroudakis, Julie Absil, Thierry
Metens, Philippe David
P6.156
Whole Brain Volume
Measured from 1.5T Vs. 3T MRI in Healthy
Subjects and Patients with Multiple
Sclerosis Renxin Chu, Shahamat Tauhid,
Bonnie Glanz, Brian Healy, Gloria Kim, Vinit
Oommen, Fariha Khalid, Mohit Neema,
Rohit Bakshi
P6.157
Correlation of Regional Brain
Atrophy with Clinical Scores in Multiple
Sclerosis Alaleh Raji, Gerhard Winkler,
Lothar Spies, Roland Opfer
P6.158
Medial Thalamic Local
Functional Connectivity Is Altered in the
Setting of Thalamic Atrophy in Multiple
Sclerosis Kelly Wong, Sean Tobyne,
Amanda Johnson, Lance Shaull, Eric
Klawiter
P6.159
Optic Nerve Cross-sectional
Area Measurement with High-resolution,
Isotropic MRI in Optic Neuritis Katherine
Gao, Winston Liu, Govind Nair, Irene
Cortese, Henry McFarland, Noa Raz, Netta
Levin, Bradley Katz, Daniel Reich
113
Thursday
April 23
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Session VI
P6.160
Long-term Treatment Effect
of Multiple Sclerosis Therapeutics
on Regional and Global Brain Atrophy
Cross-sectional Analysed by Quantitative
MRI Alaleh Raji, Gerhard Winkler, Lothar
Spies, Roland Opfer
P6.161
High Field Spinal Cord MRI in
Multiple Sclerosis: Towards Resolving the
Clinico-radiological Paradox Siddharama
Pawate, Adrienne Dula, Robert Barry,
Richard Dortch, Bailey Lyttle, Shilpa Reddy,
Megan Barry, Subramaniam Sriram, John
Gore, Seth Smith
P6.162
Gray Matter Atrophy
and Clinical Evolution in Progressive
MS Rezwan Ghassemi, Aaron Miller,
Stephen Krieger, Jonathan Howard, Claire
Riley, Yadira Bencosome, Fred Lublin,
Matilde Inglese
P6.163
Clinical Evaluation of Brain and
Cord Atrophy in Multiple Sclerosis Luisa
Vuolo, Govind Nair, Nadia Biassou, Nicholas
Patronas, Winston Liu, Dewey Blake, Joan
Ohayon, Irene Cortese, Daniel Reich
P6.164
Validation of Routine Highresolution 3T MRI Morphometry in Multiple
Sclerosis Subhash Tummala, Fariha Khalid,
Nicola Moscufo, Michele Cavallari, Rohit
Bakshi, Charles Guttmann, Howard Weiner,
Dominik Meier
P6.165
Early Spinal Cord MRI
Abnormalities Are Associated with
MS-related Disability Five Years After
a Clinically Isolated Syndrome Wallace
Brownlee, Patricia Alves Da Mota, Ferran
Padros, Josephine Swanton, Katherine
Miszkiel, Daniel Altmann, Sebastien
Ourselin, Claudia Wheeler-Kingshott, Olga
Ciccarelli, David Miller
P6.166
Spinal Cord Atrophy
as a Primary Outcome Measure in
Primary Progressive Multiple Sclerosis
Neuroprotective Trials Niamh Cawley,
Khaled Abdel-Aziz, Torben Schneider, Daniel
Altmann, Claudia Wheeler-Kingshott, David
Miller, Alan Thompson, Olga Ciccarelli
P6.167
Spinal Cord Atrophy and
Clinical Disability in Primary-progressive
MS: A 1-year Follow-up Study Serena
Ruggieri, Maria Petracca, Colleen Farrell,
Jonathan Howard, Claire Riley, Michelle
Fabian, Fred Lublin, Matilde Inglese
P6.168
Spinal Cord Lesions and
Relationship to Spinal Cord Atrophy and
Disability in Multiple Sclerosis Navid
Seraji-Bozorgzad, Fen Bao, Evanthia
Bernitsas, Carla Santiago Martinez, Anna
Piasecki, Christina Caon, Omar Khan
P6.169
T1- Vs. T2-based MRI
Measures of Spinal Cord Volume in Healthy
Subjects and Patients with Multiple
Sclerosis Gloria Kim, Fariha Khalid, Vinit
Oommen, Shahamat Tauhid, Renxin Chu,
Mark Horsfield, Brian Healy, Rohit Bakshi
P6.170
A Longitudinal Study of
Cerebral Gray Matter Volume in Patients
Receiving Natalizumab for Multiple
Sclerosis Shahamat Tauhid, Alicia Chua,
Brian Healy, James Stankiewicz, Howard
Weiner, Rohit Bakshi
114
7:30 a.m.–12:00 p.m.
P6.171
Early Clinical and MRI
Predictors of Different Disability Outcomes
in Multiple Sclerosis Patients over the
10 Years Interval Dana Horakova, Lukas
Sobisek, Jan Krasensky, Tomas Uher,
Tomas Kalincik, Zdenek Seidl, Eva Havrdova,
Manuela Vaneckova
Aging, Dementia, Cognitive,
and Behavioral Neurology:
Neuroimaging and Practice
Guidelines
P6.172
Does Dorsal Striatum Mediate
Stimulus-response Learning or Decision
Making? Penny MacDonald, Nole Hiebert,
Adrian Owen, Ken Seergobin
P6.173
Serial Imaging with
[11C]PBR28 Suggests Increased
Neuroinflammation During the Progression
of Alzheimer’s Disease William Kreisl, Chul
Hyoung Lyoo, Monica Wei, Joseph Snow,
Kimberly Jenko, Cheryl Morse, Sami Zoghbi,
Victor Pike, R Turner, Robert Innis
P6.174
Risk Factors, Consequences
and Rating Methodology: Enlarged
Virchow Robin Spaces in Brain MRIs in
the Framingham Study Nikita Jain, Sudha
Seshadri, Jose Romero, Charles DeCarli,
Alexa Beiser
P6.175
Argentina- Alzheimer’s
Disease Neuroimaging Initiative (ArgADNI): Clinical Characterization Maria
Russo, Patricio Chrem Mendez, Marcos
Fernandez Suarez, Federico Nahas, Gabriela
Cohen, Jorge Campos, Deborah Gustafson,
Salvador Guinjoan, Ezequiel Surace, Silvia
Vazquez, Silvia Vazquez, Gustavo Sevlever,
Ricardo Allegri
P6.176
Functional Connectivity
of the Claustrum in Mild Cognitive
Impairment and the Impact of the ApoE
ε4 Allele Matteo De Marco, Annamaria
Vallelunga, Davide Duzzi, Francesca
Meneghello, Annalena Venneri
P6.177
Sex Differences in the
Relationship Between Hippocampal
Volume and Verbal Memory
Performance Erin Sundermann, Anat
Biegon, Leah Rubin, Richard Lipton, Susan
Landau, Pauline Maki
P6.178
The Dementia Factor: A
Retrospective Analysis of Care of Patients
with Dementia in Tertiary Medical
Center Riddhi Patira, S. Ausim Azizi
P6.179
Does DSM-5 Change Who
Gets Diagnosed with Alzheimer Disease,
and Who’s Checking? Joel Shenker, Kunal
Bhatia, Jithendhar Kandimalla, Anant
Wadhwa
P6.180
Who Uses the Datasupported, AAN Practice Parameters
for Detecting and Diagnosing Alzheimer
Disease, and How Often? Joel Shenker,
Kunal Bhatia, Jithendhar Kandimalla, Anant
Wadhwa
Aging, Dementia, Cognitive, and
Behavioral Neurology: Dementia:
Psychosocial Aspects
P6.181
Effectiveness of Reality
Orientation in the Treatment of Alzheimer’s
Disease Carlos Camargo, Filipe Justus,
Giuliano Retzlaff
P6.182
Dementia Care Training
for Primary Care Providers: Project
ECHO™ Janice Knoefel, Carla Herman
P6.183
City and Rural Driving
Performance in Healthy Controls, MCI, and
AD Patients: Preliminary Results from a
Driving Simulation Experiment with the Use
of Distraction Alexandra Economou, Mary
Kosmidis, Ion Beratis, Nikolaos Andronas,
George Yannis, Sokratis Papageorgiou
P6.184
Subjective Cognitive
Complaints and Vehicle Driving Diego
Nadile, Maria Gonzalez Toledo, Fatima
Pagani Cassara, Agustina Tamargo,
Alejandro Thomson, Santiago O´Neill
P6.185
Coping and Distress and
Risk of Dementia in Older Adults with
Amnestic Mild Cognitive Impairment Julie
Jiang, Mindy Katz, Robert White, Molly
Zimmerman, Mimi Kim, Richard Lipton
P6.186
Motorway Driving
Performance in Healthy Controls, MCI, and
AD Patients: Preliminary Results from a
Driving Simulation Experiment Alexandra
Economou, Ion Beratis, Nikolaos Andronas,
John Papatriantafyllou, George Yannis,
Sokratis Papageorgiou
P6.187
An Inverted U-shaped
Dose-response Curve for Aerobic
Exercise Intensity Associated with
Improved Cognitive Function in an Elderly,
Community-dwelling Cohort Keith
Albrektson, Sarah Tarrant, Amanda Pursell,
Dasha Kenlan, Andrew Welleford, Gregory
Jicha
P6.188
SOCIABLE: A Comprehensive
ICT Cognitive Training Programme
for Healthy and Cognitively Impaired
Elderly Paraskevi Sakka, Eva Ntanasi,
Panagiota Zoi, Faidra Kalligerou, Stelios
Pantelopoulos
P6.189
Individualized Neuro-cognitive
Rehabilitation Can Reverse Cognitive
and Memory Impairment Irrespective of
Etiology: Prospective Pilot Study Suresh
Kumar, Jitendra Kumar, Ajay Jawahar,
Monika Kumar
P6.191
Tractography Activation
Patterns in Dorsolateral Prefrontal Cortex
Suggest Better Clinical Responses in Deep
Brain Stimulation (DBS) of the Anterior
Limb of the Internal Capsule and Nucleus
Accumbens (ALIC-NA) for Obsessivecompulsive Disorder (OCD) Christian
Hartmann, J. Lujan, Ashutosh Chaturvedi,
Wayne Goodman, Michael Okun, Cameron
McIntyre, Ihtsham Haq
P6.192
Attachment Style as a
Predictor for the Effects of Oxytocin on
Social Cognition Katie Hsih, Brandon
Chuang, Charltien Long, Jennifer Akazawa,
Sophia Vinogradov, Joshua Woolley
P6.193
Behavioral Profiles of
Cutaneous T-cell Lymphoma and
Psoriasis Alan Lerner, Mansi Sethi, Joselin
Tacastacas, Timothy Wuerz, Christopher
Bailey, Philip Fastenau, Pingfu Fu, Frances
Lissemore, Christian Schenk, Kevin Cooper
P6.194
Characterization of Content
Specific Delusions After Right Hemispheric
Ischemic Stroke Natasa Dragicevic,
Michael Hoffmann
P6.195
Upper/Lower Facial
Expressions Are Dynamically Timed and
Motorically Independent Smita Gupta,
Elliott Ross
P6.196
Neural Correlates of Action
Recognition and Object Knowledge in
Neurodegenerative Disease Miguel
Santos, Ignacio Illan-Gala, Giulia Vinceti,
Maria Luisa Mandelli, Honey Hubbard,
Zachary Miller, Gil Rabinovici, Bruce Miller,
Maria Gorno Tempini
P6.197
Influence of the Affective
Valence of Visual Materials in
Recognition Among Healthy Individuals
and Patients with Alzheimer's Disease
Dementia Natalia Irrazabal, Gastón Saux,
Carolina Feldberg, Veronica Somale, Galeno
Rojas, Ignacio Demey
P6.198
Differential Apathy Profiles
in Alzheimer’s Disease and Parkinson’s
Disease Nicholas Lim, Lauren Massimo,
Whitney Fitts, Nabila Dahodwala, Murray
Grossman
P6.199
Neuropathological Substrate
of Self-conscious Emotion Deficits in
Neurodegenerative Dementia Salvatore
Spina, Virginia Sturm, Sandy Lwi, Alice
Verstaen, Marcela Otero, Lea Grinberg,
Robert Levenson, Bruce Miller, William
Seeley
Aging, Dementia, Cognitive,
and Behavioral Neurology:
Neuropsychiatry and Behavioral
Neurology
Aging, Dementia, Cognitive, and
Behavioral Neurology: Cognition
and Cognitive Assessment
P6.190
Assessment-Basic (MoCA-B): A New
Mild Cognitive Impairment Screening
Test for Illiterate and Low Educated
Elderly Parunyou Julayanont, Sookjaroen
Tangwongchai, Solaphat Hemrungrojn,
Chawit Tunvirachasakul, Kammant
Phanthumchinda, Ziad Nasreddine
Brain Structural Abnormalities
in Patients with Major Depression with
or Without Generalized Anxiety Disorder
Comorbidity Elisa Canu, Milutin Kostic,
Federica Agosta, Ana Munjiza, Pilar Ferraro,
Danilo Pesic, Massimiliano Copetti, Amir
Peljto, Dusica Lecic Tosevski, Massimo
Filippi
P6.200 The Montreal Cognitive
P6.201 The Utility of ACE-III in a
Heterogeneous Early Onset Dementia Clinic
Population Marwa Elamin, Guy Holloway,
Zubair Khan, Thomas Bak
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VI
P6.202 Comparison of Office Mental
Status Examinations to Screen Cognitive
Performance in Adults with Autism
Spectrum Disorders Bryan Woodruff, Dona
Locke, Joseph Hentz, Christopher Smith,
Yonas Geda
P6.203 Introducing a Brief Screening
a Tool for Motor Signs in Patients with
Dementia Marwa Elamin, Gary Bennett,
Alex Symonds, Survankar Pal, Sharon
Abrahams, Mario Parra, Thomas Bak, Peter
Connick
P6.204 Association Between Etiology
and Patterns of Neurocognitive Impairment
Detected with Wechsler Memory Scale
(WMS-IV) Assessment: Prospective Study
in 71 Consecutive Patients Ajay Jawahar,
Suresh Kumar, Jeffery Goins, Monika Kumar
P6.205 Semantic Memory
Impairment: A Neuropsychological
Hallmark of Late Onset Alzheimer
Disease Mathieu Ceccaldi, Sven Joubert,
Natalina Gour, Lejla Koric, Mira Didic,
Claude Guériot, Jean-Philippe Ranjeva, Eric
Guedj, Olivier Felician
P6.206 Bilingualism Does Not
Delay the Age at Onset of Dementia—a
Study from Memory Clinic in South
India Ratnavalli Ellajosyula, Jwala
Narayanan, Siddharth Ramanan, Swathy
Chandrashekar, Prerana Sabnis
P6.207 Semantic Recall Speed in
Older Adults, Mild Cognitive Impairment
and Alzheimer's Disease Frances
Lissemore, Steve Lenio, Alan Lerner, Paula
Ogrocki, Johnny Sams, Kathleen Smyth,
Curtis Tatsuoka, Wojbor Woyczynski,
Elisabeth Welter, Martha Sajatovic
P6.208 The Effect of Obesity on
Severity of Cognitive Impairment and
Neuropsychiatric Symptoms in MCI
Subjects Ashley Hannah, Ahmad Alsibai,
Andrea Bozoki
P6.209 Genetic Association Study
of Cognitive Performance Jonathan Katz,
Chuanhui Dong, Yaakov Stern, Clinton
Wright, Susan Blanton, Ralph Sacco
Aging, Dementia, Cognitive, and
Behavioral Neurology: White
Matter and Diffusion Imaging
P6.210
Alzheimer’s Disease Dementia
Involves the Corpus Callosum and the
Cingulum: A Diffusion Tensor Imaging
Study Ignacio Demey, Fernando Ventrice,
Galeno Rojas, Victoria Zubiri, Veronica
Somale
P6.211
Olfactory Identification
Deficit as a Predictor of White Matter
Tract Impairment in Alzheimer’s
Disease Matthew Woodward, Michael
Dwyer, Chaitanya Amrutkar, Robert
Zivadinov, Kinga Szigeti
P6.212
Hippocampal Mean Diffusivity
Is a Biomarker of Neuronal Injury in
Patients with Mild Cognitive Impairment
and Alzheimer´s Disease Dementia Ignacio
Demey, Fernando Ventrice, Galeno Rojas,
Ricardo Allegri, Victoria Zubiri, Veronica
Somale
P6.213
The Longitudinal Relationship
Between Inflammatory Burden and Gait
Speed Is Influenced by White Matter
Microstructural Characteristics: Secondary
Analysis of the Health ABC Study Neelesh
Nadkarni, Robert Boudreau, Oscar Lopez,
Howard Aizenstein, Stephen Kritchevsky,
Kristine Yaffe, Stephanie Studenski, Anne
Newman, Caterina Rosano
P6.214
Brain Structural Changes in
the Course of Alzheimer’s Disease Marina
Weiler, Federica Agosta, Elisa Canu,
Giuseppe Magnani, Massimiliano Copetti,
Roberto Santangelo, Monica Falautano,
Giancarlo Comi, Andrea Falini, Massimo
Filippi
P6.215
White Matter Degeneration
in Atypical Alzheimer’s Disease Francesca
Caso, Federica Agosta, Daniele Mattavelli,
Raffaella Migliaccio, Elisa Canu, Giuseppe
Magnani, Alessandra Marcone, Laura
Ferrari, Massimiliano Copetti, Monica
Falautano, Giancarlo Comi, Andrea Falini,
Massimo Filippi
P6.216
Abnormalities of the Uncinate
Fasciculus Correlate with Behavioral
Symptoms in Primary Progressive
Aphasia Lucio D'Anna, M. Mesulam,
Michel Thiebaut De Schotten, Estrid
Jakobsen, Christina Wieneke, Flavio
Dell'acqua, Emily Rogalski, Marco Catani
P6.217
Diabetes Mellitus-related
Cognitive Impairment and White Matter
Microstuctural Integrity: A Cross-sectional
Study with the Use of Diffusion Tensor
Imaging Vasileios-Arsenios Lioutas, Freddy
Alfaro-Martinez, Chen Chih Chung, WooKyoung Yoo, Vera Novak
P6.218
P6.223 Detachable Tip
P6.235 Long-term Impact of
P6.224 Rupture Arteriovenous
P6.236 IV Thrombolysis in Minor
Microcatheters for Liquid Embolization
of Brain Arteriovenous Malformations
(AVMs): A US Single Center
Experience Asif Khan, Nabeel Herial,
Mushtaq Qureshi, Gregory Sherr,
Muhammad Suri, Adnan Qureshi
Malformation Presenting as Thalamic
Hypertensive Hemorrhage Santoshi
Billakota, Nadal El-Husseini, Shahid Nimjee
P6.225 Pediatric Cavernous Sinus
Thrombosis: A Case Series and Review of
the Literature Douglas Smith, Daniel Licht,
Arastoo Vossough, Gregory Vorona
P6.226 Novel Approach to Clinico-
neuroradiological Correlation and
Prognostication in Cerebral Venous Sinus
Thrombosis Kalaimani Elango, Balaji
Nagarajan, Shankar Balakrishnan, Bhanu
Kesavamurthy, Lakshmi Ranganathan,
Cheran Elangovan, Kannan Vellaichamy
P6.227 Spontaneous Superior
Ophthalmic Vein Thrombosis: A Case
Report Karanbir Singh, Deeya Gaindh,
Ghulam Mustafa, Haris Kamal, Ashkan
Mowla
Cerebrovascular Disease and
Interventional Neurology: Acute
Thrombolysis
P6.228 Acute Ischemic Stroke in
Acute Myocardial Infarction Patients
Receiving IV Rt-PA: An Analysis of
Thrombolysis in Myocardial Infarction
(TIMI) II Trial Nauman Jahangir, Ahmed
Malik, Muhammad Afzal, Adnan Qureshi
Implementation of a Stroke Protocol on
Door to Needle Time in Administration
of Intravenous Recombinant Tissue
Plasmonigen Activator (IV-tPA) Wenzhuan
He, Zaid Al-Qudah, Weizhen Wang, Vivek
Tank, Machteld Hillen
Stroke: Using MRI Based Vessel and
Perfusion Abnormalities to Identify a
Subpopulation That May Benefit Aabha
Shah, Lawrence Latour, Tyler Brown,
Richard Benson, Amie Hsia, John Lynch,
Zurab Nadareishvili, Marie Luby
P6.237 IV Thrombolysis for
Acute Cervical Internal Carotid Artery
Occlusion Wan Yee Kong, Benjamin Tan,
Hock Luen Teoh, Raymond Seet, Bernard
Chan, Rahul Rathakrishnan, Derek Soon,
Vijay Sharma, Vijay Sharma, Leonard Yeo
Cerebrovascular Disease and
Interventional Neurology:
Thrombolysis Complications
P6.238 Neuroimaging Findings of
Post-thrombolysis Cerebral Hemorrhage in
Acute Ischemic Stroke Vivien Lee, Shawna
Cutting, Sarah Song, Laurel Cherian, James
Conners
P6.239 Prior Asymptomatic
Intraparenchymal Hemorrhage Does
Not Increase the Risk for Intracranial
Hemorrhage After Intravenous
Thrombolysis Mahmoud AbdelRazek,
Ashkan Mowla, Wendy Zimmer, Rabab
Elsadek, Noureldin Abdelhamid, Lobna
Elsadek, Katelyn Kavak, Salman Farooq,
Haris Kamal, Annemarie Crumlish, Peyman
Shirani, Robert Sawyer
Neurocognitive Changes
in High-altitude U-2 Pilots: Relationship
Between Microstructural Integrity of
White Matter Tracks and Neurocognitive
Outcomes Adam Willis, John Sladky,
David Tate, Joe Wood, Paul Sherman, Peter
Kochunov, Steve McGuire
P6.229 Impact of Off-label Use of
Cerebrovascular Disease and
Interventional Neurology: AVM
and Cerebral Venous Thrombosis
Making Early in the Academic Year Evgeny
Sidorov, Margaret Elaine Haxton, Lawrence
Gorman, David Gordon, Shuchi Chaudhary
Factors Predisposing to Hemorrhagic
Conversion of Ischemic Stroke After
Thrombolysis Ashkan Mowla, Haris Kamal,
Peyman Shirani, Robert Sawyer Jr, Marilou
Ching, Aaron McMurtray, Kelly Smith,
Ping Li, Salman Farooq, Karanbir Singh,
Mahmoud AbdelRazek, Sandhya Mehla,
Ann Marie Crumlish, Bijal Mehta
P6.219
P6.231 24 Hours Post TPA
Surveillance Head CT, What Does It Add
to Patient Care Krishna Nalleballe, Madhu
Jasti, Neville Jadeja, Sanjeeva Onteddu
P6.241 Knowledge Regarding Oral
Acute Hydrocephalus
Associated with Brainstem Microarteriovenous Malformation Janhavi
Modak, Robert Brown, Paul Schwartz,
Martin Ollenschleger
P6.220 Clinical Presentations,
Venous Drainage Patterns, and Treatment
Outcomes in Carotid Cavernous
Fistula David Altschul, Yamin Shwe,
Santiago Ortega-Gutierrez, Srinivasan
Paramasivam, Alejandro Berenstein,
Johanna Fifi
P6.221 Flow Diversion Versus
Conventional Treatment for Carotid
Cavernous Aneurysms Norman Ajiboye
P6.222 Spinal Dural Arteriovenous
Fistulas Mimicking Demyelinating
Disease Anita Tipirneni, Amer Malik,
Melissa Ortega, Dileep Yavagal
Fast, Easy, Online Registration · AAN.com/view/AM15
TPA on NIH Stroke Scale Score in Ischemic
Stroke James Anaissie, Elizabeth Waring,
Dominique Monlezun, Jr, Tara Kimbrough,
Alexander George, Alyana Samai, Sheryl
Martin-Schild
P6.230 Delay in IV TPA Decision
P6.232 Early Improvement After IV
TPA at the Largest Safety-net Hospital
in New England: The Boston Medical
Center Experience Abdullah Tawakul,
Guannan Ge, Helena Lau, Thanh Nguyen,
Jose Romero, Viken Babikian, Carlos Kase,
Hesham Masoud
P6.233 Conjugate Gaze Deviation
on CT in Patients Treated with IV-TPA
Associated with Vascular Occlusions
and Worse Outcomes Nirav Shah, Anita
Tipirneni, Nirav Bhatt, Diego Condes, Jose
Romano
P6.234 Title: CTP Mismatch Imaging
Predicts Outcome of IV-rtPA Treatment
Within the 3 Hour Window James Frey,
Carol Darbonne, Joni Clark, Kristina
Chapple, Allison Tucker, Lynn Ashby, Glynnis
Zieman
P6.240 Clinical and Laboratory
Anticoagulation Therapy Among Patients
with Stroke and Those at High Risk of
Thromboembolic Events Rohit Bhatia,
Annu Alphonsa, Kamlesh Sharma, Gautam
Sharma
P6.242 Contemporary Trends in the
Ischemic Stroke “Weekend Effect” on IV
Thrombolytic Use, In-hospital Mortality,
Discharge Disposition, Hospital Charges,
and Length of Stay Vishal Jani, Sopan
Lahewala, Shilpkumar Arora, Achint Patel,
Arshad Majid, Syed Hussain, Anmar Razak,
Adnan Safdar, Asif Khan, Nabeel Herial, Erin
Shell, Julie Bey, Marylou Mitchell, Abraham
Maaz, Adnan Qureshi
P6.243 Urticarial Allergic Reaction to
Alteplase: A Case Report Laura Papolin,
Danielle Mendes, Marcos Lange, Francisco
Germiniani, Rodrigo Harger, Viviane Zetola,
Jamileh Chamma
115
Thursday
April 23
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Poster Session VI
P6.244 Explaining the Unexplained:
Neurologic Deterioration in Acute Ischemic
Stroke Michael Mcmanus, Nerses
Sanossian, Latisha Ali, Sidney Starkman,
Neal Rao, Jason Hinman, Doojin Kim, Paul
Vespa, Manuel Blanco, Mateo CalderonArnulphi, Alireza Noorian, Kwan Ng, Conrad
Liang, Sunil Sheth, Fabien Scalzo, Jeffrey
Saver, David Liebeskind
P6.245 Fever and Dynamic Neurologic
Worsening After Ischemic and Hemorrhagic
Brain Injury Matthew Maas, Michael
Berman, Brandon Francis, Eric Liotta, Shyam
Prabhakaran, Andrew Naidech
P6.246 Clinical and In-hospital
Process Variables Are Associated with
Hospital Length-of-stay in Acute Ischemic
Stroke Patients Sun Kim, Jared Conley,
Lucy Kalanithi, Waimei Tai
P6.247 Susceptibility Weighted MRI
and Regional Cerebrovascular Reservoir
Capacity in Angiography Proven Large
Artery Disease in Acute Ischemic Stroke
and Transient Ischemic Attack Si Baek Lee,
Yoo Dong Won, Do-Sung Yoo
Child Neurology and
Developmental Neurology: Other
P6.248 Reversible Splenial Lesions
in Kawasaki Disease in a 7-year-old
Boy—First Reported Case in North
America Venu Parachuri, Akshat Katyayan,
Kumar Sannagowdara, Nadir Khan
P6.249 Quality of Life in
7:30 a.m.–12:00 p.m.
P6.255 Evaluation of Efficacy and
Safety Baseline Parameters in Patients
with Duchenne Muscular Dystrophy (DMD)
from Three Placebo-controlled Studies of
Drisapersen (DRIS) Giles Campion, Thomas
Voit, Nathalie Goemans, Rosamund Wilson,
Claire Wardell, Craig McDonald
P6.256 Ultrasound Assessment of
Obstetric Brachial Plexus Injury Edward
Smith, Kathryn Xixis, Gerald Grant, Stuart
Grant
P6.257 An Adult Presenting with
Neurological Symptoms Attributed to
Hyperhomocysteinemia That Resolved
with Treatment Devorah Segal, Zubeda
Sheikh, Kevin Shahbahrami, Jyothirmayi
Garikparthy, Angel Monserrate, Aleksey
Tentler, Machteld Hillen, Ling Shih, Beth
Pletcher
Child Neurology and
Developmental Neurology:
Inflammation and White Matter
Disease
P6.258 Acute Flaccid Paralysis in a
Cluster of Six Children at the Hospital for
Sick Children: August-September 2014.
Toronto, ON Maryam Nabavi Nouri,
Samantha Irwin, Susan Richardson, Helen
Branson, Christoph Licht, Jamie Hutchison,
Ari Bitnun, Ann Yeh
P6.259 Case Series of Three Patients
of Acute Flaccid Myelitis Ashutosh Kumar,
Kanika Arora, Jayne Ness
Childhood Pantothenate Kinase
Neurodegeneration Treated with Deep
Brain Stimulation Bennett Lavenstein,
Chima Oluigbo
P6.260 Idopathic Non-polio Polio-
P6.250 Feasibility of a Randomized-
P6.261
control Trial: Improving Medication
Adherence in Pediatric MS with a
Remote Motivational Interviewing
Intervention Stephanie Grover, Austin
Noguera, Carolyn Schwartz, Ruth Slater,
Petra Breiner, Elizabeth Quon, E. Ann Yeh
P6.251 Mortality in Children with
Cerebral Palsy Treated with Intrathecal
Baclofen Pump V Vedanarayanan, Vandana
Vedanarayanan, Colette Parker, Michelle
White, Lamar Davis
P6.252 Botulinum Toxin for the
Treatment of Extra-pyramidal Symptoms of
Lesch-Nyhan Syndrome Nassim Zecavati,
Cesar Santos, Temitayo Oyegbile
P6.253 Clinical Relevance of VGKC-
complex Antibodies in Children Yael
Hacohen, Rahul Singh, Bethan Lang, Cheryl
Hemingway, Ming Lim, Angela Vincent
P6.254 A Comparative Analysis of
Findings by MPCR, MLPA and Muscle
Biopsy in a Cohort of Children with
Duchenne Muscular Dystrophy: A First
Study Manjunath Poojar, Preethish
Kumar Veeramani, Kiran Polavarapu,
Atchayaram Nalini, Narayanappa Gayathri,
Ravinder Singh, Priya Treesa Thomas, Anil
Ramakrishna
116
like Flaccid Paralysis Salman Rashid,
Muhammad Ubaidulhaq, Huiyuan Jiang,
Aimee Luat
EMG/NCV Changes in 2
Pediatric Patients with Acute Onset Flaccid
Paralysis Brian Droker, Emmanuelle
Tiongson, Quyen Luc, Kiarash Sadrieh, Tena
Rosser, Jay Desai, Leigh Ramos-Platt
P6.262 Methotrexate Experience
in Eight Pediatric Patients with AntiN-methyl-D-aspartate-receptor
Encephalitis Alfredo Ramirez, Antonio
Bravo-Oro, Ildefonso Rodriguez-Leyva,
Carlos Abud-Mendoza
P6.263 Gait Disturbance as the Initial
Presenting Symptom in Young Children
with Anti-NMDA Receptor (Anti-NMDAR)
Encephalitis: A Case Series Anusha
Yeshokumar, Jessica Klein, Kristin
Baranano, Carlos Pardo-Villamizar
P6.264 Paroxysmal Sympathetic
Hyperactivity (PSH) in Critically Ill Children
with Encephalitis and Meningoencephalitis:
Morbidity and Risk Factor Analysis Raquel
Farias-Moeller, Elizabeth Wells, Nathan
Dean, Jessica Carpenter
P6.265 A Pediatric Case of CLIPPERS
(Chronic Lymphocytic Inflammation
with Pontine Perivascular Enhancement
Responsive to Steroids) Sally Mathias,
Deborah Hickman, Donita Lightner, Charles
Smith, Robert Baumann
P6.266 Hemolytic Uremic Syndrome
P6.277 In Vitro Study of Impact
P6.267 Microstructural Thalamic
Epilepsy/Clinical
Neurophysiology (EEG):
Surgery/Autoimmune Epilepsy
(HUS) with Reversible Cerebral Vasospasm
and Splenial Lesion Responsive to the
High-dose Intravenous Magnesium Sulfate
(MgSO4) Salman Rashid, Anza Memon,
Mitchel Williams
and Cortico-thalamic Correlates of
Cognitive Impairment in Pediatric Multiple
Sclerosis Ermelinda De Meo, Maria Rocca,
Lucia Moiola, Angelo Ghezzi, Pierangelo
Veggiotti, Ruggero Capra, Maria Amato,
Agnese Fiorino, Lorena Pippolo, Maria
Carmela Pera, Giancarlo Comi, Andrea
Falini, Massimo Filippi
P6.268 Catastrophic Encephalopathy
as Presenting Picture of Susac's Syndrome
in Two Children Silvia Tenembaum,
Marcela Parada Marcilla, Alejandra
Gonzalez, Guillermo Agosta
Child Neurology and
Developmental Neurology:
Electrophysiology, Epilepsy, and
Other
P6.269 Quantitative Analysis of
Surface Electromyography for Pediatric
Neuromuscular Disorders Mana
Higashihara, Masahiro Sonoo, Akihiko
Ishiyama, Yu Nagashima, Haruo Uesugi,
Madoka Mori-Yoshimura, Miho Murata,
Shigeo Murayama, Hirofumi Komaki
P6.270 Epilepsy and
Electroencephalographic Features
in Patients with Phelan McDermid
Syndrome Xiangping Zhou, Andrea
Gropman, Precilla D'Souza, Audrey Thurm,
Sara Inati
P6.271 TBC1D24: A Novel Mutation
Causing Intellectual Disability and
Epilepsy Aaron Cardon, Jimmy Holder
P6.272 Utility of Obtaining a Serum
Basic Metabolic Panel in the Setting of
a First-time Nonfebrile Seizure Britton
Zuccarelli, Ara Hall
P6.273 RG1662, a Selective GABAA
α5 Receptor Negative Allosteric Modulator,
Increases Gamma Power in Young Adults
with Down Syndrome Federico Bolognani,
Lisa Squassante, Xavier Liogier d'Ardhuy,
Maria-Clemencia Hernandez, Frederic
Knoflach, Ivan Baldinotti, Jana Noeldeke,
Christoph Wandel, Stephan Nave, Omar
Khwaja
P6.274
Intraventricular Hemorrhage
in the Asphyxiated Newborns Treated with
Hypothermia: A Centre Experience Ghalia
Alyazidi, Elodie Boudes, Michael Shevell,
Pia Wintermark
P6.275 The Clinical and Radiographic
Manifestations of Trans-tentorial
Herniation in a Neonate Mitra Assadi
Khansare, Renee Behme, Olga Goldfarb,
Esther Nimchinsky
of Piericidin on 3D Neurosphere
Culture Mohamed El-Hawary, Mohamed
Rakha, Ahmed Lotfy, Mohamed Moheb
Elgamal, Mohamed Salama, Mohamed
Sobh
P6.278 Seizure Outcome
After Epilepsy Surgery in Patients
with Intractable Non-lesional
Epilepsy Niravkumar Barot, Hai Chen,
Pradeep Modur, Paul Van Ness, Mark
Agostini, Ryan Hays, Christopher Madden,
Bruce Mickey, Kan Ding
P6.279 Behavioral Response
Following Hypothalamic Hamartoma
Treatment in Adults Danilo Vitorovic, Laura
Lehnhoff
P6.280 Does Postoperative EEG
Predict Seizure Recurrence After
Epilepsy Surgery? Sarah Hodges, Daniel
Goldenholz, William Theodore, Sara Inati
P6.281 “A Circuitous Journey”:
Parent Perspectives of Getting to Pediatric
Resective Epilepsy Surgery Christine
Baca, Huibrie Pieters, Tomoko Iwaki, Gary
Mathern, Barbara Vickrey
P6.282 Intractable Reflex Epilepsy
Treated Successfully with Deep Brain
Stimulation Anteneh Feyissa, Squire Stead,
Jamie Van Gompel, Jeffrey Britton
P6.283 Patients with
Neurofibromatosis Type-1 and Temporal
Epilepsy Can Be Good Candidates for
Epilepsy Surgery Leon Weinstock, Shirisha
Ale, Ping Li, Naeem Mahfooz, Lucia Balos,
Veetai Li
P6.284 The Frequency of Serum
Neural Autoantibodies in Suspected
Autoimmune Epilepsy Brian Sansoucy,
Malgorzata Jaremko, Kaylan Burnham,
Keith Mourneau, Amy Goldberger, Vishal
Patel, Zhenyuan Wang, Funda Suer, Sat Dev
Batish, Joseph Higgins
P6.285 Autoimmune Epilepsy:
Clinical Features, Management and
Outcomes Ryan Hays, Divyanshu Dubey,
Niyatee Samudra, Mark Agostini, Kan
Ding, Puneet Gupta, Paul Van Ness, Steven
Vernino
P6.286 NMDA-receptor Encephalitis:
An Unsual Case of Refractory Status
Epilepticus Catherine Legault, Sarah
Lapointe, Paul Giacomini, Jeanne
Teitelbaum, Roberta La Piana, Donatella
Tampieri, Annalisa Romano
P6.287 Autoimmune Seizure
Syndrome in a Patient with Addison’s
Disease Shubhi Agrawal, Krikor Tufenkjian,
Sanjay Singh
P6.276
Clinical Outcomes Among
Transferred Children with Ischemic and
Hemorrhagic Stroke in the Nationwide
Inpatient Sample Mohammad Qureshi,
Malik Adil, Gabriel Vidal, Ahmed Malik,
Mushtaq Qureshi, Adnan Qureshi
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VI
Epilepsy/Clinical
Neurophysiology (EEG):
Imaging/Lifestyle
P6.288 Hybrid PET/MR May Improve
Diagnostic Yield of Epileptic Lesions Hae
Won Shin, Valerie Jewells, Arif Sheikh,
Hongyu An, Eldad Hadar, Linh Ngo, Zhu
Hongtu, Wei Gao, Dinggang Shen, Weili Lin
P6.289 Volumetric Analysis of
Unilateral Focal Epilepsy in Children Allison
Dixon, Nasser Kashou, Gogi Kumar
P6.300 Pilot Study of Raltegravir,
P6.313
Neuropathic Pain Treatments
and Quality of Life Results in Leprosy
Patients Ricardo Dornas, Osvaldo
Nascimento, Camila Pupe, Lucas Araujo,
Eduardo Davidovich, Felipe Vianna, Bruno
Coutinho, Caroline Bittar
P6.325 Neurocysticercosis and
P6.314
P6.326 Recurrent Aseptic Meningitis
Associated with Chikungunya Virus
Infection Anna Bank, Ayush Batra, Rene
Colorado, Jennifer Lyons
First Reported Case of a Brain
Abscess with Ustekinumab for Psoriatic
Arthritis Haseeb Rahman, Abraham
Thomas, Daoud Rahman, Bushra Javed,
Popovich Jovan
P6.302 Neurological Manifestations
P6.315
into the Spinal Cord in Poorly Treated
Patients Rosette Jabbour, Lamya Ann
Atweh, Samir Atweh
an Integrase Inhibitor, in Human T-cell
Lymphotrophic Virus-1 (HTLV-1) Associated
Myelopathy, Tropical Spastic Paraparesis
(HAM/TSP) Raya Massoud, Breanna
Caruso, Yoshimi Akahata, Joan Ohayon,
Steven Jacobson
P6.301Myeloradiculopathy
Presenting with First Time Seizure Vineet
Punia, Anjali Dagar, David Marks
of Acute Dengue Virus Infection: A Study
from Tropical Country- India Devashish
Ruikar, Sita Jayalakshmi, Mohandas Surath
P6.291 Sensitivity of MRI in Patients
P6.303 Role of C-Jun N-terminal
P6.290 Utility of MRI in Patients
with New Onset Seizures Who Have
Normal CT Imaging and Neurologic
Examinations Ryan Smith, Adnan Subei,
Ivan Garza, Michael Flink
P6.292 A Round Hyperdense Middle
Cerebral Artery Sign in a Patient with
Seizures: An Unusual Presentation of a
Brain Tumor Rather Than a Subarachnoid
Hemorrhage Rodica Petrea, Charles
Rothberg, Arun Patil, William Hunter,
Edward Adickes, Angel Mironov, Sanjay
Singh
P6.293 Concordance Rate Between
the Wada Test and FMRI for Language
Lateralization in Patients with Medically
Intractable Epilepsy Andreu Massot-Tarrus,
Reza Mousavi, Frank Bihari, Susan HaymanAbello, Brent Hayman-Abello, Seyed
Mirsattari
P6.294 Epilepsy in the Elderly:
Temporal Lobe Atrophy Present in
Many Cases of Epilepsy of Unknown
Etiology Emannuelle Lapointe, Christian
Bocti, Charles Deacon, Louis Royer-Perron,
Stephen Cunnane
P6.295 Type II Cortical Dysplasia
in Dominant Frontal Lobe Presenting
as Gelastic Epilepsy Sophie Peeters,
Divyanshu Dubey, Drew Thodeson, Michael
Dowling, Deepa Sirsi, Susan Arnold, Rana
Said
Kinase (JNK) Signaling in Varicella
Zoster Virus Infection of Neurons Arun
Venkatesan, Labchan Rajbhandari, Sravya
Kurapati, Tomohiko Sadaoka, Jeffrey Cohen
P6.304 Concentration Dependent
Inhibitory Effect of a Nucleoside-based
Analog Against Human Herpesvirus-6
Replication Naomi Lee, Emily Leibovitch,
Steven Jacobson
P6.305 Quantitative Detection of
Human Herpesvirus-6 with Digital Droplet
PCR in a Patient with Post-transplant HHV6 Encephalitis Bridgette Jeanne Billioux,
Steven Jacobson
P6.306 Successful Treatment
of Eastern Equine Encephalitis with
Early, Empiric Initiation of Intravenous
Immunoglobulin: A Case Report Michael
Erkkinen, Maya Srikanth, Jennifer Lyons,
Henrikas Vaitkevicius
P6.307 Neurological Manifestations
in Dengue Seropositive Patients Navneet
Kumar, Gaurav Gupta, Kanhaiya Agrawal,
Atul Garg
Lyme and Other CNS Infections
P6.308 An Unusual Presentation of
Neuro Lyme Mohamed Tom, Muhanad
Mohamed, Stephen Holloway
P6.309 Treatment of North American
Seizure Control in Epileptic Patients Ashraf
Abdou, Amr El Fatatry, Horya Sad Allah,
Naglaa Abd Elhakeem
Lyme Neuroborrelliosis with Oral
Doxycycline and Intravenous Ceftriaxone:
A Comparative Case Series Joseph Alario,
Kelly Baldwin
P6.297 Benefits of Exercise in
P6.310
P6.296 Effect of Ramadan Fasting on
Patients with Epilepsy: A Literature
Review Frank Gilliam, Robert Hogan,
Gregory Gilmet
HTLV and Other Viral Infections
P6.298HTLV-1-associated
Myelopathy/Tropical Spastic
Paraparesis: Clinical and Neuroimaging
Findings Francisco Carod, Hudson
Mesquita
P6.299Common γ-chain
Blocking Peptide Reduces in Vitro
Immune Activation Markers in HTLV-1
Associated Myelopathy/ Tropical Spastic
Paraparesis Raya Massoud, Yoshimi
Akahata, Yutaka Tagaya, Nazli Azimi, Asjad
Basheer, Steven Jacobson
Borrelia Hispanica: An
Emerging Infectious Agent Causing
Neuroborreliosis Maria Cerdan, Iria
Sánchez Martínez, Begoña Palazon
Cabanes, Ester Carreon Guarnizo, Pedro
Anda Fernandez, Raquel Escudero Nieto,
Jose Meca La Llana
P6.311
Clinical, Laboratory
Findings, and Complications of Scrub
Typhus- Meningoencephalitis: Case
Series Prasanna Venkatesan Eswaradass,
C Eswaradass
P6.312
Subarachnoid Hemorrhage:
A Rare Complication of Pyogenic Bacterial
Meningitis Parunyou Julayanont, Helen
Wang, Pavis Laengvejkal, Sahawat
Tantikittichaikul, John DeToledo
Fast, Easy, Online Registration · AAN.com/view/AM15
Fulminant Necrotizing
Encephalitis Associated with Malignant
Cerebral Edema and Transtentorial
Herniation in the Setting of Acute Seasonal
Influenza Pneumonia James Boyd,
Mohamed-Ali Babi, Gilman Allen, Charlotte
Teneback, Christopher Commichau
P6.316
A Unique Case of
Leptomeningitis Associated with
Rheumatoid-like Arthritis and Nonpathogenic Naegleria Species Milena
Rodriguez Alvarez, Neha Mirchandani, Imad
Khan, Karen Medin, Roberta Seidman,
Susan Madison-Antenucci, Noel Espina,
Allen Teal, Kimberly Mergen
P6.317
Utility of Broad-range
PCR Testing in Suspected CNS
Infections Lauren Koffman, Rodica
Bernatowicz, Nabin Shrestha, Adarsh
Bhimraj
Fungi, Parasites, and Other
Infectious Disorders
P6.318
Blood Stream Infections in
NNICU: Blight to ICU Stay Man Mohan
Mehndiratta
P6.319
Linezolid in Children with Drug
Resistant Tuberculosis and Associated
Peripheral Neuropathy Amit Dey
P6.320 A Rare Presentation of
Disseminated Histoplasmosis Mimicking
Metastatic Cancer in Apparently
Immunocompetent Individual Doungporn
Ruthirago, Nebiyou Wondimagegnehu,
Pakpoom Tantrachoti, Kenneth Nugent
P6.321 Diagnostic Challenges of
Acapsular Cryptococcus Neoformans in an
Immunocompetent Individual Manifesting
as Chronic Hydrocephalus Kedar Mahajan,
Robin Dharia, Lori Sheehan
P6.322 Severe Immune
Reconstitution-like Inflammatory
Syndrome from Cryptococcus Gotti
Menigoencephalitis Treated with
Cyclophosphamide Christopher Way, Rene
Patino, James Nomura, Annette LangerGould
Epilepsy in Bhutan: A Cross-sectional
Study Kate Brizzi, Damber Nirola, Erica
McKenzie, Sonam Deki, Lhab Tshering,
Sonam Pelden, Tshokey Tshokey, Chencho
Dorji, Farrah Mateen
from Sacral Subarachnoid Cysticercosis:
A Tale in Tail Rajesh Gupta, Tracey Cho,
Haatem Reda, Nagagopal Venna
P6.327 Migration of Toxocara Canis
History of Neurology
P6.328 Did Charcot Have Vascular
Parkinsonism? Helio Afonso Teive,
Francisco Germiniani, Renato Munhoz
P6.329 Strange Fits of Passion
and Spin-offs Behind the Discoveries of
Myasthenia Gravis Sankar Bandyopadhyay
P6.330 Deep Brain Stimulation: The
Past, the Present, and the Future Lauren
Davis
P6.331 ‘Rest or Go West’- The
Forgotten Legacy of Silas Weir
Mitchell Raghav Govindarajan
P6.332 The Essential Role of Pierre
Marie to Neurological Sciences Francisco
Germiniani, Helio Afonso Teive, Gustavo de
Almeida
P6.333 Historical Perspective of
Neurology in Iran Hadi Mohammad Khanli,
Shrikant Mishra, Bhavesh Trikamji
P6.334 Spectrum of Neurological
Disorders Among 19th Century and
Early to Mid-20th Century United States
Presidents Raghav Govindarajan
P6.335 Retired Diagnoses from the
19th and 20th Centuries: Simple, Sick and
Nervous Headaches Noah Rosen, Robert
Duarte
P6.336 Neurology Workforce
in Hawai‘i: Current and Historical
Observations Diane Chen, Marissa Sakoda,
Alexander Wei, J. Douglas Miles
P6.337 Alice in Wonderland
Syndrome: A History Edward Fine, Poojah
Sofat, Naeem Mahfooz, Alyssa Fiddler,
Osman Farooq
P6.323 Brachial Plexus Neuritis as
Presenting Manifestation of Disseminated
Coccidioidomycosis Rahul Shah, Bing Liao,
Elena Shanina, Glenn Smith
P6.324 Fulminant Cerebral
Zygomycosis in a Healthy Man: A Case of
Heroin Inhalation Joao Mc-ONeil Plancher,
Simona Ferioli, Christopher Kiefer
117
Thursday
April 23
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
Scientific Sessions
S38 Diet and Hormonal
Factors in Multiple
Sclerosis
1:00 p.m.
S38.001
High-dose Vitamin D
Supplementation Reduces IL-17producing CD4+ T-cells and Effectormemory CD4+ T-cells in Multiple
Sclerosis Patients Pavan Bhargava,
Elias Sotirchos, Christopher Eckstein,
Achilles Ntranos, Anne Gocke, Ellen
Mowry, Peter Calabresi
1:15 p.m.
S38.002
Fat, Fiber, and Pediatric MS Brandon
Seminatore, Jennifer Graves,
Amy Waldman, Timothy Lotze,
Teri Schreiner, Anita Belman,
Benjamin Greenberg, Bianca
Weinstock-Guttman, Gregory Aaen,
Jan-Mendelt Tillema, Janace Hart,
Jayne Ness, Jennifer Rubin, Lauren
Krupp, Mark Gorman, Leslie Benson,
Moses Rodriguez, Tanuja Chitnis,
Soe Mar, Lisa Barcellos, John Rose,
Shelly Roalstad, Timothy Simmons,
Charlie Casper, Emmanuelle
Waubant
1:30 p.m.
S38.003
A Case-control Study of Dietary Salt
Intake and Risk of Pediatric Multiple
Sclerosis (MS) Jamie McDonald,
Jennifer Graves, Amy Waldman,
Timothy Lotze, Teri Schreiner, Anita
Belman, Benjamin Greenberg,
Bianca Weinstock-Guttman, Gregory
Aaen, Jan-Mendelt Tillema, Janace
Hart, Jayne Ness, Jennifer Rubin,
Lauren Krupp, Mark Gorman, Leslie
Benson, Moses Rodriguez, Tanuja
Chitnis, Soe Mar, Lisa Barcellos,
John Rose, Shelly Roalstad,
Timothy Simmons, T.Charles Casper,
Emmanuelle Waubant
1:45 p.m.
S38.004
Sodium Chloride-high Diet
Promotes Pro-inflammatory
Macrophage Activation and
Aggravates Central Nervous
System Autoimmunity Luisa Klotz,
Stephanie Hucke, Melanie Eschborn,
Engbers Annika, Heinz Wiendl
2:00 p.m.
S38.005
The Male 2D:4D Digit Ratio: A Proxy
for Prenatal Androgen Exposure
and a Risk Biomarker for Multiple
Sclerosis. Riley Bove, Muhammad
Taimur Malik, Camilo Diaz-Cruz,
David Bargiela, Alicia Chua, Taylor
Saraceno, Emily Greeke, Bonnie
Glanz, Brian Healy, Tanuja Chitnis
2:15 p.m.
S38.006
Association Between Low
Testosterone and Brain Atrophy in
Men with Multiple Sclerosis. Riley
Bove, Brian Healy, Svetlana Egorova,
Bonnie Glanz, Rohit Bakshi, Philip
De Jager, Karen Miller, Charles
Guttmann, Tanuja Chitnis
2:30 p.m.
S38.007
Genes and Environment in Multiple
Sclerosis (GEMS) Study: Leveraging
Electronic Communication to Enable
a Prospective Study of Individuals
at Risk of Multiple Sclerosis Zongqi
Xia, Lori Chibnik, Philip De Jager
118
S39 Cerebrovascular
Disease and Interventional
Neurology: Intracerebral
Hemorrhage
1:00 p.m.
S39.001
Systemic Inflammatory Response
Syndrome During Hospitalization
for Intracerebral Hemorrhage
Drives Poor Functional Outcome at
Discharge Amelia Boehme, Angela
Hays Shapshak, Karen Albright,
Niren Kapoor, Kimberly Kicielinski,
David Miller, Mitchell Elkind, Mark
Harrigan
1:15 p.m.
S39.002
Time Trends of Inflammatory Markers
in Cerebrospinal Fluid of Patients
with Spontaneous Intracerebral and
Intraventricular Hemorrhage Wendy
Ziai, Adrian Parry-Jones, Saman
Nekoovaght-Tak, Andrew Mould,
Carol Thompson, Santosh Murthy,
Daniel Hanley
1:30 p.m.
S39.003
Prehospital Initiation of Magnesium
Sulfate in Patients with Acute
Intracerebral Hemorrhage Nerses
Sanossian, Sidney Starkman, David
Liebeskind, Scott Hamilton, Marc
Eckstein, Samuel Stratton, Franklin
Pratt, Robin Conwit, Gene Sung,
Jeffrey Saver
1:45 p.m.
S39.004
Utility of Immediate CTangiograpahy After Intracerebral
Hemorrhage Omran Kaskar, Larry
Goldstein, Michael James
2:00 p.m.
S39.005
Rate of Peri-hematomal Edema
Expansion Predicts Outcome After
Intracerebral Hemorrhage Sebastian
Urday, Lauren Beslow, David
Goldstein, Feng Dai, Fan Zhang,
Anastasia Vashkevich, Alison Ayres,
Thomas Battey, Marc Simard,
Jonathan Rosand, W. Kimberly,
Kevin Sheth
2:15 p.m.
S39.006
Accurate Outcome Predictions for
Intracerebral Hemorrhage Patients
Are More Likely Than Inaccurate
Predictions to Be Influenced by Comorbidities Not Included in Clinical
Scales David Hwang, Cameron Dell,
Mary Sparks, Tiffany Watson, Carl
Langefeld, Mary Comeau, Jonathan
Rosand, Thomas Battey, Sebastian
Koch, Mario Perez, Michael James,
Jessica McFarlin, Jennifer Osborne,
Daniel Woo, Steven Kittner, Kevin
Sheth
2:30 p.m.
S39.007
Depression Equally Common After
Intracerebral Hemorrhage as It Is
After Acute Ischemic Stroke Mary
Denny, Suhas Bajgur, Kim Yen Thi
Vu, Rahul Karamchandani, Amrou
Sarraj, Sean Savitz
Thursday, April 23
S40 Movement Disorders:
Functional Imaging in
Parkinson's Disease
1:00 p.m. Presentation of
Movement Disorders Research
Award
Recipient:
Christopher Goetz, MD, FAAN
Chicago, IL
1:30 p.m.
S40.003
Assessment of Parkinson Disease
Progression Using 123- I I-ioflupane
SPECT: Update from the Parkinson
Progression Marker Initiative
Trial John Seibyl, Danna Jennings,
Kenneth Marek
1:45 p.m.
S40.004
Putaminal Dopamine Turnover
Predicts Levodopa-induced Motor
Complications in de Novo Parkinson’s
Disease Matthias Löhle, Julia
Mende, Martin Wolz, Bettina
Beuthien-Baumann, Liane Oehme,
Jörg van den Hoff, Jörg Kotzerke,
Heinz Reichmann, Alexander Storch
2:00 p.m.
S40.005
White Matter Microstructural
Damage and Cognitive Impairment
in Parkinson’s Disease Sebastiano
Galantucci, Federica Agosta, Delia
Gagliardi, Francesca Caso, Iva
Stankovic, Igor Petrovic, Tanya
Stojkovic, Vladimir Kostic, Massimo
Filippi
2:15 p.m.
S40.006
Clinical Correlates of Raphe
Serotonergic System Dysfunction
in Early Parkinson’s Disease. Zahi
Qamhawi, David Towey, Gennaro
Pagano, John Seibyl, Kenneth
Marek, Per Borghammer, David
Brooks, Nicola Pavese
2:30 p.m.
S40.007
Effects of Aerobic Exercise on
Striatum and Substantia Nigra in
Parkinson’s Disease Ergun Uc,
Vincent Magnotta, Hans Johnson,
Kasra Zarei, Martin Cassell, Joel
Bruss, Kevin Doerschug, Teri
Thomsen, Joel Kline, Steven
Anderson, Matthew Rizzo, Arthur
Kramer, Michelle Voss, Jeffrey
Dawson, Warren Darling
S41 Aging, Dementia,
Cognitive, and Behavioral
Neurology: Imaging: Aging
and Alzheimer's Disease
1:00 p.m. Presentation of
Norman Geschwind Prize in
Behavioral Neurology
Recipient:
Andrew Kayser, MD, PhD
San Francisco, CA
1:15 p.m.
S41.002
Variation in Longevity Gene
KLOTHO Is Associated with Greater
Cortical Volumes in Aging Jennifer
Yokoyama, Virginia Sturm, Luke
Bonham, Eric Klein, Konstantinos
Arfanakis, Lei Yu, Giovanni Coppola,
Joel Kramer, David Bennett, Bruce
Miller, Dena Dubal
1:30 p.m.
S41.003
Maintenance of Physical and
Cognitive Function Late in
Life: A Shared Neuroimaging
Signature? Caterina Rosano,
Howard Aizenstein, Kristine
Yaffe, Anne Newman, Stephanie
Studenski, Andrea Rosso, Joe
Verghese
1:45 p.m.
S41.004
The Neuropsychology of Preclinical
Alzheimer’s Disease: Differential
Sensitivity of Component
Processes of Memory Performance
on Biomarker Evidence of
Amyloidosis Kathryn Papp, Dorene
Rentz, Elizabeth Mormino, Rebecca
Amariglio, Samantha Burnham,
Keith Johnson, Reisa Sperling
2:00 p.m.
S41.005
Cognitive Decline, Ventricular
Enlargement, and Hippocampal
Atrophy in Mild Cognitive
Impairment Anna Blanken, David
Avila, Naira Goukasian, Holly
Wilhalme, John Ringman, Ellen
Woo, Liana Apostolova
S42 New Developments in
Peripheral Neuropathies
1:00 p.m.
S42.001
Polyneuropathies and Chronic
Inflammatory Demyelinating
Polyradiculoneuropathy in Multiple
Sclerosis Narupat Suanprasert, P.
James B. Dyck, Chafic Karam, Bruce
Taylor
1:15 p.m.
S42.002
Distinctive Patterns of Sonographic
Nerve Enlargement Between
Acquired Axonal and Demyelinating
Neuropathies. Stephan Goedee,
Jan-Thies Van Asseldonk, Leonard
Van den Berg, Leendert Visser
1:30 p.m.
S42.003
CMT X in Women: Electrodiagnostic
Findings Nivedita Jerath
1:45 p.m.
S42.004
Nerve Pathologic Features
Differentiate POEMS Syndrome from
CIDP Ezequiel Piccione, JaNean
Engelstad, Michelle Mauermann,
Angela Dispenzieri, P. James B. Dyck
2:00 p.m.
S42.005
Acute-onset Chronic Inflammatory
Demyelinating Polyneuropathy. An
Electrodiagnostic Study Mohammad
Anadani, Bashar Katirji
2:15 p.m.
S42.006
An Exon Trap with Proper Poly-A
Site in the GBE1 Is the Common
Missing Cause in Adult Polyglucosan
Body Disease Orhan H. Akman,
Or Kakhlon, Jorida Coku, Lorenzo
Peverelli, Hanna Rosenmann,
Lea Rozenstein-Tsalkovich, Julie
Turnbull, Vardiella Meiner, Liat
Chama, Israela Lerer, Shoshi
Shpitzen, Eran Leitersdorf, Carmen
Paradas Lopez, Mary Wallace,
Raphael Schiffmann, Salvatore
DiMauro, Alexander Lossos, Berge
Minassian
2:15 p.m.
S41.006
FDG-PET of the Brain and
Neuropsychiatric Symptoms in
Normal Cognitive Aging: The Mayo
Clinic Study of Aging Hanna Ruider,
Janina Krell-Roesch, Gorazd
Stokin, Val Lowe, Rosebud Roberts,
Michelle Mielke, David Knopman,
Teresa Christianson, Clifford Jack,
Ronald Petersen, Yonas Geda
2:30 p.m.
S41.007
Progression of Cerebral Atrophy and
Hypometabolism in the Presence
of β-amyloidosis in Mild Cognitive
Impairment David Knopman, Clifford
Jack, Emily Lundt, Heather Wiste,
Stephen Weigand, Prashanthi
Vemuri, Val Lowe, Kejal Kantarci,
Jeffrey Gunter, Matthew Senjem,
Michelle Mielke, Rosebud Roberts,
Bradley Boeve, Mary Machulda,
Ronald Petersen
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Invited Science: Epilepsy
1:00 p.m.–2:45 p.m.
1:00 p.m.
S43.001
Radiosensitization of Glioblastoma
Stem Cells by Targeting High-affinity
Glucose Uptake Kailin Yang, William
Flavahan, Samuel Chao, Jeremy Rich
1:15 p.m.
S43.002
Transforming Growth Factor-β
Pathway Activity in Human
Malignant Gliomas—an in Vivo
Study Dorothee Gramatzki, Karl Frei,
Isabel Tritschler, Judith Johanna
Schröder, Larisa Espinoza, Elisabeth
Rushing, Michael Weller
1:30 p.m.
S43.003
Neuronal Activity-regulated
Secretion of Neuroligin-3 Promotes
Glioma Growth Michelle Monje,
Humsa Venkatesh, Viola Caretti,
Tessa Johung, Alyssa Noll, Hannes
Vogel, Parag Mallick, Markus Bredel
1:45 p.m.
S43.004
Highly Precise Quantification of
Multiple Human Herpesviruses in
Glioblastoma Samples by Droplet
Digital PCR Cheng-Te Lin, Emily
Leibovitch, M.I. Almira-Suarez,
Steven Jacobson
2:00 p.m.
S43.005
Multicenter Phase I Dose Escalation
Study of Hypofractionated
Stereotactic Radiotherapy with
Bevacizumab in the Treatment
of Recurrent Malignant
Glioma Elizabeth Neil, Jennifer
Clarke, Kathryn Beal, Phillip Gutin,
Barani Igor, Thomas Kaley, Andrew
Lassman, Malbora Perezic-Mustafa,
Robert Young, Antonio Omuro
2:15 p.m.
S43.006
A Phase 1 Study Evaluating ABT414 with Temozolomide (TMZ) or
Concurrent Radiotherapy (RT) and
TMZ in Glioblastoma (GBM) Andrew
Lassman, Hui Gan, Lisa Fichtel, Ryan
Merrell, Martin Van Den Bent, Priya
Kumthekar, Andrew Scott, Michelle
Pedersen, Erica Gomez, JuDee
Fischer, William Ames, Hao Xiong,
Ho-Jin Lee, Wijith Munasinghe, Lisa
Roberts-Rapp, Peter Ansell, Kyle
Holen, David Reardon
S44 History of Neurology
1:00 p.m. Presentation of
Lawrence C. McHenry Award: An
Award for the History of Neurology
Recipient:
Michel Shamy, MD, MA, FRCPC
Ottawa, ON, Canada
1:30 p.m.
S44.003
Transcontinental Crossings Francois
Boller, Henry Kaminski, Alissa
Romano
1:45 p.m.
S44.004
Asterixis—History and
Terminology Gian Pal, Mark Lin,
Robert Laureno
2:00 p.m.
S44.005
Did the "Woman in the Attic"
in Jane Eyre Have Huntington
Disease? Elizabeth Coon, Anhar
Hassan
2:15 p.m.
S44.006
The Luckiest Creature Alive: George
Orwell’s Traumatic Brachial Plexus
Injury Ryan Jacobson
2:30 p.m.
S44.007
Pearce Bailey: Shrewd Selection
of the Second President of the
Emerging American Academy of
Neurology Elan Louis
S45 Neuroepidemiology:
Multiple Sclerosis,
Cerebrovascular, and
Aging
1:00 p.m. Presentation of
Bruce S. Schoenberg International
Award in Neuroepidemiology
Recipient:
Stojan Peric, MD, PhD
Belgrade, Serbia
1:30 p.m.
S45.003
Risk Factors for Disease Progression
in a Diverse US Population-based
Multiple Sclerosis Cohort Mitchell
Wallin, William Culpepper, John
Kurtzke
1:45 p.m.
S45.004
Greater Consumption of Coffee
Is Associated with Reduced
Odds of Multiple Sclerosis Ellen
Mowry, Anna Hedstrom, Milena
Gianfrancesco, Xiaorong Shao,
Catherine Schaefer, Lisa Barcellos,
Tomas Olsson, Lars Alfredsson
2:00 p.m.
S45.005
Retinal Microvascular Signs and Agerelated Macular Degeneration Are
Associated with Incident Cerebral
Microbleeds According to Location
in Older People: The AGES-Reykjavik
Study Jie Ding, Chengxuan Qiu,
Sigurdur Sigurdsson, Qian Zhang,
Gudny Eiriksdottir, Vilmundur
Gudnason, Mark Van Buchem, Mary
Frances Cotch, Lenore Launer
Thursday, April 23, 1:00 p.m.–2:45 p.m.
1:00 p.m–1:20 p.m.
Increased Cerebral Oxygenation Precedes
Generalized Tonic Clonic Seizures
1:20 p.m–1:40 p.m.
Factors Influencing Driving Impairment in Persons
with Refractory Epilepsy
1:40 p.m–2:00 p.m.
Management of Children with Refractory Epilepsy.
A Decision Analysis Comparing Medical Versus
Surgical Treatment
2:00 p.m–2:20 p.m.
Temporal Lobe Epilepsy in Patients with
Nonlesional MRI and Normal Memory: An SEEG
Study
2:20 p.m–2:40 p.m.
Neural Mechanism of Impaired Consciousness
in Typical Childhood Absence Seizures
2:40 p.m–2:45 p.m.
Questions and Answers
2:15 p.m.
S45.006
Neighborhood Socioeconomic
Status, Cognitive Function, and Small
Vessel Disease Andrea Rosso,
Jason Flatt, Gina Lovasi, Arleen
Brown, Michelle Carlson, Ana Diez
Roux, Karen Matthews, Caterina
Rosano, Peter Gianaros
2:30 p.m.
S45.007
Maternal Morbidity and Mortality in
Pregnant Women with Epilepsy in the
United States Sarah MacDonald,
Brian Bateman, Thomas McElrath,
Sonia Hernández-Díaz
2:30 p.m.
S43.007
Phase II Study of Arsenic Trioxide and
Temozolomide in Combination with
Radiation Therapy in Patients with
Malignant Gliomas Priya Kumthekar,
Sean Grimm, Katie McCarthy, Irene
Helenowski, Alfred Rademaker,
Jeffrey Raizer
Fast, Easy, Online Registration · AAN.com/view/AM15
Thursday
April 23
S43 Neuro-oncology:
Basic Science and Clinical
Trials
New Trends and Cutting-Edge Research
from the American Epilepsy Society*
*Program subject to change
119
Integrated Neuroscience Session
Thursday, April 23
I11C The Promise of Novel Biomarker Approaches
in Advancing Treatment
1:00 p.m.–5:00 p.m.
Coordinators: Massimo Pandolfo, MD, FAAN, and Deborah Hall, MD, PhD
Part I
1:00 p.m.–2:45 p.m.
1:00 p.m.–1:05 p.m.
Introduction
1:05 p.m.–1:35 p.m.
Invited Speaker
Massimo Pandolfo, MD, FAAN, and Deborah Hall, MD, PhD
Part II
2:55 p.m.–4:35 p.m.
2:55 p.m.–3:25 p.m.
Invited Speaker
3:25 p.m.–3:30 p.m.
I11-3A Data Blitz
I11-3B Data Blitz
Immunologic and Radiological Biomarkers of Clinical Trials
in Multiple Sclerosis Suhayl S. Dhib-Jalbut, MD, FAAN
Biomarkers in Therapy Development James Kaiser, MD
Identification of Gene Networks and Pathways Associated with Nabiximols
Treatment in Multiple Sclerosis Patients Filippo Martinelli Boneschi, Laura Ferrè,
Melissa Sorosina, Elisabetta Mascia, Arturo Nuara, Vittorio Martinelli, Letizia
Leocani, Ferdinando Clarelli, Federica Esposito, Giancarlo Comi
1:35 p.m.–1:40 p.m.
I11-1A Data Blitz
1:40 p.m.–1:45 p.m.
I11-1B Data Blitz
3:30 p.m.–3:35 p.m.
1:45 p.m.–1:55 p.m.
Audience Q&A
1:55 p.m.–2:25 p.m.
Invited Speaker
3:35 p.m.–3:45 p.m.
Audience Q&A
3:45 p.m.–4:15 p.m.
Invited Speaker
4:15 p.m.–4:20 p.m.
I11-4A Data Blitz
4:20 p.m.–4:25 p.m.
I11-4B Data Blitz
4:25 p.m.–4:35 p.m.
Audience Q&A
TIA Biomarkers Determined Through Proteomics Paul George, Michael Mlynash,
Christopher Adams, Calvin Kuo, Stephanie Kemp, Madelleine Garcia, Gregory
Albers, Jean-Marc Olivot
ALS Monocytes Exhibit a Pro-inflammatory Gene Expression Weihua Zhao,
David Beers, Hooten Christopher, Stanley Appel
Biomarker Assessment in Clinical Trials: Personalizing Brain Tumor
Treatment Evanthia Galanis, MD
2:25 p.m.–2:30 p.m.
Biomarkers in Clinical Trials in Rare Diseases: The Case of Friedreich's
Ataxia Massimo Pandolfo, MD, FAAN
I11-2A Data Blitz
Non-invasive Monitoring of Treatment Response in IDH-mutant Glioma Patients
by 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate Ovidiu
Andronesi, Franziska Loebel, Wolfgang Bogner, Malgorzata Marjanska, Jorg
Dietrich, Tracy Batchelor, Elizabeth Gerstner, Andrew Chi, Bruce Rosen, Daniel
Cahill
2:30 p.m.–2:35 p.m.
I11-2B Data Blitz
Structural Brain Changes in Patients Undergoing Autologous Stem Cell
Transplantation for Lymphoma Isabel Arrillaga-Romany, Kourosh Jafari-Khouzani,
Yi-Bin Chen, Bruce Rosen, Tracy Batchelor, Jorg Dietrich
2:35 p.m.–2:45 p.m.
Audience Q&A
2:45 p.m.–2:55 p.m.
Break
Immune Profiling of NMO Patients Receiving Rituximab Immunotherapy Lauren
Collison, Chris Ayers, Jessica Jackson, Kenny Frazier, Benjamin Greenberg, Don
Healey
Monitoring Loss of Striatal Phosphodiesterase 10A (PDE10A) with [18F]MNI-659
and PET: A Biomarker of Early Huntington Disease (HD) Progression David
Russell, Danna Jennings, Olivier Barret, Gilles Tamagnan, Vincent Carroll, David
Alagille, Thomas Morley, Caroline Papin, John Seibyl, Kenneth Marek
Biomarkers of Disease Severity in Myotonic Dystrophy During Skeletal Muscle
Rehabilitation Corrado Angelini, Chiara Fritegotto, Paola Cudia
Guided Poster Rounds
I11-5A
Cortical Lesion Burden on
7-tesla MRI Is Associated with Cognitive
and Physical Disability in Multiple
Sclerosis Daniel Harrison, Snehashis Roy,
Dzung Pham, Susan Courtney, Brian Caffo,
Peter Van Zijl, Peter Calabresi
I11-5B
Neural Origin Plasma
Exosomes Provide Novel Biomarkers for
Brain Insulin Resistance in Alzheimer's
Disease Dimitrios Kapogiannis, Adam
Boxer, Erin Abner, Arya Biragyn, Umesh
Masharani, Lynda Frassetto, Ronald
Petersen, Bruce Miller, Edward Goetzl
I11-5C
Assessment of Parkinson
Disease Progression Using 123- I
I-ioflupane SPECT: Update from the
Parkinson Progression Marker Initiative
Trial John Seibyl, Danna Jennings,
Kenneth Marek
120
4:35 p.m.–5:00 p.m
I11-5D
Spontanous Remyelination
Has a Major Impact on Clinical Disability
in Multiple Sclerosis: A Longitudinal PET
Study with 11C-PIB Benedetta Bodini,
Mattia Veronese, Daniel Garcia-Lorenzo,
Marco Battaglini, Emilie Poirion, Leorah
Freeman, Caroline Papeix, Bernard Zalc,
Maya Tchikviladze, Catherine Lubetzki,
Michel Bottlaender, Federico Turkheimer,
Bruno Stankoff
I11-5E
Imaging Tau Pathology
in Vivo in FTLD Spectrum Tauopathies
with [18F] T807 PET Bradford Dickerson,
Sara Makaretz, Christina Caso, Michael
Stepanovic, Daisy Hochberg, Megan
Quimby, Michael Brickhouse, Kimiko
Domoto-Reilly, Scott McGinnis, Aaron
Schultz, Neil Vasdev, Keith Johnson
I11-5F
TIA Biomarkers Determined
Through Proteomics Paul George, Michael
Mlynash, Christopher Adams, Calvin Kuo,
Stephanie Kemp, Madelleine Garcia,
Gregory Albers, Jean-Marc Olivot
I11-5G
ALS Monocytes
Exhibit a Pro-inflammatory Gene
Expression Weihua Zhao, David Beers,
Hooten Christopher, Stanley Appel
I11-5H
Non-invasive Monitoring of
Treatment Response in IDH-mutant Glioma
Patients by 3D Functional Spectroscopic
Mapping of 2-Hydroxyglutarate Ovidiu
Andronesi, Franziska Loebel, Wolfgang
Bogner, Malgorzata Marjanska, Jorg
Dietrich, Tracy Batchelor, Elizabeth
Gerstner, Andrew Chi, Bruce Rosen, Daniel
Cahill
I11-5I
Structural Brain Changes
in Patients Undergoing Autologous Stem
Cell Transplantation for Lymphoma Isabel
Arrillaga-Romany, Kourosh Jafari-Khouzani,
Yi-Bin Chen, Bruce Rosen, Tracy Batchelor,
Jorg Dietrich
I11-5K
Immune Profiling of
NMO Patients Receiving Rituximab
Immunotherapy Lauren Collison, Chris
Ayers, Jessica Jackson, Kenny Frazier,
Benjamin Greenberg, Don Healey
I11-5L
Monitoring Loss of
Striatal Phosphodiesterase 10A
(PDE10A) with [18F]MNI-659 and PET: A
Biomarker of Early Huntington Disease
(HD) Progression David Russell, Danna
Jennings, Olivier Barret, Gilles Tamagnan,
Vincent Carroll, David Alagille, Thomas
Morley, Caroline Papin, John Seibyl,
Kenneth Marek
I11-5M
Biomarkers of Disease
Severity in Myotonic Dystrophy During
Skeletal Muscle Rehabilitation Corrado
Angelini, Chiara Fritegotto, Paola Cudia
I11-5J
Identification of Gene
Networks and Pathways Associated
with Nabiximols Treatment in Multiple
Sclerosis Patients Filippo Martinelli
Boneschi, Laura Ferrè, Melissa Sorosina,
Elisabetta Mascia, Arturo Nuara, Vittorio
Martinelli, Letizia Leocani, Ferdinando
Clarelli, Federica Esposito, Giancarlo Comi
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Integrated Neuroscience Session
I12Obesity and Neurological Disorders
1:00 p.m.–5:00 p.m.
Coordinators: Deborah I. Friedman, MD, and Janet C. Rucker, MD
Part I
1:00 p.m.–2:45 p.m.
Part II
2:55 p.m.–4:35 p.m.
1:00 p.m.–1:05 p.m.
Introduction
2:45 p.m.–3:10 p.m.
Invited Speaker
1:05 p.m.–1:30 p.m.
Invited Speaker
3:10 p.m.–3:15 p.m.
I12-3A Data Blitz
1:30 p.m.–1:35 p.m.
I12-1A Data Blitz
3:15 p.m.–3:20 p.m.
I12-3B Data Blitz
1:35 p.m.–1:40 p.m.
I12-1B Data Blitz
3:20 p.m.–3:30 p.m.
Audience Q&A
3:30 p.m.–3:55 p.m.
Invited Speaker
Deborah I. Friedman, MD, and Janet C. Rucker, MD
Obesity and Idiopathic Intracranial Hypertension Michael Wall, MD, FAAN
Effects of Intervention on Optical Imaging of Papilledema in the Idiopathic
Intracranial Hypertension Treatment Trial Mark Kupersmith
Obesity and Overweight Are Highly Prevalent in Pediatric Secondary
Pseudotumor Cerebri Syndrome Grace Paley, Claire Sheldon, Evanette Burrows,
Marianne Chilutti, Grant Liu, Shana McCormack
Obesity and Sleep: Beyond Obstructive Sleep Apnea Hrayr P. Attarian, MD
Effect of “Snoring Alone” and “Snoring Plus Phenomenon” on Cardiovascular
Diseases, or Fatal or Nonfatal Stroke Yousef Mohammad, Ahmed Malik, Omar
Saeed, Muhammad Suri, Adnan Qureshi
Overdiagnosis of Idiopathic Intracranial Hypertension (IIH) Adeniyi Fisayo, Valerie
Biousse, Nancy Newman, Beau Bruce
Adipocytokines and Migraine B. Lee Peterlin, DO
1:40 p.m.–1:50 p.m.
Audience Q&A
1:50 p.m.–2:15 p.m.
Invited Speaker
3:55 p.m.–4:20 p.m. Invited Speaker
2:15 p.m.–2:20 p.m.
I12-2A Data Blitz
4:20 p.m.–4:25 p.m.
I12-4A Data Blitz
2:20 p.m.–2:25 p.m.
I12-2B Data Blitz
4:25 p.m.–4:30 p.m.
I12-4B Data Blitz
2:25 p.m.–2:35 p.m.
Audience Q&A
4:30 p.m.–4:35 p.m.
Audience Q&A
2:35 p.m.–2:45 p.m.
Break
Obesity and Stroke Bruce I. Ovbiagele, MD, MSc, FAAN
Body Weight and Survival After Stroke: Exploring the “Obesity Paradox” in the
Framingham Study Hugo Javier Aparicio, Jayandra Himali, Alexa Beiser, Carlos
Kase, Philip Wolf, Sudha Seshadri
Metabolic Syndrome and Ischemic Stroke Risk by Sex: Meta-analysis Michelle
Lin, Gustavo Saposnik, Qiyun Shi, Amy Towfighi
Obesity and Neurocognitive Decline Hussein N. Yassine, MD
Adiponectin Deficiency Induced Cognitive Impairment in Aging Mice Through
Reductions in Insulin Sensitivity and AMPK Activation Roy Chun-Laam Ng
The Effect of Obesity on Severity of Cognitive Impairment and Neuropsychiatric
Symptoms in MCI Subjects Ashley Hannah, Ahmad Alsibai, Andrea Bozoki
Guided Poster Rounds
Cognitive Dysfunction
in Obese Individuals with or Without
Metabolic Risk Factors Ala Abu Saleh,
Radi Shahien, Nimer Assy
I12-5B
CSF Characteristics in
Patients with High Frisén Papilledema
Grades from the IIHTT John Pula, Jorge
Kattah, Luis Mejico, Michael McDermott,
Michael Wall
I12-5C
Effect of Weight Loss
Surgery on Cardiovascular Death,
Nonfatal Myocardial Infarction, or
Nonfatal Stroke in Overweight and Obese
Post-menopausal Women Omar Saeed,
Ahmed Malik, Adnan Qureshi
I12-5D
Body Mass Index and
Stroke Subtype in a Young Adult Stroke
Population Jina Youn, Thandar Aung,
Mohammad Afrasiabi, Joni Clark
I12-5E
Eating Behavior and
Metabolic Changes Across the
Spectrum of Motor Neuron Disease and
Frontotemporal Dementia Rebekah
Ahmed, Elana Henning, Lauren Bartley,
Glenda Halliday, Olivier Piguet, Sadaf
Farooqi, John Hodges, Matthew Kiernan
I12-5F Effects of Intervention
on Optical Imaging of Papilledema in
the Idiopathic Intracranial Hypertension
Treatment Trial Mark Kupersmith
I12-5G Obesity and Overweight
Are Highly Prevalent in Pediatric
Secondary Pseudotumor Cerebri
Syndrome Grace Paley, Claire Sheldon,
Evanette Burrows, Marianne Chilutti, Grant
Liu, Shana McCormack
Fast, Easy, Online Registration · AAN.com/view/AM15
I12-5H Body Weight and Survival
After Stroke: Exploring the “Obesity
Paradox” in the Framingham Study Hugo
Javier Aparicio, Jayandra Himali, Alexa
Beiser, Carlos Kase, Philip Wolf, Sudha
Seshadri
I12-5I Metabolic Syndrome and
Ischemic Stroke Risk by Sex: Metaanalysis Michelle Lin, Gustavo Saposnik,
Qiyun Shi, Amy Towfighi
I12-5J Effect of “snoring Alone”
and “Snoring Plus Phenomenon” on
Cardiovascular Diseases, or Fatal or
Nonfatal Stroke Yousef Mohammad,
Ahmed Malik, Omar Saeed, Muhammad
Suri, Adnan Qureshi
I12-5K Overdiagnosis of Idiopathic
Intracranial Hypertension (IIH) Adeniyi
Fisayo, Valerie Biousse, Nancy Newman,
Beau Bruce
I12-5L Adiponectin Deficiency
Induced Cognitive Impairment in Aging
Mice Through Reductions in Insulin
Sensitivity and AMPK Activation Roy
Chun-Laam Ng
I12-5M The Effect of Obesity on
Severity of Cognitive Impairment and
Neuropsychiatric Symptoms in MCI
Subjects Ashley Hannah, Ahmad Alsibai,
Andrea Bozoki
121
Thursday
April 23
I12-5A
4:35 p.m.–5:00 p.m.
Poster Session VII
Thursday, April 23
P7 Poster
Session VII
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Discussion Session: Epilepsy/Clinical Neurophysiology (EEG)
2:00 p.m.–6:30 p.m.
Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and
facilitate questions with poster authors during the 90-minute author standby time.
P7.001
Indomethacin Increases the
Latency to Seizure Onset and Decreased
the Number of Seizures in Zebrafish Seizure
Model Patricia Barbalho, Iscia LopesCendes, Claudia Maurer-Morelli
P7.002
Iatrogenic Radiation Exposure
from Neuroimaging May Increase the Risk
of Cancer and Mortality in Patients with
Epilepsy Travis Losey
P7.003
Gray Matter Volume Is
Reduced in Focal Compared to Idiopathic
Generalized Epilepsy Monica Dhakar,
Fen Bao, Reena Pullukat, Michael Aronov,
Lindsay Miller, Jasmine Bhangu, Carla
Santiago Martinez, Deepti Zutshi, Maysaa
Basha, Aashit Shah, Omar Khan
P7.004
Predictors of In-hospital
Mortality in Status Epilepticus; Data
from the Nationwide Inpatient Sample
Database, 2008-2012 Nassim Naderi,
Derek Moriyama, Jack Lin, Mona Sazgar,
Indranil Sen-Gupta, Lilit Mnatsakanyan
P7.005
The Time Course
and Prognostic Values of
Electroencephalographic Patterns After
Anoxic Brain Injury Adithya Sivaraju, Emily
Gilmore, Jeremy Moeller, David Greer,
Lawrence Hirsch, Nicolas Gaspard
P7.006
The Sabril® Registry After 5
Years: Patient Characteristics and Vision
Loss Robert Sergott, Rod Foroozan, John
Pellock, Edward Faught, W. Donald Shields,
Gregory Krauss, Adam Ziemann, Deborah
Lee, Yekaterina Dribinsky, Sarah Torri, Jouko
Isojarvi
P7.008
P7.007
P7.009
Responder Rates by Study
Phase in Conversion to Lacosamide
Monotherapy Study: A Post-hoc
Analysis John Stern, Michael Sperling,
Steve Chung, Philippe Ryvlin, Robert
Wechsler, Svetlana Dimova, Marc De
Backer, Tyler Story, Melissa Brock, Cindy
McShea, Paulette Williams, Konrad
Werhahn
Adjunctive Perampanel in
Adolescents with Inadequately Controlled
Partial Seizures: Efficacy and Safety
Results from Study 235 (Phase II) J. Ben
Renfroe, Lieven Lagae, Betsy Williams,
Haichen Yang, Dinesh Kumar, Antonio
Laurenza
Assessing the Role of Cultural
Perceptions and Knowledge of Epilepsy on
Medication Adherence in a Multi-ethnic
Epilepsy Clinic: A Pilot Study Katherine
Werbaneth, Elizabeth Wilson, Alexis
Ciambotti, Georgia Montouris
P7.010
Reasons for Treatment
Discontinuation and Switch in Patients with
Epilepsy: A Retrospective Observational
Study in a US Population Maria Malmenäs,
Thirupathi Pattipaka, Fulton Velez
e-Poster Session: MS and CNS Inflammatory Diseases II
Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees
are invited to explore more deeply through touch screen displays.
P7.011
Cancer Risk Is Not Increased
in People with Relapsing Multiple Sclerosis
Taking Cladribine Julia Pakpoor, Giulio
Disanto, Daniel Altmann, Sue Pavitt,
Benjamin Turner, Monica Marta, Gunnar
Juliusson, David Baker, Jeremy Chataway,
Klaus Schmierer
P7.012
Long-term Impact of Early
MS Treatment with Interferon Beta-1b
(IFNB-1b): Clinical, MRI, Employment, and
Patient-reported Outcomes (PROs) at the
11-year Follow-up of BENEFIT (BENEFIT
11) Gilles Edan, Mark Freedman, Xavier
Montalban, David Miller, Hans Hartung,
Bernhard Hemmer, Edward Fox, Frederik
Barkhof, Sven Schippling, Andrea Schulze,
Dirk Pleimes, Christoph Pohl, Rupert
Sandbrink, Gustavo Suarez, Eva-Maria
Wicklein, Ludwig Kappos
P7.013
Thalamic Volume Is
Associated with White Matter Integrity
Measures in Multiple Sclerosis Mikolaj
Pawlak, Alicja Kalinowska-Lyszczarz,
Slawomir Michalak, Wlodzimierz Paprzycki,
Radoslaw Kazmierski, Wojciech Kozubski
P7.014
Increased Coinfection of
Human Herpesviruses 6A (HHV-6A)
and HHV-6B in Multiple Sclerosis
Patients Emily Leibovitch, Giovanna
Manzano, Breanna Caruso, Joan Ohayon,
Daniel Reich, Steven Jacobson
P7.015
An 8-year-old Girl with Chronic
Inflammatory Optic Neuritis (CRION): The
Youngest Reported Case to Date Ian
Rossman, Mary Rensel
P7.016
The Clinical Course of Hair
Thinning Associated with Teriflunomide:
Case Series of Patients Who Participated in
a Hair Photography Project Keith Edwards,
Lori Hendin Travis, Annette Okai, Scott
Jackson, Francisco Gomez, Lisa Farnett,
Steve Cavalier, Darren Stam, Ken Liu
P7.017
Baseline Demographics and
Disease Characteristics from ORATORIO,
a Phase III Trial Evaluating Ocrelizumab
in Patients with Primary Progressive
Multiple Sclerosis Xavier Montalban,
Bernhard Hemmer, Kottil Rammohan, Gavin
Giovannoni, Jerome De Seze, Amit Bar-Or,
Douglas Arnold, Annette Sauter, David
Leppert, Peter Chin, Hideki Garren, Jerry
Wolinsky
P7.018
Immune-cell NT-3 and BetaNGF Are Linked to Regional Brain Volume
in Multiple Sclerosis Alicja KalinowskaLyszczarz, Mikolaj Pawlak, Slawomir
Michalak, Wlodzimierz Paprzycki, Wojciech
Kozubski
P7.019
Time off from Work: A
Matched Comparison of Fingolimod
and BRACE in Patients with Multiple
Sclerosis from the PANGAEA and PEARL
Studies Hans-Peter Duerr, Jonathan Alsop,
Niklas Bergvall, Christian Cornelissen,
Stefan Viktor Vormfelde, Tjalf Ziemssen
P7.020
Evaluation of Correlations
Between Cerebral MRI Volumes, Retinal
Thickness, Cognitive Involvement and
Clinical Features in Parenchymal NeuroBehçet Patients Tuncay Gündüz, Murat
Kurtuncu, Zeliha Matur, Baris Topcular,
Basar Bilgic, Utku Limon, Burak Tanyildiz,
Belgin Izgi, Nergis Erdogan, Ali Oge, Hakan
Gurvit, Firdevs Gulsen Demir
Epilepsy/Clinical
Neurophysiology (EEG):
Clinical Epilepsy
P7.022
Electrocardiographic Features
and SUDEP Risk in Patients with Epilepsy:
A Case-control Study Katia Lin, Jorge
Sousa, Guilherme Fialho
P7.024
Meta-analysis of Risk
Factors for Early and Late Seizures After
Acute Stroke Steven Tobochnik, Neha
Vijayvargiya, Mercedes Jacobson
P7.026
P7.021
P7.023
P7.025
P7.027
Disturbed Subjective and
Objective Parameters of Sleep in Patients
with Drug-resistant Mesial Temporal Lobe
Epilepsy Katia Lin, Aline Scarlatelli-Lima,
Lucia Sukys-Claudino
122
Sleep Disturbances in Persons
with Epilepsy in Nigeria Taofiki Sunmonu,
Morenikeji Komolafe, Olubunmi Ogunrin,
Birinus Ezeala, Sani Abubakar, Emmanuel
Iwuozo
Changes in Cardiovascular
Autonomic Function in Patients with Newly
Diagnosed Epilepsy Rajesh Goita
Headaches and
Psychosomatic Complaints in Seizure
Disorders Brannon Vines, Cristina
Wohlgehagen, Jerzy Szaflarski
Post-transplant Acute
Symptomatic Seizures. Long-term
Recurrence and Development of Epilepsy Maria Gonzalez Toledo, Analia Calle, Maria
Elena Fontela, Agustina Tamargo, Diego
Nadile, Fatima Pagani Cassara, Alejandro
Thomson, Alfredo Thomson
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VII
P7.028
Orgasmic Auras as an Initial
Symptom of a Primary Brain Tumor: A Case
Report and Literature Review Robert
Glover, Patrick LaSala, Karen Weidenheim,
Jerome Graber
P7.043
P7.029
P7.044
SeizED: Seizures in the
Emergency Department Angela Peters,
Ligia Onofrei, Helen Barkan
P7.030
Development of a Claimsbased Classifier to Identify Lennox-Gastaut
Syndrome J. Eric Pina-Garza, Francis
Vekeman, Wendy Cheng, Ed Tuttle, Phillippe
Giguere-Duval, Arman Oganisian, Joseph
Damron, Mei-Sheng Duh, Vivienne Shen,
Jouko Isojarvi, Georgia Montouris
P7.031
User Retention and Utilization
of an Online Digital Health Platform for
Epilepsy John Hixson, Kate Bertko, Paul
Wicks
P7.032
Effects of Education on
Nurses' Assessments on an Epilepsy
Monitoring Unit Mona Stecker
P7.033
Pregnancy Outcome
in Patients with Epilepsy-corniche
Experience Fathima Farook
P7.034
Down Syndrome (DS)
and Epilepsy in Adult Patients Martin
Kriebaum, Maria Pacha, Oscar Martinez
P7.035
The Factors That Trigger
Seizures in Elderly Patients Serkan Demir,
Erdem Togrol, Fatih Ozdag, Ali Sonkaya
P7.036
Childhood Trauma Is
Associated with Stress Precipitated
Epileptic Seizures in Adults Ikjae Lee,
Adrienne Fleck, Michael Privitera, Michael
Walters
Pharmacokinetic Properties
of Chronic Administration of Eteplirsen
in the Treatment of Boys with Duchenne
Muscular Dystrophy (DMD) J Saoud, J
Zhang, L Warner, C Kincaid, P Duda, E Kaye
Evaluation of Th17 Cell
Infiltration in Thymectomy Materials of
Acetycholine Receptor Antibody-positive
Myasthenia Gravis Patients Can Ebru
Bekircan-Kurt, Lala Mehdikhanov, Sevgen
Oner, Gunes Esendagli, Erdem Karabulut,
Asli Kurne, Sevim Erdem-Ozdamar, Ersin Tan
P7.045
Myasthenia Gravis:
Thymectomy and Quality of Life Yury
Bykov, Aleksandr Smolin
P7.046
A Randomized Study of
Exercise in Spinal and Bulbar Muscular
Atrophy Christopher Grunseich, Ilona Kats,
Dara Bakar, Angela Kokkinis, Ellen Levy,
Michaele Smith, Joseph Shrader, Galen
Joe, Joshua Woolstenhulme, Willie Ching,
Bart Drinkard, Cris Zampieri, Laboni Ghosh,
Derrick Fox, Tyler Lanman, Sungyoung Auh,
Alice Schindler, Kenneth Fischbeck
Enterovirus-D68 Associated
Acute Anterior Horn Cell Injury Jason
Williams, Anna Fermin, Deborah Bradshaw
P7.041
Differentiating Depression
from PBA-related Crying in ALS: Use of
PHQ-9 and CNS-LS Nimish Thakore, Jhanvi
Menon, Erik Pioro
P7.042
Electrical Impedance
Myography and Quantitative Ultrasound
as Biomarkers of Disease Progression
in Duchenne Muscular Dystrophy: A
Preliminary Analysis Seward Rutkove, Craig
Zaidman, Jim Wu, Kush Kapur, Basil Darras
Prevalence of Cardiac
Arrhythmia in Myasthenia Gravis Rachana
Gandhi, Raja Boddepalli, Raghav
Govindarajan, Efrain Salgado
P7.058
Ptosis in a Cohort of Patient
with Late Onset Pompe Disease (LOPD)
from Argentina Claudio Mazia, Marcelo
Francisco Rugiero, Alberto Dubrovsky,
Juan Politei, Valeria Lujan Salutto, Ernesto
Augusto Fulgenzi, Agustin Jauregui, Patricia
Santoro, Valeria Alvarez
P7.059
Effectiveness of Prednisone
in the Treatment of Ocular Myasthenia
(EPITOME) Michael Benatar, Michael
McDermott, Donald Sanders, Gil Wolfe,
Richard Barohn, Richard Nowak, Michael
Hehir, Vern Juel, Hans Katzberg, Alrabi
Tawil
Neuromuscular Disease:
Clinical Science
P7.050
P7.040
P7.057
P7.048
P7.038
Primary Lateral Sclerosis
Plus Corticobasal Syndrome: A Case
Series Kimberly Johnson, Mazen
Dimachkie, Mamatha Pasnoor, Jeffrey
Statland, Omar Jawdat, Richard Barohn,
Melanie Glenn, Richard Dubinsky, Jeffrey
Burns, April McVey
Generalized Myasthenia
Gravis in Argentina: Serological Profile and
Clinical Characteristics. A Hospital-based
Study Florencia Aguirre, Mariela Laura Paz,
Valeria Cores, Juliana Leoni, Andres Villa
Neuromuscular Disease:
Clinical Trials and Treatment
P7.049
P7.039
P7.056
Inclusion Body Myositis Treated
with Intravenous Immunoglobulin: A Longterm Study Murata Kenya, Hidefumi Ito
Clinical Characteristics of
New-onset Epilepsy in Patients with Down
Syndrome and Dementia Taha Gholipour,
Rani Sarkis, Zeina El-Chemali
Clinical Approach of
Neuromuscular Disease
The Wide Clinical Phenotype
of Kennedy’s Disease Giorgia Querin,
Cinzia Bertolin, Marco Volpe, Gabriella Zara,
Elisa Da Re, Francesca Zoccarato, Nicola
Caretta, Carlo Foresta, Sonia Marcato,
Massimo Iafrate, Domenico Corrado, Maria
Silvano, Elena Pegoraro, Davide Pareyson,
Maria Pennuto, Gianni Soraru
P7.047
P7.037
A Case Report of Exacerbation
of Myoclonus in Idiopathic Generalized
Epilepsy from Use of Lacosamide Arun
Swaminathan, Siddharth Kapoor
P7.055
Hypoglossal Nerve Palsy Is
Associated with a Variety of Etiologies
and Sometimes Results in Tongue
Myokymia Amro Stino, Benn Smith
Spectrum of Valosin
Containing Protein (VCP)-opathy: A Case
Series Mohamed Kazamel, Eric Sorenson,
Kathleen McEvoy, Andrew Engel, Lyell
Jones, Andrea Leep Hunderfund, Michelle
Mauermann, Margherita Milone
P7.051
Clinical Utility of Voltage
Gated Calcium Channel Antibody
Titers Karin Mente, Adham Jammoul, Luay
Shayya, Pravin George, Yuebing Li
Magnetic Resonance Imaging
Assessments of Two Doses of Drisapersen
in the Treatment of Ambulant Boys with
Duchenne Muscular Dystrophy Courtney
Bishop, Rexford Newbould, Robert Janiczek,
Giles Campion
P7.060
Ultra-high Dose
Methylcobalamin (E0302) Prolongs Survival
of ALS: Report of 7 Years’ Randomised
Double-blind, Phase 3 Clinical Trial
(ClinicalTrials.gov NCT00444613) Ryuji
Kaji, Shigeki Kuzuhara, Yasuo Iwasaki,
Koichi Okamoto, Masanori Nakagawa,
Takashi Imai, Takao Takase, Hiroki Shimizu,
Kunio Tashiro
P7.061
ManNAc Is Safe and
Increases Sialic Acid Production in GNE
Myopathy Bradley Class, Frank Celeste, Xin
Xu, Amy Wang, May Christine Malicdan,
Lea Latham, Carla Ciccone, Marjan Huizing,
William Gahl, Nuria Carillo-Carrasco
A Study on Natural History of
Duchenne Muscular Dystrophy—Indian
Perspective Ravinder Singh, Manjunath
Poojar, Atchayaram Nalini, K Thennarasu,
Piyush Ostwal, Kiran Polavarapu, Gayathri
N, Preethish Kumar V
Conception, Design and
Realization of a Longitudinal Study for
Patients Affected by Hereditary Inclusion
Body Myopathy Due to Mutation of GNE
Gene: Looking for Clinical and Biological
Biomarkers for Upcoming Therapeutic Trial
(ClinBio-GNE) Teresa Gidaro, Dominique
Duchene, Gwenn Ollivier, Valerie Decostre,
Jean-Yves Hogrel, Pierre Carlier, Anthony
Behin, Laurent Servais
P7.053
P7.063
P7.052
Stiff Person Syndrome: A Case
Series Duaa Jabari, Mazen Dimachkie,
Jeffrey Statland, Ahmad Abuzinadah, Omar
Jawdat, Melanie Glenn, April McVey, Arthur
Dick, Richard Dubinsky, Laura Herbelin,
Richard Barohn, Mamatha Pasnoor
P7.054Non-neuromuscular
Manifestations of Spinal and Bulbar
Muscular Atrophy Dara Bakar, Christopher
Grunseich, Ilona Kats, Angela Kokkinis, Alice
Schindler, Carlo Rinaldi, Kenneth Fischbeck
Fast, Easy, Online Registration · AAN.com/view/AM15
P7.062
"Toe Off" Style Carbon Fiber
Ankle Foot Orthoses in Neuromuscular
Disease: The OSUMC Experience Wendy
King, Ani Mnatsakanian, John Kissel
P7.064
Comparison of Length of
Hospital Stay Between Treatment with
Plasma Exchange Versus IVIg in Mild
Guillain-Barré Syndrome Vladimir Klinov,
Joseph Campellone
P7.065
Acthar in Dermatomyositis
and Polymyositis Treatment Registry: An
Interim Analysis Todd Levine
P7.066
Predicting Responsiveness
to Study Drug Before Randomization in
the DAPPER Trial of 3,4-Diaminopyridine
(3,4-DAP) in Lambert-Eaton Myasthenic
Syndrome (LEMS) Donald Sanders, Laura
Jacobus, Kathy Ales, David Jacobus
P7.067
A Phase IIa Double-blind,
Placebo-controlled Study to Evaluate
the Safety of Oral Fingolimod in Patients
with Amyotrophic Lateral Sclerosis
(ALS) James Berry, Sabrina Paganoni,
Nazem Atassi, Namita Goyal, Michael
Rivner, Ericka Simpson, Stanley Appel,
Daniela Grasso, Nicte Mejia, Farrah
Mateen, Merit Cudkowicz, Steven Perrin
P7.068
First Human Use of High
Dose IV Trehalose: Safety, Tolerability
and Pharmacokinetic Results from the
Oculopharyngeal Muscular Dystrophy
(OPMD) Therapy Trial Zohar Argov,
Hadassa Vornovitsky, Sergiu Blumen,
Yoseph Caraco
P7.069
Low Dose Prednisone in
Seropositive Myasthenia Gravis Ahmad
Abuzinadah, Mamatha Pasnoor, Jeffrey
Statland, Duaa Jabari, April McVey, Laura
Herbelin, Omar Jawdat, Melanie Glenn,
Richard Barohn, Mazen Dimachkie
Clinical Studies of
Neuromuscular Disease
P7.070
Myasthenia Gravis
Exacerbation After Discontinuing
Mycophenolate: A Case-control
Study Bjorn Oskarsson, David Richman,
David Rocke
P7.071
Prompt Diagnosis of GBS
Is Improved by Emergency Department
Neurological Consultation and Associated
with Better Outcomes Divyanshu Dubey,
Marrissa Kopatic, Matthew Freeman,
Anshudha Sawhney, Worthy Warnack,
Steven Vernino
P7.072
YouTube and Peripheral
Neuropathy: What Patients Want? Harsh
Gupta, Rajan Patel, Betul Gundogdu, Manoj
Mittal, Archana Hinduja
P7.073Withdrawn
P7.074
Novel OPA1 Mutation in
Syndromic Mitochondrial Dominant Optic
Atrophy (DOA+): A Case Report Varoon
Thavapalan, Tsao-Wei Liang, Goran
Rakocevic
P7.075
Six-minute Walk Test Is
Reliable and Valid in Spinal Muscular
Atrophy Sally Dunaway, Jacqueline
Montes, Samantha Kramer, Jonathan
Marra, Rachel Salazar, Claudia Chiriboga,
Carol Garber, Darryl De Vivo
P7.076
The Utility of Paraneoplastic
Antibody Testing in the Diagnosis of Motor
Neuron Disease Najwa Al-Bustani, William
Simonson, Desiree Marshall, Jennifer Vetrovs,
Mark Wener, Michael Weiss, Leo Wang
P7.077
Antilipemic Agents and
Creatine Phosphokinase: Epidemiologic
Study and Clinical Anatomical Analyses
of 55 Patients Alzira Carvalho, Miriam Eva
Koch, Pâmela Melo, Thaiane Fagundes,
David Feder
123
Thursday
April 23
2:00 p.m.–6:30 p.m.
Poster Session VII
P7.078
Ocular LEMS or MG and LEMS
Overlap Syndrome? Watcharasarn
Rattananan, Mohammad Alsharabati, Shin Oh
P7.079
Determining the Yield of
Electrodiagnostic (EDX) Studies in Patients
Referred for Neck And/ or Upper Extremity
Pain Rajesh Gupta, Nicholas Silvestri
P7.084
Neuropathy: Clinical Trials,
Diagnostic Testing, and
Treatment
P7.085
P7.090
Clinical Manifestations of
Isolated Elevated Homosysteine-induced
Peripheral Neuropathy in Adults Varun
Shandal, Jin Luo
Neuropathy: Clinical Science
The Clinical Features of
Neuropathies Associated with Monoclonal
Gammopathies Aline Herlopian, Ayman
Al-salaimeh, Betul Gundogdu, Tawfiq AlLahham
P7.080
P7.086
Clinical Features of HNPP
Patients with the 17p11.2 Deletion Aline
Oliveira, Raquel Pereira, Vanessa Marques,
Amilton Barreira, Wilson Marques
P7.081
Prevalence and
Characteristic Features of Anti-human
Neurofascin 155 Antibody-associated
Chronic Inflammatory Demyelinating
Polyradiculoneuropathy Hidenori Ogata,
Dai Matsuse, Ryo Yamasaki, Nobutoshi
Kawamura, Takuya Matsushita, Jun-ichi Kira
P7.082
Neuropathy Symptoms Are
Associated with Increased Fall Risk in
Patients Receiving Potentially Neurotoxic
Chemotherapy Noah Kolb, A. Smith, J.
Singleton, Summer Brown, Bob Wong,
Susan Beck, Kathi Mooney
2:00 p.m.–6:30 p.m.
A Case Report and Management
of Familial Amyloid Polyneuropathy Transmitted
by Domino Liver Transplantation with Disease
Onset at Less Than 3 Years Sharmi Shafi,
Pierre Bourque
P7.087
Elevated Plasma Level of
Homosysteine and Peripheral Neuropathy
in Adults Jin Luo
P7.088
Chronic Severe
Polyradiculoneuropathy with
Ophthalmoplegia and Encephalopathy
Due to Thiamine Deficiency in a Bariatric
Surgery Patient Carolyn Mehaffey, Aline
Herlopian, Betul Gundogdu
P7.089
Dermal Nodes in Diabetic
Neuropathy Amanda Peltier, M. Iliza
Butera, Yaping Shi, Lily Wang, Jun Li
P7.083
Elevated SNCAM-1
Concentrations in Sera from Patients
with Polyneuropathies Adam Niezgoda,
Jacek Losy, Slawomir Michalak, Wojciech
RED: 15AM RunWalk Ad_AL, Hh
Kozubski
Placed in Abstract Listing
8.25"x5.4375", Full Bleed +0.125" 2C
Incidence and Risk Factors for
Neuropathy Following Primary Total Knee
Arthroplasty Joseph Nguyen, Edwin Su,
Stephen Lyman, Erin Manning, Kelianne
Cummings, Anita Wu, Mayu Sasaki, Teena
Shetty
P7.091
The Relationship Between
Cerebrospinal Fluid Protein Levels and
Electrophysiologic Abnormalities in
Guillain-Barré Syndrome Hannah Homafar,
Amanda Lakraj, Richard Nowak, Kimberly
Robeson, Jonathan Goldstein, Huned
Patwa, Daniel DiCapua
P7.092
Incidence and Risk Factors for
Neuropathy Following Primary Total Hip
Arthroplasty Joseph Nguyen, Edwin Su,
Stephen Lyman, Erin Manning, Kelianne
Cummings, Anita Wu, Mayu Sasaki,
Teena Shetty
P7.093
Clinical Characteristics and
Treatment Response of Patients with
Chronic Inflammatory Demyelinating
Neuropathy Refractory to Standard
Therapy Artem Kaplan, Thomas Brannagan
P7.095
A Novel Evidence Based
Phone System Reduces Symptoms of
Chemotherapy Induced Neuropathy Noah
Kolb, A. Smith, J. Singleton, Summer
Brown, Bob Wong, William Dunson Jr.,
Debbie Wujcik, Susan Beck, Kathi Mooney
P7.096
Small Fiber Neuropathy:
Gender Differences in Skin Biopsy and
Clinical Findings Joshua Weaver, KyungWha Kim, Bridget Carey, Jennifer Langsdorf,
Russell Chin
P7.097
Effect of FTY720 (Fingolimod)
in a New Preclinical Rat Model for
Chronic Inflammatory Demyelinating
Polyradiculoneuropathy (CIDP) Susana
Brun, Laurent Kremer, Elisabeth Trifilieff,
Jerome De Seze
P7.098
Biopsy and EMG Findings
in a Case of Late-onset Dropped
Head Syndrome After Mantle Field
Radiotherapy Amro Stino, Mark Ross
P7.099
The Rarity of Tarsal Tunnel
Syndrome: Analysis of Cases Referred to
an EMG Laboratory Brion Reichler, Darryl
Sneag
P7.094
Subcutaneous Immunoglobulin
(IgPRO20) for Maintenance Treatment in
Patients with Multifocal Motor Neuropathy Hans Katzberg, Vilija Rasutis, Vera Bril
Run/Walk for Brain Research
On your mark, get set…help cure BRAIN DISEASE!
Join your colleagues on Tuesday, April 21, 2015, at 6:30 a.m., for a friendly run/walk. All proceeds will
go to the American Brain Foundation to help support research.
Sign up for the Run/Walk at AAN.com/view/RunWalk
Sponsored by:
Poster Session VII
Aging, Dementia, Cognitive,
and Behavioral Neurology:
Clinical Trials
P7.100
A Randomized, Double-blind,
Placebo-controlled, 24-week, Phase 2b
Outcomes Study of 3 Different Doses of
Encenicline or Placebo in Subjects with
Mild to Moderate Probable Alzheimer’s
Disease Hans Moebius, Gordon Loewen,
Nancy Dgetluck, Dana Hilt
P7.101
Efficacy and Tolerability of
Memantine Extended Release Added to
Stable Donepezil Regimen in Individuals
with Moderate to Severe Alzheimer’s
Disease: Subset Analysis of a Randomized
Clinical Trial George Grossberg, Gustavo
Alva, Suzanne Hendrix, Robert Hofbauer,
Vojislav Pejovic, Stephen Graham
P7.102
Use of Quantile Regression
to Characterize Solanezumab Effects
Across Percentiles of Disease Progression
in EXPEDITION Alzheimer's Disease
Trials Yun-Fei Chen, Xiwen Ma, Karen
Sundell, Karla Alaka, Kory Schuh, Joel
Raskin, Robert Dean
P7.103
Effects of Testosterone
Supplementation and Serum Levels
on Cortical Volume in Healthy Older
Men Jeremy Hua, Donald Rojas, Jason
Tregellas, Christopher Filley, Robert
Schwartz, Victoria Pelak
P7.104
Caregiver Treatment
Preference/Satisfaction and Efficacy
Among Patients in the OPtimising
Transdermal Exelon in Mild-to-moderate
Alzheimer’s Disease (OPTIMA)
Study Steven Ferris, Xiangyi Meng, Drew
Velting
P7.105
Effects of a Distinct Phenolic
Complex on Working Memory Performance
in Healthy Men and Women with Ageassociated Memory Impairment Brenda
Fonseca, Kelli Herrlinger, Kristin Nieman,
Michael Ceddia, Linda Fullmer, Kristen
Sanoshy, Kathleen Kelley, Kevin Maki
P7.106
Adding Memantine to Stable
Cholinesterase Inhibitor Therapy in Patients
with Moderate to Severe Alzheimer’s
Disease Is Associated with Improvement
in Various Neuropsychiatric Symptoms: A
Pooled Analysis Gustavo Alva, Noel Ellison,
Suzanne Hendrix, Vojislav Pejovic, Victor
Otcheretko
P7.107
A Phase II Study to Evaluate
the Efficacy and Safety of Plasma
Replacement with 5% Albumin in Betaamyloid Peptide Clearance in Cerebrospinal
Fluid and Plasma, and Its Clinical Effects in
Patients with Mild-moderate Alzheimer's
Disease Merce Boada, Oscar Lopez, Laura
Nunez, Pilar Ortiz, Fernando Anaya, Isabel
Hernandez, Javier Olazaran, Lluis Tarraga,
Mar Buendia, Ramon Pla, Isidro Ferrer,
Thomas Obisesan, Joshua Shua-Haim,
Antonio Paez
P7.108
Delayed-start Analyses of
Solanezumab Phase 3 Studies in Mild
Alzheimer’s Disease Hong Liu-Seifert, Scott
Andersen, Karen Holdridge, Eric Siemers
P7.109
PRISM II: An Open-label
Study to Assess the Safety, Tolerability,
and Effectiveness of Dextromethorphan
20 Mg/Quinidine 10 Mg for Treatment
of Pseudobulbar Affect Secondary to
Dementia, Stroke, or Traumatic Brain Injury:
Results from the Alzheimer’s Disease/
Dementia Cohort Rachelle Doody, Stephen
D'Amico, Andrew Cutler, Paul Shin, Fred
Ledon, Charles Yonan, Joao Siffert
Cerebrovascular Disease
and Interventional Neurology:
Stroke in Young
P7.120
Young-aged Stroke in Korea:
Changing Patterns of Risk Factors and
Etiologies Han A Kim, Jong Kim,
Bum Joon Kim
Aging, Dementia, Cognitive,
and Behavioral Neurology:
Cardio- and Cerebrovascular
Factors in Dementia
Detection of Paroxysmal
Atrial Fibrillation in Very Young Cryptogenic
Ischemic Stroke Patients Under 40 Years:
A Three Week ECG-Holter Monitoring
Study Michal Kral, Daniel Sanak, Martin
Hutyra, Marian Fedorco, David Skoloudik,
Petr Kanovsky
P7.110
P7.122
Cognitive Dysfunction
in Obese Individuals with or Without
Metabolic Risk Factors Ala Abu Saleh,
Radi Shahien, Nimer Assy
P7.111
Refined Sugar Intake
Is Associated with Lower Cognitive
Performance Across the Cognitive
Continuum but Is Not Associated with
Preclinical Cognitive Decline in Intact
Elderly Subjects Dasha Kenlan, Sarah
Tarrant, Amanda Pursell, Andrew Welleford,
Keith Albrektson, Gregory Jicha
P7.112
Cardiovascular Comorbidities
and Medication in Dementia
Disorders Pavla Cermakova, Kristina
Johnell, Johan Fastbom, Bengt Winblad,
Maria Eriksdotter-Jonhagen, Dorota Religa
P7.113
Involvement of Microbleeds,
Representative of Cerebral Amyloid
Angiopathy, in Cognitive Dysfunction
in Alzheimer’s Disease and Parkinson’s
Disease: An MRI Study Tomohiko Murai,
Masako Kinoshita, Yoshifumi Nakaya, Akio
Ikeda, Ryosuke Takahashi
P7.114Endothelium-mediated
Changes in Vascular Tone and
Cognitive Function in Patients with
Subjective Cognitive Impairment: A Pilot
Study Gereon Nelles, Einat Monovic,
Adrian Schembri, Maria Polidori
P7.115
The Association Between
Pulse Pressure and Memory Functioning
over Time Depends on Baseline Systolic
Blood Pressure Eric McDade, Zhaowen
Sun, Ching-Wen Lee, Beth Snitz, ChungChou Chang, Mary Ganguli
P7.121
Misdiagnosis in Young
Patients with Ischemic Stroke Luciana
Leon, Fatima Pantiu, Julieta Quiroga, Pablo
Bonardo, Claudia Uribe, Julieta Mazziotti,
Alberto Zinnerman, Alejandra Martinez,
Andrea Sotelo, Lorena Jure, Pedro Nofal,
Eduardo Bendersky, Luciano Alberto
Sposato, Patricia Riccio, Ricardo Reisin,
Manuel Fernandez Pardal
P7.123
"Spicy Strokes": Synthetic
Cannabis and Strokes in Young Ahmad El
Kouzi, Fazeel Siddiqui
P7.124
Stroke in the Young: Etiologies
and Risk Factors Pandompatam Govind,
Roomana Ahad, Ahmed Iftekhar
P7.132
Selective Serotonin Reuptake
Inhibitors for Prevention of Post Stroke
Depression: A Meta-analysis Dan Neftalie
Juangco, Jeshya Ang, Fran Efendy, Joven
Cuanang
P7.133
Cognition and Major
Depression After Frontal and Cerebellar
Stroke Mario Dulay, Krissa Agbayani, Rajan
Gadhia, Jenny Lai, John Volpi, David Chiu, Y.
Jonathan Zhang, Gavin Britz
P7.134
Anxiety Influences TIA
Diagnosis William Sugrue, Deepa Bhupali,
Daniel Labovitz
P7.135
Competitiveness in Passive
NBA Spectating and Cerebrovascular
Accident Frequency Danielle Weiss,
William Grubb, Nirav Shah
P7.136
Basal Ganglia Stroke
and Apathy: A Clinico-radiological
Study Emmanuel Thomas, Irina ViakhirevaDovganyuk, Emmanuelle Volle, Douraied
Ben Salem, Marc Verin, Richard Levy, Serge
Timsit
P7.137
The Quantitative Analysis of
Temporal Lobes and Hippocampi in Patients
Diagnosed with Transient Global Amnesia
(TGA) Raja Boddepalli, Dennys Reyes,
Efrain Salgado, Fabian Candocia, Rachana
Gandhi, Avi Oppenheimer.
P7.125
Cerebrovascular Disease
and Interventional Neurology:
Race, Ethnicity, and Stroke
P7.126
P7.138
Impact of Stroke Misdiagnosis
on Short-term and Discharge Use of
Vascular Medications in Young Adults Seemant Chaturvedi, Kumar Rajamani
Body Mass Index and
Stroke Subtype in a Young Adult Stroke
Population Jina Youn, Thandar Aung,
Mohammad Afrasiabi, Joni Clark
P7.127
Incidence of Ischemic
or Hemorrhagic Non-fatal Strokes
in Hemophiliac Adults and Teenage
Children Cara Bezzina, Ahmed Malik,
Adnan Qureshi
P7.128
Primary Angiitis of the Central
Nervous System (PACNS) Presenting
with Intracerebral Hemorrhage (ICH):
Three Cases Associated with Chronic
Use of Over-the-counter Vasoconstrictive
Drugs Ruchira Jha, Jacob George, Aneesh
Singhal
Intravenous Tissue
Plasminogen Activator Treatment for
Acute Ischemic Stroke in the REGARDS
Study Kara Sands, Karen Albright, Justin
Blackburn, Amelia Boehme, George
Howard, Virginia Howard, Suzanne Judd,
Brett Kissela, Nita Limdi, David Rhodes,
Harn Shiue, April Sisson, Monika Safford
P7.139
Quality Assessment of
Vascular Disease Prevention Practices
in High Risk Urban Women Seemant
Chaturvedi, David Pieper, Diane Levine,
Neelima Thati, Ramesh Madhavan, Marie
Mateo, Lavoisier Cardozo, Marybeth
Lepczyk
P7.116
Cerebrovascular Disease
and Interventional Neurology:
Stroke, Depression, and Anxiety
P7.117
Racial Variation in Association
of Elevated Factor VIII and Stroke
Outcome Lauren Dowell, Amelia Boehme,
Alyana Samai, Alexander George, Laurie
Schluter, Ramy El Khoury, Sheryl MartinSchild
P7.129
Post-stroke Depression (PSD) in
Sub-Saharan Africans—Validation of the
Japanese Stroke Scale for Depression. (JSS-D) Frank Imarhiagbe, Owolabi Afolabi, Anthony
Kubeyinje, Fatai Akemokwe, Francis Odiase
P7.141
P7.130
Interactive Voice
Response—a Novel Approach to
Post-stroke Depression Monitoring Lesli
Rusche-Skolarus, Paul Pfeiffer, Linda
Williams, Jason Mackey, John Piette, Lewis
Morgenstern
P7.142
P7.131
P7.143
Vazonat Efficiency in Patients
with Atherosclerotic Encephalopathy Stage
I-II Kunduz Karbozova
Regular Aspirin Use Does
Not Reduce Risk of Incident Cognitive
Decline Brendan Kelley, Leslie McClure,
Frederick Unverzagt, Brett Kissela, Dawn
Kleindorfer, George Howard, Virginia
Wadley
P7.118
Early Diagnosis of Vascular
Cognitive Impairment Is Associated
with Improved Adherence with Medical
Treatment of Vascular Risk Factors Angelia
Kirkpatrick, Elliott Ross, Leslie Guthery, Calin
Prodan
P7.119
Heart-heath Intervention
Reduces Cognitive Decline in Mild Cognitive
Impairment of the Cerebrovascular Type:
A Randomized, Placebo-controlled Clinical
Trial Gregory Jicha, Richard Murphy,
Martha Biddle, Debra Moser
Fast, Easy, Online Registration · AAN.com/view/AM15
Risk Factors and Lesion
Localization Correlations with Post Stroke
Depression Sopio Mataradze, Tinatin
Kherkheulidze, Maia Beridze, Marika
Alphaidze, Davit Eliauri
P7.140
Racial Differences in the Risk
Factors, Severity, Outcomes, and Treatment
in Acute Ischemic Stroke Muhammad
Ahmed Chauhan, Syed Ali, Nicolas Bianchi,
Archana Hinduja
Race Does Not Predict
Discharge Functional Status in Acute
Ischemic Stroke Patients with Renal
Impairment After Systemic TPA Kara
Sands, Gyanendra Kumar, Harn Shiue, Reza
Bavarsad Shahripour, Andrei Alexandrov
Comparison of Major
Modifiable Stroke Risk Factors Associated
with Lacunar Strokes in Anterior and
Posterior Circulation in Multiethnic
Cohort Sebina Bulic, Natalie Valle, Amy
Towfighi
125
Thursday
April 23
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session VII
P7.144
An Association Between
Diabetes and Late Hospital Arrival Among
Low-income Hispanic Stroke Patients Ellyn
Leighton-Herrmann, Olajide Williams
P7.145
Narrative Communication
Using a Gospel Musical and Telenovela
May Improve EMS Activation for Stroke
Among Blacks and Hispanics Olajide
Williams, Amparo Abel-Bey, James Noble,
Lenfis Valdez, Ellyn Leighton-Herrmann,
Alexandra DeSorbo, Madeleine Gordillo,
Joseph Ravenell, Mildred Ramirez, Jeanne
Teresi, Girardin Jean-Louis, Olugbenga
Ogedegbe
P7.146
Are There Different
Rates of Acute Stroke Risk Factors in
the South Texas Mexican American
Population? Wondwossen Tekle, Ameer
Hassan, Ahmed Malik, Lisa Jones-Fullingim,
Christina Sanchez, Vishal Jani, Olive
Sanchez, Erlinda Abantao, Adnan Qureshi
P7.147
Clinical Profile, Risk Factors,
Etiology and Outcome of Stroke in Young
Filipino Adults Ty Alekzander Talamera,
Ma. Cristina San Jose, Jennifer Ann
Sanchez, Jose Leonard Pascual IV
Neuro Trauma, Critical Care,
and Sports Neurology
P7.148
Changes in Resting State
Functional Connectivity Across a Season
of High School Football Michael Clark,
Samuel Kuzminski, Kevin Guskiewicz, Jeffrey
Petrella
P7.149
Earlier Cooling in Post Cardiac
Arrest Patients Fails to Show Benefit Preet
Varade, Kushak Suchdev, Shamaehah
Javed, Gregory Norris, Mohammad Ibrahim
P7.150
Management of Refractory
ICP in a Case of Fulminant Acute
Disseminated Encephalomyelitis Nicole
Mahdi, Syed Omar Shah, Michelle Ghobrial,
Rodney Bell, Matthew Vibbert, Jacqueline
Urtecho
P7.151
DTI Changes in Bilateral
Uncinate Fasiculus Following Acute, but
Not Chronic Symptomatic Concussion in
Adolescence Rejean Guerriero, Marie
Drottar, William Meehan III, P. Grant,
Rebekah Mannix
P7.152
Clinical Correlates of Diffusion
Tensor Imaging in Repetitive Head
Trauma Charles Bernick, Sarah Banks,
Wanyong Shin
P7.153
Do Football Helmet Add-ons
Reduce Concussion Risk? John Lloyd,
Francis Conidi
P7.154
Comparable Levels of
Phosphorylated Tau in Epileptic Brain and
Chronic Traumatic Encephalopathy Briana
Prager, Vikram Puvenna, Chaitali Ghosh,
Damir Janigro
P7.155
Younger Children Recover
Faster and Have Less Premorbid Conditions
Than Adolescents with Concussion Rejean
Guerriero, Karameh Hawash, Michael Pepin,
Robert Wolff, William Meehan III
126
2:00 p.m.–6:30 p.m.
P7.156
Volumetric Measurements of
Cytotoxic and Vasogenic Edema Following
Traumatic Brain Injury Using Magnetic
Resonance Imaging Brian Stephens, Emily
Spessert, George Knaysi, Martin Cota,
Lawrence Latour, Ramon Diaz-Arrastia
P7.157
Association Patterns of
Intraventricular and Intraparenchymal
Simultaneous ICP Measurements Zakraus
Mahdavi, Stephen Figueroa, DaiWai Olson,
Christiana Hall, Venkatesh Aiyagari
P7.158
Sensitivity and Specificity
of Altered Propulsive Force Following
Concussion Jessie Oldham, Kelsey Evans,
Erik Wikstrom, Thomas Buckley
P7.159
Initial Concussion
Presentation Does Not Predict Acute
Impairments in Transitional Dynamic
Postural Control Jessie Oldham, Kelsey
Evans, Erik Wikstrom, Thomas Buckley
P7.160
The Impact of Games
Played on Age Related Changes in White
Matter Mean Diffusivity Among Retired
NFL Athletes Kyle Womack, Jeremy
Strain, Kevin Chen, Jeffrey Spence, Nyaz
Didehbani, Munro Cullum, John Hart
P7.168
Induced Normothermia
in Severe Traumatic Brain Injury
Patients Deborah Green-LaRoche,
Tudor Sturzoiu, Helena Lau, Anna Marisa
Cervantes-Arslanian, Joseph Burns
P7.169
Barriers to Recovery from
Concussion Teena Shetty, Kelianne
Cummings, Kristin Halvorsen, Maxwell
Singer, Joseph Nguyen
P7.170
Multiple Past Concussions
in High School Athletes with
ADHD Magdalena Wojtowicz, Grant
Iverson, Rebekah Mannix, Brian Brooks,
Bruce Maxwell, Ross Zafonte, Paul Berkner
P7.171
Bedside Clinical Predictors
of Bad Outcome in Hypoxic Ischemic
Encephalopathy Patients After Cardiac
Arrest Treated with Therapeutic
Hypothermia Gemmalynn Sarapuddin,
Artemio Roxas Jr.
P7.172
Predictors of Outcome in
Status Epilepticus in the Neuro ICU Jules
Osias, Paul McVey, Serkan Ayvaz, Jennifer
Frontera, Laurie McWilliams-Dunnigan
P7.181
Observed Specific Pattern
of Cognitive Impairment in Patients with
Mild Traumatic Brain Injury: A Prospective
Study of 35 Patients Ajay Jawahar, Suresh
Kumar, Monika Kumar
P7.182
Determining Inter-rater
Reliability of Eye Tracking Methods for Use
with Persons with Severe Traumatic Brain
Injury Lorene Leung, Rachel Cohn, Therese
O'Neil-Pirozzi, Yelena Guller, Swathi Iyer,
Hong Pan, Emily Stern, Joseph Giacino
P7.183
An FMRI-based Visual
Cognition Paradigm for Detection
of Command-following and
Communication Yelena Guller, Hong Pan,
Swathi Iyer, Lorene Leung, Rachel Cohn,
Benjamin Fuchs, Courtney Haley, Therese
O'Neil-Pirozzi, Joseph Giacino, Emily Stern
P7.184
Effect of Lesion Burden
on Recovery and on Response to
Amantadine in Patients with Disorders
of Consciousness After Traumatic Brain
Injury Douglas Katz, John Whyte, Helena
Chang, Noam Eshkar, Kathleen Kalmar,
David Long, Stuart Yablon, Emilia Bagiella,
Joseph Giacino
Postural Stability in Veterans
with Mild Traumatic Brain Injury and
Disequilibrium Mark Walker, Tao Pan, Ke
Liao, Kristen Roenigk, Janis Daly
Early Mobility Program in the
Neurocritical Care Unit—Appropriateness
of Referral for Physical Therapy Laura
Bishop, Beth McDaniel, Susan Reeves,
Janet Crumpler, Stacey Wolfe, Keith Scott,
Aarti Sarwal
P7.162
7 Tesla Brain MRI
Characteristics Among Concussion
Patients Andrew Russman, Richard Figler,
Se-Hong Oh, Mark Lowe, Stephen Jones
P7.174
P7.163
Physicians' Management
Practices and Perceived Health Risks when
Postconcussion Symptoms Persist Sean
Rose, Anastasia Fischer, Geoffrey Heyer
P7.175
Efficacy of Minocycline in
Female Rats After Mild Diffuse Traumatic
Brain Injury L. Turtzo, Neekita Janaria,
Jacob Lescher, William Tu, Joseph Frank
The Relationship Between
Cognitive Reserve and Neuropsychological
Outcomes After TBI Uzma Hussain,
Maryanne Sacco, Jacob Leary, Shannon
McNally, Katherine Lopez, John Dsurney,
Leighton Chan
P7.164
P7.176
P7.187
P7.161
Von Willberand Factor and
Cellular Fibronectin Plasma Concentrations
Are Increased in Mild Traumatic Brain Injury
(TBI) with MRI Evidence of Microvascular
Injury Tanya Bogoslovsky, Bao-Xi Qu,
Martin Cota, Lawrence Latour, Ramon DiazArrastia
P7.165
A Systematic Video Analysis
of Concussion in the National Rugby
League Andrew Gardner, Grant Iverson,
Magdalena Wojtowicz, Christopher Levi,
Michael Makdissi, Tanya Quinn, Sandy
Shultz, David Wright, Peter Stanwell
P7.166
Evolution of Traumatic
Parenchymal Intracranial Hematomas
(ICHs): Comparison of High Density and
Low Density Components and Relationship
to Outcome Sean Wilkes, Erin McCormack,
Erika Silverman, Leah Harburg, Ross Passo,
Tanya Bogoslovsky, Jason Schroeder, Carol
Moore, Kimbra Kenney, Dzung Pham, Ramon
Diaz-Arrastia
P7.167
Characterization of
Baseline EEG Abnormalities the Brain
Injury and Mechanisms of Action of
Hyperbaric Oxygen (HBO2) for Persistent
Post-concussive Symptoms After Mild
Traumatic Brain Injury (mTBI) Study
(BIMA) Christopher Williams, Mark Spitz,
John Foley, Lindell Weaver, Anne Lindblad,
Michael Wierzbicki
P7.173
Neuro-rehabilitation: Traumatic
Brain Injury
Psychiatric Symptoms as
a Predictor of Outcome in Patients with
Post-concussive Syndrome Arun Chhabra,
Allison Weathers, Bichun Ouyang
Knowledge, Awareness, and
Attitudes Regarding Concussion Among
Middle Schoolers Thor Stead, Yasamin
Daneshvar, Sarah Ayala, Latha Ganti
P7.177
Neurologic Exam Findings and
Clinical Manifestations of Post-concussion
Syndrome in a Pediatric Population Devon
Cohen, Francis Conidi
P7.178
EEG Monitoring in Patients
with Hypothermia Post Cardiac Arrest—a
Comparison of 'Evolving' Patterns and
Outcomes Kushak Suchdev, Preet Varade,
Lusine Avedian, Shyam Rao, Srilatha
Thadur, Wazim Mohamed, Deepti Zutshi
P7.179
Pathological Correlation
of Diffusion Tensor Imaging and
Magnetization Transfer Biomarkers in a
Preclinical Model of Mild Traumatic Brain
Injury Rashida Williams, William Tu, Jacob
Lescher, Christine Turtzo, Joseph Frank
P7.180
Correlations of Focal Lesion
Volume with Intracranial Hypertension
and Brain Tissue Hypoxia After Severe
Traumatic Brain Injury (TBI) Leah Harburg,
Erin McCormack, Carol Moore, Kimbra
Kenney, Jason Barber, Nancy Temkin,
Ramon Diaz-Arrastia
P7.185
Montreal Cognitive
Assessment, a Screening Tool for Mild
Traumatic Brain Injury Suresh Kumar, Ajay
Jawahar, Pooja Shah, Monika Kumar
P7.186
'From Start-up-to-CEO':
Fostering Guided Experiential Learning
of Goal-oriented Attention Regulation
Through Game-assisted Training Following
Brain Injury Fred Loya, Deborah Binder,
Nicholas Rodriguez, Michelle Madore,
Bruce Buchanan, Audrey Kossman, Michael
Sapiro, Tatjana Novakovic-Agopian,
Anthony Chen
P7.188
Cognitive Reserve and
Preservation of Functioning Following
Traumatic Brain Injury Jacob Leary, Carleen
Schwimmer, Uzma Hussain, Katherine
Lopez, Shannon McNally, John Dsurney,
Leighton Chan
P7.189
FMRI-based Detection
of Covert Command-following and
Communication in a Patient with Severe
Traumatic Brain Injury Yelena Guller, Hong
Pan, Swathi Iyer, Lorene Leung, Rachel
Cohn, Therese O'Neil-Pirozzi, Emily Stern,
Joseph Giacino
P7.190
Despite Initial Moribund
Appearance, Critically Ill Traumatic Brain
Injury Patients with Diffuse Axonal Injury
Have Improved Survival Rebecca Compton,
Raphael Carandang, Wiley Hall, Susanne
Muehlschlegel
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VII
Neuro-rehabilitation
P7.191
Non-motor Symptoms in
Patients with SPG4 Mutations Katiane
Servelhere, Jonas Saute, Adriana Moro,
Alberto Martinez, Ingrid De Vasconcellos,
Laura Jardim, Helio Afonso Teive, Iscia
Lopes-Cendes, Anelyssa D´Abreu,
Marcondes Franca, Jr.
P7.192
Investigating Exercise
as an Approach to Remodeling Motor
Unit Fibre Type in Amyotrophic Lateral
Sclerosis Alyson Plecash, Ge Lu, Austin Hill,
Blair Leavitt
P7.193
Sit to Stand (STS) - Maneuver:
Construct Validity of a Novel Measure
of Lower Extremity (LE) Function in ALS
Patients Mohammed Sanjak, Glenn Boyles,
Kristen Thomas, Scott Holsten, Elena
Bravver, William Bockenek, J Scott Story,
Scott Lindblom, Thomas Paccico, Benjamin
Brooks
P7.194
Kinematic Analysis of Arm
Reaching Movements in Diverse Neurologic
Populations Christine Kang, Susan Conroy,
Anindo Roy, Christopher Bever
P7.195
Balance-based Torsoweighting (BBTW): A Novel Therapy to
Prevent Falls in Patients with Peripheral
Neuropathy Hasan Askari, Christine
Tilburg, Robert Burger, Mohammad
Salajegheh
P7.196
Action Observation and Mirror
Neuron System Recruitment: Effect of
Type of Task on Motor Facilitation Silvia
Fumagalli, Maria Rocca, Roberto Gatti,
Massimo Filippi
P7.197
Plasticity of Sensorimotor
System Induced by Sustained Pressure
Stimulation According to Vojta
Therapy Pavel Hok, Petr Hlustik, Miroslav
Kutin, Jaroslav Opavsky, Zbynek Tudos,
Petr Kanovsky
MS and CNS Inflammatory
Diseases: Clinical Trials
P7.198
Efficacy Results of the
Phase 2 Portion of the RADIANCE
Trial: A Randomized, Double-blind,
Placebo-controlled Trial of Oral RPC1063
in Adults with Relapsing Multiple
Sclerosis Giancarlo Comi, Jeffrey Cohen,
Douglas Arnold, Amit Bar-Or, Sheila
Gujrathi, Jeffrey Hartung, Allan Olson,
Matthew Cravets, Paul Frohna, Krzysztof
Selmaj
P7.199
Safety and Tolerability Results
of the Phase 2 Portion of the RADIANCE
Trial: A Randomized, Double-blind,
Placebo-controlled Trial of Oral RPC1063
in Relapsing Multiple Sclerosis Krzysztof
Selmaj, Douglas Arnold, Giancarlo Comi,
Amit Bar-Or, Sheila Gujrathi, Jeffrey
Hartung, Allan Olson, Matthew Cravets,
Paul Frohna, Jeffrey Cohen
P7.200 Interim Analysis of a Phase
I Clinical Trial Investigating Intrathecal
Administration of Mesenchymal Stem
Cell-neural Progenitors in Multiple
Sclerosis Violaine Harris, Tamara Vyshkina,
Sydney Chirls, Saud Sadiq
P7.201
Baseline Demographics and
Disease Characteristics from OPERA I
and II, Two Phase III Trials Evaluating
Ocrelizumab in Patients with Relapsing
Multiple Sclerosis Stephen Hauser,
Giancarlo Comi, Hans-Peter Hartung,
Fred Lublin, Krzysztof Selmaj, Anthony
Traboulsee, Amit Bar-Or, Douglas Arnold,
Gaelle Klingelschmitt, David Leppert,
Algirdas Kakarieka, Hideki Garren,
Ludwig Kappos
P7.202
Efficacy Analysis of the AntiLINGO-1 Monoclonal Antibody BIIB033
in Acute Optic Neuritis: The RENEW
Trial Diego Cadavid, Laura Balcer, Steven
Galetta, Orhan Aktas, Tjalf Ziemssen, Ludo
Vanopdenbosch, Helmut Butzkueven, Focke
Ziemssen, Luca Massacesi, Yi Chai, Lei Xu,
Stefanie Freeman
P7.209
Treatment with Daclizumab
HYP Improved Disease-specific Patientreported Outcomes Versus Interferon
Beta-1a in Multiple Sclerosis in the Phase 3
DECIDE Trial Ying Liu, Timothy Vollmer, Eva
Havrdova, Katherine Riester, Andrew Lee,
Glenn Phillips, Jacob Elkins
P7.218
P7.210
P7.219
ARPEGGIO: A Randomized,
Placebo-controlled Study to Evaluate
Oral Laquinimod in Patients with
Primary Progressive Multiple Sclerosis
(PPMS) Frederik Barkhof, Gavin Giovannoni,
Hans-Peter Hartung, Bruce Cree, Antonio
Uccelli, Maria Pia Sormani, Stephen Krieger,
Bernard Uitdehaag, Timothy Vollmer, Xavier
Montalban, Joshua Steinerman, Nissim
Sasson, Tali Gorfine, Volker Knappertz
A Phase 3b/4 Long-term
Study of Alemtuzumab in Patients with
Relapsing-remitting Multiple Sclerosis:
TOPAZ Study Design Vesna Brinar, Gavin
Giovannoni, Eva Havrdova, Cary Twyman,
Basil Sharrack, Tjalf Ziemssen, Francesca
Baldinetti, Marco Rizzo, Leah Martell,
Edward Fox
P7.220
No Evidence of Disease
Activity in Patients with Relapsing MS
Treated with Interferon Beta-1a SC Tiw
Versus Interferon Beta-1a IM Qw in the
EVIDENCE Study Patricia Coyle, Juanzhi
Fang, Ali Hassan, Choon Cha, Fernando
Dangond, Anthony Reder, Mark Freedman
Safety and Tolerability of
Anti-LINGO-1 Monoclonal Antibody
BIIB033 in Acute Optic Neuritis: The
RENEW Trial Stefanie Freeman, Ludo
Vanopdenbosch, Helmut Butzkueven, Tjalf
Ziemssen, Orhan Aktas, Focke Ziemssen,
Luca Massacesi, Yi Chai, Lei Xu, Diego
Cadavid
Safety and Immunogenicity of
Two Dosing Frequencies of Subcutaneous
Interferon (scIFN) β-1a in Patients with
a First Clinical Demyelinating Event
(FCDE): 5-year Results of Phase III,
Double-blind, Multicenter Trials (REFLEX/
REFLEXION) Mark Freedman, Giancarlo
Comi, Nicola De Stefano, Frederik Barkhof,
Bernard Uitdehaag, Ludwig Kappos, Tanya
Fischer, Liang Chen
P7.204
BIIB033, Anti-LINGO-1
Antibody, for Treatment of Relapsing Forms
of Multiple Sclerosis: Baseline Data of the
Phase 2 SYNERGY Trial Diego Cadavid,
Keith Edwards, Raymond Hupperts, Jelena
Drulovic, Krzysztof Selmaj, Robert Naismith,
Luigi Maria Grimaldi, Alexey Boiko, Oscar
Fernandez, Eli Silber, Howard Rossman,
Stefanie Freeman, Yi Chai, Lei Xu
P7.212
P7.205
Disease Activity During the
First Year Predicts Clinical Long-term
Outcomes: Impact of Fingolimod in the
TRANSFORMS Phase III Trial and Its
Extension Pavle Repovic, Erik Burton,
Xiangyi Meng, Daniela Piani Meier, Frederik
Barkhof
P7.213
Effects of Anti-LINGO-1
Monoclonal Antibody BIIB033 on Visionrelated Quality-of-life in Subjects with
Acute Optic Neuritis: Results from the
RENEW Study Jennifer Petrillo, Jeremy
Hobart, Laura Balcer, Yi Chai, Lei Xu, Diego
Cadavid
The 9-hole Peg Test (9-HPT)
Has a Stronger Correlation Than the
Expanded Disability Status Scale (EDSS)
with Patient-reported Upper Extremity
Impairment as Assessed Using ABILHAND
in Patients with Secondary Progressive
Multiple Sclerosis (SPMS): Analysis
of Baseline Data from the ASCEND
Study Daniel Mikol, Myla Goldman, HansPeter Hartung, Eva Havrdova, Douglas Jeffery,
Raj Kapoor, Aaron Miller, Finn Sellebjerg, Yun
Chen, Crystal Watson, Diego Cadavid
P7.206
P7.214
P7.223
P7.203
Effect of Two Dosing
Frequencies of Subcutaneous Interferon
(scIFN) β-1a on Conversion to Multiple
Sclerosis (MS) in Patients with a First
Clinical Demyelinating Event (FCDE):
5-year Results of Phase III, Doubleblind, Multicenter Trials (REFLEX/
REFLEXION) Mark Freedman, Giancarlo
Comi, Nicola De Stefano, Frederik Barkhof,
Bernard Uitdehaag, Ludwig Kappos, Tanya
Fischer, Liang Chen
P7.207
Multi-center, Randomized,
Double-blinded Assessment of Dimethyl
Fumarate in Extending the Time to a First
Attack in Radiologically Isolated Syndrome
(RIS) (ARISE Trial) Darin Okuda, Christine
Lebrun Frenay, Aksel Siva, Christophe
Hotermans, Christian Von Hehn, Gina
Remington, Braeden Newton, Teresa
Frohman, Elliot Frohman, Orhun Kantarci,
Daniel Pelletier
P7.208
Analysis of Efficacy by
Multifocal Visual Evoked Potentials in
Subjects Treated with the Anti-LINGO-1
Monoclonal Antibody BIIB033 in Acute
Optic Neuritis: The RENEW Trial Alexander
Klistorner, Letizia Leocani, Mominul Islam,
Philipp Albrecht, Helmut Butzkueven, Tjalf
Ziemssen, Focke Ziemssen, Yi Chai, Lei Xu,
Diego Cadavid
Fast, Easy, Online Registration · AAN.com/view/AM15
P7.211
Patient Experience with
Glatiramer Acetate 40 Mg/1 ML Threetimes Weekly Treatment for Relapsingremitting Multiple Sclerosis: Results from
the GLACIER Extension Study Daniel Wynn,
Scott Kolodny, Svetlana Rubinchick, Joshua
Steinerman, Volker Knappertz, Jerry Wolinsky
Teriflunomide Shows
Consistent Clinical Efficacy on Severe
Relapses Across Two Phase 3 Trials in
Patients with Relapsing Forms of Multiple
Sclerosis, TEMSO and TOWER Richard
Macdonell, Martin Stangel, Matthias
Mäurer, Deborah Dukovic, Philippe Truffinet,
Sylvie Bozzi, Catherine Dive-Pouletty, Mark
Freedman
NN 102/SPRINT-MS Phase
II Trial of Ibudilast in Progressive MS:
Baseline Characteristics Robert Fox,
Christopher Coffey, Merit Cudkowicz, Trevis
Gleason, Andrew Goodman, Eric Klawiter,
Kazuko Matsuda, Michelle McGovern,
Elizabeth McNeil, Robert Naismith, Jon
Yankey
P7.215
Differential Recovery from
Relapse Between Treatment Groups in
the CONFIRM Study of Delayed-release
Dimethyl Fumarate Andrew Chan, J.
Theodore Phillips, Robert Fox, Annie Zhang,
James Potts, Nuwan Kurukulasuriya
P7.216
Baseline Characteristics
of Patients Enrolled in CONCERTO—a
Study of 0.6 and 1.2 Mg/day Oral
Laquinimod for Relapsing-remitting
Multiple Sclerosis Giancarlo Comi, Timothy
Vollmer, Xavier Montalban, Tjalf Ziemssen,
Alexey Boyko, Patrick Vermersch, Tamar
Rachmilewitz, Nissim Sasson, Tali Gorfine,
Volker Knappertz, Maria Rocca,
Massimo Filippi
P7.217
Relapse Outcomes in Patients
with Multiple Sclerosis Treated with
Fingolimod: Subgroup Analyses of Three
Phase 3 Fingolimod Trials Tobias Derfuss,
Daniel Ontaneda, Jacqueline Nicholas,
Xiangyi Meng, Kathleen Hawker
P7.221
Multiple Sclerosis Patients
with No Evidence of Disease Activity
in the 2-year AFFIRM Study Have
Better Outcomes with Long-term
Natalizumab Treatment Than Patients
Who Had Evidence of Disease Activity in
AFFIRM Paul O'Connor, Andrew Goodman,
Ludwig Kappos, Fred Lublin, Qunming Dong,
Daniel Mikol, Richard Rudick
P7.222
12-year Clinical Efficacy and
Safety Data for Teriflunomide: Results
from a Phase 2 Extension Study Marcelo
Kremenchutzky, Mark Freedman, Amit
Bar-Or, Deborah Dukovic, Myriam Benamor,
Philippe Truffinet, Paul O'Connor
P7.224
RNFL as a Surrogate
Outcome Marker in Patients with Multiple
Sclerosis: Design of the OCTiMS Study,
Baseline Characteristics and OCT Test
Reproducibility Peter Calabresi, Frederik
Barkhof, Ari Green, Randy Kardon,
Friedemann Paul, Jaume Sastre-Garriga,
Sven Schippling, Patrick Vermersch, Pablo
Villoslada, Catherine Agoropoulou, Ying
Zhang, Diego Silva, Axel Petzold
P7.225
Long-term Safety of
Daclizumab HYP in Patients with
Relapsing-remitting Multiple Sclerosis:
3–4-year Results from the SELECTED
Extension Study Ralf Gold, Gavin
Giovannoni, Krzysztof Selmaj, Eva Havrdova,
Dusan Stefoski, Ernst-Wilhelm Radue, Till
Sprenger, Xavier Montalban, Kimberly
Umans, Steven Greenberg, Jacob Elkins,
Gulden Ozen, Marianne Sweetser
127
Thursday
April 23
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session VII
P7.226
Long-term Efficacy of
Daclizumab HYP in Relapsing-remitting
Multiple Sclerosis: 3-year Results from the
SELECTED Extension Study Ernst-Wilhelm
Radue, Gavin Giovannoni, Ralf Gold,
Krzysztof Selmaj, Eva Havrdova, Dusan
Stefoski, Till Sprenger, Xavier Montalban,
Yaoshi Wu, Gulden Ozen, Randy Robinson,
Mark Beatty
2:00 p.m.–6:30 p.m.
P7.235
Long-term Follow-up of
the Safety of Delayed-release Dimethyl
Fumarate in RRMS: Interim Results from
the ENDORSE Extension Study Carlo
Pozzilli, J. Theodore Phillips, Robert Fox,
Krzysztof Selmaj, Ray Zhang, Mark Novas,
Marianne Sweetser, Ralf Gold
Long-term Efficacy of
Delayed-release Dimethyl Fumarate in
Newly Diagnosed Patients with RRMS: An
Integrated Analysis of DEFINE, CONFIRM,
and ENDORSE Ralf Gold, Gavin Giovannoni,
J. Theodore Phillips, Robert Fox, Annie
Zhang, Nuwan Kurukulasuriya
Quality of Life in Patients with
Relapsing-remitting Multiple Sclerosis
Treated with Delayed-release Dimethyl
Fumarate: A Three-year Interim Analysis
of ENDORSE Mariko Kita, Ludwig Kappos,
Robert Fox, Ralf Gold, Gavin Giovannoni, J.
Theodore Phillips, Sujata Sarda, Macaulay
Okwuokenye, Jessica Kong, Nuwan
Kurukulasuriya
P7.228
P7.237
P7.227
Clinical Efficacy of Delayedrelease Dimethyl Fumarate in Newly
Diagnosed Relapsing-remitting Multiple
Sclerosis Patients with Highly Active
Disease: An Integrated Analysis of the
Phase 3 DEFINE and CONFIRM Studies J
Phillips, Ralf Gold, Gavin Giovannoni, Robert
Fox, Annie Zhang, Nuwan Kurukulasuriya
P7.229
Long-term Efficacy of Delayedrelease Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis According
to Prior Therapy: Integrated Analysis of
the DEFINE, CONFIRM, and ENDORSE
Studies Amit Bar-Or, Michael Hutchinson,
Ralf Gold, Robert Fox, Eva Havrdova,
Gavin Giovannoni, James Potts, Nuwan
Kurukulasuriya
P7.230
Safety and Tolerability
Results from the DECIDE Study: A Phase
3 Active-comparator Study of Daclizumab
HYP in Relapsing-remitting Multiple
Sclerosis Krzysztof Selmaj, Ludwig Kappos,
Douglas Arnold, Eva Havrdova, Alexey
Boyko, Michael Kaufman, Heinz Wiendl,
John Rose, Steven Greenberg, Katherine
Riester, Marianne Sweetser, Jacob Elkins
P7.236
Comparative Utility of
Different Progression Metrics in PPMS:
Re-analysis of the PROMiSe Clinical Trial
Dataset Marcus Koch, Joshua Steinerman,
Volker Knappertz, Nissim Sasson, Gavin
Giovannoni, Gary Cutter, Jerry Wolinsky
P7.238
Delayed-release Dimethyl
Fumarate and Pregnancy: Preclinical
Studies and Pregnancy Outcomes
from Clinical Trials and Postmarketing
Experience Jie Li, Ralf Gold, Robert Fox,
J. Theodore Phillips, Eva Havrdova, Amit
Bar-Or, Ludwig Kappos, Norman Kim,
Patricia Valencia, Lauren Oliva, Mark Novas,
Marianne Sweetser, Nuwan Kurukulasuriya
P7.239
Disease Activity in the
First Year Predicts Longer-term Clinical
Outcomes in the Pooled Population of the
Phase III FREEDOMS and FREEDOMS II
Studies Aaron Boster, Kathleen Hawker,
Shannon Ritter, Davorka Tomic, Till
Sprenger
Efficacy of Delayed-release
Dimethyl Fumarate for RRMS in Prior
Interferon Users in the DEFINE and
CONFIRM Studies Oscar Fernandez,
Gavin Giovannoni, Robert Fox, Ralf Gold, J.
Theodore Phillips, Macaulay Okwuokenye,
Annie Zhang, Nuwan Kurukulasuriya
Rationale for EDSS-plus, the
Primary Composite Endpoint of Disability
Progression in the ASCEND Phase 3 Study
of Natalizumab for Secondary Progressive
Multiple Sclerosis: A Post Hoc Analysis
of IMPACT Study Data Daniel Mikol, Jeff
Cohen, Mark Freedman, Myla Goldman,
Hans-Peter Hartung, Eva Havrdova, Douglas
Jeffery, Raj Kapoor, Aaron Miller, Finn
Sellebjerg, Deborah Kinch, Sophia Lee,
Diego Cadavid
P7.232
P7.241
P7.231
Efficacy of Delayed-release
Dimethyl Fumarate in Multiple Sclerosis
Patients with Moderate Disability:
An Integrated Analysis of the Phase 3
DEFINE and CONFIRM Studies Michael
Hutchinson, Robert Fox, Ralf Gold,
Annie Zhang, Minhua Yang, Macaulay
Okwuokenye, Nuwan Kurukulasuriya
P7.233
Effect of Delayed-release
Dimethyl Fumarate on Total Disability
Burden in the CONFIRM Study of
Relapsing-remitting Multiple Sclerosis:
Area Under the Curve Analysis of Changes
from Baseline in Expanded Disability Status
Scale Scores Nuwan Kurukulasuriya,
Robert Fox, Ralf Gold, James Xiao, Annie
Zhang, Amit Bar-Or
P7.234
Five-year Follow-up of
Delayed-release Dimethyl Fumarate in
RRMS: Integrated Clinical Efficacy Data
from the DEFINE, CONFIRM, and ENDORSE
Studies Amit Bar-Or, Ralf Gold, Robert Fox,
J. Theodore Phillips, Michael Hutchinson,
Ludwig Kappos, Sarah Sheikh, Ray Zhang,
Minhua Yang, Nuwan Kurukulasuriya
128
P7.240
Clinical Effectiveness and
Impact on Patient-reported Outcomes
of Delayed-release Dimethyl Fumarate
in Relapsing Multiple Sclerosis Patients
After Suboptimal Response to Glatiramer
Acetate: A Prospective, Multicenter,
Open-label, Single-arm, Observational
Study (RESPOND) Kiren Kresa-Reahl, Pavle
Repovic, Derrick Robertson, Macaulay
Okwuokenye, Christian Von Hehn, Monica
Mann, Leslie Meltzer
P7.242
1-year Efficacy and Tolerability
Results for IFN Beta-1a SC Tiw Treatment
and Predictive Value of 6-month MRI:
Exploratory Analysis of PRISMS Data
in Patients with RRMS Mark Cascione,
Fernando Dangond, Juanzhi Fang, Aaron
Miller, Amy Perrin Ross
P7.243
Sustained Low Rate of Brain
Volume Loss Under Long-term Delayedrelease Dimethyl Fumarate Treatment in
Relapsing-remitting Multiple Sclerosis
Patients: Results from the ENDORSE
Study Ludwig Kappos, Robert Fox, Ralf
Gold, Douglas Arnold, James Potts, Annie
Zhang, Nuwan Kurukulasuriya
P7.244
Natalizumab Reduces Total
Disability Burden Relative to Placebo in
Patients with Relapsing-remitting Multiple
Sclerosis Regardless of the Occurrence
of Relapses or Confirmed Disability
Progression or Improvement over 2 Years
in the AFFIRM Study Gavin Giovannoni,
Shibeshih Belachew, Qunming Dong,
Richard Rudick, Daniel Mikol, Shulian Shang
P7.245
The Effect of Fingolimod
on T1-hypointense Lesions Developed
On-study and Evolution of Pre-existing
Gd+ Lesions, Stratified by Lesion Size: A
Posthoc Analysis of FREEDOMS Study Till
Sprenger, Ernst-Wilhelm Radue, Nicole
Mueller-Lenke, Gordon Francis, Dieter
Haering, Davorka Tomic, Ludwig Kappos
P7.246
Durable Effect of
Alemtuzumab on MRI Activity in
Treatment-naive Active Relapsingremitting Multiple Sclerosis Patients:
4-year Follow-up of CARE-MS I Douglas
Arnold, Anthony Traboulsee, Alasdair Coles,
Jeffrey Cohen, Edward Fox, Hans-Peter
Hartung, Eva Havrdova, Krzysztof Selmaj,
David Margolin, Yang Zhao, Michael
Panzara, D Alastair S Compston
P7.247
Effect of Delayed-release
Dimethyl Fumarate on No Evident Disease
Activity in Newly Diagnosed Relapsingremitting Multiple Sclerosis Patients: An
Integrated Analysis of the Phase 3 DEFINE
and CONFIRM Studies Eva Havrdova,
Gavin Giovannoni, Ralf Gold, Robert Fox,
Ludwig Kappos, J. Theodore Phillips, Annie
Zhang, Nuwan Kurukulasuriya
P7.248
Switching to Alemtuzumab
from Subcutaneous Interferon Beta-1a
After CARE-MS II Further Improved MRI
Outcomes in Patients with Relapsingremitting Multiple Sclerosis Daniel
Pelletier, Frederik Barkhof, Alasdair Coles,
Jeffrey Cohen, Alastair Compston, Edward
Fox, Hans-Peter Hartung, Eva Havrdova,
David Margolin, Linda Kasten, Michael
Panzara, Douglas Arnold
P7.249
Durable Effect of
Alemtuzumab on MRI Outcomes in
Patients with Relapsing-remitting Multiple
Sclerosis Who Relapsed on Prior Therapy:
4-year Follow-up of CARE-MS II Anthony
Traboulsee, Alasdair Coles, Jeffrey Cohen,
D Alastair S Compston, Edward Fox, HansPeter Hartung, Eva Havrdova, Krzysztof
Selmaj, David Margolin, Yang Zhao, Michael
Panzara, Douglas Arnold
P7.250
Effect of Two Dosing
Frequencies of Subcutaneous Interferon
(scIFN) β-1a on MRI Lesion and Brain
Volume Changes in Patients with a First
Clinical Demyelinating Event (FCDE):
5-year Results of Phase III REFLEX Study
Extension (REFLEXION) Frederik Barkhof,
Giancarlo Comi, Mark Freedman, Bernard
Uitdehaag, Tanya Fischer, Liang Chen,
Ludwig Kappos, Nicola De Stefano
P7.251
Development of Chronic Black
Holes (CBH) Predicts Long-term Disability:
Post-hoc Analysis of Magnetic Resonance
Imaging (MRI) Data in the PRISMS
Study Tony Traboulsee, David Li, Juanzhi
Fang, Fernando Dangond, Ludwig Kappos
P7.252
Daclizumab HYP Reduced
Brain MRI Lesion Activity Compared
with Interferon Beta-1a: Results from the
DECIDE Study John Rose, Heinz Wiendl,
Douglas Arnold, Ludwig Kappos, Eva
Havrdova, Krzysztof Selmaj, Alexey Boyko,
Michael Kaufman, Steven Greenberg,
Marianne Sweetser, Katherine Riester,
Jacob Elkins
P7.253
Positive MRI Outcomes in
Patients with Early Multiple Sclerosis
Treated with Teriflunomide: Subgroup
Analyses from the TOPIC Phase 3
Study Aaron Miller, Philippe Truffinet,
Deborah Bauer, Jerry Wolinsky
P7.254
Early Onset and Predictive
Value of MRI Measures Among Patients
Receiving Interferon Beta-1a SC Tiw for
RRMS: Post Hoc Analyses of PRISMS-2
Data David Li, Mark Cascione, Juanzhi Fang,
Fernando Dangond, Anthony Traboulsee,
Guojun Zhao, Yan Cheng, Aaron Miller
P7.255
MRI Indicators of Brain Tissue
Loss: 3-year Results of the Glatiramer
Acetate Low-frequency Administration
(GALA) Open-label Extension Study
in Relapsing-remitting Multiple
Sclerosis Robert Zivadinov, Michael Dwyer,
Niels Bergsland, Deepa Ramasamy, Ellen
Carl, Matthew Davis, Joshua Steinerman,
Omar Khan
P7.256
In Relapsing Multiple
Sclerosis, Peginterferon Beta-1a Reduces
MRI Lesions Following Relapses Bernd
Kieseier, Douglas Arnold, Scott Newsome,
Xiaojun You, Shifang Liu, Serena Hung,
Bjoern Sperling
P7.257
Early Effects of Interferon
Beta-1a SC Tiw Versus Interferon Beta-1a
IM Qw on MRI Outcomes in Patients
with Relapsing MS in the EVIDENCE
Study Anthony Reder, Mark Freedman,
Juanzhi Fang, Ali Hassan, Choon Cha,
Fernando Dangond, Patricia Coyle
P7.258
Long-term MRI Followup of Patients in the ALLEGRO Study:
Results from the Yearly Frequent MRI
Sub-cohort Maria Rocca, Sebastiano
Galantucci, Yuval Dadon, Tali Gorfine, David
Ladkani, Nissim Sasson, Giancarlo Comi,
Massimo Filippi
P7.259
Smaller Baseline Brain Volume
and Higher Atrophy Rate over Two Years Is
Associated with Poorer Clinical Outcomes:
Post Hoc Analysis of the MS-STAT Trial
in Secondary Progressive MS Jeremy
Chataway, Jennifer Nicholas, Julie Wych,
Nadine Schuerer, Ali Alsanousi, Dennis
Chan, David MacManus, Kelvin Hunter, Val
Anderson, Charles Bangham, Shona Clegg,
Casper Nielsen, Nick Fox, David Wilkie,
Virginia Calder, John Greenwood, Chris
Frost, Richard Nicholas
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Poster Session VII
P7.260
Natalizumab-treated Patients
with Multiple Sclerosis Have Low Rates
of Brain Volume Decrease and Low MRI
Disease Activity in the Long-term STRATA
Study Andrew Goodman, Douglas Arnold,
Ludwig Kappos, Fred Lublin, Paul O'Connor,
Shibeshih Belachew, Daniel Mikol, Richard
Rudick, Jonathan Smith, Harold Koendgen
P7.261
Switching to Alemtuzumab
from Subcutaneous Interferon Beta-1a
After CARE-MS I Further Improved MRI
Outcomes in Patients with Relapsingremitting Multiple Sclerosis Frederik
Barkhof, Daniel Pelletier, Alasdair Coles,
Jeffrey Cohen, D Alastair S Compston,
Edward Fox, Hans-Peter Hartung, Eva
Havrdova, David Margolin, Linda Kasten,
Michael Panzara, Douglas Arnold
P7.262
Five-year Follow-up of
Delayed-release Dimethyl Fumarate in
Relapsing-remitting Multiple Sclerosis:
MRI Outcomes from DEFINE, CONFIRM,
and ENDORSE Tarek Yousry, Douglas
Arnold, Robert Fox, Ralf Gold, Eva Havrdova,
Ludwig Kappos, David MacManus, Sarah
Sheikh, Ray Zhang, Minhua Yang, Nuwan
Kurukulasuriya, Vissia Viglietta
P7.263
Alemtuzumab Slows Brain
Volume Loss Over 4 Years Despite Most
Relapsing-remitting Multiple Sclerosis
Patients Not Receiving Treatment for 3
Years Alasdair Coles, Douglas Arnold,
Jeffrey Cohen, Edward Fox, Hans-Peter
Hartung, Eva Havrdova, Krzysztof Selmaj,
David Margolin, Linda Kasten, Michael
Panzara, D Alastair S Compston
P7.264
Slowing of Brain Volume
Loss in Patients with Relapsing-remitting
Multiple Sclerosis After Switching from
Subcutaneous Interferon Beta-1a to
Alemtuzumab Jeffrey Cohen, Douglas
Arnold, Alasdair Coles, Edward Fox, HansPeter Hartung, Eva Havrdova, Krzysztof
Selmaj, David Margolin, Linda Kasten,
Michael Panzara, D Alastair S Compston
P7.265
Incidence of Infection
Decreases Over Time in Alemtuzumabtreated Patients with Relapsing-remitting
Multiple Sclerosis: 4-year Follow-up of
the CARE-MS Studies Lily Jung Henson,
Douglas Arnold, Jeffrey Cohen, Alasdair
Coles, Edward Fox, Hans-Peter Hartung, Eva
Havrdova, Krzysztof Selmaj, David Margolin,
Bella Ertik, Jeffrey Palmer, Michael Panzara,
D Alastair S Compston
P7.266
Long-term Efficacy in MRI
and No Evidence of Disease Activity
Outcomes in Patients with Relapsingremitting Multiple Sclerosis Treated with
Peginterferon Beta-1a Douglas Arnold,
Xiaojun You, Shulian Shang, Bjoern
Sperling, Vladimir Evilevitch
P7.267
The Efficacy of Peginterferon
Beta-1a in Early and Later-stage Patients
with Multiple Sclerosis: A 1-year Subgroup
Analysis Based on Disease Duration from
the ADVANCE Study Bernd Kieseier, Scott
Newsome, Shulian Shang, Shifang Liu,
Serena Hung, Bjoern Sperling
P7.268
Pooled Safety Analyses from
Teriflunomide Clinical Studies Thomas
Leist, Mark Freedman, Ludwig Kappos,
Tomas Olsson, Aaron Miller, Jerry Wolinsky,
Paul O'Connor, Myriam Benamor, Philippe
Truffinet, Deborah Dukovic, Giancarlo Comi
P7.269
Durable Efficacy of
Alemtuzumab in Patients with Highly
Active Relapsing-remitting Multiple
Sclerosis Who Relapsed on a Prior
Therapy Barry Singer, Edward Fox, Stephen
Krieger, Hans-Peter Hartung, Lilyana
Amezcua, David Margolin, Linda Kasten,
Alasdair Coles
P7.270
Improvement in Clinical
Outcomes in Treatment-naive Relapsingremitting Multiple Sclerosis Patients Who
Switched from Subcutaneous Interferon
Beta-1a to Alemtuzumab Hans-Peter
Hartung, Gavin Giovannoni, Douglas Arnold,
Alasdair Coles, Edward Fox, Eva Havrdova,
Krzysztof Selmaj, David Margolin, Jeffrey
Palmer, Michael Panzara, D Alastair S
Compston
P7.271
No Evidence of Disease
Activity in Patients with Relapsing MS
Treated with Interferon Beta-1a SC Tiw
Versus Interferon Beta-1a IM Qw: Subgroup
Analyses of the EVIDENCE Study Juanzhi
Fang, Patricia Coyle, Ali Hassan, Choon Cha,
Fernando Dangond, Anthony Reder, Mark
Freedman
P7.272
The Efficacy of Alemtuzumab
Is Maintained in Patients Who Develop
Thyroid Adverse Events Samuel Hunter,
Douglas Arnold, Alasdair Coles, Jeffrey
Cohen, Edward Fox, Hans-Peter Hartung,
Eva Havrdova, David Margolin, Bella Ertik,
Jeffrey Palmer, Michael Panzara, D Alastair
S Compston
P7.273
Efficacy and Safety of a
Three-times Weekly Dosing Regimen of
Glatiramer Acetate in Relapsing-remitting
Multiple Sclerosis Patients: 3-year Results
of the Glatiramer Acetate Low-frequency
Administration (GALA) Open-label
Extension Study Omar Khan, Peter
Rieckmann, Alexey Boyko, Krzysztof Selmaj,
Natalia Ashtamker, Mat Davis, Scott
Kolodny, Robert Zivadinov
P7.274
Efficacy of Teriflunomide in
Early-stage MS: Reanalysis of the TOPIC
Study Using 2010 McDonald Diagnostic
Criteria Flavia Nelson, Francois Evoy,
Thomas Berger, Philippe Truffinet, Deborah
Bauer, Aaron Miller, Jerry Wolinsky
P7.275
Safety and Efficacy of
Teriflunomide in Patients Switching from
Subcutaneous Interferon Beta-1a Jérôme
de Seze, Tomas Olsson, Anna Czlonkowska,
Myriam Benamor, Philippe Truffinet,
Deborah Dukovic, Patrick Vermersch
P7.276
Durable Effect of
Alemtuzumab on Clinical Outcomes in
Patients with Relapsing-remitting Multiple
Sclerosis Who Relapsed on Prior Therapy:
4-year Follow-up of CARE-MS II Eva
Havrdova, Gavin Giovannoni, Douglas
Arnold, Alasdair Coles, Edward Fox, HansPeter Hartung, Krzysztof Selmaj, David
Margolin, Jeffrey Palmer, Michael Panzara,
D Alastair S Compston
Fast, Easy, Online Registration · AAN.com/view/AM15
Administration of
Alemtuzumab on Nonconsecutive Days
Does Not Impact Infusion-associated
Reactions, Efficacy, or Lymphocyte
Depletion Sibyl Wray, Alexey Boyko, Tiffany
Braley, Omar Khan, David Margolin, Jeffrey
Palmer, Alasdair Coles
Movement Disorders:
Miscellaneous
P7.278
P7.286
P7.277
Improvement in Clinical
Outcomes Following Switch from
Subcutaneous Interferon Beta-1a to
Alemtuzumab: CARE-MS II Extension
Study Edward Fox, Gavin Giovannoni,
Douglas Arnold, Alasdair Coles, Hans-Peter
Hartung, Eva Havrdova, Krzysztof Selmaj,
David Margolin, Jeffrey Palmer, Michael
Panzara, D Alastair S Compston
P7.279
Teriflunomide Significantly
Increased Time to First Relapse in TEMSO,
TOWER, and TOPIC William Honeycutt,
Christine Lebrun Frenay, John King, Andrew
Chan, Sandra Vukusic, Jeffrey Gross,
Deborah Dukovic, Philippe Truffinet, JeanPierre Bouchard
P7.280
Long-term Follow-up of
the Effect of Delayed-release Dimethyl
Fumarate on No Evidence of Disease
Activity in Patients with Multiple
Sclerosis Gavin Giovannoni, Eva Havrdova,
Ralf Gold, Robert Fox, Ludwig Kappos, J.
Theodore Phillips, Annie Zhang, Nuwan
Kurukulasuriya
P7.281
Design of a Non-interventional
Study to Establish Effectiveness, Quality
of Life, Cognition, Health-related and
Work Capacity Data on Alemtuzumab in
Multiple Sclerosis Patients in Germany
(TREAT-MS) Ulrich Engelmann, Sigbert
Jahn, Alexandra Leptich, Raimar Kern, Tjalf
Ziemssen
P7.282
Results of a Phase 1b
Study to Confirm Safety and Tolerability
of Olesoxime in Multiple Sclerosis
Patients Jean Pelletier, Jean-Philippe
Ranjeva, Ayman Tourbah, Gilles Edan,
Christian Barillot, Sophie Le La Mer,
Bertrand Audoin, Audrey Rico Lamy, Lydie
Crespy, Ben Ridley, Wafaa Zaaraoui,
Sylviane Confort-Gouny, Maxime Guye,
Adil Maarouf, Nathalie Caucheteux, MariePierre Chaunu, Christophe Portefaix, Laurent
Pierot, Olivier Commowick, Anne Kerbrat,
Laurence Catanese, Valerie Cuvier, Julien
Veys, Rebecca Pruss, Wilfried Hauke
P7.283
Evaluation of Comprehensive
Alemtuzumab Infusion Guidance in
Patients with Relapsing-remitting Multiple
Sclerosis: EMERALD Study Design Patrick
Vermersch, Rafael Arroyo-Gonzalez, Oscar
Fernandez, Francesca Baldinetti, Stanley
Krolczyk, Leah Martell, Thibault Moreau,
Ludo Vanopdenbosch
P7.284
Normalized Brain Volume
Predicts Cognitive Performance in MS: An
Analysis of a Large Cohort from Fingolimod
Phase III Studies Maria Pia Sormani,
Ludwig Kappos, Jeffrey Cohen, Frederik
Barkhof, Till Sprenger, Daniela Piani Meier,
Dieter Haering, Davorka Tomic, Nicola De
Stefano
P7.285
Early Neurological Worsening
in Wilson’s Disease Patients Anna
Czlonkowska, Tomasz Litwin, Michal
Karlinski, Karolina Dziezyc
Complementary Medicine
and Cannabis Use by Parkinson’s Disease
Patients in Colorado Taylor Finseth, Jessica
Hedeman, Robert Brown, Kristina Johnson,
Matthew Binder, Benzi Kluger
P7.287
Description of a New Rapidaccess Clinic for Parkinson’s Disease
Patients: The Navigator Model Priti Gros,
Doulia Hamad, Lucie Lachance, Jennifer
Doran, Anne-Louise Lafontaine
P7.288
Typical, Atypical, and Vascular
Parkinsonism in Jamaica: An 8-year
Prospective Study Amza Ali, Keith Josephs
P7.289
More Severe Parkinsonism Is
Associated with Lower Physical Activityrelated Energy Expenditure in PD Jonathan
Snider, Vikas Kotagal, Martijn Muller,
Robert Koeppe, Phillip Scott, Roger Albin,
Kirk Frey, Nicolaas Bohnen
P7.290
Neurologic Manifestations
of Lesch Nyhan Syndrome Improved with
Bilateral Deep Brain Stimulation, a Case
Report Ramsey Falconer, Sean Rogers,
Yasar Torres-Yaghi, Kris Grajny, Fahd Amjad
P7.291
Neurodegeneration and Brain
Iron Accumulation Disorders in Hungary:
Genotype-phenotype Analysis Maria
Molnar, Zoltan Grosz, Renata Bencsik, Peter
Balicza, Peter Klivényi, Gertrud Tamás, Peter
Acs, Bernadette Kalman
P7.292
Neuroborreliosis Parkinsonism
and Rapid Eye Movement Sleep Behavior
Disorder Katherine Werbaneth, JoseRafael Zuzuarregui, Anna Hohler
P7.293
Systematic Review of
Parkinson’s Disease Related Mobile
Applications Dronacharya Lamichhane,
Melissa Armstrong
Movement Disorders: Restless
Legs Syndrome
P7.294
The Effect of Gabapentin
Enacarbil (GEn) on Pain Outcomes in Adults
with Moderate-to-severe and Severe
Primary Restless Legs Syndrome (RLS):
Pooled Analyses from 3 Randomized
Controlled Trials Neal Hermanowicz, Mark
Buchfuhrer, Daniel Wynn, Mark Jaros,
Richard Kim, Gwendoline Shang
P7.295
Incobotulinum Toxin-A (inco-A)
in Restless Legs Syndrome (RLS)—a
Randomized Double Blind Cross over
Study Rezvan Rostami, Duarte Machado,
Diana Richardson, Bahman Jabbari
P7.296
RESTIFFIC, a Unique
Pressure Foot Wrap, Is More Effective
Than a Dopamine Agonist in Reducing the
Symptoms of Moderate to Severe Restless
Leg Syndrome John Sullivan, Dan Olson
P7.297
Restless Limb Syndrome(RLS)
and Bruxism: A Subgroup Analysis and
Dose-response Data David Dickoff,
Roshana Sirkin, Stephanie Dontje, Naomi
Ditkoff, Nicole Silberman
129
Thursday
April 23
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
Poster Session VII
P7.298
Rotigotine in Patients
with Restless Legs Syndrome and
End-stage Renal Disease Requiring
Hemodialysis John Winkelman, Yves
Dauvilliers, Markku Partinen, Heike Benes,
Virpi Rauta, Hanna Schröder, Nadine
Goldammer, Elisabeth Dohin, Erwin
Schollmayer
P7.299
The Effect of Gabapentin
Enacarbil (GEn) on Quality-of-life (QoL)
Outcomes in Adult Patients with Moderateto-severe and Severe Primary Restless
Legs Syndrome (RLS): Pooled Analyses
from Two 12-week Trials Alon Avidan,
Stuart Isaacson, Mark Jaros, Richard Kim,
Gwendoline Shang
P7.300 The Effect of Gabapentin
Enacarbil (GEn) on Mood Outcomes in Adult
Patients with Moderate-to-severe and
Severe Primary Restless Legs Syndrome
(RLS): Pooled Analyses from Three 12-week
Trials Daniel Lee, Margaret Park, David
Kreitzman, Aaron Ellenbogen, Mark Jaros,
Richard Kim, Gwendoline Shang
P7.301
Prevalence of Restless Legs
Syndrome in an Atypical Parkinson's
Disease Patient Population Jose-Rafael
Zuzuarregui, Katherine Werbaneth, Jing Qin,
Christopher Tonn, Chantale Murray, Sok Lee,
Anna Hohler
P7.302
Fatigue and Cardiac
Sympathetic Denervation in Parkinson
Disease Corneliu Luca, Danielle Spengler,
Mike Georgiou, Aldo Serafini, Carlos Singer
2:00 p.m.–6:30 p.m.
P7.308
Aggression in Nightmares
and Unpleasant Dreams and in People
Reporting Recurrent Nightmares April
Minsky, Patrick McNamara, Victoria Pae,
Erica Harris, Edward Pace-Schott, Sanford
Auerbach
P7.321
P7.333
P7.309
Practice, Policy, and Ethics
P7.334
Improving Knowledge of
ICSD-3 and DSM-5 Criteria for Diagnosing
Narcolepsy Nimish Mehta, Stacey Hughes,
Stacey Ullman, Priscilla Scherer
P7.310
Pain and Sleep Disturbance
in the Elderly: Evaluation of the Role of
Stress and Depression vahid eslami, Molly
Zimmerman, Trishdeep Grewal, Mindy Katz,
Richard Lipton
P7.311
Cross-cultural Chronotypes:
Medical Students in America, Malaysia and
the UAE Nicoline Schiess, Sami Shaban,
Charlene Gamaldo, Rachel Marie Salas
P7.312
Are Periodic Leg Movements
Increased in the Painful Restless Legs
Syndrome? Elias Karroum, Christopher
Earley, Richard Allen
Sleep: Respiratory Disorders and
Other
P7.313
Does OSA Hypercoagulability
Operates Through Protein C and S
Pathways? Mohamad Ayass, Sundose
Hassan, Gul Nowshad
Sleep: Restless Legs and REM
Disorders
The Alteration of Cyclic
Alternating Pattern in Obstructive Sleep
Apnea Syndrome with and Without
Excessive Daytime Sleepiness Selda
Korkmaz, Tugce Bilecenoglu, Yuksel Peker,
Tahir Yoldas, Murat Aksu
P7.303
P7.315
Hyperdopaminergism in
Lenticulostriate Stroke-induced Restless
Legs Syndrome: A Neuro Imaging
Study Elisabeth Ruppert, Marc Bataillard,
Izzie Namer, Laurent Tatu, Valérie Wolff,
Reana Velizarova, Aurelien Hacquard, Ulker
Killic-Huck, Patrice Bourgin
P7.304
First 1-year Real-life Study to
Assess Management of Augmentation of
Restless Legs Syndrome by Switching to
Rotigotine Transdermal System Claudia
Trenkwalder, Monica Canelo, Heike
Benes, Michael Lang, Hanna Schröder,
Daniela Kelling, Reinhard Berkels, Erwin
Schollmayer, Tanja Heidbrede
P7.305
Impulse Control Disorders
Are Associated with REM Sleep Behavior
Disorder in Patients with Parkinson’s
Disease: A Video-Polysomnographic
Study Maria Livia Fantini, Maurizio
Zibetti, Michela Figorilli, Beudin Patricia,
Ana Marques, Debilly Bérangère, Derost
Philippe, Miguel Ulla, Nicolas Vitello,
Tiphaine Vidal, Monica Puligheddu,
Alessandro Cicolin, Leonardo Lopiano,
Franck Durif
P7.306
REM Sleep Behavior Disorder:
How Useful Is It for the Differential
Diagnosis of Parkinsonism? Helio Afonso
Teive, Renato Munhoz
P7.307
REM Sleep Without Atonia
Severity Predicts Cognitive Impairment
in REM Sleep Behavior Disorder David
Sandness, Erik St. Louis, Stuart McCarter,
Bradley Boeve, Michael Silber
130
P7.314
Clinically Moderate to Severe
Insomnia Without Excessive Daytime
Sleepiness in Diabetic Patients with
Chronic Neuropathic Limb Pain Martin
Rakusa, Matej Rakusa, Miro Cokolic
P7.316
Improving Nocturnal Sleep
and Excessive Daytime Somnolence in
Moderate to Severe Obstructive Sleep
Apnea-hypopnea Syndrome by Using
Oral Appliances Elena Cuspineda Bravo,
Michele Garcia Menendez, Ana Olivares
Torres, Calixto Machado
P7.317
An Ambulatory Treatment
Pathway Expedites the Diagnosis
and Treatment of Sleep Apnea After
Cerebrovascular Events Sara Elias, Fadi
Frankul, James Im, Karl Boyle, Sandra Black,
Richard Swartz, Brian Murray, Mark Boulos
P7.318
Is Traumatic Brain Injury
Associated with PAP Adherence in
Obstructive Sleep Apnea: A Pilot
Study Lynn Kataria, Julie Chapman, Brian
Ahuja, Marshall Balish
P7.319
Sleep and Concussion Review
and Evaluation (SCORE): Sleep Disorders in
Pediatric Sports-related Concussions PingRu Ko, Carey Lockhart, John Lockhart,
Maida Chen
P7.320
Sleep Macrostructure and
Microstructure in Acute and Chronic Spinal
Cord Injury Patients Pietro Guaraldi, Giulia
Milioli, Giovanna Calandra-Buonaura,
Annagrazia Cecere, Giuseppe De Scisciolo,
Mario Giovanni Terzano, Federica Provini,
Liborio Parrino, Pietro Cortelli
Implementing a Clinical IPad
Application to Detect Sleep Disorders
Is Feasible Across Multiple Non-sleep
Outpatient Clinics Ankur Doshi, Charlene
Gamaldo, Aadi Kalloo, Rebecca Choi, Rachel
Marie Salas
P7.322
Assessment of the Timeliness
of Administration of Second Line
Antiepileptic Drugs for Status Epilepticus
After the Implementation of a Status
Epilepticus Bundle Order Set: A Single
Institution Experience Mark Callow, Aaron
Cook, Ahmed Mahmoud, Alexandra Boske,
Rachel Ward-Mitchell, Meriem Bensalem
Owen
P7.323
Impact of EEG Laboratory
Resources and Timeliness of Initiation
of Continuous Video-EEG Monitoring: A
Single Institution Experience Mark Callow,
Heather Hatton, Dustine Arnold, Meriem
Bensalem Owen
P7.324
Physician Communication
About Driving Restrictions After Episodic
Loss of Consciousness Natalie Wheeler,
James Burke, Eric Adelman
P7.325
Patient Perspectives on
Physician Compensation and Conflict of
Interest in Industry-sponsored Clinical
Trials for Multiple Sclerosis Andrew
Solomon, Eran Klein, John Corboy, James
Bernat
P7.326
An Analysis of After Hours
MRI Scans in a Busy Tertiary Hospital
Neuro Intensive Care Unit—Is Your
Patient Safety Is at Jeopardy? Premkumar
Nattanmai Chandrasekaran, Lori Shutter
P7.327
Diagnostic Imaging Delays and
Efforts to Minimize for Neurology Patients
in the Hospital Setting Ryan Crooks,
Loretta Schnepel, Scott Silliman
P7.328
PDSA Cycle and
Implementation of Worldwide Best
Practices to Achieve Faster Door to
Needle Waimei Tai, Stephanie Casal, JJ
Baumann, Daisha Marsh, Gregory Albers
P7.329
Stroke Care Cost Variability
Between Physicians at a Comprehensive
Stroke Center Is Low Michael Dobbs,
Sarah Heck, Bernard Boulanger
P7.330
Standardizing Stroke
Evaluation in the Cardiac Catheterization
Lab: Aldrete-FAST Score Michelle
Johansen, Andrew Southerland, Michael
Ragosta, Mary Lee Jensen, Bradford
Worrall, Nina Solenski
A Quantitative Evaluation
of Undisclosed Conflicts of Interest in
Neuropsychopharmacology, General
Pharmacology, and Pharmacotherapy
Textbooks Brian Piper, Hassenet Telku,
Drew Lambert
Using a Spine Registry to
Improve Understanding of the Variability,
Progression, and Treatment of Spinal
Disease Fernando Diaz, Risa Tyo, Aaron
Anderson, Christina Cook
P7.335
Neurohospitalist Billing
Practices Compared to Hospital
Medicine Pearce Korb, Amy Franks, Serena
Scott, Anunta Virapongse, Jennifer Simpson
P7.336
Predicting Patient Attendance
in the Neuromuscular Clinic: A Logistic
Regression Analysis Matthew Lincoln,
Michael Sawa
P7.337
A Quality Improvement
Strategy for Documenting Last
Pyridostigmine Dose Prior to the
Performance of Nerve Conduction Studies/
Electromyography Amy Visser, Charles
Kassardjian, Elie Naddaf, Mohamed
Kazamel, Andrea Leep Hunderfund
P7.338
Spatiotemporal Gait
Parameters as a Potential Outcome
Measure for CIDP Russell Chin, Mary Vo,
Bridget Carey, Jennifer Langsdorf, Naomi
Feuer, Norman Latov
P7.339
Determining Moral and Legal
Responsibility in Patients with Behavioralvariant Frontotemporal Dementia Richard
Darby
P7.340
Documentation of Advance
Healthcare Planning in the Electronic
Health Records of Elderly Outpatients with
Dementia or Cognitive Impairment Kendra
Peterson, Susan Sullivan, Catherine
Madison
P7.341
Choice of Initial
Pharmacotherapy Treatment in Older Adults
with Parkinson’s Disease: Associations
with Health Outcomes ElizaBeth Grubb,
Robert Feldman, Jan Faiola, James
Eubanks, Michael Treglia, Maureen Lage
P7.342
Quality Measures in Parkinson
Disease: Assessment of Frequency
of Documenting Quality Measures in
PD Sarah Pirio Richardson, Kayla Gosselin,
Amanda Deligtisch
P7.343
A Retrospective Review of
Amyotrophic Lateral Sclerosis Patients
and Adherence to American Academy of
Neurology's Practice Parameter Rashmi
Rajendra, Amparo Gutierrez
P7.331
A Survey and Intervention to
Improve Effective Communication Between
Critical Care Team and Neurology Team
in a Busy Neurointensive Care Unit-A
Portal to Improve Patient Care Premkumar
Nattanmai Chandrasekaran, Lori Shutter
P7.332
Balancing Autonomy and
Beneficence in Acute Stroke Therapy:
Neurologist Attitudes Toward Delaying
Thrombolysis in Order to Obtain Informed
Consent Brett Kaplan, Jessica Cranston,
Jeffrey Saver
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Industry Therapeutic Updates
Tuesday, April 21, 2O15 and Wednesday, April 22, 2O15
Starting at 7:00 p.m.
Registration is free and open to registered Annual Meeting attendees.
Representatives from the following companies invite you to an informational session on therapeutic updates. This
program provides you the opportunity to learn about current therapies and projects in the industry pipeline.
Tuesday, April 21
ACADIA Pharmaceuticals
Beyond Motor Symptoms: Parkinson’s Disease Psychosis
Location: Marriott Marquis Washington, DC
Liberty Ballroom M–P
Biogen Idec
Relapsing MS and Tecfidera® (dimethyl fumarate):
An Interactive, Case-based Presentation
Location: Marriott Marquis Washington, DC
Independence Ballroom A–E
BioMarin Pharmaceutical Inc./PTC Therapeutics
Location: Marriott Marquis Washington, DC
Liberty Ballroom I–L
Genzyme, A Sanofi Company
Location: Marriott Marquis Washington, DC
Room Salon 6
Novartis Pharma AG Basel, Switzerland
Location: Renaissance Washington, DC Downtown
Grand Ballroom Central/South
Sunovion Pharmaceuticals Inc.
Welcome to Aptiom® (eslicarbazepine acetate)
Location: Marriott Marquis Washington, DC
Ballroom Salon 7–10
*Commitments as of 2/9/15
Wednesday, April 22
FORUM Pharmaceuticals Inc.
Treatment of Alzheimer’s Disease: Where Are We Now,
and Where Are We Headed?
Location: Marriott Marquis Washington, DC
Independence Ballroom A–H
Novartis Pharma AG Basel, Switzerland
Location: Marriott Marquis Washington, DC
Liberty Ballroom I–P
RSVP is recommended for these events.
Please visit AAN.com/view/ITU for more information.
No CME will be given by any accredited organization for
the Industry Therapeutic Updates, and the AAN cannot
affirm claims pertaining to FDA off-label medication,
research use of pre-FDA drugs, or other research
information that might be discussed. Industry Therapeutic
Updates are industry events.
Scientific Sessions
S46 Neuromyelitis Optica
3:15 p.m.
S46.001
“Spinal” Movement Disorders in
NMO Patients: An Under-recognized
Phenomenon Hesham Abboud,
Michael Levy
3:30 p.m.
S46.002
Tobacco Smoking and Severity
of Neuromyelitis Optica Laurent
Kremer, Nasrin Asgari, Maureen
Mealy, Kerry Mutch, Michael Lewy,
Anu Jacob, Nicolas Collongues,
Jerome De Seze
3:45 p.m.
S46.003
Effects of Neuromyelitis Optica
(NMO)-IgG for Leukocyte
Transmigration at the Blood-brain
Barrier Yukio Takeshita, Birgit
Obermeier, Anne Cotleur, Fumitaka
Shimizu, Simona Spampinato,
Thomas Kryzer, Vanda Lennon,
Yasuteru Sano, Takashi Kanda,
Richard Ransohoff
4:00 p.m.
S46.004
Immune Profiling of NMO
Patients Receiving Rituximab
Immunotherapy Lauren Collison,
Chris Ayers, Jessica Jackson, Kenny
Frazier, Benjamin Greenberg, Don
Healey
4:15 p.m.
S46.005
Short Myelitis Lesions in Aquaporin4-IgG-positive Neuromyelitis Optica
Spectrum Disorders Eoin Flanagan,
Brian Weinshenker, Karl Krecke,
Vanda Lennon, Claudia Lucchinetti,
Andrew McKeon, Dean Wingerchuk,
Elizabeth Shuster, Yujuan Jiao, Erika
Horta, Sean Pittock
4:30 p.m.
S46.006
A Combined Neuroimaging and
Neuropathological Study for
Longitudinally Extensive Spinal
Cord Lesions in Neuromyelitis
Optica: With Special Reference to
Lesion Distribution and Extension
Patterns Hayashida Shotaro,
Katsuhisa Masaki, Tomomi
Yonekawa, Noriko Isobe, Takuya
Matsushita, Jun-ichi Kira
4:45 p.m.
S46.007
Phase Contrast MRI Distinguishes
Between Neuromyelitis Optica and
Multiple Sclerosis Lesions Tim
Sinnecker, Petr Dusek, Lutz Harms,
Sanjeev Chawla, Sophie Hahndorf,
Katharina Mueller, Thoralf Niendorf,
Ilya Kister, Friedemann Paul, Yulin
Ge, Jens Wuerfel
S47 Cerebrovascular
Disease and Interventional
Neurology
3:15 p.m.
S47.001
An Electronic Decision Support
Tool for Stroke Prevention in Atrial
Fibrillation (SPAF): An Integrated
Primary-tertiary Care Model of
Care. Evan Jolliffe, Ian Rosemergy,
Jeremiah Lanford, David Abernethy,
Annemarei Ranta
3:30 p.m.
S47.002
Stroke After Cardiac Valve
Replacement: Distribution, Etiology,
and Risk Factors Allie Massaro,
Steven Messé, Michael Acker, Scott
Kasner, Jose Torres, Molly Fanning,
Tania Giovannetti, Sarah Ratcliffe,
Michel Bilello, Wilson Szeto, Joseph
Bavaria, W Clark Hargrove III, Emile
Mohler III, Thomas Floyd
3:45 p.m.
S47.003
Rate and Risk Factors of Recurrent
30-day Readmissions Following
Hospitalization for Ischemic
Stroke Yogesh Moradiya, Santosh
Murthy, Sneha Modi, Neeraj Naval
4:00 p.m.
S47.004
Are Treatment Preferences of Those
Who Died Ever Heard?: The Lack
of Documentation of Preferences
in a State-wide Cohort of Patients
Who Died Following Ischemic
Stroke Maisha Robinson, Barbara
Vickrey, Robert Holloway, Kelly
Chong, Linda Williams, Punam
Parikh, Mei Leng, David Zingmond
4:15 p.m.
S47.005
Anatomical Scans Predict Acute
Spatial Neglect Joseph Posner,
Kaitlin Krebs, Chris Rorden, Argye
Hillis
4:30 p.m.
S47.006
Predictors of Seizure Presentation
Associated with Cerebral
Arteriovenous Malformations
in a Prospective Cohort of 1,007
Patients Dale Ding, Robert Starke,
Mark Quigg, Chun-Po Yen, Colin
Przybylowski, Blair Dodson, Jason
Sheehan
4:45 p.m.
S47.007
Prevalence of Asymptomatic
Cerebral Aneurysm in General
Population and Ischemic Stroke
Patient Ji Hwa Kim, Yeo-Jin Oh,
Sang Won Han, Jong Yun Lee,
Kyung-Yul Lee
Thursday, April 23
S48 Parkinson's Disease
3:15 p.m. Presentation of
Jon Stolk Award in Movement
Disorders for Young Investigators
Recipient:
Allison Willis, MD, MS
Philadelphia, PA
3:30 p.m.
S48.002
Motor Subtypes of Parkinson
Disease Are Unstable over Time F. Rainer Von Coelln, Erik Barr, Ann
Gruber-Baldini, Stephen Reich,
Melissa Armstrong, Lisa Shulman
S49 Aging, Dementia,
Cognitive, and Behavioral
Neurology: Imaging:
Behavioral Neurology and
Non-Alzheimer's Disease
Dementias
3:15 p.m.
S49.001
A Role for the Dorsal Dentate
Gyrus in Color Context Pattern
Separation Nicholas Musso,
Raymond Kesner
3:45 p.m.
S48.003
Sex Differences in Parkinson’s
Disease Caregiving Krunal Shah,
Pei Qinglin, Samuel Wu, Peter
Schmidt, Fernando Cubillos, Nabila
Dahodwala
3:30 p.m.
S49.002
Altered Resting-state Network
Connectivity in Stroke Patients
with and Without Apraxia of
Speech Anneliese New, Ballard
Kirrie, Amy Parkinson, Joseph Duffy,
Malcolm McNeil, Olivier Piguet,
Michael Hornberger, Cathy Price,
Simon Eickhoff, Donald Robin
4:00 p.m.
S48.004
Parkinson’s Disease Progression
Is Associated with Increased
Putaminal Serotonin to Dopamine
Transporter Ratio: Relevance for
Dyskinesias Andreas Roussakis,
Marios Politis, David Towey, Paola
Piccini
3:45 p.m.
S49.003
Personal Experience with Dance
and Cortical Gray Matter Thickness
in the Cognitively Normal and Mild
Cognitive Impaired Elderly Shai
Porat, Kristy Hwang, Ellen Woo,
Theodore Zanto, Naira Goukasian,
Liana Apostolova
4:15 p.m.
S48.005
Interdisciplinary Deep Brain
Stimulation Screening and the
Relationship to Unintended
Hospitalizations and Quality of
Life Hokuto Morita, Masa-Aki
Higuchi, Dan Topiol, Dawn Bowers,
Herbert Ward, Lisa Warren,
Meredith DeFranco, Michelle
Troche, Shankar Kulkarni, Kelly
Foote, Michael Okun
4:00 p.m.
S49.004
Associations Between Cortical
Thickness and Hippocampal
Volume with Metacognition Naira
Goukasian, Ellen Woo, Anna
Blanken, Kristy Hwang, Shai
Porat, Genevieve Rodriguez, John
Ringman, Liana Apostolova
4:30 p.m.
S48.006
The Profile of the Hospitalized and
Re-hospitalized Parkinson Disease
Patient: 5-year Data from the
National Parkinson Foundation Leili
Shahgholi, Sol De Jesus, Samuel
Wu, Qinnglin Pei, Anhar Hassan,
Peter Schmidt, Michael Okun
4:45 p.m.
S48.007
Neural Stem Cell Based Therapy
for Parkinson’s Disease Ruslan
Semechkin, Rodolfo Gonzalez, Ibon
Garitaonandia, Tatiana Abramihina,
Maxim Poustovoitov, Andrew Crain,
Alexander Noskov, Louise Laurent,
Evan Snyder, Eugene Redmond
4:15 p.m.
S49.005
Atrophy in Distinct Corticolimbic
Networks Subserving Socialaffective Behavior in Semanticvariant Primary Progressive
Aphasia David Perez, Sara
Makaretz, Christina Caso, Michael
Stepanovic, Michael Brickhouse,
Megan Quimby, Daisy Hochberg,
Chenjie Xia, Bradford Dickerson
4:30 p.m.
S49.006
Grey and White Matter MRI
Signatures of the Frontotemporal
Lobar Degeneration
Continuum Massimo Filippi,
Federica Agosta, Sebastiano
Galantucci, Giuseppe Magnani,
Alessandra Marcone, Daniele
Martinelli, M. Antonietta Volonte,
Nilo Riva, Sandro Iannaccone, Pilar
Ferraro, Francesca Caso, Adriano
Chio, Andrea Falini, Giancarlo Comi
4:45 p.m.
S49.007
Imaging Tau Pathology in Vivo
in FTLD Spectrum Tauopathies
with [18F] T807 PET Bradford
Dickerson, Sara Makaretz, Christina
Caso, Michael Stepanovic, Daisy
Hochberg, Megan Quimby, Michael
Brickhouse, Kimiko Domoto-Reilly,
Scott McGinnis, Aaron Schultz, Neil
Vasdev, Keith Johnson
S50 Treatment Trials in
Neuromuscular Diseases
3:15 p.m.
S50.001
Prednisone/Prednisolone and
Deflazacort Differ in Long Term
Outcomes on Ambulation and Side
Effects in the CINRG Duchenne
Natural History Study Luca Bello,
Heather Gordish-Dressman, Lauren
Morgenroth, Erik Henricson, Tina
Duong, Eric Hoffman, Avital Cnaan,
Craig McDonald
3:30 p.m.
S50.002
A Phase 4 Prospective Study in
Patients with Adult Pompe Disease
Treated with Alglucosidase
Alfa Beth Thurberg, Pierre Carlier,
John Kissel, Benedikt Schoser, Alan
Pestronk, Richard Barohn, Ozlem
Goker-Alpan, Tahseen Mozaffar,
Loren Pena, Zachary Simmons, Volker
Straub, Peter Young, Raheel Sahfi,
Carl Bjartmar, Ans Van Der Ploeg
3:45 p.m.
S50.003
Transplantation of an IPSC-derived
CD15+CXCR4+VLA4+ Neural Stem
Cell Subpopulation as a New Therapy
for ALS. Chiara Simone, Monica
Nizzardo, Federica Rizzo, Monica
Bucchia, Agnese Ramirez, Nereo
Bresolin, Giacomo Comi, Stefania
Corti
4:00 p.m.
S50.004
A Phase 2 Study of Mexiletine
in Sporadic Amyotrophic Lateral
Sclerosis Michael Weiss, Zachary
Simmons, Nazem Atassi, Michael
Graves, Nicholas Parziale, Johnny
Salameh, Colin Quinn, Robert
Brown, B Distad, Jaya Trivedi,
Jeremy Shefner, Anuradha Duleep,
Richard Barohn, Mazen Dimachkie,
April McVey, Alan Pestronk, Andrea
Swenson, Eric Macklin, Angela Knox,
Katelyn Gilardi, Merit Cudkowicz
4:15 p.m.
S50.005
A Single-center, Randomized,
Double-blind, Placebo-controlled,
Six-month Clinical Trial Followed by
an Open-label Extension to Evaluate
the Safety, Tolerability and Clinical
Endpoint Responsiveness of the
Phosphodiesterase Type 4 (PDE4)
Inhibitor Ibudilast (MN-166) in
Subjects with Amyotrophic Lateral
Sclerosis (ALS) - STEP-IBUDILASTALS-DB-OLE-1 Benjamin Brooks,
Elena Bravver, Mohammed Sanjak,
Velma Langford, Cynthia Lary,
Mohamed Alwan, Joanne Nemeth,
Priscilla Russo, Nicole Smith, Nicole
Lucas, Mindy Nichols, Sharon Belcher,
Kathryn Wright, Amber Ward, Scott
Holsten, Michael Fischer, William
Bockenek, Urvi Desai, Scott C
Lindblom, Thomas Pacicco, Kazuko
Matsuda, Joanna Dojillo
4:30 p.m.
S50.006
A Phase 3 Study to Evaluate ISISRx
TTR in Patients with Transthyretin
Familial Amyloid Polyneuropathy
(TTR-FAP): Study Design and
Baseline Demographics Merrill
Benson, John Kincaid, Elizabeth
Ackermann, Brett Monia
4:45 p.m.
S50.007
Effects of Dalfampridine in Hereditary
Spastic Paraparesis Aksel Siva,
Ugur Uygunoglu, Melih Tutuncu,
Aysegul Gunduz, M. Ali Akalin,
Sabahattin Saipoglu
132
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
S51 Headache: Imaging
and Physiology
3:15 p.m. Presentation of Harold
Wolff-John Graham: An Award for
Headache/Facial Pain Research
Recipient:
Henrik Schytz, MD, PhD
Glostrup, Denmark
3:30 p.m.
S51.002
Botulinum Toxin Type A and Rat
Trigeminal Regions: The Search
for Mechanism of Antinociceptive
Action in Migraine and Other
Headaches Zdravko Lackovic
3:45 p.m.
S51.003
Physiological Discrimination of
Headache Disorders Natalie Rea,
Lindsay Hunter, Jonas Peterson, Jeremy
Theriot, Melissa Cortez, K.C. Brennan
4:00 p.m.
S51.004
Acute Headache Diagnoses in
Pregnancy: A 5-year Registry
Study Matthew Robbins,
Constantine Farmakidis, Ashlesha
Dayal, Richard Lipton
4:15 p.m.
S51.005
Structural Cortical Brain
Abnormalities in Patients with
Vestibular Migraine Roberta
Messina, Maria Rocca, Bruno
Colombo, Roberto Teggi, Andrea
Falini, Giancarlo Comi, Massimo Filippi
4:30 p.m.
S51.006
Prolonged Trigeminal Sensitization
Induces Gut Dysbiosis: Implications
for Migraine Pathology Jordan
Hawkins, Rhy Norton, Paul Durham
4:45 p.m.
S51.007
Resting State Functional Connectivity
Abnormalities in Pediatric Patients
with Migraine Roberta Messina,
Maria Rocca, Bruno Colombo,
Ermelinda De Meo, Andrea Falini,
Giancarlo Comi, Massimo Filippi
S52 General Neurology:
Neural Networks and
Neuromodulation
3:15 p.m.
S52.001
Predicting the Network Effects of
Focal Brain Lesions Aaron Boes,
David Fischer, Samar Ayache, Joel
Geerling, Sashank Prasad, Hesheng
Liu, Qi Liu, Brian Edlow, Verne
Caviness, Jean-Pascal Lefaucheur,
Alvaro Pascual-Leone, Michael Fox
3:30 p.m.
S52.002
Using Neural Networks to Predict
the Effects and Guide the Application
of Transcranial Direct Current
Stimulation David Fischer, Peter
Fried, Alvaro Pascual-Leone,
Michael Fox
3:45 p.m.
S52.003
The Neuroanatomic Basis of Coma
in Humans: A Study of Brainstem
Lesions and Their Cortical
Networks David Fischer, Aaron
Boes, Joel Geerling, Brian Edlow,
Alvaro Pascual-Leone, Michael Fox
4:00 p.m.
S52.004
Overexpressed Nucleic Acid in
Aicardi-Goutières Syndrome Patient
Fibroblasts Adeline Vanderver,
Asako Takanohashi, Guy Helman,
Ji-Young Kang, Arya Dahal, Ryan
Taft, Robert Crouch
4:15 p.m.
S52.005
A Novel Method for Measuring
Oxidative Stress in Patients with
Stroke Symptoms Jeffrey Wagner,
Kristin Salottolo, Christopher Fanale,
Michelle Whaley, Kathryn McCarthy,
David BarOr
4:30 p.m.
S52.006
Oxygen Extraction Fraction
and Microvascular
Permeability in X-linked
Adrenoleukodystrophy Patricia
Musolino, Arne Lauer, Mikkel
Bo Hansen, Jayashree KalpathyCramer, Kim Mouridsen, Bruce
Rosen, Florian Eichler
S53 Sleep
3:15 p.m. Presentation of
Wayne A. Hening Sleep Medicine
Investigator Award
Recipient:
Mark Wu, MD, PhD
Baltimore, MD
3:30 p.m. Presentation of Sleep
Science Award
Recipient:
Thomas Scammell, MD
Boston, MA
4:00 p.m.
S53.004
Quantitative Analysis of REM Sleep
Without Atonia in Neurocognitive
Syndromes Ho-Yann Jong, Bradley
Boeve, Erik St. Louis
4:15 p.m.
S53.005
The Association of Sleep Apnea and
Stroke with Cognitive Performance:
The REasons for Geographic
and Racial Differences in Stroke
(REGARDS) Study Jennifer Molano,
Dawn Kleindorfer, Leslie McClure,
Frederick Unverzagt, Virginia
Wadley, Virginia Howard
4:30 p.m.
S53.006
Clinical Profile of Suvorexant over
3 Months in Elderly Patients with
Insomnia: Subgroup Analysis of
Phase-3 Data William Herring,
Kathryn Connor, Neely Ivgy-May,
Duane Snavely, Ellen Snyder, David
Michelson
4:45 p.m.
S53.007
Simplifying the Diagnosis of Sleep
Apnea After Stroke: Evaluation of
Five Simple Screening Tools Fadi
Frakul, Sara Elias, James Im, Karl
Boyle, Sandra Black, Brian Murray,
Richard Swartz, Mark Boulos
4:45 p.m.
S52.007
Optogenetic Neuromodulation Genko Oyama, Nobutaka Hattori
Fast, Easy, Online Registration · AAN.com/view/AM15
International
Experience
We invite all of our international attendees
to join us at the International Experience.
This is a unique place to network,
participate in informal sessions, and learn
more about the AAN as well as other
organizations worldwide.
Tentative Schedule of Events:
Sunday, April 19:
Asia Day
¡¡ Featuring talks by Mamta Bhushan Singh,
MBBS, MD, DM, and Man Mohan Mehndiratta,
MD, MBBS, FAAN
Monday, April 20:
Africa Day
¡¡ Featuring talks by Omar Siddiqi, MD, and
David Renner, MD
Tuesday, April 21:
Global Neurology Day
¡¡ Featuring a preview of the Global Health
Integrated Neuroscience Session and talks
by Mark Hallett, MD, FAAN, and
Kelly Baldwin, MD
Wednesday, April 22:
Latin America, Caribbean Day
¡¡ Featuring talks by Amza Ali, MD, FRCP, FAAN,
and Oscar H. Del Brutto, MD, FAAN
Thursday, April 23:
Europe Day
¡¡ Featuring talks by Walter Struhal, MD
Thursday
April 23
3:15 p.m–5:00 p.m.
133
Highlights for Students, Residents, and Fellows
The AAN Annual Meeting is an ideal setting for students, residents, and fellows to gain exposure to a variety of
interests and career disciplines, as well as network with leading neurologists and neurology professionals from
around the world.
Registration
Opportunities to Save Money
FREE for Medical Students
Rush Line Tickets
Annual Meeting registration is FREE to medical students, graduate
students, and PhD candidates who present a student ID card or are
AAN members.
Check in at the Registration Booth located in the Convention Center
each morning for FREE tickets to Education Programs for that day.
A minimum of two tickets will be held for each
program, available on a first-come, first-served
basis.
Only $100 for Junior Residents
and Junior Fellows
Get 50% Off Education
Program Registration
Annual Meeting registration is only
$100 (a $740 savings from nonmember
neurologist registration!) before the
March 27, 2015, early registration
deadline.
Junior members who register for two Education
Programs at full price will receive
50% off the cost of a third
Education Program of equal or
lesser value.
Registration Packages
This year, we have three registration options available to
attendees. As students and juniors, you receive deep discounts
on registration options. Choose the package that works for you!
¡¡ Meeting Registration—education courses available for an
additional fee
¡¡ Silver Registration Package*—includes all your education
courses at one flat rate
¡¡ Gold Registration Package*—includes Silver Registration
Package plus Annual Meeting On Demand
See details and pricing on page 8.
*Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver
and Gold Registration Package pricing. Attendee must identify courses to be
included as part of Silver and Gold Registration Package. Courses are subject to
closure due to reaching maximum capacity. Attendee is only permitted to select
courses that he/she plans to be in the room for. Attendee will not be able to
register for courses with conflicting time schedules.
134
Volunteer Opportunities
Serve as a program monitor or a
workshop volunteer to gain free
access to the specific program
(see page 145).
2O15 Medical Student, Residents,
and Fellows Guide
A detailed guide highlighting all events and opportunities
of interest to Students, Residents, and Fellows is available at
AAN.com/view/resident .
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Are You A First-time
AAN Annual Meeting Attendee?
Welcome! With more than 12,000 attendees and nearly 300 top-quality sessions, the AAN Annual Meeting is the
world’s largest gathering of neurologists. Below are resources designed to help navigate your week.
1. Attend AAN Annual Meeting Orientation
• Overview of the meeting
• What’s included with your badge
• Networking opportunities
Orientation sessions will be held at the
Walter E. Washington Convention Center:
• Sunday, April 19
1:00 p.m. to 1:30 p.m.
• Wednesday, April 22
8:00 a.m. to 8:30 a.m.
Both sessions will be held in the Innovation Room
2. Register with AAN Mentor Connect
Register with AAN Mentor Connect to be paired
up with an experienced AAN member during the
meeting. AAN Mentor Connect is a members-only
benefit, courtesy of the Neurology Career Center.
3. Join the Annual Meeting LinkedIn Group
Network with attendees before, during and
after the meeting, with the Annual Meeting
LinkedIn group at AAN.com/view/AMLinkedIn.
4. Download the Annual Meeting Mobile App
The app puts all the information you need, itinerary,
room locations, program slides, and syllabi,
conveniently on your mobile phone or iPad.
Look for the full version in March 2015.
5. On-site Resources
• An information booth will be located in the
convention center
• Plan a visit to Academy Central for information
on AAN products and resources
• The Residents Experience offers students and
residents a unique place to network and relax
• The International Experience provides a place for
international attendees to gather and participate
in discussions on a variety of topics
Learn more at
AAN.com/view/FirstTimeAttendee
Connect at Social Events
There’s no better way to combine an evening of great fun and entertainment with unparalleled networking than
to attend the Capitol City Celebration, Closing Party—or both. Whether you attend the Annual Meeting at the
beginning of the week, or the end, these parties are not-to-be-missed.
Capitol
City Celebration
Sunday, April 19
6:00 p.m.–10:00 p.m.
Exhibit Hall Opening Reception
Neurobowl® 6:00 p.m.–8:00 p.m.
Monday, April 20 4:30 p.m.–6:30 p.m.
This popular event hosted by AAN
former president Thomas R. Swift, MD,
FAAN, is one of the Annual Meeting’s
premier happenings. Neurobowl
showcases the best and brightest in
neurology competing for the coveted
Neurobowl trophy in an entertaining
game-show format.
Attend the opening reception to mingle with fellow attendees and
preview the latest products and services available in the neurologic
industry. Light hors d’oeuvres and beverages will be served. The
exhibits will be open at this time.
Sponsored by:
Main Stage Music: Doctor’s
Orders 8:00 p.m.–10:00 p.m.
This energetic 10-piece
variety band based in
the Washington, DC/
Baltimore area will have
you on your feet with its
diverse repertoire covering
everything from Top 40 to ’70s to ’80s to standards. Fronted by
dynamic singer/saxophonist Kyle Johnson and Miriamm Wright—of
Peaches and Herb fame—”the chemistry of the band is obvious from
the first chord,” says guitarist Bill McCarron. “It’s not like it’s really a
conscious effort on our part, we just have a blast playing together.”
No doubt, you’ll have a blast listening to them.
Neuro Jazz
8:30 p.m.–9:30 p.m.
Swing out to your favorite jazz standards while enjoying a
scrumptious dessert. This four-piece ensemble, led by AAN member
Phillip Pearl, MD, FAAN, will have your toes
tapping and fingers snapping to some of the
most enduring tunes of our time.
Run/Walk
Tuesday, April 21 6:30 a.m.–8:30 a.m.
Support research in neurology and join us for a 5k run or one mile
walk along the Washington, DC, waterfront. Both occasional and
seasoned runners—and walkers—will enjoy this beautiful trek for
a good cause. All proceeds will go to the American Brain Foundation
to help support research. The race is open to all meeting attendees
and their families. Water and refreshments will be available following
the race. The registration fee is $40.
Bus service to and from the race site will be provided.
For registration and details, visit AAN.com/view/RunWalk or contact
Andrew Halverson at [email protected] or (612) 928-6117.
Closing Party
Friday, April 24 6:00 p.m.–8:00 p.m.
Celebrate the end of a great meeting at a
special early-evening happy hour event!
¡¡ Enjoy music, drinks, and socializing
with colleagues
¡¡ Make plans to explore beautiful
Washington, DC, afterwards
136
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Reunion/In Conjunction with Meetings
Reconnect with your peers and program directors, and network with
your fellow alumni at various department reunion meetings occurring
throughout the Annual Meeting. These In Conjunction With (ICW)
Meetings, formerly known as Affiliate Meetings, are designed for
functions that include Annual Meeting attendees but are not planned
by or sponsored by the AAN.
If your department is interested in hosting its alumni meeting
during the 2015 Annual Meeting, reserve your meeting today at
AAN.com/view/ICW or by contacting Nancy Poechmann at
[email protected] or (612) 928-6103.
Awards Luncheon
Wednesday, April 22 12:00 p.m.–1:30 p.m.
Join AAN leaders as they honor the recipients of the 2015 AAN and
American Brain Foundation Awards. From enterprising high school
students to world-renowned researchers, this program recognizes
some of the top accomplishments in neuroscience research. Former
US Vice President, former US Ambassador to Japan, former US
Senator, and Honorary Chairman of the American Brain Foundation
CESC: 15AM Closing Party_Abstract Listing, halfpage horizontal
of Trustees
Walter
F. Mondale will accept the 2015 Public
Usage: HighBoard
resolution
PDF for Abstract
Listing
Spec: 8.25” Leadership
x 5.4375”, +.125”
bleeds, 2C Award via video during the luncheon. Past
in Neurology
esteemed recipients include Ben Utecht, Billy McLaughlin, Dame
Julie Andrews, Cuba Gooding Jr., Leeza Gibbons, and Michael J. Fox.
Tickets are available for $60 through registration. Buy a ticket and
show your support for award recipients.
Reserve a Department Table and Be Recognized
Bring your department together and gain exposure for your team at
the Awards Luncheon by reserving a department table. Give your
residents and fellows the chance to sit together with department
faculty and chairs in a place of honor among the top minds in the
neurology/neuroscience academic community. To reserve a table,
download the reservation form at AAN.com/view/AM15.
For questions, contact Laurie Dixon at [email protected] or
(612) 928-6154.
Celebrate the end of a great meeting at a special
early-evening happy hour event!
¡ Enjoy music, drinks, and socializing with colleagues
¡ Make plans to explore beautiful Washington, DC, afterwards
Closing
Party
Friday, April 24
6:00 p.m.–8:00 p.m.
Fast, Easy, Online Registration · AAN.com/view/AM15
137
Things to do in DC
Looking for Interesting and Unique Things to Do While in the DC Area?
While most people are aware of options like the Washington Memorial, the White House, and the
Smithsonian Museums, Washington, DC is home to multiple unique places to visit.
National Park Service Memorials
National Museum of Women in the Arts
While strolling along the famous National Mall, be sure and visit
some of these beautiful new memorials, conveniently situated near
the famous Lincoln Memorial:
¡¡ Korean War Veterans Memorial
¡¡ World War II Memorial
¡¡ Franklin Delano Roosevelt Memorial
¡¡ Martin Luther King, Jr. Memorial
Founded in 1987, the National Museum of Women in the Arts is
the only major museum in the world solely dedicated to recognizing
women’s creative contributions. Learn more
at NMWA.org .
Learn more at NPS.gov/nama/index.htm .
Hillwood Estate Museum and
Gardens
Discover the grand estate of Post Cereal
heiress Marjorie Merriweather Post.
Situated on 25 acres overlooking Rock Creek
Park in northwest Washington, DC, the beautiful estate boasts a
world-renowned collection of Russian and French decorative arts,
as well as extensive gardens and special exhibitions. Learn more
at HillwoodMuseum.org .
Octagon Museum
Built between 1798 and 1801 by John Tayloe
III at the suggestion of George Washington,
the house was offered to President Madison
and his family in 1814 as temporary quarters
after the White House was burned in the
War of 1812. The Treaty of Ghent was signed
here in February 1815, thus ending the war
between Great Britain and the US. Since
1898 the Octagon has served as the national headquarters for the
American Institute of Architects. Learn more at
AIA.org/conferences/the-octagon .
Frederick Douglass National Historic Site
Visit Cedar Hill, home of the famed abolitionist Frederick Douglass
who was born into slavery and escaped to spend the rest of his life
fighting for justice and equality for all people. This National Historic
Site, administered by the National Park Service, works to preserve
the legacy of Douglass’s tireless struggle and inspire people today.
Learn more at NPS.gov/frdo/index.htm .
Freer and Sackler Galleries: The Smithsonian¹s
Museums of Asian Art
This first-class museum features world-renowned collections,
exhibitions, and public programs that offer inspiring encounters
with Asian art and culture for diverse audiences. Learn more
at Asia.si.edu.
Smithsonian National Postal Museum
Housed in the historic 1914 City Post Office Building next door to
Union Station, the Smithsonian National Postal Museum occupies
100,000 square feet of the building with 35,000 square feet devoted
to exhibition space. The museum also houses a 6,000-square-foot
research library, a stamp store, and a museum shop. Learn more at
PostalMuseum.si.edu .
Georgetown
Take a stroll along the quaint cobblestone streets of this bustling
historic neighborhood. Founded in 1751—predating Washington,
DC—the area is a paradise for history and historic architecture lovers,
shoppers, and foodies alike. Learn more at Georgetowndc.com .
138
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Thank You
2O15 Industry Roundtable Members*
Industry Roundtable support enables the American Academy of Neurology to improve
patient care through their support of neuroscience research, education, and patient outreach.
$40,000
$30,000
ACADIA Pharmaceuticals
BioMarin Pharmaceuticals, Inc.
FORUM Pharmaceuticals
$20,000
AbbVie, Inc.
Actavis
Eisai Inc.
Eli Lilly and Company
Medtronic, Inc.
Piramal Imaging S.A.
Sunovion Pharmaceuticals Inc.
Upsher-Smith Laboratories Inc.
*Commitments as of February 3, 2015
Enhance your Annual Meeting experience
with these educational products.
1. AAN Annual Meeting On Demand is a CME accredited comprehensive digital library with more than 500
hours* of presentations from the 2015 AAN Annual Meeting educational programs (including the Syllabi On CD and
Neurology Update On Demand library). Watch presenters’ slides while listening to fully synchronized audio as if you
were actually attending each session.
Features of AAN Annual Meeting On Demand include:
• Online access to content within 24 hours of live presentations.
• NEW: CME credit available.
• The most advanced search engine in the industry delivers a direct link to the specific presentations
and slides containing your search terms. That means less time searching and more time learning.
• Our Recently Viewed feature allows you to revisit presentations and pick up
exactly where you left off.
• Downloadable MP3 files provide the option of listening to any (or all) lectures while driving, traveling,
or any occasion where audio is most convenient.
• A complimentary portable hard drive is included for offline viewing when internet is not convenient
or available.
2. Neurology Update On Demand offers a paired-down library of approximately 70 hours* of presentations
focused on the latest updates in the field of neurology. Sessions in this online-only catalog will be available within
24 hours of the live presentation.
3. Syllabi On CD serves as a quick reference tool with syllabi summaries of more than 160 programs presented
during the 2015 Annual Meeting.
* Total hours of presentations available subject to speaker permissions.
For Annual Meeting Attendees:
New Registration Option: Gold Registration Package
Gold Registration Package
Before
March 27, 2015
After
March 27, 2015
MEMBER
$1,399
$1,599
NONMEMBER
$2,499
$2,799
JUNIOR*
$599
$699
Annual Meeting
On Demand
Neurology
Update
Syllabi
CD
MEMBER
$399
$299
$199
NONMEMBER
$499
$399
$249
JUNIOR
$199
$149
$99
One price secures you access to all education courses** at the Annual
Meeting and includes a copy of AAN Annual Meeting On Demand.
With so many options during the meeting and concurrent sessions,
the Gold Registration Package is the best value for attendees who
want to maximize their time during the meeting.
* Junior pricing also applies to Non-Neurologist members.
** Skills Workshops, Skills Pavilions, and Leadership Programs are excluded from the Gold
Registration Package. Attendees must identify courses to be included as part of Gold Registration
Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that
he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules.
Select the Gold Registration Package when you register for the meeting!
On Demand Add On:
If you decide not to choose the Gold Registration
Package, you can still add any On Demand product or
Syllabi On CD to your registration.
Order Online: AAN.com/view/Register
Attendee Pricing
On Demand attendee discounts expire April 25, 2015.
Not attending the 2015 meeting?
If you are not attending the 2015 Annual Meeting, you
can still pre-order On Demand products prior to the
meeting and receive a special discount.
Order Online: AANonDemand.com/PreMeeting
Order by Phone: (800) 501-2303 or (818) 844-3299
Pre-meeting discounts expire April 25, 2015.
Non-Attendee Pricing
Annual Meeting
On Demand
Neurology
Update
Syllabi
CD
MEMBER
$699
$499
$299
NONMEMBER
$699
$499
$299
JUNIOR
$199
$149
$99
General Information
Accreditation/CME/Core Competencies
Accreditation
The American Academy of Neurology
Institute (AANI), the education
subsidiary of the American Academy
of Neurology, is accredited by the
Accreditation Council for Continuing
Medical Education (ACCME) to provide
continuing medical education (CME)
for physicians.
Once again, this year’s Annual Meeting CME offerings, at the
program and lecture level, are identified according to these
competencies. Through identifying individual programs by
competencies, attendees can easily identify and attend
programs that meet each core competency.
AMA CME Definition/Educational
Content of Certified CME
AMA Credit Designation
The AANI designates this live activity for a maximum of (*) AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
CME/Participation Records
AANI has mechanisms in place to record, and when authorized by
the participating physician, verify participation in the CME activity.
To receive CME for the
Annual Meeting live program,
participants must: (1) register
for the program(s); (2) attend
the program(s); (3) submit
the evaluation form for the
program(s). CME is given
only when all three steps are
completed. AAN member CME
and participation transcripts are
available approximately four to
six weeks following the close
of the meeting via the AAN’s
NeuroTracker AAN.com/view/
NeuroTracker. Nonmembers’
CME credits and participation
transcripts will be sent via email.
Core Competencies
The AANI develops its activities/educational interventions in
the context of the desirable physician attributes. Specifically, the
AANI develops its educational interventions in the context of the
Accreditation Council for Graduate Medical Education (ACGME)
Core Competencies which include:
¡¡ Patient Care
¡¡ Medical Knowledge
¡¡ Interpersonal and Communication Skills
¡¡ Practice-based Learning and Improvement
¡¡ Professionalism
¡¡ Systems-based Practice
142
For more information on the definitions of the ACGME core
competencies, please consult the following webpage:
ACGME.org/outcome/comp/compmin.asp
The AMA HOD and the Council on Medical Education have defined
continuing medical education as follows: CME consists of educational
activities which serve to maintain, develop, or increase the
knowledge, skills, and professional performance and relationships
that a physician uses to provide services for patients, the public, or
the profession. The content of CME is the body of knowledge and
skills generally recognized and accepted by the profession as within
the basic medical sciences, the discipline of clinical medicine and the
provision of health care to the
public. (HOD policy #300.988)
Certified CME is defined as:
1. Nonpromotional learning
activities certified for credit prior
to the activity by an organization
authorized by the credit system
owner, or
2. Nonpromotional learning
activities for which the credit
system owner directly awards
credit
Accredited CME providers may
certify nonclinical subjects (e.g.
office management, patientphysician communications,
faculty development) for AMA PRA Category 1 Credit™ as long
as these are appropriate to a physician audience and benefit the
profession, patient care, or public health.
CME activities may describe or explain complementary and
alternative health care practices. As with any CME activity, these
need to include discussion of the existing level of scientific evidence
that supports the practices. However, education that advocates
specific alternative therapies or teaches how to perform associated
procedures, without scientific evidence or general acceptance among
the profession that supports their efficacy and safety, cannot be
certified for AMA PRA Category 1 Credit™.
Content Validation
The AANI, as an ACCME accredited provider, is responsible for
validating the clinical content of CME activities that it provides.
Specifically, 1. All the recommendations involving clinical medicine
in a CME activity must be based on evidence that is accepted
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
within the profession of medicine as adequate justification for
their indications and contraindications in the care of patients. 2. All
scientific research referred to, reported, or used in CME in support or
justification of a patient care recommendation must conform to the
generally accepted standards of experimental design, data collection,
and analysis.
Disclaimers/Disclosures
AAN/AANI Education/Scientific Disclaimer
The primary purpose of the Annual Meeting is to meet the
educational needs of its members and address practice gaps by
providing practice-oriented and scientifically based educational
activities that will maintain and advance competence and
performance in the field of neurology.
A diversity of opinions exists in the medical field and the views of the
Annual Meeting faculty do not represent those of the AAN/AANI or
constitute endorsement by the AAN/AANI. The AAN/AANI disclaims
any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed
at the Annual Meeting.
Relationship Disclosure and Conflict
of Interest Resolution
According to AANI and ACCME policies, everyone who is in a
position to control the content of an education activity must disclose
financial relationships with any commercial interest to the provider.
An individual who refuses to disclose relevant financial relationships
is disqualified from being a planning committee member, a teacher,
or an author of CME, and cannot have control of, or responsibility for,
the development, management, presentation or evaluation of the
CME activity. In addition, the AANI must implement a mechanism
to identify and resolve all conflicts of interest prior to the education
activity being delivered to learners. The resolution of conflict is
handled by the Education and Science Committees. Disclosures for
everyone in the position to control Annual Meeting content can be
found on the AAN Annual Meeting website. In addition, education
and science faculty disclosures can also be found in the syllabi, slides,
handouts, and/or are given verbally from the podium.
Unlabeled Use Disclosure
The AANI requires all Annual Meeting presenters to disclose if a
therapy/product is not labeled for the use being discussed or if the
therapy/product is still investigational. Unlabeled use disclosures
can be found in the program materials.
General Information
Education Grants
Metro Passes
Some Annual Meeting education and scientific programs are
supported in part by educational grants from commercial entities.
Disclosure of the educational grant is done through acknowledgment
statements on the program materials, signs outside of the room, and
verbally from the podium. Although educational grants are received,
all programs are developed and implemented solely by the Education
Committee and Science Committee. The terms, conditions, and
purposes of the commercial support are documented in a written
agreement between the AANI and commercial supporter. The AAN
uses grant funds to support and enhance existing, as well as new,
education programs.
2015 Annual Meeting attendees staying at any AAN-contracted
hotel outside of a one-mile radius of the Walter E. Washington
Convention Center will have a new, convenient way to get to and
from the convention center—and around Washington, DC! In
lieu of shuttle service, qualifying attendees will each receive a
complimentary Metro pass for use during their stay. Note that shuttle
service will be available between select AAN-contracted hotels and
the Capitol City Celebration on Sunday, April 19.
Services
Child Care Information
A variety of child care options are available in Washington, DC.
Check with the concierge at your hotel on or before your arrival to
make your arrangements.
Luggage Check
No luggage check is available at the Walter E. Washington
Convention
Center. Check
with
your concierge at your hotel to make
RED: 15AM MobileApp
Ad_AMRAP,
halfpage
horizontal
Usage: High resolution
PDF for AMRAP
your arrangements.
Spec: 8.25” x 5.4375”, +.125” bleeds, 4C
Internet Kiosks
The Internet kiosks provide attendees with computer workstations
and Internet access. Check email, search the AAN website, or
complete online evaluations to obtain CME credit.
Wireless Connection
Wireless Internet hotspots will be available at the Walter E.
Washington Convention Center.
Business Center
The Walter E. Washington Convention Center has a business center
that offers administrative and office services, including copy machines,
faxes, and shipping services. The business center is located on the
lobby level of the Walter E. Washington Convention Center.
No Busing
for 2015
Instead we are offering…
In place of bus service, the AAN is providing metro passes to Annual Meeting
attendees staying at any AAN contracted hotel outside a one-mile radius of the
Walter E. Washington Convention Center.
When booking your hotel, visit the transportation tab to check the quickest route
and form of transportation for you!
Learn more at AAN.com/view/BookHotel.
Shuttle service will be made available
for the Capitol City Celebration.
First Aid Station
A First Aid station is located on the lobby level of the Walter E.
Washington Convention Center. The station is staffed by licensed
medical professionals and fully equipped with supplies, including
automatic external defibrillators (AED). The station is operational
throughout the duration of the Annual Meeting.
Volunteer Opportunities
Education and Scientific Program Monitors
A prayer room will be available in the Convention Center for
attendees looking for a quiet space for thought, reflection, and prayer.
Monitors are needed for all education program offerings and
scientific platform sessions to assist directors, faculty, session cochairs, and staff as required. The AAN will waive all monitors’ Annual
Meeting registration and education program fees as well as grant
CME credit for the monitored program. Space is available on a firstcome, first-served basis. For an application form or more information,
contact Laurie Dixon at [email protected] or (612) 928-6154.
Mothers Room
Skills Workshop Volunteers
A private room will be available in the Convention Center for nursing
mothers and others with sensitive personal health needs. Please
note that this room will not be staffed.
Volunteers are needed to participate in the Neurophysiologic
Intraoperative Monitoring Skills Workshop on Monday, April 20,
Neuromuscular Ultrasound Skills Pavilion on Wednesday, April
22, and the EMG Skills Workshop: Basic on Friday, April 24. Skills
workshop subjects will receive a waived meeting registration and
workshop fee as well as payment of $40 per noninvasive session
and $60 per invasive session. Space is available on a first-come,
first-served basis. For more information, contact Ashley Hubbard at
[email protected] .
Prayer Room
Guidelines
Photography and Recording of Programs
The AAN strictly prohibits all unauthorized photography (flash,
digital, or otherwise), audio and/or video recording during the Annual
Meeting. Equipment will be confiscated. Photography is allowed only
in the Poster Sessions.
Consent to Use of Photographic Images
Registration and attendance at, or participation in, AAN/AANI
meetings and other related activities constitutes attendee’s
authorization to AAN’s use and distribution (both now and in the
future) of the attendee’s image or voice in photographs, video
recordings, electronic reproductions, audio recordings, and other
media throughout the world and royalty free.
Weather/Attire
The climate in Washington, DC, in April is generally warm and
pleasant. In April, temperatures usually range from 60 degrees to
70 degrees Fahrenheit. The AAN promotes business casual attire
for the duration of the Annual Meeting. Consider bringing a light
jacket or sweater to Annual Meeting activities since meeting room
temperatures and personal comfort levels vary.
Cell Phones
The AAN requests that attendees turn cellular phones and pagers to
vibrate mode upon entering all Annual Meeting programs.
Language
The official language of the Annual Meeting is
English. No simultaneous translation is available.
No Smoking
The Walter E. Washington Convention Center is
a nonsmoking facility. For the health and comfort
of everyone, smoking is prohibited at Annual
Meeting functions, which include all education
and scientific activities and social functions.
Press Room
Only authorized media may use the Press Room
at the Annual Meeting. Journalists must check in
at the Press Room and provide proper credentials.
For more information, contact Rachel Seroka at
[email protected] or (612) 807-6968.
Fast, Easy, Online Registration · AAN.com/view/AM15
145
Hotel Reservations
Why Book a Hotel Room Through the AAN?
Booking your room through the official AAN housing company assures you are getting a room at the hotel
that best fits your needs. You are also helping the AAN maintain consistent and competitive registration fees.
The reason is simple. When a city is selected as the site for the AAN Annual Meeting, contracts are signed with
several hotels reserving a specific number of rooms to be available for meeting attendees. If these rooms are
not sold, the AAN is liable financially. Penalties incurred affect the overall costs of the Annual Meeting and what
the AAN charges for registration, exhibit space, and other services.
Discounted hotel rates are available until March 18, 2015, or until the block is filled. After this date, reservations
and rates are subject to availability.
Save on Hotel Reservations
Take advantage of the AAN’s special hotel rates to make your trip
more affordable. Annual Meeting hotel reservations are processed
by Convention Management Resources (CMR).
AAN Online Hotel Reservations
AAN.com/view/BookHotel
The AAN makes it easy and convenient to book your hotel rooms for
the 67th Annual Meeting. Booking online allows you to:
¡¡ Take advantage of the AAN’s special hotel rates
¡¡ View room descriptions, photos, and availability
¡¡ Access maps of hotel proximity to Annual Meeting locations
Telephone Reservations
All correspondence, questions, and inquiries should be
directed to CMR at:
Phone:
US/Canada (800) 676-4226
International (415) 979-2283
Hours:
Credit card reservations only
Monday–Friday
6:00 a.m.–6:00 p.m. (PT)
Deposits
¡¡ All hotels require a credit card guarantee or a check deposit
of $300 (US dollars) per room and $500 (US dollars) per suite.
Deposits will be credited towards your first night’s room and tax.
¡¡ No hotel reservation will be processed without a credit card
guarantee or a deposit.
¡¡ Deposits are refundable up to seven days prior to arrival, after
which there will be no refunds.
¡¡ Credit cards will be charged for one night’s room and tax if you
fail to arrive on the confirmed date of arrival or if you fail to
cancel your reservation at least seven days prior to arrival.
Confirmations, Changes, and Cancellations
¡¡ You will receive your hotel confirmation from CMR.
This is the only confirmation you will receive.
¡¡ Please check your arrival and departure dates on the
confirmation carefully.
¡¡ After March 18, 2015, contact CMR to book a room.
After this date, however, rooms are subject to availability.
Note: Some hotels may charge a penalty for changes made to your
departure date after you have checked in.
Group Accommodations
Deadline: March 9, 2015
Blocks of 10 or more sleeping rooms are considered a group. Email
your written request to [email protected] and you will be
contacted by an AAN Housing Consultant.
Additional Tax/Assessments
¡¡ Rates do not include the 15.5% hotel tax.
¡¡ An $8 per night assessment fee is included to offset the
expense of the meeting.
Travel Information
Reservations and Discounts
The official travel agency for the Annual Meeting is Association
Travel Pros. For 2%–10% discounted airline tickets to the Annual
Meeting, contact them at:
Phone: (877) 309-4330
Email: [email protected]
Hours: Monday–Friday, 8:30 a.m.–5:30 p.m. CT
Closed weekends and holidays
A $25 service fee will be assessed per ticket for reservations made
via phone. You may also book online with all airline meeting discounts
applied at www.aantvlmeetings.com . A $10 service fee will apply to
online bookings.
Direct Through Airlines
You may also contact your preferred airline directly. You must
reference the AAN Annual Meeting and provide the appropriate
airline discount codes listed below.
Airline Discount Codes Phone Number Website
Delta
United
NMK82
ZTDX158803
(800) 328-1111
(800) 521-4041
Delta.com
United.com
Discounts are subject to availability, so book well in advance. Normal
mileage and status upgrades apply for all airline programs. A service
fee will be charged for reservations made via phone.
Travel Website
For travel forms and information updates, visit the AAN Annual
Meeting website at AAN.com/view/AM15.
Travel Tips
Travel Documents/Passports and Entry Requirements
Non-US visitors must have valid travel documents/passports to enter
Washington, DC, to provide proof of their citizenship. Document
requirements vary depending on your country of origin, citizenship,
the reason for your visit, and the length of your stay, and may include
passport or a birth certificate, photo ID, and/or a visa.
For more information, or to request a Letter of Announcement for the
2015 Annual Meeting, visit AAN.com/view/AMInfo.
Airports That Service Washington, DC
The Washington, DC, area is served by three airports. The Ronald
Reagan Washington National Airport (National Airport) is located
the closest to the Walter E. Washington Convention Center at
approximately 6.5 miles distance; the Dulles International Airport
(Chantilly, Virginia) is located approximately 28 miles from the
convention center; and Baltimore/Washington International
Thurgood Marshall Airport is located approximately 32 miles from the
convention center. Pricing and direct flight service may vary among
the airports.
Currency
Washington, DC’s currency is the US dollar; currency exchange is
available at banks and kiosks throughout the city and at the airport.
Cash machines/ATMs are available in most banks, hotels, and
shopping centers. For denominations under one dollar, the currency
is coins.
You will need to present this form, along with your passport, visa (if
any), and return tickets to the CBP officer.
Measurements
Washington, DC, uses the United States customary system for
weights and measurements. If you choose to drive in Washington,
DC, be aware the speed limits are posted in miles per hour.
Medication
If you are entering Washington, DC, with prescription drugs and
syringes: keep the medication in its original, labeled container;
include medical certificate with syringes showing they are for
medical use and have them declared to US Customs officials; bring an
extra prescription in case your medication is lost and/or to attest to
your need to take such prescriptions; and carry the generic name of
prescription medicines.
Time Zone
Washington, DC, is in the Eastern Time Zone. In April it will be the
same time as New York, one hour ahead of Chicago, three hours
ahead of Los Angeles, five hours behind London, and 13 hours
behind Tokyo.
For more information, visit AAN.com/view/AMInfo.
Customs and Immigration
From an international point of arrival, upon arriving in Washington,
DC, you will be required to go through a US Customs and Border
Protection (CBP) inspection. Before you land, your flight crew will
distribute an Immigration and Customs Declaration Form for you to
complete; forms are also available at the airport upon your arrival.
Fast, Easy, Online Registration · AAN.com/view/AM15
147
Hotel Street Map and Amenities
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
148
Hotel Name and Address
Beacon Hotel & Corporate Quarters
1615 Rhode Island Ave NW
Cambria Suites Washington DC Convention Center
899 O Street NW
Capital Hilton
1001 16th St NW
Comfort Inn Convention Center
1201 13th St NW
Courtyard by Marriott Washington Convention Center
900 F St. NW
Courtyard Embassy Row
1600 Rhode Island Ave NW
Courtyard DC Capitol
1325 2nd St NE Washington DC 20002
Donovan House, a Kimpton Hotel
1155 14th St NW
DoubleTree Hotel Washington DC
1515 Rhode Island Ave NW
The Dupont Circle Hotel
1500 New Hampshire Ave. NW
Embassy Suites DC Convention Center
900 10th St NW
Embassy Suites Washington DC Downtown
1250 22nd St. NW
Fairfield Inn & Suites Washington, DC / Downtown
500 H St. NW
Grand Hyatt Washington, DC
1000 H St NW
Hamilton Crowne Plaza
1001 14th St NW
Hampton Inn Washington Convention Center
901 6th St NW
Hyatt Place Washington DC/US Capitol
33 New York Ave NE
Henley Park Hotel
926 Massachusetts NW
Hilton Garden Inn Washington DC
815 14th St NW
Hotel George
15 E St. NW
Hotel Helix
1430 Rhode Island Ave NW
Hotel Madera
1310 New Hampshire Ave NW
Hotel Monaco Washington DC
700 F St. NW
Hotel Palomar Washington DC
2121 P St NW
Hotel Rouge
1315 16th St NW
JW Marriott Washington DC
1331 Pennsylvania Ave NW
Liaison Capitol Hill
415 New Jersey Ave NW
Rate
Distance to
Convention
Center
$259
14 Blocks
N
$12.00
1
$269
2 Blocks
N
No Charge
1
$310
9 Blocks
N
$12.95
1
$190
5 Blocks
N
No Charge
0
$299
6 Blocks
N
No Charge
1
$259
14 Blocks
N
No Charge
1
$244
14 Blocks
Y
No Charge
1
$299
9 Blocks
N
No Charge
1
$269
11 Blocks
N
$9.95
1
$259
10 Blocks
Y
No Charge
1
$299
1.5 Blocks
N
$9.95
1
$269
15 Blocks
Y
$14.95
1
$289
5 Blocks
N
No Charge
1
$329
4 Blocks
N
$10.99
2
$299
6 Blocks
N
$12.95
1
$269–279
2 Blocks
N
No Charge
0
$249 Sing /
$269 Doub
10 Blocks
Y
No Charge
0
$299
1 Block
N
No Charge
1
$319
8 Blocks
N
No Charge
1
$329
10 Blocks
N
$10.00
1
$299
13 Blocks
N
$10.00
1
$309
16 Blocks
Y
$9.95
1
$349
5 Blocks
N
$10.00
Per Stay
1
$300
23 Blocks
Y
$12.95
1
$289
12 Blocks
Y
$11.99
1
$329
12 Blocks
N
$12.95
1
$309
12 Blocks
Y
$12.95
1
Metro Pass
Comped
Internet
Cost per
Day
Number of
Restaurants
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Hotel Name and Address
Loews Madison Hotel
1177 15th St. NW
Marriott Marquis Washington, DC—Headquarter Hotel
901 Massachusetts Ave NW
Marriott Metro Center
775 12th St. NW
Morrison-Clark Inn
1015 L St. NW
Phoenix Park Hotel
520 North Capitol St. NW
Renaissance Washington, DC Downtown
999 9th St. NW
Renaissance Washington DC Dupont Circle Hotel
1143 New Hampshire Ave. NW
Topaz Hotel
1733 N St NW
Washington Court Hotel
525 New Jersey Ave. NW
Washington Marriott Georgetown
1221 22nd St NW
Washington Plaza Hotel
10 Thomas Cir. NW
Westin Washington DC City Center
1400 M St. NW
Willard InterContinental Washington
1401 Pennsylvania Ave
28
29
30
31
32
33
34
35
36
37
38
39
sh
eN
mp
8 Blocks
N
$13.95
1
$329
Connected
N
$12.95
4
$313
6 Blocks
N
$12.95
1
$309
3.5 Blocks
N
No Charge
1
$269
11 Blocks
N
No Charge
1
$319
1 Block
N
$12.95
2
$285
18 Blocks
Y
$16.95
1
$299
14 Blocks
Y
$10.95
1
$319
12 Blocks
Y
$10.99
1
$285
15 Blocks
Y
$12.95
1
$295
4.5 Blocks
N
No Charge
1
$289
6 Blocks
N
$12.95
1
$359
12 Blocks
N
$10.95
1
NW
Av e
w
Ne
Q St NW
M
W
10
Lo
Du
sac
hus
ett s
35
ire
ticu
Av
nec
eN
W
C on
L St NW
K St NW
New
sh
ha
w
Ne
ia A
M
ve N
I St NW
19
H St NW
W
Ne
ork
wY
N
Av e
13
M
10th St NW
11th St NW
I St NW
I St NW
H St NW
Ma
ssa
c hu
sett
sA
ve N
H St NW
W
G St NW
G St NW
M
E St NW
D St NW
Ave
NW
an
aA
ve
NW
W
23th St NW
M
Constitution Ave NW
isi
Ave N
ania
Jersey
C St NW
nsylv
u
Lo
Constitution Ave NW
27
D St NW
W
ve N
New
Pe n
na A
First St NW
M
M
Indiana Ave NW
2nd St NW
4th St NW
India
M
3rd St NW
7th St NW
8th St NW
D St NW
Constitution Ave NW
32
20
36
E St NW
D St NW
C St NW
K St NW
23
W
C St NW
M
L St NW
K St NW
F St NW
5
9th St NW
eN
26
G Pl NW
Pennsylvania Ave NW
E St NW
Av
40
W
F St NW
12th St NW
ia
ve N
13th St NW
gin
A
York
14th St NW
Vir
New
15th St NW
E St NW
17th St NW
18th St NW
19th St NW
20th St NW
21th St NW
E St NW
F St NW
H St NW
14
M
G St NW
L St NW
I St NW
30
G St NW
F St NW
33
6th St NW
22th St NW
23th St NW
H St NW
G St NW
NW
16
W
H St NW
H St NW
Av e
K St NW
I St NW
M
York
2nd St NW
lvan
7
North Capitol St NW
I St NW
nsy
17
W
W
18 29
First St NW
31
NW
11
Pe n
ve N
M St NW
Ave N
Av e
M St NW
M
Jersey
ett s
Ne
A
ork
wY
New
hus
O St NW
4th St NW
15
sac
O St NW
5th St NW
13th St NW
3
Ma s
L St NW
6th St NW
M St NW
8
K St NW
I St NW
7th St NW
4
P St NW
N St NW
9th St NW
38
P St NW
Walter E. Washington Convention Center
801 Mt Vernon Pl NW
Washington, DC 20001
N St NW
10th St NW
as Circl
14th St NW
K St NW
L St NW
39
28
15th St NW
M
Sumner Row
17th St NW
18th St NW
W
le N
K St NW
19th St NW
on C
ngt irc
6
M St NW
De Sales St
De Sales Row
L St NW
la
NW
16th St NW
20th St NW
21th St NW
22th St NW
23th St NW
L St NW
de Is
ve
nd A
N St NW
eNW
Rho
M St NW
athe
2
O St NW
21
9
11th St NW
St . M
W
Jefferson Pl
1
ws Ct
Q St NW
NW
P St NW
12th St NW
eN
mp
t Av
N St NW
25
NW
Av e
8th St NW
Av e
O St NW
land
NW
Ma s
de Is
n Circle N
ga
P St NW
37
34
Rho
W
P St NW
21 St NW
22 St NW
12
Q St NW
Church St NW
NW
nt Circle
po
Q St NW
Church St NW
Av e
eN
on t
s Av
Verm
sett
Verm
on t
Corcoran St NW
Thom
c hu
22
Wash
i
$319
R St NW
ha
W
R St NW
O St NW
M
Number of
Restaurants
ire
t Av
ssa
24
M St NW
Internet
Cost per
Day
Metro Pass
Comped
Av
eN
ticu
W
nec
Ma
Rate
C on
40
Distance to
Convention
Center
Constitution Ave NW
= Metro Station
Madison Dr NW
Madison Dr NW
3rd St NW
4th St NW
7th St NW
12th St NW
15th St NW
14th St NW
17th St NW
Thank
You
2O15 Annual Meeting Supporters
The American Academy of Neurology (AAN) thanks the following companies, foundations, and organizations for their
demonstrated vision, commitment, and strong support of programs which find answers and improve lives through
neurologic education and research.
Acadia Pharmaceuticals Inc.
¡ Industry Therapeutic Update
The Allergan Foundation
¡ Minority Scholarship Fund
¡ Resident Scholarship Fund
Allergan, Inc.
¡ Brain Health Fair—Platinum Event Sponsor
Athena Diagnostics
¡ Exhibit Hall Passport
Biogen Idec.
¡ C27 Controversies in Multiple Sclerosis Therapy
¡ C80 Multiple Sclerosis Overview II: Clinical Advances
¡ C151 Multiple Sclerosis Therapy II:
Disease-modifying Treatment
¡ AANextra
¡ Carpet Marketing
¡ Digital Billboard
¡ Exhibit Hall Opening Reception
¡ Emerging Leaders Forum
¡ Industry Therapeutic Update
BioMarin Pharmaceutical Inc.
and PTC Thrapeutic
¡ Industry Therapeutic Update
Eisai, Inc.
¡ Exhibit Hall Passport and Passport
Premier Sponsorship
ElectroCore
¡ Exhibit Hall Passport
Eli Lilly and Company
¡ Emerging Leaders Forum
EMD Serono, Inc.
¡ Exhibit Guide
¡ Exhibit Hall Passport
FORUM Pharmaceuticals Inc.
¡
¡
¡
¡
AANextra
Door Drop Insert
Exhibit Guide
Industry Therapeutic Update
Geisinger Health System
¡ Exhibit Hall Passport
Genentech, Inc.
¡
¡
¡
¡
¡
¡
¡
Abstract Listing
Carpet Marketing
Cell Phone Charging Station
Door Drop Bag Sponsorship
Exhibit Guide
Exhibit Hall Footprints
Exhibit Hall Pillar Wrap
Genzyme, a Sanofi Company
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
Novartis Pharmaceuticals Corporation
5K Run/1K Walk for Brain Research
AANextra
USB Abstracts
Door Drop Inserts
Emerging Leaders Forum
Exhibit Guide
Fellow Scholarship Fund
Industry Therapeutic Update
Exhibit Hall Pillar Wrap
Posters Online
Presentation Stage
Resident Scholarship Fund
¡
¡
¡
¡
¡
¡
AANextra
Airport Dioramas
Industry Therapeutic Update
Mobile App
Taxi TV Ad
Women in Leadership
Sunovion Pharmaceuticals Inc.
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
IMPAX Pharmaceuticals
¡ AANextra
¡ Exhibit Guide
¡ Exhibit Hall Passport
Intermountain Healthcare
¡ Exhibit Guide
AANextra
Abstract Listing
Cell Phone Charging Locker
Digital Billboard
Door Drop Inserts
Exhibit Hall Coffee Break
Exhibit Guide
Exhibit Hall Passport
Exhibit Hall Footprints
Industry Therapeutic Update
Presentation Stage
KRONUS, Inc.
Supernus
Lundbeck LLC
Teva CNS
¡ Exhibit Hall Passport
¡ Exhibit Guide
¡
¡
¡
¡
¡
¡
¡
¡
¡
5K Run/1K Walk for Brain Research
AANextra
Exhibit Guide
Exhibit Hall Passport
Presentation Stage
5K Run/1K Walk for Brain Research
Door Drop Bag Sponsorship
Exhibit Guide
Hotel Key Card/Sleeve
Upsher-Smith Laboratories, Inc.
¡ C57 Therapy of Epilepsy
¡ Exhibit Hall Passport
Mallinckrodt Pharmaceuticals
¡ Door Drop Insert
¡ Exhibit Guide
¡ Footprint
VR1 Inc.
¡ Exhibit Hall Passport
Medtronic, Inc.
Walgreens Infusion Services
Merz Pharmaceuticals, LLC
Wolters Kluwer Health – Publisher of
the AAN Publications
¡ C3 Deep Brain Stimulation Management
¡ Exhibit Hall Passport
¡ C101 Hyperkinetic Movement Disorders: Diagnosis
and Treatment
MOBE, LLC
¡ Exhibit Hall Passport
MotherToBaby Pregnancy Studies
Conducted By OTIS
¡ Exhibit Hall Passport
Mylan
¡
¡
¡
¡
AANextra
Abstract Listing
Cell Phone Charging Station
Exhibit Hall Passport
¡
¡
¡
¡
¡
¡
¡
¡
AMTRAK Posters
Bookbags
Brain Health Fair Bookbag
Brain Health Fair – Silver Event Sponsor
Cell Phone Charging Station Lockers
Exhibit Hall Passport
Geo-Targeted Taxi TV Ad
Wi-Fi Access
* Commitments received as of January 27, 2015
67th Annual Meeting *Current
Exhibitors
as of February 6, 2015
AbbVie Inc.
Blackrock NeuroMed
EMD Serono
ABCN/ABRET
Brain Biosciences Inc
ACADIA Pharmaceuticals Inc.
CADASIL Association
Encore Medical Education LLC & AAN
Business Development
ACRM/American Congress of Rehabilitation
Medicine
Cadwell Laboratories, Inc.
Actavis (formerly Forest Pharmaceuticals,
Inc.)
Captureproof, Inc.
ACTRIMS
Agency for Toxic Substances and
Disease Registry
Cambridge University Press
Carle Physician Group
Catalyst Pharmaceutical Partners, Inc.
Cefaly Technology
Epilepsy Foundation
Esaote
European Academy of Neurology (EAN)
Forum Pharmaceuticals, Inc.
GBS/CIDP Foundation International
Geisinger Health System
GeneDx
Alexion Pharmaceuticals
Centura Health
Allergan, Inc.
Cerora, Inc
Allina Health
Charleston Area Medical Center
Genzyme - a Sanofi Company
Alnylam Pharmaceuticals
Children's Hospitals and Clinics of
Minnesota
Global Neuro-Diagnostics
Glut1 Deficiency Foundation
Clinical Neurology News. com
Great Lakes NeuroTechnologies
CNS Vital Signs
Greenville Health System
Community Health Systems
Grifols USA
American Board of Psychiatry & Neurology
Compumedics USA
Gundersen Health System
American Headache Society
ContextMedia Health
Hayes Locums
American Heart Association
Coram CVS Specialty Infusion Services
Health Volunteers Overseas
American Neurological Association
Corinthian Reference Lab, LLC
HSHS Medical Group
American Physician Institute Beat the
Boards Courses
CorTechs Labs, Inc.
Hydrocephalus Association
CRC Press / Taylor & Francis
Hyperion Medical
American Society for Apheresis (ASFA)
Cure SMA
IcoMetrix Nv
Appalachian Regional Healthcare, Inc.
Cyberonics
IMPAX Pharmaceuticals
Athena Diagnostics, Inc.
Cytokinetics Inc.
Impeto Medical
Auspex Pharmaceuticals
Defense and Veterans Brain Injury Center
Interacoustics
Avanir Pharmaceuticals Medical Affairs
Demos Medical Publishing
Intermountain Healthcare, Inc.
Avanir Pharmaceuticals, Inc.
DENT Neurologic Institute
AxelaCare Health Solutions
Depomed, Inc.
International Essential Tremor
Foundation (IETF)
B. Braun CeGaT, LLC
DigiTrace Care Services, Inc.
Balancewear By Motion Therapeutics Inc
Dysautonomia International
Bayer HealthCare
Dystonia Medical Research Foundation
Benign Essential Blepharospasm
Research Foundation, Inc.
Eisai Inc.
Alzheimer's Association
Ambry Genetics
American Association of Neuromuscular
and Electrodiagnostic Medicine
Biogen Idec
BioMarin Pharmaceutical Inc.
BKIN Technologies Ltd
Electrical Geodesics, Inc. (EGI)
Electro-Cap International, Inc.
ElectroCore
Elsevier, Inc.
Fast, Easy, Online Registration · AAN.com/view/AM15
Genentech
International Parkinson and
Movement Disorder Society (MD)
IPSEN
Jackson & Coker
Jan Medical Inc.
Jari Electrode Supply
JTECH Medical
KabaFusion
151
67th Annual Meeting Exhibitors
Karger Publishers
Nihon Kohden America, Inc.
Synapse Biomedical, Inc
KEGO FMI
Northern Health
TeleSpecialists, LLC
Kennedy Krieger Institute
Novartis Pharmaceuticals Corporation
TEVA Neuroscience, Inc.
KRONUS, Inc.
Ochsner Health System
The Delta Companies
Lantheus Medical Imaging, Inc.
Omim Inc.
The Electrode Store
Lewy Body Dementia Association
Opexa Therapeutics
The Guthy-Jackson Charitable Foundation
LocumTenens. com
Otometrics/Audiology Systems
The JAMA Network
Lundbeck
Otto Trading Inc.
Magstim
Oxford University Press
The Michael J. Fox Foundation
for Parkinson's Research
Mallinckrodt Pharmaceuticals
(formerly Questcor)
PeaceHealth
Mayo Clinic
Personalis, Inc.
Mayo Medical Laboratories
McGraw-Hill Medical
MD Conference Express
Medical Motion
Medical Neurogenetics
MedLink Corporation
MedPro RX
Medtronic, Inc.
Merz Neurosciences a Division of
Merz North America, Inc.
MOBE, LLC
MotherToBaby Pregnancy Studies
Conduceted By OTIS
Pernix Therapeutics
Pikeville Medical Center, Inc.
Piramal Imaging
Polar Products Inc.
Practical Neurology
PracticeLink. com
Prevention Genetics
ProtoKinetics, Gait Analysis Walkways
Providence Health & Services
RDL Reference Laboratory
Riverside Health
Rochester Electro-Medical, Inc.
RosmanSearch, Inc.
Multigon Industries, Inc.
RSC Diagnostic Services
Multiple Sclerosis Association of America
Sage Therapeutics
Multiple Sclerosis Foundation
Salem Health
Mylan Inc.
Society for Neuroscience
National Ataxia Foundation
Society of Nuclear Medicine and
Molecular Imaging
National Institute of Neurological Disorders
and Stroke (NINDS)
National Institutes of Health - FITBIR
National Multiple Sclerosis Society
National Spasmodic Torticollis Association
Natus Neurology Incorporated
Neurology Career Center
Neurology Reviews
Neurovirtual USA, Inc.
152
The MSA Coalition
The Myositis Association
The Sturge-Weber Foundation
The Transverse Myelitis Association
Tourette Syndrome Association
Transgenomic, Inc
UCB, Inc.
United Council for Neurologic
Subspecialties (UCNS)
Upsher-Smith Laboratories, Inc.
US Bioservices Specialty Pharmacy
US WorldMeds
Vaya Pharma
Via Christi Health
VR1 Inc.
Walgreens Infusion Services
Wiley
Wolters Kluwer Health
World Parkinson Coalition Inc.
WR Medical Electronics
XenoPort, Inc.
Soleo Health (formerly Biomed
Pharmaceuticals)
Sony Electronics
SpecialtyCare
Spectrum Health Medical Group
Springer
Sunovion Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc.
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
67th Annual Meeting Committee Members
Meeting Management Committee
Science Committee
Practice Committee
Stefan M. Pulst, MD, FAAN, Chair
Brenda Banwell, MD
Neil A. Busis, MD, FAAN
Terrence L. Cascino, MD, FAAN
Cynthia L. Comella, MD, FAAN
John Corboy, MD, FAAN
Lisa M. DeAngelis, MD, FAAN
Mill Etienne, MD, MPH, CPH
Jonathan P. Hosey, MD, FAAN
Carlayne E. Jackson, MD, FAAN
Ralph F. Józefowicz, MD, FAAN
Jennifer R. Molano, MD
John C. Morris, MD, FAAN
Timothy A. Pedley, MD, FAAN
Ronald C. Petersen, PhD, MD
Maisha T. Robinson, MD
Stephen M. Sergay, MB BCh, FAAN
Bruce Sigsbee, MD, FAAN
Thomas R. Swift, MD, FAAN
Lisa M. DeAngelis, MD, FAAN, Chair
Natalia Sana Rost, MD, FAAN, Vice Chair
Michael G. Benatar, MBChB, DPhil, FAAN
Gregory K. Bergey, MD, FAAN
Edward H. Bertram, MD
David Q. Beversdorf, MD
Paul M. George, MD, PhD, MSE
Neill R. Graff-Radford, MD, FAAN
Joseph Jankovic, MD, FAAN
Shafali Jeste, MD
Eric Klawiter, MD
Walter J. Koroshetz, MD, FAAN
Randolph S. Marshall, MD, FAAN
Mark F. Mehler, MD, FAAN
Jose G. Merino, MD, MPhil
Massimo Pandolfo, MD
Rosebud Roberts, MD
Walter A. Rocca, MD, MPH
Nina F. Schor, MD, PhD
Mark H. Tuszynski, MD, PhD
Barbara G. Vickrey, MD, MPH, FAAN
Aleksandar Videnovic, MD, MSc
Ryan R. Walsh, MD, PhD
Jonathan P. Hosey, MD, FAAN, Chair
Heidi B. Schwarz, MD, FAAN, Vice Chair
Wayne E. Anderson, MD, FAAN
Carmel Armon, MD, FAAN
Sarah M. Benish, MD
Bruce H. Cohen, MD, FAAN
Richard M. Dubinsky, MD, FAAN, MPH
Miriam L. Freimer, MD
Joseph V. Fritz, PhD
Larry B. Goldstein, MD, FAAN, FAHA
Raghav Govindarajan, MD
Cynthia L. Harden, MD
Anna D. Hohler, MD, FAAN
Donald J. Iverson, MD, FAAN
Michael J. Kaminski, MD, FAAN
David J. Likosky, MD, SFHM
Pushpa Narayanaswami, MBBS, MD, FAAN
Marilyn M. Rymer, MD
Don B. Smith, MD, FAAN
James C. Stevens, MD, FAAN
Jack W. Tsao, MD, DPhil, FAAN
Raissa Villanueva, MD
David Z. Wang, DO, FAAN, FAHA
Medical Economics and
Management Committee
Abstract Reviewers
Education Committee
Cynthia L. Comella, MD, FAAN, Chair
Steven L. Lewis, MD, FAAN, Vice Chair
Allen J. Aksamit, Jr., MD, FAAN
Imran I. Ali, MD, FAAN
Allison Brashear, MD, MBA, FAAN
Bruce A. C. Cree, MD, PhD, MCR
Barry M. Czeisler, MD, MS
John W. Engstrom, MD, FAAN
Charles C. Flippen, II, MD, FAAN
Blair Ford, MD, FAAN
J. Clay Goodman, MD, FAAN
Laurie Gutmann, MD, FAAN
Jonathan P. Hosey, MD, FAAN
Jaffar Khan, MD, FAAN
Rebecca K. Lehman, MD
Janis Miyasaki, MD, FAAN
Mark L. Moster, MD, FAAN
Bruce I. Ovbiagele, MD, MSc, FAAN
Lori Ann Schuh, MD, FAAN
Joseph I. Sirven, MD, FAAN
A. Gordon Smith, MD, FAAN
Orly Avitzur, MD, MBA, FAAN, Chair
Gregory J. Esper, MD, Vice Chair
Allison Brashear, MD, MBA, FAAN
Neil A. Busis, MD, FAAN
Bruce H. Cohen, MD, FAAN
David A. Evans, MBA
Terry D. Fife, MD, FAAN
William S. Henderson, FACMPE
Jonathan P. Hosey, MD, FAAN
Lyell K. Jones, MD
Joel M. Kaufman, MD, FAAN
Constantine Moschonas, MD
John Ney, MD
Marianna V. Spanaki-Varelas, MD, PhD
Fast, Easy, Online Registration · AAN.com/view/AM15
Karen C. Albright, DO, MPH
Anthony A. Amato, MD, FAAN
Lilyana M. Amezcua, MD
Beau M. Ances, MD, PhD, MS
Christopher D. Anderson, MD, PhD
Liana Apostolova, MD
Agnieszka Ardelt, MD, PhD
Charles E. Argoff, MD
Melissa Armstrong, MD
Ganesh Asaithambi, MD
Misha-Miroslav Backonja, MD
Jonathan Baets, MD, PhD
Laura J. Balcer, MD, MSCE, FAAN
Robert H. Baloh, MD, PhD
Brenda Banwell, MD
Kevin M. Barrett, MD
Tracy T. Batchelor, MD, MPH
Danielle Becker, MD
Joseph R. Berger, MD, FAAN
Gregory K. Bergey, MD, FAAN
Robert A. Bermel, MD
Bibiana Bielekova, MD
Arnaud Biraben, MD
Gretchen L. Birbeck, MD, MPH, DTMH, FAAN
153
67th Annual Meeting Committee Members
Christopher J. Boes, MD, FAAN
Bradley F. Boeve, MD
Riley Bove, MD
K.C. Brennan, MD
James Brewer, MD, PhD
Amy Brodtmann, MBBS, FRACP
Krzysztof Bujarski, MD
Jeffrey M. Burns, MD
Rami Burstein, PhD
Peter A. Calabresi, MD, FAAN
Brian Callaghan, MD
Sarah Camargos, MD
Jonathan L. Carter, MD
Antonia Ceccarelli, MD
Sherita Chapman, MD
Seemant Chaturvedi, MD, FAAN, FAHA
Vinay Chaudhry, MD, FAAN
William P. Cheshire, Jr., MD, FAAN
Claudia A. Chiriboga, MD
Shilpa Chitnis, MD, PhD
Tanuja Chitnis, MD
Tracey Cho, MD
Bruce H. Cohen, MD, FAAN
Howard Colman, MD, PhD
Francis X. Conidi, MD, DO
Wayne T. Cornblath, MD, FAAN
Fiona Evann Costello, MD
Ricardo Cruciani, MD
Debra G. Davis, MD
Kathryn A. Davis, MD
John F. De Groot, MD
Philip De Jager, MD, PhD
Gabriele C. De Luca, MD, PhD
Eduardo Adonias De Sousa, MD, FAAN
Al De Weerd, MD, PhD
Bradford Dickerson, MD
Dennis W. Dickson, MD
Elliot Dimberg, MD
Marc Dinkin, MD
David W. Dodick, MD
E. Ray Dorsey, MD, MBA
John E. Duda, MD
Paul L. Durham, PhD
P. James B. Dyck, MD, FAAN
Eric R. Eggenberger, DO, FAAN
Adam D. Falchook, MD
Alfonso Fasano, MD, PhD
Brent L. Fogel, MD, PhD
Nathan B. Fountain, MD
Robert J. Fox, MD, FAAN
Yitzchak Frank, MD
154
Samuel A. Frank, MD
Gary M. Franklin, MD, MPH, FAAN
Roy L. Freeman, MD
Deborah I. Friedman, MD, FAAN
Steven Frucht, MD
Juan Fueyo, MD
Susan Gauthier, DO
Barry E. Gidal, PhD
Christopher Glisson, DO
Jennifer G. Goldman, MD
Alica M. Goldman, MD
Myla Goldman, MD
Nicole Gonzales, MD
Jean Gotman, PhD
Andrew W. Grande, MD
Jennifer Graves, MD, PhD
Ari Green, MD
Benjamin M. Greenberg, MD
Waldo Guerrero, MD
Rashmi B. Halker, MD
May Han, MD
John Hart, MD
Cara E. Harth, MD
Anhar Hassan, MBBCH
Victor W. Henderson, MD, FAAN
Susan T. Herman, MD
Andrew G. Herzog, MD, MSc, FAAN
Holly E. Hinson, MD
Michio Hirano, MD, FAAN
Khe Hoang-Xuan, MD
Timea M. Hodics, MD
Ahmet Hoke, MD, PhD
Julia Holtmann, MD
William T. Hu, MD, PhD
David Y. Huang, MD, PhD
Rebecca N. Ichord, MD
Matilde Inglese, MD, PhD
Richard S. Isaacson, MD, BA
Michael S. Jaffee, MD, FAAN
Sarah Janicki, MD
Imad T. Jarjour, MD, FAAN
Adil Javed, MD, PhD
Matthew Jensen, MD
Nathalie Jette, MD, MSc, FRCPC
Glen Jickling, MD
Joohi Jimenez Shahed, MD
Barbara C. Jobst, MD, FAAN
Michael Anthony Leander Johnson, MD
Lyell K. Jones, MD
Keith A. Josephs, Jr., MD
Vern C. Juel, MD, FAAN
Orhun H. Kantarci, MD
Kejal Kantarci, MD
Chafic Y. Karam, MD
Jonathan S. Katz, MD
Horacio C. Kaufmann, MD, FAAN
Claudia Kawas, MD
Adam Kelly, MD
Omar A. Khan, MD, PhD
Doojin Kim, MD
John T. Kissel, MD, FAAN
Christopher J. Klein, MD
Peter J. Koehler, MD, PhD, FAAN
Matthew A. Koenig, MD
Steven C. Kosa, MD
Mohamad Koubeissi, MD, FAAN
Jeff Kraakevik, MD
Stephen Krieger, MD
W. Curt LaFrance, Jr., MD, MPH, FAAN
Annette M. Langer-Gould, MD, PhD
Douglas J. Lanska, MD, FAAN
Gabriel Leger, MD, FRCPC
Enrique C. Leira, MD, MS
Robin Lemmens, MD, PhD
Joao M. Lemos, MD
Michael Levy, MD
David S. Liebeskind, MD, FAAN
Giancarlo Logroscino, MD, PhD, FAAN
W. T. Longstreth, Jr., MD, FAAN
Fred D. Lublin, MD, FAAN
Jennifer Lyons, MD
Jennifer J. Majersik, MD
David E. Mandelbaum, MD, PhD, FAAN
Silva Markovic Plese, MD
Ruth-Ann Marrie, MD
Randolph S. Marshall, MD, FAAN
Juan Martin, MD
Sheryl Martin-Schild, MD, PhD
Farrah J. Mateen, MD
Stephan A. Mayer, MD
Micheline B. McCarthy, MD, PhD, FAAN
Jennifer McGuire, MD
Margherita Milone, MD
Vivek Misra, MD
Walter R. Morgan, MD
Elena Moro, MD
Martha Morrell, MD, FAAN
Mariana Moscovich, MD, PhD
Ellen M. Mowry, MD
Tahseen Mozaffar, MD, FAAN
Maciej M. Mrugala, MD
Michael T. Mullen, MD
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
Kassandra L. Munger, ScD
Renato Puppi Munhoz, MD
Abraham J. Nagy, MD
Stephanie J. Nahas, MD
Robert T. Naismith, MD
Avindra Nath, MBBS, FAAN
Lorene M. Nelson, PhD
James M. Noble, MD
Katherine H. Noe, MD, PhD
Paul Alan Nyquist, MD, MPH
Darin T. Okuda, MD, FAAN
Michael S. Okun, MD, FAAN
Antonio M. P. Omuro, MD
Jill L. Ostrem, MD
Joseph E. Parisi, MD
Marc C. Patterson, MD, FAAN, FRACP
Addie Patterson, DO
Steven G. Pavlakis, MD, FAAN
Daniel Pelletier, MD
Page B. Pennell, MD
Joanna Pera, MD
Istvan Pirko, MD, FAAN
Sean J. Pittock, MD
Michael Pourfar, MD
John Pula, MD
Svetlana Pundik, MD
Mark S. Quigg, MD
John M. Ravits, MD, FAAN
Daniel Reich, MD, PhD
Stephen G. Reich, MD, FAAN
Fredy J. Revilla, MD, FAAN
John Matthew Ringman, MD
Peter N. Riskind, MD, PhD
Carrie E. Robertson, MD
Gustavo C. Roman, MD, FAAN
Yelena Roshchina, MD
Devon I. Rubin, MD, FAAN
Janet C. Rucker, MD
Marwan N. Sabbagh, MD, FAAN
Joseph E. Safdieh, MD, FAAN
Nerses Sanossian, MD
Lauren Hachmann Sansing, MD
Amrou Sarraj, MD
Justin A. Sattin, MD
Sean I. Savitz, MD
Andreas Schulze-Bonhage
Todd J. Schwedt, MD
Stephen Selkirk, MD
Linda M. Selwa, MD, FAAN
Vikram Shakkottai, MD, PhD
Kevin N. Sheth, MD
Ludy Chen Shih, MD
Nancy L. Sicotte, MD, FAAN
Donald H. Silberberg, MD, FAAN
Lisa C. Silbert, MD, FAAN
Tanya Simuni, MD
Carlos Singer, MD
Wolfgang Singer, MD
Mamta Bhushan Singh, MBBS, MD, DM
Wade S. Smith, MD, PhD
Sarah Song, MD
Eric J. Sorenson, MD, FAAN
Andrew Mebane Southerland, MD
Rebecca Spain, MD
David C. Spencer, MD, FAAN
Michael R. Sperling, MD, FAAN
Nathan P. Staff, MD, PhD
John M. Stern, MD, FAAN
Rebecca L. Sugg, MD
Victor W. Sung, MD
Caroline M. Tanner, MD, PhD, FAAN
Alrabi Tawil, MD, FAAN
Edmond Teng, MD, PhD
Matthew J. Thurtell, MD
David L. Tirschwell, MD, FAAN
Amy Towfighi, MD
Helen Tremlett, PhD, BPharm
Samuel Tsappidi, MD
Alexandros C. Tselis, MD, PhD, FAAN
David Vaillancourt, PhD
Gregory P. Van Stavern, MD
David Walk, MD
Harrison C. Walker, MD
Annabel K. Wang, MD
Michael F. Waters, MD, PhD, FAAN
Nathaniel F. Watson, MD
James C. Watson, MD
Emmanuelle Waubant, MD, FAAN
Bianca Weinstock-Guttman, MD
Michael D. Weiss, MD, FAAN
Patrick Y. Wen, MD, FAAN
Jennifer Louise Whitwell, PhD
Wolfgang Wick, MD
Christina Wilson, MD
Dean M. Wingerchuk, MD, FAAN
Elaine C. Wirrell, MD
George F. Wittenberg, MD, PhD
David A. Wolk, MD
Jan Wollack, MD, PhD
Kyle B. Womack, MD
Bradford B. Worrall, MD, MSc, FAAN
Clinton B. Wright, MD
Fast, Easy, Online Registration · AAN.com/view/AM15
Teddy Yuan-Hao Wu, MD
James P. Wymer, MD, PhD, FAAN
Dileep R. Yavagal, MD
Scott S. Zamvil, MD, PhD, FAAN
Theresa A. Zesiewicz, MD, FAAN
Wendy C. Ziai, MD
155
Meeting Management and Contacts
Hotel Reservation Deadline:
Meeting Registration and Housing
Travel Reservation Services
Airline Reservations:
Association Travel Pros
Early Registration Deadline:
Phone:
Credit card reservations only
US/Canada (800) 676-4226
International (415) 979-2283
March 27, 2015
Hours: Monday–Friday
6:00 a.m.–6:00 p.m. PT
Registration, Hotel, and Travel
Reservations:
Email:
Registration: [email protected]
Housing: [email protected]
March 18, 2015
AAN.com/view/AM15
Phone: (877) 309-4330
www.aantvlmeetings.com
Hours:
Monday–Friday, 8:30 a.m.–5:30 p.m. CT
Closed weekends and holidays
Email:
[email protected]
Annual Meeting Oversight
Science Program
Resident and Student Activities
Catherine M. Rydell, CAE
Chief Executive Officer/Executive Director,
AAN, AAN Institute, and American Brain
Foundation
[email protected]
Lucy Persaud Samaroo
Manager, Graduate Education
Christine E. Phelps
Deputy Executive Director, AANI/
American Brain Foundation
Kris Fridgen
Senior Director, Education,
Science, and Conferences
Erin Jackson
Senior Science Manager,
Annual Meeting and Conferences
Nate Kosher
Senior Science Administrator,
Annual Meeting and Conferences
Registration
[email protected]
Kevin Heinz
Associate Director,
Annual Meeting and Conferences
Laurie Dixon
Senior Administrator, Registration
and Logistics
Education Program
Housing
[email protected]
Julie Ratzloff
Manager, Housing and Special Events
Amy Nostdahl
Senior Education Manager,
Annual Meeting and Conferences
Ashley Hubbard
Senior Education Specialist,
Annual Meeting and Conferences
Cheryl Alementi
Program Manager, Undergraduate Education
Practice and Public Policy Issues
[email protected]
Rod Larson
Chief Health Policy Officer
For direct email and phone contacts,
please contact Member Services at:
[email protected]
Toll Free: (800) 879-1960 or
International: (612) 928-6000
In Conjunction With Events
Nancy Poechmann
Manager, Meeting Logistics and Travel
Exhibits
Franziska Schwarz
Manager, Exhibits and Services
Industry Relations
Deborah Woodard
Senior Manager, Industry Affairs
Alberta Zais
Senior Manager,
Corporate and Strategic Partnerships
Compliance Issues
Susan Rodmyre
Senior Director, Education
156
2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information
2O15 AAN Women in
Leadership Program
Whether you want to be a mentor or an advocate, to guide or inspire others, you need to
cultivate the skills to be an effective leader. Based on overwhelming popularity, the 2015 AAN
Annual Meeting will feature two leadership courses designed for women. Space is limited and
you must apply to take the program. Choose the course that’s right for you!
Sunday, April 19, 2015, 9:00 a.m.–5:00 p.m.
Leadership for Women
Women who are early- to mid-career interested in learning from successful female members in
the field of neurology, including members of the AAN Board of Directors, about how to lead
at senior levels should apply today for Leadership for Women. Selected recipients will receive
complimentary registration for this course.
Directors:
Allison Brashear, MD, MBA, FAAN | Winston Salem, NC
Barbara Hoese, President | Pentecore Coaching, Minneapolis, MN
Space is limited and the application deadline is March 13, 2015.
Apply now at AAN.com/view/WomenLead
Monday, April 20, 2015, 9:00 a.m.–5:00 p.m.
Advanced Leadership for Women
Women who are mid-career and currently in a leadership role looking to grow their current
leadership capacity should apply today for the Advanced Leadership for Women. Selected
recipients will receive complimentary registration for this course.
Directors:
Lisa M. DeAngelis, MD, FAAN | New York, NY
Barbara Hoese, President | Pentecore Coaching, Minneapolis, MN
Space is limited and the application deadline is March 13, 2015.
Apply now at AAN.com/view/AdvLead
Supported by:
PAID
Permit No. 3840
Twin Cities, MN
201 Chicago Avenue
Minneapolis, MN 55415
2O15 Scientific Abstract Listing and Meeting Information
Non-Profit Org.
US Postage
Register Today for the 67th AAN Annual Meeting
April 18–April 25, 2O15 · Washington, DC
¡¡ Hotel Reservation Deadline: March 18, 2015
¡¡ Early Registration Deadline: March 27, 2015
AMERICAN ACADEMY OF NEUROLOGY
AAN.com/view/AM15
AAN Member Services: (800) 879-1960 Use #AANAM and follow the AAN